
<html lang="en"     class="pb-page"  data-request-id="dcf7435f-b80a-4335-8a74-557b372b03a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-10;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c02245;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches" /></meta><meta name="dc.Creator" content="Adrian  Hall" /></meta><meta name="dc.Creator" content="Hugues  Chanteux" /></meta><meta name="dc.Creator" content="Karelle  Ménochet" /></meta><meta name="dc.Creator" content="Marie  Ledecq" /></meta><meta name="dc.Creator" content="Monika-Sarah E. D.  Schulze" /></meta><meta name="dc.Description" content="This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activit..." /></meta><meta name="Description" content="This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 18, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02245" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02245" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02245" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02245" /></link>
        
    
    

<title>Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02245" /></meta><meta property="og:title" content="Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0141.jpeg" /></meta><meta property="og:description" content="This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common in recent years. Analysis of this work highlights several important molecular interactions, and the resultant structural modifications to reduce PXR activity are summarized. The computational approaches undertaken to support the design of new drugs devoid of PXR activation potential are also discussed. Finally, the SAR of empirical design strategies to reduce PXR activity is reviewed, and the key SAR transformations are discussed and summarized. In conclusion, this perspective demonstrates that PXR activity can be greatly diminished or negated on active drug discovery projects with the knowledge now available. This perspective should be useful to anyone who seeks to reduce PXR activity on a drug discovery project." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02245"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02245">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02245&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02245&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02245&amp;href=/doi/10.1021/acs.jmedchem.0c02245" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 6413-6522</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00028" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Adrian Hall</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adrian Hall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4b0a2f39222a2565032a27270b3e282965282426"><span class="__cf_email__" data-cfemail="3d7c594f545c5313755c51517d485e5f135e5250">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Hall">Adrian Hall</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7869-6835" title="Orcid link">http://orcid.org/0000-0001-7869-6835</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hugues Chanteux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hugues Chanteux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hugues++Chanteux">Hugues Chanteux</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karelle Ménochet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karelle Ménochet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UCB, 216 Bath Road, Slough, SL1 3WE, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karelle++M%C3%A9nochet">Karelle Ménochet</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marie Ledecq</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie Ledecq</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie++Ledecq">Marie Ledecq</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Monika-Sarah E. D. Schulze</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monika-Sarah E. D. Schulze</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UCB, 216 Bath Road, Slough, SL1 3WE, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monika-Sarah+E.+D.++Schulze">Monika-Sarah E. D. Schulze</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3799-0808" title="Orcid link">http://orcid.org/0000-0002-3799-0808</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02245&amp;href=/doi/10.1021%2Facs.jmedchem.0c02245" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 6413–6522</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 18, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 December 2020</li><li><span class="item_label"><b>Published</b> online</span>18 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02245" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02245</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6413%26pageCount%3D110%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAdrian%2BHall%252C%2BHugues%2BChanteux%252C%2BKarelle%2BM%25C3%25A9nochet%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D10%26contentID%3Dacs.jmedchem.0c02245%26title%3DDesigning%2BOut%2BPXR%2BActivity%2Bon%2BDrug%2BDiscovery%2BProjects%253A%2BA%2BReview%2Bof%2BStructure-Based%2BMethods%252C%2BEmpirical%2Band%2BComputational%2BApproaches%26numPages%3D110%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6522%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02245"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2255</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02245" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Hall&quot;},{&quot;first_name&quot;:&quot;Hugues&quot;,&quot;last_name&quot;:&quot;Chanteux&quot;},{&quot;first_name&quot;:&quot;Karelle&quot;,&quot;last_name&quot;:&quot;Ménochet&quot;},{&quot;first_name&quot;:&quot;Marie&quot;,&quot;last_name&quot;:&quot;Ledecq&quot;},{&quot;first_name&quot;:&quot;Monika-Sarah&quot;,&quot;last_name&quot;:&quot;E. D. Schulze&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6413-6522&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02245&quot;},&quot;abstract&quot;:&quot;This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common in recent years. Analysis of this work highlights several important molecular interactions, and the resultant structural modifications to reduce PXR activity are summarized. The computational approaches undertaken to support the design of new drugs devoid of PXR activation potential are also discussed. Finally, the SAR of empirical design strategies to reduce PXR activity is reviewed, and the key SAR transformations are discussed and summarized. In conclusion, this perspective demonstrates that PXR activity can be greatly diminished or negated on active drug discovery projects with the knowledge now available. This perspective should be useful to anyone who seeks to reduce PXR activity on a drug discovery project.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02245&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02245" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02245&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02245" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02245&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02245" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02245&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02245&amp;href=/doi/10.1021/acs.jmedchem.0c02245" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02245" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02245" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (16 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02245%26sid%3Dliteratum%253Aachs%26pmid%3D34003642%26genre%3Darticle%26aulast%3DHall%26date%3D2021%26atitle%3DDesigning%2BOut%2BPXR%2BActivity%2Bon%2BDrug%2BDiscovery%2BProjects%253A%2BA%2BReview%2Bof%2BStructure-Based%2BMethods%252C%2BEmpirical%2Band%2BComputational%2BApproaches%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D10%26spage%3D6413%26epage%3D6522%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291120" title="Hydrophobicity">Hydrophobicity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/jmcmar.2021.64.issue-10/20210527/jmcmar.2021.64.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0141.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0141.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common in recent years. Analysis of this work highlights several important molecular interactions, and the resultant structural modifications to reduce PXR activity are summarized. The computational approaches undertaken to support the design of new drugs devoid of PXR activation potential are also discussed. Finally, the SAR of empirical design strategies to reduce PXR activity is reviewed, and the key SAR transformations are discussed and summarized. In conclusion, this perspective demonstrates that PXR activity can be greatly diminished or negated on active drug discovery projects with the knowledge now available. This perspective should be useful to anyone who seeks to reduce PXR activity on a drug discovery project.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pregnane xenobiotic receptor, more commonly known as pregnane X receptor or PXR but also known as the steroid and xenobiotic sensing nuclear receptor (SXR) and (human) pregnane activated receptor (PAR), is a type II orphan nuclear receptor, encoded by the NR1I2 gene located on chromosome 3, group I, member 2 (NR1I2). It was discovered by several groups in 1998 when it was linked to CYP3A4 induction.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> It is involved in many cell processes including bile acid and cholesterol transport and metabolism, cancer, and inflammation.<a onclick="showRef(event, 'ref1 ref3 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref3 ref5 ref6">(1,3,5,6)</a> PXR has been mostly studied due to its potential to induce the expression of enzymes and transporters responsible for the absorption, distribution, metabolism, and elimination of endogenous molecules and xenobiotics. Indeed, gene targets of PXR include not only key cytochrome P450 enzymes (CYP2B, CYP2C, and CYP3A) but also efflux and uptake transporters of the ATP-binding cassette and solute carrier transporter families.<a onclick="showRef(event, 'ref2 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref2 ref7 ref8 ref9">(2,7−9)</a> So far, the key clinical observations have involved induction of CYP3A4, the predominant CYP enzyme responsible for metabolizing xenobiotics in the liver and the intestines.</div><div class="NLM_p">PXR contains a DNA-binding domain at the N-terminus of the protein, the role of which is to bind the response elements of the target gene promoter region.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> At the C-terminus of the protein, the ligand binding domain (LBD) contains the pocket that interacts with the ligand as well as the activation function-2 (AF-2). Ligand binding occurs in the cytoplasm and leads to a conformational change which in turn triggers the release of the chaperone complex, thus allowing translocation of PXR to the nucleus.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In the nucleus, PXR forms a heterodimer with retinoid X receptor (RXR) before interacting with further transcriptional coactivator proteins, binding to the target gene promoter and activating protein expression, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Crystallographic studies have shown that the PXR-RXRα heterodimer can further dimerize, via a PXR–PXR interaction, to give a heterotetramer,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><i>vide infra</i>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. While the DNA-binding domain is well conserved across species, the same is not true for the ligand binding domain, which translates to pharmacological differences.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> For instance, while rifampicin is a strong inducer of CYP3A4 in human, it has only a weak impact on CYP expression in rodents.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of ligand activation of PXR through the formation of a heterodimer with RXR and subsequent gene expression via binding to the PXR response element. Adapted from Tebbens et al. (ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>). Copyright 2018 MDPI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PXR is mostly expressed in the liver and the intestine,<a onclick="showRef(event, 'ref1 ref4 ref16'); return false;" href="javascript:void(0);" class="ref ref1 ref4 ref16">(1,4,16)</a> which correlates with the location of the enzymes and transporters it regulates. CYP3A4 is the most abundant CYP enzyme in the liver, and a wide variety of xenobiotics are known to induce its expression through activation of PXR leading to clinically relevant drug–drug interactions (DDI) that translate into loss of pharmacological activity, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Rifampicin is a strong CYP3A4 inducer and has been investigated extensively preclinically and clinically. It is recommended as a standard CYP3A4 inducer in DDI studies in the clinic.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Indeed, the area under the curve (AUC) of an oral dose of midazolam (2–15 mg), a stereotypical CYP3A4 substrate, was decreased by 86–98% following oral rifampicin treatment for 5 days at 600 mg <i>quaque die</i> (QD).<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23 ref24">(18−24)</a> Similarly, it is noteworthy that induction of CYP3A4 by rifampicin reduces the exposure of oral contraceptives; coadministration of rifampicin (600 mg QD) led to a decrease in the exposure of progestins by 46–89% compared to the absence of an inducer.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Another example of PXR-mediated DDIs include a 65% reduction in the AUC of rosiglitazone coadministrated with rifampicin (600 mg QD).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In some instances, a drug can induce an increase of its own clearance. For example, carbamazepine is mostly cleared by CYP3A4 metabolism and it also activates PXR. As a result, the clearance of carbamazepine increases following repeat administration leading to a reduction in systemic concentrations,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> a phenomenon known as autoinduction. In addition to CYP3A4 induction examples have also been reported whereby activation of PXR results in DDIs via other mechanisms. For instance, isavuconazonium (200 mg QD) decreased the exposure of bupropion by 42% through PXR-mediated induction of CYP2B6.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of the heterotetrameric complex formed by PXR in orange, RXRα in cyan, SRC-1 in dark blue, and the cocrystallized activator SR12813 in green. The AF-2 domain is highlighted in red (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Over the years, tools have been developed to screen out the PXR activation potential of xenobiotics. As a result, out of the 103 new molecular entities (NME) approved by the FDA between 2013 and 2016, only 7 exhibited a clinically relevant DDI through PXR activation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The greatest DDI was observed with lumacaftor (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, 150 mg of BID for 14 days) causing an 80% decrease in AUC of ivacaftor (200 mg QD for 14 days). In all cases, these DDI risks impacted the label granted by the health authorities. In most cases, use of these PXR activators was contraindicated with sensitive or narrow therapeutic range CYP3A4 substrates. In addition, the systemic concentration of the victim drug had to be monitored and the dose adjusted if necessary. These data show that the drive to reduce or eliminate PXR activation has shifted to the preclinical drug discovery arena where there has been considerable success. This may be attributed to the fact that scientists now have access to effective screening methods which has resulted in significant progress in designing out PXR activity by several means, as highlighted herein.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> lists some of the drugs known to induce CYP3A4 (via PXR activation) clinically, i.e. the perpetrator, and the consequences they have on the exposure of the victim drug (the CYP3A4 substrate). This highlights some of the structural features as well as the structural diversity found with PXR activators and serves to showcase the impact that induction can have. Rifampicin is included more than once as it provides a benchmark.</div><div class="NLM_p">Although most of the research on PXR has focused on limiting its activation by xenobiotic ligands, the discovery of PXR antagonists has also generated some interest recently.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> In 2002, ketoconazole was identified as an inhibitor of PXR activation.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Subsequently it was proposed that antagonists bind in the vicinity of the AF-2 helix leading to allosteric modulation of PXR activation, as described in <a class="ref internalNav" href="#sec3" aria-label="section 3">section 3</a> on the structural biology of PXR.<a onclick="showRef(event, 'ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92">(90−92)</a> Following the identification of ketoconazole as a PXR antagonist, numerous azoles have been found to have a similar effect, such as enilconazole,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> FLB-12,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> or SPA70,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a><i>vide infra</i> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The potential clinical applications of PXR antagonists include the reversal of metabolic enzyme and transporter induction. In addition, antagonists have the potential to limit PXR-mediated drug resistance to anticancer chemotherapy as the involvement of PXR in resistance to chemotherapy has been shown in several <i>in vitro</i> and <i>in vivo</i> assays in head and neck, colorectal, and ovarian cancers.<a onclick="showRef(event, 'ref6 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref6 ref96 ref97">(6,96,97)</a> For instance, silencing shRNA targeted toward PXR significantly decreased the tumor renewal potential of human colon cancer cells implanted in mice after chemotherapy. Despite the interest in this field for the last 20 years, no antagonists have been approved.</div><div class="NLM_p">CYP induction is a complex, multistep process and can occur via different mechanisms. The first two mechanisms involve stabilization of mRNA and/or protein which results in increased protein levels.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> The third mechanism entails activation of transcription factors and up-regulation of gene expression.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> This latter mechanism is the main one involved in the induction of CYP450 mediated by new chemical entities and occurs mainly through the activation of PXR, CAR, and AhR transcription factors.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">Many different <i>in vitro</i> and <i>in vivo</i> models are available to evaluate the PXR-mediated CYP3A4 induction potential of compounds.<a onclick="showRef(event, 'ref103 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref103 ref104 ref105">(103−105)</a> The binding of a compound to the LBD of PXR is the common denominator of all these models; however, induction of CYP3A4 does not solely rely on PXR binding even though this is the first step of the process. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, there are several steps before the activation of transcription.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">The CYP3A4 induction liability of new chemical entities (NCEs) can be assessed using a huge variety of assays, but the inherent limitations of each assay needs to be carefully considered when it comes to interpretation, decision-making, and translation to the clinic. Though a PXR binding assay<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> may provide accurate information about the interaction between a compound and PXR LBD, it cannot be used to predict the magnitude of a clinical DDI since it does not discriminate between agonists and antagonists. Positive findings in binding assays should always be re-evaluated in another, more relevant, assay such as a reporter gene or human hepatocyte assay. In addition, PXR LBD assays will not identify compounds that modulate PXR activation via other signaling pathways, as observed with some kinase inhibitors.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Although binding assays are robust and offer significant throughput, they bring limited value, hence other assays are preferable to assess CYP3A4 induction. Among the possible assays, the reporter gene or PXR transactivation assay is widely used in early discovery. Vectors containing full length human PXR and the response element from the CYP3A4 gene linked with a reporter gene (usually luciferase) are introduced to hepatoma cell lines such as HepG2 or HuH7. The use of hepatoma cell lines is essential because they stably express key functional coactivators and repressors required for PXR activity and binding. These cell-based assays offer many advantages in a drug discovery setting aiming to identify and/or reduce the CYP3A4 induction liability of new drug candidates. For example, these assays are relatively straightforward and use inexpensive cell lines which are compatible with automated high-throughput screening. In addition, several literature reports have demonstrated that this type of assay can be used to predict the risk associated with CYP3A4 induction in the clinic by comparing and normalizing the response observed to a well described CYP3A4 inducer, such as rifampicin.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> Such assays have established the link between PXR activation and CYP3A4 induction observed in primary human hepatocytes or HepaRG cells.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> Though PXR assays are useful to identify PXR agonists and rank order new compounds for their potential to activate CYP3A4 transcription, they are usually not adequate for the quantitative prediction of CYP3A4 induction in the clinic. Indeed, other mechanisms (cross talk with CAR, induction via other intracellular signaling pathways, etc.) involved in CYP3A4 induction are not present in these assays and may provide false negative results and/or underestimate the CYP3A4 induction potential of the drug candidate. In addition, the cell lines used in PXR assays have little metabolic activity and minimal expression of drug transporters, which can impact the levels of drug and/or metabolites available for interaction with PXR.</div><div class="NLM_p">The use of primary human hepatocytes overcomes the main challenges faced with standard PXR assays. They are physiologically more relevant as they possess the full molecular machinery and can replicate all the mechanisms by which CYP3A4 can be induced.<a onclick="showRef(event, 'ref102 ref114'); return false;" href="javascript:void(0);" class="ref ref102 ref114">(102,114)</a> Being the closest <i>in vitro</i> system to the <i>in vivo</i> situation, they are recommended by U.S. and European regulatory agencies as the reference <i>in vitro</i> model to assess the CYP3A4 induction potential of a new drug candidate. Characterization of the CYP3A4 induction potential in human hepatocytes is a well-established approach for the accurate prediction of the DDI risk associated with <i>in vivo</i> CYP3A4 induction.<a onclick="showRef(event, 'ref115 ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117">(115−117)</a> A decade ago, the use of primary hepatocytes was limited by their availability; however, with the improvement of cryopreserving techniques,<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> supplies of large, and high-quality, batches of hepatocytes are now available. The interindividual variability among donors remains the main drawback of primary hepatocytes, which requires an assessment in three different donors to be compliant with regulatory guidelines. However, access to large batches of hepatocytes has rendered the use of primary hepatocytes convenient and powerful in drug discovery as it also allows the compilation of a database. As with any other cell line, their use is compatible with high-throughput screening,<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> even though this type of assay can require a 4–5 day experiment. For these reasons, it is frequently used as a preliminary assessment of the CYP3A4 induction potential of a new drug candidate.</div><div class="NLM_p">In the last 2 decades, several alternatives to the use of primary human hepatocytes have been investigated. Efforts have mainly focused on immortalized cell lines like HepG2, HuH7, Fa2N4, and HepaRG. The main drivers for this were the potential of a more convenient, accessible, and reproducible assay than human hepatocytes. Among the different options available, Hepa-RG is by far the most validated and used alternative to human hepatocytes for the prediction of CYP3A4 induction.<a onclick="showRef(event, 'ref113 ref122 ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref113 ref122 ref123 ref124">(113,122−124)</a> The use of immortalized hepatocyte cell lines has required extensive qualification and validation to ensure that the test system is appropriate for the identification of CYP3A4 inducers. HepG2 was found to express very low levels of CYP450 compared to primary human hepatocytes and CYP3A4 induction with rifampicin was low,<a onclick="showRef(event, 'ref113 ref125'); return false;" href="javascript:void(0);" class="ref ref113 ref125">(113,125)</a> while the Fa2N4 cell line lacks CAR expression and cannot be used to fully evaluate CYP3A4 induction since the cross-talk between PXR and CAR is absent.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> HuH7 has been less studied, but recent work has shown that a long culture time (4 weeks under confluence) is required to detect CYP3A4 induction mediated by rifampicin.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> More studies are needed to evaluate the full potential of HuH7 as a potential replacement of primary hepatocytes.</div><div class="NLM_p">Nowadays, the development of more physiologically relevant <i>in vitro</i> models has been the main focus of research, building on tissue architecture to maintain the <i>in vivo</i>-like phenotype of the liver and improve hepatic functionality.<a onclick="showRef(event, 'ref128 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref128 ref129 ref130">(128−130)</a> Many different approaches have been explored and include systems such as organ-on-a-chip,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> spheroids<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> and 3D bioprinting.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Though progress in these areas has been exponential, and recent work has shown promising results, it is still in the early days and more validation is warranted before integrating these new tools into the drug discovery arena.</div><div class="NLM_p">Across these different <i>in vitro</i> assays, several end points can be determined to characterize the CYP induction potential, such as CYP3A4 activity, quantification of CYP3A4 mRNA, luciferase activity, etc. Regardless of the end point used, new compounds can always be rank ordered based on their CYP induction profile (<i>in vitro</i> potency using <i>E</i><sub>max</sub>/EC<sub>50</sub>) or can be filtered out by using specific and predefined cutoff values based on historical data (<i>x</i>% of a positive control at a predefined concentration). A positive control (usually rifampicin for CYP3A4 induction) should always be used in <i>in vitro</i> assays to account for interlab and interassay variability and to normalize the data, which also allows comparison with historical data.</div><div class="NLM_p">When it comes to translation of <i>in vitro</i> CYP induction data to a clinical DDI, different approaches (FDA/EMA) can be used, but much more information on the compound in question is required, such as the predicted active dose in humans as well as the expected unbound plasma concentration.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> Depending on the type of <i>in vitro</i> induction data available from discovery, additional <i>in vitro</i> induction data might be needed to confirm previous data using gold standards and/or to firm up the prediction (full dose–response, three different donors, etc).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">One of the challenges in the evaluation of the CYP3A4 induction liability of a new drug candidate is the need to work mainly with human-based models. Though PXR DNA-binding domains are fairly well conserved between species (>92% identity),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> the ligand-binding domains of PXR show significant species difference with only about 80% similarity at the amino acid level.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> These species differences can translate into significant differences in the CYP3A induction potential as demonstrated with rifampicin and pregnenolone-16α-carbonitrile in rodents and humans.<a onclick="showRef(event, 'ref14 ref137'); return false;" href="javascript:void(0);" class="ref ref14 ref137">(14,137)</a> Nevertheless, CYP induction in rodents should not be overlooked since it may cause serious developability issues. Indeed, owing to the high dose levels tested in toxicity studies, decreased exposure following repeated administration in rodent studies is often observed due to autoinduction mechanisms (induction of P450 enzymes which directly impact the clearance of the compound). This can sometimes lead to low exposure, thereby compromising further development because of inadequate safety margins. Similarly, autoinduction in mice and rats may also hinder the exploration of efficacy in chronic pharmacology studies. However, these CYP induction findings in rodents do not inform on the risk of clinically relevant induction of CYP3A, mainly because of the species differences in CYP induction, but also due to the dose and/or the unbound plasma exposure achieved which might not be clinically relevant.</div><div class="NLM_p">In contrast to rodents, monkeys have been used as a model to predict CYP3A4 induction as their PXR protein shares ∼95% homology with the human counterpart, and they have shown a similar pattern of transactivation and CYP3A induction. Indeed, both <i>in vitro</i> and <i>in vivo</i> approaches have demonstrated that the CYP3A induction observed in monkey is very similar to that observed with human models or <i>in vivo</i>.<a onclick="showRef(event, 'ref138 ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref138 ref139 ref140">(138−140)</a></div><div class="NLM_p">The possibility of using <i>in vivo</i> models to assess CYP induction offers additional advantages over the <i>in vitro</i> models, as they always need to be extrapolated to the <i>in vivo</i> situation. Indeed, there are specific features of drug disposition (absorption, clearance, liver disposition, metabolites, etc.) that are more complicated to integrate in the translation of <i>in vitro</i> data. However, the use of <i>in vivo</i> monkey models for the prediction of CYP3A induction in humans does not preclude the need to demonstrate, using <i>in vitro</i> models, that monkey PXR is transactivated similarly to human PXR.</div><div class="NLM_p last">For practical and ethical considerations, alternative <i>in vivo</i> models to the monkey have been developed by humanizing mouse PXR and/or CYP3A (deletion of the murine gene and replacement by the human one). Promising results have been obtained in showing comparable DDI profiles to the human situation.<a onclick="showRef(event, 'ref141 ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref141 ref142 ref143">(141−143)</a> Nonetheless, a humanized PXR/CYP3A mouse model remains a mouse when it comes to the disposition of the CYP3A inducer, meaning that its absorption (rate and extent), protein binding, clearance, and distribution should be as close as possible to humans in order for the results to be robust. If this is not the case, then the differences need to be considered cautiously when results in the humanized mouse model are translated to human in order to avoid misleading predictions. The same applies to <i>in vivo</i> monkey models where ADME properties of the inducer need to be similar between monkey and human to ensure optimal prediction. Since species-dependent ADME properties are quite common, this is most likely the reason why such approaches are not widely used in drug development for the prediction of CYP3A induction. Instead, they are typically used on an ad-hoc basis for more specific reasons, in order to overcome some challenges of <i>in vitro</i> models and/or further confirm/infer the CYP3A induction risk when confidence in the DDI prediction based only <i>in vitro</i> data is low.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Structural Biology of PXR</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35881" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35881" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PXR shares a common domain structure with other members of the nuclear receptor superfamily, which encompasses three types of functional domains: a DNA-binding domain (DBD), a ligand-binding domain (LBD), and transactivation domains (activation function 1 (AF-1) and 2 (AF-2)). The highly conserved DBD is at the N-terminus and binds short stretches of DNA in the regulatory regions of target genes with two zinc-finger motifs, a P-box motif and a D-box motif.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The LBD is at the C-terminus of PXR and forms a heterodimer with another nuclear receptor retinoid X receptor (RXR),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> which is important for gene regulation and furthermore binds coactivators<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> (<i>e.g</i>., steroid receptor coactivator-1, SRC-1). The transactivation domains consist of a ligand-independent AF-1 domain at the N-terminus and a C-terminal ligand-dependent transcription AF-2 domain.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p">Through a novel sequence insertion in the LBD, PXR forms a homodimer unique to the nuclear receptor superfamily (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Terminal β-strands from each monomeric LBD generates a 10-stranded intermolecular β-sheet with conserved tryptophan and tyrosine residues providing a tryptophan–zipper interaction. It has been shown that the PXR homodimer is stable in solution, and although disruption of the homodimer does not interfere with DNA, RXR, or ligand binding, it does reduce receptor activity and eliminates recruitment of the coactivator SRC-1.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Furthermore, together with RXR, PXR forms a heterotetramer and both PXR and RXR have higher affinity for the coactivator SRC-1 when part of the PXR-RXR heterotetramer than each LBD alone.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Impact of Cytochrome P450 Inducers on the Pharmacokinetics of Their Victim Drugs in the Clinic<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48 ref49 ref50 ref51 ref52 ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48 ref49 ref50 ref51 ref52 ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87">(30−87)</a><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0110.gif" alt="" id="gr110" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0111.gif" alt="" id="GRAPHIC-d7e350-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0112.gif" alt="" id="GRAPHIC-d7e351-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0113.gif" alt="" id="GRAPHIC-d7e352-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0114.gif" alt="" id="GRAPHIC-d7e353-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0115.gif" alt="" id="GRAPHIC-d7e354-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0116.gif" alt="" id="GRAPHIC-d7e355-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0117.gif" alt="" id="GRAPHIC-d7e356-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0118.gif" alt="" id="GRAPHIC-d7e357-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0144.gif" alt="" id="GRAPHIC-d7e358-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0145.gif" alt="" id="GRAPHIC-d7e359-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">This information is based on an extract from the UW Drug Interaction Database (DIDB), Copyright University of Washington, accessed in August 2020. The table consists of 3 categories, strong, medium, and weak inducers, and is grouped by the victim drug and where possible also by the perpetrator.</p></div></div><div></div></div><div class="NLM_p">There are three crystal structures which show the quaternary organizations of full-length nuclear receptors on DNA and provide useful insight into the orientation of DNA and DBDs relative to the LBDs, the PPARγ/RXRα heterodimer,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> the hepatocyte nuclear factor HNF-4α homodimer,<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> and the RXRα-LXRβ heterodimer.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> depicts the heterotetrameric complex structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a>) formed between PXR and RXRα, for which both proteins have been fused at their C-termini to the following region of human steroid receptor coactivator-1 (SRC-1): 678-SSHSSLTERHKI<b>LHRLL</b>QEGSPS-700, with the LxxLL motif in bold. It had been previously shown that the PXR LBD contacts 15 residues of the LxxLL motif of SRC-1.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Full-length SRC-1 contains multiple LxxLL motifs that are known to bind to various nuclear receptor AF-2 regions. In <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, the activator SR12813 (compound <b>62</b>, in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) is represented in green: the addition of SR12813 compresses the overall structure of the ligand-bound complex compared to the apo complex; this observation supports the general belief that the binding of activating ligands serves to stabilize nuclear receptor complexes.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. List of PXR Crystal Structures Deposited in the PDB, in Chronological Order<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0119.gif" alt="" id="gr111" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0120.gif" alt="" id="GRAPHIC-d7e725-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0121.gif" alt="" id="GRAPHIC-d7e726-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0122.gif" alt="" id="GRAPHIC-d7e727-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0146.gif" alt="" id="GRAPHIC-d7e728-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">N/A, not applicable.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Reference <a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Reference <a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a>. MEC, minimum efficacious concentration.</p></div></div><div></div></div><div class="NLM_p">The structure of the human PXR LBD was first reported in 2001.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> To date (November 13, 2020), there are 31 structures of the LBD, encompassing with ligand and apo structures, deposited in the Protein Data Bank (PDB) and listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Of these structures, 5 are apo and the remaining 26 are with ligands. One of these ligands, compound <b>67</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, has been deposited as two separate entries (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT">4SOT</a>) representing 2 poses, while compound <b>75</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, has two poses but only 1 entry (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a>), hence 30 rows in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. This results in 21 unique ligand-PXR structures, plus one that contains 2 ligands, trans nonachlor (TNC; compound <b>68</b>) with 17α-ethinylestradiol (compound <b>42</b>) (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G">4X1G</a>). The first with the ligand structure was solved with SR12813 (compound <b>62</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and appeared in 2001. The next was with hyperforin (compound <b>7</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the major pharmacological component of St. John’s Wort) in 2003, followed by rifampicin (compound <b>1</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) in 2005, T0901317 (compound <b>63</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) in 2007, and PNU-142721 (compound <b>65</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) in 2008. Since 2014, 15 structures with ligands have been deposited, showing an increase in the frequency and the adoption of PXR structural biology within drug discovery projects. Structures with SR12813 encompass 4 entries, and there are individual structures with trans nonachlor and 17α-ethinylestradiol as well as a structure with both ligands bound simultaneously. Taken together, these structures highlight the diversity of ligands which bind to PXR and the range of possible binding modes and molecular interactions which are possible and are discussed in further detail below.</div><div class="NLM_p">Two constructs have been used for PXR crystallography, one construct using a complex with a separate SRC-1 coactivator peptide,<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> which has lower stability compared to the other construct with the SRC-1 peptide tethered to PXR with a peptidyl linker.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Furthermore, adnectins have been developed that target the coactivator SRC-1 binding site and have been used as crystallization chaperones displacing the SRC-1 peptide.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p">The PXR LBD is characterized by the typical nuclear receptor fold, an “α-helical sandwich”, but unlike other nuclear receptors, the small β-sheet is extended to a five-stranded antiparallel β-sheet which serves as the homodimerization interface. Further, the α6 helix is often converted to a loop and thought to be responsible to accommodate different ligands in the binding site.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><div class="NLM_p">The volume of the PXR binding pocket is noticeably larger than for other nuclear receptors, and the volume has been measured to be greater than 1000 Å<sup>3</sup>.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> PXR is highly promiscuous and binds ligands with different dimensions and chemical properties, which can be accommodated by occupying different parts of the binding pocket and adapting to allow various binding modes. These properties make it challenging to predict the binding modes of compounds as there can be small differences in energies between potential binding modes.</div><div class="NLM_p">The PXR ligand binding cavity is formed by about 30 amino acids (including 8 polar residues capable of forming hydrogen bonds). This large binding cavity can be viewed as four distinct subregions whose residues form a hydrophobic cage (green residues, Val211, Leu213, Phe288, Trp299, Cys301, Tyr306, Leu308, Leu324, His327), a polar rim (blue residues, Ser247, Met250, Phe251, Phe281, Cys284, Gln285, Glu321, Met323, His407, Arg410), a hydrophobic side (orange residues, Leu411, Ile414, Phe420, Met425, Phe429), and a polar channel (magenta residues, Leu206, Cys207, Lys210, Tyr225, Lys226, Pro227, Pro228, Ile236, Ser238, Leu239, Leu240, His242, Met243, Ala244, Met246), <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, from a SiteMap representation performed within Maestro (Schrodinger).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Two hydrophobic patches (in yellow) show the potential hydrophobic interactions that can be formed with the hydrophobic cage on the left and the hydrophobic side on the right. Red and blue areas highlight the potential H bond interactions that can arise between the ligand and the polar rim on the top and the polar channel on the bottom.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Main residues delineating the PXR binding pocket. The residues corresponding to the hydrophobic cage (on the left), the polar rim (on the top), the hydrophobic side (on the right), and the polar channel (on the bottom) are represented, respectively, in green, blue, orange, and magenta. (B) Binding site description using the SiteMap (Schrodinger) representation.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Hydrophobic areas are represented in yellow, HB acceptor areas are in red, and HB donor areas are in blue. Small white dots cover the region where chemical matter can bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This intuitive description of the ligand binding pocket is broadly in agreement with a publication from Ngan and collaborators.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Starting from seven crystal structures of PXR available at the end of the 2000s, they used a computational solvent mapping approach to study the promiscuous nature of the protein and characterize the potential recognition points within its ligand binding pocket.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> They highlighted 28 residues delineating the ligand binding site, which are mainly hydrophobic in nature such as Leu206, Leu209, Val211, Leu239, Leu240, Met243, Ala244, Met246, Phe251, Phe281, Phe288, Trp299, Tyr306, Leu411, Ile414, and Phe420 but also polar such as Ser208, Ser247, Cys284, and Gln285 or potentially charged such as Glu321, His327, His407, and Arg410.</div><div class="NLM_p">By moving 16 molecular probes, small organic molecules containing various functional groups, around the protein surface they identified five well-defined hot spots (regions of the protein surface that are the major contributors to the binding free energy): four hot spots located on four different sides of the nearly spherical binding pocket and a fifth close to its center. The most important hot spot is constituted by three highly conserved residues, Trp299, Phe288, Tyr306, corresponding to what we call the hydrophobic cage, plus an additional polar residue Gln285 (on the polar rim as termed by us), which is the residue that forms the highest number of hydrogen bonds with the molecular probes. Most of the cocrystallized ligands interact with PXR through this hotspot. The second hot spot includes residues Met243, Met246, Ser247, Phe251, Phe281, Cys284, Gln285, and Phe288 corresponding to some extent to what we call the “polar rim”. Residues Phe281, His407, Arg410, Leu411, Ile414, and Phe420 form the third hot spot located opposite to the hydrophobic cage which we have defined the “hydrophobic side”. The fourth hot spot is termed the “center region” and corresponds to residues Leu240, Met243, Ala244, Ser247, His407, Leu411, and Phe420, which have partial overlap with the other hot spots. The fifth hot spot, corresponding to the “polar channel”, contains residues Leu206, Leu209, Lys210, Val211, Leu239, Leu240, and Met243 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). All hot spots have at least one conserved residue among all mammalian PXRs: Trp299, Phe288, and Tyr306 in the first hot spot, Phe288 in the second, Ile414 in the third, Leu240 in the fourth, and Leu240 in the fifth. Each hot spot also has less conserved residues, with a moveable side chain that gives flexibility to accommodate a large variety of ligands: Gln285 for the first hot spot; residues Met243, Met246, and Gln285 in the second hot spot; His407, Arg410, and Leu411 in the third hot spot; Met243 and Leu411 in the fourth; and Leu206, Leu209, Lys210, and Val211 in the fifth.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Residues involved in the five hot spots described by Ngan et al. (a) Residues belonging to the first hot spot are colored in light green. (b) Residues belonging to the second hot spot are colored in cyan. (c) Residues corresponding to the third hot spot are colored in faded red. (d) Residues corresponding to the fourth hot spot are colored in faded orange. (e) Residues corresponding to the fifth hot spot are colored in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most of the cocrystallized ligands interact with PXR through the first hotspot, i.e., the hydrophobic cage. Depending on their size and shape, the ligands then extend into two, three, or four additional hot spot regions. Trp299 and Tyr306 are located on the five-stranded antiparallel β sheet involved in the homodimerization interface. The dimerization is essential for PXR activation,<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> but the dimerization interface is located more than 30 Å away from the coactivator binding site at the AF-2 helix surface. The ligand binding event could affect the correlated motion of domains it connects, spanning from the first hotspot, the hydrophobic cage, to the third one, the hydrophobic side located at the back of the AF-2 helix, and forming potentially additional interactions with the other hot spots.</div><div class="NLM_p">A variety of ligands have been cocrystallized with the LBD of the human PXR. Among them, the PXR cocrystal structure with the macrolide antibiotic rifampicin (<b>1</b>),<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX">1SKX</a>), an established PXR agonist and one of the largest known ligands of the receptor, shows structural disorder in PXR and indicates the key role structural flexibility plays in PXR’s promiscuity and suggests that certain regions of the pocket may not require a structure for the receptor to be activated. Rifampicin (<b>1</b>) interacts with 18 side chains of the LBD and forms four hydrogen bonds (Ser247, His407, and Gln285). Three disordered regions (178–209, 229–235, 310–317) in the structure cluster together at the bottom of the LBD to create a flexible floor which is structurally unique to the PXR ligand-binding pocket and seems to be critical to its promiscuous binding and response to xenobiotics.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of the hPXR-LBD in complex with rifampicin (<b>1</b>) (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX">1SKX</a>) and chemical structure of rifampicin (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure of PXR with PNU-142721 (<b>65</b>), an HIV reverse transcriptase inhibitor, represents a typical binding mode for a druglike molecule and is shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. The aza-benzofuran forms key interactions with the hydrophobic cage, namely, a π–π interaction with Phe288 and edge-to-face interactions with Trp299 and Tyr306. The aminopyrimidine forms van der Waals interactions with residues from various regions, including the polar rim (blue) and hydrophobic channel (magenta) but also reaching out to the hydrophobic side (orange residues). In addition, Gln285 on the polar rim (blue residues) forms a hydrogen bond with the N-atom of the aza-benzofuran (not shown). Interestingly, a metabolite of PNU-141721 (<b>65</b>), whereby the Cl-atom has been replaced by −SMe, was found to be a more potent activator of PXR. The increased activity was rationalized to be due to increased hydrophobic contacts between the thiomethyl group and PXR, with the side chains of Met425 and Phe429 on the hydrophobic side (orange residues). The authors utilized the structural information to speculate on molecular modifications that could be implemented to reduce PXR activity. Thus, as the Cl to SMe change had been found to increase activity, this position could also be used to reduce activity, for example, by deletion of the Cl-atom or possibly even by incorporation of polarity. However, this region was also known to be an important pharmacophoric element for HIV reverse-transcriptase activity. It was also known that there was more tolerance of changes to the aza-benzofuran moiety in terms of HIV activity, thus the authors speculated that substitution of the 2-position of the aza-benzofuran could be investigated as this would be anticipated to clash with Trp299 and destabilize the interaction with the tight hydrophobic cage.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of the hPXR-LBD in complex with the PNU-142721 (<b>65</b>) (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R8D">3R8D</a>) and chemical structure of PNU-142721 (<b>65</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example of the promiscuity of PXR is demonstrated by the PXR cocrystal structure with two ligands bound simultaneously, the pesticide trans-nonachlor (TNC, <b>68</b>), and the synthetic estrogen 17α-ethinylestradiol (<b>42</b>), the active component of contraceptive pills<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G">4X1G</a>; <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The two ligands show cooperative binding and lead to synergistic activation. 17α-Ethinylestradiol (<b>42</b>) is engaged in several hydrogen bonds and binds in a defined location. TNC (<b>68</b>) has no polar groups and forms nonpolar interactions with 10 residues (including Phe281, Phe288, Trp299, Tyr306, Met323) and exhibits poorly defined electron density likely reflecting different positions and orientations in the pocket. Individually 17α-ethinylestradiol (<b>42</b>) and TNC (<b>68</b>) are too small to make the necessary interactions to stabilize the active conformation of PXR but together they fill a larger part of the ligand binding site similarly to full PXR agonists like rifampicin (<b>1</b>) and SR12813 (<b>62</b>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of the hPXR-LBD in complex with the synthetic estrogen 17α-ethinylestradiol (<b>42</b>) and the pesticide trans-nonachlor (TNC, <b>68</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G">4X1G</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The promiscuity of PXR is also demonstrated by the different cocrystal structures with the cholesterol-lowering drug SR12813<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> (<b>62</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HVL">3HVL</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH">1ILH</a>), which reveals five distinct ligand orientations, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. Each ligand orientation forms distinct interactions with residues in the ligand-binding cavity, enabled by the low number of polar residues distributed throughout the hydrophobic pocket which allows ligands to bind in different modes.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Five binding modes observed in the PXR-LBD for SR12813 (<b>62</b>) (in gray): (a–c) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH">1ILH</a> crystal structure, and three alternate binding modes were observed; (d) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a> crystal structure; and (e) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a> crystal structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, advanced molecular dynamics (MD) simulations were run to explore the motion of PXR during the ligand binding process,<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> trying to rationalize the different binding modes observed with SR12813 (<b>62</b>) and to better understand the conformational rearrangement of the LBD upon ligand entrance.</div><div class="NLM_p">Several runs of steered molecular dynamics (SMD) were run on the PXR ligand binding domain starting from each binding pose. From this analysis, it appeared that the binding mode observed in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a> is the most stable among the available experimental geometries. This is not surprising: in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a> crystal structure, the presence of a partner proteins SRC-1 and RXR contribute to stabilize a specific ligand geometry and is probably representative of a more relevant environment for PXR activation. On the other hand, geometries observed in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH">1ILH</a> crystal structure are unstable: rapid drift and internal ligand reorientations occur during the simulation. Prediction of the binding path using MD binding methods was also performed to identify entry or exit pathways on the surface of PXR, as the LBD cavity is buried and does not present any channel for solvent access. By analyzing water entrance in an apo structure, two potential entrance channels were identified: the first one was formed between α2 and α3 and the second one between α2 and α6. The entry of SR12813 (<b>62</b>) starting from both potential channels was then simulated: the ligand seems to favor the second channel, i.e., between α2 and α6. During the simulation of the path through the second entrance, the authors observed that the ligand causes a shift of the α6 helix, producing the disruption of a salt-bridge between the Glu321 and Arg410 residues, which acts as a gate for SR12813 (<b>62</b>). Mutation of these residues alters the basal activity of PXR, highlighting their relevance in the binding process.</div><div class="NLM_p">Binding of an agonist to the cavity leads to exposure of the hydrophobic side of the C-terminal αAF helix representing the AF-2 domain which facilitates coactivator binding.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> On the contrary, binding of antagonists can stabilize the AF-2 domain in an alternative orientation leading to corepressor binding and PXR inactivation.</div><div class="NLM_p">The PXR antagonists exemplified by azole derivatives such as ketoconazole are described as binders of the AF-2 (activation function 2) surface, disrupting the interaction between PXR and its coactivator SRC-1.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> In the absence of a cocrystal structure of PXR interacting with an antagonist, this assumption relies on mutagenesis data and computational modeling.</div><div class="NLM_p">A first pharmacophore model as well as docking studies were proposed in 2007 by Ekins et al.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The pharmacophore model contains two hydrogen bond acceptors, one aromatic ring and one hydrophobic feature. Docking studies of azole compounds in the PXR crystal structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NLR">1NLR</a> indeed suggests a distinct binding site from the activators, at the AF-2 surface, confirmed by mutagenesis data.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Key interacting residues are predominantly hydrophobic or charged, such as Lys252, Ile255, Lys259, Pro423, Leu424, Glu427, and Leu428 (represented in red in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) on one side of the hydrophobic groove and Phe264, Ile269, Glu270, Gln272, Ile273, Ser274, and Leu276 (represented in yellow in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) on the other site of the binding pocket. At the center of the binding pocket, Lys277 (represented in purple in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) seems to be a key residue for the recognition of azoles by the binding groove of the PXR AF-2 domain. These computational approaches have been used to perform virtual screens of commercial databases followed by <i>in vitro</i> testing, leading to the identification of new PXR antagonists.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Putative distinct binding site for antagonists (molecular surface in cyan). The AF-2 region is represented in red and the SRC-1 coactivator in dark blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, it has been shown that very close analogues can have opposite functional consequences as exemplified by compounds SJB7 and SPA70 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) that are, respectively, PXR agonist and antagonist.<a onclick="showRef(event, 'ref95 ref176'); return false;" href="javascript:void(0);" class="ref ref95 ref176">(95,176)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of the closely related agonist <b>70</b> (SJB7) and antagonist <b>79</b> (SPA70).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this case, both compounds seem to bind in the regular agonist binding pocket, interacting with the hydrophobic cage residues Phe288, Trp299, and Tyr306, but it is unclear why SPA70 (<b>79</b>) behaves as an antagonist. Mutagenesis studies coupled with MD simulations suggested that, in the wild type PXR, agonists stabilize the AF-2 helix in an “inward” position while the binding of antagonist SPA70 (<b>79</b>) induces a displacement of this helix into an “outward” position. When Trp299 is mutated to Ala, SPA70 (<b>79</b>) behaves as an agonist: it slides deeper in the space induced by the mutation, further away from the AF-2 domain. This behavior prevents the displacement of the AF-2 helix which remains in an “inward” position. A model of the chemical PXR modulation was proposed to explain the agonist or antagonist behavior: when the AF-2 helix is in an “inward” position, the interaction with the coactivator SRC-1 is favored. However, when the AF-2 helix is in an “outward” position, the binding of the corepressor is favored, triggering the antagonist function. A recent review has presented the current knowledge in the field of PXR antagonists,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> explaining in detail the role of the AF-2 helix orientation in the nuclear receptor’s agonist or antagonist function and the subsequent strategies that can be adopted to design PXR antagonists.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  Structure-Based Approaches to Dial Out Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent years, several companies (AZ, Bayer, BMS, GSK, Sanofi, and Xenon) have published their efforts to use structural biology to reduce PXR activation. This work highlights the impact of structural biology and how it is being utilized in contemporary drug discovery to reduce unwanted activity, rather than to optimize primary activity. As can be seen from this section and highlighted by the range of different primary pharmacological targets (covering GPCRs/7TM receptors, voltage-gated ion channels, ligand-gated ion channels, and nuclear receptors, i.e., PXR/LXRβ, CCR1, S1P<sub>1</sub>, mGluR2, RORγ, P2X4, Na<sub>V</sub>1.6, HIV1 integrase, and thrombin), this approach is broadly applicable and can serve across many therapeutic projects. The majority of these projects (CCR1, S1P<sub>1</sub>, mGluR2, Na<sub>V</sub>1.6 and P2X4) did not have crystal structures available of the primary pharmacological targets, whereas structures were used simultaneously for RORγ, HIV integrase, and thrombin. However structural information is available for some, e.g., S1P<sub>1</sub>, albeit not with ligands from the series discussed herein. Despite this, the use of structural biology for PXR as an antitarget has proven very useful and effective in providing insights in to reducing PXR activity. Only the RORγ, HIV integrase, and thrombin projects have structural information on both the primary pharmacological target and PXR, which in all cases, proved crucial to design in selectivity, especially RORγ as both are highly related nuclear hormone receptors. The following section discusses the projects mentioned in turn, approximately by chronology. This means that the work of companies that have utilized PXR structural biology systematically across a range of drug targets, i.e., BMS, is not grouped, but this order also provides some consistency with the empirical SAR section (<i>vide infra</i>). Additional observations are added where appropriate, and the data set is reviewed at the end of the section, drawing out similarities and differences in the manner in which ligands interact with PXR.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  PXR and LXR, GSK, 2007. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a></h3><div class="NLM_p">The first publication describing the use of structural biology to modulate the SAR of PXR appeared in 2007 when a group at GSK disclosed the structure of the LXR agonist T0901317 (<b>63</b>) in complex with PXR and utilized this information to compare the interactions with LXRβ and to try to design selective PXR antagonists.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">The PXR structure revealed T0901317 (<b>63</b>) makes several interactions with PXR, particularly in the hydrophobic cage (green residues) which is occupied by the phenyl sulfone, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. The phenyl ring forms a π–π interaction with Phe288 in addition to edge-to-face interactions with Trp299 and Tyr306. One O-atom of the sulfonamide forms a hydrogen bond with the side chain amide of Gln285 in the polar rim (blue residues) while the other O-atom appears to interact weakly (suboptimal angle) with His327 in the hydrophobic cage (green residues). In addition, the alcohol of the hexafluoro-isopropyl alcohol (HFIPA) forms a hydrogen bond with the imidazole of His407, also on the polar rim while the trifluoromethyl groups form numerous van der Waals contacts with the hydrophobic side (orange residues), including Met425, which was postulated to hold the receptor in the active conformation. The authors noted that T0901317 (<b>63</b>) occupied only 442 Å<sup>3</sup> of the large binding pocket, totaling 1334 Å<sup>3</sup> and that the ligand contacted a total of 15 residues in comparison to the 18 for the much larger rifampicin. The group also compared the structure of PXR to that of the ligand bound to LXRβ, which highlighted the smaller binding pocket (650 Å<sup>3</sup>) and several differences that could be exploited to design selectivity for one or other receptors. However, it was noted that the receptors shared one polar and eight hydrophobic interactions. An important difference is that Gln285, which hydrogen bonds with the sulfonamide O-atom in PXR is replaced by Leu313 in LXRβ thereby removing a polar interaction. The H-bond between the sulfonamide and His327 in PXR is fulfilled by Thr316 in LXRβ, although this residue is shifted in terms of location. The interaction between the HFIPA and His407 in PXR is made by His435 in LXRβ. To see if selective PXR antagonists could be identified from this series, the group prepared some novel analogues where the HFIPA was modified as this group is adjacent to the αAF (activation function) in PXR and antagonists of other nuclear receptors act by sterically disrupting the αAF position.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (Left) T0901317 (<b>63</b>) bound to PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a>). (Right) T0901317 bound to LXRβ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQC">1PQC</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some key aspects of the SAR are summarized in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>. The importance of the van der Waals interactions made by the trifluoromethyl groups is demonstrated by <b>80</b> (deletion of a CF<sub>3</sub> group) and further highlighted by the simple replacement of one of the CF<sub>3</sub> groups by a methyl group, as seen in <b>81</b>. Similar activity was noted for larger alkyl groups, whereas a larger fluoroalkyl group (−CF<sub>2</sub>CF<sub>2</sub>CF<sub>3</sub>) gave similar results to T0901317 (<b>63</b>), data not shown. Despite the low activity observed with alkyl groups, the cyclohexyl ring was found to be an effective replacement for a CF<sub>3</sub> group, <b>82</b>, resulting in equipotent activity to T0901317 (<b>63</b>) and giving complete selectivity over LXRβ due to the more restricted size of the LXR pocket in this region. A phenyl ring, <b>83</b>, was also found to give similar data to the cyclohexyl derivative and again provided selectivity over LXRβ. More surprisingly, it was found that PXR could accommodate the phenyl acetylene group seen in <b>84</b> and that this large group still resulted in agonism of PXR.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. PXR SAR versus LXRβ SAR for analogues of T0901317 (<b>63</b>), described by GSK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Thus, the SAR described show that the design of PXR antagonists is challenging, even with structural information. However, the SAR also demonstrated that some simple changes could modulate PXR activity and that it was also possible to obtain PXR agonists that were selective over LXRβ, but that obtaining LXRβ agonists with selectivity over PXR was challenging as none of the ligands showed preferential activity for LXRβ.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  RORγ Inverse Agonists, Genentech and Argenta, 2013. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a></h3><div class="NLM_p">Another example of using T0901317 as a starting point was disclosed by Genentech and Argenta.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Although the group did not solve a PXR crystal structure, they did use the structure of T0901317 (<b>63</b>) with PXR, published by GSK, to try to improve the selectivity of T0901317 (<b>63</b>) for RORγ over PXR. The group also crystallized T0901317 (<b>63</b>) with RORγ, where it was found to have a folded conformation with the phenylsulfonamide group showing a parallel-displaced intramolecular π–π stacking interaction with the aniline phenyl ring. Utilizing the published structure of T0901317 (<b>63</b>) with PXR, it was observed that the ligand did not display the same conformation or intramolecular π–π stacking interaction, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. The interactions with PXR have been discussed above.</div><div class="NLM_p">The group used a cellular (HEK293) firefly luciferase assay to assess PXR activation. In this assay, T0901317 (<b>63</b>) was a weak agonist, whereas in the GSK assay, <i>vide supra</i>, <a class="ref internalNav" href="#sec5_1" aria-label="section 5.1">section 5.1</a>, it was almost a full agonist, as it was in the assays conducted by BMS, <i>vide infra</i>, <a class="ref internalNav" href="#sec3_6" aria-label="section 3.6">section 3.6</a>.</div><div class="NLM_p">While the group at GSK had focused their SAR on the HFIPA moiety, the groups from Genentech and Argenta focused on the trifluoroethyl group and the phenyl sulfonamide. Thus, switching the N-trifluoroethyl group of <b>63</b> to an ethyl group resulted in <b>85</b>, which showed a marked reduction in RORγ activity but no impact on PXR activation, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. More impact was observed by adding substituents to the <i>para</i>-position of the phenyl sulfonamide. Addition of a fluorine atom, to give <b>86</b>, maintained RORγ activity but reduced PXR activation by more than 5-fold, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. A 16-fold reduction in PXR activation was observed with the <i>para</i>-cyano analogue <b>87</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. Both <b>86</b> and <b>87</b> were designed to increase RORγ activity by increasing the π–π interaction between the ligands and Phe367 in RORγ, an interaction that is not observed in PXR or LXR. It is possible that the addition of electronegative substituents in the <i>para</i>-position of the phenylsulfonamide destabilize the interaction with Tyr306 or even Met246, although this does not appear to have been the intent. Interestingly, the crystal structure suggests that <i>ortho</i>-substitution of this ring may disrupt the edge-to-face interaction with Trp299 or replacement of the O-atom of the sulfonamide by an N-substituent (to give a sulfonimidamide) may disrupt the interaction with Gln285. These insights highlight the power of the use of structure-based design to decrease PXR activation.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PXR SAR for a series of T0901317 (<b>63</b>) analogues as RORγ inverse agonists from Genentech and Argenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.3.  CCR1 Antagonists, BMS, 2013–2014. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9">4NY9</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT">4SOT</a></h3><div class="NLM_p">The BMS group have disclosed examples of several projects where PXR activation was an issue (<i>vide infra</i>) and were the first group to publish in the medicinal chemistry literature attempts to reduce PXR activation by solving a structure with PXR specifically for this purpose. The first disclosure of the use of PXR structural biology to dial out PXR activity was for a series of CCR1 antagonists, typified by <b>88</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> This compound was found to have good activity for CCR1 but potent activity at PXR, in comparison to that desired, PXR EC<sub>50</sub> > 50 μM. Simple addition of polar groups in the <i>meta</i>-position of the right-hand phenyl ring resulted in a drastic drop in PXR activity, exemplified by <b>89</b> and <b>90</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>. Assuming no change in binding mode, the addition of these functional groups would not be accommodated sterically (or electronically) by hydrophobic cage, which is where this region of the molecule would be expected to bind. Despite this, the compounds were ultimately found to be deficient in their pharmacokinetic profiles which prevented further advancement and thus necessitated additional work to circumvent PXR activity.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. CCR1 antagonists from BMS showing the initial compound, <b>88</b>, and two analogues with polar groups, <b>89</b> and <b>90</b>, on the right-hand side phenyl ring, which reduces PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacing the right-hand phenyl ring in the series by a cyclopentyl ring to give <b>91</b> was found to be well tolerated but did not improve PXR activity, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>. However, this compound was of interest as it had a long residence time on the receptor, <i>t</i><sub>1/2</sub> > 200 min, and presented the opportunity to explore the effect of substitution of the cyclopentyl ring against PXR activity, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>. It was hypothesized that adding a polar group on the cyclopentyl moiety may reduce PXR in an analogous way to that seen with derivatives <b>89</b> and <b>90</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>. The addition of a primary amine and a hydroxyl group was systematically investigated, but hydroxylation at the 3-position proved most interesting, <b>92</b>–<b>95</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cyclopentyl amide CCR1 antagonist <b>91</b>, from BMS, with the four hydroxylated isomers <b>92</b>–<b>95</b>, showing differing effects on PXR activity. NB for <b>92</b> two sets of data are reported in the same paper, i.e., CCR1 IC<sub>50</sub> 1.7 nM and Chemotaxis IC<sub>50</sub> 4.6 nM also listed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>cis</i>-isomers <b>94</b> and <b>95</b> proved to have lower <i>in vitro</i> metabolic stability and showed some degree of PXR activity and were therefore not investigated further. Both <i>trans</i>-isomers, <b>92</b> and <b>93</b>, displayed good overall profiles, but <b>92</b> (BMS-457) was profiled further due to its more potent on-target activity. This compound was assessed as a potential preclinical candidate in all assays including <i>in vitro</i> and <i>in vivo</i> metabolic profiling across species. The compound also showed minimal hERG activity <i>in vitro</i> (14% inhibition at 10 μM, IC<sub>50</sub> > 80 μM; 3% inhibition at 10 μM in a patch clamp assay); however, in advanced safety profiling in rabbits and dogs, it caused significant concentration related QTc prolongation and thus the development of the compound was terminated.</div><div class="NLM_p">Intrigued by the disparity in the PXR activity of the isomers <b>92</b> and <b>95</b> (EC<sub>20</sub> 41 and 5.3 μM, respectively) and to better understand the subtle differences in PXR activity seen with other analogues, crystal structures were determined with PXR for two analogues, <b>66</b> and <b>67</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures and profiles of CCR1 antagonists <b>66</b> and <b>67</b> from BMS that were successfully crystallized with PXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Overall, both compounds were found to bind to PXR in a similar manner; however, several interesting aspects were uncovered. First, for <b>66</b>, structure with PXR shown in <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, the compound does not form a π–π interaction with Trp299 in the hydrophobic cage (green residues) unlike many other compounds and appears to form little positive interactions with this region of PXR. Initially the BMS group were surprised that despite containing a polar hydroxyl group on the right-hand side, <b>66</b> still showed potent PXR activity as it had been anticipated that the hydroxyl group would project into a hydrophobic region in PXR. However, the crystal structure with PXR revealed that the O-atom of the isoproproxy group forms an intramolecular H-bond with the amide NH, thereby reducing the molecular volume, masking polarity and projecting the methyl groups into the hydrophobic cage region in PXR. This structure again serves to highlight the need to consider the 3D conformations of compounds, in this case the propensity to form an intramolecular H-bond is enhanced by the <i>gem</i>-dimethyl substitution causing a Thorpe–Ingold effect.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The O-atom of the central piperidinyl amide accepts a hydrogen bond from Gln285 and a water molecule that in turn interacts with the side chain of Ser247; both residues are part of the polar rim (blue residues). The hydroxyl in the 4-position of the piperidine forms a weak hydrogen bond with the imidazole of His407, also in the polar rim. The <i>para</i>-chlorophenyl ring binds in a lipophilic environment and forms several van der Waals contacts with lipophilic side chains, <i>e.g</i>., Met425 and Ile414 on the hydrophobic side (orange residues) and Ala244, Met243, and Leu240 in the polar channel (magenta residues).</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Crystal structure of <b>66</b> in complex with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9">4NY9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, for <b>67</b>, two binding modes were observed (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a>), highlighting the promiscuity of PXR and the challenges in docking. The first pose, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, is very similar to that observed with <b>66</b>, whereby the O-atom of the central piperidinyl amide accepts a hydrogen bond from Gln285 and a water molecule that in turn interacts with the side chain of Ser247, both of which are on the polar rim (blue residues). The hydroxyl in the 4-position of the piperidine forms a hydrogen bond with the imidazole of His407, again on the polar rim. The <i>para</i>-chlorophenyl ring binds in a lipophilic environment and forms several van der Waals contacts with lipophilic side chains as outlined above.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. First binding mode of <b>67</b> showing overall similarity to that of <b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second binding mode (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT">4SOT</a>)<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> makes the same contacts again, with the only difference being the orientation of the cyclopropylmethylene group, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Second binding mode of <b>67</b> showing the different conformation of the cyclopropylmethyl group relative to the pose shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S0T">4S0T</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent docking studies with <b>92</b> and <b>95</b> to rationalize the differences in PXR activity suggested that the <i>cis</i>-isomer (<b>95</b>) forms an intramolecular H-bond in a similar manner to <b>66</b>, which is permitted by the <i>cis</i>-configuration. The <i>trans</i>-isomer <b>92</b> is unable to adopt this conformation, which results in the hydroxyl group being unfavorably placed in a very lipophilic environment.</div><div class="NLM_p">A follow up publication described the further utilization of PXR structural biology to optimize this series, utilizing BMS457 (<b>92</b>) as the starting point.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> In addition to the CV liabilities identified with <b>92</b>, it was also found that the hydroxycylopentane underwent oxidative metabolism <i>in vivo</i> in the rat to form the corresponding ketone, which carried more of a PXR liability (EC<sub>50</sub> 6 μM), although it is unknown if this compound was the cause of the <i>in vivo</i> CV effects. Interestingly, this ketone had not initially been observed <i>in vitro</i> in human, rat, or mouse liver microsomes. To address these shortcomings, it was decided to replace the amide with a urea, which it was hypothesized would restrict the conformational freedom and thus help to alleviate the PXR activity. To this end, a series of matched pairs of amides and ureas were prepared and characterized, data for which are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. As can be seen, switching from the unsubstituted cyclopentyl amide (<b>91</b>) to the corresponding urea (<b>96</b>) retained CCR1 activity but dramatically reduced PXR activity. Next, the hydroxylated urea analogues of <b>92</b>–<b>95</b>, were investigated, <b>97</b>–<b>100</b>, which are compared head-to-head in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Comparison of Cyclopentyl Amides (<b>91</b>–<b>95</b>) and Cyclopentyl Ureas (<b>96</b>–<b>100</b>) from BMS CCR1 Antagonist Project<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0126.gif" alt="" id="GRAPHIC-d7e1794-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0127.gif" alt="" id="gr112" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Some of the data in this manuscript differ very slightly from the previous report.</p></div></div><div></div></div><div class="NLM_p">In general, the ureas retained equivalent CCR1 potency but had weaker PXR activity than the corresponding amides, apart from <b>98</b> which had more potent PXR activity than the amide <b>93</b>. From this series, no analogues had the optimal balance of properties, for example, <b>97</b> displayed suboptimal potency in the chemotaxis assay, <b>98</b> and <b>100</b> retained PXR activity, while <b>99</b> had insufficient metabolic stability.</div><div class="NLM_p">Continuing the effort to add polar groups in this region of the molecule to diminish PXR binding, the urea analogue of <b>66</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) was made, namely, <b>101</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>. This compound retained CCR1 activity and showed minimal PXR activity and good metabolic stability.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Profile of optimized CCR1 antagonist and development candidate BMS-817399 (<b>101</b>) from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The crystal structure of <b>66</b> bound to PXR, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, was used to rationalize the decreased PXR activity of <b>101</b>. The urea derivative <b>101</b> can adopt several conformations and could also form a more compact structure, like <b>66</b>, with an intramolecular H-bond between the urea NH and the alcohol, although in this instance it would be the outer NH of the urea and not the inner NH that corresponds to the amide NH in <b>66</b>. Docking this conformation, and assuming the rest of the molecule forms the same interactions with PXR as <b>66</b>, results in predicted steric clashes with PXR, namely, between the methyl groups of the isopropanol moiety and Phe288. Similarly, all the lowest energy conformations of <i>cis</i> and <i>trans</i>-ureas were predicted to clash sterically with PXR. Thus, in summary, it appears that PXR activity is reduced by homologation, whereby the rigidity of the urea plays a key role in the result, i.e., simple homologation with a more flexible moiety may have allowed a more compact conformation which may still have been accommodated in the large binding pocket of PXR.</div><div class="NLM_p last">BMS-817399 (<b>101</b>) progressed through preclinical development and was ultimately progressed to PhII testing in rheumatoid arthritis patients, demonstrating the effective utility of PXR structural biology to design out PXR activity. Unfortunately, no data has been published to demonstrate that BMS-817399 did not induce CYP3A4 levels in humans to fully validate the approach.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4.  S1P<sub>1</sub> Antagonists, AZ, 2015. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a></h3><div class="NLM_p">In 2015, researchers at AstraZeneca disclosed their use of PXR structural biology to dial out PXR activity from a series of sphingosine 1-phosphate (S1P<sub>1</sub>) receptor antagonists.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> The group had identified potent compounds, which appeared to be noncompetitive antagonists, typified by <b>69</b> and <b>102</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>. Despite its potent <i>in vitro</i> activity, <b>69</b> was found to have low bioavailability in the rat (<5%). Furthermore <b>69</b> showed high <i>in vitro</i> metabolism in HLM, CL<sub>int</sub> > 100 μL/min/mg protein. Metabolite identification studies revealed that a major route of metabolism was de-ethylation of the benzimidazole. Replacement of the Cl-atom by an F-atom to give <b>102</b> resulted in a dramatic improvement in metabolic stability (HLM, CL<sub>int</sub> 26 μL/min/mg protein) with minimal impact on potency. As further SAR had not yielded compounds with vastly improved overall profiles, <b>69</b> and <b>102</b> were profiled further and <b>69</b> was found to have an acceptable <i>in vivo</i> metabolic profile in the rat, CL 33 mL/min/kg and Fpo 43%.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of two tool S1P<sub>1</sub> antagonists, <b>69</b> and <b>102</b>, from AstraZeneca that <i>in vivo</i> profiling revealed CYP3A4 induction, which was ultimately discovered to be caused by PXR induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was thus decided to advance <b>69</b> and <b>102</b> to <i>in vivo</i> efficacy studies to assess if S1P<sub>1</sub> receptor antagonism would prove efficacious and to understand the PK–PD relationship. Both <b>69</b> and <b>102</b> were dosed orally to mice at 50 or 100 mg/kg for 5 days. While there was no significant increase in exposure at the higher dose, implicating insufficient solubility and/or permeability, it was observed that the plasma exposure of both compounds was lower on day 5 than day 1: the 50 mg/kg dose of <b>69</b> gave plasma exposure of approximately 6700 ng/mL 1 h postdose on day 1 and approximately 1800 ng/mL 1 h postdose on day 5. Similarly, the 50 mg/kg dose of <b>102</b> gave plasma exposure of approximately 9000 ng/mL 1 h postdose on day 1 and approximately 1000 ng/mL 1 h postdose on day 5. Thus, this autoinduction in the mouse implies the potential for CYP450 induction.</div><div class="NLM_p">Follow up experiments with <b>69</b> in primary human hepatocytes with 48 h incubation at concentrations of 0.2, 2, and 20 μM showed increased metabolism of a CYP3A4 substrate (testosterone metabolism to 6-β-hydroxytestosterone) at the 2 μM and 20 μM concentrations, i.e., approximately 150% and 180% increases, respectively, where the percentage is relative to that of the reference standard rifampicin. This data also supports an induction potential, via PXR activation, in the human. Profiling further compounds revealed this to be a general effect within the series. Due to the risk of CYP450 induction/autoinduction, it was decided to set up a higher throughput human assay. However, the hepatocyte assay is time-consuming and prone to variation (due to differences in donor samples/tissue), and it was deemed unsuitable for routine screening. Therefore, a cell-based reporter gene PXR assay was implemented with compounds tested at a single concentration of 10 μM and activity compared to that of the positive control rifampicin at 10 μM. The strategy to reduce PXR activity was to reduce lipophilicity, as assessed by measured log <i>D</i> at pH 7.4. A reduction in lipophilicity was targeted by two means: introduction of polar groups and reducing lipophilicity by replacement of C-atoms by heteroatoms or replacement of groups by less lipophilic equivalents. A trend was observed which supported the strategy, i.e., 75% of compounds with log <i>D</i> ≤ 2 showed ≤ 30% PXR activation at 10 μM, whereas 70% of compounds with log <i>D</i> > 2 showed > 30% activation of PXR at 10 μM. Ultimately, a combination of several approaches yielded the most promising compounds, whereby an aza-benzimidazole replaced the benzimidazole, the phenyl moiety of the sulfonamide was replaced by a pyridine and the halogen (Cl or F) was replaced by a nitrile group, thus yielding <b>103</b> and <b>104</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>, whereby a c-Pr group has also replaced the CF<sub>3</sub> group in <b>104</b>.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Optimized compounds from AZ S1P<sub>1</sub> antagonist series (<b>103</b> and <b>104</b>) with significantly reduced PXR induction potential.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, the attempt to reduce lipophilicity resulted in the incorporation of a 2-cyanopyridine, in both <b>103</b> and <b>104</b>. While this transformation helped to address the PXR activation to some degree (the corresponding phenyl analogues were equipotent S1P<sub>1</sub> antagonists with similar PXR activation, 32% and 27% activation for the matched pairs of <b>103</b> and <b>104</b> respectively, not shown), the 2-cyanopyridine may be considered a liability as the nitrile is more electrophilic when on a pyridine ring than a phenyl ring and may therefore undergo reaction with cysteines in proteins<a onclick="showRef(event, 'ref180 ref181 ref182 ref183 ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref180 ref181 ref182 ref183 ref184 ref185">(180−185)</a> and in some instances may release cyanide via metabolism.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> The electrophilicity and hence the propensity of the nitrile moiety to undergo nucleophilic attack by thiols is further enhanced by the sulfonamide in the <i>para</i>-position.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> However, it is unknown if these were issues for <b>103</b> and <b>104</b>.</div><div class="NLM_p">Subsequent to understanding the SAR, a crystal structure of PXR in complex with <b>69</b> was generated, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>. Inspection of the PXR structure with <b>69</b> reveals that the molecule adopts a folded or U-shaped conformation, favored by an intramolecular π-stacking interaction between the chloro-phenyl ring and the benzimidazole. The ligand forms multiple contacts with PXR including a key π-stacking interaction between Trp299 in the hydrophobic cage (green residues) and the <i>p</i>-chloro-phenyl ring of the sulfonamide. This ring also forms an edge-to-face interaction with Phe288 (also part of the hydrophobic cage). The N-3 atom of the benzimidazole accepts a hydrogen bond from the side chain of Gln285, on the polar rim (blue residues), while the NH of the sulfonamide donates a hydrogen bond to the oxygen of the amide side chain of Gln285. The binding of <b>69</b> to PXR is unusual in that it does not form hydrogen bonds with either His407 or Ser247 (both on the polar rim, blue residues), which are common features for many ligands. Furthermore, due to the folded conformation of <b>69</b>, it also does not interact with the other lipophilic regions on the hydrophobic side (orange residues), defined by Phe420, Ile414, and Met425, that is important for many ligands.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structure of PXR in complex with <b>69</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This structural insight highlights that while the strategy to reduce lipophilicity was successful, it primarily relied on the addition of the nitrile group. The crystal structure suggests this beneficial effect may be due to detrimental molecular interactions with PXR, whereby the Cl to CN switch may cause a steric clash with Tyr306, which forms part of the hydrophobic cage (green residues) around the ligand, in close vicinity to a key π-stacking interaction with Trp299.</div><div class="NLM_p">Compounds <b>103</b> and <b>104</b> were further profiled to assess their developability and to assess their potential for autoinduction in preclinical species <i>in vivo</i>. To this end, both compounds were dosed to mice (20 mg/kg) and rats (25 mg/kg) where they showed no decrease in plasma exposure 1 h after administration on day 5 versus the same time point on day 1. However, a 50 mg/kg dose of both compounds in mice did result in decreases in exposure, which appeared slightly more pronounced for <b>103</b>.</div><div class="NLM_p last">In summary, solving a crystal structure of compounds from the series with PXR facilitated an understanding of how to reduce PXR activity and improved analogues were identified. However, the <i>in vivo</i> assessment of the compounds highlighted the likelihood of CYP3A4 induction at higher doses/concentrations and implies the PXR activity goal may not have been high enough. This also highlights the need to consider the PXR activation potential in line with the achieved <i>in vivo</i> concentrations.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5.  mGluR2 PAMs, Sanofi, 2018. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP">6DUP</a></h3><div class="NLM_p">In search of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor mGluR2, it was discovered that compounds such as <b>105</b> (which shows some structural similarity to Pretomanib (<b>41</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) induced the expression of CYP3A4, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Screening was performed in cultured primary human hepatocytes at 1, 3, 10 and 30 μM, 48 h incubation, after which CYP3A4 was measured; the data were expressed as a percentage induction of rifampicin at 10 μM, whereby 10 μM rifampicin = 100% induction. Additionally, in a Linklight PXR activation assay in HepG2 cells at 10 μM <b>105</b> was found to elicit 62% activation, again relative to rifampicin at 10 μM.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. mGluR2 PAMs (<b>105</b> and <b>72</b>) from Sanofi which identified PXR induction as an issue for the series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on these data, the close analogue <b>72</b> was crystallized with PXR to gain insight into potential areas to mitigate PXR interactions. The compound was found to bind in a folded conformation with the pyrimidone moiety forming an intramolecular π-stacking interaction with the inner phenyl ring of the biphenyl moiety, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>, and make mainly hydrophobic/aromatic interactions with PXR, such as an edge-to-face interaction between the pyrimidone moiety and Tyr306 (hydrophobic cage, green residues) and a π–π interaction with Phe288, also in the hydrophobic cage (green residues). The ligand also makes extensive van der Waals contacts between the trifluoromethyl biphenyl moiety and Met243 and Met246 on the polar channel (magenta), Phe251 and Phe281 on the polar rim (blue), and Leu411, Phe420, Phe429, and Met425 on the hydrophobic side (orange). The trifluoromethyl-phenyl ring also forms an edge-to-face interaction with His407 (polar rim, blue residues). In addition, the O-atom of the oxazoline moiety accepts a hydrogen bond from the side chain primary amide of Gln285 on the polar rim (blue residues).</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structure of PXR in complex with <b>72</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP">6DUP</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on this information, two strategies were identified to try to decrease the PXR activity, outlined in <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Regions highlighted to target and associated molecular modifications based on the crystal structure of <b>72</b> with PXR. N/A = not available.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first of these was to replace the trifluoromethylphenyl moiety in <b>72</b> or the dimethylphenyl moiety in <b>105</b> by alkyl groups to decrease some of the van der Waals contacts made by this group with the polar rim, polar channel, and hydrophobic side, resulting in compounds such as <b>106</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>. Although this modification did reduce PXR activity, it also had a detrimental effect on mGluR2 activity but still validated the approach.</div><div class="NLM_p">The second strategy was to add substituents to the pyrimidone moiety to impair the edge-to-face interaction with the phenol side chain of Tyr306 (hydrophobic cage) and cause a steric clash. To this end, both substitution vectors were explored with <b>108</b> showing a slightly stronger reduction in PXR activity than <b>107</b>, validating the approach, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>.</div><div class="NLM_p last">Interestingly, inspection of the structure also reveals that the benzylic methylene group at the 5-position of the oxazoline ring packs tightly against the indole of Trp299 (hydrophobic cage), implying that substitution of this position would incur a detrimental steric clash. Furthermore, substitution of this position would have an impact on the conformation of the molecule which could also be used to destabilize the conformation which binds to PXR, assuming the conformation is different to that bound to mGluR2. Similarly, the methylene moiety on the oxazoline ring (4-position) is also near Trp299 and substitution here would also likely cause a detrimental steric interaction. However, this avenue was not described.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.6.  RORγ Inverse Agonists, BMS, 2018–2020. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS">6BNS</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BN6">6BN6</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a></h3><div class="NLM_p">Following on from the CCR1 work, more recently the BMS group have published on a second target, namely, RORγ inverse agonists, whereby PXR structural biology was again used to separate primary activity from undesired PXR activity.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> In this instance, the primary target is a nuclear receptor and thereby presented a selectivity challenge over other closely related nuclear receptors such as PXR and LXR, which exists in two forms LXRα and LXRβ. Similar challenges have been already highlighted in <a class="ref internalNav" href="#sec3_1" aria-label="sections 3.1">sections 3.1</a> and <a class="ref internalNav" href="#sec3_2" aria-label="3.2">3.2</a>. These factors thereby make this a more challenging prospect; however, crystal structures were solved with a ligand and the primary target, RORγ, and PXR, allowing the researchers to exploit differences in the binding sites and, in this case at least, differences in the ligand conformation, when bound to each target. Furthermore, while a structure of LXR was not solved with a ligand from this series, publicly available structures enabled docking to aid the design of selectivity over this target.</div><div class="NLM_p">An HTS of the BMS collection resulted in the identification of <b>109</b> which showed moderate potency at RORγ (EC<sub>50</sub> 165 nM) but no selectivity over LXR, LXRα EC<sub>50</sub> 190 nM, LXRβ EC<sub>50</sub> 185 nM, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>. Furthermore, <b>109</b> showed potent PXR activity, EC<sub>50</sub> 20 nM, being a full agonist with 100% efficacy. It is also apparent that the structure of <b>109</b> bears considerable similarity with the known PXR ligand T0901317 (<b>63</b>), <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>, with which it shares a similar pharmacological profile.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structure and pharmacological profile of BMS RORγ inverse agonist hit <b>109</b> alongside related literature reference T0901317 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the outset of the project, structures were not available for RORγ or PXR, hence SAR was conducted empirically. Initial investigations revealed that replacement of the S-atom of the thioether by groups such as O, NH, NMe, CH<sub>2</sub>, and CMe<sub>2</sub> did not improve potency or selectivity, and all were essentially equipotent at PXR. It was next decided to investigate SAR pragmatically by probing substitution adjacent to the thioether. Adding an acetic ester had little impact, <b>110</b>, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>; however the corresponding amide (<b>111</b>) decreased PXR activity, hinting that polarity may be a driver and simultaneously diminishing LXR activity. Capitalizing on the promise of <b>111</b> resulted in the extension of the amide with further polar groups, similar to those used in the CCR1 antagonist project, <i>vide supra</i>, and resulted in the two enantiomers <b>71</b> and <b>112</b>, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>. Interestingly, while <b>71</b> showed good activity at RORγ, the enantiomer (<b>112</b>) was substantially weaker, whereas as both were essentially equipotent at PXR.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. RORγ inverse agonists from BMS with substitution α-to the thioether, <b>110</b>–<b>112</b> and <b>71</b>, showing the effect of the amide and the different effects on RORγ and PXR for the enantiomers <b>71</b> and <b>112</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At this stage, X-ray structures of <b>71</b> in complex with both RORγ and PXR were obtained, which are depicted in <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structure of RORγ inverse agonist <b>71</b> (in gray) from BMS in complex with (a) PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS">6BNS</a>) and (b) RORγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BN6">6BN6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The presence of the sulfonamide again allows the <i>p</i>-fluorophenyl ring to adopt a conformation positioning it perpendicular to the rest of the molecule and optimally orientating it to form a π–π interaction with the indole side chain of Trp299 in the hydrophobic cage (green residues) of PXR. The group α-to the thioether adopts an extended conformation, and the NH of the amide donates a H-bond to the backbone carbonyls of Leu209 (polar channel, magenta residues), while the alcohol of the hexafluoro isopropanol moiety forms a hydrogen bond with the imidazole of His407 and a water-mediated H-bond with Ser247, both on the polar rim (blue residues). The trifluoromethyl groups sit in the hydrophobic side (orange region) but also interact with Met243 and Leu240 in the polar channel (magenta). This is one of the few compounds that occupies the polar channel, with the side chain amide that is in the α-position to the sulfur atom. The fluoro-phenyl ring forms a π–π interaction with the tryptophan of Trp299 and an edge-to-face interaction with Tyr306 (both in the hydrophobic cage, green residues). One fluorine atom of a trifluoromethyl group is within the van der Waals radius of the side chain hydroxyl of Ser247 (polar rim, blue residues), implying a potential interaction.</div><div class="NLM_p">In the RORγ structure, the hexafluoro isopropanol moiety appears to interact with the side chain imidazole of His479. This interaction is not observed, or is weaker, for later ligands, <i>e.g</i>., <b>75</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>, which thereby enabled a key breakthrough. The C–S bond of the sulfonamide is rotated relative to that observed in PXR, thus positioning the <i>p</i>-fluorophenyl ring roughly on top of, but not parallel to, the thiomorpholine. The terminal isopropyl alcohol of the amide donates a hydrogen bond to the guanidine moiety of the side chain of Arg367, whereas this group does not interact with PXR and by contrast sits in a relatively hydrophobic environment. Other differences were observed around the interactions of the acetamide.</div><div class="NLM_p">Interestingly, the conformation of <b>71</b> bound to PXR positioned the acetamide group in a <i>pseudo</i>-equatorial position. The same conformation was observed in the small molecule crystal structure (CCDC 1586092) of <b>71</b>, implying the conformation bound to PXR may be the low energy one. In support of this, the acetamide also occupied the <i>pseudo</i>-equatorial position when bound to RORγ.</div><div class="NLM_p">However, differences were observed in the conformation of the phenylsulfonamide when bound to the two targets; in the RORγ structure, the sulfonamide occupies a <i>pseudo</i>-axial position whereas in the PXR structure it is <i>pseudo</i>-equatorial. Based on these observations it was decided to move the acetamide group adjacent to the sulfonamide as this was anticipated to result in a steric clash with the β1 sheet in PXR, which resulted in compound <b>113</b>, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>, which demonstrated considerably weaker PXR activity. The sulfonamide of <b>113</b> was also observed to adopt a <i>pseudo</i>-axial orientation in, i.e., favoring the conformation observed in RORγ, which played an important role in the later design, <i>vide infra</i>.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Optimized RORγ inverse agonists from BMS, <b>113</b>–<b>115</b>, that were designed based on the information gleaned from the structure of <b>71</b> with PXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As with enantiomers <b>71</b> and <b>112</b>, the regioisomer <b>113</b> showed a similar pattern whereby both enantiomers were equipotent at PXR, but one enantiomer retained activity at RORγ, while the other was almost inactive. However, in this case, the absolute stereochemistry of the active enantiomer (<b>113</b>), was undetermined. Despite the significant improvement in PXR selectivity, <i>in vitro</i> metabolic stability in human and mouse liver microsomes (HLM and MLM, respectively) was insufficient. Therefore, replacement of the S-atom in <b>113</b> by a methylene group resulted in <b>114</b>, which showed improved PXR selectivity and better stability in HLM, but further optimization was still required. Further homologation of the amide group in combination with fluorination resulted in <b>115</b>, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>, which maintained sufficient PXR selectivity while providing improved metabolic stability in HLM and MLM. Although the PXR activity had been reduced considerably through the optimization process, concerns remained that <b>115</b> was a full agonist at PXR. To ascertain how significant an issue this may be, <b>115</b> was incubated with mouse hepatocytes at 1, 3, and 10 μM, whereby it was found that CYP3a11 (the mouse equivalent of CYP3A4) was upregulated by 21-, 47-, and 40-fold, respectively. A subsequent study was conducted <i>in vivo</i> where mice were dosed with <b>115</b> at 30 and 100 mg/kg p.o. b.i.d. for 5 days and plasma concentrations were measured on days 1 and 5. In the 30 mg/kg group, exposure was 6.3-fold and 6.5-fold lower on day 5 than day 1 at 1 and 7.5 h postdose, respectively. Similarly, in the 100 mg/kg group on day 5, exposure was 4–9-fold and 40-fold lower at 1 and 7.5 h postdose. At 1 h postdose on day 1, the plasma concentration (assumed total, not free) was 3488 nM in the 30 mg/kg group and 13 895 nM in the 100 mg/kg group, i.e., at concentrations in line with those that caused significant CYP3a11 induction in mouse hepatocytes. However, it is unknown how these plasma concentrations relate to the liver concentration. In addition, CYP3a11 mRNA levels in the liver were increased by approximately 3.5-fold and 5.5-fold at the 30 and 100 mg/kg dose levels, respectively. The conclusion from these studies is that the reduced exposure is most likely due to autoinduction, i.e., the upregulation of CYP3a11, whereby the compound is also a CYP3a11 substrate which therefore results in decreased exposure. These results serve to highlight the need to consider the intrinsic efficacy at PXR in addition to the EC<sub>50</sub>. Thus, despite the excellent progress in reducing the PXR liability, compounds such as <b>115</b> were not suitable to test in chronic disease models of autoimmunity due to the decreased exposure upon repeat administration. Hence, further optimization is required.</div><div class="NLM_p">A recent paper from the same group describes the subsequent optimization of this series.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> As mentioned above, the 4-fluorophenyl sulfone moiety in compounds such as <b>115</b> adopts a pseudoaxial orientation which allows the 4-fluorophenyl ring to sit above the phenyl ring of the THIQ, thus forming a folded or U-shaped conformation. To mimic this conformation, the group designed the cyclopentyl derivative <b>75</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>. This compound was predicted to mimic the desired conformation and found to have reasonable potency at RORγ but was also a very potent PXR agonist, EC<sub>50</sub> 10 nM (110%), i.e., similar levels to the starting compound, <b>109</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>. Replacement of the cyclopentyl ring by a pyrrolidine (<b>116</b>) resulted in a slight decrease in RORγ activity but a much more pronounced decrease in PXR activity, thereby widening the selectivity window, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>.</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Evolution of BMS RORγ inverse agonist series from initial design (<b>75</b>) through <b>116</b> and <b>117</b> to compounds with enhanced PXR selectivity (<b>118</b>–<b>120</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Functionalization of the pyrrolidine N-atom resulted in compounds such as <b>117</b> (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>) which allowed exploration of a similar region as exploited by the acetamide in compounds such as <b>114</b> and <b>115</b>, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>. Addition of polarity resulted in derivatives such <b>118</b>–<b>129</b>, all of which had substantially weaker PXR activity but with similar or improved RORγ activity, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>.</div><div class="NLM_p">To aid the optimization of the series and reduce PXR activity, a crystal structure of PXR was solved with <b>75</b>, which is depicted in <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>. Interestingly, two different conformations were observed for <b>75</b>, due to a rotation of the C–S bond, highlighting some degree of flexibility by the ligand and again some of the challenges with docking to PXR. In both structures, the HFIPA donates a hydrogen bond to the imidazole of His407 (polar rim, blue residues) with the trifluoromethyl groups sitting in hydrophobic environments (hydrophobic side, orange residues) but also contacting the polar channel). The cyclopentyl ring is superimposed in both instances and sits in a hydrophobic environment, forming van der Waals interactions with the inward facing side chains of Met323 (polar rim, blue residues) and Leu324, Val211, and Trp299 (hydrophobic cage, green residues). In one pose, the sulfone O-atom accepts a hydrogen bond from the side chain amide of Gln285 (polar rim, blue residues) whist the <i>p</i>-fluorophenyl ring forms a π–π interaction with the side chain of Phe288 and an edge-to-face interaction with Tyr306 (both part of the hydrophobic cage, green residues). In both cases, the only flexible portion is the conformation of the <i>para</i>-fluorophenyl ring and an edge-to-face interaction with the side chain of Tyr306. In the second pose, rotation of the C–S bond precludes the sulfone from accepting any hydrogen bonds and orientates the <i>p</i>-fluorophenyl ring above the other phenyl ring in a folded conformation, rather than interacting with the hydrophobic cage of PXR and more closely resembling the original design intent.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structure of PXR with <b>75</b>, pose a in gray and pose b in cyan (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Combining the analysis of the PXR structure with <b>75</b> and the structural knowledge of RORγ supported the strategy to convert the cyclopentyl ring to a pyrrolidine and then incorporate additional polar groups which would clash with PXR and thus diminish activity. This growth vector was also targeted to allow interaction with Arg367 in RORγ which was also anticipated to enhance primary activity.</div><div class="NLM_p">An additional important difference in the binding interactions is the role of the HFIPA group in this class of structures; in PXR it forms an important H-bond with the side chain of His407, <i>e.g</i>., <b>71</b> and <b>75</b>, and often to Ser247 <i>via</i> a water molecule, as for <b>71</b>, whereas in RORγ it sits in a lipophilic environment and in this instance does not appear to form any hydrogen bonds, although with <b>71</b> it appears to form a single H-bond with His479. This contrasts with the earlier RORγ inverse agonists described here, such as <b>71</b>, where the HFIPA moiety donates a hydrogen bond to Arg367 in RORγ. Thus, the possibility to change this functional group was investigated, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>. First, replacing one of the CF<sub>3</sub> groups on <b>75</b> by Me resulted in a 24-fold decrease in PXR activity but was accompanied by a 6-fold decrease in RORγ activity, <b>121</b>. However, conversion of the OH in the HFIPA moiety to a fluorine atom, <b>122</b>, decreased RORγ activity by approximately 2-fold but had a dramatic effect on PXR activity, causing a reduction of 100-fold. The impact on PXR activity highlights the strength of a hydrogen bond in a hydrophobic environment, possibly in addition to a water-mediated H-bond. The loss of an HBD interaction by this transformation is corroborated by methylation of the hydroxyl group in <b>75</b>, which results in a similar (92-fold) reduction in PXR activity, but a more pronounced reduction in RORγ activity than the OH to F switch (not shown). Although there is an equivalent histidine residue in RORγ, His458, the ligand does not appear to form a direct interaction with this residue. Finally, the HFPIA moiety adopts a very similar torsional angle to the corresponding heptafluoro-isopropyl moiety in related ligands bound to RORγ, so it appears that a change in torsional angle is not the cause to the activity difference.</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. SAR around the HFIPA group of <b>75</b>, highlighting the importance of the CF<sub>3</sub> groups (<b>121</b>) and the hydrogen bond donating interaction with PXR (<b>122</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Combining the OH to F switch (<b>122</b>), <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>, with the polar groups outlined by <b>118</b>–<b>120</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>, resulted in compounds such as <b>123</b>–<b>126</b>, <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>, which show optimal selectivity over PXR. Furthermore, not only was the selectivity enhanced, but this combination also resulted in decreased efficacy at PXR, which is an important factor to consider and already highlighted as an issue previously by the BMS group, <i>vide supra</i>, <b>115</b>, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>. Notably, it is a combination of the two structural modifications that resulted in the substantially decreased efficacy as the change of HFIPA to the heptafluoro-isopropyl only reduced the PXR EC<sub>50</sub>, as demonstrated by <b>122</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>, although the incorporation of polarity on the RHS of the molecule did show some reduction in PXR efficacy as well as EC<sub>50</sub>, demonstrated by <b>118</b>–<b>120</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>. Ultimately <b>126</b> showed good <i>in vivo</i> PK in the mouse (Fpo 99%, Cl 7.2 mL/min/kg, Vss 3.4 L/kg, t1/2 7.2 h) and demonstrated efficacy in several <i>in vivo</i> models. Furthermore, <b>126</b> did not show reduced exposure in the mouse but did show potent inhibition of CYP2C8, IC<sub>50</sub> 0.68 μM.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Combination of the heptafluoro isopropyl group on the left-hand side with the polar right-hand side groups resulted in an optimal balance between on target activity and PXR selectivity, including efficacy at PXR, <b>123</b>–<b>126</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the substantially improved profile of <b>126</b>, it was deemed that its RORγ activity was insufficient, and a 10-fold increase was sought. To do this, the group introduced an additional ring to provide conformational constraint, locking the compound in the conformation seen in the RORγ crystal structure, resulting in <b>127</b>, <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>. This modification showed approximately 17-fold improvement in the RORγ assay (GAL4 luciferase) and approximately 51-fold improvement in the IL17 human whole blood (hWB) assay.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Locking the conformation of <b>126</b> resulted in a substantial increase in activity (<b>127</b>). Optimization of other properties while maintaining PXR selectivity resulted in compounds such as <b>128</b> and ultimately the development compound BMS-986251 (<b>129</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, the PXR activity for <b>127</b> is not reported; however, a close analogue with optimized properties, <b>128</b>, <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>, shows that PXR selectivity is maintained, although the efficacy is not reported. Based on its promising profile, including reduced CYP inhibition, particularly CYP2C8 IC<sub>50</sub> 15 μM, and <i>in vivo</i> efficacy, <b>128</b> was progressed to preclinical toxicology studies.</div><div class="NLM_p last">Returning to <b>127</b>, close inspection of the RORγ crystal structure resulted in the addition of a methyl group to the cyclohexane, causing it to rotate (approximately 75°) and allowing the methyl group to interact with Ala368. This subtle modification ultimately resulted in the discovery of <b>129</b> (BMS-986251), <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Although the detailed results from <i>in vivo</i> repeat dose studies and CYP3A4 induction are not described, it may be assumed that the fact the compound progressed through preclinical studies and to the clinic that the CYP3A4 induction was not a major issue. Thus, this work highlights the benefits of using PXR structural information to reduce this activity. Furthermore, the use of on-target and antitarget (PXR) structural biology has demonstrated that it is particularly fruitful.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.7.  NaV1.6 blockers, Xenon, 2019. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41">6S41</a></h3><div class="NLM_p">Xenon recently disclosed their use of structural biology to reduce the PXR activity of aryl sulfonamide inhibitors of the voltage-gated sodium channel Na<sub>V</sub>1.6, which were being developed for the treatment of epilepsy.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Compounds such as <b>73</b> (XPC-4755), <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>, are somewhat structurally related to Na<sub>V</sub>1.7 inhibitors, which have been developed by several groups and which are also known to have PXR activity, <i>vide supra</i>. Indeed, PXR assessment of compounds from this series revealed exemplars such as <b>73</b> exhibited activation of PXR, EC<sub>50</sub> 0.4 μM, with 103% activation at 10 μM, relative to the activation of rifampicin at 10 μM. Initial attempts to mitigate PXR activation centered on reduction of lipophilicity as the PXR binding site was known to be lipophilic; however, this had little effect. No correlation was observed between measured log <i>D</i> and PXR EC<sub>50</sub> as highlighted by selected examples (<b>130</b>–<b>132</b>) in <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>.</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Selected examples from Xenon Na<sub>V</sub>1.6 project highlighting lack of correlation between measured log <i>D</i> and PXR activity (EC<sub>50</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand the molecular interactions with PXR, the structure of <b>73</b> (XPC-4755) was solved with the PXR ligand binding domain, <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>. As can be seen, the molecule adopts a U-shaped conformation, which has some similarities to the P2X4 ligands from Bayer, <i>vide infra</i>, with the difluoro phenyl ring and the aminothiazole orientating perpendicular to the central <i>para</i>-amino phenyl sulfonamide ring. Both oxygen atoms of the sulfonamide of <b>73</b> accept hydrogen bonds from Ser247 side chain alcohol and His407 imidazole on the polar rim (blue residues), in a similar, but distinct, manner and similar region to sulfonamide in the Bayer P2X4 antagonist. The N-benzyl moiety of <b>73</b> binds in the tight hydrophobic cage defined by His327, Tyr306, Phe288, Leu324, and Met323. As typical of many ligands, Trp299 in the hydrophobic cage (green residues) forms a key π–π interaction with the difluoro phenyl ring. The aminothiazole interacts with Phe420 and Leu411 (hydrophobic side, orange) and also Leu240 and Met243 (polar channel, magenta).</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Na<sub>V</sub>1.6 blocker <b>73</b> (XPC-4755) bound to PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41">6S41</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Docking of several analogues predicted a similar binding mode. From analysis of the structures, it was proposed that large/charged groups in the <i>ortho</i> and <i>meta</i>-positions of the benzylic phenyl ring may disrupt PXR binding. To this end, compounds such as <b>133</b> and <b>134</b> were prepared and profiled, <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>.</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of <b>133</b> and <b>134</b> highlighting the differences in PXR induction and MDR1 ER for substitution at the <i>meta</i> (<b>133</b>) versus <i>ortho</i> (<b>134</b>) positions of the benzylic phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Placement of basic amines in the <i>meta</i>-position dramatically reduced PXR activation, as highlighted by <b>133</b>, PXR EC<sub>50</sub> > 20 μM, <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>. However, this compound was found to be a strong Pgp substrate with MDR1 efflux ratio (ER) of 24.1 which would likely result in low CNS penetration and hence weaker efficacy or higher doses to achieve the desired brain concentrations. Similar data was observed for a close analogue supporting that this was a general effect for this substitution pattern. Alternatively, substitution at the <i>ortho</i>-position also reduced PXR activation, albeit to a lesser extent than substitution of the <i>meta</i>-position, but in this instance did not result in Pgp-mediated efflux, <b>134</b>, <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>. At first glance, the marked difference in Pgp efflux may appear surprising, given the fact that the compounds have the same calculated properties. However, conformational analysis by quantum mechanics and single crystal X-ray indicated that <b>134</b> forms an intramolecular hydrogen bond between the azetidine N-atom and the anlinic NH which could explain the lesser recognition by Pgp and possibly also the difference in log <i>D</i>. The more folded conformation of <b>134</b>, versus the more extended conformation of <b>133</b>, may also explain the better fit of <b>134</b> in the PXR binding pocket than <b>133</b>.</div><div class="NLM_p">This investigation ultimately culminated in the identification of three key compounds, <b>135</b>–<b>137</b>, <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>, with bulky benzylic amines in the <i>ortho</i>-position of the phenyl ring which displayed an optimal balance of properties and reduced potential for PXR activation.</div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures and summary data for optimized compounds <b>135</b>–<b>137</b> from the Xenon Na<sub>V</sub>1.6 inhibitor project.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to the properties noted in <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>, the compounds showed weak hERG activity (all ≥22 μM) and minimal CYP inhibition as well as good levels of CNS penetration <i>in vivo</i>. Despite this, the most promising compounds, <b>136</b> (XPC-6444) and <b>137</b> (XPC-6379) could not be progressed further as a suitable maximum tolerated dose could not be determined despite various formulation efforts to maximize exposure in preclinical species. This is most likely attributable to low solubility, <i>e.g</i>., <b>136</b> (XPC-6444) < 22 μM and <b>137</b> (XPC-6379) < 10 μM, respectively. However, the work again highlights the use of PXR structural biology to allow focused structural modifications to reduce PXR activity.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.8.  P2X4 Antagonists, Bayer, 2019. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY">6HTY</a></h3><div class="NLM_p">Bayer have recently disclosed some of their efforts to dial out PXR activity, using structural biology, from a series of P2X4 inhibitors. BAY-1797,<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a><b>138</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>, represents one of the starting points from a series of sulfonamides which was identified by HTS. Profiling in human hepatocytes revealed that <b>138</b> showed CYP3A4 induction. As it was deemed that the human hepatocyte induction assay was not suitable for routine screening, a luciferase reporter gene assay was routinely employed for screening. This assay utilized a human hepatoma cell line, either HepG2 with transient PXR transfection or DPX-2 with stable transfection of PXR. Rifampicin (<b>1</b>) was used as a positive control at 16.5 μM which was found to give a 100% response. PXR data for compounds was quoted as minimum efficacious concentrations (MEC), which was defined as >4-fold standard deviation over the DMSO control for HepG2 cells or >10% of rifampicin (<b>1</b>) using DPX-2 cells.</div><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Phenylsulfonamide P2X4 inhibitors from Bayer, highlighting starting point <b>138</b> (BAY-1797) and selected SAR examples, including substitution of the phenyl acetamide moiety at the <i>ortho</i>-position (<b>139</b>–<b>141</b>), <i>para</i>-position (<b>142</b> and <b>143</b>), and the benzylic position (<b>74</b>). MEC = minimum efficacious concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial SAR investigations to mitigate PXR activity investigated substitution around the phenyl acetamide moiety. A methyl scan at the <i>ortho</i>, <i>meta</i>, and <i>para</i>-positions revealed the <i>ortho</i>-position was optimal for P2X4 activity but had little effect on the PXR activity, even slightly increasing the liability, <b>139</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>. Alternative groups were tolerated in the <i>ortho</i>-position but did not impact PXR activity, such as Cl, <b>140</b> (<a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>); however, the <i>ortho</i>-fluoro derivative <b>141</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>, showed dramatically decreased PXR activity. The impact of the F-atom is (<b>141</b>) is striking, particularly given that other electronegative groups such as Cl (<b>140</b>) and CF<sub>3</sub> (not shown) in the <i>ortho</i>-position did not show a similar effect. This also highlights the worthiness of investigating seemingly small structural changes. While <i>para</i>-substitution dramatically reduced PXR activity, <b>142</b> and <b>143</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>, this also had a negative impact on P2X4 activity. Methylation of the benzylic position (<b>74</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>) did not impact PXR activity but again decreased P2X4 activity.</div><div class="NLM_p">To better understand the interaction with PXR, several compounds were selected for crystallization studies, and triaging was conducted via a thermal shift assay with compounds showing a >4 K increase in thermal stability being prioritized. This resulted in the determination of the structure of <b>74</b> with PXR, <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>, as a single enantiomer following cocrystallization at 10 mM.</div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure of P2X4 antagonist <b>74</b> with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY">6HTY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure shows that the <i>R</i>-isomer crystallized and highlights several key interactions. The phenyl ring of the phenyl acetamide binds in the hydrophobic cage defined by several aromatic residues (green residues) and makes a key π–π interaction with Trp299, as seen with several other ligands. Additionally, the phenyl ring forms an edge-to-face interaction with the phenyl group on the side chain of Phe288 and with the phenolic moiety of Tyr306, also both in the hydrophobic cage (green residues). Taken together, these interactions result in tight binding with PXR, in a rigidified lipophilic aromatic environment. Further interactions occur via the O-atom of the amide of <b>74</b> which interacts with the S-atom of Met323 (polar rim); however, this appears to a be a weak interaction as there are two conformations of the Met side chain resolved and only one forms this interaction. The phenolic ether of <b>74</b> potentially forms a weak H-bond with the imidazole moiety of His407 on the polar rim (blue residues), which in turn is held in place by a π–π interaction with the side chain of Phe281 (also on the polar rim). The sulfonamide of <b>74</b> forms extensive interactions with PXR, accepting two hydrogen bonds, with Gln285 and Cys284, and donating one to Ser247, all of which are on the polar rim (blue residues). The <i>meta</i>-chlorophenyl ring interacts with the hydrophobic side (orange), such as Ile414 and Phe420, and the polar channel (magenta), Leu240 and Met243. Taken together, it can be seen that <b>74</b> forms an extensive range of interactions with PXR, thus accounting for the measured activity.</div><div class="NLM_p">Overall, <b>74</b> makes very similar contacts and occupies a similar space, albeit with some differences in the central ring conformation, to the Na<sub>V</sub>1.6 blocker <b>73</b> (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a> and <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a>) from Xenon, see <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">42</a></a> for an overlay of the two structures.</div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Overlay of the crystal structures of PXR LBD bound to <b>73</b> (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S41">4S41</a>) and to <b>74</b> (in cyan) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HTY">4HTY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the structure of <b>74</b> bound to PXR, <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>, it is apparent that substitution in the <i>para</i>-position of the phenyl acetamide, such as <b>142</b> and <b>143</b> would result in disruption of the edge-to-face interaction with the side chain of Tyr106 (hydrophobic cage) and also likely result in a significant steric clash, which in combination would explain the marked decrease in PXR activity for these analogues. As mentioned above, the PXR activity of the <i>ortho</i>-fluoro derivative <b>141</b> cannot be explained by simple steric or electronic arguments given the activity of <b>139</b> and <b>140</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>. However, the addition of the F-atom may disrupt the interaction with Phe288 (hydrophobic cage). The addition of the fluorine atom would not be anticipated to affect the conformation of the phenyl acetamide as the phenyl ring of the phenyl acetamide is almost orthogonal to that of the plane of the amide in the PXR structure. This also appears to be the preferred conformation of <i>ortho</i>-fluorophenyl acetamides based on examples from CSD and PDB. Furthermore, the benzylic methyl group in <b>74</b>, <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>, also reinforces the preferred conformation of the phenyl acetamide by reducing the conformational freedom around the benzylic moiety. This can be seen by the difference in PXR activity between <b>74</b> (PXR MEC 0.31 μM) and the unsubstituted analogue <b>138</b> (PXR MEC 1.66 μM), whereby the lack of benzylic substitution in <b>138</b> increases the conformational freedom. These two subtle differences (<i>ortho</i>-fluoro substitution causes a decrease of 4-fold activity whereas the benzylic methyl causes an increase of 5-fold) likely account for the dramatic difference in activity, which can be seen between <b>141</b> and <b>74</b>, i.e., almost 22-fold and serves to remind medicinal chemists about the importance of conformation effects driven by subtle substitution patterns.</div><div class="NLM_p">Inspection of the structure <b>74</b> with PXR led the group at Bayer to postulate that large, and preferably polar, groups in the <i>meta</i> and <i>para</i>-positions of the phenol ether, i.e., the <i>m</i>-chlorophenyl ring in <b>140</b>, would disrupt PXR binding. To this end, compounds such as <b>144</b> were made, <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>. As predicted, this compound had dramatically reduced PXR activity, but P2X4 activity was also diminished. Moving the morpholinone group to the <i>meta</i>-position, as in <b>145</b>, also showed weak PXR activity and much improved P2X4 activity. Likewise, <b>146</b>, with a morpholine amide in the <i>meta</i>-position showed very weak PXR activity and further improved P2X4 activity. A positional scan with the less bulky iso-propanol group (<b>147</b>–<b>149</b>) showed little improvement when in the <i>ortho</i>-position (<b>147</b>) or the <i>meta</i>-position (<b>148</b>) but a more pronounced effect when in the <i>para</i>-position (<b>149</b>). As can be seen from the PXR data on the <i>ortho</i> and <i>meta</i>-isomers (<b>147</b> and <b>148</b>), the drop in PXR activity observed with <b>149</b> is not due to physicochemical properties, although <b>147</b> may display different physicochemical properties and conformation due to a potential intramolecular hydrogen bond.</div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Summary of substituted phenolic ethers from Bayer P2X4 antagonist series designed using the PXR crystal structure in complex with <b>74</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further design efforts investigated homologation of the phenyl ring to a benzyl group, <b>150</b>, which unfortunately increased PXR activity, <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>. As this compound displayed potent inhibition of P2X4, further alkyl ethers were prepared. The smaller cyclobutylmethyl ether, <b>151</b>, retained P2X4 potency and PXR activity, but the oxetane analogue <b>152</b> showed a marked reduction in PXR activity, presumably due to the increased polarity. Unfortunately, P2X4 activity was also reduced. A compromise between P2X4 activity, metabolic stability in rat hepatocytes, and PXR activity was found in the tetrahydropyran-4-methyl derivative <b>153</b>, <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>. Taken together, the addition of a polar ethereal O-atom in this region of the molecule clearly had a strong effect in diminishing PXR activity. Looking at the region of PXR this group would bind to implies that this effect is likely due to the presence of the polar ether in a highly lipophilic environment, rather than a direct electronic clash. This serves to highlight this as a useful strategy and the strong effect a simple structural change can have.</div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Further P2X4 inhibitors from Bayer designed with the use of PXR crystallography to reduce PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Reassessment of the phenyl acetamide moiety resulted in the identification of <b>154</b>, which displayed slightly improved P2X4 activity and metabolic stability in rat hepatocytes and an <i>in vivo</i> rat PK profile, <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>. Interestingly, switching the <i>ortho</i>-chlorophenyl acetamide to the <i>ortho</i>-fluoro analogue, <b>155</b>, again reduced PXR activity but also significantly reduced P2X4 activity. As <b>153</b> and <b>154</b> offered the best overall profiles, they were selected for further characterization. The reduced PXR activity was confirmed in human hepatocytes where a CYP3A4 induction NOEL of >10000 μg/mL for <b>153</b> and 3333 μg/mL for <b>154</b> was measured, which compares favorably to <b>138</b> (41 μg/mL). Despite this, it was found that their pharmacokinetic profiles were inferior to <b>138</b>, with their <i>in vivo</i> half-lives projected to be insufficient to support the desired human profile of once or twice daily dosing. However, the use of PXR crystallography to reduce PXR activity was clearly demonstrated.</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.9.  HIV-1 Integrase Inhibitors, BMS, 2020. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9">6XP9</a></h3><div class="NLM_p">Very recently, the BMS group have described the use of PXR crystal structures to optimize selectivity over PXR on a third therapeutic target, namely, HIV-1 integrase.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Again, in this case, crystal structures of ligands were available for both the primary target (HIV-1 integrase) and PXR. Thus, the macrocyclic allosteric inhibitor of HIV-1 integrase <b>156</b>, <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>, was found to be a potent activator of PXR, using a HepG2 assay, with the <i>Y</i><sub>max</sub> denoting the maximal activation relative to rifampicin at 10 μM. Despite its potent activity, efforts to crystallize <b>156</b> with PXR were unsuccessful.</div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures and PXR activity of HIV-1 integrase allosteric inhibitors from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, efforts to crystallize a related, nonmacrocyclic analogue, <b>77</b>, <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>, were successful and yielded structures with both HIV-1 integrase and PXR. As can be seen in <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">46</a></a>, the conformation of the acetic acid moiety is different in both proteins, and although conformational restriction of this moiety may appear an attractive strategy it was deemed challenging to achieve the required conformation. Inspection of the crystal structure of <b>77</b> with PXR reveals the <i>tert</i>-butoxy group interacts with the polar rim (Gln285 and Met323) and partially the hydrophobic cage (Trp299 and His327). The chromane ring occupies the hydrophobic cage (green residues) and interacts with Phe288, Cys301, and Trp299 and also Met246 in the polar channel (magenta). The unsubstituted phenyl ring points toward the polar channel (magenta residues) defined by Leu239, Pro227, and Tyr225 but also interacts with Tyr306, Val211, and Leu213 in the hydrophobic cage (green residues).</div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. (a) Crystal structure of PXR LBD in interaction with <b>77</b> (left) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9">6XP9</a>) and (b) crystal structure of HIV-1 integrase in interaction with <b>77</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UM8">6UM8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The group hypothesized that placement of a bulky polar/charged group in the southern region would deliver detrimental interactions with PXR as this region is hydrophobic, thus the desolvation penalty would not be compensated. This region of the molecule is not in close contact with PXR, but the additional group was hypothesized to clash with residues on the polar channel; however, this area of PXR is not resolved in the structure which makes it difficult to be definitive. This resulted in the synthesis of amine derivatives, exemplified by <b>157</b>, <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>, which completely negated PXR activity.</div><div class="NLM_p last">This work serves as another powerful example of the use of PXR structural biology, in concert with primary target structural information, to alleviate undesired PXR activity.</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.10.  Thrombin Inhibitors, Bayer, 2020. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI">6TFI</a></h3><div class="NLM_p">Very recently, the Bayer group have disclosed a second pharmacological target, thrombin, where PXR induction was encountered as an issue.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> This project benefited from the availability of structural information for the primary target as well as PXR, which proved particularly useful as the ligands displayed a very similar conformation when bound to both targets. PXR activation was again assessed via a reporter gene transactivation assay in HepG2 cells, whereby rifampicin was used as a positive control, giving a full effect at 16.7 μM. Confirmation was conducted via incubation with human hepatocytes (48 h) and measuring CYP3A4 mRNA.</div><div class="NLM_p">Early profiling of selected derivatives from the series identified PXR as an issue; it is noteworthy that the compounds display a PXR structural alert of a benzyl group linked to an HBA (benzoxazole). Thus, compounds such as <b>78</b>, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>, activated PXR in the HepG2 reporter gene assay. Switching from the morpholine to the hydroxypiperidine, <b>158</b> alleviated the issue to some degree, but removal of a methyl group (<b>159</b>) increased PXR activation, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>. The PXR activation in the reporter gene assay (MEC 0.69 μM, 296 ng/mL) was confirmed in the primary human hepatocyte assay where the compound showed a NOEL at a similar concentration of 370 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>.</div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. PXR SAR from a series of thrombin inhibitors from Bayer, showing attempts to weaken PXR activity by increasing polarity in the hydrophobic cage, <b>160</b>, and decreasing the strength of the H-bond interaction with Gln285 on the polar rim, <b>161</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on these data, the group attempted to cocrystallize PXR with compounds <b>78</b> and <b>159</b>, which resulted in a structure of PXR with <b>78</b>, <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>, revealing that the <i>m</i>-chlorobenzyl group was indeed a key pharmacophoric element, forming a characteristic π–π interaction with Trp299 in the hydrophobic cage (green residues), <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>. The <i>m</i>-chlorophenyl ring also forms potential edge-to-face interactions with the side chains of Tyr306 and Phe288 also in the hydrophobic cage, although the geometries do not appear optimal. The N-atom of the benzoxazole accepts a hydrogen bond from the side chain amide of Gln285 on the polar rim which acts as a second key pharmacophore. The carbonyl of the dimethyl morpholine amide is approximately 60° out of the plane of the benzoxazole which orientates the dimethyl morpholine toward several regions of PXR which consist of lipophilic residues, such as Phe420, Leu411, Ile414, on the hydrophobic side (orange residues) and Leu206 and Leu240 in the polar channel (magenta residues).</div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Crystal structure of thrombin inhibitor <b>78</b> from Bayer with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI">6TFI</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of this structure in combination with forced docking of <b>160</b> provided some explanation for the different PXR activities. Thus, it was hypothesized that the amide of <b>159</b> adopts a slightly different conformation to <b>78</b> which allows the hydroxyl on the piperidine to form a hydrogen bond with the side chain on His407 in the polar channel (magenta residues), thereby explaining the increased activity. This hypothesis also accounts for the decreased PXR activity of the dimethyl analogue, <b>158</b>, as the second methyl group was proposed to sterically encumber this hydrogen bond.</div><div class="NLM_p">Thus, the structure of <b>78</b> with PXR in combination with closely related compounds bound to thrombin allowed the group to postulate a strategy to reduce PXR activity. First, the group targeted the hydrophobic cage with increased polarity, i.e., <b>160</b>, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>, which had a significant impact but also reduced thrombin activity. Second, alternative core bicyclics to the benzoxazole were assessed that had weaker calculated HBA potential, such as the triazolopyridine <b>161</b>, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>, which dramatically reduced PXR activity as intended but also negatively impacted thrombin activity.</div><div class="NLM_p">Further optimization of the series focused on changes to the amide to optimize thrombin activity while balancing PXR activation, in combination with the changes highlighted by <b>160</b> and <b>161</b>, and substitution of the benzylic carbon to optimize metabolic stability. This resulted in compounds such as those detailed in <a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">49</a></a>, all of which maintained some degree of PXR activation. Interestingly though, while <b>162</b> increased CYP3A4 in human hepatocytes, other analogues such as <b>163</b> – <b>166</b> had no effect up to 10 000 ng/mL (approximately 20 μM, assuming MW 500 g/mol). The reasons for the discrepancy between the HepG2 reporter gene assay and the human hepatocyte assay are not understood but could be due to some of the reasons discussed in the introduction, for example, lower uptake in hepatocytes and/or lower metabolic stability. In this regard, it is noteworthy that <b>159</b>, <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>, was the most metabolically stable compound (<i>in vivo</i> in rat), CL 28.3 mL/min/kg and gave the best correlation across the assays, which may go some way to explain the differences in results. However, this does not hold up for <b>162</b> which has similar <i>in vivo</i> clearance to <b>163</b> and <b>165</b>, but the human hepatocyte NOEL (1111 ng/mL) is closer to the PXR reporter gene assay value (0.26 μM, i.e., 130 ng/mL). It could be argued that some of the compounds, such as <b>164</b> and <b>165</b> correlate reasonably well across the assays, despite the relatively high <i>in vivo</i> clearance of <b>165</b>.</div><figure id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0049.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Summary profiles of key thrombin inhibitors from Bayer showing the best balance between PXR activation and overall profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the overall balance of properties, <b>166</b> was selected as a development compound and progressed to clinical trials.</div><div class="NLM_p">In summary, this work again highlights the use of PXR crystal structures in conjunction with structural information of the primary target to allow fine-tuning of PXR activity. It also highlights that there may be discrepancies between PXR reporter gene assays and CYP3A4 induction in primary human hepatocytes, and therefore, it is prudent to check the correlation between these assays for each series of compounds.</div><div class="NLM_p">In conclusion, this section has discussed each of the 10 structurally targeted approaches in turn. In most cases, 1 crystal structure has been published per drug discovery target; however, the CCR1 and RORγ projects have each published structures of 2 ligands. Furthermore, for each project the structure with PXR revealed 1 ligand from each project to have 2 different poses, again highlighting the accommodating nature of the PXR binding pocket. In each case, use of the structural information was beneficial in modulating PXR activity. The analysis shows that many of the projects targeted the hydrophobic cage to reduce PXR activity, and this was always successful, perhaps due to its rigidity and very hydrophobic nature, implying this could be a general strategy. However, the Bayer thrombin example made moderate impact via this strategy. The hydrophobic region (orange residues) was also targeted on multiple occasions and was also successful, again suggesting this could be a general strategy. In many cases, more than one region on PXR was targeted, i.e., the hydrophobic cage (green residues), the hydrophobic side (orange residues), and polar rim (blue residues) demonstrating that multiple molecular regions can be targeted and the use of PXR crystallography can highlight specific changes that merit investigation.</div><div class="NLM_p">Finally, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> shows that several projects solved crystal structures of the target protein with ligands from the series under investigation. This offers a very powerful means by which to diminish PXR activity as it enables researchers to target specific regions of the series of compounds in question based on the differences in interactions with the different target proteins. It also enables the exploitation of conformation differences of ligands bound to the different proteins, should this be the case.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of Projects Which Have Used PXR Structural Biology to Reduce the PXR Liability within a Series and the Regions of PXR the Molecular Alterations Have Targeted</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">primary target</th><th class="colsep0 rowsep0" align="center">PXR region targeted</th><th class="colsep0 rowsep0" align="center">PDB code(s)</th><th class="colsep0 rowsep0" align="center">structure used for primary target</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PXR/LXRβ</td><td class="colsep0 rowsep0" align="left">polar rim/hydrophobic side</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a></td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RORγ</td><td class="colsep0 rowsep0" align="left">polar rim and hydrophobic cage</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a></td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">CCR1</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">hydrophobic cage and polar channel</td><td class="colsep0 rowsep0" align="left" valign="middle"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9">4NY9</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT">4SOT</a>;</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT">4SOT</a> same ligand, 2 poses</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S1P<sub>1</sub></td><td class="colsep0 rowsep0" align="left">hydrophobic cage</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a></td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mGluR2</td><td class="colsep0 rowsep0" align="left">hydrophobic cage and polar rim</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP">6DUP</a></td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">RORγ</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">polar rim and polar channel/hydrophobic side</td><td class="colsep0 rowsep0" align="left" valign="middle"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS">6BNS</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a>;</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a> contains 2 poses</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Na<sub>V</sub>1.6</td><td class="colsep0 rowsep0" align="left">hydrophobic cage</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41">6S41</a></td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P2X4</td><td class="colsep0 rowsep0" align="left">hydrophobic cage and hydrophobic side/polar channel</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY">6HTY</a></td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1 integrase</td><td class="colsep0 rowsep0" align="left">hydrophobic side</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9">6XP9</a></td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thrombin</td><td class="colsep0 rowsep0" align="left">hydrophobic side, polar channel (and hydrophobic cage)</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI">6TFI</a></td><td class="colsep0 rowsep0" align="left">yes</td></tr></tbody></table></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">4.  Computational Approaches to Reduce PXR Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This section outlines the computational approaches that have been investigated/developed to understand the binding of ligands to PXR and encompasses three subsections: pharmacophore modeling, QSAR and machine learning, and structure-based approaches, including docking. It builds on a previous review published in 2012, which listed all the ligand-based and structure-based <i>in silico</i> studies of PXR activation undertaken at that time.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.1.  Pharmacophore Modeling</h3><div class="NLM_p">Among the ligand-based approaches, several pharmacophore models have been proposed to define the key binding features of PXR ligands.<a onclick="showRef(event, 'ref90 ref190 ref191'); return false;" href="javascript:void(0);" class="ref ref90 ref190 ref191">(90,190,191)</a> Consistent with the interactions observed in the crystal structures of human PXR cocrystallized with a wide variety of ligands (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), a PXR pharmacophore typically includes several hydrophobic features as well as at least 1 or 2 hydrogen bond donor(s) or acceptor(s). Starting from a small training set of known PXR activators (<i>n</i> = 12), a first pharmacophore model including four hydrophobic features and one hydrogen bond acceptor was derived by the group of Ekins in 2002. In a later study, the authors proposed alternative pharmacophore models derived from a slightly larger set of steroidal compounds (<i>n</i> = 30) or diverse ligands (<i>n</i> = 31)<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> and used them to predict PXR activation by antibiotics,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> suggesting the potential benefit of using <i>in silico</i> predictions as a first filter before <i>in vitro</i> evaluation.</div><div class="NLM_p">In parallel to this approach, Schuster and Langer have published several PXR pharmacophore models built from (i) the interactions observed between SR12813 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and PXR cocrystallized with the activation peptide SRC-1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a>) and (ii) training sets of diverse PXR activators (<i>n</i> = 15).<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> In this study, the structure-based pharmacophore is characterized by six hydrophobic features and 1 HBA that forms a H-bond interaction with His407. Three of the six hydrophobic features are systematically matched by active PXR ligands, while the three others were defined as “leave one out” features reflecting multiple sites of possible interactions. In the ligand-based pharmacophore models, most of the features are again hydrophobic, except for 1 key HBA which forms H bond interaction with Gln285. This last feature is shared by nearly all PXR ligands, with some notable exceptions such as the one seen in the cocrystal structure formed by the Xenon ligand XPC-4755 (<b>73</b>) with the PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41">6S41</a>).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> From this ligand-based analysis, it appears that a second H bond interaction with His407 can also be considered as a secondary pharmacophoric feature, contributing to the potency of the ligands. Hydrophobic features seem beneficial for the ligand binding affinity but not essential for PXR activation. These hypotheses were evaluated on a test set of 54 compounds with known PXR activities. A pharmacophore-based virtual screen was performed by Lemaire et al,, whereby the authors used the crystal structure of PXR in complex with the antibiotic rifampicin (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX">1SKX</a>) to design a 2D pharmacophore model that was subsequently used to screen the Chembridge database.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Around 500 molecules were retrieved and docked into the ligand binding domain of the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX">1SKX</a> crystal structure, leading to the identification of 9 new hPXR agonists out of the 13 evaluated.</div><div class="NLM_p">More recently, Lagarde and co-workers have investigated the ability of selective 3D pharmacophores to discriminate agonists and antagonists of 27 nuclear receptors including PXR.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> They systematically screened the NRLiSt BDB database, a freely available benchmarking database dedicated to nuclear receptors,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> using ligand-based and structure-based pharmacophore models and a combination of both approaches. It appears from their study that the best performance is obtained when combining structure-based and ligand-based pharmacophore approaches. For the PXR agonists, the main pharmacophoric features are, as expected, hydrophobic with two key HB acceptors allowing interactions with Gln285 and His407. For PXR antagonists, additional HBD and HBA are included in the pharmacophore.</div><div class="NLM_p last">Finally, Torimoto-Katori et al developed a structure-based pharmacophore model that was evaluated using two sets of compounds;<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> first, an original data set of 68 proprietary compounds from the Mitsubishi Tanabe Pharma Corporation (MTPC), and second, 2500 drugs from the NIH Chemical Genomics Center (NCGC) Pharmaceutical Collection (NPC). The pharmacophore model was built using extracted interactions occurring in 14 crystal structures of PXR bound to various ligands and further refined using 19 known drugs with PXR activation potential. This pharmacophore model retains the usual features corresponding to key interactions: one HBA positioned to interact with Ser247 and four hydrophobic features corresponding to interactions with Phe281/Trp299, Phe420, Leu206/Leu209/Leu239, and Phe288/Trp299. Excluded volumes were used to restrict the ligand binding pocket based on the PXR crystal structure in complex with hyperforin (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M13">1M13</a>). The prediction accuracies of the model were good on both validation sets raising, respectively, 0.78 and 0.86 on the MTPC and NPC data sets. The statistics of the predictions were good on the whole for the smaller MTPC data set, but the sensitivity (0.17) and the positive predictability value (0.27) were particularly disappointing when using the larger, more diverse and unbalanced NPC data set (10% of PXR activators), highlighting the limitation of the model and the need to investigate alternative approaches such as the ones combining structure-based and ligand-based modeling, in order to identify compounds that are potentially at risk in term of PXR activation before conducting <i>in vitro</i> assays and to help in the design of compounds devoid of CYP3A4 induction during drug development.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.2.  QSAR and Machine Learning</h3><div class="NLM_p">Several QSAR and machine learning methods have been applied to various PXR data sets to discriminate activators from nonactivators and in some cases predict activity using regression models: partial least squares (PLS),<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> recursive partitioning (RP),<a onclick="showRef(event, 'ref199 ref200'); return false;" href="javascript:void(0);" class="ref ref199 ref200">(199,200)</a> random forest (RF),<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> decision tree (DT),<a onclick="showRef(event, 'ref58 ref201'); return false;" href="javascript:void(0);" class="ref ref58 ref201">(58,201)</a> regression-tree,<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> support vector machine (SVM),<a onclick="showRef(event, 'ref58 ref200 ref202 ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref58 ref200 ref202 ref203 ref204">(58,200,202−204)</a> k-nearest neighbors (k-NN),<a onclick="showRef(event, 'ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref203 ref204">(203,204)</a> probabilistic neural network (PNN),<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Kohonen neural network (KNN),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> artificial neural network (ANN),<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Bayesian modeling,<a onclick="showRef(event, 'ref205 ref206 ref207 ref208 ref209'); return false;" href="javascript:void(0);" class="ref ref205 ref206 ref207 ref208 ref209">(205−209)</a> partial logistic regression (PLR),<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> and 3D/4D/5D-QSAR.<a onclick="showRef(event, 'ref205 ref211'); return false;" href="javascript:void(0);" class="ref ref205 ref211">(205,211)</a></div><div class="NLM_p">The first QSAR models were developed in the 2000s by exploring several machine learning methodologies sometimes in combination or in comparison with docking. At that time, only a limited amount of data and crystal structures were available, resulting in models built and validated on relatively small data sets covering limited chemical space.<a onclick="showRef(event, 'ref198 ref199 ref200 ref202 ref203 ref205 ref206'); return false;" href="javascript:void(0);" class="ref ref198 ref199 ref200 ref202 ref203 ref205 ref206">(198−200,202,203,205,206)</a> For example, Ung and co-workers investigated in parallel three machine learning approaches (k-NN, PNN, SVM) on a data set including 128 activators and 77 nonactivators based on a 100 μM EC<sub>50</sub> threshold, using a set of common molecular descriptors encompassing several parameters, such as hydrophobicity, H-bond acceptor capability, and molecular globularity.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> On a small test set of 15 PXR activators, the best performance was obtained with the SVM classifier characterized by an overall accuracy of about 80% in a 10-fold cross validation test. Naive Bayesian classification was investigated by Pan and co-workers using a training set of 177 compounds and on a larger test set of 145 compounds.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Several combinations of 2D molecular descriptors and fingerprints were studied, leading to a specificity of 92% and an overall accuracy of 69% on the test set for the best classifier. This method was used to screen a subset of the FDA drug database (SCUT database), 17 compounds from the top 25 hits were chosen for testing and led to the identification of 9 new PXR activators, showing that simple binary classification methods are valuable tools to identify novel activators of PXR before their <i>in vitro</i> evaluation.</div><div class="NLM_p">Progressively larger data sets have become available when compiling all the published literature data, leading to better prediction performance/chemical space coverage.<a onclick="showRef(event, 'ref58 ref201 ref204 ref208 ref209 ref210'); return false;" href="javascript:void(0);" class="ref ref58 ref201 ref204 ref208 ref209 ref210">(58,201,204,208−210)</a> For example, Dybdahl and collaborators used a total of 631 compounds evaluated in a binding assay as a diverse training set to develop a PLR QSAR model through the Leadscope Predictive Data Miner modeling system.<a onclick="showRef(event, 'ref210 ref212'); return false;" href="javascript:void(0);" class="ref ref210 ref212">(210,212)</a> The performance of the model was evaluated on an external test set of 120 compounds whose PXR activities were coming from a cell-based reporter gene assay. It showed good specificity (83.5%) but lower sensitivity (58%) for an overall accuracy of 70%. The lower sensitivity on the test set was explained by the fact that the reporter gene assay also identifies positives acting through routes other than direct ligand binding. This model was used to screen a large database (>50 000 compounds) of environmental (EINECS) chemicals: 35% of which were predicted to be potential PXR activators. This observation was in line with a previous report showing that a huge proportion of environmental chemicals have PXR activity.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Moreover, they investigated the correlation between the PXR predictions and predictions from other toxicologic end points, as activation of PXR may lead to perturbations of many different pathways involving metabolic enzymes and transporters. They found that indeed the predicted PXR ligands are overrepresented among chemicals predicted to cause adverse effects such as genotoxicity, teratogenicity, estrogen receptor activation, and androgen receptor antagonism.</div><div class="NLM_p">Pharmaceutical companies can usually benefit from a huge amount of homogeneous and annotated proprietary data. This provides the possibility to explore ADMET data on a larger scale. Chen and collaborators have capitalized on the Merck data collections to perform a head-to-head comparison between Naïve Bayesian and random forest modeling on 18 ADMET and drug target end points, including human PXR.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> In the case of PXR, the data set was so huge that only a selected subset, totaling 50000 randomly chosen compounds, was used, making it the largest PXR data set ever considered. To ensure that the models could be used for prospective predictions, a time split approach was applied to define the training and test sets: based on the experiment date, 25% more recent compounds were chosen to form the test set. For most of the modeled end points, including PXR, the best performance was obtained with random forest using atom pairs and donor acceptor pairs (APDP) descriptors.</div><div class="NLM_p">PXR predictions are included in the toxicity end points covered by a machine learning based pipeline/webserver for holistic toxicity predictions such as eMolTox<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> or KnowTox,<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> which uses the publicly available ToxCast database<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> as its main source of information.</div><div class="NLM_p">Several attempts were made to develop regression QSAR models aimed to predict PXR potencies. In the early 2000s, Jacobs used a PLS modeling approach combined with Volsurf descriptors obtained from the 3D conformation of a small set of 33 PXR ligands.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> The PLS model showed a relatively good correlation between predicted and experimental data with a correlation coefficient (<i>r</i><sup>2</sup>) of 0.83 but suffers from the limited amount of data available at that time and the absence of a test set to rigorously evaluate the model. In 2012, Matter and collaborators working at Sanofi used several QSAR approaches/descriptors in parallel on two data sets including hundreds of structurally diverse compounds, split into training, test, and external sets.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> 2D and 3D descriptors were generated including MOE, Volsurf, Parasurf, and CATS descriptors. Several DT classifiers were developed and performed well on the test and external sets, qualifying them for application as filters to identify PXR activators. In parallel, a regression tree approach combined with a variable selection process based on a genetic algorithm led to a relatively good regression model characterized by <i>r</i><sup>2</sup> of 0.86 on the training set of 240 molecules and a <i>r</i><sup>2</sup> of 0.77 on the test set of 33 compounds. However, when the model was confronted with an external set of 33 compounds that were not used for model building or variable selection, the <i>r</i><sup>2</sup> was only 0.45. The authors concluded that these tools can be applied collectively to allow <i>in silico</i> prioritization for <i>in vitro</i> testing and early identification of compounds with potential risk of PXR activation.</div><div class="NLM_p">In addition to the alignment-independent QSAR approaches described in the previous paragraphs, several alignment-dependent approaches have also been investigated by Ekins et al., such as 3D-comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), and 4D- and 5D-QSAR.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> They used a data set of 115 steroids, characterized by a range of ligand binding activity split into a training set of 95 compounds and a test set of 20 compounds as well as 5 crystal structures of PXR for the docking studies. CoMFA and CoMSIA approaches were disappointing as they were unable to generalize beyond the molecules in the training set. In fact, they relied on manually superposed rigid input molecules, deployed in 3D conformations that may not be biologically relevant. This is obviously a limitation for a structurally diverse data set and for a flexible target such as PXR that can accommodate several different ligand binding modes. 4D- and 5D-QSAR both consider an ensemble of different ligand conformations which theoretically increase the chances of defining the active conformation. The 5D-QSAR can accommodate different ligand bioactive conformations from several docking poses/alignments in parallel resulting in a less rigid alignment and in theory a better treatment of weak binders. Again, the 4D-QSAR models were poorly predictive of the activity of compounds in the test set, while the 5-D QSAR appeared to perform slightly better with the test set.</div><div class="NLM_p">In 2014, Handa and collaborators<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> published a CoMFA 3D-QSAR model to predict PXR activation based on ligand docking to multiple PXR protein structures (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILG">1ILG</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH">1ILH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M13">1M13</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R8D">3R8D</a>) sampled from the trajectory of a molecular dynamics simulation, in order to better take into account the intrinsic flexibility of the nuclear receptor. To select a true binding pose, the binding free energy was estimated via the computation of the molecular mechanics-generalized born/surface area (MM-GB/SA) score. The selected docking poses were then superposed, and their alignment was used to build the 3D-QSAR model. A good correlation was observed between predicted and experimental data extracted from a small data set of 28 diverse PXR ligands (training set), with a correlation coefficient (<i>r</i><sup>2</sup>) of 0.97 and a cross-validated correlation coefficient (<i>q</i><sup>2</sup>) of 0.52. On a very small test set of eight compounds, the same <i>r</i><sup>2</sup> was obtained suggesting the potential of this kind of approach to predict the potency of novel compounds in the early stage of the drug discovery process.</div><div class="NLM_p last">Ligand based QSAR models aim to provide a reliable classification of active and inactive molecules, but they might also serve to identify structural features/descriptors that are different among both classes of compounds and further help in the design of new molecules. Most of the QSAR publications on PXR report the important features used by the models to discriminate activators from nonactivators. There are some commonalities that can be observed and, for most of them, rationalized by the orthogonal inspection of intermolecular interactions in the crystal structures. In 2015, Shi and collaborators studied the distribution of eight molecular descriptors (MW, <i>A</i> log <i>P</i>, log <i>D</i>, log <i>S</i>, number of H bond donors and acceptors, number of rotational bonds, PSA) for activators and nonactivators.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> As expected, different distributions were obtained for <i>A</i> log <i>P</i> and log <i>D</i> in agreement with other studies,<a onclick="showRef(event, 'ref58 ref90 ref91 ref191 ref193 ref200 ref201 ref203 ref205 ref208 ref210'); return false;" href="javascript:void(0);" class="ref ref58 ref90 ref91 ref191 ref193 ref200 ref201 ref203 ref205 ref208 ref210">(58,90,91,191,193,200,201,203,205,208,210)</a> showing that activators tend to be more hydrophobic than nonactivators. They can indeed form stronger hydrophobic interactions with the hydrophobic binding site of PXR. However, this trend is not sufficient to achieve acceptable discriminating capacity to separate activators from nonactivators using a single physicochemical parameter. Their study of structural features, highlighted by Bayesian modeling, revealed that flexibility is also an important structural pattern for PXR activation, as PXR activators must be flexible enough to enter into the buried ligand binding pocket. A high content of halogen atoms and unsaturated chains/rings relevant for hydrophobic contacts, aromatic rings for π-π stacking, as well a small number of nitrogen atoms are also positive features for PXR activation. Unfavorable structural fragments are more polar, containing hydroxyl or amine groups.<a onclick="showRef(event, 'ref201 ref209'); return false;" href="javascript:void(0);" class="ref ref201 ref209">(201,209)</a> The shape of PXR ligands is also an important parameter: typically, binders are characterized by high MW and globular shape.<a onclick="showRef(event, 'ref200 ref201 ref203 ref208 ref210'); return false;" href="javascript:void(0);" class="ref ref200 ref201 ref203 ref208 ref210">(200,201,203,208,210)</a> Other key descriptors to discriminate activators from nonactivators are related to electrostatics/hydrogen bonding and especially the ratio between HBD and HBA properties or the 3D descriptors computed from the molecular electrostatic potential.<a onclick="showRef(event, 'ref58 ref201 ref203'); return false;" href="javascript:void(0);" class="ref ref58 ref201 ref203">(58,201,203)</a> Starting from these observations, some recommendations were proposed to avoid PXR activation, such as putting polar groups at the end of an activator, adding a large rigid group, or removing the central HB acceptor.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.3.  Structure-Based Approaches, Including Docking</h3><div class="NLM_p">The first crystal structures of PXR in complex with the ligand SR12813 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) or in its apo form were released in 2001, opening the field of structure-based modeling.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Since then, 30 structures (corresponding to 31 entries) have been deposited in the Protein Data Bank (PDB). A huge variety of ligands have been cocrystallized with PXR, including natural products,<a onclick="showRef(event, 'ref151 ref154 ref166'); return false;" href="javascript:void(0);" class="ref ref151 ref154 ref166">(151,154,166)</a> steroids,<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> and macrocycles<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> as well as diverse drugs, pesticides, and synthetic ligands,<a onclick="showRef(event, 'ref95 ref145 ref153 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref218'); return false;" href="javascript:void(0);" class="ref ref95 ref145 ref153 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref218">(95,145,153,156−165,218)</a> highlighting the variety of specific interactions that can be formed between PXR and its ligands and demonstrating the promiscuity of the PXR ligand binding domain.</div><div class="NLM_p">The 3D structures cocrystallized with specific ligands/drugs were, in most cases, used to rationalize and design out PXR binding in several medicinal chemistry programs.<a onclick="showRef(event, 'ref157 ref160 ref161 ref162 ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref157 ref160 ref161 ref162 ref163 ref164">(157,160−164)</a> These specific aspects are discussed in detail in the previous section (<a class="ref internalNav" href="#sec3" aria-label="section 3">section 3</a>) of this perspective.</div><div class="NLM_p">Classical rigid docking methodologies were initially investigated by Ekins and collaborators to evaluate their ability to identify PXR activators and were compared to the performance of machine learning approaches.<a onclick="showRef(event, 'ref200 ref202 ref205 ref219'); return false;" href="javascript:void(0);" class="ref ref200 ref202 ref205 ref219">(200,202,205,219)</a> Some challenges related to the promiscuous nature of the PXR ligand binding pocket were pointed out: a huge volume able to accommodate a diversity of ligands covering a large range of sizes and chemical properties; flexibility that allows the adjustment of the binding site to the size of the ligand; the coexistence of several interacting points, leading in some cases to multiple binding modes for the same ligand. To overcome the challenge related to the flexibility of the protein, the possibility to classify a set of 115 steroids into activators and nonactivators was investigated, using parallel docking with GOLD in the six crystal structures of PXR available at that time.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> A specific scoring scheme was designed where GOLDSCORE was weighted based on the similarity to reference activators of PXR, the 5α-androstan-3β-ol and the cocrystallized 17β-estradiol to discriminate activators from nonactivators. The overall performance of these classifications was relatively poor with overall accuracies below 60%. The performance of the docking approach was systematically compared to 2D/3D/4D/5D-QSAR studies showing some benefit of using 5D-QSAR in this specific set of compounds. In parallel, a larger data set of 297 molecules was docked into 4 different crystal structures of PXR to investigate more deeply the influence of the docking score schemes and compare them systematically to machine learning predictions.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> In this case, the best docking prediction accuracy (around 60%) was obtained with the GOLDSCORE weighted by molecular shape descriptors. It was however outperformed by an SVM classification models characterized by overall accuracies on the test set around 70–80%. A similar docking approach was performed on another set of pesticides and industrial chemicals from the ToxCast database.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> The aim of this study was to run a virtual screen of the database to see if it was possible to identify PXR activators prior to <i>in vitro</i> evaluation. All 308 ToxCast compounds were docked into 5 crystal structures of PXR, 15 of them were selected based on their consensus docking score; 11 compounds were tested <i>in vitro</i> leading to the identification of 6 strong and 2 weak agonists. The docking-based classification of the entire ToxCast data set was then further assessed by experimental results. The best classification performances were characterized by an overall accuracy around 56%, a specificity of 51% but a good sensitivity of 74%.</div><div class="NLM_p">In parallel, Gao and collaborators from Merck<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> (see also <a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>) used in-house molecular docking methodologies to analyze structural classes of hPXR activators. They tried to rationalize the structure activity relationships (SAR) observed for these series, by analyzing the potential interactions formed with the PXR binding pocket and proposed some structural modifications to avoid PXR activation. In agreement with the published pharmacophores of PXR agonists,<a onclick="showRef(event, 'ref90 ref191 ref193 ref195 ref197'); return false;" href="javascript:void(0);" class="ref ref90 ref191 ref193 ref195 ref197">(90,191,193,195,197)</a> hydrophobic regions separated by a more polar linker are typical characteristics of PXR agonists. Despite the challenge of observing several docking modes, they demonstrated that adding polar groups at the end of the molecule, introducing substituents able to induce steric hindrance and destabilize helix 11 and 12 of the hydrophobic side of the PXR binding pocket or removing the central H-bond acceptor feature can help to reduce PXR agonist activity (<i>vide infra</i>, <a class="ref internalNav" href="#sec5" aria-label="section 5">section 5</a>, empirical medicinal chemistry approaches to reduce PXR activity). This study opened the field of structure-based design out of PXR activation in specific medicinal chemistry programs developed in the next section of this perspective.</div><div class="NLM_p">To study the structural determinants of ligand binding to the PXR, Xiao et al. evaluated the <i>K</i><sub>d</sub> of 37 marketed drugs on a tethered PXR-SRC construct. These <i>K</i><sub>d</sub> values correlated well with the EC<sub>50</sub> values obtained with a reporter-gene assay and were used to classify the drugs into strong, moderate/weak, and nonbinders.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> Nonbinders were characterized by low MW (<300 Da) or a shape incompatible with the PXR binding pocket. Strong and moderate binders were systematically docked into the PXR binding pocket. They observed that strong binders displayed one or multiple H-bond acceptor(s) or donor(s), potentially serving as an anchoring point in the binding pocket; additional hydrophobic interactions, mostly through aromatic π–π interactions, may further enhance the binding affinity, while the conformational flexibility of the binders can also be an asset for fitting into the binding site of PXR. In another paper, Chen and collaborators used molecular docking and hybrid quantum mechanics/molecular mechanics (QM/MM) to investigate the promiscuous interaction of PXR with hundreds of diverse activators and nonactivators.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> They also proposed a new method called multiple binding mode-based quantitative structure activity relationship (MBMB-QSAR) to predict the binding affinity of PXR ligands. For activators, docking scores reflecting higher binding affinities were indicative of a tighter binding mode; a limited number of binding modes were also observed, while nonactivators bind randomly into the PXR pocket. These few dominant modes are induced by H-bond interactions formed with two main dominant polar spots located on the hydrophobic surface of the binding pocket formed by residues Glu285/His327 and His407/Arg410. The MBMB-QSAR methodology was subsequently used to characterize the nonbonded interaction profile of PXR with its ligands considering multiple potential binding modes. A total of 63 descriptors encompassing 3 types of interactions (hydrophobic, electrostatic, and steric potentials) for 21 amino acids delineating the PXR binding site were generated and averaged over the different binding modes obtained by docking to set up the interaction profile and predict the activating potency of new compounds through a PLS regression model. From this model it appears that the most important contributions to PXR activation are the hydrophobic and electrostatic forces as previously described in several QSAR studies on PXR.</div><div class="NLM_p">More specific data sets were investigated using molecular docking: molecular interactions formed by dioxins within PXR and CAR nuclear receptor binding sites<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> and by herb ingredients that can potentially lead to herb–drug interactions.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> In this later study, a combination of pharmacophore modeling and docking-based rank aggregation was used to identify PXR agonists. A structure-based pharmacophore model was first generated using three different crystal structures of PXR in interaction with SR12813 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The performance of the model was evaluated using a set of 266 compounds with known PXR activities, showing good specificity (82%) and a sensitivity of 54%. The pharmacophore model was then used to screen 820 ingredient structures coming from 421 herbs. A total of 305 ingredients from the list of 820 were picked out by the pharmacophore model. In a second step, they were docked within the PXR binding pocket and ranked based on four different energy scoring functions. This methodology performed quite well: the top-ranked 10 herb ingredients are found in 14 different herbs; 5 of these herbs sharing 6 of the 10 top-ranked ingredients are known to be involved in herb–drug interactions. Four top-ranked ingredients could not be associated with herb–drug interactions, meaning that either they are not PXR agonists and can be considered as false positives or that these interactions are not described yet in the literature.</div><div class="NLM_p last">In summary, multiple computational approaches have been developed to help drug discovery scientists predict PXR activity and, ultimately, to diminish it with the design of new analogues. The methodologies described here highlight the progress that has been made in the field but also some of the remaining challenges, such as dealing with the intrinsic flexibility of the PXR ligand binding domain, its promiscuous nature, and the heterogeneity of data.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">5.  Empirical Medicinal Chemistry Approaches to Reduce PXR Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Before the use of PXR structural information and cocrystallization with ligands from a series under active optimization, medicinal chemists used empirical approaches to reduce PXR activity, from which several key aspects were gleaned. It has been known that PXR likes lipophilic ligands and ligands which contain aromatic groups. This is in line with the observation that the initial ligands crystallized with PXR were all lipophilic. Therefore, a frequently used strategy has been to add polar functional groups to ligands to reduce PXR activity. Alternatively, similar strategies such as reducing lipophilicity without adding additional groups have been employed. However, as can be seen from this section, there are several other applicable structural modifications, some of which are very subtle, which can be employed.</div><div class="NLM_p">Examples from the literature are now discussed in turn by target, in approximate chronological order, although later papers on the same target are covered in the same section, where SAR against PXR has been disclosed. As this is not comprehensive, preference for inclusion has been given to reports in the medicinal chemistry literature as part of drug discovery projects, as lessons from this are most likely to be able to impact future medicinal chemistry and drug discovery projects. Furthermore, the focus on examples utilized is targeted toward structural modifications that resulted in modulation of PXR activity, as again this is likely to be the most useful knowledge. Although some examples included in this section do use some structural knowledge, such as docking, they are not included in the structurally enabled section as they do not have a ligand from the series under investigation crystallized with PXR.</div><div class="NLM_p">PXR activation has been encountered with ligands acting on a wide range of primary targets include kinases (IGF-1R), enzymes (11β-HSD1, IDH1, DOT1L, HCV NS5B, EZH2), ion channels (T-type Ca<sup>2+</sup>, Na<sub>V</sub>1.7, P2X3, TRPM8, CFTR), GPCRs (B<sub>1</sub>, nociceptin, smoothened, orexin), nuclear receptors (RORγ), and HBV core protein nucleocapsid assembly inhibitors. The targets impacted cover a range of diseases including oncology, epilepsy, diabetes, obesity, dyslipidemia, HBV, HCV, pain, cystic fibrosis, psoriasis, psoriatic arthritis, ankylosing spondylitis, cough, panic, depression, and anxiety. The analysis shows that Amgen, BMS, and Merck have been major players and pioneers in establishing the SAR of PXR reduction. Initial reports appeared in 2005 from Merck, with several landmark papers from Merck and BMS being particularly noteworthy.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">5.1.  HCV NS5B 2005 (Merck), 2014 (Novartis), and 2017 (Vertex)</h3><div class="NLM_p">One of the earliest disclosures of PXR SAR came from Merck in 2005, when the group encountered PXR activation as part of a project to optimize zwitterionic inhibitors of HCV NS5B.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> In this case, it was found that a small change in structure resulted in substantially less activity at PXR. This is highlighted in <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a> by two matched pairs, <b>167</b> versus <b>168</b> and <b>169</b> versus <b>170</b>. Docking to PXR suggested that the amide carbonyl accepts an H-bond from His407, while the carboxylic acid accepts a H-bond from Ser247 (polar rim). The phenyl and cyclohexyl rings were predicted to bind in the lipophilic pocket formed by Trp299, Phe288, and Tyr305, i.e., the hydrophobic cage. The flexibility of the methylene group of the amide could allow it to be accommodated. Ultimately it was proposed that the structural switch highlighted in <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a> reduces the conformational flexibility in the amide region which ultimately causes a steric clash with helix 11 of PXR and concomitant reduction in PXR activation. The SAR was also rationalized in a subsequent landmark paper on understanding PXR activity at the molecular level from SAR and docking.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a></div><figure id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. SAR around the amide of HCV NS5B inhibitors from Merck showing that replacement of the flexible amide group in <b>167</b> and <b>169</b> by a more rigid piperidine, as found in <b>168</b> and <b>170</b>, reduces PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fine tuning of this series resulted in optimal derivatives such as <b>171</b>, <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a>, which displayed no PXR activation up to 10 μM.</div><div class="NLM_p">More recently, Novartis described their efforts to diminish PXR activity in a series of thiophene carboxylic acid series, exemplified by <b>172</b>, which was a potent inhibitor of NS5B. Off-target profiling highlighted PXR induction as an issue, with <b>172</b> displaying 141% activation at 10 μM, relative to rifampicin at 10 μM, in a reporter gene assay, <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a>.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Based on this information, the group explored SAR to reduce PXR activity and targeted <25% activation relative to rifampicin (at 10 μM). Inspection of published PXR crystal structures available at the time led the group to introduce polarity, as had been postulated as a general strategy by others, <i>vide infra</i>. Switching from the piperidone in <b>172</b> to a morpholinone in <b>173</b> did diminish PXR activity to some extent; however, the PXR activation was confirmed in human hepatocytes where a 10 μM concentration of this compound increased testosterone (a 3A4 substrate) metabolism by 61% in addition to increasing 3A4 mRNA by 66% (relative to rifampicin at 10 μM). Dimethylation of <b>173</b> resulted in <b>174</b>, which showed increased PXR activation; however, addition of an ethanol moiety, as in <b>175</b>, strongly reduced PXR activity while maintaining potency, highlighting the importance of the alcohol in diminishing PXR activity, <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a>.</div><figure id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0051.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. SAR from a series of carboxylic acid HCV NS5B inhibitors from Novartis, highlighting the positive impact of adding an alcohol and the impact a methyl group may have.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, addition of a methyl group on the morphinone to give <b>176</b> brought back PXR activity, whereas the diastereomer <b>177</b> displayed significantly weaker PXR activity, <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a>. However, addition of a methyl group next to the hydroxyl moiety, such as <b>178</b> and <b>179</b>, was well tolerated as both retained low PXR activation, <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a>, highlighting the importance of the location of the methyl group. Further profiling <b>179</b> in human hepatocytes revealed low potential for induction, with only a 2% increase in testosterone metabolism at 10 μM, supporting the further development of this compound.</div><div class="NLM_p">Subsequently, Vertex have disclosed their SAR against PXR for a very similar series, depicted in <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> Using a luciferase reporter gene assay (24 h incubation) in DPX2 cells (a human hepatoma cell line) <b>180</b> showed weaker PXR activation than <b>181</b>, albeit with a similar EC<sub>50</sub> value, showing the chiral center has a marked impact.</div><figure id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0052.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. HCV NS5B inhibitors from Vertex showing the impact of chirality on PXR activity and that adding carbon atoms can be beneficial in certain cases. PXR activation is relative to 20 μM rifampicin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Increasing the size of the piperidone ring to give the homopiperidones <b>182</b> and <b>183</b> almost completely ablated PXR activation, despite the net addition of a methylene moiety in both cases.</div><div class="NLM_p last">These three examples show that very slight changes to structures can have a marked impact on PXR activation. Thus, compounds that are isomeric, or very close to being isomeric, can have drastically different profiles. Furthermore, sometimes adding lipophilicity can be beneficial in terms of reducing PXR activation.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">5.2.  11β-HSD1 2007–2016 (Merck, Amgen, BMS, SK Bio)</h3><div class="NLM_p">The search for inhibitors of 11β-HSD1 presents an interesting case in terms of undesired PXR activity. Numerous companies have worked on this target and have established that these compounds have inherent PXR liabilities despite spanning several chemical series. This could be due to several reasons, such as the inherent lipophilicity of the ligands due to the nature of the active site, with the endogenous substrate being a steroid, namely, cortisone. Furthermore, the pharmacophore of 11β-HSD1 and PXR appear to have similarities, such as a key central H-bond acceptor with lipophilic or aromatic groups at either side. Indeed, an example from BMS (<i>e.g</i>., compounds from the <b>223</b> series, <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>) shows that inhibitors can be pseudosymmetrical and structural modifications can cause a 180° rotation in the 11β-HSD1 binding site, <i>vide infra</i>.</div><div class="NLM_p">A very early example of unwanted PXR activity and the use of docking to understand and reduce PXR activity was published by Merck in 2007.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> At the time, only five PXR crystal structures were in the public domain and only three were with ligands: SR12813 (<b>62</b>), rifampicin (<b>1</b>), and hyperforin (<b>7</b>), <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. As one of the structures with SR12813 (<b>62</b>) contained three poses for the ligand, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a> (with SR12813) was used for docking studies, as this ligand pose was considered the agonist conformation. Two assays were used to assess PXR activation. The first employed a HepG2 cell reporter gene assay with 48 h incubation with compounds as a higher throughput assay. Compound activity was expressed as a percentage of that observed with 10 μM rifampicin. The second assay utilized cryopreserved human hepatocytes from three different donors and measured the fold induction of CYP3A4 mRNA relative to vehicle treated cells, i.e., not relative to rifampicin. The authors also note that compounds that show >30% activation at 10 μM relative to rifampicin in the HepG2 assay were considered to have a risk of CYP3A4 induction in the clinic, based on experience and analysis of internal data.</div><div class="NLM_p">PXR data generated in these assays highlighted the CYP induction risk for compounds, such as <b>184</b>, <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>, demonstrated PXR activation similar to rifampicin in the HepG2 assay and which was confirmed in the primary hepatocyte assay.</div><figure id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0053.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. SAR on PXR activation for a series of 11β-HSD1 inhibitors from Merck (<b>184</b>–<b>187</b>), showing the positive impact of the <i>meta</i>- and <i>para</i>-ethylsulfone on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Docking <b>184</b> into a published PXR structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a>) led to two potential poses, where the molecule was rotated 180° around its central axis, not unlike 11β-HSD1 itself, <i>vide infra</i>, BMS work, <i>e.g</i>., <b>223</b>, <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>. In both cases the central triazole accepts a hydrogen bond from His407 (polar rim, blue residues) and the <i>spiro</i>-cyclobutane ring causes a bent conformation as seen with many other ligands bound to PXR. In one pose the <i>p</i>-chlorophenyl ring forms a π–π interaction with Trp299 (hydrophobic cage, green residues) while the biphenyl moiety sits in the pocket defined by Phe429 on the hydrophobic side (orange residues). In the alternate pose, the biphenyl moiety sits in the hydrophobic cage, forming a π–π interaction with Phe288 and edge-to-edge interactions with Phe299 and Tyr306, while the <i>p</i>-chlorophenyl ring interacts with Phe281 on the polar rim (blue residues). Based on these simulations, it was proposed that adding a large polar group at the <i>meta</i>- or <i>para</i>-position of the outer phenyl ring of the biphenyl moiety would decrease PXR activity. Thus, as predicted, installation of an ethylsulfone on the right-hand side phenyl ring had a beneficial effect on PXR activity when in the <i>meta</i>- (<b>186</b>) and <i>para</i>-positions (<b>187</b>) but not the <i>ortho</i>-position (<b>185</b>), <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>. Taken together, this SAR supports the hypothesis that the sulfone not only reduces the lipophilicity of the compounds but likely clashes sterically and/or electronically with PXR. In addition to impacting physicochemical properties, <i>ortho</i>-derivative <b>185</b> would also impact the dihedral angle, causing the outer phenyl ring into an orthogonal conformation.</div><div class="NLM_p">A later paper from the same group provided further analogues that showed the same diminution of PXR activity could be achieved with a methyl sulfone in the <i>meta</i>- or <i>para</i>-positions (not shown).<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a></div><div class="NLM_p">Reduction of lipophilicity by replacement of the outer phenyl ring by heteroaromatics was less successful in mitigating PXR activity, as shown by pyridyl derivatives <b>188</b>–<b>190</b>, with the 2-pyridyl derivative (<b>188</b>) clearly showing the weakest impact, <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>. The imidazole derivative <b>191</b>, <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>, shows a stronger reduction in PXR activity, and the methyl imidazole <b>192</b> shows a further reduction in PXR EC<sub>50</sub>, <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>.</div><figure id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0054.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. 11β-HSD1 inhibitors from Merck showing attempts to diminish PXR activation by reducing lipophilicity via replacement of the outer phenyl ring of <b>184</b> by aromatic heterocycles (<b>188</b>–<b>192</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further heteroaromatic ring systems were investigated as replacements for the outer phenyl ring of the biphenyl moiety.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> Positive effects were observed with pyrimidine (<b>193</b>), pyrazine (<b>194</b>), and isoxazoles (<b>195</b> and <b>196</b>), whereas the thiophene derivative (<b>197</b>) offered no improvement, <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">55</a></a>. These data support the general strategy of reducing lipophilicity to reduce PXR activation, with the underlying cause likely to be the polar group being placed in a very lipophilic region or introducing a negative electronic interaction.</div><figure id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0055.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Further variation of the outer phenyl ring of <b>184</b> with heteroaromatic ring systems showing polar groups such as pyrimidine (<b>193</b>), pyrazine (<b>194</b>), and isoxazole (<b>195</b> and <b>196</b>) have a beneficial effect on PXR activation, whereas lipophilic systems such as thiophene (<b>197</b>) do not.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Within this series, some interesting observations were made around the role of the Cl-atom on the biphenyl moiety of <b>184</b> and its replacements. Deletion of the Cl-atom (<b>198</b>) had no impact on PXR activity, <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">56</a></a>. However, when the Cl-atom of <b>189</b> was replaced by a F-atom (<b>199</b>), it resulted in a strong reduction in PXR activity, <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">56</a></a>. Similar beneficial effects on PXR by fluorine substitution have been noted elsewhere in this perspective. Interestingly, on the contrary, when the same change was made to the pyrazine analogue <b>194</b>, to give <b>200</b>, the opposite effect on PXR activation was observed, <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">55</a></a>. This SAR serves to highlight the worthiness, and unpredictability, of apparently simple structural modifications.</div><figure id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0056.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Divergent SAR for Cl-replacements from a series of 11β-HSD1 inhibitors from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacement of the outer phenyl ring of the biphenyl moiety by polar, nonaromatic groups was also investigated, <a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">57</a></a>. This met with some success, as highlighted by derivatives such as the carboxylic acid (<b>201</b>) and corresponding amide (<b>202</b>) as well as the reversed amide (<b>203</b>). While the decreased activation of PXR relative to <b>184</b> could be interpreted as being due to a reduction in lipophilicity or detrimental electronic effect, complete removal of the phenyl ring (<b>204</b>) also had a beneficial effect on PXR activation and provides a good control experiment. Thus, it appears the outer phenyl ring forms a beneficial interaction with PXR.</div><figure id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0057.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Effect on PXR activation of replacement of the outer phenyl ring on the right-hand side by polar groups (<b>201</b>–<b>203</b>) or removal (<b>204</b>) from a series of 11β-HSD1 inhibitors from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From this work, <b>194</b> proved to have the best overall profile but suffered from high clearance in rodent PK studies. Addition of a fluorine atom to the cyclobutyl ring to reduce clearance, a tactic that had proved successful for other analogues, resulted in the identification of <b>205</b>, <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">58</a></a>. This compound had an almost identical profile in terms of primary pharmacology and PXR induction but significantly improved the rodent PK profile.</div><figure id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0058.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Reduction of clearance by addition of a fluorine atom to the cyclobutyl ring of <b>194</b> resulted in the identification of <b>205</b>, which maintained low PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amgen have also had a longstanding project to identify inhibitors of 11β-HSD1 covering two series, both of which were found to possess inherent PXR liabilities. The first paper from the group was published in 2008 and details an aminothiazolone series exemplified by <b>206</b>, <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> Compound <b>206</b> was found to activate PXR by 45% at 20 μM, relative to the control, rifampicin, at 12.5 μM, with all data expressed relative to the same control. This reporter gene assay (HEK) was utilized as the main screen with selected compounds profiled in human hepatocytes.</div><figure id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0059.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. SAR of PXR activation from a series of aminothiazolone 11β-HSD1 inhibitors from Amgen, showing that polar groups attached to the highlighted phenyl ring can reduce PXR activity, <b>208</b> and <b>209</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The initial strategy to reduce PXR activation entailed replacement of the trifluoromethyl group with more polar groups to reduce lipophilicity, although it was felt a phenyl ring would offer a more convenient platform to introduce polarity. Initial SAR was conducted with the 4-fluorophenyl group on the left-hand side instead of the 2-fluoro derivative in <b>206</b>. Thus, replacement of the CF<sub>3</sub> group by a 4-fluorophenyl ring resulted in increased PXR activation, <b>207</b>. However, switching the F-atom to a primary amide (<b>208</b>) or a primary alcohol (<b>209</b>) markedly reduced PXR activation relative to <b>207</b>, <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>.</div><div class="NLM_p">Inspired by derivative <b>209</b>, further alcohol derivatives were prepared without the phenyl ring, which revealed several shorter linkers were appropriate, such as the iso-propanol derivative <b>210</b>; however, larger moieties like cyclopentanol (<b>211</b>) increased PXR activation (<a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">60</a></a>). Focusing on <b>210</b>, deletion of the <i>para</i>-fluorine on the left-hand side (<b>212</b>) significantly increased PXR activation. The beneficial effect of the fluorine atom could also be obtained in the <i>ortho</i>-position, <b>213</b>, and is not simply due to an electronic effect as the corresponding Cl derivative <b>214</b> displays stronger PXR activation, potentially due to its increased lipophilicity. This SAR again highlights the marked benefit a fluorine atom on an aromatic ring can have.</div><figure id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0060.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Alkyl alcohol derivatives <b>210</b> and <b>211</b> and the beneficial effect of fluorination of the left-hand side phenyl ring (<b>210</b>, <b>212</b>, <b>213</b>, and <b>214</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As one single enantiomer of <b>210</b> (S-isomer) was more potent, it was profiled further in comparison to <b>206</b>. In the PXR assay (S)-<b>210</b> showed 6% activation at 20 μM, its diastereomer (R)-<b>210</b> also showed low induction, 11% at the same concentration. More detailed characterization was undertaken by incubating the compounds with cryopreserved human hepatocytes from two donors and measuring mRNA levels after incubation for 48 h at 20 μM. In this assay <b>210</b> elicited an increase of 45% and 13% from donors 1 and 2, respectively, relative to rifampicin at 20 μM, while <b>206</b> caused an increase of 110% (donor1) and 67% (donor 2) respectively. The same assay was also used to assess the effect on CYP3A4 activity by compound incubation, by measuring the conversion of midazolam to 1′-hydroxy midazolam. In this assay, <b>210</b> showed an increase in metabolism of 17% (donor 1) and 10% (donor 2), whereas <b>206</b> showed increases of 64% (donor 1) and 56% (donor 2) relative to rifampicin. Thus, the reduced PXR activation was validated for <b>210</b>.</div><div class="NLM_p">The same group from Amgen have detailed challenges with PXR activation with a different chemical series. Compounds, such as <b>215</b>, <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">61</a></a>, which bears some structural similarity to T0901317 (<b>63</b>), <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, were found to activate PXR when tested at 2 μM in a HepG2 luciferase assay. PXR activation was again expressed relative to rifampicin (<b>1</b>), but this time at 10 μM.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> Homologation (<b>216</b>) made little impact as did addition of a <i>spiro</i>-cyclopropane (<b>217</b>), <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">61</a></a>. However, replacement of the nitrile moiety by a more polar primary amide significantly mitigated PXR activation, as shown by <b>218</b> and <b>219</b>. Interestingly, the diastereomer of <b>218</b>, i.e., <b>220</b> was found to strongly activate PXR, demonstrating the beneficial effect of the primary amide was not simply lipophilicity driven but most likely due to a negative interaction with PXR or a steric clash. Finally, replacement of the cyclohexane ring by a piperidine, thereby removing a chiral center, resulted in <b>221</b> and <b>222</b>, <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">61</a></a>, both of which are essentially devoid of PXR activation, showing the piperidine mimics the <i>trans</i>-cyclohexane ring.</div><figure id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0061.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. PXR SAR for a series of amide 11β-HSD1 inhibitors from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>222</b> was crystallized with 11β-HSD1 and shows an L-shape conformation due to the cyclopropyl group on the central amide occupying the <i>trans</i>-position of the amide. The conformation, coupled with the central HBA (amide carbonyl), is likely to predispose this series in a favorable confirmation to bind to PXR.</div><div class="NLM_p">More recently BMS have disclosed their efforts to mitigate undesired PXR activity in one of their series of 11β-HSD1 inhibitors exemplified by <b>223</b>, <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>,<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> which bears some similarities to the triazole series from Merck. Variation of the substitution of the aryl ether had little impact on PXR activation, as shown in <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>, with Cl-substitution (<b>224</b>–<b>226</b>) actually increasing PXR activity and fluorine (<b>227</b>) having no impact in this instance. The methylpyridine (<b>228</b>) did bring some benefit, <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>.</div><figure id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0062.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. PXR SAR for aryl ether modification from a series of BMS 11β-HSD1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Switching from aryl ethers to alkyl ethers proved more fruitful in mitigating PXR activity. Although simple reduction made no impact, demonstrated by cyclohexyl derivative <b>229</b>, <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">63</a></a>, addition of a polar O-atom to give THP <b>230</b> significantly reduced PXR activation, although both derivatives compromised on primary activity. Switching to directly linked alkyl groups was also fruitful as a simple methyl group (<b>231</b>) offered a substantial improvement but also diminished 11β-HSD1 inhibition. A cyclopropyl group (<b>232</b>) was also beneficial, whereas an isopropyl group (<b>233</b>) was a potent PXR activator.</div><figure id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0063.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. PXR SAR for alkyl ether derivatives (<b>229</b> and <b>230</b>) and directly linked alkyl groups (<b>231</b>–<b>233</b>) from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several compounds from this series were crystallized with 11β-HSD1 which revealed that compounds can rotate 180° in their binding mode depending on the nature of the groups attached to the central triazolopyridine. In both binding modes, the triazole N-atoms act as H-bond acceptors. These features fit well with the pharmacophoric features required to interact with PXR, which could also potentially accommodate more than one binding mode by the nature of the <i>pseudo</i>-symmetrical ligands detailed here.</div><div class="NLM_p">A more recent example on the same target comes from the Life Science R &D Centre at SK Chemicals in Korea who found their series, exemplified by <b>234</b>, <a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">64</a></a>, to activate PXR. This liability was completely negated by the addition of a fluorine atom and a nitrogen atom, resulting in the pyrimidine derivative <b>235</b> (SKI2852), <a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">64</a></a>, which was selected as a development candidate.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> Unfortunately, no further data is given for the individual changes, so it is impossible to ascertain the impact of each change. However, this again highlights the worthiness of simple molecular changes, including the importance a fluorine atom can make.</div><figure id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0064.jpeg" id="gr64" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Subtle structural modification of <b>234</b> resulted in <b>235</b>, with significant diminution of PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">5.3.  B1 Antagonists 2008 (Merck)</h3><div class="NLM_p">Another early example of a project at Merck that encountered issues with PXR activation is the bradykinin B1 receptor antagonist project.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> Derivatives such as <b>236</b>, <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">65</a></a>, were found to activate PXR to a similar extent to rifampicin (99%) in a PXR assay where compounds were screened at 10 μM and PXR activation is expressed relative to that observed for the positive control (rifampicin) also at 10 μM.</div><figure id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0065.jpeg" id="gr65" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. B1 antagonists from Merck showing that replacement of a trifluoromethyl amide (<b>236</b>) by more polar groups (<b>237</b>–<b>239</b>) can have a beneficial effect on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacement of the peripheral trifluoromethyl amide was investigated, as exemplified by analogues of <b>236</b> in <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">65</a></a>. Replacement of the CF<sub>3</sub> group by an isoxazole (<b>237</b>) significantly reduced PXR activation while maintaining primary activity. Substitution at the 5-position of the isoxazole of <b>237</b> with a methyl group had minimal impact on PXR activity, but larger alkyl groups (ethyl and <i>cyclo</i>-propyl) increased PXR activation (data not shown). The regioisomeric isoxazole <b>238</b> had a similar profile with slightly improved primary pharmacology, <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">65</a></a>.</div><div class="NLM_p">Addition of a methoxy group to the isoxazole of <b>238</b> had a further beneficial effect on PXR activity, resulting in <b>239</b>; however, an ethoxy group or a Cl-atom increased PXR activity (data not shown), thus highlighting the methoxy-isoxazole as optimal.</div><div class="NLM_p last">Taken together, these results again highlight that reducing lipophilicity at the periphery or compounds can have a beneficial effect on PXR and that addition of further lipophilic groups can be accommodated by PXR and may increase the liability.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">5.4.  Merck T-Type Ca<sup>2+</sup> Antagonists 2010 (Merck)</h3><div class="NLM_p">In 2010, the Merck group described some SAR showing the challenges encountered with PXR activation in a series of T-type Ca<sup>2+</sup> antagonists.<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> The chemotype was identified from an HTS and came from a series of non-nucleoside reverse transcriptase inhibitors related to Efavirenz (<b>17</b>), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, which is known to activate PXR. Compounds were again screened in the HepG2 reporter gene assay and were classified as having a high potential for clinical drug–drug interaction with >40% activation at 10 μM, relative to rifampicin), moderate potential with 15% and 40% activation, and low potential with <15% activation. Compounds such as TTA-Q2 (<b>240</b>), <a data-tab="pane-pcw-Figures" href="#fig66" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig66" id="" class=" internalNav">66</a></a>, showed moderate PXR activation, but as shown by TTA-Q3 (<b>241</b>), replacement of the N-cyclopropyl group by trifluoroethyl significantly increased PXR activity, albeit with the addition of a F-atom in the <i>para</i>-position of the phenyl ring. Replacement of the ethyl group in TTA-Q3 (<b>241</b>) by a cyclopropyl group (TTA-Q5, <b>242</b>) improved primary activity but exacerbated PXR activation. Introduction of polarity in the <i>para</i>-position of the phenyl ring, which was suggested to reduce PXR activity by molecular modeling, resulted in TTA-Q6 (<b>243</b>) but had minimal impact on PXR activity.</div><figure id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0066.jpeg" id="gr66" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. SAR for PXR activation from a series of T-type Ca<sup>2+</sup> antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to their overall profiles, TTA-Q3 (<b>241</b>) and TTA-Q6 (<b>243</b>) were profiled in human hepatocytes where they showed 45% and 20% increases in CYP3A4 mRNA, respectively, relative to rifampicin at 1 μM.</div><div class="NLM_p">In a subsequent paper, further SAR was described, showing limited impact on PXR activation and highlighting the challenges inherent within this series to balance primary potency and PK and CNS penetration with PXR activation.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> SAR investigations of the chloro-phenyl ring identified the difluoro-substitution exemplified by <b>244</b> as optimal; however, PXR activity was still an issue, <a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">67</a></a>. Changing the trifluoroethyl group to difluoroethyl made minimal impact (<b>245</b>, <a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">67</a></a>) but resulted in a compound that was further profiled <i>in vivo</i> due to the optimal balance of other properties. Further attempts to reduce PXR activity, by introducing polarity, included substitution of the N-1 position which resulted in compounds such as <b>246</b>. Homologation of the ethyl group resulted in <b>247</b> which further reduced PXR induction. Both compounds showed low metabolic stability in HLM, while <b>246</b> was also found to be a Pgp substrate and therefore not optimal for CNS indications as intended (epilepsy), highlighting the challenges to modulate PXR activity, while balancing other properties in this series.</div><figure id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0067.jpeg" id="gr67" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Further PXR SAR from Merck T-type Ca<sup>2+</sup> channel blockers showing the benefit of polarity (N-oxide) and removing fluorine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">5.5.  IGF-1R Kinase 2008 and 2010 (BMS)</h3><div class="NLM_p">While searching for a candidate inhibitor for the insulin-like growth factor-1 receptor (IGF-1R) kinase, the main series from BMS was found to activate PXR. During the project, the group screened 400 compounds against PXR and published the work detailing the SAR<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> in addition to a paper describing the identification of the candidate molecule, BMS-695735.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> The SAR paper provides excellent insights to PXR SAR and is one of the few papers to be published exclusively on this topic.</div><div class="NLM_p">It was noted that compounds exhibiting 30–40% of the activation of rifampicin at 10 μM were considered to be at risk of inducing CYP3A4; therefore, <30% activation of PXR at 10 μM was targeted. A first-generation compound, BMS-536924 (<b>248</b>) was found to strongly activate PXR, EC<sub>50</sub> 1.1 μM, <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>. In the end, this undesired activity was mitigated by extensive SAR which culminated in the identification of BMS-695735 (<b>249</b>), <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>, where two structural modifications were ultimately required to deliver a compound with the desired profile.</div><figure id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0068.jpeg" id="gr68" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Summary showing the structural modification from BSM-536924 (<b>248</b>) to BMS-695735 (<b>249</b>) to overcome PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As part of this work, the PXR SAR activation for the two discrete areas of the molecule were published and serve to highlight some valuable modifications that may be of use on other projects. First, targeting the lower part of the molecule, replacement of the <i>meta</i>-chlorophenyl ring with five-membered heterocycles such as pyrazole and imidazole was targeted to reduce lipophilicity. It should be noted that the benzylic alcohol was also deleted. As can be seen, comparing <b>248</b> with the chloro-pyrazole analogue <b>250</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, reveals little change in PXR activation. Interestingly, despite its minimal impact effect on PXR activation, it is this group that was ultimately present in the structure of BMS-695735 (<b>249</b>), <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>. Replacing the chloro-pyrazole by the corresponding methyl-pyrazole (<b>251</b>) had minimal impact on IGF-1R potency but substantially reduced PXR transactivation, implying the chlorine atom, or its impact on the electronics of the pyrazole, plays an important role in PXR activation. The unsubstituted pyrazole (<b>252</b>) showed a similar PXR profile but with reduced IGF-1R activity. Incorporation of polar groups (<b>253</b>–<b>255</b>) further reduced PXR transactivation but also diminished IGF-1R activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of PXR Activation for Pyrazole and Imidazole Analogues of IGF-1R Inhibitor BMS-536924 from BMS</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0128.gif" alt="" id="GRAPHIC-d7e5670-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0129.gif" alt="" id="gr113" /></img><div></div></div><div class="NLM_p">Turning to imidazole revealed a similar trend. The dichloro-methylimidazole derivative <b>256</b> retained strong PXR transactivation. However, deletion of one chlorine atom (<b>257</b>) substantially alleviated PXR transactivation, which was further enhanced by removal of the second chlorine atom to give <b>258</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><div class="NLM_p">Analysis of the pyrazole and imidazole subseries showed that PXR activation increased with increasing lipophilicity (ACD log <i>D</i>), with compounds requiring a calculated log <i>D</i> ≥ 0.5 for activation of PXR. The analogues profiled had a range of ACD log <i>D</i> values −2.3 to 1.9.</div><div class="NLM_p">Investigation of replacements for the morpholine moiety proved extremely fruitful. Simply replacing the morpholine in <b>248</b> by a piperazine (<b>259</b>) resulted in a dramatic reduction in PXR transactivation in conjunction with a boost in IGF-1R potency, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Substitution of the piperazine N-atom resulted in a stepwise increase in PXR transactivation, <b>260</b> and <b>261</b>. The amino pyrrolidine derivatives <b>262</b> and <b>263</b> show an interesting difference in PXR activity solely due to the inversion of the stereocenter. Switching the piperazine to a substituted piperidine such as <b>264</b> or <b>265</b> showed PXR activity could also be maintained at a low level with larger groups, although this is likely to be due to the polarity of these groups as the 1,3-dioxolane derivative <b>266</b> showed potent PXR transactivation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of PXR Activation for a Morpholine Analogues of IGF-1R Inhibitor BMS-536924 (<b>248</b>) from BMS</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0130.gif" alt="" id="GRAPHIC-d7e5741-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0131.gif" alt="" id="gr114" /></img><div></div></div><div class="NLM_p">In this subseries, a plot of ACD log <i>D</i> versus PXR activation revealed no correlation, implying the reduced PXR activation for analogues is due to a detrimental structural interaction with PXR. In addition, the range of ACD log <i>D</i> values reflected the higher lipophilicity of these derivatives (ACD log <i>D</i> range ∼0.5–4.0), with one derivative showing ACD log <i>D</i> ∼4.0 with negligible PXR activation.</div><div class="NLM_p">As this work had highlighted the impact of the piperidine-piperazine moiety (<b>265</b>) as a replacement for the morpholine and the potential of the chloro-pyrazole (<b>250</b>) and chloro-imidazole (<b>257</b>) ring systems in the southern region, several combination derivatives were investigated, two of which, <b>267</b> and <b>268</b>, are shown in <a data-tab="pane-pcw-Figures" href="#fig69" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig69" id="" class=" internalNav">69</a></a>. As can be seen from the PXR activation data for both, the combination provided a similarly low level of PXR activation.</div><figure id="fig69" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Figure 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0069.jpeg" id="gr69" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 69. <b>267</b> and <b>268</b> showing the two-point SAR combination still has low PXR activation in the IGF-1R inhibitor series from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig69"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although these derivatives provided low levels of PXR activation, in the end the group returned to substituted piperazines in combination with the chloro-pyrazole, which ultimately resulted in the identification of <b>249</b>, <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>, which displayed the required balance and combination of properties.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">5.6.  NOP Antagonists (Schering-Plough 2009)</h3><div class="NLM_p">In search for nociceptin (NOP) agonists for the treatment of cough and anxiety, researchers at Schering-Plough identified tropane derivatives which were found to activate PXR.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> Compounds were screened in a human PXR reporter gene assay at 1 μM, and data were reported as activation relative to the positive control, rifampicin also at 1 μM. A ratio of <0.4 of rifampicin at 1 μM was targeted. Compound <b>269</b> was found to exhibit a ratio of 0.89 relative to rifampicin and therefore deemed to have a considerable risk of CYP3A4 induction. Substitution at the <i>para</i>-position of the phenyl ring, as highlighted in <a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">70</a></a>, was found to reduce PXR activation, regardless of the nature of the substituent, thereby implying a steric interaction with PXR. Several derivatives are highlighted in <a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">70</a></a> to exemplify this. For instance, a F-atom (<b>270</b>) shows a marked reduction of PXR activity and again highlights the worthiness of fluorine substitution when wishing to reduce PXR activity. Chlorine, <b>271</b>, showed a further reduction, but no subsequent benefit was observed with Br (data not shown). A methoxy group had a similar effect to Cl, as shown by <b>272</b>. Other polar groups, <i>e.g</i>., a primary amide (not shown), also had a similar activity on PXR but diminished NOP activity.</div><figure id="fig70" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Figure 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0070.jpeg" id="gr70" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 70. SAR of PXR activation within a series of NOP agonists from Schering-Plough showing the SAR for substitution on the phenyl ring (<b>269</b>–<b>272</b>) and the amide (<b>269</b>, <b>273</b>–<b>276</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig70"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It was found that amide substitution generally worsened PXR activation. Thus methylation of <b>269</b> resulted in <b>273</b>, which showed an inferior PXR profile. This was further exacerbated by the ethyl analogue <b>274</b> and even further by the <i>iso</i>-propyl derivative <b>275</b>. Incorporation of some polarity did not improve the situation, as shown by <b>276</b>; however, it should be noted that this derivative could form an intramolecular hydrogen bond, thus masking polarity and resulting in less steric demand.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">5.7.  Smoothened Antagonists (Amgen, 2010)</h3><div class="NLM_p">In 2010 Amgen, disclosed issues with PXR activation for a series of smoothened antagonists.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> Compounds such as <b>277</b> were found to activate PXR in a HepG2 luciferase reporter assay where it showed 81% activation at 2 μM, relative to the positive control, rifampicin. Deletion of the trifluoromethyl group (<b>278</b>) reduced PXR activation to 30% at 2 μM, <a data-tab="pane-pcw-Figures" href="#fig71" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig71" id="" class=" internalNav">71</a></a>. Interestingly, deletion of the methyl group on the piperazine also reduced PXR activation (<b>279</b>), whereas moving it on the piperazine ring (<b>280</b>) had no effect, implicating a role of lipophilicity in the PXR interaction. This was further supported by the replacement of the trifluoromethyl group in <b>277</b> by a hydroxymethyl moiety (<b>281</b>) which also reduced lipophilicity and PXR activation.</div><figure id="fig71" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Figure 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0071.jpeg" id="gr71" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 71. SAR of PXR activation in a series of smoothened antagonists (<b>277</b>–<b>281</b>) from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig71"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, replacement of the left-hand phenyl ring by pyridine did not impact PXR activation despite the reduction in lipophilicity, thereby contesting the thesis that the PXR activity of the series was driven by lipophilicity, <b>281</b>–<b>283</b>, <a data-tab="pane-pcw-Figures" href="#fig72" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig72" id="" class=" internalNav">72</a></a>. The three pyridyl isomers also showed decreased smoothened activity (>10-fold). Both 2-pyrazine (5.4% of control at 2 μM) and 5-pyrimidine (7.1% of control at 2 μM) analogues did show reduced PXR activation but were inactive at smoothened (not shown). Thus, this SAR against PXR is reminiscent of that seen by Merck on their series of 11β-HSD1 inhibitors, <a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>, <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a> and <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">55</a> and suggests that this SAR could be implemented on other series if the primary target is accepting.</div><figure id="fig72" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Figure 72</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0072.jpeg" id="gr72" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 72. Minimal impact on PXR activity by replacing the left-hand side phenyl ring (<b>278</b>) by pyridine (<b>281</b>–<b>283</b>) for smoothened antagonists from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig72"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the contrary, replacement of the phenyl moiety of the phthalazine by pyridine had a beneficial effect on PXR with all 4 isomers showing reduced activity, as shown for the conversion of <b>278</b> to <b>284</b>–<b>287</b>, <a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">73</a></a>. As only <b>286</b> retained the same level of potency, this isomer was selected for reincorporation of the trifluoromethyl group on the left-hand side and resulted in <b>288</b>, which was ultimately profiled further and corroborated the beneficial effect of the N-atom, <a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">73</a></a>.</div><figure id="fig73" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Figure 73</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0073.jpeg" id="gr73" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 73. Effect of aza-phthalazine analogues (<b>284</b>–<b>287</b>) on PXR activity from Amgen smoothened antagonists, resulting in the optimal derivative <b>288</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig73"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">5.8.  NaV1.7 (Amgen, 2017)</h3><div class="NLM_p">Identification and optimization of Na<sub>V</sub>1.7 inhibitors for the treatment of pain has been an area of intense focus for many pharmaceutical companies in recent years. The ligands identified are typically aryl sulfonamides, containing a heteroaromatic amine, usually a thiazole or thiadiazole. These ligands bear some structural similarity with those from Xenon that inhibit Na<sub>V</sub>1.6 and activate PXR and alerted the group at Xenon to explore the PXR activation of the series, <i>vide supra</i> (<a class="ref internalNav" href="#sec3_7" aria-label="section 3.7">section 3.7</a>). Toward this end, researchers at Amgen have recently reported efforts on their series of compounds and the challenges encountered, including PXR activation.<a onclick="showRef(event, 'ref241 ref242'); return false;" href="javascript:void(0);" class="ref ref241 ref242">(241,242)</a> Compounds from this class faced several further challenges, such as formation of GSH adducts upon incubation in HLMs, attributed to the aminothiazole, CYP3A4 inhibition, and high plasma protein binding. Furthermore, it was found that attempts to reduce lipophilicity resulted in higher <i>in vivo</i> clearance, which was attributed to increased biliary clearance and ultimately found to be due to compounds being substrates for hepatobiliary transporters such as organic anion-transporting polypeptide 1B1 (OATP1B1) and multidrug resistance-associated protein 2 (MRP2).</div><div class="NLM_p">In terms of PXR/CYP3A4 induction, compounds such as the quinazoline <b>289</b> were found to increase CYP3A4 levels more than rifampicin, when incubated at 10 μM (levels are expressed as the percentage of rifampicin, also at 10 μM), <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">74</a></a>. The aminothiazole could be replaced by a 4-aminpyrimidine (with a switch to an isoquinoline template), <b>290</b>, to alleviate GSH adduct formation, albeit with a decrease in primary activity, but this potentiated CYP3A4 induction. A breakthrough was achieved when the trifluoromethyl group was replaced by a substituted phenyl ring, such as the <i>meta</i>-fluorophenyl ring in <b>291</b>, <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">74</a></a>.</div><figure id="fig74" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Figure 74</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0074.jpeg" id="gr74" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 74. Na<sub>v</sub>1.7 inhibitors from Amgen, showing reduction in CYP3A4 induction by replacing a trifluoromethyl group (<b>290</b>) by a fluoro-phenyl ring (<b>291</b>) and subsequent modulation of the aromatic amine of the sulfonamide, showing the beneficial effect of thiadiazole (<b>294</b>) and oxadiazole (<b>295</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig74"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Primary potency could be improved by adding a Cl-atom <i>para</i>-to the methoxy group to give <b>292</b>, which also maintained relatively low CYP3A4 induction. Further analogues of <b>292</b> were prepared to investigate replacements of the 4-aminopyrimidine, a selection of which (<b>293</b>–<b>296</b>) are shown in <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">74</a></a>.</div><div class="NLM_p">Six-membered aromatic diazines, such as <b>293</b>, had little impact or slightly exacerbated the CYP3A4 induction. However, five-membered rings such as thiadiazole <b>294</b> and oxadiazole <b>295</b> showed markedly reduced induction, which could in part be attributed to their reduced clog <i>D</i>. Removal of a N-atom from <b>295</b> to give <b>296</b> resulted in increased induction. Despite this, the isoxazole sulfonamide series was selected for further exploration as it showed lower <i>in vivo</i> clearance (rat and dog) than other derivatives, and as compounds are acidic and therefore have low volumes of distribution, it was considered that achieving a reasonable half-life would be driven by low clearance. As such, the SAR was investigated in other regions of the molecule in an attempt to mitigate CYP3A4 induction.</div><div class="NLM_p">Replacement of the isoquinoline core by alternative bicycles designed to reduce clog <i>D</i> had little impact. Therefore, attention turned to the southern fluoro-phenyl ring, where varying the substitution pattern proved more fruitful. A first step was to switch the Cl and F-atoms on <b>296</b>, resulting in <b>297</b>, with a moderate, beneficial effect on PXR activation, <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">75</a></a>. Replacing the <i>meta</i>-chlorophenyl ring of <b>297</b> by a <i>meta</i>-toluyl (<b>298</b>) was not favorable. However, addition of a Cl-atom in the <i>para</i>-position resulted in <b>299</b> which displayed almost no PXR activation, <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">75</a></a>. It was also found that replacement of the <i>meta</i>-chlorophenyl ring of <b>297</b> by a <i>meta</i>-trifluoromethyl phenyl ring (<b>300</b>) also completely negated PXR activation. This structural modification can also be viewed as the replacement of the methyl group in <b>298</b> by a trifluoromethyl group (<b>300</b>). Finally, the methoxy pyridine derivative (<b>301</b>) proved detrimental and significantly increased PXR activation.</div><figure id="fig75" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Figure 75</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0075.jpeg" id="gr75" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 75. Na<sub>v</sub>1.7 inhibitors from Amgen showing that subtle changes in structure can have a large impact on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig75"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The benefit of the <i>meta</i>-trifluoromethyl substitution was again highlighted by two matched pairs, <b>302</b> to <b>303</b> and <b>304</b> to <b>305</b>, highlighted in <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">76</a></a>, thus demonstrating the utility of this transformation within this series. These compounds also highlight that the addition of a nitrile group on the inner phenyl ring did not impact PXR activation, compare <b>302</b> to <b>304</b> and <b>303</b> to <b>305</b>, <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">76</a></a>.</div><figure id="fig76" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Figure 76</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0076.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0076.jpeg" id="gr76" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 76. Two further matched airs from Amgen Na<sub>v</sub>1.7 inhibitors showing the beneficial effect of the <i>meta</i>-trifluoromethyl group in reducing PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig76"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to the challenges encountered in balancing all parameters within this subseries, particularly <i>in vivo</i> clearance, PXR activation, and CYP2C9 inhibition, it was decided to investigate other templates to replace the isoquinoline. Ultimately this resulted in the quinolinone core which was subsequently utilized for optimization. Compound <b>306</b>, <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">77</a></a>, is the direct analogue of isoquinoline <b>302</b>, <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">76</a></a>, but shows a slightly better profile due to its increased potency and weaker PXR activation. Substitution <i>para</i>-to the methoxy group on the inner phenyl ring increased PXR activation (<b>307</b>–<b>309</b>), <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">77</a></a>, although the F-derivative <b>307</b>, had less impact than the Cl (<b>308</b>) or the methyl (<b>309</b>) analogues.</div><figure id="fig77" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Figure 77</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0077.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0077.jpeg" id="gr77" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 77. PXR activation SAR from Amgen Na<sub>v</sub>1.7 antagonists showing effects of substitution <i>para</i>-to the methoxy group on the inner ring and the beneficial effect of substitution at the <i>para</i>-position on the outer phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0077.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig77"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Even though a F-atom <i>para</i>-to the methoxy group increased PXR activation, it was found that this could be mitigated by substituents in the <i>para</i>-position of the outer phenyl ring. Thus, 3,4-difluorophenyl derivative <b>310</b>, representing a very subtle change from <b>307</b>, showed minimal PXR activation, as did the 3-fluoro-4-cyano derivative <b>311</b>, <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">77</a></a>.</div><div class="NLM_p">The effect of <i>para</i>-substitution was further emphasized by the three isomeric trifluoromethyl derivatives, <b>312</b>–<b>314</b>, <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">78</a></a>, which shows the <i>ortho</i>-analogue (<b>312</b>) substantially increases PXR activation, whereas <i>meta</i>-substitution (<b>313</b>) significantly atones PXR activation while <i>para</i>-substitution (<b>314</b>) essentially abolishes it. It is interesting to note that the <i>meta</i>-trifluoromethyl group did not have the same impact on PXR activity in this series (<b>313</b>) as it did in the isoquinoline series (<b>300</b>, <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">75</a></a>).</div><figure id="fig78" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Figure 78</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0078.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0078.jpeg" id="gr78" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 78. Na<sub>v</sub>1.7 inhibitors from Amgen showing the variation of PXR activation versus trifluoromethyl substitution, <b>312</b>–<b>314</b>, the effect of alternative bulky <i>meta</i>-substituents (<b>315</b>) and combinations of <i>meta</i>- and <i>para</i>-substituents (<b>316</b> and <b>317</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0078.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig78"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The beneficial effect of a bulky <i>meta</i>-substituent was confirmed by <b>315</b>, while combining <i>meta</i>- and <i>para</i>-substituents resulted in <b>316</b>, which could be further improved by increasing the size of the <i>para</i>-substituent (<b>317</b>), <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">78</a></a>. Thus, the 4-chloro-3-methyl outer phenyl ring was found to reduce PXR activity in both the quinolinone series (<b>317</b>, <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">78</a></a>) and the isoquinoline series (<b>299</b>, <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">75</a></a>).</div><div class="NLM_p">The beneficial effect of the 3,4-disubstitution pattern on PXR activation was transferable to other heteroaromatic sulfonamides, such as <b>318</b> and <b>319</b>, <a data-tab="pane-pcw-Figures" href="#fig79" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig79" id="" class=" internalNav">79</a></a>. Deletion of the F-atom <i>para</i>-to the methoxy group had no effect (not shown) and the regioisomeric pyrimidine further exemplified the 3,4-disubstitution on the outer phenyl ring (<b>320</b>). Ultimately AM-0466 (<b>321</b>) with the <i>meta</i>-trifluoromethyl group provided the best balance between PXR activation, primary activity, and CYP2C9 and CYP3A4 inhibition.</div><figure id="fig79" data-index="79" class="article__inlineFigure"><h2 class="fig-label">Figure 79</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0079.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0079.jpeg" id="gr79" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 79. Further Na<sub>v</sub>1.7 inhibitors from Amgen showing the beneficial effect of 3,4-disubstitution on PXR activation, along with AM-0466 (<b>321</b>) which had the overall best balance of properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0079.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig79"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">5.9.  IDH1 Inhibitors (Agios, 2018)</h3><div class="NLM_p">While optimizing inhibitors of isocitrate dehydrogenase 1 (IDH1), the Agios group discovered that compounds from their series, as typified by <b>322</b>, <a data-tab="pane-pcw-Figures" href="#fig80" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig80" id="" class=" internalNav">80</a></a>,<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a> activated PXR. Adding a polar hydroxyl group to the pyrroglutamide moiety made little impact, <b>323</b>. However, the same modification in combination with addition of a nitrogen atom (conversion of the pyridine to a pyrimidine) resulted in <b>324</b> with significantly diminished PXR activity but suboptimal cellular activity. Switching attention to the upper part of the molecule, replacement of a fluorine atom by a sulfonamide, <b>325</b>, drastically reduced PXR activation but resulted in high microsomal clearance. More positively, replacement of the difluoro phenyl ring by a fluoropyridine, <b>326</b>, also had the desired impact on PXR activity. <b>326</b> showed a modest decrease in exposure upon repeat dosing in rodent toxicology studies; it did not show reduced exposure in monkey studies. In human clinical studies, <b>326</b> showed a long half-life and accumulation upon repeat dosing. However, it also increased CYP3A4 enzyme activity at its recommended dose (500 mg q.d.), which is suggestive of CYP3A4 induction via PXR activation.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> This compound ultimately progressed through clinical trials and has since been launched.</div><figure id="fig80" data-index="80" class="article__inlineFigure"><h2 class="fig-label">Figure 80</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0080.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0080.jpeg" id="gr80" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 80. PXR activation SAR from a series of IDH1 inhibitors from Agios.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0080.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig80"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">5.10.  P2X3 Antagonists (Merck, 2018)</h3><div class="NLM_p">P2X3 is a ligand-gated (ATP) ion channel, believed to play a role in pain sensation, for which Merck identified the antagonist MK-3901 (<b>327</b>) as a development candidate,<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a><a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">81</a></a>. However, several issues were subsequently identified with this compound, including a potential DDI risk via activation of PXR. To identify improved analogues, further compounds were prepared, with the goal of also improving the metabolic stability via replacement of the labile groups, primarily the methyl group on the upper pyridine ring and the isoxazoline. It was found that the isoxazoline-pyridine moiety on the right-hand side could be replaced by much smaller groups, such as fluoropyridine, <b>328</b>, <a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">81</a></a>; however, this instilled potent PXR activation. Interestingly the morpholine ring, <b>329</b>, ablated PXR activity, whereas the isopropanol derivative, <b>330</b>, resulted in potent PXR activity despite the presence of the polar hydroxy group.</div><figure id="fig81" data-index="81" class="article__inlineFigure"><h2 class="fig-label">Figure 81</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0081.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0081.jpeg" id="gr81" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 81. SAR of MK-3901 (<b>327</b>) analogues versus PXR activation for a series of P2X3 antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0081.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig81"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the potent PXR activity associated with <b>330</b>, it was selected for further optimization due to its reduced plasma protein binding. Interestingly, changing the 3-fluoropyridine on the left-hand side of <b>330</b> to the 2-trifluoromethylpyridine in <b>331</b> reduced PXR activation by 8-fold, <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">82</a></a>. Conversion of the pyridine to its N-oxide, <b>332</b>, further improved the PXR profile. Finally, replacement of the metabolically labile methyl group in the northern region by a chlorine atom delivered <b>333</b> with no worsening of PXR activity, <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">82</a></a>.</div><figure id="fig82" data-index="82" class="article__inlineFigure"><h2 class="fig-label">Figure 82</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0082.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0082.jpeg" id="gr82" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 82. Final PXR SAR optimization of P2X3 antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0082.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig82"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Thus, from this work, the beneficial effect of a morpholine ring in place of an aromatic ring can be seen. Also, employing a polar group, such as a pyridine N-oxide can be very effective, but also replacing a F-atom by a trifluoromethyl group may also suffice, although this could in part be due to the isomeric pyridine on which the group was appended.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">5.11.  TRPM8 Antagonists (Amgen, 2018)</h3><div class="NLM_p">PXR activation was identified as an undesired off-target activity by the group at Amgen during the optimization of a series of TRPM8 antagonists for the treatment of migraines.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> Thus <b>334</b>, <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">83</a></a>, was found to activate PXR and thereby increase CYP3A4 mRNA levels in human hepatocytes following 5 days incubation, with the response shown relative to rifampicin at 10 μM. The strategy implemented by the group to reduce the CYP3A4 induction was to lower lipophilicity or introduce polarity on the periphery of the molecules. To this end, it was found that the right-hand side quinoline could be truncated to give the benzamide <b>335</b>, <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">83</a></a>, with a marginal improvement in 3A4 induction. Replacement of the phenyl ring by the more polar pyridone, <b>336</b>, effectively decreased lipophilicity and reduced 3A4 induction. Replacement of the CF<sub>3</sub> group on the left-hand pyridine by a fluorine, <b>337</b>, further reduced lipophilicity and alleviated 3A4 induction, <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">83</a></a>, supporting the overall strategy.</div><figure id="fig83" data-index="83" class="article__inlineFigure"><h2 class="fig-label">Figure 83</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0083.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0083.jpeg" id="gr83" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 83. SAR from the Amgen TRPM8 antagonist project showing attempts to reduce lipophilicity in order to ameliorate CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0083.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig83"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to further improve the profile of <b>337</b>, several further structural modifications were implemented, summarized in <a data-tab="pane-pcw-Figures" href="#fig84" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig84" id="" class=" internalNav">84</a></a>. Altering the substitution on the southern phenyl ring did not impact 3A4 induction (<b>338</b>). Replacing the pyridone by a nicotinic acid, <b>339</b>, reduced lipophilicity substantially but did not significantly impact CYP3A4 induction. Ultimately however, the compounds shown in <a data-tab="pane-pcw-Figures" href="#fig84" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig84" id="" class=" internalNav">84</a></a> had the best overall profiles from this series. As a result, these compounds were profiled in rat PK studies and an <i>ex vivo</i> rabbit heart cardiovascular (CV) assay, where <b>337</b> displayed a very narrow therapeutic index (TI) relative to <i>in vivo</i> efficacy. While <b>338</b> displayed a better CV TI (59-fold), it was <b>339</b> (AMG 333) which displayed the best TI (>420-fold) and was selected as a development candidate.</div><figure id="fig84" data-index="84" class="article__inlineFigure"><h2 class="fig-label">Figure 84</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0084.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0084.jpeg" id="gr84" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 84. Compounds with the best CYP3A4 induction profiles from the Amgen TRPM8 antagonist project.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0084.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig84"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">5.12.  CFTR Correctors (AbbVie, 2018–2019)</h3><div class="NLM_p">While optimizing a series of compounds as correctors of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, i.e., compounds which correct the folding of mutant CFTR and result in increased channel expression and function in the cell membrane, it was found that members of the series could cause induction of CYP3A4.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> It was already known that the CFTR corrector from Vertex, Lumacaftor (<b>8</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), induced CYP 3A4 expression,<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> which may have raised a flag due to the somewhat related chemical structure. To assess the extent of CYP3A4 induction, cryopreserved human hepatocytes were incubated with compounds for 48 h and the increase in CYP3A4 mRNA was expressed relative to that of rifampicin at 10 μM, with <20% induction relative to rifampicin considered a low potential for 3A4 induction. In this assay, <b>340</b>, <a data-tab="pane-pcw-Figures" href="#fig85" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig85" id="" class=" internalNav">85</a></a>, showed low levels of induction. Some close analogues were tested and revealed that moving the methoxy group, <b>341</b>, had minimal impact, whereas replacing the methoxy group in <b>340</b> by CF<sub>3</sub>, <b>342</b>, or even a fluorine atom, <b>343</b>, exacerbated the induction, <a data-tab="pane-pcw-Figures" href="#fig85" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig85" id="" class=" internalNav">85</a></a>.</div><figure id="fig85" data-index="85" class="article__inlineFigure"><h2 class="fig-label">Figure 85</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0085.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0085.jpeg" id="gr85" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 85. SAR from a series of CFTR correctors from AbbVie showing that slight modifications of <b>340</b> were able to reduce (<b>341</b>) or increase (<b>342</b> and <b>343</b>) CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0085.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig85"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further modification of <b>340</b> demonstrated that moving the carboxylic acid from the <i>meta</i>- to the <i>para</i>-position resulted in a dramatic increase in potency and completely negated CYP3A4 induction, <b>344</b>, <a data-tab="pane-pcw-Figures" href="#fig86" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig86" id="" class=" internalNav">86</a></a>. Ultimately, replacement of the methoxy group by a difluoro methoxy group resulted in <b>345</b> (ABBV/GLPG-2222), which maintained minimal CYP3A4 induction and had a suitable overall profile to be selected as a development compound.</div><figure id="fig86" data-index="86" class="article__inlineFigure"><h2 class="fig-label">Figure 86</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0086.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0086.jpeg" id="gr86" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 86. Further SAR from a series of CFTR correctors from AbbVie, showing the beneficial effect of moving the carboxylic acid group on potency and CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0086.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig86"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A subsequent paper from the same group has outlined further SAR from a different series, exemplified by <b>346</b>, which showed strong CYP3A4 induction, <a data-tab="pane-pcw-Figures" href="#fig87" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig87" id="" class=" internalNav">87</a></a>.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> Fortunately, simple analogues of the southern amide, such as isopropyl carbamate <b>347</b> or tetrahydropyranyl amide <b>348</b>, almost ablated CYP3A4 induction, <a data-tab="pane-pcw-Figures" href="#fig87" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig87" id="" class=" internalNav">87</a></a>.</div><figure id="fig87" data-index="87" class="article__inlineFigure"><h2 class="fig-label">Figure 87</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0087.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0087.jpeg" id="gr87" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 87. SAR from a series of CFTR correctors from AbbVie showing simple modification of the southern amide can greatly diminish CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0087.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig87"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further optimization of primary activity by addition of <i>ortho</i>-substituents to the eastern phenyl ring resulted in a marked increase in PXR activity, such as the ethyl derivative <b>349</b>, whereas the chloro-analogue <b>350</b> had minimal impact, at least at a lower concentration, <a data-tab="pane-pcw-Figures" href="#fig88" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig88" id="" class=" internalNav">88</a></a>.</div><figure id="fig88" data-index="88" class="article__inlineFigure"><h2 class="fig-label">Figure 88</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0088.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0088.jpeg" id="gr88" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 88. SAR for CYP3A4 induction for a series of CFTR correctors from AbbVie showing the effect of <i>ortho</i>-substitution of the eastern phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0088.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig88"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ultimately the balance between potency and CYP3A4 induction was met by the <i>ortho</i>-methyl derivative <b>351</b> (ABBV/GLPG-3221), although in this case CYP3A4 induction was measured at 1 μM, <a data-tab="pane-pcw-Figures" href="#fig88" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig88" id="" class=" internalNav">88</a></a>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.13.  RORγ (Phenex, Janssen, BMS 2018–2020)</h3><div class="NLM_p">The identification of inverse agonists of the retinoic acid-related orphan receptor γ (RORγ) for the treatment of T-cell mediated diseases has been a long standing goal within the pharmaceutical industry, due to its potential to lower inflammatory modulators such as IL-17. As highlighted in this perspective, one of the challenges that has plagued the clinical advancement of compounds for this target is the activation of PXR, which is a closely related nuclear receptor to RORγ. To this end researchers from Phenex in collaboration with Janssen have recently reported some of their work in the area, including data and SAR on PXR activation, which is summarized herein.</div><div class="NLM_p">The initial series was exemplified by <b>352</b>,<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a><a data-tab="pane-pcw-Figures" href="#fig89" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig89" id="" class=" internalNav">89</a></a> and showed good levels of potency in a cell assay measuring ROR-mediated transcription but also showed strong PXR activation at 1 and 10 μM. Attempts to reduce PXR activity by replacement of the THP moiety by more polar groups, such as <b>353</b> and <b>354</b>, <a data-tab="pane-pcw-Figures" href="#fig89" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig89" id="" class=" internalNav">89</a></a>, were unable to impact this undesired activity, showing that increasing polarity in the periphery of a series does not work universally.</div><figure id="fig89" data-index="89" class="article__inlineFigure"><h2 class="fig-label">Figure 89</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0089.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0089.jpeg" id="gr89" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 89. Prototypical RORγ inverse agonist from Phenex and Janssen (<b>352</b>) and related derivatives <b>353</b> and <b>354</b>, designed to increase polarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0089.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig89"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Turning to the naphthyl group revealed some interesting SAR, <a data-tab="pane-pcw-Figures" href="#fig90" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig90" id="" class=" internalNav">90</a></a>. An additional heteroatom, <b>355</b>, provided a moderate improvement in PXR activation. On the other hand, reduction of the outer phenyl ring, <b>356</b>, almost abolished PXR activation, as did replacement of the northern phenyl ring by two Cl-atoms, <b>357</b>. Interestingly, when only one Cl-atom was used, <b>358</b>, PXR activation returned.</div><figure id="fig90" data-index="90" class="article__inlineFigure"><h2 class="fig-label">Figure 90</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0090.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0090.jpeg" id="gr90" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 90. SAR for PXR activation via modulation of the naphthyl moiety in a series of RORγ inverse agonists from Phenex and Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0090.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig90"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the <i>tert</i>-butyl sulfonamide group was implicated in the formation of glutathione adducts in metabolite identification studies, it was ultimately replaced by an (<i>S</i>)-1,1,1-trifluoropropyl amine. This change, coupled with a shift to a modified template, <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">91</a></a>, exemplified by <b>359</b>, revealed some disparities in PXR SAR.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> Replacing the naphthyl moiety by the isosteric dichlorophenyl, <b>360</b>, again had a positive impact on PXR activation. One carbon elongation of the sulfonamide group (<b>361</b>) had little impact; however, deletion of a Cl-atom (<b>362</b>) markedly reduced PXR activation, in contrast to <b>358</b> above, <a data-tab="pane-pcw-Figures" href="#fig90" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig90" id="" class=" internalNav">90</a></a>, but also reduced primary activity. Replacement of the Cl-atoms in <b>361</b> by an F-atom and a difluoro methyl group resulted in <b>363</b> which displayed much less PXR activation. This compound maintained low PXR activation at 5 μM and almost negligible PXR activation at 1 μM. The low levels of PXR activation also translated to low CYP3A4 induction at 1 and 10 μM. A further diversified analogue, <b>364</b>, was also identified as part of this work, which had an amide in place of the methyl-cyclobutyl group and an isopropanol moiety in place of the lipophilic alkyl acid group on the left-hand side. Although <b>364</b> showed low levels of PXR activation, it induced CYP3A4 levels, at 10 μM, to a higher extent than <b>363</b>, <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">91</a></a>.</div><figure id="fig91" data-index="91" class="article__inlineFigure"><h2 class="fig-label">Figure 91</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0091.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0091.jpeg" id="gr91" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 91. SAR for PXR activation from a series of RORγ inverse agonists from Janssen and Phenex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0091.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig91"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to further profile <b>363</b> and <b>364</b>, both were progressed to rat 5 day tolerability studies at 300 mg/kg (<b>363</b>) and 1000 mg/kg (<b>364</b>). It was found that both compounds showed lower exposure on day 5 than day 1, also implicating rodent PXR activation and CYP450 induction as the likely cause, ultimately resulting in autoinduction. On day 1, <b>363</b> had a <i>C</i><sub>max</sub> of 303 000 ng/mL and AUC of 4 710 000 h ng/mL, whereas on day 5 the <i>C</i><sub>max</sub> had dropped to 151 000 ng/mL (51% reduction) and the AUC had decreased to 1 790 000 h ng/mL (62% reduction). Similarly, for <b>364</b>, the <i>C</i><sub>max</sub> on day 1 was 24 500 ng/mL and the AUC was 274 000 h ng/mL, whereas on day 5 the <i>C</i><sub>max</sub> had dropped to 3160 ng/mL (87% reduction) and the AUC had decreased to 51 000 h ng/mL (82% reduction). Thus, the marked decrease in exposure over the 5 day dosing period with both compounds did not support their progression. As can be seen from the <i>in vivo</i> exposure data, the plasma concentrations are high for both compounds, with total plasma <i>C</i><sub>max</sub> values of approximately 463 μM and 36 μM on day 1 for <b>363</b> and <b>364</b>, respectively.</div><div class="NLM_p">Subsequent work from the same group produced extensive PXR activation SAR for the series; however, only a few compounds are summarized as in general the structural modifications did not substantially impact this issue.<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a> Ultimately, another compound was progressed to rat 5 day tolerability studies but also showed decreased exposure upon repeat administration. This time round, the PXR activation of compounds was assessed at 1, 5, or 10 μM, some at a single concentration, some at more than one. Most of the described compounds utilized the dichlorophenyl central motif seen in <b>360</b>, <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">91</a></a>, but with an amide in place of the oxadiazole, which utilizes the 1-amino-2-methyl-propan-2-ol group identified by BMS to reduce PXR activation in their CCR1 antagonist, <i>vide supra</i>, <a class="ref internalNav" href="#sec3_3" aria-label="section 3.3">section 3.3</a>, and RORγ inverse agonist work, <i>vide supra</i>, <a class="ref internalNav" href="#sec3_6" aria-label="section 3.6">section 3.6</a>. Much of the SAR explored involved variations of the amide in the southern region of the molecule. In all, 33 amide analogues were assessed, 19 of which contained cyclic amines, a selection of which are shown in <a data-tab="pane-pcw-Figures" href="#fig92" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig92" id="" class=" internalNav">92</a></a>. The difluoro-piperidine, as seen in <b>364</b>, <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig91" id="" class=" internalNav">91</a></a>, proved one of the best groups to moderate PXR activation as shown by <b>365</b>. The unsubstituted piperidine analogue, <b>366</b>, or the 4-methylpiperidine analogues, <b>367</b>, showed more pronounced PXR activation, highlighting a beneficial effect of the F-atoms. The monofluoropiperidine <b>368</b> showed similar PXR activation to <b>365</b> but was almost 5-fold more potent at RORγ and ultimately proved to be the optimal compound from this investigation. The analogous difluoropyrrolidine, <b>369</b>, did however maintain similar PXR activation levels to <b>365</b>, <a data-tab="pane-pcw-Figures" href="#fig92" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig92" id="" class=" internalNav">92</a></a>.</div><figure id="fig92" data-index="92" class="article__inlineFigure"><h2 class="fig-label">Figure 92</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0092.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0092.jpeg" id="gr92" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 92. PXR activation SAR from a series of amide RORγ inverse agonists from Phenex and Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0092.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig92"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Variation of the sulfonamide substituent was investigated but also had little impact on PXR activation. Fixing the 4-fluoropiperidine in <b>368</b> and varying the substituent on the left-hand side amide had some, albeit limited impact, <a data-tab="pane-pcw-Figures" href="#fig93" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig93" id="" class=" internalNav">93</a></a>. For example, truncation to the primary amide <b>370</b> significantly increased PXR activation. Rigid, polar groups such as that in <b>371</b> reduced PXR activation but also reduced RORγ activity. Replacement of the alcohol by a nitrile (<b>372</b>) was neutral as was reversal of the amide (<b>373</b>). Thus, no structural changes were identified that diminished PXR activity without having a parallel impact on RORγ activity.</div><figure id="fig93" data-index="93" class="article__inlineFigure"><h2 class="fig-label">Figure 93</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0093.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0093.jpeg" id="gr93" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 93. Highlights of PXR SAR from left-hand side amide modifications from Janssen/Phenex RORγ inverse agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0093.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig93"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SAR shown highlight the challenges to negate PXR activation within this series. Most structural modifications resulted in minimal moderation of PXR activity, despite some substantial structural changes and sampling each region of the molecule. Based on its overall profile, <b>368</b> was profiled in more detail. A dose response experiment revealed an EC<sub>50</sub> of 1.7 μM at PXR. Efficacy studies in mice demonstrated a 60% reduction in IL-17A levels <i>ex vivo</i> 1 h after an oral dose of 30 mg/kg with plasma concentrations approximately 1700 ng/mL (∼2900 nM, ∼330 nM free). Compound <b>368</b> was progressed to a 14 day oral tolerability study in the rat at doses of 50 and 200 mg/kg b.i.d. (i.e., 100 mg/kg and 400 mg/kg total per day) where it showed > 90% reduction in exposure over the duration of the study; 50 mg/kg day 0 <i>C</i><sub>max</sub> 11 200 ng/mL (approximately 19.1 μM total/2.2 μM free), AUC 31 500 ng h/mL versus day 4 <i>C</i><sub>max</sub> 252 ng/mL, AUC 870 ng h/mL; 200 mg/kg b.i.d. day 0 <i>C</i><sub>max</sub> 49 400 ng/mL, AUC 282 000 ng h/mL versus day 4 <i>C</i><sub>max</sub> 1900 ng/mL, AUC 6000 ng h/mL. The exposures on day 14 were similar to those on day 4 indicating that 4 days of administration is sufficient to pick up exposure changes related to autoinduction. Analysis of the livers from this study revealed that CYP3a1 and CYP2b1 gene levels were upregulated by 18-fold at the 50 mg/kg b.i.d. dose, supporting the loss of exposure due to PXR activation (at least in part) and autoinduction. A subsequent study in rat hepatocytes showed that <b>368</b> increased CYP3a23 mRNA by approximately 5-fold at 1 μM and approximately 10-fold at 10 μM, relative to an approximate 7-fold increase for the positive control dexamethasone at 10 μM. Both concentrations of <b>368</b> resulted in increased conversion of testosterone to 6β-hydroxy testosterone, approximately 10-fold and 15-fold, respectively. This assay was therefore utilized to help identify compounds with reduced PXR activation/CYP3a induction, the results of which are due to be published.</div><div class="NLM_p">In addition to the work detailed in the SBDD section, the group at BMS have also used empirical approaches to try to reduce PXR activation for one series of RORγ inverse agonists. The series, exemplified by <b>374</b>,<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a><a data-tab="pane-pcw-Figures" href="#fig94" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig94" id="" class=" internalNav">94</a></a>, was spurned by scaffold hopping initiatives to mimic the conformation of compounds such as <b>114</b> and <b>115</b>, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a> and <b>75</b> and <b>117</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>. As with other RORγ series identified by BMS, <b>374</b> was a potent activator of PXR. Replacement of the acetyl group by more polar groups was investigated to try to diminish PXR activation, but the methyl sulfonamide and ethyl carbamate analogues had no impact on PXR activity (data not shown). The ethyl urea (<b>375</b>) provided some improvement whereas the benzyl urea (<b>376</b>) again increased PXR activity, <a data-tab="pane-pcw-Figures" href="#fig94" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig94" id="" class=" internalNav">94</a></a>. Interestingly, moving the methyl group on the piperidine (<b>376</b> and <b>377</b>) significantly increased PXR activation.</div><figure id="fig94" data-index="94" class="article__inlineFigure"><h2 class="fig-label">Figure 94</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0094.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0094.jpeg" id="gr94" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 94. Effect of replacing the acetamide group in RORγ inverse agonist <b>374</b> on PXR activation and effect of moving the methyl group on the pyrrolidine ring (<b>376</b> vs <b>377</b>). Compounds are racemic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0094.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig94"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The acetyl piperidine group (<b>378</b>), also employed in other series, <i>vide supra</i>, (<a class="ref internalNav" href="#sec3_6" aria-label="section 3.6">section 3.6</a>, <b>118</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>) also diminished PXR activity.</div><div class="NLM_p">Further exploration of this series included the addition of polar groups at the <i>para</i>-position of the benzyl group, using the fluorophenyl analogue of <b>376</b>, i.e., <b>379</b>, <a data-tab="pane-pcw-Figures" href="#fig95" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig95" id="" class=" internalNav">95</a></a>. Surprisingly, this substitution increased PXR activity, for example, the cyano derivative <b>380</b>, or more strikingly, the ethyl sulfone <b>381</b> which showed approximately a 112-fold increase in PXR activity over <b>379</b>. The impact of the ethyl sulfone on PXR activity is noteworthy, given this group showed a profound benefit when utilized by Merck in the series of 11β-HSD1 inhibitors, <i>vide supra</i>, <i>e.g</i>., <b>187</b>, <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>, <a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>.</div><figure id="fig95" data-index="95" class="article__inlineFigure"><h2 class="fig-label">Figure 95</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0095.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0095.jpeg" id="gr95" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 95. Addition of polar groups to the <i>para</i>-position of the benzyl moiety in the RORγ inverse agonist <b>379</b> increases PXR activation. Compounds are single enantiomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0095.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig95"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Returning to the acetylpiperidine moiety, this time as an enantiomerically pure fluorinated phenyl analogue, <b>382</b>, <a data-tab="pane-pcw-Figures" href="#fig96" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig96" id="" class=" internalNav">96</a></a>, fluorination of the alcohol moiety (<b>383</b>) essentially abolished PXR activity, indicating the importance of this functional group in the interaction with PXR. Although in this instance RORγ activity was also markedly decreased, this transformation was transferable and utilized in other series, which ultimately resulted in a clinical development candidate, <i>vide supra</i> BMS-986251 (<b>129</b>), <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>, and <b>122</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>, <a class="ref internalNav" href="#sec3_6" aria-label="section 3.6">section 3.6</a>. Additional attempts to increase polarity by modification of the acetyl group had little impact on PXR activity, <i>e.g</i>., <b>384</b>, or actually increased PXR activity, <b>385</b>, <a data-tab="pane-pcw-Figures" href="#fig96" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig96" id="" class=" internalNav">96</a></a>. Despite its more potent PXR activity, <b>385</b> was profiled further, based on its enhanced RORγ activity, metabolic stability and also due to its decreased <i>Y</i><sub>max</sub> at PXR.</div><figure id="fig96" data-index="96" class="article__inlineFigure"><h2 class="fig-label">Figure 96</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0096.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0096.jpeg" id="gr96" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 96. Fluorination of the HFIPA moiety in <b>382</b> drastically reduced PXR activation (<b>383</b>), whereas addition of polar groups to the acetamide on the piperidine in <b>384</b> and <b>385</b> had little impact on PXR activation. Compounds are single enantiomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0096.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig96"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">5.14.  DOT1L (Novartis 2019)</h3><div class="NLM_p">Although not containing detailed <i>in vitro</i> SAR on PXR activation, a recent paper from the Novartis group highlights some <i>in vivo</i> SAR around autoinduction, ultimately via CYP450a induction, for a series of disruptor of telomeric silencing 1-like protein (DOT1L) inhibitors.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> Profiling of <b>386</b> and <b>387</b>, <a data-tab="pane-pcw-Figures" href="#fig97" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig97" id="" class=" internalNav">97</a></a>, revealed interesting results; however, both were found to exhibit reduced exposure when administered orally over a period of several days. Thus, for <b>386</b>, a single oral dose of 100 mg/kg to mice resulted in a <i>C</i><sub>max</sub> of 24 μM and an AUC<sub>0–12h</sub> of 216 h μM, whereas when administered at 100 mg/kg b.i.d. for 20 days the <i>C</i><sub>max</sub> decreased modestly, to 12 μM, whereas the AUC dropped significantly, to 47 h μM (measured on day 20). In this instance, the reduction in the AUC appeared to be mainly driven by the shape of the AUC curve, i.e., the clearance. Follow up studies in rat and human hepatocyte assays supported the potential link between decreased exposure and P450 induction.</div><figure id="fig97" data-index="97" class="article__inlineFigure"><h2 class="fig-label">Figure 97</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0097.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0097.jpeg" id="gr97" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 97. DOT1L inhibitors from Novartis (<b>386</b>–<b>389</b>) highlighting <i>in vivo</i> SAR on autoinduction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0097.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig97"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A subtle switch in structure from <b>387</b> to <b>388</b> (changing methoxy to piperazine) or <b>389</b> (changing methyl sulfone to primary sulfonamide in conjunction with methoxy to amino group), <a data-tab="pane-pcw-Figures" href="#fig97" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig97" id="" class=" internalNav">97</a></a>, proved sufficient to alleviate the CYP induction. Thus, administration of <b>388</b> at a dose of 300 mg/kg q.d. for 7 days showed no decrease in exposure and, in fact, actually showed some degree of accumulation (<i>C</i><sub>max</sub> ∼11 μM) compared to a single dose (<i>C</i><sub>max</sub> ∼8 μM). While the AUC curves are almost identical in shape, confirming no change in clearance, it cannot be concluded if this effect is due to reduced potency for CYP induction or due to the lower <i>C</i><sub>max</sub>. However, as the <i>C</i><sub>max</sub> values are approximately within 2-fold for <b>386</b> and <b>388</b>, it appears reasonable to attribute the effect to a reduced potency for CYP induction of <b>388</b>. Similarly, dosing of <b>389</b> for 7 days at 50 mg/kg <i>s.c</i>. revealed that exposure was maintained, although no further details were provided. Caution should be taken in the interpretation of the data for <b>389</b> as it contains a sulfonamide rather than a sulfone and could simply be a decrease in plasma exposure due to increased blood cell partitioning.</div><div class="NLM_p last">Thus, the subtle structural changes shown in this example again serve to highlight the profound effect apparently small changes can have on CYP induction.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">5.15.  HBV Capsid Inhibitors (Roche 2019)</h3><div class="NLM_p">More recently, Roche encountered CYP3A4 induction with HBV compounds that inhibit the assembly of the core protein to a normal nucleocapsid. Compound <b>390</b> (HAP_R10) was advanced to clinical trials but was found to induce CYP3A4 in human hepatocytes, which was confirmed in a PhI study (<a data-tab="pane-pcw-Figures" href="#fig98" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig98" id="" class=" internalNav">98</a></a>). In order to identify compounds without CYP3A4 induction, the team conducted further SAR within the series.<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> To assess CYP3A4 induction, compounds were incubated with human hepatocytes for 24 h, with rifampicin as the positive control at 10 μM. CYP3A4 mRNA was measured as the assay read out. For routine screening, compounds were tested at a single concentration (10 μM), but compounds of interest were profiled at 1 and 0.1 μM in addition. CYP3A4 induction of less than 40% of that of rifampicin at 10 μM was targeted, based on a combination of experience within Roche and FDA guidance.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><figure id="fig98" data-index="98" class="article__inlineFigure"><h2 class="fig-label">Figure 98</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0098.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0098.jpeg" id="gr98" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 98. Structures and profiles of Roche HBV capsid inhibitors HAP_R10 (<b>390</b>) and HAP_R01 (<b>391</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0098.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig98"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The conformation of a close analogue of <b>390</b>, <b>391</b> (HAP_R01), bound to the capsid protein revealed that the halogenated phenyl ring is pseudoaxial and its plane is perpendicular to the dihydropyrimidine ring, likely influenced by the <i>ortho</i>-chlorine atom on the phenyl ring and the fact that the ester is also in the plane of the dihydropyrimidine (<a data-tab="pane-pcw-Figures" href="#fig99" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig99" id="" class=" internalNav">99</a></a>). The thiazole is also in the plane of the dihydropyrimidine, likely due to positive interactions between the S-atom and the N-atom of the dihydropyrimidine and the N-atom of the thiazole with the NH of the dihydropyrimidine, and this is similar to small molecule crystal structures, <i>e.g</i>., CCDC No. 1012347.</div><figure id="fig99" data-index="99" class="article__inlineFigure"><h2 class="fig-label">Figure 99</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0099.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0099.jpeg" id="gr99" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 99. Conformations of <b>391</b> in gray (HAP_R01) bound to Cp149, showing the conformation of the molecule, in particular the halogenated phenyl ring is perpendicular to that of the dihydropyrimidine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WRE">5WRE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0099.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig99"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to mitigate PXR induction via modulation of the phenyl substitution, several analogues were made, the key SAR of which is highlighted in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. First, shifting from the methyl ester in <b>390</b> to an ethyl ester, as shown by <b>392</b> increased CYP3A4 induction: 111% versus 173%, respectively, which could be related to the increased lipophilicity. Changing from a 2-chloro-4-fluorophenyl substitution to 2,4-difluoro, <b>393</b>, had little impact. The 4-fluorophenyl derivative <b>394</b> showed less induction, but when an additional fluorine atom was added in the 3-position to give <b>395</b> the CYP3A4 induction was markedly diminished.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Variation of the Substitution of the Phenyl Ring in a Series of HBV Capsid Inhibitors from Roche Showed a Surprising Variation in CYP3A4 Induction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0132.gif" alt="" id="GRAPHIC-d7e7622-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0133.gif" alt="" id="gr115" /></img><div></div></div><div class="NLM_p">Larger substituents than fluorine in the 3-position were not tolerated as they resulted in a loss of potency against HBV, but the 3-fluoro-4-methyl analogue, <b>396</b>, confirmed the beneficial effect of fluorine at the 3-position. However, a 3-fluorine alone was insufficient to mitigate CYP3A4 induction, <b>397</b>, and thus it seems that a 3-fluorine in conjunction with another group at the 4-position is optimal.</div><div class="NLM_p">As it was known that utilizing the methyl ester rather than the ethyl ester should also have a beneficial effect on CYP3A4 induction, as demonstrated by <b>390</b> versus <b>392</b>, reversion to the methyl ester analogue of <b>395</b>, i.e., <b>398</b>, <a data-tab="pane-pcw-Figures" href="#fig100" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig100" id="" class=" internalNav">100</a></a>, was investigated, but no significant improvement was observed. Finally, replacement of the 4-fluorine by a Cl-atom resulted in <b>399</b>, <a data-tab="pane-pcw-Figures" href="#fig100" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig100" id="" class=" internalNav">100</a></a>, which proved optimal in terms of CYP3A4 induction and primary activity. Confirmation of reduced CYP3A4 induction potential was confirmed in a dose–response assay in human hepatocytes. In addition to measuring CYP3A4 mRNA in this assay, it was also shown that there was no increase in CYP1A2 or CYP2B6 mRNA. A small molecule crystal structure of <b>399</b> revealed the substituted phenyl ring to be approximately orthogonal to that of <b>391</b>, which was postulated to be responsible for the reduced CYP3A4 induction. It was hypothesized that there may be an enthalpy penalty for the phenyl ring to achieve the optimal orientation to bind to PXR or that the conformation shown by the small molecule crystal structure may sterically hinder the N-atom in the dihydropyrimidine from accepting a hydrogen bond in PXR.</div><figure id="fig100" data-index="100" class="article__inlineFigure"><h2 class="fig-label">Figure 100</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0100.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0100.jpeg" id="gr100" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 100. Final optimization of HBV capsid inhibitors from Roche resulting in <b>398</b> and, ultimately, <b>399</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0100.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig100"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Overall, this work nicely describes how very subtle modifications can often influence CYP3A4 induction and PXR activity; the net result of switching from a 2-chloro-4-fluorophenyl ring to a 4-chloro-3-fluorophenyl ring was a dramatic reduction in CYP3A4 induction, highlighted in <a data-tab="pane-pcw-Figures" href="#fig101" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig101" id="" class=" internalNav">101</a></a>.</div><figure id="fig101" data-index="101" class="article__inlineFigure"><h2 class="fig-label">Figure 101</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0101.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0101.jpeg" id="gr101" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 101. Summary of structural modification undertaken by Roche with a very subtle change ultimately having a big impact on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0101.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig101"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Whether this is due to specific detrimental interactions with PXR, a loss of an HBA interaction or a subtle change in rotation of the phenyl ring remains unknown but serves to highlight that seemingly small structural changes are worth considering along with the associated effect on conformers.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">5.16.  EZH2 Inhibitors (Constellation, 2020)</h3><div class="NLM_p">Inhibition of enhancer of zeste homologue 2 (EZH2), which trimethylates lysine 27 of histone 3 (H3K27), has been a target of interest within the pharmaceutical industry for a significant period of time, due to its potential for the treatment of various types of oncology. Several inhibitors have now been evaluated in human clinical trials but some, such as CPI-1205 (<b>400</b>), from Constellation, have been found to show reduced exposure after multiple dosing, due to induction of CYP3A4. CYP induction may be an inherent issue with the pharmacophore, given that other EZH2 inhibitors such as Tazemetostat (<b>29</b>), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, have been found to induce CYP3A4 in the clinic. The CYP induction for CPI-1205 (<b>400</b>) presented a problem in terms of achieving efficacy as preclinical data showed that prolonged treatment was required to elicit the required reduction of H3K27. In order to mitigate this issue with second generation compounds, the Constellation group targeted prolonged EZH2 inhibition by increasing the residence time of inhibitors on EZH2 and by reducing their potential to induce CYP3A4 expression.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> Investigation of the pyridine SAR of CPI-1205 (<b>400</b>) revealed that the methylthioether analogue <b>401</b> showed improved potency and residence time, <a data-tab="pane-pcw-Figures" href="#fig102" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig102" id="" class=" internalNav">102</a></a>, but still showed strong induction of CYP3A4, in immortalized human hepatocytes (Fa2N-4 cells). Switching from the trifluoroethyl piperidine moiety to an oxetane (<b>402</b>), with the aim of reducing lipophilicity, revealed a dramatic reduction in CYP3A4 induction, <a data-tab="pane-pcw-Figures" href="#fig102" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig102" id="" class=" internalNav">102</a></a>. Moving the piperidine N-atom to give the cyclohexyl derivative with a difluoro azetidine (<b>403</b>) reintroduced CYP induction. However, the oxetane analogue <b>404</b> again mitigated this liability. Simply converting the difluoro-azetidine of <b>403</b> to a methoxy azetidine (<b>405</b>) also mitigated the CYP induction, which could be due to a reduction in lipophilicity (<b>403</b> clog <i>D</i> 3.8, <b>405</b> clog <i>D</i> 3.3) which in turn could be <i>via</i> modulation of the azetidine basicity. Replacing the cyclohexane by 1,3-dioxane (<b>406</b>) also diminished CYP3A4 upregulation, although in this case a dimethylamine substituent was employed. Within this subseries, there appeared to be a correlation between CYP3A4 upregulation and clog <i>D</i>.</div><figure id="fig102" data-index="102" class="article__inlineFigure"><h2 class="fig-label">Figure 102</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0102.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0102.jpeg" id="gr102" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 102. CYP induction SAR from a series of EZH2 inhibitors from Constellation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0102.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig102"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although <b>405</b> was dosed for 21 days in a mouse lymphoma model at 50 mg/kg b.i.d. s.c., exposure data and CYP3a levels were not reported, thus it is not possible to conclude if autoinduction was an issue <i>in vivo</i> in the mouse. However, the effect of <b>405</b> on inhibition of tumor volume growth appeared to persist for the duration of the study, which may imply exposure was maintained at least above the therapeutically active concentrations although it does not rule out some decrease. As further profiling of <b>405</b> revealed no bioavailability, further optimization was conducted.</div><div class="NLM_p">Focusing on <b>405</b> revealed that addition of fluorine atoms, <b>407</b> and <b>408</b>, or enlargement to a cyclopropyl group, <b>409</b>, resulted in increased CYP3A4 regulation, <a data-tab="pane-pcw-Figures" href="#fig103" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig103" id="" class=" internalNav">103</a></a>. Fluorination of the methoxy group provides a striking increase in CYP34A upregulation. All these structural modifications resulted in an increase in clog <i>D</i> which may, at least in part, contribute to this activity. The cyclopropyl derivative, <b>409</b>, also adds partial π-character which may contribute.</div><figure id="fig103" data-index="103" class="article__inlineFigure"><h2 class="fig-label">Figure 103</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0103.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0103.jpeg" id="gr103" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 103. Effect of varying the methyl ether of azetidine derivative <b>405</b> on CYP3A4 induction for a series of EZH2 inhibitors from Constellation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0103.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig103"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite its increased propensity to upregulate CYP3A4, cyclopropyl ether <b>409</b> was selected for further optimization, perhaps due to its long residence time. Modification of the central indole, with the goal of reducing lipophilicity to mitigate CYP3A4 upregulation resulted in azaindole derivatives <b>410</b>–<b>412</b>, <a data-tab="pane-pcw-Figures" href="#fig104" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig104" id="" class=" internalNav">104</a></a>. Interestingly, the unsubstituted azaindole <b>410</b> and its chlorinated analogue, <b>411</b>, showed a marked reduction in CYP3A4 upregulation compared to <b>409</b>. Surprisingly, the fluoro-substituted analogue <b>412</b> showed much higher CYP3A4 upregulation compared to <b>410</b> or <b>411</b>, implying an important role of the fluorine atom in 3A4 induction and ultimately PXR interaction. This subtle modification again highlights the surprising SAR that can be uncovered when trying to mitigate PXR activity. Often a fluorine atom is beneficial whereas the more lipophilic Cl-atom increases PXR activity (as highlighted elsewhere in this perspective). The SAR of this subseries also revealed no correlation between clog <i>D</i> and CYP3A4 upregulation, again supporting a specific molecular interaction.</div><figure id="fig104" data-index="104" class="article__inlineFigure"><h2 class="fig-label">Figure 104</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0104.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0104.jpeg" id="gr104" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 104. SAR from Constellation EZH2 inhibitors showing the effect of azaindole substitution on CYP3A4 upregulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0104.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig104"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ultimately, <b>410</b> was selected for further profiling based on its overall profile. Repeat dosing, 25 mg/kg b.i.d. p.o. for 21 days resulted in strong inhibition of tumor growth in a mouse lymphoma model, but again no exposure data was disclosed.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">5.17.  Orexin-1 (OX1) Antagonists (Janssen, 2020)</h3><div class="NLM_p">A recent disclosure from the Janssen group highlighted an issue with PXR activation encountered with a series of azabicyclo[2.2.1]heptanes, as selective orexin-1 (OX1) antagonists for the treatment of CNS disorders such as addiction, panic, or anxiety.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> Profiling advanced leads revealed moderate PXR induction potential, <a data-tab="pane-pcw-Figures" href="#fig105" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig105" id="" class=" internalNav">105</a></a>. Compound <b>413</b> activated PXR which resulted in an 18% induction of CYP3A4 relative to that of rifampicin at 10 μM. Addition of a fluorine atom to <b>413</b> resulted in <b>414</b>, which showed a slight increase in PXR activation, <a data-tab="pane-pcw-Figures" href="#fig105" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig105" id="" class=" internalNav">105</a></a>. Switching the trifluoromethyl pyrazine to a fluoro-trifluoromethyl pyridine (<b>415</b>) increased PXR activation, while also increasing clog <i>P</i> (values used from the publication) and decreased <i>in vitro</i> metabolic stability. Ultimately, <b>414</b> (JNJ-54717793) was selected in preference over <b>413</b> based on its lower EC<sub>50</sub> value (85 ng/mL, corresponding to an ED<sub>50</sub> of 1.3 mg/kg p.o.) in a rat <i>ex vivo</i> receptor occupancy study.</div><figure id="fig105" data-index="105" class="article__inlineFigure"><h2 class="fig-label">Figure 105</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0105.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0105.jpeg" id="gr105" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 105. PXR SAR for a series of OX1 antagonists from Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0105.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig105"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When profiled in a rat 5 day toxicology study at doses or 100, 250, and 1000 mg/kg, <b>414</b> (JNJ-54717793) showed PXR activation as determined by decreased exposure and increased CYP3A1 mRNA levels. These results were confirmed in 14 day studies in mouse and rat at 200 mg/kg/day p.o. In the mouse, the <i>C</i><sub>max</sub> values were 32 905 ng/mL on day 0 and 24 758 ng/mL on day 13, with corresponding AUC(<sub>0–24h</sub>) values of 225 157 on day 0 and 84 127 h ng/mL on day 13, corresponding to a 1.3-fold decrease in <i>C</i><sub>max</sub> and a 2.7-fold decrease in AUC. In the rat, the decrease in exposure was more pronounced; the <i>C</i><sub>max</sub> values were 30 900 (day 0), 8 800 (day 6), and 6 980 ng/mL (day 13), respectively, resulting in a 4.4-fold reduction. The corresponding AUC<sub>0–24h</sub> values were 38 600, 62 000, and 36 200 h ng/mL on days 0, 6, and 13, respectively, corresponding to an almost 11-fold reduction. In a 6 day dog study, there were no significant decreases in exposure, with <i>C</i><sub>max</sub> of 15 100 ng/mL at the NOAEL (25 mg/kg), thus approximately half the level seen in the rat and mouse. Based on these data, <b>414</b> (JNJ-54717793) was selected as a development candidate.</div><div class="NLM_p">In summary, the literature SAR on PXR/CYP3A4 induction discussed here shows several interesting aspects and that it is feasible to reduce this undesired activity in most instances.</div><div class="NLM_p last">One of the common strategies to reduce PXR activation is to reduce the lipophilicity of compounds. While this is not always successful, it is nevertheless a worthy one. Other noteworthy strategies include rigidification, exemplified by HCV NS5B (<a class="ref internalNav" href="#sec5_1" aria-label="section 5.1">section 5.1</a>); adding a sulfone, or sulfonamide, to an aromatic (phenyl) ring, exemplified by 11βHSD1 (<a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>), RORγ (<a class="ref internalNav" href="#sec5_13" aria-label="section 5.13">section 5.13</a>); replacing a phenyl ring by polar aromatic heterocycles such pyridine, pyrazine, pyrimidine, or isoxazole, exemplified by 11βHSD1 (<a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>) and smoothened (<a class="ref internalNav" href="#sec5_7" aria-label="section 5.7">section 5.7</a>), IDH1 (<a class="ref internalNav" href="#sec5_9" aria-label="section 5.9">section 5.9</a>); adding Cl or F or switching one to the other, exemplified by 11βHSD1 (<a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>), RORγ (<a class="ref internalNav" href="#sec5_13" aria-label="section 5.13">section 5.13</a>), HBV capsid (<a class="ref internalNav" href="#sec5_15" aria-label="section 5.15">section 5.15</a>), EZH2 (<a class="ref internalNav" href="#sec5_16" aria-label="section 5.16">section 5.16</a>); replacing cycloalkyl groups by heterocycles, exemplified by 11βHSD1 (<a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>), CFTR (<a class="ref internalNav" href="#sec5_12" aria-label="section 5.12">section 5.12</a>); fluorinating alkyl groups; adding a nitrile to an aromatic ring.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">6.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As can be seen from this perspective, PXR can be activated by a wide variety of ligands with very broad structural diversity. The table below, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, summarizes some of the key structural modifications observed from the analysis of the published work and can be considered as a quick guide of structural modifications worthy of consideration. Numerous strategies can be seen to be effective, including adding a neutral group (steric clash), adding a polar group, removing groups or truncating the structure, adding fluorine, removing fluorine, switching Cl to F and vice versa, reducing aromaticity while increasing polarity, replacing phenyl rings by heteroaromatics, and removing/diminishing HBA potential.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Summary of Some Key Chemotypes That Activate PXR (Example Ligand) And Key Structural Modifications Undertaken to Significantly Reduce PXR Activation (Optimized Structure)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0134.gif" alt="" id="gr116" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0135.gif" alt="" id="GRAPHIC-d7e8039-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0136.gif" alt="" id="GRAPHIC-d7e8040-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0137.gif" alt="" id="GRAPHIC-d7e8041-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0138.gif" alt="" id="GRAPHIC-d7e8042-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0139.gif" alt="" id="GRAPHIC-d7e8043-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0140.gif" alt="" id="GRAPHIC-d7e8044-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0147.gif" alt="" id="GRAPHIC-d7e8045-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0148.gif" alt="" id="GRAPHIC-d7e8046-autogenerated" /></img><div></div></div><div class="NLM_p">As can be seen, it can be difficult to define structural alerts; however, the potent PXR activators summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> serve to highlight some of the structural features that may be considered risk factors or structural alerts. However, benzylic groups are present frequently in PXR ligands and often form π-interaction with Trp299 in the hydrophobic cage and possibly edge-to-face or π–π interactions with other residues also in the hydrophobic cage, such as Phe288 and Tyr306. Furthermore, molecular features that induce a bent or folded conformation are often present in PXR ligands (<i>e.g</i>., S1P<sub>1</sub> antagonists and OX<sub>1</sub> antagonists), which also flags sulfones and sulfonamides as alerting moieties. In addition, benzylic substitution, <i>e.g</i>., by methyl or cyclopropyl, help to stabilize a bent conformation which often further enhances PXR binding.</div><div class="NLM_p">Other features include an H-bond acceptor in middle of molecule (which often interact with His407, Ser247, or Gln285) can also be key. A summary of some of these key structural elements is summarized in <a data-tab="pane-pcw-Figures" href="#fig106" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig106" id="" class=" internalNav">106</a></a>.</div><figure id="fig106" data-index="106" class="article__inlineFigure"><h2 class="fig-label">Figure 106</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0106.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0106.jpeg" id="gr106" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 106. Summary of some key recurrent/general pharmacophoric alerts for PXR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0106.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig106"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The authors recommend routine screening of PXR activity during drug discovery projects. This is most likely to be included as <i>ad hoc</i> screening or more systematically if PXR activity is found to be an issue. In this case, then a PXR activation or CYP induction assay should be added to the screening cascade to establish the SAR and to help design out the liability. In addition to screening for PXR, once it has been established that compounds from a series activate PXR, it is recommended to initiate computational chemistry activities, including docking and to cocrystallize ligands with PXR. While docking may be useful in some cases, especially if there are similarities to ligands that have been crystallized with PXR, it should always be borne in mind that multiple binding modes can exist and that ligands can alter their binding conformation or even flip. Therefore, the use of crystallography is highly recommended. Furthermore, it is beneficial to obtain structures of several ligands to establish a consistent binding mode and to understand if the structural modifications have altered the binding mode in any way.</div><div class="NLM_p">In terms of <i>in vitro</i> screening, there are several possibilities, as can been seen from the literature examples reviewed herein. A single concentration <i>in vitro</i> assay, for example, a PXR transactivation reporter gene assay is relatively straightforward. Compounds can be screened at 10 or 30 μM and ranked relative to rifampicin at 10 μM. In assays such as this, it is generally advisable to screen for function, i.e., activation, rather than binding, and to aim for very weak to no activity, i.e., no activation at 10 or even 30 μM. It is important to note that there are caveats. For example, the likely therapeutic concentrations should always be borne in mind, if estimated therapeutic concentrations are low then CYP3A4 induction may not be as problematic as anticipated. In addition to, or in place of single concentration activation assays, full dose–response assays may be preferred due to their higher information content. It is important that optimization focuses on increasing the EC<sub>50</sub> and reducing % activation as both parameters are important. Furthermore, there is the potential that these <i>in vitro</i> assays can overestimate the induction potential; therefore, it is advisable to ensure follow up, lower throughput assays, such as human hepatocyte assays measuring CYP3A4 mRNA/activity (using hepatocytes from more than one donor). These assays measuring increases in CYP3A4 mRNA can be conducted with 24 or 48 h, incubation with compounds, although longer is generally required to measure increased CYP3A4 activity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Subsequently, it is advisable to study compounds as early as possible in repeat dose studies (at least 4 or 5 days in duration) in preclinical species to evaluate the potential impact of any <i>in vitro</i> induction flag on the exposure following repeated administration. It is always worth bearing in mind the species differences and that a lack of decreased exposure in rodents does not necessarily mean this will be the case in humans. However, autoinduction (decreased exposure following repeated administration) in rodents is quite common and is important to investigate since it might complicate a drug development program by limiting the exposure that could be achieved in the toxicology studies.</div><div class="NLM_p">Finally, although PXR transactivation assays are widely used in drug discovery to assess the CYP3A induction potential of compounds, they are not optimal to predict the magnitude of a DDI (exposure changes). Therefore, they should be mainly used to identify PXR agonists and to bin, or rank order compounds, based on their potency to increase the transcription of CYP3A4. The work performed by Sinz et al. using 170 compounds suggested that PXR data combined with observed total plasma <i>C</i><sub>max</sub> at therapeutic doses could help to categorize the potential risk of CYP3A4 induction.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> This approach requires the estimated total plasma <i>C</i><sub>max</sub> at therapeutic doses which is not readily available in early drug discovery. Due to the number of assumptions made with the use of total plasma <i>C</i><sub>max</sub> as a relevant concentration for translation of the <i>in vitro</i> PXR data, this approach should be used for a qualitative assessment of the risk, <i>e.g</i>., to categorize as low, medium, or high. Although PXR assays are very useful to build SAR or bin compounds, they cannot accurately and quantitatively predict changes in exposure preclinically or clinically because of the inherent limitations associated with the assays (see the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>). Robust prediction of CYP3A4 induction in human based on <i>in vitro</i> data requires significant investment. Appropriate <i>in vitro</i> data (EC<sub>50</sub>/<i>E</i><sub>max</sub> in a physiologically relevant <i>in vitro</i> model) as well as information on disposition of drug candidates (Fu, expected active dose, expected plasma concentration at active dose, liver uptake, predicted portal vein concentration, potential role of metabolite(s), predicted gut lumen concentration for intestinal CYP3A4 induction, etc.) are essential to translate <i>in vitro</i> data to the <i>in vivo</i> situation, which requires considerable time. Therefore, it is always advisable to profile compounds in more definitive, lower throughput assays, such as human hepatocytes (for example, see Bayer thrombin inhibitors, <a class="ref internalNav" href="#sec5_10" aria-label="section 5.10">section 5.10</a>) on potentially interesting compounds to assess the risk of CYP induction in the clinic.</div><div class="NLM_p last">In conclusion, this perspective has tried to highlight the role of PXR as an undesired activity in drug discovery. The recent advances in the use of PXR crystallography to allow the informed design of new compounds has greatly increased the ability to design out this activity. The structure-guided section highlights how this has been successfully used by several companies on a range of different targets. From this section and the empirical SAR section, it can be seen that there are many different chemotypes that can activate PXR and there are many ways in which to diminish this activity. It is hoped that this perspective will serve as a useful summary and starting point for anyone who encounters an issue with PXR. Finally, some examples of key structures that activate PXR and the successful structural modifications to reduce PXR activity are summarized in conjunction with a summary of some structural alerts and some practical recommendations and considerations to enable the assessment and screening of PXR issues.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">7.  Addendum</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While this manuscript was undergoing review, a paper detailing 14 new PXR structures appeared.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a> Given its relevance to this perspective, a brief discussion of the most salient points has been added in this section, with an annex to <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), with continued numbering. Of the 14 new structures, 1 is <i>apo</i>, 9 are with 1 ligand (although 2 have two copies of the same ligand), and 4 are with two (different) bound ligands.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Additional PXR Crystal Structures Deposited in PDB Whilst This Manuscript Was Undergoing Review</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0123.gif" alt="" id="GRAPHIC-d7e8186-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0124.gif" alt="" id="GRAPHIC-d7e8187-autogenerated" /></img><div></div></div><div class="NLM_p">The <i>apo</i> structure does not differ significantly from the previously reported structure so is not discussed further. Of the nine new ligands, three show covalent interactions, highlighting that two cysteine residues in the binding site, Cys207 and Cys3284, can be covalently labeled. This is the first time a covalent interaction has been observed. Furthermore, fipronil (<b>420</b>) targets Cys284 selectively, while pretilachlor (<b>422</b>) targets Cys207 selectively, and the third (tributyl tin, <b>423</b>) labels both via two ligands in the pocket. The four structures with two ligands bound to the pocket are similar to entry 18 in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G">4X1G</a>, with TNC (<b>68</b>) and 17α-ethinylestradiol (<b>68</b>), as three of them contain an analogue of TNC (<b>68</b>) with estradiol (<b>425</b>) instead of 17α-ethinylestadiol (<b>56</b>).</div><div class="NLM_p">One of new structures, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXJ">7AXJ</a> contains estradiol (<b>425</b>) in the presence of clotrimazole (<b>417</b>) and highlights that two ligands binding simultaneously can produce a synergistic effect on PXR activity. When bound on its own, one phenyl ring of clotrimazole (<b>417</b>) forms edge-to-face interactions with Tyr306 and an offset π–π interaction with Trp299, <a data-tab="pane-pcw-Figures" href="#fig107" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig107" id="" class=" internalNav">107</a></a>. The imidazole of forms an edge-to-face withTrp299 and a H-bond with His327 (all hydrophobic cage, green). In addition there is an edge-to-face interaction with His407 (polar rim, blue) and the chlorophenyl rind of clotrimazole.</div><figure id="fig107" data-index="107" class="article__inlineFigure"><h2 class="fig-label">Figure 107</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0107.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0107.jpeg" id="gr107" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 107. (a) Structure of PXR with clotrimazole (<b>417</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXA">7AXA</a>). (b) Structure of PXR with clotrimazole (<b>417</b>) and estradiol (<b>425</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXJ">7AXJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0107.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig107"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When cobound with estradiol (<b>425</b>), <a data-tab="pane-pcw-Figures" href="#fig107" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig107" id="" class=" internalNav">107</a></a>, clotrimazole (<b>417</b>) occupies a similar region of the pocket, i.e., in the hydrophobic cage, but is flipped so that the chlorophenyl ring forms a π–π interaction with Trp299 and an edge-to-face interaction with Tyr306, thereby losing the interaction with the polar rim. The ligands do not appear to form any particular interactions. The secondary alcohol of estradiol (<b>425</b>) forms two hydrogen bonds with PXR; one with the backbone carbonyl Asp205 (polar channel, magenta) and one with the guanidine moiety of Arg410 (polar rim, blue). An additional hydrogen bond is formed between the phenol of estradiol (<b>425</b>) and the side chain of Ser247 (polar rim, blue). In addition, there is movement to accommodate the two ligands, for example, the sidechains of His407 (polar rim, blue), Leu209 (polar channel, magenta), and Met323 (polar rim, blue), while there is some movement on the hydrophobic side (orange) versus the structure with clotrimazole (<b>417</b>) alone. In contrast, the hydrophobic cage shows minimal alteration.</div><div class="NLM_p">As mentioned, two druglike molecules, fipronil (<b>420</b>) and pretilachlor (<b>422</b>) form covalent bonds with PXR. Fipronil (<b>420</b>), <a data-tab="pane-pcw-Figures" href="#fig108" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig108" id="" class=" internalNav">108</a></a>, interacts strongly with the hydrophobic cage, forming a π–π interaction between the trisubstituted phenyl ring and Phe288 and an edge-to-face interaction with Trp299. The trifluoromethyl group also forms hydrophobic interactions with Trp299 and Tyr306. The ligand extends out from the hydrophobic cage toward the polar rim (blue) where the trifluoromethyl sulfone O-atom interacts with His407 (polar rim, blue) and forms an intramolecular H-bond of the NH<sub>2</sub> on the pyrazole. The nitrile on the pyrazole appears to form a covalent bond with Cys284, as discussed in the manuscript, with the C–S distance as 2.3 Å. However, this was not confirmed by mass spectrometry, potentially due to the covalent reversible nature of the interaction, which results in a short residence time.</div><figure id="fig108" data-index="108" class="article__inlineFigure"><h2 class="fig-label">Figure 108</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0108.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0108.jpeg" id="gr108" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 108. Structure of PXR with covalent ligands. (a) Fipronil (<b>420</b>) in gray showing a covalent bond between Cys284 and the nitrile group (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXD">7AXD</a>). (b) Structure of PXR with pretilachlor showing two copies of the ligand (black and gray) in the binding pocket, one of which forms a covalent bond between Cys207 and the chloro-acetamide (<b>422</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF">7AXF</a>). (c) Rotated view of PXR with pretilachlor showing two copies of the ligand (black and gray) in the binding pocket, one of which forms a covalent bond between Cys207 and the chloro-acetamide (<b>422</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF">7AXF</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0108.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig108"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure with pretilachlor (<b>422</b>) is interesting in that it shows two copies of the ligand, one in black and one in gray, simultaneously bound, <a data-tab="pane-pcw-Figures" href="#fig108" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig108" id="" class=" internalNav">108</a></a>, one of which (gray) is bound covalently. One molecule interacts with the hydrophobic cage (green), forming an edge-to-face interaction with Phe288, while the other is closer to the polar channel (magenta) and the hydrophobic side (orange) and forms a covalent bond with Cys207 on the polar channel (magenta). Comparison of the pretilachlor-bound structure with the <i>apo</i> structure reveals a significant movement of the protein. Furthermore pretilachlor is a potent and full agonist in the luciferase reporter assay used in this study, implying the covalent interaction locks PXR in an active conformation.</div><div class="NLM_p">The authors also highlight the importance of the hydrophobic cage, or aromatic cage as they termed it, in forming interactions with several ligands. This is exemplified in different ways for ligands such as ferutinin (<b>419</b>), oxadiazon (<b>421</b>), and α-zearalanol (<b>424</b>), <a data-tab="pane-pcw-Figures" href="#fig109" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig109" id="" class=" internalNav">109</a></a>. For ferutinin (<b>419</b>), the cyclopentyl ring occupies the hydrophobic cage (green). The ligand also forms a hydrogen bonds with Gln285 and Glu321, via the phenol, (polar rim, blue) in addition to bridging water-mediated H-bonds, <i>e.g</i>., Ser247. In the case of oxadiazon (<b>421</b>), the <i>t</i>-Bu group interacts with Trp299, Phe288, and Tyr306 highlighting that π–π or edge-to-face interactions are not necessarily required to interact with the hydrophobic cage. In addition, the ligand also demonstrates halogen bonds can be effective in binding to PXR. Finally α-zearalanol (<b>424</b>) predominantly forms lipophilic contacts with the hydrophobic cage (green) but also makes a hydrogen bond with Gln285 (polar rim, blue) and partly interacts with the polar channel (magenta).</div><figure id="fig109" data-index="109" class="article__inlineFigure"><h2 class="fig-label">Figure 109</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0109.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0109.jpeg" id="gr109" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 109. Structure of PXR with (a) ferutinin (<b>419</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXC">7AXC</a>). (b) Oxadiazon (<b>421</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXE">7AXE</a>). (c) α-Zearalanol (<b>424</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXH">7AXH</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0109.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig109"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02245" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Hall</span> - <span class="hlFld-Affiliation affiliation">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7869-6835" title="Orcid link">http://orcid.org/0000-0001-7869-6835</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5e4c1d7ccc4cb8bedc4c9c9e5d0c6c78bc6cac8"><span class="__cf_email__" data-cfemail="9fdefbedf6fef1b1d7fef3f3dfeafcfdb1fcf0f2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hugues Chanteux</span> - <span class="hlFld-Affiliation affiliation">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karelle Ménochet</span> - <span class="hlFld-Affiliation affiliation">UCB, 216 Bath Road, Slough, SL1 3WE, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie Ledecq</span> - <span class="hlFld-Affiliation affiliation">UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika-Sarah E. D. Schulze</span> - <span class="hlFld-Affiliation affiliation">UCB, 216 Bath Road, Slough, SL1 3WE, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3799-0808" title="Orcid link">http://orcid.org/0000-0002-3799-0808</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of UCB and may hold stock and/or stock options.<br /></br><p class="inlineNote">The pictures representing the crystallographic structures were built within the Maestro interface (Schrödinger release 2021-1: Maestro, Schrödinger, LLC, New York, NY, 2021).</p></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="110" class="article__inlineFigure"><h2 class="fig-label">Adrian Hall</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=BIO-d7e8784-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Adrian Hall</b> completed his degree and Ph.D. at Heriot-Watt University in Edinburgh followed by postdoctoral studies at the Université de Montreal with Prof. S. Hanessian. Subsequently, he began his industrial career at GlaxoWellcome in Stevenage, U.K. Following the formation of GlaxoSmithKline, he moved to the Harlow site, via The Frythe. He then moved to Eisai European Knowledge Centre, firstly as Group Leader then as Head of Chemistry. Currently, Adrian is Senior Director and Head of Medicinal Chemistry at UCB for the Braine-L’Alleud site in Belgium. He has contributed to the identification of multiple development candidates in the neuroscience area and is an active member of the Royal Society of Chemistry (RSC) Bioorganic and Medicinal Chemistry Sector (BMCS) through which he has organized many conferences.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="111" class="article__inlineFigure"><h2 class="fig-label">Hugues Chanteux</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=BIO-d7e8789-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hugues Chanteux</b> completed a Ph.D. in pharmaceutical sciences at Catholic University of Louvain in Belgium. He joined UCB Pharma in 2005 where he started his career in the preclinical DMPK department. From his experience as head of the <i>in vitro</i> ADME lab for more than 10 years, Hugues has an in-depth expertise of <i>in vitro</i> assays to characterize the DDI potential of NCEs. For more than 5 years, he has also been involved in PBPK modelling activities to support drug development with the main focus to understand, characterize, and predict DDIs. Recently, he joined the clinical pharmacology department where he is in charge of the design and interpretation of clinical pharmacology studies and further develops clinical PBPK activities to support clinical study design, NDA, and labelling.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="112" class="article__inlineFigure"><h2 class="fig-label">Karelle Ménochet</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=BIO-d7e8800-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Karelle Ménochet</b> started her career in Discovery DMPK at Parke-Davis/Pfizer, Fresnes (France), followed by AstraZeneca Charnwood, Loughborough (U.K.). She completed a Ph.D. in pharmaceutical sciences at the Centre for Applied Pharmacokinetic Research (University of Manchester, U.K.) under the supervision of Prof. A. Galetin and Prof. J. B. Houston. Karelle joined UCB Pharma in 2012 in the preclinical DMPK department. She has gained a broad knowledge of drug discovery and development through her roles as DMPK project representative, <i>in vivo</i> group leader, biomarker lead and nonclinical PKPD lead for NCE and NBE. She is currently Head of nonclinical PKPD.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="113" class="article__inlineFigure"><h2 class="fig-label">Marie Ledecq</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=BIO-d7e8808-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marie Ledecq</b> completed Ph.D. studies in chemical sciences at the University of Namur (Belgium) under the supervision of Prof. F. Durant and Prof. J. Wouters, where she gained expertise in molecular modelling and physicochemical characterization of small molecules. She joined UCB Pharma in 2007 in the CADD group as a computational chemist, where she developed a broad experience in ligand and structure-based drug design and in QSAR modeling. She has contributed to numerous therapeutic NCE projects as the CADD representative, from hit identification to candidate selection phases. She is particularly interested in multiparameter optimization challenges where computational-aided drug design can accelerate the drug discovery process.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="114" class="article__inlineFigure"><h2 class="fig-label">Monika-Sarah E. D. Schulze</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=BIO-d7e8813-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Monika-Sarah E. D. Schulze</b> completed her Ph.D. studies at Dana-Farber Cancer Institute in Boston (U.S.) after gaining expertise in protein crystallography in the group of Prof. Georg E. Schulz during her Master’s degree at University of Freiburg (Germany). Following postdoctoral studies at Harvard Medical School (U.S.), Monika-Sarah joined the Structural Biology department of UCB (U.K.) as a protein crystallographer in 2013. During her career, she delivered structural insight in real time for early phase NCE and NBE projects including off-target studies to reduce DDI risk and is an inventor on patent applications for small molecule modulators and antibodies. As structural biology lead for NCE projects from hit identification to candidate selection, she gained in-depth knowledge of drug discovery and development. She is currently leading the structural design of new modalities.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Baudhuin Ledecq for the design of the graphical abstract and the four reviewers for spending January evaluating this perspective in detail.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion and toxicity</p></td></tr><tr><td class="NLM_term">AF</td><td class="NLM_def"><p class="first last">activation function</p></td></tr><tr><td class="NLM_term">ANN</td><td class="NLM_def"><p class="first last">artificial neural network</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">AZ</td><td class="NLM_def"><p class="first last">AstraZeneca</p></td></tr><tr><td class="NLM_term">BMS</td><td class="NLM_def"><p class="first last">Bristol Myers Squibb</p></td></tr><tr><td class="NLM_term">CAR</td><td class="NLM_def"><p class="first last">constitutive androstane receptor</p></td></tr><tr><td class="NLM_term">CCDC</td><td class="NLM_def"><p class="first last">Cambridge Crystallographic Data Centre</p></td></tr><tr><td class="NLM_term">CCR</td><td class="NLM_def"><p class="first last">C–C chemokine receptor</p></td></tr><tr><td class="NLM_term">CFTR</td><td class="NLM_def"><p class="first last">cystic fibrosis transmembrane conductance regulator</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CoMFA</td><td class="NLM_def"><p class="first last">comparative molecular field analysis</p></td></tr><tr><td class="NLM_term">CoMSIA</td><td class="NLM_def"><p class="first last">comparative molecular similarity indices analysis</p></td></tr><tr><td class="NLM_term">CSD</td><td class="NLM_def"><p class="first last">Cambridge Structural Database</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DBD</td><td class="NLM_def"><p class="first last">DNA-binding domain</p></td></tr><tr><td class="NLM_term">DT</td><td class="NLM_def"><p class="first last">decision tree</p></td></tr><tr><td class="NLM_term">EINECS</td><td class="NLM_def"><p class="first last">European INventory of Existing Commercial chemical Substances</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">GlaxoSmithKline</p></td></tr><tr><td class="NLM_term">HB</td><td class="NLM_def"><p class="first last">hydrogen bond</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HFIPA</td><td class="NLM_def"><p class="first last">hexafluoro-isopropyl alcohol</p></td></tr><tr><td class="NLM_term">HMG-CoA</td><td class="NLM_def"><p class="first last">3-hydroxy-3-methyl-glutaryl coenzyme A</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HNF</td><td class="NLM_def"><p class="first last">hepatocyte nuclear factor</p></td></tr><tr><td class="NLM_term">HSD</td><td class="NLM_def"><p class="first last">hydroxysteroid dehydrogenase</p></td></tr><tr><td class="NLM_term">IGF</td><td class="NLM_def"><p class="first last">insulin-like growth factor</p></td></tr><tr><td class="NLM_term">KNN</td><td class="NLM_def"><p class="first last">Kohonen neural network</p></td></tr><tr><td class="NLM_term">LBD</td><td class="NLM_def"><p class="first last">ligand-binding domain</p></td></tr><tr><td class="NLM_term">LXR</td><td class="NLM_def"><p class="first last">liver-X-receptor</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1 (aka Pgp)</p></td></tr><tr><td class="NLM_term">MEC</td><td class="NLM_def"><p class="first last">minimum efficacious concentrations</p></td></tr><tr><td class="NLM_term">MTPC</td><td class="NLM_def"><p class="first last">Mitsubishi Tanabe Pharma Corporation</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">NN</td><td class="NLM_def"><p class="first last">nearest neighbor</p></td></tr><tr><td class="NLM_term">NNRTI</td><td class="NLM_def"><p class="first last">non-nucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">pregnane activated receptor</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PLR</td><td class="NLM_def"><p class="first last">partial logistic regression</p></td></tr><tr><td class="NLM_term">PLS</td><td class="NLM_def"><p class="first last">partial least squares</p></td></tr><tr><td class="NLM_term">PNN</td><td class="NLM_def"><p class="first last">probabilistic neural network</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure activity relationship</p></td></tr><tr><td class="NLM_term">ROR</td><td class="NLM_def"><p class="first last">retinoic acid-related orphan receptor</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">recursive partitioning</p></td></tr><tr><td class="NLM_term">RXR</td><td class="NLM_def"><p class="first last">retinoid-X-receptor/retinoic acid receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure activity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug discovery</p></td></tr><tr><td class="NLM_term">SRC-1</td><td class="NLM_def"><p class="first last">steroid receptor co-activator-1</p></td></tr><tr><td class="NLM_term">SVM</td><td class="NLM_def"><p class="first last">support vector machine</p></td></tr><tr><td class="NLM_term">THIQ</td><td class="NLM_def"><p class="first last">tetrahydroisoquinoline</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 258 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterström, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. M.</span></span> <span> </span><span class="NLM_article-title">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80900-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0092-8674%2800%2980900-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9489701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=73-82&issue=1&author=S.+A.+Kliewerauthor=J.+T.+Mooreauthor=L.+Wadeauthor=J.+L.+Staudingerauthor=M.+A.+Watsonauthor=S.+A.+Jonesauthor=D.+D.+McKeeauthor=B.+B.+Oliverauthor=T.+M.+Willsonauthor=R.+H.+Zetterstr%C3%B6mauthor=T.+Perlmannauthor=J.+M.+Lehmann&title=An+orphan+nuclear+receptor+activated+by+pregnanes+defines+a+novel+steroid+signaling+pathway&doi=10.1016%2FS0092-8674%2800%2980900-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span></div><div class="casAuthors">Kliewer, Steven A.; Moore, John T.; Wade, Laura; Staudinger, Jeff L.; Watson, Michael A.; Jones, Stacey A.; McKee, David D.; Oliver, Beverly B.; Willson, Timothy M.; Zetterstrom, Rolf H.; Perlmann, Thomas; Lehmann, Jurgen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors.  We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids.  PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids.  Notably, PXR.1 is efficaciously activated by pregnenolone 16α-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo.  Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcj-Q4c6TTLVg90H21EOLACvtfcHk0lgc1y7LrsgwlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D&md5=1c24d97b161b497c4d2503e7b7adb778</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980900-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980900-9%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DL.%26aulast%3DStaudinger%26aufirst%3DJ.%2BL.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZetterstr%25C3%25B6m%26aufirst%3DR.%2BH.%26aulast%3DPerlmann%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520orphan%2520nuclear%2520receptor%2520activated%2520by%2520pregnanes%2520defines%2520a%2520novel%2520steroid%2520signaling%2520pathway%26jtitle%3DCell%26date%3D1998%26volume%3D92%26issue%3D1%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0092-8674%2800%2980900-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span> <span> </span><span class="NLM_article-title">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1023</span>, <span class="refDoi"> DOI: 10.1172/JCI3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1172%2FJCI3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9727070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1016-1023&issue=5&author=J.+M.+Lehmannauthor=D.+D.+McKeeauthor=M.+A.+Watsonauthor=T.+M.+Willsonauthor=J.+T.+Mooreauthor=S.+A.+Kliewer&title=The+human+orphan+nuclear+receptor+PXR+is+activated+by+compounds+that+regulate+CYP3A4+gene+expression+and+cause+drug+interactions&doi=10.1172%2FJCI3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span></div><div class="casAuthors">Lehmann, Jurgen M.; McKee, David D.; Watson, Michael A.; Willson, Timothy M.; Moore, John T.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the oxidative metab. of a wide variety of xenobiotics including an estd. 60% of all clin. used drugs.  Although expression of the CYP3A4 gene is known to be induced in response to a variety of compds., the mechanism underlying this induction, which represents a basis for drug interactions in patients, has remained unclear.  The authors report the identification of a human (h) orphan nuclear receptor, termed the pregnane X receptor (PXR), that binds to a response element in the CYP3A4 promoter and is activated by a range of drugs known to induce CYP3A4 expression.  Comparison of hPXR with the recently cloned mouse PXR reveals marked differences in their activation by certain drugs, which may account in part for the species-specific effects of compds. on CYP3A gene expression.  These findings provide a mol. explanation for the ability of disparate chems. to induce CYP3A4 levels and, furthermore, provide a basis for developing in vitro assays to aid in predicting whether drugs will interact in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7B4VVObDCH7Vg90H21EOLACvtfcHk0liOuB3sgzQYQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D&md5=536bd0a0a80d2d6b36cdc7747a8e0fd0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1172%2FJCI3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3703%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DThe%2520human%2520orphan%2520nuclear%2520receptor%2520PXR%2520is%2520activated%2520by%2520compounds%2520that%2520regulate%2520CYP3A4%2520gene%2520expression%2520and%2520cause%2520drug%2520interactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26issue%3D5%26spage%3D1016%26epage%3D1023%26doi%3D10.1172%2FJCI3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juguilon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolado, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Meter, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">SXR, a novel steroid and xenobiotic-sensing nuclear receptor</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3195</span>– <span class="NLM_lpage">3205</span>, <span class="refDoi"> DOI: 10.1101/gad.12.20.3195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1101%2Fgad.12.20.3195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9784494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVSnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=3195-3205&issue=20&author=B.+Blumbergauthor=W.+Sabbaghauthor=H.+Juguilonauthor=J.+Boladoauthor=C.+M.+van%0AMeterauthor=E.+S.+Ongauthor=R.+M.+Evans&title=SXR%2C+a+novel+steroid+and+xenobiotic-sensing+nuclear+receptor&doi=10.1101%2Fgad.12.20.3195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">SXR, a novel steroid and xenobiotic-sensing nuclear receptor</span></div><div class="casAuthors">Blumberg, Bruce; Sabbagh, Walid, Jr.; Juguilon, Henry; Bolado, Jack, Jr.; Van Meter, Casey M.; Ong, Estelita S.; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3195-3205</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">An important requirement for physiol. homeostasis is the detoxification and removal of endogenous hormones and xenobiotic compds. with biol. activity.  Much of the detoxification is performed by cytochrome P 450 enzymes, many of which have broad substrate specificity and are inducible by hundreds of different compds., including steroids.  The ingestion of dietary steroids and lipids induces the same enzymes; therefore, they would appear to be integrated into a coordinated metabolic pathway.  Instead of possessing hundreds of receptors, one for each inducing compd., we propose the existence of a few broad specificity, low-affinity sensing receptors that would monitor aggregate levels of inducers to trigger prodn. of metabolizing enzymes.  In support of this model, we have isolated a novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), which activates transcription in response to a diversity of natural and synthetic compds.  SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P 450 genes and is expressed in tissues in which these catabolic enzymes are expressed.  These results strongly support the steroid sensor hypothesis and suggest that broad specificity sensing receptors may represent a novel branch of the nuclear receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe45GV6SpF3rVg90H21EOLACvtfcHk0liOuB3sgzQYQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVSnsb8%253D&md5=cd22f265a573af0102e47d412172c499</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.20.3195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.20.3195%26sid%3Dliteratum%253Aachs%26aulast%3DBlumberg%26aufirst%3DB.%26aulast%3DSabbagh%26aufirst%3DW.%26aulast%3DJuguilon%26aufirst%3DH.%26aulast%3DBolado%26aufirst%3DJ.%26aulast%3Dvan%2BMeter%26aufirst%3DC.%2BM.%26aulast%3DOng%26aufirst%3DE.%2BS.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DSXR%252C%2520a%2520novel%2520steroid%2520and%2520xenobiotic-sensing%2520nuclear%2520receptor%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26issue%3D20%26spage%3D3195%26epage%3D3205%26doi%3D10.1101%2Fgad.12.20.3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertilsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendeberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydow-Bäckman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postlind, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenstam, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12208</span>– <span class="NLM_lpage">12213</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.21.12208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1073%2Fpnas.95.21.12208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9770465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXmsl2rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12208-12213&issue=21&author=G.+Bertilssonauthor=J.+Heidrichauthor=K.+Svenssonauthor=M.+Asmanauthor=L.+Jendebergauthor=M.+Sydow-B%C3%A4ckmanauthor=R.+Ohlssonauthor=H.+Postlindauthor=P.+Blomquistauthor=A.+Berkenstam&title=Identification+of+a+human+nuclear+receptor+defines+a+new+signaling+pathway+for+CYP3A+induction&doi=10.1073%2Fpnas.95.21.12208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction</span></div><div class="casAuthors">Bertilsson, Goran; Heidrich, Jessica; Svensson, Kristian; Asman, Michael; Jendeberg, Lena; Sydow-Backman, Mona; Ohlsson, Rolf; Postlind, Hans; Blomquist, Patrik; Berkenstam, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12208-12213</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nuclear receptors regulate metabolic pathways in response to changes in the environment by appropriate alterations in gene expression of key metabolic enzymes.  Here, a computational search approach based on iteratively built hidden Markov models of nuclear receptors was used to identify a human nuclear receptor, termed hPAR, that is expressed in liver and intestines.  HPAR was efficiently activated by pregnanes and by clin. used drugs including rifampicin, an antibiotic known to selectively induce human but not murine CYP3A expression.  The CYP3A drug-metabolizing enzymes are expressed in gut and liver in response to environmental chems. and clin. used drugs.  Interestingly, hPAR is not activated by pregnenolone 16α-carbonitrile, which is a potent inducer of murine CYP3A genes and an activator of the mouse receptor PXR.1.  Furthermore, hPAR was found to bind to and trans-activate through a conserved regulatory sequence present in human but not murine CYP3A genes.  These results provide evidence that hPAR and PXR.1 may represent orthologous genes from different species that have evolved to regulate overlapping target genes in response to pharmacol. distinct CYP3A activators, and have potential implications for the in vitro identification of drug interactions important to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6lbkuDG1xyLVg90H21EOLACvtfcHk0liOuB3sgzQYQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsl2rs7w%253D&md5=d53e043b07c6aff3de4c5d4204def3bc</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.21.12208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.21.12208%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DG.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DSvensson%26aufirst%3DK.%26aulast%3DAsman%26aufirst%3DM.%26aulast%3DJendeberg%26aufirst%3DL.%26aulast%3DSydow-B%25C3%25A4ckman%26aufirst%3DM.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DPostlind%26aufirst%3DH.%26aulast%3DBlomquist%26aufirst%3DP.%26aulast%3DBerkenstam%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520human%2520nuclear%2520receptor%2520defines%2520a%2520new%2520signaling%2520pathway%2520for%2520CYP3A%2520induction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D21%26spage%3D12208%26epage%3D12213%26doi%3D10.1073%2Fpnas.95.21.12208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>345</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fjpet.112.201863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23536316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=473-482&issue=3&author=W.+Douauthor=J.+Zhangauthor=E.+Zhangauthor=A.+Sunauthor=L.+Dingauthor=G.+Chouauthor=Z.+Wangauthor=S.+Mani&title=Chrysin+ameliorates+chemically+induced+colitis+in+the+mouse+through+modulation+of+a+PXR%2FNF-%CE%BAB+signaling+pathway&doi=10.1124%2Fjpet.112.201863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway</span></div><div class="casAuthors">Dou, Wei; Zhang, Jingjing; Zhang, Eryun; Sun, Aning; Ding, Lili; Chou, Guixin; Wang, Zhengtao; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted activation of pregnane X receptor (PXR) in recent years has become a therapeutic strategy for inflammatory bowel disease.  Chrysin is a naturally occurring flavonoid with anti-inflammation activity.  The current study investigated the role of chrysin as a putative mouse PXR agonist in preventing exptl. colitis.  Pre-administration of chrysin ameliorated inflammatory symptoms in mouse models of colitis (dextran sodium sulfate- and 2,4,6-trinitrobenzene sulfonic acid-induced) and resulted in down-regulation of nuclear transcription factor κB (NF-κB) target genes (inducible NO synthase, intercellular adhesion mol.-1, monocyte chemotactic protein-1, cyclooxygenase 2, tumor necrosis factor-α, and interleukin 6) in the colon mucosa.  Chrysin inhibited the phosphorylation/degrdn. of inhibitor κBα (IκBα), which correlated with the decrease in the activity of myeloperoxidase and the levels of tumor necrosis factor-κ and interleukin 6 in the colon.  Consistent with the in vivo results, chrysin blocked lipopolysaccharide -stimulated nuclear translocation of NF-κB p65 in mouse macrophage RAW264.7.  Furthermore, chrysin dose-dependently activated human/mouse PXR in reporter gene assays and up-regulated xenobiotic detoxification genes in the colon mucosa, but not in the liver.  Silencing of PXR by RNA interference demonstrated necessity of PXR in mediating chrysin's ability to induce xenobiotic detoxification genes and NF-κB inactivation.  The repression of NF-κB transcription activity by chrysin was confirmed by in vitro PXR transduction.  These findings suggest that the effect of chrysin in preventing chem. induced colitis is mediated in large part by a PXR/NF-κB pathway.  The data also suggest that chrysin or chrysin-like flavonoids could be further developed as intestine-specific PXR activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozsbOWiIBkibVg90H21EOLACvtfcHk0lhIRSHTFUwNkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL8%253D&md5=bb07302041857fc39100674b245ed48d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201863%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DChou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DChrysin%2520ameliorates%2520chemically%2520induced%2520colitis%2520in%2520the%2520mouse%2520through%2520modulation%2520of%2520a%2520PXR%252FNF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26issue%3D3%26spage%3D473%26epage%3D482%26doi%3D10.1124%2Fjpet.112.201863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gironella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garambois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudhomme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgaux, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollande, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannequin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span> <span> </span><span class="NLM_article-title">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">56558</span>– <span class="NLM_lpage">56573</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.18632%2Foncotarget.10646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27448961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ktVyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=56558-56573&issue=35&author=C.+Planqueauthor=F.+Rajabiauthor=F.+Grilletauthor=P.+Finettiauthor=F.+Bertucciauthor=M.+Gironellaauthor=J.+J.+Lozanoauthor=B.+Beucherauthor=J.+Giraudauthor=V.+Garamboisauthor=C.+Vincentauthor=D.+Brownauthor=L.+Cailloauthor=J.+Kantarauthor=A.+Pelegrinauthor=M.+Prudhommeauthor=J.+Ripocheauthor=J.+F.+Bourgauxauthor=C.+Ginestierauthor=A.+Castellsauthor=F.+Hollandeauthor=J.+Pannequinauthor=J.+M.+Pascussi&title=Pregnane+X-receptor+promotes+stem+cell-mediated+colon+cancer+relapse&doi=10.18632%2Foncotarget.10646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</span></div><div class="casAuthors">Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Finetti Pascal; Bertucci Francois; Gironella Meritxell; Lozano Juan Jose; Castells Antoni; Garambois Veronique; Vincent Charles; Pelegrin Andre; Brown Daniel; Hollande Frederic; Kantar Jovana; Prudhomme Michel; Ripoche Jeremie; Bourgaux Jean Francois; Ginestier Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">56558-56573</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs).  Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence.  First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance.  Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy.  This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpvV4km2DSQK2q3xNe7a7QfW6udTcc2eZB9TcB24Jp_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ktVyqsg%253D%253D&md5=00ab1dd5dbf30db9dddfc20c28964a63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10646%26sid%3Dliteratum%253Aachs%26aulast%3DPlanque%26aufirst%3DC.%26aulast%3DRajabi%26aufirst%3DF.%26aulast%3DGrillet%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DGironella%26aufirst%3DM.%26aulast%3DLozano%26aufirst%3DJ.%2BJ.%26aulast%3DBeucher%26aufirst%3DB.%26aulast%3DGiraud%26aufirst%3DJ.%26aulast%3DGarambois%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DCaillo%26aufirst%3DL.%26aulast%3DKantar%26aufirst%3DJ.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DPrudhomme%26aufirst%3DM.%26aulast%3DRipoche%26aufirst%3DJ.%26aulast%3DBourgaux%26aufirst%3DJ.%2BF.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DCastells%26aufirst%3DA.%26aulast%3DHollande%26aufirst%3DF.%26aulast%3DPannequin%26aufirst%3DJ.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26atitle%3DPregnane%2520X-receptor%2520promotes%2520stem%2520cell-mediated%2520colon%2520cancer%2520relapse%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D35%26spage%3D56558%26epage%3D56573%26doi%3D10.18632%2Foncotarget.10646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.2011.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21832990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=575-581&issue=4&author=K.+Maedaauthor=Y.+Ikedaauthor=T.+Fujitaauthor=K.+Yoshidaauthor=Y.+Azumaauthor=Y.+Haruyamaauthor=N.+Yamaneauthor=Y.+Kumagaiauthor=Y.+Sugiyama&title=Identification+of+the+rate-determining+process+in+the+hepatic+clearance+of+atorvastatin+in+a+clinical+cassette+microdosing+study&doi=10.1038%2Fclpt.2011.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study</span></div><div class="casAuthors">Maeda, K.; Ikeda, Y.; Fujita, T.; Yoshida, K.; Azuma, Y.; Haruyama, Y.; Yamane, N.; Kumagai, Y.; Sugiyama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clearance of atorvastatin occurs through hepatic uptake by org. anion transporting polypeptides (OATPs) and subsequent metab. by cytochrome P 450 (CYP) 3A4.  To demonstrate the relative importance of OATPs and CYP3A4 in the hepatic elimination of atorvastatin in vivo, a clin. cassette microdose study was performed.  A cocktail consisting of a microdose of atorvastatin along with probe substrates for OATPs (pravastatin) and CYP3A4 (midazolam) was orally administered to eight healthy volunteers.  The pharmacokinetics of this cocktail was obsd. at baseline, after an oral dose of 600 mg rifampicin (an inhibitor of OATPs), and after an i.v. dose of 200 mg itraconazole (a CYP3A4 inhibitor).  Rifampicin increased the pravastatin dose-normalized area under the plasma concn.-time curve (AUC) (4.6-fold), and itraconazole significantly increased the midazolam dose-normalized AUC (1.7-fold).  The atorvastatin dose-normalized AUC increased 12-fold when coadministered with rifampicin but did not change when coadministered with itraconazole.  These results indicate that hepatic uptake via OATPs makes the dominant contribution to the hepatic elimination of atorvastatin at a subtherapeutic microdose.  Clin. Pharmacol. & Therapeutics (2011) 90 4, 575-581. doi:10.1038/clpt.2011.142.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RhNvYVyyPLVg90H21EOLACvtfcHk0lia-z_MwwRyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqtbbM&md5=8bcac4f57a99151af0aee27d96370525</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.142%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DY.%26aulast%3DHaruyama%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DN.%26aulast%3DKumagai%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520the%2520rate-determining%2520process%2520in%2520the%2520hepatic%2520clearance%2520of%2520atorvastatin%2520in%2520a%2520clinical%2520cassette%2520microdosing%2520study%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D90%26issue%3D4%26spage%3D575%26epage%3D581%26doi%3D10.1038%2Fclpt.2011.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">14581</span>– <span class="NLM_lpage">14587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010173200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M010173200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11297522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=14581-14587&issue=18&author=A.+Geickauthor=M.+Eichelbaumauthor=O.+Burk&title=Nuclear+receptor+response+elements+mediate+induction+of+intestinal+MDR1+by+rifampin&doi=10.1074%2Fjbc.M010173200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span></div><div class="casAuthors">Geick, Anke; Eichelbaum, Michel; Burk, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">14581-14587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intestinal P-glycoprotein, which is encoded by the MDR1 gene, plays an important role in the absorption and presystemic elimination of many xenobiotics.  Hence, an understanding of the factors regulating its expression and function is of substantial interest.  In addn. to genetic factors, exposure to drugs such as rifampin can profoundly affect its expression.  So far, the mechanisms by which rifampin induces MDR1 expression are poorly understood.  Recent studies demonstrate that the nuclear receptor PXR (pregnane X receptor) is involved in xenobiotic induction of CYP3A4.  Because CYP3A4 and MDR1 are often co-induced, we investigated whether a similar mechanism is also involved in MDR1 induction.  The human colon carcinoma cell line LS174T was used as an intestinal model to study induction because in these cells the endogenous MDR1 gene is highly inducible by rifampin.  The 5'-upstream region of human MDR1 was examd. for the presence of potential PXR response elements.  Several binding sites were identified that form a complex regulatory cluster at about -8 kilobase pairs.  Only one DR4 motif within this cluster is necessary for induction by rifampin.  We conclude that induction of MDR1 is mediated by a DR4 motif in the upstream enhancer at about -8 kilobase pairs, to which PXR binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDciMSSWDvqbVg90H21EOLACvtfcHk0lia-z_MwwRyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D&md5=756631447fee46a9a89df3bb5a263ea5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010173200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010173200%26sid%3Dliteratum%253Aachs%26aulast%3DGeick%26aufirst%3DA.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBurk%26aufirst%3DO.%26atitle%3DNuclear%2520receptor%2520response%2520elements%2520mediate%2520induction%2520of%2520intestinal%2520MDR1%2520by%2520rifampin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D18%26spage%3D14581%26epage%3D14587%26doi%3D10.1074%2Fjbc.M010173200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kast, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anisfeld, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontonoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2908</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109326200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M109326200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11706036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=2908-2915&issue=4&author=H.+R.+Kastauthor=B.+Goodwinauthor=P.+T.+Tarrauthor=S.+A.+Jonesauthor=A.+M.+Anisfeldauthor=C.+M.+Stoltzauthor=P.+Tontonozauthor=S.+Kliewerauthor=T.+M.+Willsonauthor=P.+A.+Edwards&title=Regulation+of+multidrug+resistance-associated+protein+2+%28ABCC2%29+by+the+nuclear+receptors+pregnane+X+receptor%2C+farnesoid+X-activated+receptor%2C+and+constitutive+androstane+receptor&doi=10.1074%2Fjbc.M109326200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor</span></div><div class="casAuthors">Kast, Heidi R.; Goodwin, Bryan; Tarr, Paul T.; Jones, Stacey A.; Anisfeld, Andrew M.; Stoltz, Catherine M.; Tontonoz, Peter; Kliewer, Steve; Willson, Timothy M.; Edwards, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2908-2915</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The multidrug resistance-assocd. protein 2 (MRP2, ABCC2), mediates the efflux of several conjugated compds. across the apical membrane of the hepatocyte into the bile canaliculi.  We identified MRP2 in a screen designed to isolate genes that are regulated by the farnesoid X-activated receptor (FXR, NR1H4).  MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands.  In addn., we have shown that MRP2 expression is regulated by the pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3).  Thus, treatment of rodent hepatocytes with PXR or CAR agonists results in a robust induction of MRP2 mRNA levels.  The dexamethasone- and pregnenolone 16α-carbonitrile-dependent induction of MRP2 expression was not evident in hepatocytes derived from PXR null mice.  In contrast, induction of MRP2 by phenobarbital, an activator of CAR, was comparable in wild-type and PXR null mice.  An unusual 26-bp sequence was identified 440 bp upstream of the MRP2 transcription initiation site that contains an everted repeat of the AGTTCA hexad sepd. by 8 nucleotides (ER-8).  PXR, CAR, and FXR bound with high affinity to this element as heterodimers with the retinoid X receptor α (RXRα, NR2B1).  Luciferase reporter gene constructs contg. 1 kb of the rat MRP2 promoter were prepd. and transiently transfected into HepG2 cells.  Luciferase activity was induced in a PXR-, CAR-, or FXR-dependent manner.  Furthermore, the isolated ER-8 element was capable of conferring PXR, CAR, and FXR responsiveness on a heterologous thymidine kinase promoter.  Mutation of the ER-8 element abolished the nuclear receptor response.  These studies demonstrate that MRP2 is regulated by three distinct nuclear receptor signaling pathways that converge on a common response element in the 5'-flanking region of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVkHAzOXsXVrVg90H21EOLACvtfcHk0liJCNEOiAKFKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVSgt7c%253D&md5=4695a74d9fe74de16c078ef355c33af4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109326200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109326200%26sid%3Dliteratum%253Aachs%26aulast%3DKast%26aufirst%3DH.%2BR.%26aulast%3DGoodwin%26aufirst%3DB.%26aulast%3DTarr%26aufirst%3DP.%2BT.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DAnisfeld%26aufirst%3DA.%2BM.%26aulast%3DStoltz%26aufirst%3DC.%2BM.%26aulast%3DTontonoz%26aufirst%3DP.%26aulast%3DKliewer%26aufirst%3DS.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DEdwards%26aufirst%3DP.%2BA.%26atitle%3DRegulation%2520of%2520multidrug%2520resistance-associated%2520protein%25202%2520%2528ABCC2%2529%2520by%2520the%2520nuclear%2520receptors%2520pregnane%2520X%2520receptor%252C%2520farnesoid%2520X-activated%2520receptor%252C%2520and%2520constitutive%2520androstane%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D4%26spage%3D2908%26epage%3D2915%26doi%3D10.1074%2Fjbc.M109326200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squires, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negishi, M.</span></span> <span> </span><span class="NLM_article-title">Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">49307</span>– <span class="NLM_lpage">49314</span>, <span class="refDoi"> DOI: 10.1074/jbc.M407281200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M407281200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15347657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslKis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=49307-49314&issue=47&author=E.+J.+Squiresauthor=T.+Sueyoshiauthor=M.+Negishi&title=Cytoplasmic+localization+of+pregnane+X+receptor+and+ligand-dependent+nuclear+translocation+in+mouse+liver&doi=10.1074%2Fjbc.M407281200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoplasmic Localization of Pregnane X Receptor and Ligand-dependent Nuclear Translocation in Mouse Liver</span></div><div class="casAuthors">Squires, E. James; Sueyoshi, Tatsuya; Negishi, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">49307-49314</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) plays an important role in the response to xenobiotics and endogenous toxins.  We have used a specific anti-PXR antibody in the Western blotting of mouse liver nuclear exts. to show that PXR is accumulated in the nucleus after treatment with 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN), followed by an increase in Cyp3a11 mRNA.  Expression of wild type PXR and various mutants as green fluorescent fusion proteins in mouse livers showed that PXR was retained in the cytoplasm from where PCN treatment translocated PXR into the nucleus.  Furthermore, the xenochem. response signal, the nuclear translocation signal, and the activation function 2 domain were all required for the nuclear translocation to occur.  Immunopptn. expts. using the hsp90 antibody demonstrated the presence of PXR in a complex with the endogenous cytoplasmic constitutive active/androstane receptor retention protein (CCRP) in HepG2 cells.  Fluorescence resonance energy transfer anal. of mouse liver sections after co-expression of cyan fluorescent protein-CCRP and yellow fluorescent protein-PXR also indicated that CCRP and PXR were closely assocd. in vivo.  Overexpression of exogenous CCRP increased the cytoplasmic level of the PXR·CCRP·hsp90 complex, whereas a decrease in endogenous CCRP by treatment with small interfering RNA for CCRP repressed the PXR-mediated reporter activity in HepG2 cells.  We conclude that the CCRP mediates the retention of PXR in the cytosol and modulates the activation of PXR in response to PCN treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkTHaprvFNEbVg90H21EOLACvtfcHk0liJCNEOiAKFKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslKis7c%253D&md5=b2999e9f5af168accfc3d7be4749f58f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M407281200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M407281200%26sid%3Dliteratum%253Aachs%26aulast%3DSquires%26aufirst%3DE.%2BJ.%26aulast%3DSueyoshi%26aufirst%3DT.%26aulast%3DNegishi%26aufirst%3DM.%26atitle%3DCytoplasmic%2520localization%2520of%2520pregnane%2520X%2520receptor%2520and%2520ligand-dependent%2520nuclear%2520translocation%2520in%2520mouse%2520liver%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D47%26spage%3D49307%26epage%3D49314%26doi%3D10.1074%2Fjbc.M407281200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. D.</span></span> <span> </span><span class="NLM_article-title">Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT)</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1124/mol.105.013375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.105.013375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16219912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlWgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=99-108&issue=1&author=D.+R.+Johnsonauthor=C.+W.+Liauthor=L.+Y.+Chenauthor=J.+C.+Ghoshauthor=J.+D.+Chen&title=Regulation+and+binding+of+pregnane+X+receptor+by+nuclear+receptor+corepressor+silencing+mediator+of+retinoid+and+thyroid+hormone+receptors+%28SMRT%29&doi=10.1124%2Fmol.105.013375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT)</span></div><div class="casAuthors">Johnson, David R.; Li, Chia-Wei; Chen, Liuh-Yow; Ghosh, Jagadish C.; Chen, J. Don</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-108</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is an orphan nuclear receptor predominantly expressed in liver and intestine.  PXR coordinates hepatic responses to prevent liver injury induced by environmental toxins.  PXR activates cytochrome P 450 3A4 gene expression upon binding to rifampicin (Rif) and clotrimazole (CTZ) by recruiting transcriptional coactivators.  It remains unclear whether and how PXR regulates gene expression in the absence of ligand.  In this study, the authors analyzed interactions between PXR and the silencing mediator of retinoid and thyroid hormone receptors (SMRT) and detd. the role of SMRT in regulating PXR activity.  The authors show that SMRT interacts with PXR in glutathione S-transferase pull-down, yeast two-hybrid, and mammalian two-hybrid assays.  The interaction is mediated through the ligand-binding domain of PXR and the SMRT's nuclear receptor-interacting domain 2.  The PXR-SMRT interaction is sensitive to species-specific ligands, and Rif causes an exchange of the corepressor SMRT with the p160 coactivator known as receptor-assocd. coactivator 3 (RAC3).  Deletion of the PXR's activation function 2 helix enhances SMRT binding and abolishes ligand-dependent dissocn. of SMRT.  Coexpression of PXR with SMRT results in colocalization at discrete nuclear foci.  Finally, transient transfection assays show that overexpression of SMRT inhibits PXR's transactivation of the Cyp3A4 promoter, whereas silencing of SMRT enhances the reporter expression.  Taken together, the authors' results suggest that the corepressor SMRT may bind to and regulate the transcriptional activity of PXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCt76NaFMaEbVg90H21EOLACvtfcHk0liJCNEOiAKFKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlWgtg%253D%253D&md5=9d68053e214e7abcbdd3fe0ad4f30721</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.013375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.013375%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DL.%2BY.%26aulast%3DGhosh%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DJ.%2BD.%26atitle%3DRegulation%2520and%2520binding%2520of%2520pregnane%2520X%2520receptor%2520by%2520nuclear%2520receptor%2520corepressor%2520silencing%2520mediator%2520of%2520retinoid%2520and%2520thyroid%2520hormone%2520receptors%2520%2528SMRT%2529%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D69%26issue%3D1%26spage%3D99%26epage%3D108%26doi%3D10.1124%2Fmol.105.013375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labhart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span> <span> </span><span class="NLM_article-title">Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn1047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fnar%2Fgkn1047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19129222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivFSgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1160-1173&issue=4&author=N.+Hariparsadauthor=X.+Chuauthor=J.+Yabutauthor=P.+Labhartauthor=D.+P.+Hartleyauthor=X.+Daiauthor=R.+Evers&title=Identification+of+pregnane-X+receptor+target+genes+and+coactivator+and+corepressor+binding+to+promoter+elements+in+human+hepatocytes&doi=10.1093%2Fnar%2Fgkn1047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes</span></div><div class="casAuthors">Hariparsad, Niresh; Chu, Xiaoyan; Yabut, Jocelyn; Labhart, Paul; Hartley, Dylan P.; Dai, Xudong; Evers, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1160-1173</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Chromatin immunopptn. (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes.  Genes, both previously known to be involved and not known to be involved in drug disposition, with PXR response elements (PXREs) located upstream, within or downstream from their potentially assocd. genes, were identified.  Validation expts. identified several new drug disposition genes with PXR binding sites.  Of these, only CYP4F12 demonstrated increased binding in the presence of rifampicin.  The role of PXR in the basal and inductive response of CYP4F12 was confirmed in hepatocytes in which PXR was silenced.  We also assessed the assocn. of PXR-coactivators and -corepressors with known and newly identified PXREs.  Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.  Promoter-dependent patterns were obsd. with respect to the binding of various coactivators and corepressors involved in the regulation of CYP4F12, CYP3A4, CYP2B6, UGT1A1 and P-glycoprotein.  In conclusion, these findings indicate that PXR is involved in the regulation of CYP4F12 and that PXR along with SRC1 binds to a broad range of promoters but that many of these are not inducible by rifampicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn_9fDtL602LVg90H21EOLACvtfcHk0lgCTCGzlNwn_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivFSgtr0%253D&md5=4d857deb5a6ba9519ad7d9f3d1d76df4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn1047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn1047%26sid%3Dliteratum%253Aachs%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DLabhart%26aufirst%3DP.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DEvers%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520pregnane-X%2520receptor%2520target%2520genes%2520and%2520coactivator%2520and%2520corepressor%2520binding%2520to%2520promoter%2520elements%2520in%2520human%2520hepatocytes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2009%26volume%3D37%26issue%3D4%26spage%3D1160%26epage%3D1173%26doi%3D10.1093%2Fnar%2Fgkn1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talmage, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollet, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural and functional analysis of the human nuclear xenobiotic receptor PXR in complex with RXRalpha</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>425</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2561</span>– <span class="NLM_lpage">2577</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2013.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jmb.2013.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23602807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1altL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2013&pages=2561-2577&issue=14&author=B.+D.+Wallaceauthor=L.+Bettsauthor=G.+Talmageauthor=R.+M.+Polletauthor=N.+S.+Holmanauthor=M.+R.+Redinbo&title=Structural+and+functional+analysis+of+the+human+nuclear+xenobiotic+receptor+PXR+in+complex+with+RXRalpha&doi=10.1016%2Fj.jmb.2013.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of the Human Nuclear Xenobiotic Receptor PXR in Complex with RXRα</span></div><div class="casAuthors">Wallace, Bret D.; Betts, Laurie; Talmage, Garrick; Pollet, Rebecca M.; Holman, Natalie S.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2561-2577</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human nuclear xenobiotic receptor PXR recognizes a range of potentially harmful drugs and endobiotic chems. but must complex with the nuclear receptor RXRα to control the expression of numerous drug metab. genes.  To date, the structural basis and functional consequences of this interaction have remained unclear.  Here, we present 2.8-Å-resoln. crystal structures of the heterodimeric complex formed between the ligand-binding domains of human PXR and RXRα.  These structures establish that PXR and RXRα form a heterotetramer unprecedented in the nuclear receptor family of ligand-regulated transcription factors.  We further show that both PXR and RXRα bind to the transcriptional coregulator SRC-1 with higher affinity when they are part of the PXR/RXRα heterotetramer complex than they do when each ligand-binding domain is examd. alone.  Furthermore, we purify the full-length forms of each receptor from recombinant bacterial expression systems and characterize their interactions with a range of direct and everted repeat DNA elements.  Taken together, these data advance our understanding of PXR, the master regulator of drug metab. gene expression in humans, in its functional partnership with RXRα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGo2ung3hwFbVg90H21EOLACvtfcHk0lgCTCGzlNwn_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1altL8%253D&md5=4e9381bfb79f59d050f26f3e3ce6c77f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DB.%2BD.%26aulast%3DBetts%26aufirst%3DL.%26aulast%3DTalmage%26aufirst%3DG.%26aulast%3DPollet%26aufirst%3DR.%2BM.%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520and%2520functional%2520analysis%2520of%2520the%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%2520in%2520complex%2520with%2520RXRalpha%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D425%26issue%3D14%26spage%3D2561%26epage%3D2577%26doi%3D10.1016%2Fj.jmb.2013.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkinson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span> <span> </span><span class="NLM_article-title">The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1210/mend.14.1.0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fmend.14.1.0409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10628745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=27-39&issue=1&author=S.+A.+Jonesauthor=L.+B.+Mooreauthor=J.+L.+Shenkauthor=G.+B.+Wiselyauthor=G.+A.+Hamiltonauthor=D.+D.+McKeeauthor=N.+C.+Tomkinsonauthor=E.+L.+LeCluyseauthor=M.+H.+Lambertauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=J.+T.+Moore&title=The+pregnane+X+receptor%3A+a+promiscuous+xenobiotic+receptor+that+has+diverged+during+evolution&doi=10.1210%2Fmend.14.1.0409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution</span></div><div class="casAuthors">Jones, Stacey A.; Moore, Linda B.; Shenk, Jennifer L.; Wisely, G. Bruce; Hamilton, Geraldine A.; McKee, David D.; Tomkinson, Nicholas C. O.; LeCluyse, Edward L.; Lambert, Millard H.; Willson, Timothy M.; Kliewer, Steven A.; Moore, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transcription of genes encoding cytochrome P 450 3A (CYP3A) monooxygenases is induced by a variety of xenobiotics and natural steroids.  There are marked differences in the compds. that induce CYP3A gene expression between species.  Recently, the mouse and human pregnane X receptor (PXR) were shown to be activated by compds. that induce CYP3A expression.  However, most studies of CYP3A regulation have been performed using rabbit and rat hepatocytes.  Here, the authors report the cloning and characterization of PXR from these two species.  PXR is remarkably divergent between species, with the rabbit, rat, and human receptors sharing only approx. 80% amino acid identity in their ligand-binding domains.  This sequence divergence is reflected by marked pharmacol. differences in PXR activation profiles.  For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.  Conversely, pregnane 16α-carbonitrile is a more potent activator of the rat and mouse PXR than the human and rabbit receptor.  The activities of xenobiotics in PXR activation assays correlate well with their ability to induce CYP3A expression in primary hepatocytes.  Through the use of a novel scintillation proximity binding assay, the authors demonstrate that many of the compds. that induce CYP3A expression bind directly to human PXR.  These data establish PXR as a promiscuous xenobiotic receptor that has diverged during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cu4x3jOH8rVg90H21EOLACvtfcHk0lgCTCGzlNwn_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D&md5=50bbd39e3285b9293b8a452798b5cffd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fmend.14.1.0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.14.1.0409%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DShenk%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DTomkinson%26aufirst%3DN.%2BC.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520pregnane%2520X%2520receptor%253A%2520a%2520promiscuous%2520xenobiotic%2520receptor%2520that%2520has%2520diverged%2520during%2520evolution%26jtitle%3DMol.%2520Endocrinol.%26date%3D2000%26volume%3D14%26issue%3D1%26spage%3D27%26epage%3D39%26doi%3D10.1210%2Fmend.14.1.0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tebbens, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanzendorfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavek, P.</span></span> <span> </span><span class="NLM_article-title">Mathematical models in the description of pregnane X receptor (PXR)-regulated cytochrome P450 enzyme induction</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1785</span>, <span class="refDoi"> DOI: 10.3390/ijms19061785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3390%2Fijms19061785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1785&issue=6&author=J.+D.+Tebbensauthor=M.+Azarauthor=E.+Friedmannauthor=M.+Lanzendorferauthor=P.+Pavek&title=Mathematical+models+in+the+description+of+pregnane+X+receptor+%28PXR%29-regulated+cytochrome+P450+enzyme+induction&doi=10.3390%2Fijms19061785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mathematical models in the description of pregnane X receptor (PXR)-regulated cytochrome P450 enzyme induction</span></div><div class="casAuthors">Tebbens, Jurjen Duintjer; Azar, Malek; Friedmann, Elfriede; Lanzendorfer, Martin; Pavek, Petr</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1785/1-1785/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The pregnane X receptor (PXR) is a drug/xenobiotic-activated transcription factor of crucial importance for major cytochrome P 450 xenobiotic-metabolizing enzymes (CYP) expression and regulation in the liver and the intestine.  One of the major target genes regulated by PXR is the cytochrome P 450 enzyme (CYP3A4), which is the most important human drug-metabolizing enzyme.  In addn., PXR is supposed to be involved both in basal and/or inducible expression of many other CYPs, such as CYP2B6, CYP2C8, 2C9 and 2C19, CYP3A5, CYP3A7, and CYP2A6.  Interestingly, the dynamics of PXR-mediated target genes regulation has not been systematically studied and we have only a few mechanistic math. and biol. based models describing gene expression dynamics after PXR activation in cellular models.  Furthermore, few indirect math. PKPD models for prediction of CYP3A metabolic activity in vivo have been built based on compartmental models with respect to drug-drug interactions or hormonal crosstalk.  Importantly, several neg. feedback loops have been described in PXR regulation.  Although current math. models propose these adaptive mechanisms, a comprehensive math. model based on sufficient exptl. data is still missing.  In the current review, we summarize and compare these models and address some issues that should be considered for the improvement of PXR-mediated gene regulation modeling as well as for our better understanding of the quant. and spatial dynamics of CYPs expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBUJxLhKakwLVg90H21EOLACvtfcHk0lguIUI64ekpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmt7rM&md5=0a5256ce321c39f19b475e635601c5c4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3390%2Fijms19061785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061785%26sid%3Dliteratum%253Aachs%26aulast%3DTebbens%26aufirst%3DJ.%2BD.%26aulast%3DAzar%26aufirst%3DM.%26aulast%3DFriedmann%26aufirst%3DE.%26aulast%3DLanzendorfer%26aufirst%3DM.%26aulast%3DPavek%26aufirst%3DP.%26atitle%3DMathematical%2520models%2520in%2520the%2520description%2520of%2520pregnane%2520X%2520receptor%2520%2528PXR%2529-regulated%2520cytochrome%2520P450%2520enzyme%2520induction%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D6%26spage%3D1785%26doi%3D10.3390%2Fijms19061785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.2133/dmpk.19.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2133%2Fdmpk.19.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15499180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=135-149&issue=2&author=M.+Nishimuraauthor=S.+Naitoauthor=T.+Yokoi&title=Tissue-specific+mRNA+expression+profiles+of+human+nuclear+receptor+subfamilies&doi=10.2133%2Fdmpk.19.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies</span></div><div class="casAuthors">Nishimura, Masuhiro; Naito, Shinsaku; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-149</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Pairs of forward and reverse primers and TaqMan probes specific to each human nuclear receptor were prepd.  Anal. of the mRNA expression level of each target of 43 nuclear receptors in total RNA from single and pooled specimens of various human organs (liver, kidney, adrenal gland, lung, heart, brain, cerebellum, skeletal muscle, spleen, thymus, thyroid gland, prostate, testis, uterus, placenta, bone marrow, trachea, and salivary gland) was performed by real-time reverse transcription PCR using an ABI PRISM 7700 sequence detector system.  The mRNA expression of 33 nuclear receptors (NR1A1, 1A2, 1B1, 1B2, 1B3, 1C1, 1C2, 1C3, 1D1, 1D2, 1F1, 1F2, 1F3, 1H2, 1H3, 1I1, 1I2, 2B1, 2B2, 2B3, 2C1, 2C2, 2F1, 2F2, 3A2, 3B1, 3C1, 3C2, 3C4, 4A1, 4A2, 4A3, and 6A1) was successfully detected in all of the tissues by this method.  NR1H4, 2A1, and 3C3 mRNAs were not detectable in the heart, heart, and liver, resp.  NR5A2 mRNA was not detectable in either the brain or cerebellum.  NR3A1 mRNA was not detectable in the small intestine, colon, brain, and cerebellum.  NR5A1 mRNA was not detectable in the kidney, stomach, small intestine, and colon.  NR1I3 mRNA was detected in the liver, kidney, stomach, small intestine, adrenal gland, lung, brain, skeletal muscle, thymus, thyroid gland, prostate, testis, placenta, and trachea.  NR2A2 mRNA was detected in the liver, kidney, prostate, testis, uterus, and trachea.  NR2E1 mRNA was detected in the adrenal gland, brain, cerebellum, testis, placenta, and bone marrow.  NR2E3 mRNA was detected in the adrenal gland, thyroid gland, prostate, testis, uterus, trachea, and salivary gland.  This study provides information concerning the tissue distribution of the mRNA expression of 43 human nuclear receptors.  The mRNA expression profiles of CYP3A4, CYP3A5 and ABC-transporters are also shown.  These results are valuable for establishing a nuclear receptor-mediated screening system for new chem. entities in new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLCRH2amGMZbVg90H21EOLACvtfcHk0lguIUI64ekpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKjs7Y%253D&md5=e6df59832fc0ae5e0d57846d40eec10a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.19.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.19.135%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DS.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DTissue-specific%2520mRNA%2520expression%2520profiles%2520of%2520human%2520nuclear%2520receptor%2520subfamilies%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2004%26volume%3D19%26issue%3D2%26spage%3D135%26epage%3D149%26doi%3D10.2133%2Fdmpk.19.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">FDA</span>.  <i>Clinical drug interaction studies—Cytochrome
P450
enzyme- and transporter-mediated drug interactions guidance for industry</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Clinical+drug+interaction+studies%E2%80%94Cytochrome%0AP450%0Aenzyme-+and+transporter-mediated+drug+interactions+guidance+for+industry.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DClinical%2520drug%2520interaction%2520studies%25E2%2580%2594Cytochrome%250AP450%250Aenzyme-%2520and%2520transporter-mediated%2520drug%2520interactions%2520guidance%2520for%2520industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laaksovirta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1996.tb00021.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1528-1157.1996.tb00021.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8598183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK28XitV2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=253-257&issue=3&author=J.+T.+Backmanauthor=K.+T.+Olkkolaauthor=M.+Ojalaauthor=H.+Laaksovirtaauthor=P.+J.+Neuvonen&title=Concentrations+and+effects+of+oral+midazolam+are+greatly+reduced+in+patients+treated+with+carbamazepine+or+phenytoin&doi=10.1111%2Fj.1528-1157.1996.tb00021.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin</span></div><div class="casAuthors">Backman, Janne T.; Olkkola, Klaus T.; Ojala, Mikael; Laaksovirta, Hannu; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-7</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Midazolam is a short-acting benzodiazepine which is used as an oral hypnotic agent in several countries.  We studied the pharmacokinetic and pharmacodynamic aspects of an oral 15-mg dose of midazolam in 6 patients with epilepsy who are also taking carbamazepine (CBZ) or phenytoin (PHT).  We compared results with those obtained in 7 noninduced control subjects.  Plasma concns. and effects of midazolam were measured for 10 h.  In patients with epilepsy, the area under the plasma concn.-time curve (AUC) of midazolam (mean ± SEM) was only 5.7% (0.60 ± 0.16 vs. 10.5 ± 0.6 μg .sum. min/mL), and the peak midazolam concn. was 7.4% (5.2 ± 1.2 vs. 70.4 ± 9.0 ng/mL) of its value in control subjects (p < 0.001).  The elimination half-life (t1/2) of midazolam was 1.3 ± 0.2 h in patients and 3.1 ± 0.1 h in controls (p < 0.001).  The low plasma midazolam concns. in the patient group were assocd. with reduced pharmacodynamic effects as compared with control subjects [e.g., the Crit. Flicker Fusion Test (CFFT), p < 0.05].  Induction of CYP3A (cytochrome P-450IIIA) enzymes by CBZ and PHT is the most likely explanation of the great difference in the pharmacokinetic and pharmacodynamic profiles of oral midazolam in the two groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGHtYt08VebVg90H21EOLACvtfcHk0lguIUI64ekpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitV2nt78%253D&md5=a58e249913a7637724e54a19604398aa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1996.tb00021.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1996.tb00021.x%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DOjala%26aufirst%3DM.%26aulast%3DLaaksovirta%26aufirst%3DH.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DConcentrations%2520and%2520effects%2520of%2520oral%2520midazolam%2520are%2520greatly%2520reduced%2520in%2520patients%2520treated%2520with%2520carbamazepine%2520or%2520phenytoin%26jtitle%3DEpilepsia%26date%3D1996%26volume%3D37%26issue%3D3%26spage%3D253%26epage%3D257%26doi%3D10.1111%2Fj.1528-1157.1996.tb00021.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffels, P.</span></span> <span> </span><span class="NLM_article-title">Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2004.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15536460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=452-466&issue=5&author=E.+D.+Kharaschauthor=A.+Walkerauthor=C.+Hofferauthor=P.+Sheffels&title=Intravenous+and+oral+alfentanil+as+in+vivo+probes+for+hepatic+and+first-pass+cytochrome+P450+3A+activity%3A+noninvasive+assessment+by+use+of+pupillary+miosis&doi=10.1016%2Fj.clpt.2004.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis</span></div><div class="casAuthors">Kharasch, Evan D.; Walker, Alysa; Hoffer, Christine; Sheffels, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">452-466</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Systemic clearance of i.v. (IV) alfentanil (ALF) is an in vivo probe for hepatic cytochrome P 450 (CYP) 3A activity, miosis is a surrogate for plasma ALF concns., and IV ALF miosis is a noninvasive probe for hepatic CYP3A.  This investigation characterized the bioavailability and first-pass metab. of oral ALF and tested the hypotheses that (1) first-pass ALF clearance reflects first-pass CYP3A activity, (2) miosis after oral ALF will reflect intestinal and hepatic CYP3A activity, and (3) miosis can approx. plasma concn.-based pharmacokinetic measures for IV and oral ALF as a noninvasive in vivo probe for hepatic and first-pass CYP3A activity and drug interactions.  Results were compared with those for midazolam (MDZ), an alternative CYP3A probe.  Ten volunteers were studied by use of a randomized, 9-way, crossover design after administration of rifampin (INN, rifampicin) (hepatic and intestinal CYP3A induction), troleandomycin (TAO) (hepatic and intestinal CYP3A inhibition), grapefruit juice (selective intestine CYP3A inhibition), or nothing (control).  For each condition, they received 1 mg IV MDZ and then 15 μg/kg IV ALF, as well as 3 mg oral MDZ and then oral ALF (23 or 60 μg/kg) on another day.  Plasma concns. were detd. by liq. chromatog.-mass spectrometry.  Dark-adapted pupil diams. were measured coincident with blood sampling.  ALF effect was analyzed similarly to concn. to yield an effect "clearance" (Dose/Area under the pupil diam. change vs. time curve).  Bioavailability (Foral), hepatic extn. (EH), and intestinal availability (FG) were 0.26 ± 0.08, 0.52 ± 0.09, and 0.56 ± 0.20, resp., for MDZ and 0.42 ± 0.15, 0.28 ± 0.09, and 0.56 ± 0.18, resp., for ALF.  Oral clearance (CL/F) was 34.7 ± 12.8 and 10.9 ± 3.5 mL · kg-1 · min-1, resp., for MDZ and ALF.  After rifampin, TAO, and grapefruit juice, ALF Foral was 0.04 ± 0.02 (P < .05, vs. control), 0.99 ± 0.18 (P < .05, vs. control), and 0.62 ± 0.18 (P < .05, vs. control), resp.; EH was 0.69 ± 0.14 (P < .05, vs. control), 0.04 ± 0.01 (P < .05, vs. control), and 0.26 ± 0.08, resp.; FG was 0.16 ± 0.10 (P < .05, vs. control), 1.0 ± 0.2 (P < .05, vs. control), and 0.85 ± 0.30 (P < .05, vs. control), resp.; CL/F was 339 ± 233 (P < .05, vs. control), 0.62 ± 0.26 (P < .05, vs. control), and 6.7 ± 2.5 (P < .05, vs. control), resp., and effect clearance was 2.1 ± 1.1 (P < .05, vs. control), 0.087 ± 0.056 (P < .05, vs. control), and 0.54 ± 0.30 (0.73 ± 0.43 mg · mm-1 · h-1 in controls), resp.  There were significant correlations between ALF and MDZ systemic clearances (r2 = 0.92), EH (r2 = 0.93), and CL/F (r2 = 0.97), as well as between oral ALF effect (miosis) clearance and oral clearance (r2 = 0.59).  ALF and MDZ have similar intestinal extn. but low and intermediate hepatic extn., resp.  Systemic and oral clearances of ALF are excellent in vivo probes for hepatic and first-pass CYP3A activities and drug interactions.  Miosis was an acceptable surrogate for plasma ALF.  ALF miosis may be a suitable noninvasive in vivo probe for both hepatic and first-pass CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEwLXDAh9aLVg90H21EOLACvtfcHk0lj1063Jn_HbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWntL4%253D&md5=754fbcb7a0cf7588f8c83b868cb5051d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DHoffer%26aufirst%3DC.%26aulast%3DSheffels%26aufirst%3DP.%26atitle%3DIntravenous%2520and%2520oral%2520alfentanil%2520as%2520in%2520vivo%2520probes%2520for%2520hepatic%2520and%2520first-pass%2520cytochrome%2520P450%25203A%2520activity%253A%2520noninvasive%2520assessment%2520by%2520use%2520of%2520pupillary%2520miosis%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D76%26issue%3D5%26spage%3D452%26epage%3D466%26doi%3D10.1016%2Fj.clpt.2004.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Link, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grignaschi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmann, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krähenbühl, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2008.03201.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2008.03201.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18537963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSgur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2008&pages=473-484&issue=4&author=B.+Linkauthor=M.+Haschkeauthor=N.+Grignaschiauthor=M.+Bodmerauthor=Y.+Z.+Aschmannauthor=M.+Wenkauthor=S.+Kr%C3%A4henb%C3%BChl&title=Pharmacokinetics+of+intravenous+and+oral+midazolam+in+plasma+and+saliva+in+humans%3A+usefulness+of+saliva+as+matrix+for+CYP3A+phenotyping&doi=10.1111%2Fj.1365-2125.2008.03201.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping</span></div><div class="casAuthors">Link, Bettina; Haschke, Manuel; Grignaschi, Nathalie; Bodmer, Michael; Aschmann, Yvonne Zysset; Wenk, Markus; Krahenbuhl, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-484</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suitable for CYP3A phenotyping.  This was a two way cross-over study in eight subjects treated with 2 mg midazolam IV or 7.5 mg orally under basal conditions and after CYP3A induction with rifampicin.  Under basal conditions and IV administration, midazolam and 1'-hydroxymidazolam (plasma, saliva), 4-hydroxymidazolam and 1'-hydroxymidazolam-glucuronide (plasma) were detectable.  After rifampicin, the AUC of midazolam [mean differences plasma 53.7 (95% CI 4.6, 102.9) and saliva 0.83 (95% CI 0.52, 1.14) ng ml-1 h] and 1'-hydroxymidazolam [mean difference plasma 11.8 (95% CI 7.9, 15.7) ng ml-1 h] had decreased significantly.  There was a significant correlation between the midazolam concns. in plasma and saliva (basal conditions: r = 0.864, P<0.0001; after rifampicin: r = 0.842, P < 0.0001).  After oral administration and basal conditions, midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam were detectable in plasma and saliva.  After treatment with rifampicin, the AUC of midazolam [mean difference plasma 104.5 (95% CI 74.1, 134.9) ng/mL-1/h] and 1'-hydroxymidazolam [mean differences plasma 51.9 (95% CI 34.8, 69.1) and saliva 2.3 (95% CI 1.9, 2.7) ng/mL-1/h] had decreased significantly.  The parameters sepg. best between basal conditions and post-rifampicin were: (1'-hydroxymidazolam + 1'-hydroxymidazolam-glucuronide)/midazolam at 20-30 min (plasma) and the AUC of midazolam (saliva) after IV, and the AUC of midazolam (plasma) and of 1'-hydroxymidazolam (plasma and saliva) after oral administration.  Saliva appears to be a suitable matrix for non-invasive CYP3A phenotyping using midazolam as a probe drug, but sensitive anal. methods are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0tF4kmcSBYrVg90H21EOLACvtfcHk0lj1063Jn_HbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSgur%252FL&md5=b4f2efb5b97bc43f1799eef5448f6bea</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2008.03201.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2008.03201.x%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DB.%26aulast%3DHaschke%26aufirst%3DM.%26aulast%3DGrignaschi%26aufirst%3DN.%26aulast%3DBodmer%26aufirst%3DM.%26aulast%3DAschmann%26aufirst%3DY.%2BZ.%26aulast%3DWenk%26aufirst%3DM.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520intravenous%2520and%2520oral%2520midazolam%2520in%2520plasma%2520and%2520saliva%2520in%2520humans%253A%2520usefulness%2520of%2520saliva%2520as%2520matrix%2520for%2520CYP3A%2520phenotyping%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D66%26issue%3D4%26spage%3D473%26epage%3D484%26doi%3D10.1111%2Fj.1365-2125.2008.03201.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannaprasaht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosius, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haehner-Daniels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(03)00187-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0009-9236%2803%2900187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12966371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVKmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=275-287&issue=3&author=J.+C.+Gorskiauthor=S.+Vannaprasahtauthor=M.+A.+Hammanauthor=W.+T.+Ambrosiusauthor=M.+A.+Bruceauthor=B.+Haehner-Danielsauthor=S.+D.+Hall&title=The+effect+of+age%2C+sex%2C+and+rifampin+administration+on+intestinal+and+hepatic+cytochrome+P450+3A+activity&doi=10.1016%2FS0009-9236%2803%2900187-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity</span></div><div class="casAuthors">Gorski, J. Christopher; Vannaprasaht, Suda; Hamman, Mitchell A.; Ambrosius, Walter T.; Bruce, Melissa A.; Haehner-Daniels, Barbara; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-287</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">The relative susceptibility of intestinal and hepatic cytochrome P 450 (CYP) 3A to induction by rifampin (INN, rifampicin), as a function of age and sex, was investigated with the CYP3A substrate midazolam.  Fourteen young women (mean age, 26±4 yr), 14 young men (mean age, 27±4 yr), 14 elderly women (mean age, 72±5 yr), and 10 elderly men (mean age, 70±4 yr) received simultaneous i.v. doses (0.05 mg/kg over a 30-min period) and oral doses of midazolam (3-8 mg of a stable isotope, 15N3-midazolam) before and after 7 days of rifampin dosing (600 mg once daily in the evening).  Serum and urine samples were assayed for midazolam, 15N3-midazolam, and metabolites by liq. chromatog.-mass spectrometry.  No significant difference (P ≥.05) in the baseline systemic and oral clearance of midazolam was obsd. between male and female or young and old volunteers.  Rifampin significantly (P <.0001) increased the systemic and oral clearance of midazolam from 0.44±0.2 L · h/kg and 1.56±0.8 L · h/kg to 0.96±0.3 L · h/kg and 34.4±21.2 L · h/kg, resp.  Likewise, the oral clearance of midazolam was significantly (P <.0001) increased in women and men, from 1.64±0.87 L · kg/h and 1.46±0.7 L · kg/h to 28.4±13.2 L · kg/h and 41.6±26.5 L · kg/h, resp.  A significant (P =.0023) effect of sex was noted in the extent of induction of the oral clearance of midazolam, being greater in men than in women.  In contrast, the extent of midazolam systemic clearance induction was greater in women than in men (P =.0107).  Age did not influence the extent of intestinal and hepatic CYP3A induction as detd. by the oral and systemic clearance of midazolam.  Rifampin dosing significantly (P <.0001) reduced the oral availability by 88%, from 0.32±0.13 to 0.04±0.02.  Correspondingly, hepatic and intestinal availabilities were significantly (P <.0001) reduced after rifampin administration.  After rifampin, the correlation coeff. for the relationship between oral availability and intestinal availability was significantly (P <.0001) reduced from 0.96 to 0.67, which reflects the increasing contribution of hepatic extn. to the detn. of midazolam oral availability.  A significant nonlinear inverse relationship was obsd. between the percent change in systemic clearance of midazolam and the initial baseline midazolam systemic clearance (r = -0.68, N = 52, P <.0001).  Likewise, a significant inverse relationship was obsd. between the percent change in oral clearance and the baseline oral clearance (r = -0.39, N = 52, P =.0041).  A significant inverse relationship between the ratio of hepatic intrinsic clearance in the presence of rifampin to that in the absence of rifampin and the corresponding ratio of intestinal intrinsic clearance was obsd. (Spearman correlation coeff. [r] = -0.68, P <.0001) and indicates that in a given individual the extent of induction was high at either the hepatic or the intestinal site but not both.  Sex-related differences exist in the extent of intestinal and hepatic CYP3A induction by rifampin.  The extent of induction at hepatic and intestinal sites was inversely dependent and reflected the independent regulation of CYP3A expression at these sites.  The large interindividual variation in the extent of induction is explained in part by the variation in baseline expression of CYP3A.  Sex-related differences in response to CYP3A inducers will be substrate-dependent and reflect the relative contribution of hepatic and intestinal sites of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWH-YrwUmxRLVg90H21EOLACvtfcHk0lj1063Jn_HbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVKmtr8%253D&md5=25d07c6b4a27d3d88327de58d2e52629</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2803%2900187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252803%252900187-5%26sid%3Dliteratum%253Aachs%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DVannaprasaht%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DAmbrosius%26aufirst%3DW.%2BT.%26aulast%3DBruce%26aufirst%3DM.%2BA.%26aulast%3DHaehner-Daniels%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effect%2520of%2520age%252C%2520sex%252C%2520and%2520rifampin%2520administration%2520on%2520intestinal%2520and%2520hepatic%2520cytochrome%2520P450%25203A%2520activity%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D74%26issue%3D3%26spage%3D275%26epage%3D287%26doi%3D10.1016%2FS0009-9236%2803%2900187-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafziger, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazierad, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. S.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Comparison of midazolam and simvastatin as cytochrome P450 3A probes</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2005.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16580903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFaiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2006&pages=350-361&issue=4&author=E.+Chungauthor=A.+N.+Nafzigerauthor=D.+J.+Kazieradauthor=J.+S.+Bertino&title=Comparison+of+midazolam+and+simvastatin+as+cytochrome+P450+3A+probes&doi=10.1016%2Fj.clpt.2005.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of midazolam and simvastatin as cytochrome P450 3A probes</span></div><div class="casAuthors">Chung, Ellen; Nafziger, Anne N.; Kazierad, David J.; Bertino, Joseph S., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">350-361</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The objective was to compare simvastatin with the validated probe midazolam in the assessment of cytochrome P 450 (CYP) 3A activity.  This study used an open-label, fixed-sequential, 3-way crossover study design.  Nineteen subjects received oral doses of 0.075 mg/kg midazolam and 40 mg simvastatin during 3 phases (baseline, after inhibition with 400 mg ketoconazole for 10 days, and after induction with 600 mg rifampin [INN, rifampicin] for 9 days).  Serial plasma concns. of midazolam and simvastatin were obtained.  Oral clearances of midazolam and simvastatin were compared.  Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL-min-1-kg-1 [range, 12-57 mL-min-1-kg-1] to 2.7 mL-min-1-kg-1 [range, 1.2-8.5 mL-min-1-kg-1], P <0.001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL-min-1-kg-1 [range, 125-371 mL-min-1-kg-1], P <0.001).  Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL-min-1-kg-1 [range, 151-1478 mL-min-1-kg-1] to 25 mL-min-1-kg-1 [range, 8.0-147 mL-min-1-kg-1], P <0.001) and increased after rifampin (to a geometric mean of 3536 mL-min-1-kg-1 [range, 413-10,329 mL-min-1-kg-1], P <0.001).  The change in simvastatin clearance was highly variable from baseline to inhibition (6- to 33-fold decrease) and from baseline to induction (2- to 39-fold increase) compared with midazolam (7- to 18-fold decrease during inhibition and 4- to 12-fold increase during induction).  Midazolam and simvastatin oral clearances were correlated for all study phases (r = 0.5 and P = .03 for baseline and r = 0.53 and P = .02 for inhibition) but were weakest for induction (r = -0.031, P = .22).  The area under the concn.-time curve inhibitory ratio for midazolam was 9.4 vs. 12.4 for simvastatin (r = 0.3, P = .03).  Compared with midazolam, simvastatin is a nonvalidated, suboptimal probe for studying CYP3A drug interactions because of its lack of CYP3A specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQIWqkhAoKLVg90H21EOLACvtfcHk0lhH-ucj2g4Gcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFaiurs%253D&md5=24127314b6d2fa174c8267b0b376eec7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DE.%26aulast%3DNafziger%26aufirst%3DA.%2BN.%26aulast%3DKazierad%26aufirst%3DD.%2BJ.%26aulast%3DBertino%26aufirst%3DJ.%2BS.%26atitle%3DComparison%2520of%2520midazolam%2520and%2520simvastatin%2520as%2520cytochrome%2520P450%25203A%2520probes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D79%26issue%3D4%26spage%3D350%26epage%3D361%26doi%3D10.1016%2Fj.clpt.2005.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieniaszek, H. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammaitoni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdieh, H.</span></span> <span> </span><span class="NLM_article-title">Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1177/0091270004271969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F0091270004271969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15703368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=337-345&issue=3&author=M.+Adamsauthor=H.+J.+Pieniaszekauthor=A.+R.+Gammaitoniauthor=H.+Ahdieh&title=Oxymorphone+extended+release+does+not+affect+CYP2C9+or+CYP3A4+metabolic+pathways&doi=10.1177%2F0091270004271969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways</span></div><div class="casAuthors">Adams, Michael; Pieniaszek, Henry J.; Gammaitoni, Arnold R.; Ahdieh, Harry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-345</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two 14-day, randomized, open-label, parallel-group studies examd. the effects of extended-release (ER) oxymorphone on CYP2C9 or CYP3A4 metabolic activities in healthy subjects.  On days -1, 7, and 14, subjects received either a CYP2C9 probe (tolbutamide 500 mg) or CYP3A4 probes (midazolam and [14C N-methyl]-erythromycin for the erythromycin breath test).  Subjects were randomized to 5 groups: high-dose oxymorphone ER (3 × 20 mg q12h) + naltrexone (50 mg q24h); low-dose oxymorphone ER (10-20 mg q12h); rifampin (2 × 300 mg q24h), an inducer of CYP2C9 and CYP3A4 activities; naltrexone (50 mg q24h); or CYP probes alone (controls).  Probe metab. was significantly altered by rifampin on days 7 and 14 (P < .05), whereas probe metab. was not significantly affected by low-dose oxymorphone ER or by high-dose oxymorphone ER plus naltrexone.  Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJL3BWGW4DbVg90H21EOLACvtfcHk0lhH-ucj2g4Gcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Sltr0%253D&md5=2dc48bf668df1c3a905158cdd588c7f7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1177%2F0091270004271969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270004271969%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DPieniaszek%26aufirst%3DH.%2BJ.%26aulast%3DGammaitoni%26aufirst%3DA.%2BR.%26aulast%3DAhdieh%26aufirst%3DH.%26atitle%3DOxymorphone%2520extended%2520release%2520does%2520not%2520affect%2520CYP2C9%2520or%2520CYP3A4%2520metabolic%2520pathways%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26issue%3D3%26spage%3D337%26epage%3D345%26doi%3D10.1177%2F0091270004271969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masica, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. R.</span></span> <span> </span><span class="NLM_article-title">Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women</span>. <i>Pharmacogenetics</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1097/00008571-200310000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F00008571-200310000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=14515058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1arurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=595-606&issue=10&author=M.+D.+Floydauthor=G.+Gervasiniauthor=A.+L.+Masicaauthor=G.+Mayoauthor=A.+L.+Georgeauthor=K.+Bhatauthor=R.+B.+Kimauthor=G.+R.+Wilkinson&title=Genotype-phenotype+associations+for+common+CYP3A4+and+CYP3A5+variants+in+the+basal+and+induced+metabolism+of+midazolam+in+European-+and+African-American+men+and+women&doi=10.1097%2F00008571-200310000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women</span></div><div class="casAuthors">Floyd, Michael D.; Gervasini, Guillermo; Masica, Andrew L.; Mayo, Gail; George, Alfred L., Jr.; Bhat, Kolari; Kim, Richard B.; Wilkinson, Grant R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">595-606</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">CYP3A activity in adults varies between individuals and it has been suggested that this has a genetic basis, possibly related to variant alleles in CYP3A4 and CYP3A5 genes.  Accordingly, genotype-phenotype assocns. were investigated under constitutive and induced conditions.  Midazolam's systemic and oral clearances, and the erythromycin breath test (ERBT) were detd. in 57 healthy subjects: 23 (11 men, 12 women) European- and 34 (14 men, 20 women) African-Americans.  Studies were undertaken in the basal state and after 14-15 days pretreatment with rifampin.  DNA was characterized for the common polymorphisms CYP3A4*1B, CYP3A5*3, CYP3A5*6 and CYP3A5*7 by direct sequencing, and for exon 21 and exon 26 variants of MDR1 by allele-specific, real-time polymerase chain reaction.  In 95% of subjects, the basal systemic clearance of midazolam was unimodally distributed and variability was less than four-fold whereas, in 98% of the study population, oral clearance varied five-fold.  No population or sex-related differences were apparent.  Similar findings were obsd. with the ERBT.  Rifampin pretreatment markedly increased the systemic (two-fold) and oral clearance (16-fold) of midazolam, and the ERBT (two-fold) but the variabilities were unchanged.  No assocns. were noted between these phenotypic measures and any of the studied genotypes, except for oral clearance and its fold-increase after rifampin.  These were related to the presence of CYP3A4*1B and the inversely linked CYP3A5*3 polymorphism, with the extent of induction being approx. 50% greater in CYP3A5*3 homozygotes compared to wild-type subjects.  In most healthy subjects, variability in intestinal and hepatic CYP3A activity, using midazolam as an in-vivo probe, is modest and common polymorphisms in CYP3A4 and CYP3A5 do not appear to have important functional significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94c27EOq4fLVg90H21EOLACvtfcHk0lhH-ucj2g4Gcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1arurw%253D&md5=7d9bb419ac29b71b8f511c801d6552b5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00008571-200310000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200310000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DFloyd%26aufirst%3DM.%2BD.%26aulast%3DGervasini%26aufirst%3DG.%26aulast%3DMasica%26aufirst%3DA.%2BL.%26aulast%3DMayo%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DA.%2BL.%26aulast%3DBhat%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DWilkinson%26aufirst%3DG.%2BR.%26atitle%3DGenotype-phenotype%2520associations%2520for%2520common%2520CYP3A4%2520and%2520CYP3A5%2520variants%2520in%2520the%2520basal%2520and%2520induced%2520metabolism%2520of%2520midazolam%2520in%2520European-%2520and%2520African-American%2520men%2520and%2520women%26jtitle%3DPharmacogenetics%26date%3D2003%26volume%3D13%26issue%3D10%26spage%3D595%26epage%3D606%26doi%3D10.1097%2F00008571-200310000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gashaw, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudny-Klöppel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höchel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, C.</span></span> <span> </span><span class="NLM_article-title">The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1002/cpt.1848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpt.1848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32275771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFegsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=798-807&author=H.+Wiesingerauthor=S.+Kleinauthor=A.+Rottmannauthor=B.+Nowotnyauthor=K.+Rieckeauthor=I.+Gashawauthor=M.+Brudny-Kl%C3%B6ppelauthor=R.+Frickeauthor=J.+H%C3%B6chelauthor=C.+Friedrich&title=The+effects+of+weak+and+strong+CYP3A+induction+by+rifampicin+on+the+pharmacokinetics+of+five+progestins+and+ethinylestradiol+compared+to+midazolam&doi=10.1002%2Fcpt.1848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam</span></div><div class="casAuthors">Wiesinger, Herbert; Klein, Stefan; Rottmann, Antje; Nowotny, Bettina; Riecke, Kai; Gashaw, Isabella; Brudny-Kloeppel, Margarete; Fricke, Robert; Hoechel, Joachim; Friedrich, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">798-807</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">It is known that co-administration of CYP3A inducers may decrease the effectiveness of oral contraceptives contg. progestins as mono-prepns. or combined with ethinylestradiol.  Rifampicin was used to induce CYP3A.  The progestins chosen as victim drugs were levonorgestrel, norethindrone, desogestrel, and dienogest as mono-products, and drospirenone combined with ethinylestradiol.  Postmenopausal women (n = 12-14 per treatment group) received, in fixed sequence, a single dose of the victim drug plus midazolam without rifampicin, with rifampicin 10 mg/day and with rifampicin 600 mg/day.  The effects on progestin exposure were compared with the effects on midazolam exposure.  Weak CYP3A induction, as confirmed by a mean decrease in midazolam exposure by 46%, resulted in minor changes in progestin exposure (mean decreases: 15-37%).  Strong CYP3A induction, in contrast, resulted in mean decreases by 57-90% (mean decrease in midazolam exposure 86%).  Our data might provide an impetus to revisit the currently applied clin. recommendations for oral contraceptives, esp. for levonorgestrel and norethindrone-contg. products, and they might give an indication as to which progestin could be used, if requested, by women taking weak CYP3A inducers-although it is acknowledged that the exact exposure-response relationship for contraceptive efficacy is currently unclear for most progestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9zztv3A-QvbVg90H21EOLACvtfcHk0ljoVv5Hhn8NpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFegsb7P&md5=aef222a027f40ed3defda0b263c355a1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1848%26sid%3Dliteratum%253Aachs%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DRottmann%26aufirst%3DA.%26aulast%3DNowotny%26aufirst%3DB.%26aulast%3DRiecke%26aufirst%3DK.%26aulast%3DGashaw%26aufirst%3DI.%26aulast%3DBrudny-Kl%25C3%25B6ppel%26aufirst%3DM.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DH%25C3%25B6chel%26aufirst%3DJ.%26aulast%3DFriedrich%26aufirst%3DC.%26atitle%3DThe%2520effects%2520of%2520weak%2520and%2520strong%2520CYP3A%2520induction%2520by%2520rifampicin%2520on%2520the%2520pharmacokinetics%2520of%2520five%2520progestins%2520and%2520ethinylestradiol%2520compared%2520to%2520midazolam%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D798%26epage%3D807%26doi%3D10.1002%2Fcpt.1848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. G.</span></span> <span> </span><span class="NLM_article-title">Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2003.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2003.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15001966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslenur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=157-162&issue=3&author=J.+Y.+Parkauthor=K.+A.+Kimauthor=M.+H.+Kangauthor=S.+L.+Kimauthor=J.+G.+Shin&title=Effect+of+rifampin+on+the+pharmacokinetics+of+rosiglitazone+in+healthy+subjects&doi=10.1016%2Fj.clpt.2003.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects</span></div><div class="casAuthors">Park, Ji-Young; Kim, Kyoung-Ah; Kang, Mun-Ho; Kim, Su-Lyun; Shin, Jae-Gook</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-162</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background and objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs.  Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone.  Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans.  Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo.  On day 7, a single dose of 8 mg rosiglitazone was administered orally.  Plasma rosiglitazone concns. were measured.  Results: Rifampin significantly decreased the mean area under the plasma concn.-time curve for rosiglitazone by 65% (2947.9 ng · h/mL vs. 991.5 ng · h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 h (P < .001).  The peak plasma concn. of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL vs. 362.3 ng/mL, P < .01).  The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h vs. 8.5 L/h, P < .001).  Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P 450 (CYP) 2C8 and, to a lesser extent, CYP2C9.  Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUpZwrbrEVP7Vg90H21EOLACvtfcHk0ljoVv5Hhn8NpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslenur8%253D&md5=08b2974d5e193e8b7a0cba297a8fc5bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2003.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2003.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BA.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BL.%26aulast%3DShin%26aufirst%3DJ.%2BG.%26atitle%3DEffect%2520of%2520rifampin%2520on%2520the%2520pharmacokinetics%2520of%2520rosiglitazone%2520in%2520healthy%2520subjects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D75%26issue%3D3%26spage%3D157%26epage%3D162%26doi%3D10.1016%2Fj.clpt.2003.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höjer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterloh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, A.</span></span> <span> </span><span class="NLM_article-title">Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/clpt.1980.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.1980.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=7351120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADyaL3c%252FptVOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1980&pages=83-88&issue=1&author=L.+Bertilssonauthor=B.+H%C3%B6jerauthor=G.+Tybringauthor=J.+Osterlohauthor=A.+Rane&title=Autoinduction+of+carbamazepine+metabolism+in+children+examined+by+a+stable+isotope+technique&doi=10.1038%2Fclpt.1980.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique</span></div><div class="casAuthors">Bertilsson L; Hojer B; Tybring G; Osterloh J; Rane A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-8</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Autoinduction of carbamazepine (CBZ) metabolism was investigated in 3 children (10 to 13 yr old) using tetradeuterium-labeled CBZ (CBZ-D4).  Prior to treatment, CBZ and CBZ-D4 given as a mixture had almost identical kinetics in each patient.  During maintenance therapy with CBZ, part of the CBZ was exchanged for CBZ-D4 on 3 occasions.  The clearance of CBZ-D4 given on the second day of therapy was 0.036 +/- 0.003 1 . kg-1 . hr-1, whereas it had been 0.028 +/- 0.003 before treatment.  After 17 to 32 days of treatment, clearance doubled (0.056 +/- 0.010) but during the next 4 mo there was no further increase, indicating that the autoinduction was complete within 1 mo.  As a corollary there was a decrease in steady-state plasma levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGB0Nwy1WbIcNIRw0GKUoEfW6udTcc2eYZXDC-16Lu2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c%252FptVOitQ%253D%253D&md5=5623f7a43881f44514fb361048d14833</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1980.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1980.13%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DL.%26aulast%3DH%25C3%25B6jer%26aufirst%3DB.%26aulast%3DTybring%26aufirst%3DG.%26aulast%3DOsterloh%26aufirst%3DJ.%26aulast%3DRane%26aufirst%3DA.%26atitle%3DAutoinduction%2520of%2520carbamazepine%2520metabolism%2520in%2520children%2520examined%2520by%2520a%2520stable%2520isotope%2520technique%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1980%26volume%3D27%26issue%3D1%26spage%3D83%26epage%3D88%26doi%3D10.1038%2Fclpt.1980.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwater, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lademacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammelsberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects</span>. <i>Clin Pharmacol Drug Dev</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1002/cpdd.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpdd.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27273149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=54-65&issue=1&author=T.+Yamazakiauthor=A.+Desaiauthor=R.+Goldwaterauthor=D.+Hanauthor=C.+Howiesonauthor=S.+Akhtarauthor=D.+Kowalskiauthor=C.+Lademacherauthor=H.+Pearlmanauthor=D.+Rammelsbergauthor=R.+Townsend&title=Pharmacokinetic+effects+of+isavuconazole+coadministration+with+the+cytochrome+P450+enzyme+substrates+bupropion%2C+repaglinide%2C+caffeine%2C+dextromethorphan%2C+and+methadone+in+healthy+subjects&doi=10.1002%2Fcpdd.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects</span></div><div class="casAuthors">Yamazaki, Takao; Desai, Amit; Goldwater, Ronald; Han, David; Howieson, Corrie; Akhtar, Shahzad; Kowalski, Donna; Lademacher, Christopher; Pearlman, Helene; Rammelsberg, Diane; Townsend, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-65</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This report describes phase 1 clin. trials performed to assess interactions of oral isavuconazole at the clin. targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P 450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n = 24), and methadone (CYP2B6/CYP2C19/CYP3A4; 10 mg; n = 23).  Compared with each drug alone, coadministration with isavuconazole changed the area under the concn.-time curves (AUC∞) and max. concns. (Cmax) as follows: bupropion, AUC∞ reduced 42%, Cmax reduced 31%; repaglinide, AUC∞ reduced 8%, Cmax reduced 14%; caffeine, AUC∞ increased 4%, Cmax reduced 1%; dextromethorphan, AUC∞ increased 18%, Cmax increased 17%; R-methadone, AUC∞ reduced 10%, Cmax increased 3%; S-methadone, AUC∞ reduced 35%, Cmax increased 1%.  In all studies, there were no deaths, 1 serious adverse event (dextromethorphan study; perioral numbness, numbness of right arm and leg), and adverse events leading to study discontinuation were rare.  Thus, isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2-, CYP2C8-, or CYP2D6-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-9FdRdpH2bVg90H21EOLACvtfcHk0lgXlhUjwI_ZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhtb0%253D&md5=6f05bf602e3aa7f8a63f6653df9d0719</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.281%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DD.%26aulast%3DHowieson%26aufirst%3DC.%26aulast%3DAkhtar%26aufirst%3DS.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3DLademacher%26aufirst%3DC.%26aulast%3DPearlman%26aufirst%3DH.%26aulast%3DRammelsberg%26aufirst%3DD.%26aulast%3DTownsend%26aufirst%3DR.%26atitle%3DPharmacokinetic%2520effects%2520of%2520isavuconazole%2520coadministration%2520with%2520the%2520cytochrome%2520P450%2520enzyme%2520substrates%2520bupropion%252C%2520repaglinide%252C%2520caffeine%252C%2520dextromethorphan%252C%2520and%2520methadone%2520in%2520healthy%2520subjects%26jtitle%3DClin%2520Pharmacol%2520Drug%2520Dev%26date%3D2017%26volume%3D6%26issue%3D1%26spage%3D54%26epage%3D65%26doi%3D10.1002%2Fcpdd.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay-Sontheimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragueneau-Majlessi, I.</span></span> <span> </span><span class="NLM_article-title">Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.117.078691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29572333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWlsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=835-845&issue=6&author=J.+Yuauthor=Z.+Zhouauthor=J.+Tay-Sontheimerauthor=R.+H.+Levyauthor=I.+Ragueneau-Majlessi&title=Risk+of+clinically+relevant+pharmacokinetic-based+drug-drug+interactions+with+drugs+approved+by+the+U.S.+Food+and+Drug+Administration+between+2013+and+2016&doi=10.1124%2Fdmd.117.078691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016</span></div><div class="casAuthors">Yu, Jingjing; Zhou, Zhu; Tay-Sontheimer, Jessica; Levy, Rene H.; Ragueneau-Majlessi, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">835-845</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A total of 103 drugs (including 14 combination drugs)were approved by the U.S.  Food and Drug Administration from 2013 to 2016.  Pharmacokineticbased drug interaction profiles were analyzed using the University of Washington Drug Interaction Database, and the clin. relevance of these observations was characterized based on information from new drug application reviews.CYP3Awas involved in approx. two-thirds of all drug-drug interactions (DDIs).  Transporters (alone or with enzymes) participated in about half of all interactions, but most of these were weak-to-moderate interactions.When considered as victims, eight new mol. entities (NMEs; cobimetinib, ibrutinib, isavuconazole, ivabradine, naloxegol, paritaprevir, simeprevir, and venetoclax)were identified as sensitive substrates of CYP3A, two NMEs (pirfenidone and tasimelteon) were sensitive substratesofCYP1A2, oneNME(dasabuvir)was a sensitive substrate of CYP2C8, one NME (eliglustat) was a sensitive substrate of CYP2D6, and one NME (grazoprevir) was a sensitive substrate of OATP1B1/3 (with changes in exposure greater than 5-fold when coadministered with a strong inhibitor).  Approx. 75%of identified CYP3A substrates were also substrates of P-glycoprotein.  As perpetrators, most clin. DDIs involved weak-to-moderate inhibition or induction.  Only idelalisib showed strong inhibition of CYP3A, and lumacaftor behaved as a strong CYP3A inducer.  Among drugs with large changes in exposure (5-fold),whether as victim or perpetrator, the mostrepresented therapeutic classes were antivirals and oncol. drugs, suggesting a significant risk of clin. DDIs in these patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopgUFlZcyDRLVg90H21EOLACvtfcHk0lgXlhUjwI_ZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWlsLnE&md5=fd09c08cc94f829a16f6b07225e25da4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078691%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DTay-Sontheimer%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DR.%2BH.%26aulast%3DRagueneau-Majlessi%26aufirst%3DI.%26atitle%3DRisk%2520of%2520clinically%2520relevant%2520pharmacokinetic-based%2520drug-drug%2520interactions%2520with%2520drugs%2520approved%2520by%2520the%2520U.S.%2520Food%2520and%2520Drug%2520Administration%2520between%25202013%2520and%25202016%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D6%26spage%3D835%26epage%3D845%26doi%3D10.1124%2Fdmd.117.078691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span> <span> </span><span class="NLM_article-title">No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1002/hep.20568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fhep.20568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15726657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=595-602&issue=3&author=K.+Dilgerauthor=A.+Denkauthor=M.+H.+Heegauthor=U.+Beuers&title=No+relevant+effect+of+ursodeoxycholic+acid+on+cytochrome+P450+3A+metabolism+in+primary+biliary+cirrhosis&doi=10.1002%2Fhep.20568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis</span></div><div class="casAuthors">Dilger, Karin; Denk, Annette; Heeg, Malte H. J.; Beuers, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis.  CYP3A is of key importance in human drug metab., being involved in presystemic extn. of more than 50% of all drugs currently available and of various endogenous compds.  Therefore, we compared the induction potential of UDCA with that of the prototypical inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol.  Twelve patients with early-stage primary biliary cirrhosis and eight healthy volunteers were treated with UDCA (15 mg/kg daily) for 3 wk and subsequently with rifampicin (600 mg/d) for 1 wk.  Extensive pharmacokinetic profiling of oral budesonide (3 mg) was performed by detn. of budesonide and phase I metabolites (6β-hydroxybudesonide, 16α-hydroxyprednisolone) in plasma and urine at baseline and at the end of each treatment.  In parallel, urinary 6β-hydroxycortisol, a validated marker of CYP3A induction, was detd.  UDCA did not affect biotransformation of budesonide and urinary excretion of 6β-hydroxycortisol either in patients or in healthy volunteers.  Ratios of areas under plasma concn.-time curves (AUC0-12 h during UDCA/AUC0-12 h before UDCA) of both metabolites were not higher than those of budesonide itself.  In contrast, administration of rifampicin markedly induced CYP3A metab., resulting in abolished budesonide plasma levels and high urinary excretion of 6β-hydroxycortisol.  Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC16α-hydroxyprednisolone/AUCbudesonide in patients: baseline, 8.6 ± 3.9; UDCA, 10.7 ± 7.1; rifampicin, 527.0 ± 248.7).  In conclusion, UDCA is not a relevant inducer of CYP3A enzymes in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwI3pysXls_7Vg90H21EOLACvtfcHk0lgXlhUjwI_ZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFCrs70%253D&md5=3cd18b1f7a644a2bf1c6f6618e32e0ee</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fhep.20568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.20568%26sid%3Dliteratum%253Aachs%26aulast%3DDilger%26aufirst%3DK.%26aulast%3DDenk%26aufirst%3DA.%26aulast%3DHeeg%26aufirst%3DM.%2BH.%26aulast%3DBeuers%26aufirst%3DU.%26atitle%3DNo%2520relevant%2520effect%2520of%2520ursodeoxycholic%2520acid%2520on%2520cytochrome%2520P450%25203A%2520metabolism%2520in%2520primary%2520biliary%2520cirrhosis%26jtitle%3DHepatology%26date%3D2005%26volume%3D41%26issue%3D3%26spage%3D595%26epage%3D602%26doi%3D10.1002%2Fhep.20568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Erp, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guchelaar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploeger, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romijn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span> <span> </span><span class="NLM_article-title">Mitotane has a strong and a durable inducing effect on CYP3A4 activity</span>. <i>Eur. J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1530/EJE-10-0956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1530%2FEJE-10-0956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21220434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=621-626&issue=4&author=N.+P.+van%0AErpauthor=H.+J.+Guchelaarauthor=B.+A.+Ploegerauthor=J.+A.+Romijnauthor=J.+Hartighauthor=H.+Gelderblom&title=Mitotane+has+a+strong+and+a+durable+inducing+effect+on+CYP3A4+activity&doi=10.1530%2FEJE-10-0956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotane has a strong and a durable inducing effect on CYP3A4 activity</span></div><div class="casAuthors">van Erp, Nielka P.; Guchelaar, Henk-Jan; Ploeger, Bart A.; Romijn, Johannes A.; den Hartigh, Jan; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">621-626</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">The effects of mitotane on the pharmacokinetics (PK) of co-administered drugs are mostly unknown.  The aim of the present study was to describe the effects of mitotane on the PK of the phenotypic probe midazolam and of the tyrosine kinase inhibitor sunitinib.  A serendipitous observation was made in two of nine patients who volunteered in a sunitinib pharmacokinetic study.  Both patients were diagnosed with adrenocortical carcinoma (ACC) and were exposed to mitotane.  The sunitinib PK study was designed to det. the relationship between CYP3A4 activity and sunitinib exposure using 7.5 mg midazolam orally as a phenotypic probe.  Serial blood samples for PK anal. of midazolam, 1-hydroxy-midazolam, and sunitinib were collected at steady-state sunitinib PK (between days 14 and 20).  To confirm this observation in the mitotane-exposed patients, midazolam PK was evaluated in two addnl. patients with ACC and mitotane treatment.  The 4 mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC0-12h (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg × h/l resp. P = 0.001) and increased 1-hydroxy-midazolam exposure (mean AUC0-12h (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg × h/l, P = 0.008).  Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg × h/l vs. 1344 (1079-1609) (mean (95% CI)) μg × h/l).  Mitotane has a strong and long-lasting inducing effect on CYP3A4 activity, which will result in clin. relevant interactions with multiple drugs since many drugs are metabolized by this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlCXR5puxBArVg90H21EOLACvtfcHk0lgt_judgpqIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGhsLk%253D&md5=b7360167aa432627a6645d08c3c34735</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1530%2FEJE-10-0956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEJE-10-0956%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BErp%26aufirst%3DN.%2BP.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26aulast%3DPloeger%26aufirst%3DB.%2BA.%26aulast%3DRomijn%26aufirst%3DJ.%2BA.%26aulast%3DHartigh%26aufirst%3DJ.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DMitotane%2520has%2520a%2520strong%2520and%2520a%2520durable%2520inducing%2520effect%2520on%2520CYP3A4%2520activity%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2011%26volume%3D164%26issue%3D4%26spage%3D621%26epage%3D626%26doi%3D10.1530%2FEJE-10-0956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milad, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span> <span> </span><span class="NLM_article-title">Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.050526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fjpet.103.050526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12766253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=1027-1034&issue=3&author=J.+Sahiauthor=M.+A.+Miladauthor=X.+Zhengauthor=K.+A.+Roseauthor=H.+Wangauthor=L.+Stilgenbauerauthor=D.+Gilbertauthor=S.+Jolleyauthor=R.+H.+Sternauthor=E.+L.+LeCluyse&title=Avasimibe+induces+CYP3A4+and+multiple+drug+resistance+protein+1+gene+expression+through+activation+of+the+pregnane+X+receptor&doi=10.1124%2Fjpet.103.050526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor</span></div><div class="casAuthors">Sahi, Jasminder; Milad, Mark A.; Zheng, Xianxian; Rose, Kelly A.; Wang, Hongbing; Stilgenbauer, Linda; Gilbert, Darryl; Jolley, Summer; Stern, Ralph H.; Lecluyse, Edward L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro and clin. studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions.  Clin., 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were obsd. after 50 and 750 mg of avasimibe daily for 7 days, resp.  A 40% decrease in digoxin (P-glycoprotein substrate) area under the curve was obsd. with 750 mg of avasimibe daily for 10 days.  In vitro studies were conducted to define the mechanisms of these interactions.  Induction was obsd. in CYP3A4 activity and immunoreactive protein (EC50 of 200-400 nM) in primary human hepatocytes treated with avasimibe.  Rifampin treatment yielded similar results.  Microarray anal. revealed avasimibe (1 μM) increased CYP3A4 mRNA 20-fold, compared with a 23-fold increase with 50 μM rifampin.  Avasimibe induced P-glycoprotein mRNA by about 2-fold and immunoreactive protein in a dose-dependent manner.  Transient transfection assays showed that avasimibe is a potent activator of the human pregnane X receptor (hPXR) and more active than rifampin on an equimolar basis.  Drug-drug interaction studies for CYP3A4 using pooled human hepatic microsomes and avasimibe at various concns., revealed IC50 values of 20.7, 1.6, and 3.1 μM using testosterone, midazolam, and felodipine as probe substrates, resp.  Our results indicate that avasimibe causes clin. significant drug-drug interactions through direct activation of hPXR and the subsequent induction of its target genes CYP3A4 and multiple drug resistance protein 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFlGRnInRzLVg90H21EOLACvtfcHk0lgt_judgpqIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVeht7s%253D&md5=7d74f67f0192f2c7de913d1995328479</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.050526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.050526%26sid%3Dliteratum%253Aachs%26aulast%3DSahi%26aufirst%3DJ.%26aulast%3DMilad%26aufirst%3DM.%2BA.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DRose%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DStilgenbauer%26aufirst%3DL.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DStern%26aufirst%3DR.%2BH.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26atitle%3DAvasimibe%2520induces%2520CYP3A4%2520and%2520multiple%2520drug%2520resistance%2520protein%25201%2520gene%2520expression%2520through%2520activation%2520of%2520the%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26issue%3D3%26spage%3D1027%26epage%3D1034%26doi%3D10.1124%2Fjpet.103.050526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulat, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitselos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug-drug interaction of apalutamide, Part 1: Clinical studies in healthy men and patients with castration-resistant prostate cancer</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00882-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs40262-020-00882-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32338345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1ajsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=1135-1148&author=I.+Duranauthor=J.+Carlesauthor=I.+Bulatauthor=P.+Hellemansauthor=A.+Mitselosauthor=P.+Wardauthor=J.+Jiaoauthor=D.+Armasauthor=C.+Chien&title=Pharmacokinetic+drug-drug+interaction+of+apalutamide%2C+Part+1%3A+Clinical+studies+in+healthy+men+and+patients+with+castration-resistant+prostate+cancer&doi=10.1007%2Fs40262-020-00882-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer</span></div><div class="casAuthors">Duran, Ignacio; Carles, Joan; Bulat, Iurie; Hellemans, Peter; Mitselos, Anna; Ward, Peter; Jiao, James; Armas, Danielle; Chien, Caly</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1135-1148</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background and Objectives: Two phase I studies assessed the drug-drug interaction potential of apalutamide as a substrate and perpetrator.  Methods: Study A randomized 45 healthy men to single-dose apalutamide 240 mg alone or with strong inhibitors of cytochrome P 450 (CYP)3A4 (itraconazole) or CYP2C8 (gemfibrozil).  In study B, 23 patients with castration-resistant prostate cancer received probes for CYP3A4 (midazolam), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP2C8 (pioglitazone), and transporter substrates for P-glycoprotein (P-gp) (fexofenadine) and breast cancer resistance protein (BCRP)/org. anion transporting polypeptide (OATP) 1B1 (rosuvastatin) at baseline and after repeat once-daily administration of apalutamide 240 mg to steady state.  Results: Systemic exposure (area under the plasma concn.-time curve) to single-dose apalutamide increased 68% with gemfibrozil but was relatively unchanged with itraconazole (study A).  Apalutamide reduced systemic exposure to midazolam 92%, omeprazole 85%, S-warfarin 46%, fexofenadine 30%, rosuvastatin 41%, and pioglitazone 18% (study B).  After a single dose, apalutamide is predominantly metabolized by CYP2C8, and less by CYP3A4.  Conclusions: Co-administration of apalutamide with CYP3A4, CYP2C19, CYP2C9, P-gp, BCRP or OATP1B1 substrates may cause loss of activity for these medications.  Therefore, appropriate mitigation strategies are recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGChlL7246C7Vg90H21EOLACvtfcHk0lgt_judgpqIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1ajsLc%253D&md5=851e4bc001eab4d352b104d8e0551093</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00882-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00882-2%26sid%3Dliteratum%253Aachs%26aulast%3DDuran%26aufirst%3DI.%26aulast%3DCarles%26aufirst%3DJ.%26aulast%3DBulat%26aufirst%3DI.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DMitselos%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DJiao%26aufirst%3DJ.%26aulast%3DArmas%26aufirst%3DD.%26aulast%3DChien%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520drug-drug%2520interaction%2520of%2520apalutamide%252C%2520Part%25201%253A%2520Clinical%2520studies%2520in%2520healthy%2520men%2520and%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D1135%26epage%3D1148%26doi%3D10.1007%2Fs40262-020-00882-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majcher-Peszynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehleke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klammt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundkowski, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miekisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewelow, B.</span></span> <span> </span><span class="NLM_article-title">The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1007/s00228-005-0061-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00228-005-0061-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16341856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=29-36&issue=1&author=S.+C.+Muellerauthor=J.+Majcher-Peszynskaauthor=B.+Uehlekeauthor=S.+Klammtauthor=R.+G.+Mundkowskiauthor=W.+Miekischauthor=H.+Sieversauthor=S.+Bauerauthor=B.+Frankauthor=G.+Kundtauthor=B.+Drewelow&title=The+extent+of+induction+of+CYP3A+by+St.+John%E2%80%99s+wort+varies+among+products+and+is+linked+to+hyperforin+dose&doi=10.1007%2Fs00228-005-0061-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose</span></div><div class="casAuthors">Mueller, Silke C.; Majcher-Peszynska, Jolanta; Uehleke, Bernhard; Klammt, Sebastian; Mundkowski, Ralf G.; Miekisch, Wolfram; Sievers, Hartwig; Bauer, Steffen; Frank, Bruno; Kundt, Guenther; Drewelow, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective: Induction of CYP3A by St.  John's wort (SJW) exts. with high hyperforin (HYF) content is well described.  Since SJW products vary in the amt. of HYF and other main constituents, the aim of the study was to evaluate the effect on CYP3A function of SJW prepns. with a range from very low to high HYF content.  Methods: Forty-two male, healthy volunteers were randomized into six parallel SJW medication groups with varying compn. esp. with regard to HYF content.  Midazolam plasma concn. profiles were characterized after a single oral dose of 7.5 mg midazolam on the day before and on the 14th day of SJW medication.  Results: All SJW prepns. tested resulted in a decrease in midazolam AUC, although the extent of the effect differed.  The ext. LI 160 (HYF 41 mg/day) decreased midazolam AUC0-12h by 79.4% (95% CI -88.6; -70.1), which was significantly greater than the effect by any other medication (p<0.05).  SJW powder tablets 2.7 g/day (HYF 12 mg/day) resulted in a midazolam AUC0-12h decrease of 47.9% (95% CI -59.7;-36.2), while 2.7 g/day SJW powder tablets that were almost devoid of HYF (0.13 mg/day) reduced midazolam AUC0-12h by only 21.1% (95% CI -33.9; -8.3).  Considering all six SJW medications tested, the extent of midazolam AUC decrease correlated significantly with increasing HYF dose (r=-0.765, p<0.001), but not with hypericin dose (r=-0.067; p=0.673).  Conclusion: The extent of induction of CYP3A varies among St.  John's wort products and depends on hyperforin dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIIqMLdwDZbrVg90H21EOLACvtfcHk0lgTFyjuFl9qTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVOlug%253D%253D&md5=0490b22cfb82f02e54d09ea0c8b91089</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00228-005-0061-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-005-0061-3%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DS.%2BC.%26aulast%3DMajcher-Peszynska%26aufirst%3DJ.%26aulast%3DUehleke%26aufirst%3DB.%26aulast%3DKlammt%26aufirst%3DS.%26aulast%3DMundkowski%26aufirst%3DR.%2BG.%26aulast%3DMiekisch%26aufirst%3DW.%26aulast%3DSievers%26aufirst%3DH.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DB.%26aulast%3DKundt%26aufirst%3DG.%26aulast%3DDrewelow%26aufirst%3DB.%26atitle%3DThe%2520extent%2520of%2520induction%2520of%2520CYP3A%2520by%2520St.%2520John%25E2%2580%2599s%2520wort%2520varies%2520among%2520products%2520and%2520is%2520linked%2520to%2520hyperforin%2520dose%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D1%26spage%3D29%26epage%3D36%26doi%3D10.1007%2Fs00228-005-0061-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtbecker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnhaus, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidemann, H.</span></span> <span> </span><span class="NLM_article-title">The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8894514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=1121-1123&issue=10&author=N.+Holtbeckerauthor=M.+F.+Frommauthor=H.+K.+Kroemerauthor=E.+E.+Ohnhausauthor=H.+Heidemann&title=The+nifedipine-rifampin+interaction.+Evidence+for+induction+of+gut+wall+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism</span></div><div class="casAuthors">Holtbecker, Norbert; Fromm, Martin F.; Kroemer, Heyo K.; Ohnhaus, Edgar E.; Heidemann, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1121-1123</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The calcium channel blocker nifedipine is metabolized by cytochrome P 450 3A4, which is present in liver and mucosa of the small bowel.  Cytochrome P 450 3A4 is inducible by the tuberculostatic rifampin in liver and the small bowel.  The contribution of gut wall metab. to total clearance of nifedipine before and during induction has not been detd. in detail.  We therefore investigated the nifedipine-rifampin interaction, with special emphasis on the contribution of gut wass metab. to total metab. of nifedipine before and during administration of rifampin.  Pharmacokinetics of nifedipine were studied in six healthy volunteers on sep. days by administration of 20 μg/kg body wt. nifedipine i.v. and 20 mg nifedipine orally before and after 7 days of rifampin treatment (600 mg/day).  Enzyme induction did not significantly alter pharmacokinetics of nifedipine after i.v. administration.  In contrast, oral clearance of nifedipine increased from 1.5 ± 0.2 L/min to 20.9 ± 8.3 L/min (p < 0.01) and bioavailability decreased from 41.2 ± 5.4% to 5.3 ± 2.7% (p < 0.001).  Although hepatic extn. of nifedipine was not significantly altered during induction (47.4 ± 6.6% vs. 67.4 ± 20.2%; ns), the calcd. extn. of nifedipine in gut wall mucosa increased from 21.8 ± 13.3% to 75.8 ± 28.2% (p < 0.05).  We conclude that there is a relevant interaction between nifedipine and rifampin.  The redn. of nifedipine bioavailability during enzyme induction is most likely due to rifampin-induced gut wall metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcYR_QVFyE2LVg90H21EOLACvtfcHk0lgTFyjuFl9qTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeit7s%253D&md5=0ba33026eb6458617bb21b47b7fe3093</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoltbecker%26aufirst%3DN.%26aulast%3DFromm%26aufirst%3DM.%2BF.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DOhnhaus%26aufirst%3DE.%2BE.%26aulast%3DHeidemann%26aufirst%3DH.%26atitle%3DThe%2520nifedipine-rifampin%2520interaction.%2520Evidence%2520for%2520induction%2520of%2520gut%2520wall%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26issue%3D10%26spage%3D1121%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">FDA</span>.  <i>Lumacaftor NDA No. 206038</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Lumacaftor+NDA+No.+206038."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLumacaftor%2520NDA%2520No.%2520206038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayan-Oshodi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Peña, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.112.046060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22789530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1945-1952&issue=10&author=M.+A.+Ayan-Oshodiauthor=B.+A.+Willisauthor=W.+F.+Annesauthor=S.+L.+Loweauthor=S.+Friedrichauthor=A.+de+la+Pe%C3%B1aauthor=W.+Zhangauthor=T.+Brownauthor=S.+D.+Wiseauthor=S.+D.+Hall&title=The+effects+on+metabolic+clearance+when+administering+a+potent+CYP3A+autoinducer+with+the+prototypic+CYP3A+inhibitor%2C+ketoconazole&doi=10.1124%2Fdmd.112.046060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole</span></div><div class="casAuthors">Ayan-Oshodi, Mosun A.; Willis, Brian A.; Annes, William F.; Lowe, Stephen L.; Friedrich, Stuart; de la Pena, Amparo; Zhang, Wei; Brown, Thomas; Wise, Stephen D.; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1945-1952</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ketoconazole is recognized as the prototypical CYP3A inhibitor and is often used to det. the metabolic CYP3A liabilities of new chem. entities in preclin. and clin. studies.  Ketoconazole has been com. available for approx. 30 years and was marketed before drug-metabolizing enzymes were well characterized; consequently, little is known about its metabolic profile.  Semagacestat, a γ-secretase inhibitor investigated as a potential therapy for Alzheimer's disease, was detd. to be a potent CYP3A autoinducer in human hepatocytes.  Two human studies were conducted to assess the induction potential of semagacestat.  In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.  In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.  Ketoconazole decreased semagacestat CL/F by 32% after a single dose of semagacestat [geometric means ratio est., 0.68; 90% confidence interval (CI). 0.64, 0.73] and 46% at steady state (geometric means ratio est. 0.54; 90% CI, 0.51, 0.58).  Ketoconazole area under the concn.-time curve over 8 h decreased 49% from first to last day of semagacestat dosing.  Semagacestat significantly increases the oral clearance of CYP3A substrates, confirming its inducer designation.  More importantly, when administered with a potent CYP3A inducer at steady state, ketoconazole's plasma exposure decreased, indicating that it may also be cleared by CYP3A, other inducible enzymes or transporters, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSbL34aQEaCbVg90H21EOLACvtfcHk0lgTFyjuFl9qTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmsbvE&md5=2ae359568d90f744509be521e8e7adaa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046060%26sid%3Dliteratum%253Aachs%26aulast%3DAyan-Oshodi%26aufirst%3DM.%2BA.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DAnnes%26aufirst%3DW.%2BF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3Dde%2Bla%2BPe%25C3%25B1a%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DT.%26aulast%3DWise%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effects%2520on%2520metabolic%2520clearance%2520when%2520administering%2520a%2520potent%2520CYP3A%2520autoinducer%2520with%2520the%2520prototypic%2520CYP3A%2520inhibitor%252C%2520ketoconazole%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D10%26spage%3D1945%26epage%3D1952%26doi%3D10.1124%2Fdmd.112.046060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">FDA.</span> <i>Dabrafenib NDA No. 202806</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Dabrafenib+NDA+No.+202806."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DDabrafenib%2520NDA%2520No.%2520202806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">FDA.</span> <i>Cenobamate NDA No. 212839</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Cenobamate+NDA+No.+212839."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DCenobamate%2520NDA%2520No.%2520212839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">FDA.</span> <i>Lorlatinib NDA No. 210868</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Lorlatinib+NDA+No.+210868."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLorlatinib%2520NDA%2520No.%2520210868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosset, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terra, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidsey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: Integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.116.074476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28254951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=501-511&issue=5&author=J.+Q.+Dongauthor=J.+R.+Gossetauthor=O.+A.+Fahmiauthor=Z.+Linauthor=J.+R.+Chabotauthor=S.+G.+Terraauthor=V.+Leauthor=K.+Chidseyauthor=P.+Nouriauthor=A.+Kimauthor=L.+Buckbinderauthor=A.+S.+Kalgutkar&title=Examination+of+the+human+cytochrome+P4503A4+induction+potential+of+PF-06282999%2C+an+irreversible+myeloperoxidase+inactivator%3A+Integration+of+preclinical%2C+in+silico%2C+and+biomarker+methodologies+in+the+prediction+of+the+clinical+outcome&doi=10.1124%2Fdmd.116.074476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome</span></div><div class="casAuthors">Dong, Jennifer Q.; Gosset, James R.; Fahmi, Odette A.; Lin, Zhiwu; Chabot, Jeffrey R.; Terra, Steven G.; Le, Vu; Chidsey, Kristin; Nouri, Parya; Kim, Albert; Buckbinder, Leonard; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-511</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The propensity for CYP3A4 induction by 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999), an irreversible inactivator of myeloperoxidase, was examd. in the present study.  Studies using human hepatocytes revealed moderate increases in CYP3A4 mRNA and midazolam-1'-hydroxylase activity in a PF-06282999 dose-dependent fashion.  At the highest tested concn. of 300 μM, PF-06282999 caused maximal induction in CYP3A4 mRNA and enzyme activity ranging from 56% to 86% and 47% t0 72%, resp., of rifampicin response across the three hepatocyte donor pools.  In a clin. drug-drug interaction (DDI) study, the mean midazolam Cmax and area under the curve (AUC) values following 14-day treatment with PF-06282999 decreased in a dose-dependent fashion with a max. decrease in midazolam AUC0-inf and Cmax of ∼57.2% and 41.1% obsd. at the 500 mg twice daily dose.  The moderate impact on midazolam pharmacokinetics at the 500 mg twice daily dose of PF-06282999 was also reflected in statistically significant changes in plasma 4β-hydroxycholesterol/cholesterol and urinary 6β-hydroxycortisol/cortisol ratios.  Changes in plasma and urinary CYP3A4 biomarkers did not reach statistical significance at the 125 mg three times daily dose of PF-06282999, despite a modest decrease in midazolam systemic exposure.  Predicted DDI magnitude based on the in vitro induction parameters and simulated pharmacokinetics of perpetrator (PF-06282999) and victim (midazolam) using the Simcyp (Simcyp Ltd., Sheffield, United Kingdom) population-based simulator were in reasonable agreement with the obsd. clin. data.  Since the magnitude of the 4β-hydroxycholesterol or 6β-hydroxycortisol ratio change was generally smaller than the magnitude of the midazolam AUC change with PF-06282999, a pharmacokinetic interaction study with midazolam ultimately proved important for assessment of DDI via CYP3A4 induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyuhKk0yzrgrVg90H21EOLACvtfcHk0ljXF-gA_7kg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjP&md5=e824db495a6cd97c20bd4de48e4d5cc9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074476%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%2BQ.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DChabot%26aufirst%3DJ.%2BR.%26aulast%3DTerra%26aufirst%3DS.%2BG.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DChidsey%26aufirst%3DK.%26aulast%3DNouri%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DExamination%2520of%2520the%2520human%2520cytochrome%2520P4503A4%2520induction%2520potential%2520of%2520PF-06282999%252C%2520an%2520irreversible%2520myeloperoxidase%2520inactivator%253A%2520Integration%2520of%2520preclinical%252C%2520in%2520silico%252C%2520and%2520biomarker%2520methodologies%2520in%2520the%2520prediction%2520of%2520the%2520clinical%2520outcome%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D501%26epage%3D511%26doi%3D10.1124%2Fdmd.116.074476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shebley, M.</span></span> <span> </span><span class="NLM_article-title">Quantitative assessment of elagolix enzyme-transporter interplay and drug-drug interactions using physiologically based pharmacokinetic modeling</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1007/s40262-019-00833-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs40262-019-00833-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31713224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=617-627&issue=5&author=M.+S.+Chineyauthor=J.+Ngauthor=J.+P.+Gibbsauthor=M.+Shebley&title=Quantitative+assessment+of+elagolix+enzyme-transporter+interplay+and+drug-drug+interactions+using+physiologically+based+pharmacokinetic+modeling&doi=10.1007%2Fs40262-019-00833-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling</span></div><div class="casAuthors">Chiney, Manoj S.; Ng, Juki; Gibbs, John P.; Shebley, Mohamad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-627</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Elagolix is approved for the management of moderate-to-severe pain assocd. with endometriosis.  The aim of this anal. was to develop a physiol. based pharmacokinetic (PBPK) model that describes the enzyme-transporter interplay involved in the disposition of elagolix and to predict the magnitude of drug-drug interaction (DDI) potential of elagolix as an inhibitor of P-glycoprotein (P-gp) and inducer of cytochrome P 450 (CYP) 3A4.  Methods: A PBPK model (SimCYP version 15.0.86.0) was developed using elagolix data from in vitro, clin. PK and DDI studies.  Data from DDI studies were used to quantify contributions of the uptake transporter org. anion transporting polypeptide (OATP) 1B1 and CYP3A4 in the disposition of elagolix, and to quant. assess the perpetrator potential of elagolix as a CYP3A4 inducer and P-gp inhibitor.  Results: After accounting for the interplay between elagolix metab. by CYP3A4 and uptake by OATP1B1, the model-predicted PK parameters of elagolix along with the DDI AUC∞ and Cmax ratios, were within 1.5-fold of the obsd. data.  Based on model simulations, elagolix 200 mg administered twice daily is a moderate inducer of CYP3A4 (approx. 56% redn. in midazolam AUC∞).  Simulations of elagolix 150 mg administered once daily with digoxin predicted an increase in digoxin Cmax and AUC∞ by 68% and 19%, resp.  Conclusions: A PBPK model of elagolix was developed, verified, and applied to characterize the disposition interplay between CYP3A4 and OATP1B1, and to predict the DDI potential of elagolix as a perpetrator under dosing conditions that were not tested clin.  PBPK model-based predictions were used to support labeling language for DDI recommendations of elagolix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-QsvPuSLgbVg90H21EOLACvtfcHk0ljXF-gA_7kg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemu7rF&md5=7cc7a8e23faa0f6ca13f7ad80bc8ba15</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40262-019-00833-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-019-00833-6%26sid%3Dliteratum%253Aachs%26aulast%3DChiney%26aufirst%3DM.%2BS.%26aulast%3DNg%26aufirst%3DJ.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DShebley%26aufirst%3DM.%26atitle%3DQuantitative%2520assessment%2520of%2520elagolix%2520enzyme-transporter%2520interplay%2520and%2520drug-drug%2520interactions%2520using%2520physiologically%2520based%2520pharmacokinetic%2520modeling%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26issue%3D5%26spage%3D617%26epage%3D627%26doi%3D10.1007%2Fs40262-019-00833-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndongo, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vourvahis, M.</span></span> <span> </span><span class="NLM_article-title">The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1572</span>, <span class="refDoi"> DOI: 10.1007/s00228-012-1287-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00228-012-1287-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22527351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyhsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=1567-1572&issue=11&author=J.+Davisauthor=G.+Langdonauthor=G.+Laytonauthor=C.+L.+Chongauthor=M.+N.+Ndongoauthor=M.+Vourvahis&title=The+effect+of+lersivirine%2C+a+next-generation+NNRTI%2C+on+the+pharmacokinetics+of+midazolam+and+oral+contraceptives+in+healthy+subjects&doi=10.1007%2Fs00228-012-1287-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects</span></div><div class="casAuthors">Davis, John; Langdon, Grant; Layton, Gary; Chong, Chew Lan; Ndongo, Marie-Noella; Vourvahis, Manoli</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1567-1572</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a unique resistance profile that exhibits potent antiretroviral activity against wild-type human immunodeficiency virus and clin. relevant NNRTI-resistant strains.  Results from in vitro and in vivo investigations suggest that lersivirine is a cytochrome P 450 (CYP3A4) inducer that is metabolized by CYP3A4 and uridine diphosphate glucuronosyltransferase (UGT) 2B7.  In order to formally assess the effects of lersivirine on CYP3A4 metab. and/or glucuronidation, we performed studies aimed at investigating the effects of lersivirine co-administration on the pharmacokinetics (PK) of midazolam, ethinylestradiol and levonorgestrel.  Methods: Two drug-drug interaction studies were performed.  Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein.  The effects of co-administration on the PK parameters of midazolam and OCs were assessed.  Results: At clin. relevant lersivirine doses (500-1,000 mg total daily dose), the mean plasma exposure of midazolam was reduced in a dose-dependent manner by 20-36 %.  Co-administration of lersivirine 1,000 mg QD with OCs had minor PK effects, increasing ethinylestradiol exposure by 10 % and reducing levonorgestrel exposure by 13 %.  Conclusions: These data further support previous observations that lersivirine is a weak CYP3A4 inducer, a weak inhibitor of glucuronidation, and a P-glycoprotein inhibitor.  In both studies, lersivirine appeared to have a good safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH6AneMpZs4rVg90H21EOLACvtfcHk0ljqoq7VlVeO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyhsr7O&md5=f8574ca6b7efe7c4f87455af54ece715</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs00228-012-1287-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-012-1287-5%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLangdon%26aufirst%3DG.%26aulast%3DLayton%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DC.%2BL.%26aulast%3DNdongo%26aufirst%3DM.%2BN.%26aulast%3DVourvahis%26aufirst%3DM.%26atitle%3DThe%2520effect%2520of%2520lersivirine%252C%2520a%2520next-generation%2520NNRTI%252C%2520on%2520the%2520pharmacokinetics%2520of%2520midazolam%2520and%2520oral%2520contraceptives%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D68%26issue%3D11%26spage%3D1567%26epage%3D1572%26doi%3D10.1007%2Fs00228-012-1287-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">FDA.</span> <i>Telotristat ethyl NDA No. 208794</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Telotristat+ethyl+NDA+No.+208794."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTelotristat%2520ethyl%2520NDA%2520No.%2520208794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensign, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedynek, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span> <span> </span><span class="NLM_article-title">Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.2011.276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22398970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=673-684&issue=4&author=E.+D.+Kharaschauthor=D.+Whittingtonauthor=D.+Ensignauthor=C.+Hofferauthor=P.+S.+Bedynekauthor=S.+Campbellauthor=K.+Stubbertauthor=A.+Craffordauthor=A.+Londonauthor=T.+Kim&title=Mechanism+of+efavirenz+influence+on+methadone+pharmacokinetics+and+pharmacodynamics&doi=10.1038%2Fclpt.2011.276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics</span></div><div class="casAuthors">Kharasch, E. D.; Whittington, D.; Ensign, D.; Hoffer, C.; Bedynek, P. S.; Campbell, S.; Stubbert, K.; Crafford, A.; London, A.; Kim, T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">673-684</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mechanisms by which efavirenz diminishes methadone plasma concns. are unknown.  This investigation detd. efavirenz influence on clin. methadone disposition and miosis, i.v. and oral alfentanil clearance (hepatic and intestinal cytochrome P 450 3A4/5 (CYP3A4/5) activity), fexofenadine disposition (intestinal transporters activity), and efavirenz clearance and 8-hydroxylation (CYP2B6 activity), and human hepatocyte effects.  Efavirenz induced systemic and oral alfentanil clearances two- to fivefold and induced efavirenz 8-hydroxylation.  Efavirenz stereoselectively decreased methadone plasma concns. 50-70%.  Methadone systemic and oral clearances, hepatic clearance and extn. ratio, N-demethylation, and metabolite formation clearance were stereoselectively increased two- to threefold.  Bioavailability decreased.  Efavirenz shifted methadone concn.-miosis curves leftward and upward.  Efavirenz induced hepatocyte CYP2B6 and CYP3A4 expression, activity, and methadone N-demethylation.  Results show that efavirenz coinduced hepatic CYP2B6 and CYP3A4/5, coinduced hepatic and intestinal CYP3A4/5, and coinduced gastrointestinal CYP3A4/5 and efflux transporters.  Methadone disposition was most consistent with efavirenz induction of hepatic CYP2B6-mediated methadone N-demethylation.  Efavirenz may alter methadone pharmacodynamics.  Clin. Pharmacol. & Therapeutics (2012); 91 4, 673-684. doi:10.1038/clpt.2011.276.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZt1GVs-Ga7Vg90H21EOLACvtfcHk0ljqoq7VlVeO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOkurY%253D&md5=36c71279d00ba733ec5c6aa389d726e0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.276%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DEnsign%26aufirst%3DD.%26aulast%3DHoffer%26aufirst%3DC.%26aulast%3DBedynek%26aufirst%3DP.%2BS.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DStubbert%26aufirst%3DK.%26aulast%3DCrafford%26aufirst%3DA.%26aulast%3DLondon%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DT.%26atitle%3DMechanism%2520of%2520efavirenz%2520influence%2520on%2520methadone%2520pharmacokinetics%2520and%2520pharmacodynamics%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D91%26issue%3D4%26spage%3D673%26epage%3D684%26doi%3D10.1038%2Fclpt.2011.276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates sildenafil, amlodipine, tolbutamide, and repaglinide</span>. <i>Clin Pharmacol Drug Dev</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1002/cpdd.324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpdd.324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28067999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=363-376&issue=4&author=M.+Gillenauthor=C.+Yangauthor=D.+Wilsonauthor=S.+Valdezauthor=C.+Leeauthor=B.+Kerrauthor=Z.+Shen&title=Evaluation+of+pharmacokinetic+interactions+between+lesinurad%2C+a+new+selective+urate+reabsorption+inhibitor%2C+and+CYP+enzyme+substrates+sildenafil%2C+amlodipine%2C+tolbutamide%2C+and+repaglinide&doi=10.1002%2Fcpdd.324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide</span></div><div class="casAuthors">Gillen, Michael; Yang, Chun; Wilson, David; Valdez, Shakti; Lee, Caroline; Kerr, Bradley; Shen, Zancong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-376</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Lesinurad is a selective uric acid reabsorption inhibitor approved for the treatment of hyperuricemia assocd. with gout in combination with xanthine oxidase inhibitors.  In vitro assays indicate that lesinurad is an inducer of CYPs in the order CYP3A > CYP2C8 > CYP2C9 > CYP2C19 > CYP2B6 and an inhibitor of CYP2C8 and CYP2C9.  To investigate the drug interaction potential of lesinurad, clin. drug interaction studies were conducted.  Open-label studies in volunteers investigated the effects of single-/multiple-dose lesinurad on the pharmacokinetics of sildenafil and amlodipine (CYP3A4 induction), tolbutamide (CYP2C9 inhibition/induction), and repaglinide (CYP2C8 inhibition/induction).  There was no apparent induction of CYP2C8 and CYP2C9 following repeated lesinurad administration, although no inhibition of CYP2C9 and modest inhibition of CYP2C8 were obsd. following single-dose lesinurad.  Consistent with in vitro observations, lesinurad (200 mg once daily) was an inducer of CYP3A based on the effects on sildenafil exposure.  Sildenafil exposure decreased by approx. 34% for Cmax and AUC when administered with multiple-dose lesinurad 200 mg and allopurinol 300 mg, relative to sildenafil alone.  During lesinurad therapy, the possibility of reduced efficacy of concomitant drugs that are CYP3A substrates should be considered and their efficacy monitored because of induction of CYP3A by lesinurad.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo__JbrBf2wLVg90H21EOLACvtfcHk0ljqoq7VlVeO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbrE&md5=a5b4c42e2433f60af3d87cc0a8f7008d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.324%26sid%3Dliteratum%253Aachs%26aulast%3DGillen%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DValdez%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKerr%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interactions%2520between%2520lesinurad%252C%2520a%2520new%2520selective%2520urate%2520reabsorption%2520inhibitor%252C%2520and%2520CYP%2520enzyme%2520substrates%2520sildenafil%252C%2520amlodipine%252C%2520tolbutamide%252C%2520and%2520repaglinide%26jtitle%3DClin%2520Pharmacol%2520Drug%2520Dev%26date%3D2017%26volume%3D6%26issue%3D4%26spage%3D363%26epage%3D376%26doi%3D10.1002%2Fcpdd.324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2005.02383.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2005.02383.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15963102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2ktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2005&pages=107-112&issue=1&author=G.+A.+Paulauthor=J.+S.+Gibbsauthor=A.+R.+Boobisauthor=A.+Abbasauthor=M.+R.+Wilkins&title=Bosentan+decreases+the+plasma+concentration+of+sildenafil+when+coprescribed+in+pulmonary+hypertension&doi=10.1111%2Fj.1365-2125.2005.02383.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension</span></div><div class="casAuthors">Paul, Gideon A.; Gibbs, J. Simon R.; Boobis, Alan R.; Abbas, Allifia; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To det. whether bosentan decreases the plasma concn. of sildenafil in patients with pulmonary arterial hypertension.  Ten patients (aged 39-77 years) with pulmonary arterial hypertension in WHO functional class III received bosentan 62.5 mg twice daily for 1 mo, then 125 mg twice daily for a second month.  Sildenafil 100 mg was given as a single dose before starting bosentan (visit 1) and at the end of each month of bosentan treatment (visits 2 and 3).  Sildenafil and its primary metabolite, desmethylsildenafil, were measured in plasma at 0 h and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h using liq. chromatog.-tandem mass spectrometry.  Statistical anal. was by repeated measures ANOVA, using log transformed data where appropriate.  Treatment with bosentan 62.5 mg twice daily for 4 wk was assocd. with a two-fold increase in sildenafil clearance/F and a 50% decrease in the AUC (P < 0.001).  Increasing the dose of bosentan to 125 mg twice daily led to a further increase in sildenafil oral clearance and decrease in the AUC (P < 0.001 vs. 62.5 mg bosentan).  The ratio of AUC on bosentan treatment relative to that of visit 1 was 0.47 [95% confidence interval (Cl) 0.36, 0.61] for visit 2 and 0.31 (95% Cl 0.23, 0.41) for visit 3 (P < 0.001).  Sildenafil Cmax fell from 759 ng ml-1 on visit 1 to 333 ng ml-1 on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).  The AUC and plasma half-life of desmethylsildenafil was also decreased by bosentan in a dose-dependent manner (P < 0.01).  Bosentan significantly decreases the plasma concn. of sildenafil when coadministered to patients with pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr36c2mn71LT7Vg90H21EOLACvtfcHk0lgvqLlkk0jhXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2ktrc%253D&md5=34df20f64b356bb1585f3543cca2d3d3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02383.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02383.x%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DG.%2BA.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%26aulast%3DBoobis%26aufirst%3DA.%2BR.%26aulast%3DAbbas%26aufirst%3DA.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DBosentan%2520decreases%2520the%2520plasma%2520concentration%2520of%2520sildenafil%2520when%2520coprescribed%2520in%2520pulmonary%2520hypertension%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D60%26issue%3D1%26spage%3D107%26epage%3D112%26doi%3D10.1111%2Fj.1365-2125.2005.02383.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöller-Gyüre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetelmans, R. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between etravirine and non-antiretroviral drugs</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2165/11534740-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2165%2F11534740-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21142266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=25-39&issue=1&author=T.+N.+Kakudaauthor=M.+Sch%C3%B6ller-Gy%C3%BCreauthor=R.+M.+Hoetelmans&title=Pharmacokinetic+interactions+between+etravirine+and+non-antiretroviral+drugs&doi=10.2165%2F11534740-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interactions between etravirine and non-antiretroviral drugs</span></div><div class="casAuthors">Kakuda, Thomas N.; Scholler-Gyure, Monika; Hoetelmans, Richard M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.  Etravirine has been approved in several countries for use as part of highly active antiretroviral therapy in treatment-experienced patients.  In vivo, etravirine is a substrate for, and weak inducer of, the hepatic cytochrome P 450 (CYP) isoenzyme 3A4 and a substrate and weak inhibitor of CYP2C9 and CYP2C19.  Etravirine is also a weak inhibitor of P-glycoprotein.  An extensive drug-drug interaction program in HIV-neg. subjects has been carried out to assess the potential for pharmacokinetic interactions between etravirine and a variety of non-antiretroviral drugs.  Effects of atorvastatin, clarithromycin, methadone, omeprazole, oral contraceptives, paroxetine, ranitidine and sildenafil on the pharmacokinetic disposition of etravirine were of no clin. relevance.  Likewise, etravirine had no clin. significant effect on the pharmacokinetics of fluconazole, methadone, oral contraceptives, paroxetine or voriconazole.  No clin. relevant interactions are expected between etravirine and azithromycin or ribavirin, therefore, etravirine can be combined with these agents without dose adjustment.  Fluconazole and voriconazole increased etravirine exposure 1.9- and 1.4-fold, resp., in healthy subjects, however, no increase in the incidence of adverse effects was obsd. in patients receiving etravirine and fluconazole during clin. trials, therefore, etravirine can be combined with these antifungals although caution is advised.  Digoxin plasma exposure was slightly increased when co-administered with etravirine.  No dose adjustments of digoxin are needed when used in combination with etravirine, however, it is recommended that digoxin levels should be monitored.  Caution should be exercised in combining rifabutin with etravirine in the presence of certain boosted HIV protease inhibitors due to the risk of decreased exposure to etravirine.  Although adjustments to the dose of clarithromycin are unnecessary for the treatment of most infections, the use of an alternative macrolide (e.g. azithromycin) is recommended for the treatment of Mycobacterium avium complex infection since the overall activity of clarithromycin against this pathogen may be altered when co-administered with etravirine.  Dosage adjustments based on clin. response are recommended for clopidogrel, HMG-CoA reductase inhibitors (e.g. atorvastatin) and for phosphodiesterase type-5 inhibitors (e.g. sildenafil) because changes in the exposure of these medications in the presence of co-administered etravirine may occur.  When co-administered with etravirine, a dose redn. or alternative to diazepam is recommended.  When combining etravirine with warfarin, the international normalized ratio (INR) should be monitored.  Systemic dexamethasone should be co-administered with caution, or an alternative to dexamethasone be found as dexamethasone induces CYP3A4.  Caution is also warranted when co-administering etravirine with some antiarrhythmics, calcineurin inhibitors (e.g. ciclosporin) and antidepressants (e.g. citalopram).  Co-administration of etravirine with some antiepileptics (e.g. carbamazepine and phenytoin), rifampicin (rifampin), rifapentine or prepns. contg. St John's wort (Hypericum perforatum) is currently not recommended as these are potent inducers of CYP3A and/or CYP2C and may potentially decrease etravirine exposure.  Antiepileptics that are less likely to interact based on their known pharmacol. properties include gabapentin, lamotrigine, levetiracetam and pregabalin.  Overall, pharmacokinetic and clin. data show etravirine to be well tolerated and generally safe when given in combination with non-antiretroviral agents, with minimal clin. significant drug interactions and no need for dosage adjustments of etravirine in any of the cases, or of the non-antiretroviral agent in the majority of cases studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s-3t6TAjlbVg90H21EOLACvtfcHk0lgvqLlkk0jhXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKitbc%253D&md5=9ef064f3dbba198d7a267f7058a452ae</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2165%2F11534740-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11534740-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DSch%25C3%25B6ller-Gy%25C3%25BCre%26aufirst%3DM.%26aulast%3DHoetelmans%26aufirst%3DR.%2BM.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520etravirine%2520and%2520non-antiretroviral%2520drugs%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26issue%3D1%26spage%3D25%26epage%3D39%26doi%3D10.2165%2F11534740-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. H.</span></span> <span> </span><span class="NLM_article-title">Combined therapy with thioridazine decreases plasma levels of quetiapine in Taiwanese schizophrenic patients</span>. <i>Ther. Drug Monit.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1097/FTD.0b013e31825479cc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2FFTD.0b013e31825479cc" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22569350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1ant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=345-348&issue=3&author=S.+C.+Changauthor=M.+L.+Luauthor=Y.+C.+Wangauthor=F.+W.+Linauthor=S.+H.+Huangauthor=P.+H.+Kuoauthor=H.+O.+Hoauthor=T.+H.+Wu&title=Combined+therapy+with+thioridazine+decreases+plasma+levels+of+quetiapine+in+Taiwanese+schizophrenic+patients&doi=10.1097%2FFTD.0b013e31825479cc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Therapy With Thioridazine Decreases Plasma Levels of Quetiapine in Taiwanese Schizophrenic Patients</span></div><div class="casAuthors">Chang, Shen-Chieh; Lu, Mong-Liang; Wang, Yue-Chi; Lin, Fang-Wei; Huang, Shu-Huei; Kuo, Pei-Hsin; Ho, Hsiu-O.; Wu, Tzu-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Drug Monitoring</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-348</span>CODEN:
                <span class="NLM_cas:coden">TDMODV</span>;
        ISSN:<span class="NLM_cas:issn">0163-4356</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia.  Methods: Sixteen subjects with schizophrenia were recruited for this study.  The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study.  QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week.  On day 15, blood samples were collected at 12 time points within an 8-h interval.  The authors assayed the plasma levels of QTP with a high-performance liq. chromatog. system coupled with UV detector.  Results: Significantly decreased plasma levels of QTP after oral administration were obsd. in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 h, and the P values were 0.046, 0.001, and 0.005, resp.  The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 vs. 1452.3 ± 707.5 ng/mL; P = 0.002).  The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 vs. 60.3 ± 28.5 L/h; P = 0.03).  Other pharmacokinetic parameters were not significantly different.  Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP.  Although TDZ is switched to QTP, choosing larger doses of QTP for titrn. may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9M_UF7rQxv7Vg90H21EOLACvtfcHk0lgvqLlkk0jhXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1ant70%253D&md5=59af5b2d7d00e6a00606765566373919</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1097%2FFTD.0b013e31825479cc&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFTD.0b013e31825479cc%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DLu%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DLin%26aufirst%3DF.%2BW.%26aulast%3DHuang%26aufirst%3DS.%2BH.%26aulast%3DKuo%26aufirst%3DP.%2BH.%26aulast%3DHo%26aufirst%3DH.%2BO.%26aulast%3DWu%26aufirst%3DT.%2BH.%26atitle%3DCombined%2520therapy%2520with%2520thioridazine%2520decreases%2520plasma%2520levels%2520of%2520quetiapine%2520in%2520Taiwanese%2520schizophrenic%2520patients%26jtitle%3DTher.%2520Drug%2520Monit.%26date%3D2012%26volume%3D34%26issue%3D3%26spage%3D345%26epage%3D348%26doi%3D10.1097%2FFTD.0b013e31825479cc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. C.</span></span> <span> </span><span class="NLM_article-title">Evidence of an interaction between nifedipine and nafcillin in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2003.01789.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1046%2Fj.1365-2125.2003.01789.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12814453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=588-590&issue=6&author=C.+C.+Langauthor=S.+K.+Jamalauthor=Z.+Mohamedauthor=M.+R.+Mustafaauthor=A.+M.+Mustafaauthor=T.+C.+Lee&title=Evidence+of+an+interaction+between+nifedipine+and+nafcillin+in+humans&doi=10.1046%2Fj.1365-2125.2003.01789.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of an interaction between nifedipine and nafcillin in humans</span></div><div class="casAuthors">Lang, C. C.; Jamal, S. K.; Mohamed, Z.; Mustafa, M. R.; Mustafa, A. M.; Lee, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">588-590</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Aims: Nafcillin (Wyeth Labs., Philadelphia, PA, USA) has been reported to induce the metab. of cyclosporin and warfarin, which are known substrates of cytochrome P 450 (CYP).  However, there has not been any report to date on its possible interaction with nifedipine, an index substrate of the enzyme, CYP3A4.  Methods: Nine healthy normotensive subjects participated in this randomized placebo-controlled two-way crossover study examg. the effects of 5 days' pretreatment of nafcillin 500 mg or placebo four times daily on the pharmacokinetics of an oral dose of nifedipine 10 mg.  Plasma nifedipine concns. were measured by gas chromatog.-mass spectrometry.  Results: The area under the plasma nifedipine concn.-time curve (AUC0-α) in nafcillin-pretreated subjects (80.9±32.9 μg l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4±93.2 μg l-1 h-1) (P < 0.001).  Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5±42.01 h-1 vs. 56.5±32.01 h-1) (P < 0.002).  Conclusions: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjh7_0u5Y9F7Vg90H21EOLACvtfcHk0lh4RbN3E-wi5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFaitL4%253D&md5=922736f107886edf88882b47f4a137ff</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2003.01789.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2003.01789.x%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DC.%2BC.%26aulast%3DJamal%26aufirst%3DS.%2BK.%26aulast%3DMohamed%26aufirst%3DZ.%26aulast%3DMustafa%26aufirst%3DM.%2BR.%26aulast%3DMustafa%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DEvidence%2520of%2520an%2520interaction%2520between%2520nifedipine%2520and%2520nafcillin%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2003%26volume%3D55%26issue%3D6%26spage%3D588%26epage%3D590%26doi%3D10.1046%2Fj.1365-2125.2003.01789.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span> <span> </span><span class="NLM_article-title">Drug interactions with fluconazole</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">Suppl 3</span>),  <span class="NLM_fpage">S327</span>, <span class="refDoi"> DOI: 10.1093/clinids/12.Supplement_3.S327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fclinids%2F12.Supplement_3.S327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1990&pages=S327&issue=Suppl+3&author=J.+D.+Lazarauthor=K.+D.+Wilner&title=Drug+interactions+with+fluconazole&doi=10.1093%2Fclinids%2F12.Supplement_3.S327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F12.Supplement_3.S327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F12.Supplement_3.S327%26sid%3Dliteratum%253Aachs%26aulast%3DLazar%26aufirst%3DJ.%2BD.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26atitle%3DDrug%2520interactions%2520with%2520fluconazole%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1990%26volume%3D12%26issue%3DSuppl%25203%26spage%3DS327%26doi%3D10.1093%2Fclinids%2F12.Supplement_3.S327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayesekera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayewardene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevanayagam, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aweeka, F.</span></span> <span> </span><span class="NLM_article-title">Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1177/00912709922011746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F00912709922011746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10516944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=1085-1093&issue=10&author=S.+Hayashiauthor=D.+Jayesekeraauthor=A.+Jayewardeneauthor=A.+Shahauthor=L.+Thevanayagamauthor=F.+Aweeka&title=Altered+pharmacokinetics+of+indinavir+by+a+novel+nonnucleoside+reverse+transcriptase+inhibitor+%28HBY-097%29%3A+a+pharmacokinetic+evaluation+in+HIV-positive+patients&doi=10.1177%2F00912709922011746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients</span></div><div class="casAuthors">Hayashi, Sandra; Jayesekera, Deepthi; Jayewardene, Anura; Shah, Anita; Thevanayagam, Lourdes; Aweeka, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1085-1093</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">HBY-097 (HBY), an investigational nonnucleoside reverse transcriptase inhibitor (NNRTI), and indinavir (IDV) share a common metabolic pathway, cytochrome P 4503A4 (CYP3A4), and may clin. be used together as well as with zidovudine (ZDV).  Thus, the potential pharmacokinetic (PK) interaction between these drugs was evaluated.  HBY (500 mg Q8H), IDV (800 mg Q8H), and ZDV (200 mg Q8H) were given to 8 HIV-infected subjects.  Serial plasma samples were collected at baseline (ZDV and IDV alone) and day 11 (all 3 drugs) to det. PK parameters using noncompartmental anal.  PK parameters for ZDV in the presence and absence of HBY were not appreciably different.  However, both the max. (Cmax) and min. (Cmin) concns. of IDV were significantly reduced, from a mean of 7514 ± 1636 and 146 ± 81 mcg/L to 4725 ± 2494 mcg/L and 54 ± 24 mcg/L (p < .05) after addn. of HBY.  Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 ± 0.14 to 1.94 ± 0.63 L/h/kg (p < .05) with an assocd. redn. in area under the curve (AUC0-8) from 16,034 ± 4903 to 6134 ± 2701 mg/L/h (p < .05).  The increase in IDV CL/F is consistent with the obsd. metabolic induction effects of other NNRTIs.  The results of this trial showed that HBY significantly alters the pharmacokinetic parameters of IDV at the dose studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyw-i9VefTbVg90H21EOLACvtfcHk0lh4RbN3E-wi5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFWrsw%253D%253D&md5=37b1e0744e3677b2ca82e4b8fcb4bcd8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1177%2F00912709922011746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912709922011746%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DJayesekera%26aufirst%3DD.%26aulast%3DJayewardene%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DThevanayagam%26aufirst%3DL.%26aulast%3DAweeka%26aufirst%3DF.%26atitle%3DAltered%2520pharmacokinetics%2520of%2520indinavir%2520by%2520a%2520novel%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520%2528HBY-097%2529%253A%2520a%2520pharmacokinetic%2520evaluation%2520in%2520HIV-positive%2520patients%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1999%26volume%3D39%26issue%3D10%26spage%3D1085%26epage%3D1093%26doi%3D10.1177%2F00912709922011746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taburet, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiec, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morand-Joubert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chêne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clavel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, P. M.</span></span> <span> </span><span class="NLM_article-title">Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2003.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15060509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVKgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=310-323&issue=4&author=A.+M.+Taburetauthor=G.+Raguinauthor=C.+Le+Tiecauthor=C.+Drozauthor=A.+Barrailauthor=I.+Vincentauthor=L.+Morand-Joubertauthor=G.+Ch%C3%AAneauthor=F.+Clavelauthor=P.+M.+Girard&title=Interactions+between+amprenavir+and+the+lopinavir-ritonavir+combination+in+heavily+pretreated+patients+infected+with+human+immunodeficiency+virus&doi=10.1016%2Fj.clpt.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus</span></div><div class="casAuthors">Taburet, Anne-Marie; Raguin, Gilles; Le Tiec, Clotilde; Droz, Cecile; Barrail, Aurelie; Vincent, Isabelle; Morand-Joubert, Laurence; Chene, Genevieve; Clavel, Francois; Girard, Pierre-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">310-323</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: This pharmacokinetic study was designed to characterize interactions between amprenavir and the lopinavir-ritonavir combination in patients infected with human immunodeficiency virus in whom previous antiretroviral therapy had failed.  Methods: Twenty-seven patients included in a randomized clin. trial (ANRS [National Agency for AIDS Research] Protocol 104) participated in this study.  They were randomized to receive ritonavir at a dose of either 100 mg twice daily or 200 mg twice daily.  For the first 2 wk of therapy, they were randomly assigned to receive lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily), amprenavir (600 mg twice daily) plus ritonavir (100 mg twice daily), lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily) plus addnl. ritonavir (100 mg twice daily), or amprenavir (600 mg twice daily) plus ritonavir (200 mg twice daily).  From week 3 onward, all patients received amprenavir plus lopinavir-ritonavir with or without an addnl. ritonavir dose (100 mg twice daily).  The pharmacokinetics of the 3 drugs was studied in weeks 2 and 6 of therapy.  Results: Median amprenavir concns. decreased by 54% (P = .004) when lopinavir was added to the amprenavir-ritonavir regimen.  Lopinavir weakly displaced amprenavir from plasma proteins: The av. unbound fraction of amprenavir was 0.089 in week 2 and 0.114 in week 6 (P = .03), but this did not fully account for the obsd. interaction.  Increasing the ritonavir dose did not affect the amprenavir concn.  The relationship between lopinavir and ritonavir concns. fitted a max. effect (Emax) model;the av. concn. of ritonavir that yielded a lopinavir concn. of 8119 ng/mL (50% of Emax) was 602 ng/mL (coeff. of variation, 22%).  There was a significant relationship between the lopinavir inhibitory quotient and the virol. response in week 2 (P = .005).  Conclusion: Lopinavir markedly decreases the amprenavir concn. during amprenavir and lopinavir-ritonavir combination therapy.  The inhibitory quotients were more predictive of the short-term virol. response than was the level of drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThmGSjwIoPrVg90H21EOLACvtfcHk0lh4RbN3E-wi5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVKgurk%253D&md5=37a33196c0c7479cf11954b3aeaf84ab</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DTaburet%26aufirst%3DA.%2BM.%26aulast%3DRaguin%26aufirst%3DG.%26aulast%3DLe%2BTiec%26aufirst%3DC.%26aulast%3DDroz%26aufirst%3DC.%26aulast%3DBarrail%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DI.%26aulast%3DMorand-Joubert%26aufirst%3DL.%26aulast%3DCh%25C3%25AAne%26aufirst%3DG.%26aulast%3DClavel%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DP.%2BM.%26atitle%3DInteractions%2520between%2520amprenavir%2520and%2520the%2520lopinavir-ritonavir%2520combination%2520in%2520heavily%2520pretreated%2520patients%2520infected%2520with%2520human%2520immunodeficiency%2520virus%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D75%26issue%3D4%26spage%3D310%26epage%3D323%26doi%3D10.1016%2Fj.clpt.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellriegel, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span> <span> </span><span class="NLM_article-title">Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1067/mcp.2002.121217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1067%2Fmcp.2002.121217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11823757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=46-56&issue=1&author=P.+Robertsonauthor=E.+T.+Hellriegelauthor=S.+Aroraauthor=M.+Nelson&title=Effect+of+modafinil+on+the+pharmacokinetics+of+ethinyl+estradiol+and+triazolam+in+healthy+volunteers&doi=10.1067%2Fmcp.2002.121217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers</span></div><div class="casAuthors">Robertson, Philmore, Jr.; Hellriegel, Edward T.; Arora, Sanjay; Nelson, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Background: Modafinil was reported to produce a concn.-related induction of CYP3A4/5 activity in vitro in primary cultures of human hepatocytes.  Objective: The authors' objective was to det. whether the pharmacokinetics of steady-state ethinyl estradiol (INN, ethinylestradiol) and single-dose triazolam were altered after 4 wk of modafinil treatment in volunteers.  Methods: This was a placebo-controlled, single-blind, single-period study in 41 female subjects who were receiving long-term treatment with an oral contraceptive that contained ethinyl estradiol (0.035 mg) and norgestimate (0.180-0.250 mg).  Pharmacokinetic profiles for ethinyl estradiol and for a single oral dose of triazolam (0.125 mg) were obtained the day before initiation of treatment with modafinil (200 mg for 7 days, followed by 400 mg for 21 days) or placebo (28 days).  A 2nd dose of triazolam was administered with the final dose of modafinil, and pharmacokinetic profiling was repeated.  Results: The modafinil treatment group had a marked decrease in max. obsd. blood plasma concns. and areas under the plasma concn.-time curve for triazolam relative to placebo, with a much smaller decrease in these parameters for ethinyl estradiol.  The half-life of triazolam was also decreased, but the half-life of ethinyl estradiol did not appear to be affected by treatment with modafinil.  Conclusion: Modafinil induced CYP3A4/5 activity in humans in vivo, suggesting that there is potential for metabolic drug-drug interactions between modafinil and substrates of CYP3A4/5.  However, the induction appeared to be more gastrointestinal than hepatic in nature.  Therefore significant metabolic drug-drug interactions are most likely to occur with compds. (such as triazolam) that undergo significant gastrointestinal CYP3A4/5-mediated 1st-pass metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzAFw-4DlfLVg90H21EOLACvtfcHk0ljaU5vWkQ2ccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFOgsL0%253D&md5=67f43c8ddfac778f23b1c79bd95576d4</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.121217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.121217%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DP.%26aulast%3DHellriegel%26aufirst%3DE.%2BT.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DM.%26atitle%3DEffect%2520of%2520modafinil%2520on%2520the%2520pharmacokinetics%2520of%2520ethinyl%2520estradiol%2520and%2520triazolam%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D71%26issue%3D1%26spage%3D46%26epage%3D56%26doi%3D10.1067%2Fmcp.2002.121217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusawake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Adel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenendaal-Van de Meent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katashima, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2466</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0634-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs12325-017-0634-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29076107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2466-2480&issue=11&author=T.+Kusawakeauthor=M.+den+Adelauthor=D.+Groenendaal-Van+de+Meentauthor=A.+Garcia-Hernandezauthor=A.+Takadaauthor=K.+Katoauthor=Y.+Ohtsuauthor=M.+Katashima&title=Pharmacokinetic+evaluation+of+the+interactions+of+amenamevir+%28ASP2151%29+with+ketoconazole%2C+rifampicin%2C+midazolam%2C+and+warfarin+in+healthy+adults&doi=10.1007%2Fs12325-017-0634-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults</span></div><div class="casAuthors">Kusawake, Tomohiro; den Adel, Martin; Groenendaal-van de Meent, Dorien; Garcia-Hernandez, Alberto; Takada, Akitsugu; Kato, Kota; Ohtsu, Yoshiaki; Katashima, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2466-2480</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Amenamevir is a nonnucleoside antiherpes virus compd. available for treating herpes zoster infections.  Four studies aimed to det. any potential interactions between amenamevir and ketoconazole, rifampicin, midazolam, or warfarin in healthy male participants.  Methods: Two studies were open-label studies that evaluated the effects of multiple doses of ketoconazole (400 mg) and rifampicin (600 mg) on the pharmacokinetics of a single oral dose of amenamevir.  The other two studies were randomized, double-blind, parallel-group studies that evaluated the effects of multiple doses of amenamevir on the pharmacokinetics of a single dose of midazolam (7.5 mg) and warfarin (25 mg).  A drug interaction was considered to occur if the 90% confidence interval (CI) of the least squares geometric mean ratio (GMR) of amenamevir to the comparator was outside the prespecified interval of 0.80-1.25.  Results: Interactions were obsd. between amenamevir and ketoconazole, rifampicin, and midazolam, but not between amenamevir and warfarin.  After a single 400-mg dose of amenamevir, the GMRs of amenamevir plus ketoconazole or rifampicin vs. amenamevir alone for Cmax and the area under the plasma concn.-time curve from time zero to infinity (AUCinf) were 1.30 (90% CI 1.17-1.45) and 2.58 (90% CI 2.32-2.87), resp., for ketoconazole and 0.42 (90% CI 0.37-0.49) and 0.17 (90% CI 0.15-0.19), resp., for rifampicin.  Following multiple doses of amenamevir (400 mg), the GMRs of midazolam plus amenamevir vs. midazolam alone for AUCinf and Cmax were 0.53 (90% CI 0.47-0.61) and 0.63 (90% CI 0.50-0.80), resp.  After a single dose of warfarin, the (S)-warfarin and (R)-warfarin mean Cmax increased and mean AUCinf decreased in the presence of amenamevir; however, the 90% CIs of the GMRs for these parameters remained within the predefined limits.  Conclusion: These findings confirm that amenamevir (as a cytochrome P 450 3A4 substrate) can interact with ketoconazole or rifampicin, and (as a cytochrome P 450 3A4 inducer) can interact with midazolam; however, no interaction between amenamevir and (S)-warfarin was obsd., indicating that amenamevir is not an inducer of cytochrome P 450 2C9.  Funding: Astellas Pharma.  Trial registration: EudraCT2007-002227-33 (study 15L-CL-008), EudraCT2007-002228-14 (study 15L-CL-009), EudraCT2007-002761-13 (study 15L-CL-010), and EudraCT2007-002779-14 (study 15L-CL-018).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqINGVtMLmb7Vg90H21EOLACvtfcHk0ljaU5vWkQ2ccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgt7nP&md5=55908510ab40f9ca9ed5e8325d0947e2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0634-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0634-4%26sid%3Dliteratum%253Aachs%26aulast%3DKusawake%26aufirst%3DT.%26aulast%3Dden%2BAdel%26aufirst%3DM.%26aulast%3DGroenendaal-Van%2Bde%2BMeent%26aufirst%3DD.%26aulast%3DGarcia-Hernandez%26aufirst%3DA.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DKatashima%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520evaluation%2520of%2520the%2520interactions%2520of%2520amenamevir%2520%2528ASP2151%2529%2520with%2520ketoconazole%252C%2520rifampicin%252C%2520midazolam%252C%2520and%2520warfarin%2520in%2520healthy%2520adults%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26issue%3D11%26spage%3D2466%26epage%3D2480%26doi%3D10.1007%2Fs12325-017-0634-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">FDA.</span> <i>Vemurafenib NDA No. 202429</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Vemurafenib+NDA+No.+202429."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DVemurafenib%2520NDA%2520No.%2520202429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">FDA.</span> <i>Tazemetostat NDA No. 211723</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Tazemetostat+NDA+No.+211723."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTazemetostat%2520NDA%2520No.%2520211723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, K. T.</span></span> <span> </span><span class="NLM_article-title">PXR ligand classification model with SFED-weighted WHIM and CoMMA descriptors</span>. <i>SAR QSAR Environ Res</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1080/1062936X.2012.665385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F1062936X.2012.665385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22591167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XntF2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=485-504&issue=5%E2%80%936&author=S.+L.+Maauthor=J.+Y.+Joungauthor=S.+Leeauthor=K.+H.+Choauthor=K.+T.+No&title=PXR+ligand+classification+model+with+SFED-weighted+WHIM+and+CoMMA+descriptors&doi=10.1080%2F1062936X.2012.665385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PXR ligand classification model with SFED-weighted WHIM and CoMMA descriptors</span></div><div class="casAuthors">Ma, S. L.; Joung, J. Y.; Lee, S.; Cho, K. H.; No, K. T.</div><div class="citationInfo"><span class="NLM_cas:title">SAR and QSAR in Environmental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">485-504</span>CODEN:
                <span class="NLM_cas:coden">SQERED</span>;
        ISSN:<span class="NLM_cas:issn">1026-776X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Understanding which type of endogenous and exogenous compds. serve as agonists for the nuclear pregnane X receptor (PXR) would be valuable for drug discovery and development, because PXR regulates a large no. of genes related to xenobiotic metab.  Although several models have been proposed to classify human PXR activators and non-activators, models with better predictability are necessary for practical purposes in drug discovery.  Grid-weighted holistic invariant mol. (G-WHIM) and comparative mol. moment anal. (G-CoMMA) type 3D descriptors that contain information about the solvation free energy of target mols. were developed.  With these descriptors, prediction models built using decision tree (DT)-, support vector machine (SVM)-, and Kohonen neural network (KNN)-based models exhibited better predictability than previously proposed models.  Solvation free energy d.-weighted G-WHIM and G-CoMMA descriptors reveal new insights into PXR ligand classification, and incorporation with machine learning methods (DT, SVM, KNN) exhibits promising results, esp. SVM and KNN.  SVM- and KNN-based models exhibit accuracy around 0.90, and DT-based models exhibit accuracy around 0.8 for both the training and test sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolbTzawYi83rVg90H21EOLACvtfcHk0ljaU5vWkQ2ccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntF2msLw%253D&md5=2ce3c7862ac40b85c33519a0e84fd0aa</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1080%2F1062936X.2012.665385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1062936X.2012.665385%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%2BL.%26aulast%3DJoung%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DK.%2BH.%26aulast%3DNo%26aufirst%3DK.%2BT.%26atitle%3DPXR%2520ligand%2520classification%2520model%2520with%2520SFED-weighted%2520WHIM%2520and%2520CoMMA%2520descriptors%26jtitle%3DSAR%2520QSAR%2520Environ%2520Res%26date%3D2012%26volume%3D23%26issue%3D5%25E2%2580%25936%26spage%3D485%26epage%3D504%26doi%3D10.1080%2F1062936X.2012.665385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissung, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1345/aph.1P354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1345%2Faph.1P354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20959500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVynsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=1709-1717&issue=11&author=N.+F.+Smithauthor=S.+Maniauthor=E.+G.+Schuetzauthor=K.+Yasudaauthor=T.+M.+Sissungauthor=S.+E.+Batesauthor=W.+D.+Figgauthor=A.+Sparreboom&title=Induction+of+CYP3A4+by+vinblastine%3A+Role+of+the+nuclear+receptor+NR1I2&doi=10.1345%2Faph.1P354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2</span></div><div class="casAuthors">Smith, Nicola F.; Mani, Sridhar; Schuetz, Erin G.; Yasuda, Kazuto; Sissung, Tristan M.; Bates, Susan E.; Figg, William D.; Sparreboom, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1709-1717</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Harvey Whitney Books Co.</span>)
        </div><div class="casAbstract">BACKGROUND: Several microtubule targeting agents are capable of inducing CYP3A4 via activation of the pregnane X receptor (PXR; NR1I2).  OBJECTIVE: To evaluate the CYP3A4 induction potential of vinblastine both clin. and in vitro and det. the involvement of the nuclear receptors NR1I2 and the constitutive androstane receptor (NR1I3).  METHODS: Midazolam pharmacokinetics were evaluated in 6 patients who were enrolled in a Phase 1/2 study of infusional vinblastine given in combination with the ABCB1 (P-glycoprotein) antagonist valspodar (PSC 833) and received the CYP3A4 phenotyping probe midazolam on more than 1 occasion.  Genotyping was conducted in CYP3A4, CYP3A5, and ABCB1 to rule out potential pharmacogenetic influences.  Clin. data were followed-up by Western blotting and reporter assays in HepG2 and NIH3T3 cells treated with vinblastine over a dose range of 150-4800 ng/mL for 48 h.  RESULTS: In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).  No obvious effect of polymorphisms in CYP3A4, CYP3A5, and ABCB1 on midazolam clearance was obsd.  In vitro, vinblastine induced CYP3A4 protein.  Furthermore, cell-based reporter gene assays using transiently transfected HepG2 and NIH3T3 cells indicated that vinblastine (150-4800 ng/mL) weakly activated human and mouse full-length NR1I2, but had no influence on NR1I3.  CONCLUSIONS: Collectively, these findings suggest that vinblastine is able to induce CYP3A4, at least in part, via an NR1I2-dependent mechanism, and thus has the potential to facilitate its own elimination and cause interactions with other CYP3A4 substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYhdsLEZm5xLVg90H21EOLACvtfcHk0lh7gZZx-sSgUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVynsr7L&md5=242798968c96f3d0c6a419558f520712</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1345%2Faph.1P354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1P354%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BF.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DSissung%26aufirst%3DT.%2BM.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DInduction%2520of%2520CYP3A4%2520by%2520vinblastine%253A%2520Role%2520of%2520the%2520nuclear%2520receptor%2520NR1I2%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2010%26volume%3D44%26issue%3D11%26spage%3D1709%26epage%3D1717%26doi%3D10.1345%2Faph.1P354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">FDA.</span> <i>Tecovirimat NDA No. 208627</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Tecovirimat+NDA+No.+208627."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTecovirimat%2520NDA%2520No.%2520208627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K.</span></span> <span> </span><span class="NLM_article-title">The effect of ticagrelor on the metabolism of midazolam in healthy volunteers</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2013.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clinthera.2013.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23870610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFektr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=1025-1037&issue=7&author=R.+Tengauthor=K.+Butler&title=The+effect+of+ticagrelor+on+the+metabolism+of+midazolam+in+healthy+volunteers&doi=10.1016%2Fj.clinthera.2013.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Ticagrelor on the Metabolism of Midazolam in Healthy Volunteers</span></div><div class="casAuthors">Teng, Renli; Butler, Kathleen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vitro studies have demonstrated that ticagrelor, an oral antiplatelet agent, is a substrate, activator, and inhibitor of cytochrome P 450 (CYP) 3A.  Thus, potential CYP3A-mediated drug-drug interactions may occur.  The goal of this article was to report study results on the effect of ticagrelor on the pharmacokinetics of oral midazolam (oral midazolam study) and oral vs. i.v. (IV) midazolam (oral/IV midazolam study).  Secondary objectives included assessing the effect of midazolam on ticagrelor pharmacokinetic parameters, and the safety and tolerability of ticagrelor/midazolam coadministration.  Two randomized crossover studies were conducted in healthy volunteers (n = 28 in each) with ticagrelor and midazolam.  In the first study, volunteers received oral ticagrelor (400 mg daily) or placebo for 6 days, then oral midazolam (7.5 mg).  The second study regimen was a single dose of ticagrelor 270 mg, then ticagrelor 180 mg BID for 6 days with a single oral (7.5 mg) or IV (2.5 mg) dose of midazolam.  After oral midazolam administration, ticagrelor significantly reduced the AUC0-∞ of midazolam (30%-32%) and 4-hydroxymidazolam (42%-47%) but not 1-hydroxymidazolam.  After administration of IV midazolam, ticagrelor reduced the AUC0-∞ of midazolam (12%) and 4-hydroxymidazolam (23%) but not 1-hydroxymidazolam.  These results indicate that ticagrelor can weakly activate the metab. of midazolam to its major 1'-hydroxy metabolite, and at the same time, seems to weakly inhibit midazolam 4'-hydroxylation.  Furthermore, ticagrelor affects both hepatic and intestinal CYP3A activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-DTHVi2U0bVg90H21EOLACvtfcHk0lh7gZZx-sSgUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFektr7E&md5=6bc4d787cb3ab07257be3ba9c9250e41</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2013.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2013.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DK.%26atitle%3DThe%2520effect%2520of%2520ticagrelor%2520on%2520the%2520metabolism%2520of%2520midazolam%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Ther.%26date%3D2013%26volume%3D35%26issue%3D7%26spage%3D1025%26epage%3D1037%26doi%3D10.1016%2Fj.clinthera.2013.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span> <span> </span><span class="NLM_article-title">Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1002/jcph.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23585187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=642-653&issue=6&author=S.+Dhuriaauthor=H.+Einolfauthor=J.+Mangoldauthor=S.+Senauthor=H.+Guauthor=L.+Wangauthor=S.+Cameron&title=Time-dependent+inhibition+and+induction+of+human+cytochrome+P4503A4%2F5+by+an+oral+IAP+antagonist%2C+LCL161%2C+in+vitro+and+in+vivo+in+healthy+subjects&doi=10.1002%2Fjcph.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, In vitro and in vivo in healthy subjects</span></div><div class="casAuthors">Dhuria, Shyeilla; Einolf, Heidi; Mangold, James; Sen, Suman; Gu, Helen; Wang, Lai; Cameron, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642-653, 12</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tumor cells can evade programmed cell death via up-regulation of inhibitor of apoptosis proteins (IAPs).  LCL161 is a small mol. oral IAP antagonist in development for use in combination with cytotoxic agents.  The effect of LCL161 on CYP3A4/5 (CYP3A) activity was investigated in vitro and in a clin. study.  Results in human liver microsomes indicated LCL161 inhibited CYP3A in a concn.- and time-dependent manner (KI of 0.797 μM and kinact of 0.0803 min-1).  LCL161 activated human PXR in a reporter gene assay and induced CYP3A4 mRNA up to ∼5-fold in human hepatocytes.  In healthy subjects, the dual inhibitor and inductive effects of a single dose of LCL161 were characterized using single midazolam doses, given before and at three time points after the LCL161 dose.  Midazolam Cmax increased 3.22-fold and AUC(0-inf) increased 9.32-fold when administered four hours after LCL161.  Three days later, midazolam Cmax decreased by 27% andAUC(0-inf) decreased by 30%.  No drug interaction remained one week later.  The strong CYP3A inhibition by LCL161 was accurately predicted using dynamic physiol.-based pharmacokinetic (PBPK) modeling approaches in Simcyp.  However, the obsd. induction effect after the LCL161 dose could not be modeled; suggesting direct enzyme induction by LCL161 was not the underlying mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXYvIbAlEy9LVg90H21EOLACvtfcHk0lh7gZZx-sSgUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrL&md5=e677682940a7053eb24b6df9b221d59b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fjcph.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.79%26sid%3Dliteratum%253Aachs%26aulast%3DDhuria%26aufirst%3DS.%26aulast%3DEinolf%26aufirst%3DH.%26aulast%3DMangold%26aufirst%3DJ.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCameron%26aufirst%3DS.%26atitle%3DTime-dependent%2520inhibition%2520and%2520induction%2520of%2520human%2520cytochrome%2520P4503A4%252F5%2520by%2520an%2520oral%2520IAP%2520antagonist%252C%2520LCL161%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D6%26spage%3D642%26epage%3D653%26doi%3D10.1002%2Fjcph.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prien, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korjamo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graudenz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bühler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieschen, H.</span></span> <span> </span><span class="NLM_article-title">Drug-drug interaction potential of darolutamide: In vitro and clinical studies</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1007/s13318-019-00577-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs13318-019-00577-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31571146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=747-759&issue=6&author=C.+Zurthauthor=M.+Koskinenauthor=R.+Frickeauthor=O.+Prienauthor=T.+Korjamoauthor=K.+Graudenzauthor=K.+Dennerauthor=M.+Bairleinauthor=C.+J.+von+B%C3%BChlerauthor=G.+Wilkinsonauthor=H.+Gieschen&title=Drug-drug+interaction+potential+of+darolutamide%3A+In+vitro+and+clinical+studies&doi=10.1007%2Fs13318-019-00577-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies</span></div><div class="casAuthors">Zurth, Christian; Koskinen, Mikko; Fricke, Robert; Prien, Olaf; Korjamo, Timo; Graudenz, Kristina; Denner, Karsten; Bairlein, Michaela; von Buehler, Clemens-Jeremias; Wilkinson, Gary; Gieschen, Hille</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">747-759</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Drug-drug interaction potential of darolutamide was investigated in both nonclin. and clin. studies.  A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide.  Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, org. anion-transporting polypeptide (OATP)1B1, OATP1B3 and org. anion transporter (OAT)3].  In vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP.  In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity.  Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was obsd. in vitro.  Phase I data showed that darolutamide exposure increased 1.75-fold with co-administered itraconazole and decreased by 72% with rifampicin.  Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects.  Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7iTDqf-pvDrVg90H21EOLACvtfcHk0liLtC4UUYIxBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlurbN&md5=2a32b72f53f0dd3c5dd76cd4692c2962</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs13318-019-00577-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-019-00577-5%26sid%3Dliteratum%253Aachs%26aulast%3DZurth%26aufirst%3DC.%26aulast%3DKoskinen%26aufirst%3DM.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DPrien%26aufirst%3DO.%26aulast%3DKorjamo%26aufirst%3DT.%26aulast%3DGraudenz%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DBairlein%26aufirst%3DM.%26aulast%3Dvon%2BB%25C3%25BChler%26aufirst%3DC.%2BJ.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DGieschen%26aufirst%3DH.%26atitle%3DDrug-drug%2520interaction%2520potential%2520of%2520darolutamide%253A%2520In%2520vitro%2520and%2520clinical%2520studies%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2019%26volume%3D44%26issue%3D6%26spage%3D747%26epage%3D759%26doi%3D10.1007%2Fs13318-019-00577-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekersky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolbert, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.2012.01028.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fj.1875-9114.2012.01028.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22422635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=340-353&issue=4&author=M.+Walzerauthor=I.+Bekerskyauthor=R.+A.+Blumauthor=D.+Tolbert&title=Pharmacokinetic+drug+interactions+between+clobazam+and+drugs+metabolized+by+cytochrome+P450+isoenzymes&doi=10.1002%2Fj.1875-9114.2012.01028.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug interations between clobazam and drugs metabolized by cytochrome P450 isoenzymes</span></div><div class="casAuthors">Walzer, Mark; Bekersky, Ihor; Blum, Robert A.; Tolbert, Dwain</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">340-353</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To investigate potential drug-drug interactions between clobazam and cytochrome P 450 (CYP) isoenzyme substrates, inhibitors, and inducers.  Two, prospective, open-label, single-center, drug-drug interaction (DDI) studies and a population pharmacokinetics anal. of seven multi-center phase II-III trials.  Fifty-four healthy adult volunteers were enrolled in the two drug-drug interaction studies; 53 completed the studies.  The population pharmacokinetics anal. evaluated data from 171 participants from five studies with healthy volunteers and two studies with patients with Lennox-Gastaut syndrome.  Participants in these studies received clobazam and stable dosages of the following antiepileptic drugs: phenobarbital, phenytoin, carbamazepine, valproic acid, lamotrigine, felbamate, or oxcarbazepine.  In the first drug-drug interaction study, 36 participants received a single oral dose of clobazam 10 mg on day 1, followed by either ketoconazole 400 mg once/day or omeprazole 40 mg once/day on days 17-22, with a single dose of clobazam 10 mg coadministered on day 22, to study the effects of CYP3A4 or CYP2C19 inhibition, resp., on clobazam and its active metabolite N-desmethylclobazam (N-CLB).  In the second study, 18 participants received a drug cocktail consisting of caffeine 200 mg, tolbutamide 500 mg, dextromethorphan 30 mg, and midazolam 4 mg on days 1 and 19, and clobazam 40 mg/day on days 4-19, to study clobazam's effects on CYP1A2, CYP2C9, CYP2D6, and CYP3A4.  Measurements and Main Results. In the first DDI study, coadministration of ketoconazole (a CYP3A4 inhibitor) and clobazam increased clobazam's area under the concn. time curve from time zero extrapolated to infinity (AUC0-∞) 54% and decreased clobazam's max. plasma concn. (Cmax) by 15% vs. administration of clobazam alone, but the combination affected these pharmacokinetic parameters for N-CLB to a lesser degree.  The CYP2C19 inhibitor omeprazole increased AUC0-∞ and Cmax of N-CLB by 36% and 15%, resp., but did not significantly affect the pharmacokinetics of clobazam.  At steady state, N-CLB has 3-4 times greater exposure than clobazam.  In the second DDI study, no clin. significant drug-drug interactions were obsd. between clobazam 40 mg and the CYP probe substrates caffeine or tolbutamide.  Exposure to midazolam and its 1-hydroxymidazolam metabolite, however, decreased by 27% and increased 4-fold, resp.  Clobazam increased dextromethorphan (CYP2D6) AUC0-∞ by 95% and Cmax by 59%.  In the population pharmacokinetics anal., stable dosages of common antiepileptic drugs that induce CYP3A4 or CYP2C19, or inhibit CYP2C19, had negligible effects on clobazam or N-CLB.  Clobazam did not affect valproic acid or lamotrigine exposures.  Conclusion. These findings suggest no clin. meaningful drug-drug interactions between clobazam and drugs metabolized by CYP3A4, CYP2C19, CYP1A2, or CYP2C9.  Concomitant use of drugs metabolized by CYP2D6 may require dosage adjustment.  Clobazam may be administered safely as adjunctive therapy in patients with Lennox-Gastaut syndrome, without meaningful changes in clobazam pharmacokinetics that would require dosage adjustment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcoJ7hptTrrVg90H21EOLACvtfcHk0liLtC4UUYIxBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyms7w%253D&md5=82b3890f80ffddbe7ce49fb28d688104</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.2012.01028.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.2012.01028.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalzer%26aufirst%3DM.%26aulast%3DBekersky%26aufirst%3DI.%26aulast%3DBlum%26aufirst%3DR.%2BA.%26aulast%3DTolbert%26aufirst%3DD.%26atitle%3DPharmacokinetic%2520drug%2520interactions%2520between%2520clobazam%2520and%2520drugs%2520metabolized%2520by%2520cytochrome%2520P450%2520isoenzymes%26jtitle%3DPharmacotherapy%26date%3D2012%26volume%3D32%26issue%3D4%26spage%3D340%26epage%3D353%26doi%3D10.1002%2Fj.1875-9114.2012.01028.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enejosa, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisniku, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span> <span> </span><span class="NLM_article-title">Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: A study with the modified cooperstown 5 + 1 cocktail</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1002/jcph.1496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.1496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31378969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=86-95&issue=1&author=M.+F.+Mohamedauthor=T.+Fengauthor=J.+V.+Enejosaauthor=O.+Fisnikuauthor=A.+A.+Othman&title=Effects+of+upadacitinib+coadministration+on+the+pharmacokinetics+of+sensitive+cytochrome+P450+probe+substrates%3A+A+study+with+the+modified+cooperstown+5+%2B+1+cocktail&doi=10.1002%2Fjcph.1496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail</span></div><div class="casAuthors">Mohamed, Mohamed-Eslam F.; Feng, Tian; Enejosa, Jeffrey V.; Fisniku, Ogert; Othman, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P 450 (CYP) enzymes using a cocktail approach.  Healthy subjects (n = 20) received single oral doses of the modified Cooperstown 5+1 cocktail drugs (midazolam [CYP3A], caffeine [CYP1A2], warfarin + vitamin K [CYP2C9], omeprazole [CYP2C19], and dextromethorphan [CYP2D6]) without upadacitinib and on day 11 (midazolam) or 12 (all other probes) of a 15-day regimen of upadacitinib 30 mg once daily (extended-release formulation).  Serial blood samples and 12-h urine samples were collected for assays of the probe substrates and select metabolites.  The ratio (90%CI) of area under the plasma concn.-time curve from time 0 to infinity (AUCinf) central values when the cocktail drugs were administered with upadacitinib relative to when administered alone were 0.74 (0.68-0.80) for midazolam, 1.22 (1.15-1.29) for caffeine, 1.11 (1.07-1.15) for S-warfarin, 1.07 (0.95-1.22) for dextromethorphan, and 0.82 (0.72-0.94) for omeprazole.  The ratio (90%CI) was 1.09 (1.00-1.19) for 5-hydroxy-omeprazole to omeprazole AUCinf ratio and 1.17 (0.97-1.41) for dextromethorphan to dextrorphan 12-h molar urinary ratio.  Upadacitinib 30 mg once daily (a dose that is twice the optimal dose in rheumatoid arthritis based on phase 3 results) has a limited effect on CYP3A activity (26% decrease in exposure of midazolam, a sensitive CYP3A substrate) and no relevant effects on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 activity in vivo.  No clin. relevant changes in plasma exposures are expected for drugs that are substrates for the evaluated CYP enzymes when coadministered with upadacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoNYO5yLUz7Vg90H21EOLACvtfcHk0liLtC4UUYIxBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqt7bN&md5=00d87d40120c10962d1c028b66994c52</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1496%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DM.%2BF.%26aulast%3DFeng%26aufirst%3DT.%26aulast%3DEnejosa%26aufirst%3DJ.%2BV.%26aulast%3DFisniku%26aufirst%3DO.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26atitle%3DEffects%2520of%2520upadacitinib%2520coadministration%2520on%2520the%2520pharmacokinetics%2520of%2520sensitive%2520cytochrome%2520P450%2520probe%2520substrates%253A%2520A%2520study%2520with%2520the%2520modified%2520cooperstown%25205%2520%252B%25201%2520cocktail%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2020%26volume%3D60%26issue%3D1%26spage%3D86%26epage%3D95%26doi%3D10.1002%2Fjcph.1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">FDA.</span> <i>Actos Product Label</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Actos+Product+Label."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DActos%2520Product%2520Label" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. J.</span></span> <span> </span><span class="NLM_article-title">Effect of quercetin on CYP3A activity in Chinese healthy participants</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1177/0091270011406278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F0091270011406278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21680781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVKju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=940-946&issue=6&author=K.+M.+Duanauthor=S.+Y.+Wangauthor=W.+Ouyangauthor=Y.+M.+Maoauthor=L.+J.+Yang&title=Effect+of+quercetin+on+CYP3A+activity+in+Chinese+healthy+participants&doi=10.1177%2F0091270011406278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of quercetin on CYP3A activity in Chinese healthy piticipants</span></div><div class="casAuthors">Duan, Kai-Ming; Wang, Sai-Ying; Ouyang, Wen; Mao, Yan-Mei; Yang, Li-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">940-946</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aims of this study were to investigate the effect of quercetin on CYP3A activity in vivo.  An open, randomized, 2-period crossover expt. was performed in 18 healthy male volunteers.  Genotyped data were available from a total of 165 participants.  The allelic frequency was 52.5%.  Every volunteer ingested orally 500 mg quercetin or placebo once a day for 13 consecutive days.  On day 14, a single 7.5-mg midazolam tablet was administrated orally.  The plasma concns. of midazolam and 1-OH-midazolam were detd. over 24 h.  The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC0-12 h) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC0-∞ of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t1/2 (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased tmax significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), resp.  In conclusion, quercetin significantly induced CYP3A activity to substrate midazolam, and the induction was partly related to the CYP3A5 genotype, being more prominent in CYP3A5*1/*1 and CYP3A5*1/*3 individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoro5kEAympfbVg90H21EOLACvtfcHk0liNmY-b8nS7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVKju7s%253D&md5=bc55d635d25e838b0f6ed8b5762bab7f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F0091270011406278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011406278%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DK.%2BM.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DY.%2BM.%26aulast%3DYang%26aufirst%3DL.%2BJ.%26atitle%3DEffect%2520of%2520quercetin%2520on%2520CYP3A%2520activity%2520in%2520Chinese%2520healthy%2520participants%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26issue%3D6%26spage%3D940%26epage%3D946%26doi%3D10.1177%2F0091270011406278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1995.tb00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.1995.tb00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8527290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK2MXosl2ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1995&pages=270-272&issue=3&author=J.+Ahonenauthor=K.+T.+Olkkolaauthor=P.+J.+Neuvonen&title=Effect+of+itraconazole+and+terbinafine+on+the+pharmacokinetics+and+pharmacodynamics+of+midazolam+in+healthy+volunteers&doi=10.1111%2Fj.1365-2125.1995.tb00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers</span></div><div class="casAuthors">Ahonen, Jouni; Olkkola, Klaus T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">270-2</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">Twelve healthy volunteers were given orally placebo, itraconazole 100 mg or terbinafine 250 mg for 4 days.  Midazolam 7.5 mg was ingested on the fourth day, after which plasma samples were collected and psychomotor performance tests carried out for 17 h.  Itraconazole increased the area under the midazolam concn.-time curve 6-fold,, the peak concn. 2.5-fold and the elimination half-life 2-fold compared with placebo and terbinafine pretreatments.  The pharmacokinetic parameters did not differ between placebo and terbinafine phases.  The higher concns. of midazolam during the itraconazole phase were assocd. with increased effects.  In contrast to itraconazole, terbinafine had no effect on midazolam pharmacokinetics and psychomotor performance tests were unchanged from placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZRXHpFc5UbVg90H21EOLACvtfcHk0liNmY-b8nS7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosl2ltrw%253D&md5=e6ef77bc7afe344c5f6a139afba189bb</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1995.tb00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1995.tb00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DAhonen%26aufirst%3DJ.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffect%2520of%2520itraconazole%2520and%2520terbinafine%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520midazolam%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1995%26volume%3D40%26issue%3D3%26spage%3D270%26epage%3D272%26doi%3D10.1111%2Fj.1365-2125.1995.tb00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severynse-Stevens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3699</span>– <span class="NLM_lpage">3703</span>, <span class="refDoi"> DOI: 10.1128/AAC.02632-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1128%2FAAC.02632-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23689718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3699-3703&issue=8&author=H.+Winterauthor=E.+Egiziauthor=N.+Eronduauthor=A.+Ginsbergauthor=D.+J.+Rouseauthor=D.+Severynse-Stevensauthor=E.+Pauliauthor=D.+Everitt&title=Evaluation+of+pharmacokinetic+interaction+between+PA-824+and+midazolam+in+healthy+adult+subjects&doi=10.1128%2FAAC.02632-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Egizi, Erica; Erondu, Ngozi; Ginsberg, Ann; Rouse, Doris J.; Severynse-Stevens, Diana; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3699-3703</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects.  The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4.  Subjects received a single oral dose of midazolam (2 mg), followed by a 2-day washout.  After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days.  On day 14, all subjects received the final PA-824 dose coadministered with a 2-mg oral dose of midazolam.  The pharmacokinetic endpoints AUC0-t, AUC0-∞, and Cmax for midazolam and 1-hydroxy midazolam were compared between midazolam administered alone vs. midazolam coadministered with PA-824.  Statistical anal. demonstrated that the mean midazolam values of Cmax, AUC0-t, and AUC0-∞ parameters were reduced by ca. 16, 15, and 15%, resp., when PA-824 was coadministered with midazolam.  The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone.  The Cmax of 1-hydroxy midazolam was similar between treatments.  Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clin. meaningful extent and is not likely to markedly affect the pharmacokinetics of CYP3A4 metabolized drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYL4vjAgGRCrVg90H21EOLACvtfcHk0liNmY-b8nS7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L&md5=596e43ace93fca069a3d53ac661ab352</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.02632-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02632-12%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DSeverynse-Stevens%26aufirst%3DD.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interaction%2520between%2520PA-824%2520and%2520midazolam%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D8%26spage%3D3699%26epage%3D3703%26doi%3D10.1128%2FAAC.02632-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtenbaum, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alston, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brobst, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aberg, J. A.</span></span> <span> </span><span class="NLM_article-title">Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1097/01.qai.0000167156.44980.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F01.qai.0000167156.44980.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15980690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=307-312&issue=3&author=J.+G.+Gerberauthor=S.+L.+Rosenkranzauthor=C.+J.+Fichtenbaumauthor=J.+M.+Vegaauthor=A.+Yangauthor=B.+L.+Alstonauthor=S.+W.+Brobstauthor=Y.+Segalauthor=J.+A.+Aberg&title=Effect+of+efavirenz+on+the+pharmacokinetics+of+simvastatin%2C+atorvastatin%2C+and+pravastatin%3A+results+of+AIDS+Clinical+Trials+Group+5108+Study&doi=10.1097%2F01.qai.0000167156.44980.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study</span></div><div class="casAuthors">Gerber, John G.; Rosenkranz, Susan L.; Fichtenbaum, Carl J.; Vega, Jose M.; Yang, Amy; Alston, Beverly L.; Brobst, Susan W.; Segal, Yoninah; Aberg, Judith A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Efavirenz (EFV) is assocd. with hyperlipidemia when used in combination with other antiretroviral drugs.  EFV is a mixed inducer/inhibitor of cytochrome P 450 (CYP) 3A4 isoenzyme and may interact with hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4.  To assess the drug-drug interaction of EFV used in combination with simvastatin (SIM), atorvastatin (ATR), or pravastatin (PRA), an open-label trial was conducted in 52 healthy adult HIV-seroneg. subjects across AIDS Clin. Trials Group sites in the United States.  Subjects received 40 mg of SIM, 10 mg of ATR, or 40 mg of PRA daily on days 0 through 3 and days 15 through 18.  EFV was administered daily at a dose of 600 mg on days 4 through 18.  SIM, ATR, and PRA concns. were detd. before and after EFV, and EFV concns. were detd. before and after statins.  EFV reduced SIM acid exposure (area under the curve at 0 to 24 h [AUC0-24h]) by 58% (Wilcoxon signed rank test, P = 0.003) and active HMG-CoA reductase inhibitory activity by 60% (P < 0.001).  EFV reduced ATR exposure by 43% (P < 0.001) and the total active ATR exposure by 34% (P = 0.005).  EFV administration resulted in a 40% decrease in PRA exposure (P = 0.005).  SIM, ATR, and PRA had no effect on non-steady-state EFV concns.  In conclusion, EFV, when administered with SIM, ATR, or PRA, can result in significant induction of statin metab.  The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWde_DToHJxLVg90H21EOLACvtfcHk0lgpS8QFzJucyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFantL8%253D&md5=a5f79c0ecbae37bab2490bf7347061f4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1097%2F01.qai.0000167156.44980.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.qai.0000167156.44980.33%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DJ.%2BG.%26aulast%3DRosenkranz%26aufirst%3DS.%2BL.%26aulast%3DFichtenbaum%26aufirst%3DC.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DAlston%26aufirst%3DB.%2BL.%26aulast%3DBrobst%26aufirst%3DS.%2BW.%26aulast%3DSegal%26aufirst%3DY.%26aulast%3DAberg%26aufirst%3DJ.%2BA.%26atitle%3DEffect%2520of%2520efavirenz%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%252C%2520atorvastatin%252C%2520and%2520pravastatin%253A%2520results%2520of%2520AIDS%2520Clinical%2520Trials%2520Group%25205108%2520Study%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2005%26volume%3D39%26issue%3D3%26spage%3D307%26epage%3D312%26doi%3D10.1097%2F01.qai.0000167156.44980.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">FDA.</span> <i>Safinamide NDA No. 207145</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Safinamide+NDA+No.+207145."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DSafinamide%2520NDA%2520No.%2520207145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">FDA.</span> <i>Oritavancin NDA No. 206334</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Oritavancin+NDA+No.+206334."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DOritavancin%2520NDA%2520No.%2520206334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribadeneira, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. W.</span></span> <span> </span><span class="NLM_article-title">A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.04155.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2011.04155.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22122233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Klur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2012&pages=98-108&issue=1&author=D.+Zhouauthor=M.+Sunzelauthor=M.+D.+Ribadeneiraauthor=M.+A.+Smithauthor=D.+Desaiauthor=J.+Linauthor=S.+W.+Grimm&title=A+clinical+study+to+assess+CYP1A2+and+CYP3A4+induction+by+AZD7325%2C+a+selective+GABA%28A%29+receptor+modulator+-+an+in+vitro+and+in+vivo+comparison&doi=10.1111%2Fj.1365-2125.2011.04155.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator - an in vitro and in vivo comparison</span></div><div class="casAuthors">Zhou, Diansong; Sunzel, Maria; Ribadeneira, Maria D.; Smith, Mark A.; Desai, Dhaval; Lin, Jianrong; Grimm, Scott W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-108</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To investigate the potential of AZD7325 to induce CYP1A2 and CYP3A4 enzyme activities.  Induction of CYP1A2 and CYP3A4 by AZD7325 was first evaluated using cultured human hepatocytes.  The effect of multiple doses of 10 mg AZD7325 on the pharmacokinetics of midazolam and caffeine was then examd. in healthy subjects.  The highest CYP1A2 and CYP3A4 induction responses were obsd. in human hepatocytes treated with 1 or 10 μM of AZD7325, in the range of 17.9%-54.9% and 76.9%-85.7% of the pos. control responses, resp.  The results triggered the further clin. evaluation of AZD7325 induction potential.  AZD7325 reached a plasma Cmax of 0.2 μM after 10 mg daily dosing to steady-state.  AZD7325 decreased midazolam geometric mean AUC by 19% (0.81-fold, 90% CI 0.77, 0.87), but had no effect on midazolam Cmax (90% CI 0.82, 0.97).  The mean CL/F of midazolam increased from 62 l h-1 (midazolam alone) to 76 l h-1 when co-administered with AZD7325.  The AUC and Cmax of caffeine were not changed after co-administration of AZD7325, with geometric mean ratios (90% CI) of 1.17 (1.12, 1.23) and 0.99 (0.95, 1.03), resp.  While AZD7325 appeared to be a potent CYP3A4 inducer and a moderate CYP1A2 inducer from in vitro studies, the expected efficacious dose of AZD7325 had no effect on CYP1A2 activity and only a weak inducing effect on CYP3A4 activity.  This comparison of in vitro and in vivo results demonstrates the crit. role that clin. exposure plays in evaluating the CYP induction risk of a drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos460HcEeQuLVg90H21EOLACvtfcHk0lgpS8QFzJucyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Klur%252FJ&md5=c613cf8289d286c9a3b40b0e45c844fb</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.04155.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.04155.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSunzel%26aufirst%3DM.%26aulast%3DRibadeneira%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26atitle%3DA%2520clinical%2520study%2520to%2520assess%2520CYP1A2%2520and%2520CYP3A4%2520induction%2520by%2520AZD7325%252C%2520a%2520selective%2520GABA%2528A%2529%2520receptor%2520modulator%2520-%2520an%2520in%2520vitro%2520and%2520in%2520vivo%2520comparison%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D74%26issue%3D1%26spage%3D98%26epage%3D108%26doi%3D10.1111%2Fj.1365-2125.2011.04155.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">FDA.</span> <i>Pitolisant NDA No. 211150</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Pitolisant+NDA+No.+211150."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPitolisant%2520NDA%2520No.%2520211150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, A.</span></span> <span> </span><span class="NLM_article-title">Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1067/mcp.2001.120025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1067%2Fmcp.2001.120025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11753267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=518-524&issue=6&author=K.+Sugimotoauthor=M.+Ohmoriauthor=S.+Tsuruokaauthor=K.+Nishikiauthor=A.+Kawaguchiauthor=K.+Haradaauthor=M.+Arakawaauthor=K.+Sakamotoauthor=M.+Masadaauthor=I.+Miyamoriauthor=A.+Fujimura&title=Different+effects+of+St+John%E2%80%99s+wort+on+the+pharmacokinetics+of+simvastatin+and+pravastatin&doi=10.1067%2Fmcp.2001.120025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin</span></div><div class="casAuthors">Sugimoto, Koh-ichi; Ohmori, Masami; Tsuruoka, Shuichi; Nishiki, Kenta; Kawaguchi, Atsuhiro; Harada, Ken-ichi; Arakawa, Masashi; Sakamoto, Koh-ichi; Masada, Mikio; Miyamori, Isamu; Fujimura, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">518-524</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">The effects of St John's Wort on the pharmacokinetics of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors simvastatin (an inactive lactone prodrug) and pravastatin were detd.  Healthy male subjects took a St John's Wort caplet (300 mg) or matching placebo three times a day for 14 days in a double-blind, crossover study.  On day 14, a single oral dose of 10 mg simvastatin or 20 mg pravastatin was given.  Repeated St John's Wort treatment tended to lower plasma simvastatin concn. and significantly lowered concns. of simvastatin hydroxy acid, its active metabolite.  The peak concn. in plasma of simvastatin hydroxy acid tended to be decreased and its area under the plasma concn.-time curve between time zero and 24 h after administration was significantly decreased by St John's Wort.  On the other hand, St John's Wort did not influence plasma pravastatin concn.  St John's wort caused no significant differences in the elimination half-life of simvastatin or pravastatin.  Thus, Sr John's Wort decreases plasma concns. of simvastatin but not of pravastatin.  Because simvastatin is extensively metabolized by cytochrome P 4503A4 in the intestinal wall and liver, which is induced by St John's Wort, it is likely that this interaction is partly caused by the enhancement of the cytochrome P 4503A4-mediated 1st-pass metab. of simvastatin in the small intestine and liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGcpKjeXDo7Vg90H21EOLACvtfcHk0lhpekMzU3lLFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVCkuw%253D%253D&md5=a43eebdefe27b8459ae09369b6d13b26</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.120025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.120025%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DS.%26aulast%3DNishiki%26aufirst%3DK.%26aulast%3DKawaguchi%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DK.%26aulast%3DMasada%26aufirst%3DM.%26aulast%3DMiyamori%26aufirst%3DI.%26aulast%3DFujimura%26aufirst%3DA.%26atitle%3DDifferent%2520effects%2520of%2520St%2520John%25E2%2580%2599s%2520wort%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%2520and%2520pravastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D70%26issue%3D6%26spage%3D518%26epage%3D524%26doi%3D10.1067%2Fmcp.2001.120025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolan, P.</span></span> <span> </span><span class="NLM_article-title">Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1002/jcph.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24386664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=1313-1321&issue=12&author=A.+Stockisauthor=P.+Rolan&title=Effect+of+brivaracetam+%28400+mg%2Fday%29+on+the+pharmacokinetics+and+pharmacodynamics+of+a+combination+oral+contraceptive+in+healthy+women&doi=10.1002%2Fjcph.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women</span></div><div class="casAuthors">Stockis, Armel; Rolan, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Brivaracetam is a high-affinity synaptic vesicle protein 2A ligand, in Phase III clin. development for epilepsy.  This study assessed the effect of brivaracetam 400 mg/day on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (OC) contg. 30 μg ethinylestradiol and 150 μg levonorgestrel, in healthy pre-menopausal women.  This open-label, single-center, randomized, two-way crossover, multiple oral dose study (N01080) included two consecutive 28-day cycles without (control) or with brivaracetam (test), and a 28-day follow-up.  OC was taken on Days 1-21 of every cycle and brivaracetam 200 mg twice daily was administered on Days 1-20 of the test cycle.  Ethinylestradiol and levonorgestrel pharmacokinetics were detd. on Day 20 and endogenous hormones were measured frequently during both control and test cycles.  Overall, 23/24 participants (age: 19-39 years) completed the study.  AUC ratio (90% confidence interval) for brivaracetam vs. control was 0.73 (0.69, 0.78) for ethinylestradiol and 0.78 (0.72, 0.83) for levonorgestrel, outside pre-defined bioequivalence limits (0.80-1.25).  Levels of endogenous hormones were similar and normal during brivaracetam and control cycles.  Brivaracetam in combination with OC was well tolerated.  Brivaracetam 400 mg/day co-administered with a combination OC in healthy women reduced ethinylestradiol and levonorgestrel plasma levels but did not result in ovulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJLfM0GAwMFLVg90H21EOLACvtfcHk0lhpekMzU3lLFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurjN&md5=c8319a294e97ac6deabd57028c5cab0a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fjcph.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.187%26sid%3Dliteratum%253Aachs%26aulast%3DStockis%26aufirst%3DA.%26aulast%3DRolan%26aufirst%3DP.%26atitle%3DEffect%2520of%2520brivaracetam%2520%2528400%2520mg%252Fday%2529%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520a%2520combination%2520oral%2520contraceptive%2520in%2520healthy%2520women%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D12%26spage%3D1313%26epage%3D1321%26doi%3D10.1002%2Fjcph.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span> <span> </span><span class="NLM_article-title">Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1046/j.1528-1157.2003.55602.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1046%2Fj.1528-1157.2003.55602.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12681003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFymu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=540-549&issue=4&author=D.+R.+Dooseauthor=S.+S.+Wangauthor=M.+Padmanabhanauthor=S.+Schwabeauthor=D.+Jacobsauthor=M.+Bialer&title=Effect+of+topiramate+or+carbamazepine+on+the+pharmacokinetics+of+an+oral+contraceptive+containing+norethindrone+and+ethinyl+estradiol+in+healthy+obese+and+nonobese+female+subjects&doi=10.1046%2Fj.1528-1157.2003.55602.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects</span></div><div class="casAuthors">Doose, Dennis R.; Wang, Shean-Sheng; Padmanabhan, Mukund; Schwabe, Stefan; Jacobs, David; Bialer, Meir</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-549</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) contg. norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure.  Methods: This randomized, open-label, five-group study included two 28-day cycles.  Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2).  The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day.  Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m2.  The BMI of the remaining four groups was ≥27 kg/m2.  Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, resp., compared with OC monotherapy.  A similar nonsignificant difference was obsd. with the plasma levels and AUC values of norethindrone (p > 0.05).  CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, resp., and increased their resp. oral clearance by 69% and 127% (p < 0.05).  Because CBZ induces CUP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated.  Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC contg. norethindrone and ethinyl estradiol.  The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6SnEfgJ2eM7Vg90H21EOLACvtfcHk0lhpekMzU3lLFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFymu7o%253D&md5=64900949086ba7248ecf87b8cba150a5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1046%2Fj.1528-1157.2003.55602.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1528-1157.2003.55602.x%26sid%3Dliteratum%253Aachs%26aulast%3DDoose%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DS.%2BS.%26aulast%3DPadmanabhan%26aufirst%3DM.%26aulast%3DSchwabe%26aufirst%3DS.%26aulast%3DJacobs%26aufirst%3DD.%26aulast%3DBialer%26aufirst%3DM.%26atitle%3DEffect%2520of%2520topiramate%2520or%2520carbamazepine%2520on%2520the%2520pharmacokinetics%2520of%2520an%2520oral%2520contraceptive%2520containing%2520norethindrone%2520and%2520ethinyl%2520estradiol%2520in%2520healthy%2520obese%2520and%2520nonobese%2520female%2520subjects%26jtitle%3DEpilepsia%26date%3D2003%26volume%3D44%26issue%3D4%26spage%3D540%26epage%3D549%26doi%3D10.1046%2Fj.1528-1157.2003.55602.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Anaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span> <span> </span><span class="NLM_article-title">The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1007/s00280-011-1772-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00280-011-1772-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22057855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=563-571&issue=2&author=H.+A.+Wakeleeauthor=C.+H.+Takimotoauthor=A.+Lopez-Anayaauthor=Q.+Chuauthor=G.+Middletonauthor=D.+Dunlopauthor=R.+Ramlauauthor=N.+Leighlauthor=E.+K.+Rowinskyauthor=D.+Haoauthor=P.+Zatloukalauthor=C.+D.+Jacobsauthor=J.+Rodon&title=The+effect+of+bexarotene+on+atorvastatin+pharmacokinetics%3A+results+from+a+phase+I+trial+of+bexarotene+plus+chemotherapy+in+patients+with+advanced+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-011-1772-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Wakelee, Heather A.; Takimoto, Chris H.; Lopez-Anaya, Arturo; Chu, Quincy; Middleton, Gary; Dunlop, David; Ramlau, Rodryg; Leighl, Natasha; Rowinsky, Eric K.; Hao, Desiree; Zatloukal, Petr; Jacobs, Charlotte D.; Rodon, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">563-571</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bexarotene (Targretin capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metab.  This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate).  This trial was run in parallel with phase III trials of the combinations to det. whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.  Patients (n = 48) with advanced non-small cell lung cancer were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400 mg/m2/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5 days before chemotherapy due to hypertriglyceridemia induced by bexarotene.  Extensive plasma sampling to characterize the PK profiles of the lipid-lowering drugs, relevant chemotherapy agents was performed on day 1 (without bexarotene) and during chemotherapy cycles 2 or 3 (with bexarotene).  Here, we report the drug-drug interactions between the lipid-lowering agents and bexarotene.  Mean atorvastatin clearance and dose-cor. AUC values were reduced by nearly 50% with the addn. of concomitant bexarotene.  As fenofibrate was less effective at controlling hypertriglyceridemia, too few patients received this agent to make any meaningful conclusions about drug-drug interactions.  A drug-drug interaction was seen in this trial with bexarotene co-administration leading to a significant redn. in the AUC of atorvastatin.  The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metab. of atorvastatin.  Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprlFr1XJuh7rVg90H21EOLACvtfcHk0lg0Mi5m-sEOaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOkur4%253D&md5=d26136e814972944d57b60e0b5d80222</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1772-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1772-z%26sid%3Dliteratum%253Aachs%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DTakimoto%26aufirst%3DC.%2BH.%26aulast%3DLopez-Anaya%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DMiddleton%26aufirst%3DG.%26aulast%3DDunlop%26aufirst%3DD.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DHao%26aufirst%3DD.%26aulast%3DZatloukal%26aufirst%3DP.%26aulast%3DJacobs%26aufirst%3DC.%2BD.%26aulast%3DRodon%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520bexarotene%2520on%2520atorvastatin%2520pharmacokinetics%253A%2520results%2520from%2520a%2520phase%2520I%2520trial%2520of%2520bexarotene%2520plus%2520chemotherapy%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26issue%3D2%26spage%3D563%26epage%3D571%26doi%3D10.1007%2Fs00280-011-1772-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergis, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A. C.</span></span> <span> </span><span class="NLM_article-title">Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1097/00002030-200501280-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F00002030-200501280-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15668539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=145-152&issue=2&author=A.+D.+Kashubaauthor=C.+Tierneyauthor=G.+F.+Downeyauthor=E.+P.+Acostaauthor=E.+N.+Vergisauthor=K.+Klingmanauthor=J.+W.+Mellorsauthor=S.+H.+Eshlemanauthor=T.+R.+Scottauthor=A.+C.+Collier&title=Combining+fosamprenavir+with+lopinavir%2Fritonavir+substantially+reduces+amprenavir+and+lopinavir+exposure%3A+ACTG+protocol+A5143+results&doi=10.1097%2F00002030-200501280-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results</span></div><div class="casAuthors">Kashuba, Angela D. M.; Tierney, Camlin; Downey, Gerald F.; Acosta, Edward P.; Vergis, Emanuel N.; Klingman, Karin; Mellors, John W.; Eshleman, Susan H.; Scott, Trevor R.; Collier, Ann C.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients.  Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk.  Design: Multi-center, open-label, selectively randomized, steady-state pharmacokinetic study in HIV-infected subjects.  Methods: A planned independent interim review occurred after at least eight subjects were randomized to each arm.  Subjects received twice daily LPV/RTV 400/100 mg (arm A; n = 8); fosamprenavir/RTV 700/100 mg (arm B; n = 8) or LPV/RTV/fosamprenavir 400/100/700 mg (arm C; n = 17).  Plasma samples were collected over 12 h between study weeks 2 and 4.  Pharmacokinetic parameters were compared based on a one-sided t-test on log-transformed data with a Peto stopping boundary (P < 0.001).  Results: Amprenavir mean area under the curve over 12 h (AUC0-12 h) and concn. at 12 h (C12 h) (μg/mL) were, resp., 42.7 μg × h/mL (range, 33.1-55.1) and 2.4 μg/mL (range, 1.4-3.2) in arm B and 17.4 μg × h/mL (range, 4.6-41.3) and 0.9 μg/mL (range, 0.2-2.7) in arm C: geometric mean ratio (GMR) arm C:B was 0.36 [99.9% upper confidence boundary (UCB), 0.64] and 0.31 (99.9% h UCB, 0.61), resp. (P ≤ 0.0001).  Lopinavir AUC0-12 h and C12 h were, resp., 95.3 μg × h/mL (range, 60.3-119.3) and 6.3 μg/mL (range, 2.2-9.2) in arm A and 54.4 μg × h/mL (range, 23.5-112.2) and 3.0 μg/mL (range, 0.4-7.9) in arm C: GMR arm C:A of 0.52 (99.9% UCB, 0.89) and 0.39 (99.9% UCB, 0.98), resp. (P ≤ 0.0008).  Ritonavir exposure was not significantly different between arms.  Conclusion: APV and LPV exposures are significantly reduced using LPV/RTV/fosamprenavir, possibly increasing the risk of virol. failure.  Consequently, A5143 was closed to enrollment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDQz0DvFuoLVg90H21EOLACvtfcHk0lg0Mi5m-sEOaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCrsg%253D%253D&md5=ed835481eadb971ede34d3a22e321f8f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2F00002030-200501280-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002030-200501280-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26aulast%3DTierney%26aufirst%3DC.%26aulast%3DDowney%26aufirst%3DG.%2BF.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26aulast%3DVergis%26aufirst%3DE.%2BN.%26aulast%3DKlingman%26aufirst%3DK.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DEshleman%26aufirst%3DS.%2BH.%26aulast%3DScott%26aufirst%3DT.%2BR.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26atitle%3DCombining%2520fosamprenavir%2520with%2520lopinavir%252Fritonavir%2520substantially%2520reduces%2520amprenavir%2520and%2520lopinavir%2520exposure%253A%2520ACTG%2520protocol%2520A5143%2520results%26jtitle%3DAIDS%26date%3D2005%26volume%3D19%26issue%3D2%26spage%3D145%26epage%3D152%26doi%3D10.1097%2F00002030-200501280-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meraviglia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landonio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boreggio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzardini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, E.</span></span> <span> </span><span class="NLM_article-title">Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.phrs.2011.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21958880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=198-203&issue=2&author=D.+Cattaneoauthor=C.+Gervasoniauthor=V.+Cozziauthor=S.+Baldelliauthor=S.+Fucileauthor=P.+Meravigliaauthor=S.+Landonioauthor=G.+Boreggioauthor=G.+Rizzardiniauthor=E.+Clementi&title=Co-administration+of+raltegravir+reduces+daily+darunavir+exposure+in+HIV-1+infected+patients&doi=10.1016%2Fj.phrs.2011.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients</span></div><div class="casAuthors">Cattaneo, Dario; Gervasoni, Cristina; Cozzi, Valeria; Baldelli, Sara; Fucile, Serena; Meraviglia, Paola; Landonio, Simona; Boreggio, Gabriella; Rizzardini, Giuliano; Clementi, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved.  In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration.  The assessment of trough plasma drug concns. was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients.  No significant differences on darunavir and ritonavir plasma trough levels were obsd. between patients receiving or not raltegravir.  Co-administration of raltegravir was, however, assocd. with a 40% redn. in darunavir C max and estd. AUC0-24, as well a 60% increase in the estd. darunavir clearance compared with values measured in patients not given raltegravir.  Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir.  These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, esp. considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9U-nlzDZ4xrVg90H21EOLACvtfcHk0lg0Mi5m-sEOaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ohu7k%253D&md5=a4357037f03cc7fb35c38cb6d28c5cd6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DD.%26aulast%3DGervasoni%26aufirst%3DC.%26aulast%3DCozzi%26aufirst%3DV.%26aulast%3DBaldelli%26aufirst%3DS.%26aulast%3DFucile%26aufirst%3DS.%26aulast%3DMeraviglia%26aufirst%3DP.%26aulast%3DLandonio%26aufirst%3DS.%26aulast%3DBoreggio%26aufirst%3DG.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DClementi%26aufirst%3DE.%26atitle%3DCo-administration%2520of%2520raltegravir%2520reduces%2520daily%2520darunavir%2520exposure%2520in%2520HIV-1%2520infected%2520patients%26jtitle%3DPharmacol.%2520Res.%26date%3D2012%26volume%3D65%26issue%3D2%26spage%3D198%26epage%3D203%26doi%3D10.1016%2Fj.phrs.2011.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milazzo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridolfo, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avolio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antinori, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2014.12.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.ijantimicag.2014.12.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25769784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Oms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=545-549&issue=5&author=L.+Milazzoauthor=D.+Cattaneoauthor=E.+Calviauthor=C.+Gervasoniauthor=C.+Mazzaliauthor=P.+Ronziauthor=A.+M.+Periauthor=A.+L.+Ridolfoauthor=A.+D%E2%80%99Avolioauthor=S.+Antinori&title=Pharmacokinetic+interactions+between+telaprevir+and+antiretroviral+drugs+in+HIV%2FHCV-coinfected+patients+with+advanced+liver+fibrosis+and+prior+HCV+non-responders&doi=10.1016%2Fj.ijantimicag.2014.12.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders</span></div><div class="casAuthors">Milazzo, Laura; Cattaneo, Dario; Calvi, Elisa; Gervasoni, Cristina; Mazzali, Cristina; Ronzi, Paola; Peri, Anna Maria; Ridolfo, Anna Lisa; D'Avolio, Antonio; Antinori, Spinello</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">545-549</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Complex drug-drug interactions have been reported with concurrent administration of telaprevir (TVR) and human immunodeficiency virus (HIV) protease inhibitors (PIs), leading to relevant limitations of the therapeutic options for patients coinfected with hepatitis C virus (HCV) and HIV.  However, little is known about the pharmacokinetics and drug interactions between TVR and antiretrovirals in HIV/HCV-coinfected patients with advanced liver fibrosis.  Here we report the pharmacokinetics of TVR and antiretrovirals in a cohort of HIV/HCV genotype 1-coinfected patients with advanced liver fibrosis treated with TVR-based triple anti-HCV therapy.  No significant differences were obsd. in the pharmacokinetics of atazanavir, amprenavir or tenofovir at baseline and at Day 15 of TVR, whereas the AUC0-4 h of darunavir was 36% lower in the presence of TVR (AUC0-4 h 15 007 ng h/mL and 9563 ng h/mL at baseline and at Day 15 of TVR administration, resp.).  Noteworthy, the AUC0-4 h, Cmin and Cmax of raltegravir were reduced by 61%, 50% and 64%, resp.  However, none of the patient's plasma levels of tenofovir, atazanavir, amprenavir or raltegravir declined below their min. effective concns. even in assocn. with TVR, and no HIV treatment failure occurred.  A non-significant trend for lower TVR exposure was seen in patients concomitantly given amprenavir vs. those given atazanavir (AUC0-4 h, 9840 ng h/mL and 13 345 ng h/mL, resp.).  In conclusion, this study highlighted the feasibility of maintaining the current antiretroviral regimen in HIV/HCV-coinfected patients, even when significant interactions with TVR are predictable, whenever a change of HIV PIs is not deemed appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBEdb-gcc7rVg90H21EOLACvtfcHk0lhQvPebglpckA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Oms7o%253D&md5=c08f490621c83ff12a96c5af937b2a2a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2014.12.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2014.12.035%26sid%3Dliteratum%253Aachs%26aulast%3DMilazzo%26aufirst%3DL.%26aulast%3DCattaneo%26aufirst%3DD.%26aulast%3DCalvi%26aufirst%3DE.%26aulast%3DGervasoni%26aufirst%3DC.%26aulast%3DMazzali%26aufirst%3DC.%26aulast%3DRonzi%26aufirst%3DP.%26aulast%3DPeri%26aufirst%3DA.%2BM.%26aulast%3DRidolfo%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Avolio%26aufirst%3DA.%26aulast%3DAntinori%26aufirst%3DS.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520telaprevir%2520and%2520antiretroviral%2520drugs%2520in%2520HIV%252FHCV-coinfected%2520patients%2520with%2520advanced%2520liver%2520fibrosis%2520and%2520prior%2520HCV%2520non-responders%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2015%26volume%3D45%26issue%3D5%26spage%3D545%26epage%3D549%26doi%3D10.1016%2Fj.ijantimicag.2014.12.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulskotte, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zutven, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treitel, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngberg, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterton, J. R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1093/cid/cis968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fcid%2Fcis968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23155151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Wmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=718-726&issue=5&author=E.+G.+Hulskotteauthor=H.+P.+Fengauthor=F.+Xuanauthor=M.+G.+van+Zutvenauthor=M.+A.+Treitelauthor=E.+A.+Hughesauthor=E.+O%E2%80%99Maraauthor=S.+P.+Youngbergauthor=J.+A.+Wagnerauthor=J.+R.+Butterton&title=Pharmacokinetic+interactions+between+the+hepatitis+C+virus+protease+inhibitor+boceprevir+and+ritonavir-boosted+HIV-1+protease+inhibitors+atazanavir%2C+darunavir%2C+and+lopinavir&doi=10.1093%2Fcid%2Fcis968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir</span></div><div class="casAuthors">Hulskotte, Ellen G. J.; Feng, Hwa-Ping; Xuan, Fengjuan; van Zutven, Marga G. J. A.; Treitel, Michelle A.; Hughes, Eric A.; O'Mara, Edward; Youngberg, Stephen P.; Wagner, John A.; Butterton, Joan R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">718-726</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs.  Methods: A randomized, open-label study to assess the pharmacokinetic interactions between boceprevir and ritonavir-boosted protease inhibitors (PI/r) was conducted in 39 healthy adults.  Subjects received boceprevir (800 mg, 3 times daily) for 6 days and then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400 mg twice daily, or darunavir (DRV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant boceprevir on days 25-31.  Results: Boceprevir decreased the exposure of all PI/r, with area under the concn.-time curve [AUC] from time 0 to the time of the last measurable sample geometric mean ratios of 0.65 (90% confidence interval [CI], .55-.78) for ATV/r; 0.66 (90% CI, .60-.72) for LPV/r, and 0.56 (90% CI, .51-.61) for DRV/r.  Coadministration with boceprevir decreased RTV AUC during a dosing interval τ (AUCτ) by 22%-36%.  ATV/r did not significantly affect boceprevir exposure, but boceprevir AUCτ was reduced by 45% and 32% when coadministered with LPV/r and DRV/r, resp.  Overall, treatments were well tolerated with no unexpected adverse events.  Conclusions: Concomitant administration of boceprevir with PI/r resulted in reduced exposures of PI and boceprevir.  These drug-drug interactions may reduce the effectiveness of PI/r and/or boceprevir when coadministered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0dAeQ1vU3bVg90H21EOLACvtfcHk0lhQvPebglpckA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Wmt74%253D&md5=7ec9df4458b14c660c1f59bbdedb8c90</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis968%26sid%3Dliteratum%253Aachs%26aulast%3DHulskotte%26aufirst%3DE.%2BG.%26aulast%3DFeng%26aufirst%3DH.%2BP.%26aulast%3DXuan%26aufirst%3DF.%26aulast%3Dvan%2BZutven%26aufirst%3DM.%2BG.%26aulast%3DTreitel%26aufirst%3DM.%2BA.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DE.%26aulast%3DYoungberg%26aufirst%3DS.%2BP.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520the%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%2520boceprevir%2520and%2520ritonavir-boosted%2520HIV-1%2520protease%2520inhibitors%2520atazanavir%252C%2520darunavir%252C%2520and%2520lopinavir%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D718%26epage%3D726%26doi%3D10.1093%2Fcid%2Fcis968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roadcap, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilzer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasseter, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. D.</span></span> <span> </span><span class="NLM_article-title">Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1177/00912700122010311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F00912700122010311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11361054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvVaktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=573-581&issue=5&author=T.+Prueksaritanontauthor=J.+M.+Vegaauthor=J.+Zhaoauthor=K.+Gaglianoauthor=O.+Kuznetsovaauthor=B.+Musserauthor=R.+D.+Aminauthor=L.+Liuauthor=B.+A.+Roadcapauthor=S.+Dilzerauthor=K.+C.+Lasseterauthor=J.+D.+Rogers&title=Interactions+between+simvastatin+and+troglitazone+or+pioglitazone+in+healthy+subjects&doi=10.1177%2F00912700122010311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Vega, Jose M.; Zhao, Jamie; Gagliano, Kathleen; Kuznetsova, Olga; Musser, Bret; Amin, Raju D.; Liu, Lida; Roadcap, Brad A.; Dilzer, Stacy; Lasseter, K. C.; Rogers, J. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-581</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two randomized, two-period crossover studies were conducted to evaluate the effects of repeat oral dosing of troglitazone (Study I) and pioglitazone (Study II) on the pharmacokinetics of plasma HMG-CoA reductase inhibitors following multiple oral doses of simvastatin and of simvastatin on the plasma pharmacokinetics of troglitazone (Study I) in healthy subjects.  In both studies, each subject received two treatments.  Treatment A consisted of once-daily oral doses of troglitazone 400 mg (Study I) or pioglitazone 45 mg (Study II) for 24 days with coadministration of once-daily doses of simvastatin 40 mg (Study I) or 80 mg (Study II) on Days 15 through 24.  Treatment B consisted of once-daily oral doses of simvastatin 40 mg (Study I) or 80 mg (Study II) for 10 days.  In Study I, the area under the plasma concn.-time profiles (AUC) and max. plasma concns. (Cmax) of HMG-CoA reductase inhibitors in subjects who received both troglitazone and simvastatin were decreased modestly (by -30% for Cmax and ∼40% for AUC), but time to reach Cmax (tmax) did not change, as compared with those who received simvastatin alone.  Simvastatin, administered orally as a 40 mg tablet daily for 10 days, did not affect the AUC or tmax (p > 0.5) but caused a small but clin. insignificant increase (∼25%) in Cmax for troglitazone.  In Study II, pioglitazone, at the highest approved dose for clin. use, did not significantly alter any of the pharmacokinetic parameters (AUC, Cmax, and tmax) of simvastatin HMG-CoA reductase inhibitory activity.  For all treatment regimens, side effects were mild and transient, suggesting that coadministration of simvastatin with either troglitazone or pioglitazone was well tolerated.  The modest effect of troglitazone on simvastatin pharmacokinetics is in agreement with the suggestion that troglitazone is an inducer of CYP3A.  The insignificant effect of simvastatin on troglitazone pharmacokinetics is consistent with the conclusion that simvastatin is not a significant inhibitor for drug-metabolizing enzymes.  The lack of pharmacokinetic effect of pioglitazone on simvastatin supports the expectation that this combination may be used safely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSL5Nu3eJxLVg90H21EOLACvtfcHk0ljjj7iUjAMUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvVaktrw%253D&md5=890d0938b1e389f92ff329092a21801f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1177%2F00912700122010311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912700122010311%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGagliano%26aufirst%3DK.%26aulast%3DKuznetsova%26aufirst%3DO.%26aulast%3DMusser%26aufirst%3DB.%26aulast%3DAmin%26aufirst%3DR.%2BD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRoadcap%26aufirst%3DB.%2BA.%26aulast%3DDilzer%26aufirst%3DS.%26aulast%3DLasseter%26aufirst%3DK.%2BC.%26aulast%3DRogers%26aufirst%3DJ.%2BD.%26atitle%3DInteractions%2520between%2520simvastatin%2520and%2520troglitazone%2520or%2520pioglitazone%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D41%26issue%3D5%26spage%3D573%26epage%3D581%26doi%3D10.1177%2F00912700122010311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desar, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmer-Bonte, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Herpen, C. M.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fsj.bjc.6605777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21045832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=1637-1643&issue=11&author=I.+M.+Desarauthor=J.+N.+Timmer-Bonteauthor=D.+M.+Burgerauthor=W.+T.+van+der+Graafauthor=C.+M.+van+Herpen&title=A+phase+I+dose-escalation+study+to+evaluate+safety+and+tolerability+of+sorafenib+combined+with+sirolimus+in+patients+with+advanced+solid+cancer&doi=10.1038%2Fsj.bjc.6605777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer</span></div><div class="casAuthors">Desar, I. M. E.; Timmer-Bonte, J. N. H.; Burger, D. M.; van der Graaf, W. T. A.; van Herpen, C. M. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1637-1643</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically.  Methods: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was performed to det. the recommended dose of the combination in patients with solid tumors.  Secondary objectives were to det. the safety profile and max. tolerated dose (MTD), and to evaluate the pharmacokinetics (PK) of the combination.  Results: Dose-limiting toxicities were transaminitis and cutaneous toxicity.  The most frequently reported adverse events were elevated transaminases, hypophosphatemia, fatigue, anorexia, diarrhoea, nausea, rash and palmar-plantar erythrodysaesthesia.  Sirolimus did not change the PK of sorafenib; in contrast, sorafenib reduced the AUC(0-96) and Cmax of sirolimus.  No objective responses were obsd.; eight patients showed stable disease for a median of 16.3 wk (range 8-24).  The MTD of the combination was sorafenib 200 mg b.i.d. with sirolimus 1 mg q.d.  Conclusion: The combination of sorafenib and sirolimus showed enhanced toxicity, which could not be explained by the PK of both drugs.  The relative low doses at the MTD, in combination with the PK results, do not warrant further development of this combination.  British Journal of Cancer (2010) 103, 1637-1643. doi:10.1038/sj.bjc.6605777 www.bjcancer.com Published online 2 Nov. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsaC_41362rVg90H21EOLACvtfcHk0ljjj7iUjAMUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygsrvP&md5=d044f9072599d1b9898094582d8c80f2</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605777%26sid%3Dliteratum%253Aachs%26aulast%3DDesar%26aufirst%3DI.%2BM.%26aulast%3DTimmer-Bonte%26aufirst%3DJ.%2BN.%26aulast%3DBurger%26aufirst%3DD.%2BM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DW.%2BT.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520to%2520evaluate%2520safety%2520and%2520tolerability%2520of%2520sorafenib%2520combined%2520with%2520sirolimus%2520in%2520patients%2520with%2520advanced%2520solid%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26issue%3D11%26spage%3D1637%26epage%3D1643%26doi%3D10.1038%2Fsj.bjc.6605777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuseau, E.</span></span> <span> </span><span class="NLM_article-title">Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1167.2008.01665.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1528-1167.2008.01665.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18503564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1123-1141&issue=7&author=E.+Peruccaauthor=J.+Cloydauthor=D.+Critchleyauthor=E.+Fuseau&title=Rufinamide%3A+clinical+pharmacokinetics+and+concentration-response+relationships+in+patients+with+epilepsy&doi=10.1111%2Fj.1528-1167.2008.01665.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy</span></div><div class="casAuthors">Perucca, Emilio; Cloyd, James; Critchley, David; Fuseau, Eliane</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1123-1141</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Rufinamide is a new, orally active antiepileptic drug (AED), which has been found to be effective in the treatment of partial seizures and drop attacks assocd. with the Lennox-Gastaut syndrome.  When taken with food, rufinamide is relatively well absorbed in the lower dose range, with approx. dose-proportional plasma concns. up to 1,600 mg/day, but less than dose-proportional plasma concns. at higher doses due to reduced oral bioavailability.  Rufinamide is not extensively bound to plasma proteins.  During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.  The apparent vol. of distribution (Vd/F) and apparent oral clearance (CL/F) are related to body size, the best predictor being body surface area.  Rufinamide is not a substrate of cytochrome P 450 (CYP450) enzymes and is extensively metabolized via hydrolysis by carboxylesterases to a pharmacol. inactive carboxylic acid deriv., which is excreted in the urine.  Rufinamide pharmacokinetics are not affected by impaired renal function.  Potential differences in rufinamide pharmacokinetics between children and adults have not been investigated systematically in formal studies.  Although population pharmacokinetic modeling suggests that in the absence of interacting comedication rufinamide CL/F may be higher in children than in adults, a meaningful comparison of data across age groups is complicated by age-related differences in doses and in proportion of patients receiving drugs known to increase or to decrease rufinamide CL/F.  A study investigating the effect of rufinamide on the pharmacokinetics of the CYP3A4 substrate triazolam and an oral contraceptive interaction study showed that rufinamide has some enzyme-inducing potential in man.  Findings from population pharmacokinetic modeling indicate that rufinamide does not modify the CL/F of topiramate or valproic acid, but may slightly increase the CL/F of carbamazepine and lamotrigine and slightly decrease the CL/F of phenobarbital and phenytoin (all predicted changes were <20%).  These changes in the pharmacokinetics of assocd. AEDs are unlikely to make it necessary to change the dosages of these AEDs given concomitantly with rufinamide, with the exception that consideration should be given to reducing the dose of phenytoin.  Based on population pharmacokinetic modeling, lamotrigine, topiramate, or benzodiazepines do not affect the pharmacokinetics of rufinamide, but valproic acid may increase plasma rufinamide concns., esp. in children in whom plasma rufinamide concns. could be increased substantially.  Conversely, comedication with carbamazepine, vigabatrin, phenytoin, phenobarbital, and primidone was assocd. with a slight-to-moderate decrease in plasma rufinamide concns., ranging from a min. of -13.7% in female children comedicated with vigabatrin to a max. of -46.3% in female adults comedicated with phenytoin, phenobarbital, or primidone.  In population modeling using data from placebo-controlled trials, a pos. correlation has been identified between redn. in seizure frequency and steady-state plasma rufinamide concns.  The probability of adverse effects also appears to be concn.-related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu7yrQLFQJTrVg90H21EOLACvtfcHk0ljjj7iUjAMUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWmtLw%253D&md5=de55ebfc30ead7320da5d1125b310939</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1167.2008.01665.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1167.2008.01665.x%26sid%3Dliteratum%253Aachs%26aulast%3DPerucca%26aufirst%3DE.%26aulast%3DCloyd%26aufirst%3DJ.%26aulast%3DCritchley%26aufirst%3DD.%26aulast%3DFuseau%26aufirst%3DE.%26atitle%3DRufinamide%253A%2520clinical%2520pharmacokinetics%2520and%2520concentration-response%2520relationships%2520in%2520patients%2520with%2520epilepsy%26jtitle%3DEpilepsia%26date%3D2008%26volume%3D49%26issue%3D7%26spage%3D1123%26epage%3D1141%26doi%3D10.1111%2Fj.1528-1167.2008.01665.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommadossi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusek, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>179</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1086/314703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1086%2F314703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10191212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFKgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1999&pages=1116-1123&issue=5&author=R.+L.+Murphyauthor=J.+P.+Sommadossiauthor=M.+Lamsonauthor=D.+B.+Hallauthor=M.+Myersauthor=A.+Dusek&title=Antiviral+effect+and+pharmacokinetic+interaction+between+nevirapine+and+indinavir+in+persons+infected+with+human+immunodeficiency+virus+type+1&doi=10.1086%2F314703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1</span></div><div class="casAuthors">Murphy, Robert L.; Sommadossi, Jean-Pierre; Lamson, Michael; Hall, David B.; Myers, Maureen; Dusek, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1116-1123</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Nevirapine and indinavir have the potential of affecting the pharmacokinetics of each other.  In a prospective trial, 24 human immunodeficiency virus (HIV)-infected subjects on stable nucleoside or no therapy were treated with 800 mg of indinavir every 8 h.  After 7 days, 200 mg of nevirapine a day was added for 14 days and then increased to 200 mg twice a day.  At day 7 (before nevirapine), there was a sevenfold difference among the subjects in indinavir area under the curve (AUC), and there was a significant correlation between indinavir AUC (r2 = 0.378, P =.019), min. plasma concn. (Cmin; r2 = 0.359, P =.023), max. plasma concn. (Cmax; r2 = 0.340, P =.028), and plasma HIV RNA decline.  Nevirapine significantly reduced median indinavir Cmin (47.5%) and AUC (27.4%) and, to a lesser extent, Cmax (11%).  Plasma HIV RNA values were ≤20 copies/mL in 10 of 17 (58.8%) subjects at 58 wk or last visit.  These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkg36iAGYlrrVg90H21EOLACvtfcHk0lhBXvawHXuF2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFKgt7Y%253D&md5=0b19bb4c5f6fc267d8905d222595124d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1086%2F314703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F314703%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BL.%26aulast%3DSommadossi%26aufirst%3DJ.%2BP.%26aulast%3DLamson%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BB.%26aulast%3DMyers%26aufirst%3DM.%26aulast%3DDusek%26aufirst%3DA.%26atitle%3DAntiviral%2520effect%2520and%2520pharmacokinetic%2520interaction%2520between%2520nevirapine%2520and%2520indinavir%2520in%2520persons%2520infected%2520with%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D1999%26volume%3D179%26issue%3D5%26spage%3D1116%26epage%3D1123%26doi%3D10.1086%2F314703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aviles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matti
Vehaskari, V.</span></span> <span> </span><span class="NLM_article-title">Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients</span>. <i>Pediatr. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3046.2005.00263.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1399-3046.2005.00263.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15787787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVGhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=162-169&issue=2&author=J.+S.+Kimauthor=D.+H.+Avilesauthor=D.+M.+Silversteinauthor=P.+L.+Leblancauthor=V.+Matti%0AVehaskari&title=Effect+of+age%2C+ethnicity%2C+and+glucocorticoid+use+on+tacrolimus+pharmacokinetics+in+pediatric+renal+transplant+patients&doi=10.1111%2Fj.1399-3046.2005.00263.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients</span></div><div class="casAuthors">Kim, Jung Sue; Aviles, Diego H.; Silverstein, Douglas M.; LeBlanc, Pamela L.; Vehaskari, V. Matti</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Transplantation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">PETRF6</span>;
        ISSN:<span class="NLM_cas:issn">1397-3142</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Tacrolimus has become an effective alternative to cyclosporine as a component of primary immunosuppression in pediatric renal transplant patients, but the information on the pharmacokinetic characteristics of tacrolimus in young patients is still limited.  The primary objective of this study was to det. the effect of patient age, ethnicity, and concurrent steroid administration on tacrolimus pharmacokinetics in pediatric renal transplant patients.  The study population consisted of 30 pediatric patients, age 1.5-18.6 yr, who received a kidney transplant between July 1999 and Feb. 2004.  After twice daily dosing was stabilized based on clin. judgment, at least 5 days postoperatively, tacrolimus levels were drawn prior to, and 1, 2, 4, 8, and 12 h after the morning dose.  The mean dose of tacrolimus was 0.12 mg/kg/dose.  Mean trough level was 11.9 ± 5.0 ng/mL.  Mean area under the curve (AUC) was 192 ± 84 with a range of 78-360 h × (ng/mL).  The correlation between trough level and AUC was only fair (r = 0.74); later time points correlated better with AUC, and an excellent correlation (r = 0.96) was obtained between the mean of trough and 2-h level (C2) and AUC.  There was a neg. correlation between age and dose per body wt. (r = -0.68).  African-American patients had marginally lower drug exposure with similar dosing.  Three age groups (<5, 5-12, and > 12 yr) were compared with respect to dosing and AUC.  Despite similar AUC in all three groups, the mean dose per kg required to achieve the AUC was 2.7- and 1.9-fold higher in the <5 and 5-12-yr groups, resp., compared with the > 12-yr group.  Nine of the 30 patients were on a totally steroid-free regimen.  Their tacrolimus dose and trough levels were similar to those of steroid-exposed patients, but their mean AUC was 41% higher.  Our results show an inverse correlation between age and required tacrolimus dose, wide interindividual variation, and greater exposure with steroid-free regimen despite no change in trough level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4y7wCTJDA7Vg90H21EOLACvtfcHk0lhBXvawHXuF2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVGhtb0%253D&md5=8beda4598949ade638687ff5a2e427b3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3046.2005.00263.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3046.2005.00263.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DAviles%26aufirst%3DD.%2BH.%26aulast%3DSilverstein%26aufirst%3DD.%2BM.%26aulast%3DLeblanc%26aufirst%3DP.%2BL.%26aulast%3DMatti%2BVehaskari%26aufirst%3DV.%26atitle%3DEffect%2520of%2520age%252C%2520ethnicity%252C%2520and%2520glucocorticoid%2520use%2520on%2520tacrolimus%2520pharmacokinetics%2520in%2520pediatric%2520renal%2520transplant%2520patients%26jtitle%3DPediatr.%2520Transplant.%26date%3D2005%26volume%3D9%26issue%3D2%26spage%3D162%26epage%3D169%26doi%3D10.1111%2Fj.1399-3046.2005.00263.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1002/med.21648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fmed.21648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31782213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlantbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=1061-1083&issue=3&author=S.+C.+Chaiauthor=W.+C.+Wrightauthor=T.+Chen&title=Strategies+for+developing+pregnane+X+receptor+antagonists%3A+Implications+from+metabolism+to+cancer&doi=10.1002%2Fmed.21648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer</span></div><div class="casAuthors">Chai, Sergio C.; Wright, William C.; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1061-1083</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Pregnane X receptor (PXR) is a ligand-activated nuclear receptor (NR) that was originally identified as a master regulator of xenobiotic detoxification.  It regulates the expression of drug-metabolizing enzymes and transporters to control the degrdn. and excretion of endobiotics and xenobiotics, including therapeutic agents.  The metab. and disposition of drugs might compromise their efficacy and possibly cause drug toxicity and/or drug resistance.  Because many drugs can promiscuously bind and activate PXR, PXR antagonists might have therapeutic value in preventing and overcoming drug-induced PXR-mediated drug toxicity and drug resistance.  Furthermore, PXR is now known to have broader cellular functions, including the regulation of cell proliferation, and glucose and lipid metab.  Thus, PXR might be involved in human diseases such as cancer and metabolic diseases.  This review focuses on the development of PXR antagonists, which has been hampered by the promiscuity of PXR ligand binding.  However, substantial progress has been made in recent years, suggesting that it is feasible to develop selective PXR antagonists.  We discuss the current status, challenges, and strategies in developing selective PXR antagonists.  The strategies are based on the mol. mechanisms of antagonism in related NRs that can be applied to the design of PXR antagonists, primarily driven by structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmoMgI_jgLdrVg90H21EOLACvtfcHk0lhBXvawHXuF2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlantbk%253D&md5=2dae3977e2e2b600441e4e0ffff6a21e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fmed.21648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21648%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DWright%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520developing%2520pregnane%2520X%2520receptor%2520antagonists%253A%2520Implications%2520from%2520metabolism%2520to%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26issue%3D3%26spage%3D1061%26epage%3D1083%26doi%3D10.1002%2Fmed.21648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koibuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, Y.</span></span> <span> </span><span class="NLM_article-title">Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">32453</span>– <span class="NLM_lpage">32458</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111245200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M111245200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12072427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32453-32458&issue=36&author=A.+Takeshitaauthor=M.+Taguchiauthor=N.+Koibuchiauthor=Y.+Ozawa&title=Putative+role+of+the+orphan+nuclear+receptor+SXR+%28steroid+and+xenobiotic+receptor%29+in+the+mechanism+of+CYP3A4+inhibition+by+xenobiotics&doi=10.1074%2Fjbc.M111245200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition of xenobiotics</span></div><div class="casAuthors">Takeshita, Akira; Taguchi, Manabu; Koubuchi, Noriyuki; Ozawa, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">32453-32458</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the metab. of endogenous steroids and drugs in liver.  Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter. Conversely, it is not known whether SXR mediates the transcriptional repression. We thus examd. transcriptional repression of SXR and its interaction with corepressors, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) using reporter assays in the absence and presence of ligand.  Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.  Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1.  On the other hand, the anti-fungal agent ketoconazole decreased XSR interaction with both SRC-1 and sMRT.  Ketoconazole partially inhibited corticosterone-induced SXR-mediated transcription on the CYP3A4 promoter.  Taken together, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription.  Further, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8my6zcHy4z7Vg90H21EOLACvtfcHk0lhQbaSAL8qFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVWhsb0%253D&md5=1989e2742d9fc6b1bceb24b2791f0bdc</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111245200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111245200%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DTaguchi%26aufirst%3DM.%26aulast%3DKoibuchi%26aufirst%3DN.%26aulast%3DOzawa%26aufirst%3DY.%26atitle%3DPutative%2520role%2520of%2520the%2520orphan%2520nuclear%2520receptor%2520SXR%2520%2528steroid%2520and%2520xenobiotic%2520receptor%2529%2520in%2520the%2520mechanism%2520of%2520CYP3A4%2520inhibition%2520by%2520xenobiotics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D36%26spage%3D32453%26epage%3D32458%26doi%3D10.1074%2Fjbc.M111245200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span> <span> </span><span class="NLM_article-title">Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">592</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1124/mol.107.038398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.107.038398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17576789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=592-603&issue=3&author=S.+Ekinsauthor=C.+Changauthor=S.+Maniauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+Iyerauthor=V.+Kholodovychauthor=N.+Aiauthor=W.+J.+Welshauthor=M.+Sinzauthor=P.+W.+Swaanauthor=R.+Patelauthor=K.+Bachmann&title=Human+pregnane+X+receptor+antagonists+and+agonists+define+molecular+requirements+for+different+binding+sites&doi=10.1124%2Fmol.107.038398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites</span></div><div class="casAuthors">Ekins, Sean; Chang, Cheng; Mani, Sridhar; Krasowski, Matthew D.; Reschly, Erica J.; Iyer, Manisha; Kholodovych, Vladyslav; Ai, Ni; Welsh, William J.; Sinz, Michael; Swaan, Peter W.; Patel, Rachana; Bachmann, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">592-603</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metab. and transporter genes.  The receptor is promiscuous, binding many structural classes of mols. that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metab. and excretion of therapeutic agents, and causing drug-drug interactions.  It has been suggested that human PXR antagonists represent a means to counteract such interactions.  Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain.  In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse mols. with exptl. PXR agonist binding data.  We have addnl. defined a novel pharmacophore for the steroidal agonist site.  All agonist pharmacophores showed that hydrophobic features are predominant.  In contrast, a qual. comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features.  Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping.  Combining computational and exptl. data for different classes of mols. provided strong evidence for agonists and antagonists binding distinct regions on PXR.  These observations bear significant implications for future discovery of mols. that are more selective and potent antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4MHwW1VExI7Vg90H21EOLACvtfcHk0lhQbaSAL8qFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfO&md5=0a47c81ca4be5d3d6b1af2c455245819</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.038398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.038398%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DIyer%26aufirst%3DM.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DBachmann%26aufirst%3DK.%26atitle%3DHuman%2520pregnane%2520X%2520receptor%2520antagonists%2520and%2520agonists%2520define%2520molecular%2520requirements%2520for%2520different%2520binding%2520sites%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D592%26epage%3D603%26doi%3D10.1124%2Fmol.107.038398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Computational discovery of novel low micromolar human pregnane X receptor antagonists</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1124/mol.108.049437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.108.049437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18579710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVClt7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=662-672&issue=3&author=S.+Ekinsauthor=V.+Kholodovychauthor=N.+Aiauthor=M.+Sinzauthor=J.+Galauthor=L.+Geraauthor=W.+J.+Welshauthor=K.+Bachmannauthor=S.+Mani&title=Computational+discovery+of+novel+low+micromolar+human+pregnane+X+receptor+antagonists&doi=10.1124%2Fmol.108.049437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Computational discovery of novel low micromolar human pregnane X receptor antagonists</span></div><div class="casAuthors">Ekins, Sean; Kholodovych, Vladyslav; Ai, Ni; Sinz, Michael; Gal, Joseph; Gera, Lajos; Welsh, William J.; Bachmann, Kenneth; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">662-672</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Very few antagonists have been identified for the human pregnane X receptor (PXR).  These mols. may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compds. and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metab. and transporter genes.  A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features.  This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies.  Using computational approaches to search libraries of known drugs or com. available mols. is preferred over random screening.  The authors have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3',5-dimethyl-3,5'-biisoxazole-4'-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)].  The authors have also used the computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain.  The involvement of this domain was also suggested by further site-directed mutagenesis work.  The authors have addnl. described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro.  These observations are important for predicting whether further mols. may interact with PXR as antagonists in vivo with potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeljCOyj4ubVg90H21EOLACvtfcHk0lhQbaSAL8qFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVClt7jK&md5=a34d583b7283fb5e6c367e26edb91c68</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049437%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DGal%26aufirst%3DJ.%26aulast%3DGera%26aufirst%3DL.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DBachmann%26aufirst%3DK.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DComputational%2520discovery%2520of%2520novel%2520low%2520micromolar%2520human%2520pregnane%2520X%2520receptor%2520antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26issue%3D3%26spage%3D662%26epage%3D672%26doi%3D10.1124%2Fmol.108.049437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoeckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalpana, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fsj.onc.1209788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16819505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=258-268&issue=2&author=H.+Huangauthor=H.+Wangauthor=M.+Sinzauthor=M.+Zoecklerauthor=J.+Staudingerauthor=M.+R.+Redinboauthor=D.+G.+Teoticoauthor=J.+Lockerauthor=G.+V.+Kalpanaauthor=S.+Mani&title=Inhibition+of+drug+metabolism+by+blocking+the+activation+of+nuclear+receptors+by+ketoconazole&doi=10.1038%2Fsj.onc.1209788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole</span></div><div class="casAuthors">Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-268</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Individual variation in drug metab. is a major cause of unpredictable side effects during therapy.  Drug metab. is controlled by a class of orphan nuclear receptors (NRs), which regulate expression of genes such as CYP (cytochrome)3A4 and MDR-1 (multi-drug resistance-1), that are involved in this process.  We have found that xenobiotic-mediated induction of CYP3A4 and MDR-1 gene transcription was inhibited by ketoconazole, a commonly used antifungal drug.  Ketoconazole mediated its effect by inhibiting the activation of NRs, human pregnenolone X receptor and constitutive androstene receptor, involved in regulation of CYP3A4 and MDR-1.  The effect of ketoconazole was specific to the group of NRs that control xenobiotic metab.  Ketoconazole disrupted the interaction of the xenobiotic receptor PXR with the co-activator steroid receptor co-activator-1.  Ketoconazole treatment resulted in delayed metab. of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins.  These studies demonstrate for the first time that ketoconazole represses the coordinated activation of genes involved in drug metab., by blocking activation of a specific subset of NRs.  Our results suggest that ketoconazole can be used as a pan-antagonist of NRs involved in xenobiotic metab. in vivo, which may lead to novel strategies that improve drug effect and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZEHj1LOG88LVg90H21EOLACvtfcHk0liGaShrmS0lwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFOltw%253D%253D&md5=efc15e866bab4deae25bb301cb002b8b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209788%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DStaudinger%26aufirst%3DJ.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DLocker%26aufirst%3DJ.%26aulast%3DKalpana%26aufirst%3DG.%2BV.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520drug%2520metabolism%2520by%2520blocking%2520the%2520activation%2520of%2520nuclear%2520receptors%2520by%2520ketoconazole%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D2%26spage%3D258%26epage%3D268%26doi%3D10.1038%2Fsj.onc.1209788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalpana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Activated pregnenolone X-receptor is a target for ketoconazole and its analogs</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1158%2F1078-0432.CCR-06-1592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17438109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1emsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2488-2495&issue=8&author=H.+Wangauthor=H.+Huangauthor=H.+Liauthor=D.+G.+Teoticoauthor=M.+Sinzauthor=S.+D.+Bakerauthor=J.+Staudingerauthor=G.+Kalpanaauthor=M.+R.+Redinboauthor=S.+Mani&title=Activated+pregnenolone+X-receptor+is+a+target+for+ketoconazole+and+its+analogs&doi=10.1158%2F1078-0432.CCR-06-1592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Activated pregnenolone X-receptor is a target for ketoconazole and its analogs</span></div><div class="casAuthors">Wang, Hongwei; Huang, Haiyan; Li, Hao; Teotico, Denise G.; Sinz, Michael; Baker, Sharyn D.; Staudinger, Jeffrey; Kalpana, Ganjam; Redinbo, Matthew R.; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2488-2495</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Variations in biotransformation and elimination of microtubule-binding drugs are a major cause of unpredictable side effects during cancer therapy.  Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.  In vitro RNA-, protein-, and transcription-based assays in multiple cell lines derived from hepatocytes and PXR wild-type and null mouse studies were employed to show the effects of ketoconazole and its analogs on ligand-activated PXR-mediated gene transcription and translation.  The transcriptional activation of genes regulating biotransformation and transport by the liganded human nuclear xenobiotic receptor, PXR, was inhibited by the commonly used antifungal ketoconazole and related azole analogs.  Mutations at the AF-2 surface of the human PXR ligand-binding domain indicate that ketoconazole may interact with specific residues outside the ligand-binding pocket.  Furthermore, in contrast to that obsd. in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel.  These studies show that some azole compds. repress the coordinated activation of genes involved in drug metab. by blocking PXR activation.  Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogs may also serve to preserve paclitaxel blood levels on chronic dosing of drugs.  The observations may facilitate new strategies to improve the clin. efficacy of drugs and to reduce therapeutic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBWhTciBBQp7Vg90H21EOLACvtfcHk0liGaShrmS0lwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1emsrw%253D&md5=debab3778111b68a24d3d0912132ecd2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1592%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DStaudinger%26aufirst%3DJ.%26aulast%3DKalpana%26aufirst%3DG.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DActivated%2520pregnenolone%2520X-receptor%2520is%2520a%2520target%2520for%2520ketoconazole%2520and%2520its%2520analogs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D8%26spage%3D2488%26epage%3D2495%26doi%3D10.1158%2F1078-0432.CCR-06-1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvail, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.111.071787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21464197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=124-135&issue=1&author=M.+Venkateshauthor=H.+Wangauthor=J.+Cayerauthor=M.+Lerouxauthor=D.+Salvailauthor=B.+Dasauthor=J.+E.+Wrobelauthor=S.+Mani&title=In+vivo+and+in+vitro+characterization+of+a+first-in-class+novel+azole+analog+that+targets+pregnane+X+receptor+activation&doi=10.1124%2Fmol.111.071787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation</span></div><div class="casAuthors">Venkatesh, Madhukumar; Wang, Hongwei; Cayer, Julie; Leroux, Melissa; Salvail, Dany; Das, Bhaskar; Wrobel, Jay E.; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">124-135</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a master regulator of xenobiotic clearance and is implicated in deleterious drug interactions (e.g., acetaminophen hepatotoxicity) and cancer drug resistance.  However, small-mol. targeting of this receptor has been difficult; to date, directed synthesis of a relatively specific PXR inhibitor has remained elusive.  Here we report the development and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(2,4-difluorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethanone (FLB-12)] that antagonizes the activated state of PXR with limited effects on other related nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor α, peroxisome proliferator-activated receptor γ, and mouse constitutive androstane receptor).  We investigated the toxicity and PXR antagonist effect of FLB-12 in vivo.  Compared with ketoconazole, a prototypical PXR antagonist, FLB-12 is significantly less toxic to hepatocytes.  FLB-12 significantly inhibits the PXR-activated loss of righting reflex to 2,2,2-tribromoethanol (Avertin) in vivo, abrogates PXR-mediated resistance to 7-ethyl-10-hydroxycamptothecin (SN-38) in colon cancer cells in vitro, and attenuates PXR-mediated acetaminophen hepatotoxicity in vivo.  Thus, relatively selective targeting of PXR by antagonists is feasible and warrants further investigation.  This class of agents is suitable for development as chem. probes of PXR function as well as potential PXR-directed therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKnTEY7zfXbVg90H21EOLACvtfcHk0lhL_2ZgzNe62Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFajt7c%253D&md5=7839fb7bcb50ca6aa0199f8bc4431f2b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071787%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCayer%26aufirst%3DJ.%26aulast%3DLeroux%26aufirst%3DM.%26aulast%3DSalvail%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DWrobel%26aufirst%3DJ.%2BE.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520characterization%2520of%2520a%2520first-in-class%2520novel%2520azole%2520analog%2520that%2520targets%2520pregnane%2520X%2520receptor%2520activation%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D1%26spage%3D124%26epage%3D135%26doi%3D10.1124%2Fmol.111.071787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">SPA70 is a potent antagonist of human pregnane X receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">741</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00780-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fs41467-017-00780-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28963450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FjvVGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=741&author=W.+Linauthor=Y.+M.+Wangauthor=S.+C.+Chaiauthor=L.+Lvauthor=J.+Zhengauthor=J.+Wuauthor=Q.+Zhangauthor=Y.+D.+Wangauthor=P.+R.+Griffinauthor=T.+Chen&title=SPA70+is+a+potent+antagonist+of+human+pregnane+X+receptor&doi=10.1038%2Fs41467-017-00780-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">SPA70 is a potent antagonist of human pregnane X receptor</span></div><div class="casAuthors">Lin Wenwei; Wang Yue-Ming; Chai Sergio C; Wu Jing; Chen Taosheng; Lv Lili; Zhang Qijun; Zheng Jie; Griffin Patrick R; Wang Yong-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">741</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many drugs bind to and activate human pregnane X receptor (hPXR) to upregulate drug-metabolizing enzymes, resulting in decreased drug efficacy and increased resistance.  This suggests that hPXR antagonists have therapeutic value.  Here we report that SPA70 is a potent and selective hPXR antagonist.  SPA70 inhibits hPXR in human hepatocytes and humanized mouse models and enhances the chemosensitivity of cancer cells, consistent with the role of hPXR in drug resistance.  Unexpectedly, SJB7, a close analog of SPA70, is an hPXR agonist.  X-ray crystallography reveals that SJB7 resides in the ligand-binding domain (LBD) of hPXR, interacting with the AF-2 helix to stabilize the LBD for coactivator binding.  Differential hydrogen/deuterium exchange analysis demonstrates that SPA70 and SJB7 interact with the hPXR LBD.  Docking studies suggest that the lack of the para-methoxy group in SPA70 compromises its interaction with the AF-2, thus explaining its antagonism.  SPA70 is an hPXR antagonist and promising therapeutic tool.The xenobiotic-activated human pregnane X receptor (hPXR) regulates drug metabolism.  Here the authors develop hPXR modulators, which are of potential therapeutic interest and functionally and structurally characterize the antagonist SPA70 and the structurally related agonist SJB7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKzRlR5ipxKZotVjB3IRIyfW6udTcc2ebt-J3snwsR_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FjvVGhsQ%253D%253D&md5=e337c9ea0bacbf140ad9e899dd0eb264</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00780-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00780-5%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DSPA70%2520is%2520a%2520potent%2520antagonist%2520of%2520human%2520pregnane%2520X%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D741%26doi%3D10.1038%2Fs41467-017-00780-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5332</span>– <span class="NLM_lpage">5340</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1158%2F1078-0432.CCR-08-1033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18765524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5332-5340&issue=17&author=D.+Guptaauthor=M.+Venkateshauthor=H.+Wangauthor=S.+Kimauthor=M.+Sinzauthor=G.+L.+Goldbergauthor=K.+Whitneyauthor=C.+Longleyauthor=S.+Mani&title=Expanding+the+roles+for+pregnane+X+receptor+in+cancer%3A+proliferation+and+drug+resistance+in+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-08-1033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer</span></div><div class="casAuthors">Gupta, Divya; Venkatesh, Madhukumar; Wang, Hongwei; Kim, Sean; Sinz, Michael; Goldberg, Gary L.; Whitney, Kathleen; Longley, Clifford; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5332-5340</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We examd. the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand.  SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quant. reverse transcription-PCR and Western blot.  Human ovarian cancer tissue was also analyzed for PXR expression by immunochem.  Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quant. reverse transcription-PCR.  SKOV-3 cell proliferation was assessed by MTT assay.  In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts.  PXR is expressed in ovarian cancer cells.  In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2.  PXR activation in SKOV-3 cells induces cell proliferation and drug resistance.  In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth.  PXR activation, regardless of the type of ligand agonist present, promotes the "malignant" phenotype of cancer cells.  These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUEdc9ePco7Vg90H21EOLACvtfcHk0lgez8wUTUHMjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsb3M&md5=b55a327dd9111dd3065bb153ccf97e92</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1033%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DG.%2BL.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DExpanding%2520the%2520roles%2520for%2520pregnane%2520X%2520receptor%2520in%2520cancer%253A%2520proliferation%2520and%2520drug%2520resistance%2520in%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D17%26spage%3D5332%26epage%3D5340%26doi%3D10.1158%2F1078-0432.CCR-08-1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rigalli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocchetti, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold-Mende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span> <span> </span><span class="NLM_article-title">The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e0193242</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0193242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0193242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29470550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12qtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=2&author=J.+P.+Rigalliauthor=M.+Reichelauthor=T.+Reuterauthor=G.+N.+Tocchettiauthor=G.+Dyckhoffauthor=C.+Herold-Mendeauthor=D.+Theileauthor=J.+Weiss&title=The+pregnane+X+receptor+%28PXR%29+and+the+nuclear+receptor+corepressor+2+%28NCoR2%29+modulate+cell+growth+in+head+and+neck+squamous+cell+carcinoma&doi=10.1371%2Fjournal.pone.0193242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Rigalli, Juan Pablo; Reichel, Matthias; Reuter, Tasmin; Tocchetti, Guillermo Nicolas; Dyckhoff, Gerhard; Herold-Mende, Christel; Theile, Dirk; Weiss, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0193242/1-e0193242/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide.  The pregnane X receptor (PXR) is a nuclear receptor regulating several target genes assocd. with cancer malignancy.  We here demonstrated a significant effect of PXR on HNSCC cell growth, as evidenced in PXR knock-down expts.  PXR transcriptional activity is more importantly regulated by the presence of coactivators and corepressors than by PXR protein expression.  To date, there is scarce information on the regulation of PXR in HNSCC and on its role in the pathogenesis of this disease.  Coactivator and corepressor expression was screened through qRT-PCR in 8 HNSCC cell lines and correlated to PXR activity, detd. by using a reporter gene assay.  All cell lines considerably expressed all the cofactors assessed.  PXR activity neg. correlated with nuclear receptor corepressor 2 (NCoR2) expression, indicating a major role of this corepressor in PXR modulation and suggesting its potential as a surrogate for PXR activity in HNSCC.  To test the assocn. of NCoR2 with the malignant phenotype, a subset of three cell lines was transfected with an over-expression plasmid for this corepressor.  Subsequently, cell growth and chemoresistance assays were performed.  To elucidate the mechanisms underlying NCoR2 effects on cell growth, caspase 3/7 activity and protein levels of cleaved caspase 3 and PARP were evaluated.  In HNO97 cells, NCoR2 over-expression decreased cell growth, chemoresistance and increased cleaved caspase 3 levels, caspase activity and cleaved PARP levels.  On the contrary, in HNO124 and HNO210 cells, NCoR2 over-expression increased cell growth, drug resistance and decreased cleaved caspase 3 levels, caspase activity and cleaved PARP levels.  In conclusion, we demonstrated a role of PXR and NCoR2 in the modulation of cell growth in HNSCC.  This may contribute to a better understanding of the highly variable HNSCC therapeutic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GBIiOo3b07Vg90H21EOLACvtfcHk0lgez8wUTUHMjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12qtrnK&md5=d5713cab5808d1f9970e6a315c0cedc3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0193242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0193242%26sid%3Dliteratum%253Aachs%26aulast%3DRigalli%26aufirst%3DJ.%2BP.%26aulast%3DReichel%26aufirst%3DM.%26aulast%3DReuter%26aufirst%3DT.%26aulast%3DTocchetti%26aufirst%3DG.%2BN.%26aulast%3DDyckhoff%26aufirst%3DG.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DJ.%26atitle%3DThe%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520and%2520the%2520nuclear%2520receptor%2520corepressor%25202%2520%2528NCoR2%2529%2520modulate%2520cell%2520growth%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D2%26doi%3D10.1371%2Fjournal.pone.0193242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veech, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelboin, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span> <span> </span><span class="NLM_article-title">Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1210/mend-1-8-542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fmend-1-8-542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=3153476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL1cXjsFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1987&pages=542-547&issue=8&author=B.+J.+Songauthor=T.+Matsunagaauthor=J.+P.+Hardwickauthor=S.+S.+Parkauthor=R.+L.+Veechauthor=C.+S.+Yangauthor=H.+V.+Gelboinauthor=F.+J.+Gonzalez&title=Stabilization+of+cytochrome+P450j+messenger+ribonucleic+acid+in+the+diabetic+rat&doi=10.1210%2Fmend-1-8-542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat</span></div><div class="casAuthors">Song, Byung J.; Matsunaga, Tamihide; Hardwick, James P.; Park, Sang S.; Veech, Richard L.; Yang, Chung S.; Gelboin, Harry V.; Gonzalez, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">542-7</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    </div><div class="casAbstract">In streptozotocin-diabetic rats, marked increases in both cytochrome P 450j and its mRNA were obsd. in liver, lung, and kidney.  The increases in P 450j mRNA were due to specific mRNA stabilization, a mechanism which is clearly distinct from the induction mechanism elicited by either acetone or ethanol administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo53DtN2wFybVg90H21EOLACvtfcHk0lgez8wUTUHMjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXjsFOkuw%253D%253D&md5=968d99149e2cd9b2468fcb2a67ce3923</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1210%2Fmend-1-8-542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend-1-8-542%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DB.%2BJ.%26aulast%3DMatsunaga%26aufirst%3DT.%26aulast%3DHardwick%26aufirst%3DJ.%2BP.%26aulast%3DPark%26aufirst%3DS.%2BS.%26aulast%3DVeech%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BS.%26aulast%3DGelboin%26aufirst%3DH.%2BV.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26atitle%3DStabilization%2520of%2520cytochrome%2520P450j%2520messenger%2520ribonucleic%2520acid%2520in%2520the%2520diabetic%2520rat%26jtitle%3DMol.%2520Endocrinol.%26date%3D1987%26volume%3D1%26issue%3D8%26spage%3D542%26epage%3D547%26doi%3D10.1210%2Fmend-1-8-542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrighton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)84558-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0021-9258%2819%2984558-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=3486184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL28Xit1altLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=6264-2671&issue=14&author=P.+B.+Watkinsauthor=S.+A.+Wrightonauthor=E.+G.+Schuetzauthor=P.+Maurelauthor=P.+S.+Guzelian&title=Macrolide+antibiotics+inhibit+the+degradation+of+the+glucocorticoid-responsive+cytochrome+P-450p+in+rat+hepatocytes+in+vivo+and+in+primary+monolayer+culture&doi=10.1016%2FS0021-9258%2819%2984558-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture</span></div><div class="casAuthors">Watkins, Paul B.; Wrighton, Steven A.; Schuetz, Erin G.; Maurel, Patrick; Guzelian, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6264-71</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">To investigate the mechanism of induction of cytochrome P-450p, rats were treated for 4 days with the macrolide antibiotic triacetyloleandomycin (TAO) and dexamethasone (I).  I and TAO induced the synthesis of P-450p ≤70- and 35-fold over control values, resp., as estd. from measurements of P-450p mRNA translatable in a cell-free system.  However, the accumulation of P-450p holocytochrome (measured as the TAO-metabolite spectral complex) or P-450p protein (measured by quant. immunoblotting) was increased ≤150-fold by TAO but only 32-fold by I.  The possibility that TAO decreases the degrdn. of P-450p was supported by the observation that administration of TAO to I-treated rats labeled with NaH14CO3 and δ-[3H]aminolevulinic acid retarded the decay of radioactive immunoprecipitable P-450p protein (half-time = 60 vs. 14 h) and heme = 73 vs. 10 h).  To confirm these results, P-450p protein synthesis was measured as radioactivity incorporated into immunoprecipitable P-450p in primary monolayer cultures of adult rat hepatocytes incubated with [3H]leucine.  I treatment of the cultures stimulated P-450p synthesis by ≤30-fold, whereas macrolides were without effect.  However, macrolide antibiotics but not I inhibited the disappearance of radiolabeled P-450p from cultured hepatocytes similar to the results obtained in vivo.  Thus, macrolide antibiotics induced P-450p, the most rapidly turning over cytochrome yet reported by stimulating its synthesis indirectly and by blocking its degrdn. significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_PjmI9eH0rVg90H21EOLACvtfcHk0lj2hzhxn6j6nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xit1altLk%253D&md5=fab2afd10b0e3d3a5c3176bbb829a754</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2984558-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252984558-1%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DMaurel%26aufirst%3DP.%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26atitle%3DMacrolide%2520antibiotics%2520inhibit%2520the%2520degradation%2520of%2520the%2520glucocorticoid-responsive%2520cytochrome%2520P-450p%2520in%2520rat%2520hepatocytes%2520in%2520vivo%2520and%2520in%2520primary%2520monolayer%2520culture%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26issue%3D14%26spage%3D6264%26epage%3D2671%26doi%3D10.1016%2FS0021-9258%2819%2984558-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2010.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.addr.2010.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20727377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGitr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=1238-1249&issue=13&author=A.+H.+Tolsonauthor=H.+Wang&title=Regulation+of+drug-metabolizing+enzymes+by+xenobiotic+receptors%3A+PXR+and+CAR&doi=10.1016%2Fj.addr.2010.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR</span></div><div class="casAuthors">Tolson, Antonia H.; Wang, Hongbing</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug-metabolizing enzymes (DMEs) and transporters play pivotal roles in the disposition and detoxification of numerous foreign and endogenous chems.  To accommodate chem. challenges, the expression of many DMEs and transporters is up-regulated by a group of ligand-activated transcription factors namely nuclear receptors (NRs).  The importance of NRs in xenobiotic metab. and clearance is best exemplified by the most promiscuous xenobiotic receptors: pregnane X receptor (PXR, NR1I2) and constitutive androstane/activated receptor (CAR, NR1I3).  Together, these 2 receptors govern the inductive expression of a largely overlapping array of target genes encoding phase I and II DMEs, and drug transporters.  Moreover, PXR and CAR also represent 2 distinctive mechanisms of NR activation, whereby CAR demonstrates both constitutive and ligand-independent activation.  In this review, recent advances in our understanding of PXR and CAR as xenosensors are discussed with emphasis placed on the differences rather than similarities of these 2 xenobiotic receptors in ligand recognition and target gene regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7BWMbiPTmTrVg90H21EOLACvtfcHk0lj2hzhxn6j6nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGitr7E&md5=facfa8122514e1535362784fa41156c6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DTolson%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520drug-metabolizing%2520enzymes%2520by%2520xenobiotic%2520receptors%253A%2520PXR%2520and%2520CAR%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2010%26volume%3D62%26issue%3D13%26spage%3D1238%26epage%3D1249%26doi%3D10.1016%2Fj.addr.2010.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hakkola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 induction and xeno-sensing receptors pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor alpha at the crossroads of toxicokinetics and toxicodynamics</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">S5</span>),  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1111/bcpt.13004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fbcpt.13004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29527807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFWgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=42-50&issue=S5&author=J.+Hakkolaauthor=C.+Bernasconiauthor=S.+Coeckeauthor=L.+Richertauthor=T.+B.+Anderssonauthor=O.+Pelkonen&title=Cytochrome+P450+induction+and+xeno-sensing+receptors+pregnane+X+receptor%2C+constitutive+androstane+receptor%2C+aryl+hydrocarbon+receptor+and+peroxisome+proliferator-activated+receptor+alpha+at+the+crossroads+of+toxicokinetics+and+toxicodynamics&doi=10.1111%2Fbcpt.13004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics</span></div><div class="casAuthors">Hakkola, Jukka; Bernasconi, Camilla; Coecke, Sandra; Richert, Lysiane; Andersson, Tommy B.; Pelkonen, Olavi</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">S5</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pregnane X receptor (PXR), constitutive androstane receptor (CAR), aryl hydrocarbon receptor (AHR) and peroxisome proliferator-activated receptor α (PPARα) are ligand-activated transcription factors that regulate expression of many xenobiotic-metabolizing enzymes including several cytochrome P 450 (CYP) enzymes.  Many xenobiotics induce CYP enzymes through these intracellular receptors and consequently affect toxicokinetics and possible metabolic activation of the receptor ligands and other xenobiotics utilizing similar metabolic pathways.  However, it is now apparent that the xenobiotic receptors regulate also many endogenous functions and signalling pathways, and xenobiotic exposure thus may dysregulate an array of fundamental cell functions.  This MiniReview surveys and discusses the multifaceted roles of xenobiotic receptors, for which CYP induction may serve as the first alert and possibly a biomarker for exposure to xenobiotics.  With the current emergence of the adverse outcome pathway (AOP) concept, these receptors are being and will be assigned as mol. initiating events or key events in numerous discrete toxicity pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvRj8tUem0krVg90H21EOLACvtfcHk0lj2hzhxn6j6nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFWgu7o%253D&md5=d85ffb14d36b0566608bbd57cada812d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.13004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.13004%26sid%3Dliteratum%253Aachs%26aulast%3DHakkola%26aufirst%3DJ.%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DCoecke%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DPelkonen%26aufirst%3DO.%26atitle%3DCytochrome%2520P450%2520induction%2520and%2520xeno-sensing%2520receptors%2520pregnane%2520X%2520receptor%252C%2520constitutive%2520androstane%2520receptor%252C%2520aryl%2520hydrocarbon%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor%2520alpha%2520at%2520the%2520crossroads%2520of%2520toxicokinetics%2520and%2520toxicodynamics%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2018%26volume%3D123%26issue%3DS5%26spage%3D42%26epage%3D50%26doi%3D10.1111%2Fbcpt.13004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. S.</span></span> <span> </span><span class="NLM_article-title">Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10–11</span>),  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1080/00498250701534893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F00498250701534893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17968743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ahu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=1196-1224&issue=10%E2%80%9311&author=N.+J.+Hewittauthor=E.+L.+Lecluyseauthor=S.+S.+Ferguson&title=Induction+of+hepatic+cytochrome+P450+enzymes%3A+methods%2C+mechanisms%2C+recommendations%2C+and+in+vitro-in+vivo+correlations&doi=10.1080%2F00498250701534893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations</span></div><div class="casAuthors">Hewitt, N. J.; Lecluyse, E. L.; Ferguson, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10/11</span>),
    <span class="NLM_cas:pages">1196-1224</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Induction of drug-clearance pathways (Phase 1 and 2 enzymes and transporters) can have important clin. consequences.  Inducers can (1) increase the clearance of other drugs, resulting in a decreased therapeutic effect, (2) increase the activation of pro-drugs, causing an alteration in their efficacy and pharmacokinetics, and (3) increase the bioactivation of drugs that contribute to hepatotoxicity via reactive intermediates.  Nuclear receptors are key mediators of drug-induced changes in the expression of drug-clearance pathways.  However, species differences in nuclear receptor activation make the prediction of cytochrome P 450 (CYP) induction in humans from data derived from animal models problematic.  Thus, in vitro human-relevant model systems are increasingly used to evaluate enzyme induction.  In this review, the authors' current understanding of the mechanisms of enzyme induction and the in vitro methods for assessing the induction potential of new drugs will be discussed.  Relevant issues and considerations surrounding proper study design and the interpretation of in vitro results will be discussed in light of the current US Food and Drug Administration (FDA) recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhMI6NCTa3K7Vg90H21EOLACvtfcHk0ljVymy5UuNwog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ahu7vL&md5=b663184b1d69bf228dc543f6df0a665e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1080%2F00498250701534893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701534893%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DN.%2BJ.%26aulast%3DLecluyse%26aufirst%3DE.%2BL.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26atitle%3DInduction%2520of%2520hepatic%2520cytochrome%2520P450%2520enzymes%253A%2520methods%252C%2520mechanisms%252C%2520recommendations%252C%2520and%2520in%2520vitro-in%2520vivo%2520correlations%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26issue%3D10%25E2%2580%259311%26spage%3D1196%26epage%3D1224%26doi%3D10.1080%2F00498250701534893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1002/bdd.2212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbdd.2212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31778578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvVWlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3-31&issue=1%E2%80%932&author=C.+Luauthor=L.+Di&title=In+vitro+and+in+vivo+methods+to+assess+pharmacokinetic+drug-+drug+interactions+in+drug+discovery+and+development&doi=10.1002%2Fbdd.2212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development</span></div><div class="casAuthors">Lu, Chuang; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-31</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-drug interactions (DDIs) caused by the co-administration of multiple drugs are major safety concerns in the clinic.  Several drugs have been withdrawn from the market due to perpetrator or victim DDIs.  Strategies have been developed to assess DDI risks early in drug discovery to reduce DDI liabilities.  High-to-medium throughput assays are available to identify undesirable scaffolds and to guide structural modifications to minimize DDIs.  Definitive methods are used at later stages of drug discovery and development to provide a more accurate measurement of DDI parameters and to enable clin. translations.  Physiol. based pharmacokinetic modeling and simulations are powerful tools to accurately predict DDIs and to assess risks in the clinic.  Although significant advances have been made over the years, many challenges remain for clin. DDI translations.  This includes DDIs involving non-cytochrome P 450 enzymes, transporters, enzyme-transporter interplay, indirect effects from biologics, and pharmacodynamic based DDI.  This review focuses on methods that are used to assess hepatic DDIs caused by enzyme inhibition and induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGre3eY_7Kg7Vg90H21EOLACvtfcHk0ljVymy5UuNwog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvVWlsg%253D%253D&md5=9b07ed3f32112f7ae9393369a290ed2b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2212%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520methods%2520to%2520assess%2520pharmacokinetic%2520drug-%2520drug%2520interactions%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2020%26volume%3D41%26issue%3D1%25E2%2580%25932%26spage%3D3%26epage%3D31%26doi%3D10.1002%2Fbdd.2212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span> <span> </span><span class="NLM_article-title">Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1517/17460441003762717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17460441003762717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22823132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=491-511&issue=5&author=M.+Honmaauthor=M.+Kozawaauthor=H.+Suzuki&title=Methods+for+the+quantitative+evaluation+and+prediction+of+CYP+enzyme+induction+using+human+in+vitro+systems&doi=10.1517%2F17460441003762717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems</span></div><div class="casAuthors">Honma, Masashi; Kozawa, Masanari; Suzuki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-511</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  For successful drug development, it is important to investigate the potency of candidate drugs causing drug-drug interactions (DDI) during the early stages of development.  The most common mechanisms of DDIs are the inhibition and induction of CYP enzymes.  Therefore, it is important to develop compds. with lower potencies for CYP enzyme induction.  The aim of the present paper is to present an overview of the current knowledge of CYP induction mechanisms, particularly focusing on the transcriptional gene activation mediated by pregnane X receptor, aryl hydrocarbon receptor and constitutive androstane receptor.  The adoptable options of in vitro assay methods for evaluating CYP induction are also summarized.  Finally, we introduce a method for the quant. prediction of CYP3A4 induction considering the turnover of CYP3A4 mRNA and protein in hepatocytes based on the data obtained from a reporter gene assay.  In order to predict in vivo CYP enzyme induction quant. based on in vitro information, an understanding of the physiol. induction mechanisms and the features of each in vitro assay system is essential.  We also present the estn. method of in vivo CYP induction potency of each compd. based on the in vitro data which are routinely obtained but not necessarily utilized maximally in pharmaceutical companies.  It is desirable to select compds. with lower potencies for the inductive effect.  For this purpose, an accurate prioritization procedure to evaluate the induction potency of each compd. in a quant. manner considering the pharmacol. effective concn. of each compd. is necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcRC_9DT7Mw7Vg90H21EOLACvtfcHk0lgc0RBGlCaexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFGktrc%253D&md5=c41f715a0b1a5b4ed3ca83d0f4746935</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1517%2F17460441003762717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441003762717%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DM.%26aulast%3DKozawa%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DMethods%2520for%2520the%2520quantitative%2520evaluation%2520and%2520prediction%2520of%2520CYP%2520enzyme%2520induction%2520using%2520human%2520in%2520vitro%2520systems%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26issue%3D5%26spage%3D491%26epage%3D511%26doi%3D10.1517%2F17460441003762717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.3109/03602532.2012.743560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F03602532.2012.743560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23330538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=3-14&issue=1&author=M.+W.+Sinz&title=Evaluation+of+pregnane+X+receptor+%28PXR%29-mediated+CYP3A4+drug-drug+interactions+in+drug+development&doi=10.3109%2F03602532.2012.743560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development</span></div><div class="casAuthors">Sinz, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The increased capacity to rapidly eliminate drugs can have a profound effect on the efficacious exposure of coadministered drugs, esp. in today's medical world of polypharmacy.  There are numerous drug-drug interactions (DDIs) related to a loss of therapeutic efficacy and many of these are caused by pregnane X receptor (PXR)-mediated transcriptional activation of drug-metabolizing enzymes or drug transporters.  Evaluation of PXR activation and subsequent induction of proteins involved in drug elimination and distribution have become routine in drug discovery and drug development.  The assays used to evaluate PXR directly are high throughput and provide useful information on the ability of a drug's potential to ppt. a DDI.  In addn., they may serve as useful tools to support structure-activity or structure-liability relationships to eliminate or minimize the potential of new drug candidates to cause induction and, ultimately, a DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdAO7aDGKoIrVg90H21EOLACvtfcHk0lgc0RBGlCaexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaks7s%253D&md5=cd1309722b84b0e7781480a61258c329</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3109%2F03602532.2012.743560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2012.743560%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DEvaluation%2520of%2520pregnane%2520X%2520receptor%2520%2528PXR%2529-mediated%2520CYP3A4%2520drug-drug%2520interactions%2520in%2520drug%2520development%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2013%26volume%3D45%26issue%3D1%26spage%3D3%26epage%3D14%26doi%3D10.3109%2F03602532.2012.743560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1517/17425255.2013.754010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2013.754010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23327618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFehtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=253-266&issue=3&author=X.+Chaiauthor=S.+Zengauthor=W.+Xie&title=Nuclear+receptors+PXR+and+CAR%3A+implications+for+drug+metabolism+regulation%2C+pharmacogenomics+and+beyond&doi=10.1517%2F17425255.2013.754010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond</span></div><div class="casAuthors">Chai, Xiaojuan; Zeng, Su; Xie, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-266</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Orphan' nuclear receptors belong to the nuclear receptor (NR) superfamily of transcriptional factors.  Binding of ligands to these receptors results in the recruitment of the co-activators, thereby regulating the expression of cognate target genes.Areas covered: This review discusses the transcriptional regulation of P 450 genes by two major xenobiotic nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR).  Addnl. PXR and CAR target genes include those encoded for UDP-glucuronosyltransferases, glutathione S-transferases, sulfotransferases and drug transporters.  The authors discuss the involvement of PXR and CAR in endobiotic metab.  They also review the polymorphisms of PXR and CAR.Expert opinion: PXR and CAR are both xenobiotic and endobiotic receptors.  A remarkably diverse set of chems. can activate PXR and CAR.  There is significant cross-talk among xenobiotic receptors.  Future studies are needed to focus on the polymorphisms of the nuclear receptors and the complex regulatory networks among nuclear receptors.  Considerations should be given while designing PXR- or CAR-targeting pharmaceutics to avoid adverse drug effects.  In the meantime, due to the diverse functions of PXR and CAR, agonists or antagonists for these receptors may have therapeutic potentials in managing certain diseases and enhancing therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyEQ2FuTWDbVg90H21EOLACvtfcHk0lgc0RBGlCaexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFehtL8%253D&md5=a78c158ec4e88e8eda90572259b1878e</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1517%2F17425255.2013.754010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2013.754010%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DW.%26atitle%3DNuclear%2520receptors%2520PXR%2520and%2520CAR%253A%2520implications%2520for%2520drug%2520metabolism%2520regulation%252C%2520pharmacogenomics%2520and%2520beyond%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3D253%26epage%3D266%26doi%3D10.1517%2F17425255.2013.754010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamuru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">Identification of clinically used drugs that activate pregnane X receptors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.110.035105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20966043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1eltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=151-159&issue=1&author=S.+J.+Shuklaauthor=S.+Sakamuruauthor=R.+Huangauthor=T.+A.+Moellerauthor=P.+Shinnauthor=D.+Vanleerauthor=D.+S.+Auldauthor=C.+P.+Austinauthor=M.+Xia&title=Identification+of+clinically+used+drugs+that+activate+pregnane+X+receptors&doi=10.1124%2Fdmd.110.035105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of clinically used drugs that activate pregnane X receptors</span></div><div class="casAuthors">Shukla, Sunita J.; Sakamuru, Srilatha; Huang, Ruili; Moeller, Timothy A.; Shinn, Paul; Van Leer, Danielle; Auld, Douglas S.; Austin, Christopher P.; Xia, Menghang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) binds xenobiotics and regulates the expression of several drug-metabolizing enzymes and transporters.  Human PXR (hPXR) activation and CYP3A4 induction can be involved in drug-drug interactions, resulting in reduced efficacy or increased toxicity.  However, there are known species-specific differences with regard to PXR activation that should be taken into account when animal PXR data are extrapolated to humans.  We profiled 2816 clin. used drugs from the National Institutes of Health Chem. Genomics Center Pharmaceutical Collection for their ability to activate hPXR and rat PXR (rPXR) at the cellular level, induce human CYP3A4 at the cellular level, and bind human PXR at the protein level.  From 6 to 11% of drugs were identified as active across the four assays, which included assay-specific and pan-active compds.  The lowest concordance was obsd. between the hPXR and rPXR assays, and many compds. active in both assays nonetheless demonstrated significant potency differences between species.  Anal. based on clustering potency values demonstrated the greatest activity correlation between the hPXR activation and CYP3A4 induction assays.  Structure-activity relationship anal. identified chem. scaffolds that were pan-active (e.g., dihydropyridine calcium channel blockers) and others that were uniquely active in individual assays (e.g., steroids and fatty acids).  These results provide important information on PXR activation by clin. used drugs, highlight the species specificity of PXR activation by xenobiotics, and provide a means of prioritizing compds. for follow-up studies and optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-L7_KIVyFbVg90H21EOLACvtfcHk0lgc0RBGlCaexw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1eltQ%253D%253D&md5=a0798aafb8ecff60e0ce9de0aea2bfe3</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035105%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%2BJ.%26aulast%3DSakamuru%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DMoeller%26aufirst%3DT.%2BA.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DVanleer%26aufirst%3DD.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DXia%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520clinically%2520used%2520drugs%2520that%2520activate%2520pregnane%2520X%2520receptors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D1%26spage%3D151%26epage%3D159%26doi%3D10.1124%2Fdmd.110.035105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights of phenobarbital-mediated activation of human but not mouse Pregnane X Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1124/mol.119.116616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.119.116616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31436536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2019&pages=345-354&issue=3&author=L.+Liauthor=M.+A.+Welchauthor=Z.+Liauthor=B.+Mackowiakauthor=S.+Heywardauthor=P.+W.+Swaanauthor=H.+Wang&title=Mechanistic+insights+of+phenobarbital-mediated+activation+of+human+but+not+mouse+Pregnane+X+Receptor&doi=10.1124%2Fmol.119.116616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insights of phenobarbital-mediated activation of human but not mouse pregnane X receptor</span></div><div class="casAuthors">Li, Linhao; Welch, Matthew A.; Li, Zhihui; Mackowiak, Bryan; Heyward, Scott; Swaan, Peter W.; Wang, Hongbing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phenobarbital (PB), a broadly used antiseizure drug, was the first to be characterized as an inducer of cytochrome P 450 by activation of the constitutive androstane receptor (CAR).  Although PB is recognized as a conserved CAR activator among species via a well-documented indirect activation mechanism, conflicting results have been reported regarding PB regulation of the pregnane X receptor (PXR), a sister receptor of CAR, and the underlying mechanisms remain elusive.  Here, we show that in a human CAR (hCAR)-knockout (KO) HepaRG cell line, PB significantly induces the expression of CYP2B6 and CYP3A4, two shared target genes of hCAR and human PXR (hPXR).  In human primary hepatocytes and hCAR-KO HepaRG cells, PB-induced expression of CYP3A4 was markedly repressed by genetic knockdown or pharmacol. inhibition of hPXR.  Mechanistically, PB concn. dependently activates hPXR but not its mouse counterpart in cell-based luciferase assays.  Mammalian two-hybrid assays demonstrated that PB selectively increases the functional interaction between the steroid receptor coactivator-1 and hPXR but not mouse PXR.  Moreover, surface plasmon resonance binding affinity assay showed that PB directly binds to the ligand binding domain of hPXR (KD = 1.42 × 10-05).  Structure-activity anal. further revealed that the amino acid tryptophan-299 within the ligand binding pocket of hPXR plays a key role in the agonistic binding of PB and mutation of tryptophan-299 disrupts PB activation of hPXR.  Collectively, these data reveal that PB, a selective mouse CAR activator, activates both hCAR and hPXR, and provide novel mechanistic insights for PB-mediated activation of hPXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOWSbzsmNpObVg90H21EOLACvtfcHk0ljquWdUAN0uBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb3P&md5=29901e444d0457919178762d28521bf3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.116616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.116616%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWelch%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMackowiak%26aufirst%3DB.%26aulast%3DHeyward%26aufirst%3DS.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DMechanistic%2520insights%2520of%2520phenobarbital-mediated%2520activation%2520of%2520human%2520but%2520not%2520mouse%2520Pregnane%2520X%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2019%26volume%3D96%26issue%3D3%26spage%3D345%26epage%3D354%26doi%3D10.1124%2Fmol.119.116616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">30650</span>– <span class="NLM_lpage">30657</span>, <span class="refDoi"> DOI: 10.1074/jbc.M806132200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M806132200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18784074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWjtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=30650-30657&issue=45&author=W.+Linauthor=J.+Wuauthor=H.+Dongauthor=D.+Bouckauthor=F.+Y.+Zengauthor=T.+Chen&title=Cyclin-dependent+kinase+2+negatively+regulates+human+pregnane+X+receptor-mediated+CYP3A4+gene+expression+in+HepG2+liver+carcinoma+cells&doi=10.1074%2Fjbc.M806132200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent Kinase 2 Negatively Regulates Human Pregnane X Receptor-mediated CYP3A4 Gene Expression in HepG2 Liver Carcinoma Cells</span></div><div class="casAuthors">Lin, Wenwei; Wu, Jing; Dong, Hanqing; Bouck, David; Zeng, Fu-Yue; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">30650-30657</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) regulates the expression of crit. drug metab. enzymes.  One of such enzymes, cytochrome P 450 3A4 (CYP3A4), plays crit. roles in drug metab. in hepatocytes that are either quiescent or passing through the cell cycle.  It has been well established that the expression of P 450, such as CYP3A4, is markedly reduced during liver development or regeneration.  Numerous studies have implicated cellular signaling pathways in modulating the functions of nuclear receptors, including hPXR.  Here we report that inhibition of cyclin-dependent kinases (Cdks) by kenpaullone and roscovitine (two small mol. inhibitors of Cdks that we identified in a screen for compds. that activate hPXR) leads to activation of hPXR-mediated CYP3A4 gene expression in HepG2 human liver carcinoma cells.  Consistent with this finding, activation of Cdk2 attenuates the activation of CYP3A4 gene expression.  In vitro kinase assays revealed that Cdk2 directly phosphorylates hPXR.  A phosphomimetic mutation of a putative Cdk phosphorylation site, Ser350, significantly impairs the function of hPXR, whereas a phosphorylation-deficient mutation confers resistance to Cdk2.  Using HepG2 that has been stably transfected with hPXR and the CYP3A4-luciferase reporter, enriched in different phases of the cell cycle, we found that hPXR-mediated CYP3A4 expression is greatly reduced in the S phase.  Our results indicate for the first time that Cdk2 neg. regulates the activity of hPXR, and suggest an important role for Cdk2 in regulating hPXR activity and CYP3A4 expression in hepatocytes passing through the cell cycle, such as those in fetal or regenerating adult liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkgf2IueIC87Vg90H21EOLACvtfcHk0ljquWdUAN0uBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWjtL7N&md5=6251afac3aa0058f35e5cdce10892d42</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M806132200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M806132200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBouck%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DCyclin-dependent%2520kinase%25202%2520negatively%2520regulates%2520human%2520pregnane%2520X%2520receptor-mediated%2520CYP3A4%2520gene%2520expression%2520in%2520HepG2%2520liver%2520carcinoma%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D45%26spage%3D30650%26epage%3D30657%26doi%3D10.1074%2Fjbc.M806132200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.2174/138920006776873535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2174%2F138920006776873535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16724927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvV2mt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=375-388&issue=4&author=M.+Sinzauthor=S.+Kimauthor=Z.+Zhuauthor=T.+Chenauthor=M.+Anthonyauthor=K.+Dickinsonauthor=A.+D.+Rodrigues&title=Evaluation+of+170+xenobiotics+as+transactivators+of+human+pregnane+X+receptor+%28hPXR%29+and+correlation+to+known+CYP3A4+drug+interactions&doi=10.2174%2F138920006776873535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions</span></div><div class="casAuthors">Sinz, Michael; Kim, Sean; Zhu, Zhengrong; Chen, Taosheng; Anthony, Monique; Dickinson, Kenneth; Rodrigues, A. David</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-388</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The human transcription factor pregnane X receptor (hPXR) is a key regulator of enzyme expression, esp. cytochrome P 450 3A4 (CYP3A4).  Due to the prominence of CYP3A4 in the elimination of many drugs, the development of high throughput in vitro models to predict the effect of drugs on CYP3A4 expression have increased.  To better interpret and predict potential drug-drug interactions due to CYP3A4 enzyme induction, we evaluated 170 xenobiotics in a hPXR transactivation assay and compared these results to known clin. drug-drug interactions.  Of the 170 xenobiotics tested, 54% of them demonstrated some level of hPXR transactivation.  By taking into consideration cell culture conditions (soly., cytotoxicity, appropriate drug concn. in media), as well as in vivo pharmacokinetics (therapeutic plasma Cmax, distribution, route of administration, dosing regimen, liver exposure, potential to inhibit CYP3A4), the risk potential of CYP3A4 enzyme induction for most compds. reduced dramatically.  By employing this overall interpretation strategy, the final percentage of compds. predicted to significantly induce CYP3A4 reduced to 5%, all of which are known to cause drug-drug interactions.  Also, this is the first report that identifies several potent compds. that have the ability to transactivate hPXR that previously have not been identified, such as terbinafine, diclofenac, sildenafil, glimepiride, montelukast, and ticlopidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq33cLLzAqFhrVg90H21EOLACvtfcHk0ljquWdUAN0uBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvV2mt7k%253D&md5=06bec83c4e3fdf78d19b7e636ff43694</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2174%2F138920006776873535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006776873535%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DAnthony%26aufirst%3DM.%26aulast%3DDickinson%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DEvaluation%2520of%2520170%2520xenobiotics%2520as%2520transactivators%2520of%2520human%2520pregnane%2520X%2520receptor%2520%2528hPXR%2529%2520and%2520correlation%2520to%2520known%2520CYP3A4%2520drug%2520interactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26issue%3D4%26spage%3D375%26epage%3D388%26doi%3D10.2174%2F138920006776873535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span> <span> </span><span class="NLM_article-title">Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bcp.2008.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18647599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSiur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=680-689&issue=5&author=X.+Cuiauthor=A.+Thomasauthor=V.+Gerlachauthor=R.+E.+Whiteauthor=R.+A.+Morrisonauthor=K.+C.+Cheng&title=Application+and+interpretation+of+hPXR+screening+data%3A+Validation+of+reporter+signal+requirements+for+prediction+of+clinically+relevant+CYP3A4+inducers&doi=10.1016%2Fj.bcp.2008.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers</span></div><div class="casAuthors">Cui, Xiaoming; Thomas, Ann; Gerlach, Valerie; White, Ronald E.; Morrison, Richard A.; Cheng, K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">680-689</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A human pregnane X receptor (PXR) reporter-gene assay was established and validated using 19 therapeutic agents known to be clin. CYP3A4 inducers, 5 clin. non-inducers, and 6 known inducers in human hepatocytes.  The extent of CYP3A4 induction (measured as RIF ratio in comparison to rifampicin) and EC50 was obtained from the dose-response curve.  All of the clin. inducers (19/19) and human hepatocyte inducers (6/6) showed pos. responses in the PXR assay.  One out of five clin. non-inducers, pioglitazone, also showed a pos. response.  An addnl. series of 18 commonly used drugs with no reports of clin. induction was also evaluated as putative neg. controls.  Sixteen of these were neg. (89%), whereas two of these, flutamide and haloperidol showed 16-fold (RIF ratio 0.79) and 10-fold (RIF ratio 0.48) maximal induction, resp. in the reporter-gene system.  Flutamide and haloperidol were further demonstrated to cause CYP3A4 induction in human cryopreserved hepatocytes based on testosterone 6β-hydroxylation activity.  The induction potential index calcd. based on the max. RIF ratio, EC50, and in vivo max. plasma concn. was used to predict the likelihood of CYP3A4 induction in humans.  When the induction potential index is greater than 0.08, the compd. is likely to cause induction in humans.  A high-throughput screening strategy was developed based on the validation results at 1 μM and 10 μM for the same set of drugs.  A RIF ratio of 0.4 was set as more practical screening cut-off to minimize the possibility of generating false positives.  Thus, a tiered approach was implemented to use the human PXR reporter-gene assay from early lead optimization to late lead characterization in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMv10iQqK5SrVg90H21EOLACvtfcHk0lhCmle8kkJ2Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSiur7N&md5=7f355b57cafc38b5348151d3d6a3bd2f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DX.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DGerlach%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26atitle%3DApplication%2520and%2520interpretation%2520of%2520hPXR%2520screening%2520data%253A%2520Validation%2520of%2520reporter%2520signal%2520requirements%2520for%2520prediction%2520of%2520clinically%2520relevant%2520CYP3A4%2520inducers%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26issue%3D5%26spage%3D680%26epage%3D689%26doi%3D10.1016%2Fj.bcp.2008.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span> <span> </span><span class="NLM_article-title">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.7.795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.30.7.795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12065438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=795-804&issue=7&author=G.+Luoauthor=M.+Cunninghamauthor=S.+Kimauthor=T.+Burnauthor=J.+Linauthor=M.+Sinzauthor=G.+Hamiltonauthor=C.+Rizzoauthor=S.+Jolleyauthor=D.+Gilbertauthor=A.+Downeyauthor=D.+Mudraauthor=R.+Grahamauthor=K.+Carrollauthor=J.+Xieauthor=A.+Madanauthor=A.+Parkinsonauthor=D.+Christauthor=B.+Sellingauthor=E.+LeCluyseauthor=L.+S.+Gan&title=CYP3A4+induction+by+drugs%3A+correlation+between+a+pregnane+X+receptor+reporter+gene+assay+and+CYP3A4+expression+in+human+hepatocytes&doi=10.1124%2Fdmd.30.7.795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span></div><div class="casAuthors">Luo, Gang; Cunningham, Mark; Kim, Sean; Burn, Tim; Lin, Jianrong; Sinz, Michael; Hamilton, Geraldine; Rizzo, Christopher; Jolley, Summer; Gilbert, Darryl; Downey, April; Mudra, Daniel; Graham, Richard; Carroll, Kathy; Xie, Jindong; Madan, Ajay; Parkinson, Andrew; Christ, Dave; Selling, Bernard; Lecluyse, Edward; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A4 (CYP3A4) is detd. typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity.  Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers.  To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR.  Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6β-hydroxylase activity.  Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technol./Northern blotting and Western blotting, resp.  In general, PXR activation correlated with the induction potential obsd. in human hepatocyte cultures.  Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.  Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity.  It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJw2uJawzuLVg90H21EOLACvtfcHk0lhCmle8kkJ2Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D&md5=0de8fb68ebce41eed8d634cff33fad20</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.7.795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.7.795%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DDowney%26aufirst%3DA.%26aulast%3DMudra%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DChrist%26aufirst%3DD.%26aulast%3DSelling%26aufirst%3DB.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DCYP3A4%2520induction%2520by%2520drugs%253A%2520correlation%2520between%2520a%2520pregnane%2520X%2520receptor%2520reporter%2520gene%2520assay%2520and%2520CYP3A4%2520expression%2520in%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26issue%3D7%26spage%3D795%26epage%3D804%26doi%3D10.1124%2Fdmd.30.7.795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otmani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.026526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.026526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19307295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslamu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1259-1268&issue=6&author=D.+F.+McGinnityauthor=G.+Zhangauthor=J.+R.+Kennyauthor=G.+A.+Hamiltonauthor=S.+Otmaniauthor=K.+R.+Stamsauthor=S.+Haneyauthor=P.+Brassilauthor=D.+M.+Stresserauthor=R.+J.+Riley&title=Evaluation+of+multiple+in+vitro+systems+for+assessment+of+CYP3A4+induction+in+drug+discovery%3A+human+hepatocytes%2C+pregnane+X+receptor+reporter+gene%2C+and+Fa2N-4+and+HepaRG+cells&doi=10.1124%2Fdmd.109.026526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells</span></div><div class="casAuthors">McGinnity, Dermot F.; Zhang, George; Kenny, Jane R.; Hamilton, Geraldine A.; Otmani, Sara; Stams, Karen R.; Haney, Suzzette; Brassil, Patrick; Stresser, David M.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prototypic CYP3A4 inducers were tested in a pregnane X receptor (PXR) reporter gene assay, Fa2N-4 cells, HepaRG cells, and primary human hepatocytes, along with neg. controls, using CYP3A4 mRNA and activity endpoints, where appropriate.  Over half of the compds. tested (14 of 24) were identified as time-dependent inhibitors of CYP3A4 and high mRNA/activity ratios (>10) were consistent with CYP3A4 time-dependent inhibition for compds. such as troleandomycin, ritonavir, and verapamil.  Induction response was compared between two human donors; there was an excellent correlation in the EC50 ests. (r2 = 0.89, p < 0.001), and a weak but statistically significant correlation was noted for max. obsd. induction at an optimum concn. (Emax) (r2 = 0.38, p = 0.001).  Emax and EC50 ests. detd. from the PXR reporter gene assay and Fa2N-4 and HepaRG cells were compared with those from hepatocytes.  Overall, EC50 values generated using hepatocytes agreed with those generated in the PXR reporter gene assay (r2 = 0.85, p < 0.001) and Fa2N-4 (r2 = 0.65, p < 0.001) and HepaRG (r2 = 0.99, p < 0.001) cells.  However, Emax values generated in hepatocytes were only significantly correlated to those detd. in Fa2N-4 (r2 = 0.33, p = 0.005) and HepaRG cells (r2 = 0.79, p < 0.001).  "Gold std." cytochrome P 450 induction data can be generated using primary human hepatocytes, but a restricted, erratic supply and interdonor variability somewhat restrict routine application within a drug discovery setting.  HepaRG cells are a valuable recent addn. to the armory of in vitro tools for assessing CYP3A4 induction and seem to be an excellent surrogate of primary cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_-PVv-4qN7Vg90H21EOLACvtfcHk0lhvKQLyese6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslamu7k%253D&md5=206e3a4213127b750e7f27f2484eb082</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.026526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.026526%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DOtmani%26aufirst%3DS.%26aulast%3DStams%26aufirst%3DK.%2BR.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520multiple%2520in%2520vitro%2520systems%2520for%2520assessment%2520of%2520CYP3A4%2520induction%2520in%2520drug%2520discovery%253A%2520human%2520hepatocytes%252C%2520pregnane%2520X%2520receptor%2520reporter%2520gene%252C%2520and%2520Fa2N-4%2520and%2520HepaRG%2520cells%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26issue%3D6%26spage%3D1259%26epage%3D1268%26doi%3D10.1124%2Fdmd.109.026526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, Z.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1517/17425255.2016.1125881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2016.1125881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26612411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2rtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=169-174&issue=2&author=Z.+Dvorak&title=Opportunities+and+challenges+in+using+human+hepatocytes+in+cytochromes+P450+induction+assays&doi=10.1517%2F17425255.2016.1125881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays</span></div><div class="casAuthors">Dvorak, Zdenek</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-174</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Identification of inducers of xenobiotic-metabolizing cytochromes P 450 (CYP) is of topical interest.  The issue mainly concerns three sectors: (i) preclin. testing of drug candidates and testing existing drugs and their combinations; (ii) food safety applications with regard to additives, contaminants, and adulterants; (iii) environmental applications, comprising detection and identification of endocrine disruptors.: A literature search was performed using the PubMed database, covering state-of-the-art of human hepatocyte (HH) culture use, and their exploitation for the identification of P 450 inducers.  A list of CYP inducers identified by HHs is provided.: Primary cultures of HHs had long been considered as a gold std. for induction assays of xenobiotic-metabolizing enzymes.  Owing to several shortcomings of HHs, alternative approaches such as immortalization of HHs, use of cell lines, generation of clonal cell lines from HHs, use of induced pluripotent stem (iPS) cells, cells from humanized animals, etc., were employed.  While yielding particular advantage, overall, alternatives to HHs still remain an avenue for discrete applications or tech. situations.  Thus, HHs remain the most suitable model for complex CYP induction studies.  The summary may be effectively expressed by strength/weakness/opportunity/threats anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKOcaCfuyK7Vg90H21EOLACvtfcHk0lhvKQLyese6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2rtLk%253D&md5=37e9415443b9abf65ad15c0452f4a311</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1517%2F17425255.2016.1125881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2016.1125881%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520using%2520human%2520hepatocytes%2520in%2520cytochromes%2520P450%2520induction%2520assays%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2016%26volume%3D12%26issue%3D2%26spage%3D169%26epage%3D174%26doi%3D10.1517%2F17425255.2016.1125881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of models for predicting drug-drug interactions due to induction</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1517/17425255.2010.516251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2010.516251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20955108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1399-1416&issue=11&author=O.+A.+Fahmiauthor=S.+L.+Ripp&title=Evaluation+of+models+for+predicting+drug-drug+interactions+due+to+induction&doi=10.1517%2F17425255.2010.516251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of models for predicting drug-drug interactions due to induction</span></div><div class="casAuthors">Fahmi, Odette A.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1399-1416</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs.  It is, therefore, important to understand a new compd.'s potential for enzyme induction and to understand how to use the induction data generated in vitro to predict potential for drug-drug interactions in vivo.  Areas covered in this review: Recent advances in methods for using in vitro data to predict potential for CYP3A induction in vivo are reviewed.  What the reader will gain: The reader will gain a comprehensive understanding of the advantages and disadvantages of various prediction methods for induction and be able to directly compare different methods using a common in vitro data set.  Take home message: The various methods for predicting clin. CYP3A induction from in vitro induction data all have demonstrated utility; it is the authors' opinion that the correlation-based approaches offer as good or better predictivity and have simpler input requirements than more complex approaches.  Of the different correlation approaches, the relatively simple unbound Cmax/EC50 or AUC/EC50 approaches are the simplest and yet show the best correlation to the obsd. clin. data.  While the approaches discussed herein represent an improvement in our understanding of the predictive value of in vitro induction data, it is important to recognize that there is still room for improvement in quant. prediction of magnitude of drug interactions due to induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLyowSf3OMrVg90H21EOLACvtfcHk0lhvKQLyese6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN&md5=1b95f24bb423f019f8d2b349cc4af592</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.516251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.516251%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520models%2520for%2520predicting%2520drug-drug%2520interactions%2520due%2520to%2520induction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26issue%3D11%26spage%3D1399%26epage%3D1416%26doi%3D10.1517%2F17425255.2010.516251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohutsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyser, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span> <span> </span><span class="NLM_article-title">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.081927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.118.081927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29959133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGgt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1285-1303&issue=9&author=J.+R.+Kennyauthor=D.+Ramsdenauthor=D.+B.+Buckleyauthor=S.+Dallasauthor=C.+Fungauthor=M.+Mohutskyauthor=H.+J.+Einolfauthor=L.+Chenauthor=J.+G.+Dekeyserauthor=M.+Fitzgeraldauthor=T.+C.+Goosenauthor=Y.+A.+Siuauthor=R.+L.+Walskyauthor=G.+Zhangauthor=D.+Tweedieauthor=N.+Hariparsad&title=Considerations+from+the+innovation+and+quality+induction+working+group+in+response+to+drug-drug+interaction+guidances+from+regulatory+agencies%3A+focus+on+CYP3A4+mRNA+in+vitro+response+thresholds%2C+variability%2C+and+clinical+relevance&doi=10.1124%2Fdmd.118.081927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance</span></div><div class="casAuthors">Kenny, Jane R.; Ramsden, Diane; Buckley, David B.; Dallas, Shannon; Fung, Conrad; Mohutsky, Michael; Einolf, Heidi J.; Chen, Liangfu; Dekeyser, Joshua G.; Fitzgerald, Maria; Goosen, Theunis C.; Siu, Y. Amy; Walsky, Robert L.; Zhang, George; Tweedie, Donald; Hariparsad, Niresh</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1303,S1-S63</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Innovation and Quality Induction Working Group presents an assessment of best practice for data interpretation of in vitro induction, specifically, response thresholds, variability, application of controls, and translation to clin. risk assessment with focus on CYP3A4 mRNA.  Clin. CYP3A induction and in vitro data were gathered for 51 compds., 16 of which were proprietary.  A large degree of variability was obsd. in both the clin. and in vitro induction responses; however, anal. confirmed in vitro data are able to predict clin. induction risk.  Following extensive examn. of this large data set, the following recommendations are proposed. a) Cytochrome P 450 induction should continue to be evaluated in three sep. human donors in vitro. b) In light of empirically divergent responses in rifampicin control and most test inducers, normalization of data to percent pos. control appears to be of limited benefit. c) With concn. dependence, 2-fold induction is an acceptable threshold for pos. identification of in vitro CYP3A4 mRNA induction. d) To reduce the risk of false positives, in the absence of a concn.-dependent response, induction = 2-fold should be obsd. in more than one donor to classify a compd. as an in vitro inducer. e) If qualifying a compd. as neg. for CYP3A4 mRNA induction, the magnitude of maximal rifampicin response in that donor should be = 10-fold. f) Inclusion of a neg. control adds no value beyond that of the vehicle control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n28E_4a3zrVg90H21EOLACvtfcHk0lgskhNworX9Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGgt77P&md5=c81560dc8914cae6f51ef72216d4cc21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.081927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.081927%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DDallas%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DC.%26aulast%3DMohutsky%26aufirst%3DM.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDekeyser%26aufirst%3DJ.%2BG.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DSiu%26aufirst%3DY.%2BA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHariparsad%26aufirst%3DN.%26atitle%3DConsiderations%2520from%2520the%2520innovation%2520and%2520quality%2520induction%2520working%2520group%2520in%2520response%2520to%2520drug-drug%2520interaction%2520guidances%2520from%2520regulatory%2520agencies%253A%2520focus%2520on%2520CYP3A4%2520mRNA%2520in%2520vitro%2520response%2520thresholds%252C%2520variability%252C%2520and%2520clinical%2520relevance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D9%26spage%3D1285%26epage%3D1303%26doi%3D10.1124%2Fdmd.118.081927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. E.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1517/17425255.2015.1013095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2015.1013095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25659570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFymt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=557-572&issue=4&author=R.+J.+Rileyauthor=C.+E.+Wilson&title=Cytochrome+P450+time-dependent+inhibition+and+induction%3A+advances+in+assays%2C+risk+analysis+and+modelling&doi=10.1517%2F17425255.2015.1013095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling</span></div><div class="casAuthors">Riley, Robert J.; Wilson, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">557-572</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: It is widely accepted that current practice of polypharmacy inevitably increases the incidence of drug-drug interactions (DDIs).  Serious DDIs are a major liability for new mol. entities entering the pharmaceutical market.  Various strategies are employed to avoid problematic compds. for clin. development.  Progress made with reversible CYP DDIs has prompted a switch to study and model time-dependent inhibition and induction interactions.  Areas covered: An overview of popular exptl. practices is presented with discussion of techniques and algorithms used to analyze the clin. DDI risk.  Emphasis is placed on the transition from early, simple static equations, via more complex net mechanistic, static models to dynamic approaches involving multiple perpetrators and metabolites, simultaneous inhibition and induction.  Expert opinion: Inclusion of the more conservative terms for parameters required for DDI evaluation may eliminate promising chem. space, encourages poor practice and hampers innovation.  Breakthroughs have originated from understanding of 'outliers' from such analyses where CYP enzyme-transporter interplay may be involved.  The role of key transporters in drug disposition is firmly established as the chem. required to address new targets deviates from traditional 'drug-like' space.  Attempts to model more complex interactions for substrates of both CYP enzymes and drug transporters are still in their infancy and will benefit from dynamic modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphH0w3CLvVl7Vg90H21EOLACvtfcHk0lgskhNworX9Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFymt7s%253D&md5=93a365fa067fe4da49442401bacc575f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1013095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1013095%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DWilson%26aufirst%3DC.%2BE.%26atitle%3DCytochrome%2520P450%2520time-dependent%2520inhibition%2520and%2520induction%253A%2520advances%2520in%2520assays%252C%2520risk%2520analysis%2520and%2520modelling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26issue%3D4%26spage%3D557%26epage%3D572%26doi%3D10.1517%2F17425255.2015.1013095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadie-Viollon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantion, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coassolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2009.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tiv.2009.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19497360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyktLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=346-356&issue=1&author=C.+Abadie-Viollonauthor=H.+Martinauthor=N.+Blanchardauthor=D.+Pekthongauthor=P.+Bachellierauthor=G.+Mantionauthor=B.+Heydauthor=F.+Schulerauthor=P.+Coassoloauthor=E.+Alexandreauthor=L.+Richert&title=Follow-up+to+the+pre-validation+of+a+harmonised+protocol+for+assessment+of+CYP+induction+responses+in+freshly+isolated+and+cryopreserved+human+hepatocytes+with+respect+to+culture+format%2C+treatment%2C+positive+reference+inducers+and+incubation+conditions&doi=10.1016%2Fj.tiv.2009.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions</span></div><div class="casAuthors">Abadie-Viollon, Catherine; Martin, Helene; Blanchard, Nadege; Pekthong, Dumrongsak; Bachellier, Philippe; Mantion, Georges; Heyd, Bruno; Schuler, Frantz; Coassolo, Philippe; Alexandre, Eliane; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology in Vitro</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">346-356</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors have compared induction responses of human hepatocytes to known inducers of CYP1A2, CYP2B6, CYP2C and CYP3A4/5 to det. whether the culture format, treatment regimen and/or substrate incubation conditions affected the outcome.  CYP induction responses to prototypical inducers were equiv. regardless of pre-culture time (24 h or 48 h), plate format (60 mm or 24-well plates) used or whether CYP activities were measured in microsomes or whole cell monolayers.  Fold-induction of CYP3A4/5 by 1000 μM PB and 10 μM RIF were equiv.  In contrast, the fold-induction of CYP2B6 by PB was 3-fold higher that by 10 μM RIF.  In addn. to inducing CYP1A2, 50 μM OME also induced CYP3A4/5 in 50% of the donors tested.  CYP2B6 was induced in 14 out of 21 donors by BNF; however CYP3A4/5 was unaffected by BNF in these donors.  To confirm that donor-to-donor variation was not due to inter-lab. differences, the induction responses of 5 different batches of cryopreserved human hepatocytes were compared in two different labs.  The induction of CYP1A2, CYP2B6 and CYP3A4 measured in the authors' lab. were equiv. to those obtained by the com. companies, proving good between-lab. reproducibility.  In conclusion, there is some flexibility in the treatment and incubation protocols for classical CYP induction assays on human hepatocytes.  Both RIF and PB are suitable pos. control inducers of CYP3A4/5 but PB may be more appropriate for CYP2B6 induction.  BNF may be more appropriate for CYP1A2 induction than OME since, in contrast to the latter, it does not induce CYP3A4.  Induction responses using hepatocytes from the same donor but in different labs can be expected to be similar.  The good reproducibility of induction responses between labs. using cryopreserved hepatocytes underlines the usefulness of these cells for these types of studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe9LzZ7UJbUbVg90H21EOLACvtfcHk0lgskhNworX9Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyktLrP&md5=7062b5e142fa391020b2af68287780fd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2009.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2009.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DAbadie-Viollon%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DH.%26aulast%3DBlanchard%26aufirst%3DN.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DMantion%26aufirst%3DG.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DFollow-up%2520to%2520the%2520pre-validation%2520of%2520a%2520harmonised%2520protocol%2520for%2520assessment%2520of%2520CYP%2520induction%2520responses%2520in%2520freshly%2520isolated%2520and%2520cryopreserved%2520human%2520hepatocytes%2520with%2520respect%2520to%2520culture%2520format%252C%2520treatment%252C%2520positive%2520reference%2520inducers%2520and%2520incubation%2520conditions%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2010%26volume%3D24%26issue%3D1%26spage%3D346%26epage%3D356%26doi%3D10.1016%2Fj.tiv.2009.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desbans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.676693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F00498254.2012.676693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22515431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=968-979&issue=10&author=E.+Alexandreauthor=A.+Bazeauthor=C.+Parmentierauthor=C.+Desbansauthor=D.+Pekthongauthor=B.+Gerinauthor=C.+Wackauthor=P.+Bachellierauthor=B.+Heydauthor=J.+C.+Weberauthor=L.+Richert&title=Plateable+cryopreserved+human+hepatocytes+for+the+assessment+of+cytochrome+P450+inducibility%3A+experimental+condition-related+variables+affecting+their+response+to+inducers&doi=10.3109%2F00498254.2012.676693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers</span></div><div class="casAuthors">Alexandre, Eliane; Baze, Audrey; Parmentier, Celine; Desbans, Coraline; Pekthong, Dumrongsak; Gerin, Brigitte; Wack, Claudine; Bachellier, Philippe; Heyd, Bruno; Weber, Jean-Christophe; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">968-979</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The aim of the present study was to assess the stability of cryopreserved human hepatocytes over 5 years and to explore exptl. condition-related variables such as seeding d., culture matrix and medium, start and duration of treatment that could potentially affect the quality of cultures and their response to cytochrome P 450 (CYP) inducers.  63/125 Batches of cryopreserved human hepatocytes were plateable after thawing.  Of those, 17 batches showed reproducible recovery, viability, and plateability (< 5% intra-batch variability) ≤ 5 years.  When cultured in collagen home-coated 48-well plates at a seeding d. allowing 70% confluence, cryopreserved human hepatocytes display activities equiv. to fresh counterparts.  Their response to CYP inducers is maximal and equiv. to fresh counterpart for an incubation of 72 h starting at Day 2 or Day 3 after plating when cultured in modified Hepatocyte Maintenance Medium (HMM).  The no. of cryopreserved human hepatocytes can be further reduced by a cocktail of CYP substrates for the assessment of their inducibility.  Exptl. condition-related variables, such as seeding d., culture matrix and medium, start and duration of treatment, affecting the response of plateable thawed cryopreserved human hepatocytes to cytochrome P 450 inducers can be reduced by optimizing crit. steps of the protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojL5_gs2uBlbVg90H21EOLACvtfcHk0lg99BnwbEWKJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhs7rP&md5=349fd39f0ab0a8f626db248dc275f399</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.676693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.676693%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DParmentier%26aufirst%3DC.%26aulast%3DDesbans%26aufirst%3DC.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DWack%26aufirst%3DC.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DWeber%26aufirst%3DJ.%2BC.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DPlateable%2520cryopreserved%2520human%2520hepatocytes%2520for%2520the%2520assessment%2520of%2520cytochrome%2520P450%2520inducibility%253A%2520experimental%2520condition-related%2520variables%2520affecting%2520their%2520response%2520to%2520inducers%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D10%26spage%3D968%26epage%3D979%26doi%3D10.3109%2F00498254.2012.676693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, T.</span></span> <span> </span><span class="NLM_article-title">A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.028613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20699409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1912-1916&issue=11&author=N.+Kamiguchiauthor=E.+Aoyamaauthor=T.+Okudaauthor=T.+Moriwaki&title=A+96-well+plate+assay+for+CYP4503A+induction+using+cryopreserved+human+hepatocytes&doi=10.1124%2Fdmd.109.028613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes</span></div><div class="casAuthors">Kamiguchi, Naomi; Aoyama, Eiji; Okuda, Teruaki; Moriwaki, Toshiya</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1912-1916</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A reliable and practical CYP3A induction assay with cryopreserved human hepatocytes in a 96-well format was developed.  Various 96-well plates with different basement membrane were evaluated using prototypical inducers, rifampicin, phenytoin, and carbamazepine.  Thin-layer (TL) Matrigel was found to yield the highest basal and induced levels of CYP3A activity as detd. by testosterone 6β-hydroxylation.  Concn.-dependent CYP3A induction of rifampicin was reproducible with the EC50 values of 0.36 ± 0.28 μM from four batches of human hepatocytes using the 96-well plate with TL Matrigel.  The rank order of induction potency for nine inducers or noninducers at a concn. of 10 μM were well comparable among the multiple donors, by expressing the results as percentage of change compared with the pos. control, 10 μM rifampicin.  Cotreatment of avasimibe or efavirenz with 10 μM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.  From a comparison of induced CYP3A activities and gene expression levels, there were compds. that would cause induction of CYP3A4 mRNA but not activity, presumably due to their inhibitory effect on CYP3A activity.  The cotreatment assay of test compd. with rifampicin allows us to exclude the false-neg. results caused by the cytotoxicity and/or the mechanism-based inactivation, when the drug candidate's ability for CYP3A induction is evaluating the enzyme activity.  This 96-well plate assay, which is robust, reproducible, and convenient, has demonstrated the paramount applicability to the early drug discovery stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBoBVfUJb69LVg90H21EOLACvtfcHk0lg99BnwbEWKJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurrN&md5=b6d2b306c423f874e04557c2d7f8c855</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028613%26sid%3Dliteratum%253Aachs%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DAoyama%26aufirst%3DE.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DMoriwaki%26aufirst%3DT.%26atitle%3DA%252096-well%2520plate%2520assay%2520for%2520CYP4503A%2520induction%2520using%2520cryopreserved%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D11%26spage%3D1912%26epage%3D1916%26doi%3D10.1124%2Fdmd.109.028613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell’Aiera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, H.</span></span> <span> </span><span class="NLM_article-title">Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.719088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F00498254.2012.719088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23153057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=320-335&issue=4&author=B.+Gerinauthor=S.+Dell%E2%80%99Aieraauthor=L.+Richertauthor=S.+Smithauthor=H.+Chanteux&title=Assessment+of+cytochrome+P450+%281A2%2C+2B6%2C+2C9+and+3A4%29+induction+in+cryopreserved+human+hepatocytes+cultured+in+48-well+plates+using+the+cocktail+strategy&doi=10.3109%2F00498254.2012.719088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy</span></div><div class="casAuthors">Gerin, Brigitte; Dell'Aiera, Sylvie; Richert, Lysiane; Smith, Steven; Chanteux, Hugues</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-335</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. A fast, straightforward and cost-effective assay was validated for the assessment of CYP induction in cryopreserved human hepatocytes cultured in 48-well plates.  The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, resp.2.  Cryopreserved human hepatocytes were treated for 72 h with prototypical ref. inducers, β-naphthoflavone (25 μM), phenobarbital (500 μM) and rifampicin (10 μM) as pos. controls for CYP induction.  The use of a cocktail strategy has been validated and compared to the classical approach (single incubation).  The need of using phase II inhibitor (salicylamide) in CYP induction assay was also investigated.3.  By using three different batches of cryopreserved human hepatocytes and our conditions of incubations, we showed that there was no relevant drug-drug interaction using the cocktail strategy.  The same conclusions were obsd. when a broad range of enzyme activity has to be assessed (wide range of ref. inducers, i.e. EC50-Emax expt.).  In addn., the interassay reproducibility assessment showed that the day-to-day variability was minimal.4.  In summary, the study showed that the conditions used (probe substrates, concn. of probe substrate and time of incubation) for the cocktail approach were appropriate for investigations of CYP induction potential of new chem. entities.  In addn., it was also clear that the use of salicylamide in the incubation media was not mandatory and could generate drug-drug interactions.  For this reason, we recommend to not use salicylamide in CYP induction assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob8cySbzrBjbVg90H21EOLACvtfcHk0lg99BnwbEWKJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWnuro%253D&md5=42e8e42b784fc430c0c7753bfec0be4a</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.719088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.719088%26sid%3Dliteratum%253Aachs%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DDell%25E2%2580%2599Aiera%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DChanteux%26aufirst%3DH.%26atitle%3DAssessment%2520of%2520cytochrome%2520P450%2520%25281A2%252C%25202B6%252C%25202C9%2520and%25203A4%2529%2520induction%2520in%2520cryopreserved%2520human%2520hepatocytes%2520cultured%2520in%252048-well%2520plates%2520using%2520the%2520cocktail%2520strategy%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26issue%3D4%26spage%3D320%26epage%3D335%26doi%3D10.3109%2F00498254.2012.719088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilk-Zasadna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asturiol, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Vieira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coecke, S.</span></span> <span> </span><span class="NLM_article-title">Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2019.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tiv.2019.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31158489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=212-228&author=C.+Bernasconiauthor=O.+Pelkonenauthor=T.+B.+Anderssonauthor=J.+Stricklandauthor=I.+Wilk-Zasadnaauthor=D.+Asturiolauthor=T.+Coleauthor=R.+Liskaauthor=A.+Worthauthor=U.+Muller-Vieiraauthor=L.+Richertauthor=C.+Chesneauthor=S.+Coecke&title=Validation+of+in+vitro+methods+for+human+cytochrome+P450+enzyme+induction%3A+Outcome+of+a+multi-laboratory+study&doi=10.1016%2Fj.tiv.2019.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study</span></div><div class="casAuthors">Bernasconi, Camilla; Pelkonen, Olavi; Andersson, Tommy B.; Strickland, Judy; Wilk-Zasadna, Iwona; Asturiol, David; Cole, Thomas; Liska, Roman; Worth, Andrew; Muller-Vieira, Ursula; Richert, Lysiane; Chesne, Christophe; Coecke, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-228</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event assocd. with thyroid disruption, and a biomarker for toxicol. relevant nuclear receptor-mediated pathways.  This paper summarizes the results of a multi-lab. validation study of two in vitro methods that assess the potential of chems. to induce cytochrome P 450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4.  The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells.  The validation study was coordinated by the European Union Ref. Lab. for Alternatives to Animal Testing of the European Commission's Joint Research Center and involved a ring trial among six labs.  The reproducibility was assessed within and between labs. using a validation set of 13 selected chems. (known human inducers and non-inducers) tested under blind conditions.  The ability of the two methods to predict human CYP induction potential was assessed.  Chem. space anal. confirmed that the selected chems. are broadly representative of a diverse range of chems.  The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing.  Recommendations for the practical application of the two methods are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovbDBq4KT3YbVg90H21EOLACvtfcHk0ljEb6C4VxH7xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsLbM&md5=3e7abd48790f1a27f97fd5b01d5cae5c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2019.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2019.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DStrickland%26aufirst%3DJ.%26aulast%3DWilk-Zasadna%26aufirst%3DI.%26aulast%3DAsturiol%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DT.%26aulast%3DLiska%26aufirst%3DR.%26aulast%3DWorth%26aufirst%3DA.%26aulast%3DMuller-Vieira%26aufirst%3DU.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DChesne%26aufirst%3DC.%26aulast%3DCoecke%26aufirst%3DS.%26atitle%3DValidation%2520of%2520in%2520vitro%2520methods%2520for%2520human%2520cytochrome%2520P450%2520enzyme%2520induction%253A%2520Outcome%2520of%2520a%2520multi-laboratory%2520study%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2019%26volume%3D60%26spage%3D212%26epage%3D228%26doi%3D10.1016%2Fj.tiv.2019.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilmant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depelchin, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhalluin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atienzar, F. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins</span>. <i>Cell Biol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s10565-011-9208-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs10565-011-9208-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22258563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=69-87&issue=2&author=H.+H.+Geretsauthor=K.+Tilmantauthor=B.+Gerinauthor=H.+Chanteuxauthor=B.+O.+Depelchinauthor=S.+Dhalluinauthor=F.+A.+Atienzar&title=Characterization+of+primary+human+hepatocytes%2C+HepG2+cells%2C+and+HepaRG+cells+at+the+mRNA+level+and+CYP+activity+in+response+to+inducers+and+their+predictivity+for+the+detection+of+human+hepatotoxins&doi=10.1007%2Fs10565-011-9208-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins</span></div><div class="casAuthors">Gerets, H. H. J.; Tilmant, K.; Gerin, B.; Chanteux, H.; Depelchin, B. O.; Dhalluin, S.; Atienzar, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-87</span>CODEN:
                <span class="NLM_cas:coden">CBTOE2</span>;
        ISSN:<span class="NLM_cas:issn">0742-2091</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In the pharmaceutical industry, improving the early detection of drug-induced hepatotoxicity is essential as it is one of the most important reasons for attrition of candidate drugs during the later stages of drug development.  The first objective of this study was to better characterize different cellular models (i.e., HepG2, HepaRG cells, and fresh primary human hepatocytes) at the gene expression level and analyze their metabolic cytochrome P 450 capabilities.  The cellular models were exposed to three different CYP450 inducers; beta-naphthoflavone (BNF), phenobarbital (PB), and rifampicin (RIF).  HepG2 cells responded very weakly to the different inducers at the gene expression level, and this translated generally into low CYP450 activities in the induced cells compared with the control cells.  On the contrary, HepaRG cells and the three human donors were inducible after exposure to BNF, PB, and RIF according to gene expression responses and CYP450 activities.  Consequently, HepaRG cells could be used in screening as a substitute and/or in complement to primary hepatocytes for CYP induction studies.  The second objective was to investigate the predictivity of the different cellular models to detect hepatotoxins (16 hepatotoxic and 5 nonhepatotoxic compds.).  Specificity was 100% with the different cellular models tested.  Cryopreserved human hepatocytes gave the highest sensitivity, ranging from 31% to 44% (depending on the donor), followed by lower sensitivity (13%) for HepaRG and HepG2 cells (6.3%).  Overall, none of the models under study gave desirable sensitivities (80-100%).  Consequently, a high metabolic capacity and CYP inducibility in cell lines does not necessarily correlate with a high sensitivity for the detection of hepatotoxic drugs.  Further investigations are necessary to compare different cellular models and det. those that are best suited for the detection of hepatotoxic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w-GT2Vz3D7Vg90H21EOLACvtfcHk0ljEb6C4VxH7xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOntr4%253D&md5=c934bdf740236466cb9885e0f4cb2502</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1007%2Fs10565-011-9208-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10565-011-9208-4%26sid%3Dliteratum%253Aachs%26aulast%3DGerets%26aufirst%3DH.%2BH.%26aulast%3DTilmant%26aufirst%3DK.%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DChanteux%26aufirst%3DH.%26aulast%3DDepelchin%26aufirst%3DB.%2BO.%26aulast%3DDhalluin%26aufirst%3DS.%26aulast%3DAtienzar%26aufirst%3DF.%2BA.%26atitle%3DCharacterization%2520of%2520primary%2520human%2520hepatocytes%252C%2520HepG2%2520cells%252C%2520and%2520HepaRG%2520cells%2520at%2520the%2520mRNA%2520level%2520and%2520CYP%2520activity%2520in%2520response%2520to%2520inducers%2520and%2520their%2520predictivity%2520for%2520the%2520detection%2520of%2520human%2520hepatotoxins%26jtitle%3DCell%2520Biol.%2520Toxicol.%26date%3D2012%26volume%3D28%26issue%3D2%26spage%3D69%26epage%3D87%26doi%3D10.1007%2Fs10565-011-9208-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanebratt, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.107.017418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17954527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=137-145&issue=1&author=K.+P.+Kanebrattauthor=T.+B.+Andersson&title=HepaRG+cells+as+an+in+vitro+model+for+evaluation+of+cytochrome+P450+induction+in+humans&doi=10.1124%2Fdmd.107.017418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans</span></div><div class="casAuthors">Kanebratt, Kajsa P.; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-145</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">HepaRG is a highly differentiated cell line that displays several hepatocyte-like functions, including drug-metabolizing enzymes.  In this study, the HepaRG cells were characterized and evaluated as an in vitro model to predict cytochrome P 450 (P 450) enzyme induction of drugs in humans.  Exposure of HepaRG cells to prototypical inducers resulted in induction of CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 mRNA, as well as phenacetin O-dealkylase, bupropion hydroxylase, diclofenac 4'-hydroxylase, and midazolam 1'-hydroxylase activities.  The obsd. induction is consistent with the previously reported expression of the nuclear receptors pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor, which are necessary for a P 450 induction response.  To avoid problems with toxicity and soly., the induction potency of test compds. was evaluated by calcg. the concns. leading to a 2-fold increase of baseline mRNA or enzyme activity levels (F2 values) instead of EC50 values from full dose-response curves.  For CYP3A4 mRNA, the obtained F2 values were related to the in vivo exposure [area under the plasma concn. vs. time curve (AUC)] of the inducer (AUC/F2).  This score was then correlated with the decrease in AUC for a CYP3A probe drug, administered before and after treatment with the inducing agent.  By using this method an excellent correlation (R2 = 0.863) was obtained, which implies that the degree of CYP3A induction in vivo can be predicted from CYP3A4 mRNA induction in HepaRG cells.  The present study shows that HepaRG cells are a valuable model to be used for prediction of induction of drug-metabolizing P 450 enzymes in vivo in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYyE5u3pdNhrVg90H21EOLACvtfcHk0ljEb6C4VxH7xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFGkug%253D%253D&md5=90adf2af9291a73b0f7ce90a84ee301a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017418%26sid%3Dliteratum%253Aachs%26aulast%3DKanebratt%26aufirst%3DK.%2BP.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DHepaRG%2520cells%2520as%2520an%2520in%2520vitro%2520model%2520for%2520evaluation%2520of%2520cytochrome%2520P450%2520induction%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D1%26spage%3D137%26epage%3D145%26doi%3D10.1124%2Fdmd.107.017418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lechon, M. J.</span></span> <span> </span><span class="NLM_article-title">Culture and functional characterization of human hepatoma HepG2 cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1250</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-2074-7_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2F978-1-4939-2074-7_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26272135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1250&publication_year=2015&pages=77-93&author=M.+T.+Donatoauthor=L.+Tolosaauthor=M.+J.+Gomez-Lechon&title=Culture+and+functional+characterization+of+human+hepatoma+HepG2+cells&doi=10.1007%2F978-1-4939-2074-7_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Culture and functional characterization of human hepatoma HepG2 cells</span></div><div class="casAuthors">Donato, Maria Teresa; Tolosa, Laia; Gomez-Lechon, Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1250</span>
        (<span class="NLM_cas:issue">Protocols in In Vitro Hepatocyte Research</span>),
    <span class="NLM_cas:pages">77-93</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Hepatoma cell lines are frequently used as in vitro alternatives to primary human hepatocytes.  Cell lines are characterized by their unlimited life span, stable phenotype, high availability, and easy handling.  However, their major limitation is the lower expression of some metabolic activities compared with hepatocytes.  HepG2 is a human hepatoma that is most commonly used in drug metab. and hepatotoxicity studies.  HepG2 cells are nontumorigenic cells with high proliferation rates and an epithelial-like morphol. that perform many differentiated hepatic functions.  In this chapter, freezing, thawing, and subculturing procedures for HepG2 cells are described.  We further provide protocols for evaluating lipid accumulation, glycogen storage, urea synthesis, and phase I and phase II drug metabolizing activities in HepG2 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJtIIBkq4ryrVg90H21EOLACvtfcHk0ljWQBu_GOPIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtb7F&md5=a6b158d9a18180387126ef445908431a</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2074-7_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-2074-7_5%26sid%3Dliteratum%253Aachs%26aulast%3DDonato%26aufirst%3DM.%2BT.%26aulast%3DTolosa%26aufirst%3DL.%26aulast%3DGomez-Lechon%26aufirst%3DM.%2BJ.%26atitle%3DCulture%2520and%2520functional%2520characterization%2520of%2520human%2520hepatoma%2520HepG2%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2015%26volume%3D1250%26spage%3D77%26epage%3D93%26doi%3D10.1007%2F978-1-4939-2074-7_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span> <span> </span><span class="NLM_article-title">Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.108.020677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18332078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1046-1055&issue=6&author=N.+Hariparsadauthor=B.+A.+Carrauthor=R.+Eversauthor=X.+Chu&title=Comparison+of+immortalized+Fa2N-4+cells+and+human+hepatocytes+as+in+vitro+models+for+cytochrome+P450+induction&doi=10.1124%2Fdmd.108.020677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction</span></div><div class="casAuthors">Hariparsad, Niresh; Carr, Brian A.; Evers, Raymond; Chu, Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1046-1055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fa2N-4 cells have been proposed as a tool to identify CYP3A4 inducers.  To evaluate whether Fa2N-4 cells are a reliable surrogate for cryopreserved human hepatocytes, the authors assessed the basal mRNA expression of 64 drug disposition genes in Fa2N-4 cells.  Significant differences were found in the expression of major drug-metabolizing enzymes, nuclear receptors, and transporters between both cell types.  Importantly, the expression of constitutive androstane receptor (CAR) and several hepatic uptake transporters was significantly lower (>50-fold) in Fa2N-4 cells, whereas the expression of pregnane X-receptor (PXR) and aryl hydrocarbon receptor (AhR) was similar between Fa2N-4 cells and human hepatocytes.  By using an optimized induction assay for Fa2N-4 cells, CYP3A4 induction by rifampicin, the prototypical PXR activator, increased from 1.5- to 7-fold at the level of functional activity.  With nine selected compds., which are known inducers of CYP3A4 either via activation of PXR, CAR, or both, the authors evaluated CYP3A4 and CYP2B6 mRNA induction using Fa2N-4 cells and human hepatocytes.  No response was obsd. in Fa2N-4 cells treated with the selective CAR activators 6-(4-chlorophenyl)imidazo[2,1-b][1,3]-thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime and artemisinin.  CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.  This finding was in agreement with the lack of expression of CAR.  The EC50 value for rifampicin-mediated CYP3A4 induction was 10-fold higher than that in human hepatocytes.  This result could be attributed to the low expression of hepatic org. anion-transporting polypeptides OATP1B1 and OATP1B3 in Fa2N-4 cells.  In summary, the findings identify limitations of Fa2N-4 cells as a predictive induction model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3DPpt6tkQ7Vg90H21EOLACvtfcHk0ljWQBu_GOPIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbk%253D&md5=30fb194a166481cea4cf9de0f20f3ac3</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020677%26sid%3Dliteratum%253Aachs%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DCarr%26aufirst%3DB.%2BA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DX.%26atitle%3DComparison%2520of%2520immortalized%2520Fa2N-4%2520cells%2520and%2520human%2520hepatocytes%2520as%2520in%2520vitro%2520models%2520for%2520cytochrome%2520P450%2520induction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D6%26spage%3D1046%26epage%3D1055%26doi%3D10.1124%2Fdmd.108.020677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulutoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Bedon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarmush, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usta, O. B.</span></span> <span> </span><span class="NLM_article-title">A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e0229106</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0229106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0229106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32106230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&issue=2&author=B.+Bulutogluauthor=C.+Rey-Bedonauthor=S.+Mertauthor=L.+Tianauthor=Y.+Y.+Jangauthor=M.+L.+Yarmushauthor=O.+B.+Usta&title=A+comparison+of+hepato-cellular+in+vitro+platforms+to+study+CYP3A4+induction&doi=10.1371%2Fjournal.pone.0229106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction</span></div><div class="casAuthors">Bulutoglu, Beyza; Rey-Bedon, Camilo; Mert, Safak; Tian, Lipeng; Jang, Yoon-Young; Yarmush, Martin L.; Usta, O. Berk</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0229106</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In vitro studies of drug toxicity and drug-drug interactions are crucial for drug development efforts.  Currently, the utilization of primary human hepatocytes (PHHs) is the de facto std. for this purpose, due to their functional xenobiotic response and drug metabolizing CYP450 enzyme metab.  However, PHHs are scarce, expensive, require laborious maintenance, and exhibit lot-to-lot heterogeneity.  Alternative human in vitro platforms include hepatic cell lines, which are easy to access and maintain, and induced pluripotent stem cell (iPSC) derived hepatocytes.  In this study, we provide a direct comparison of drug induced CYP3A4 and PXR expression levels of PHHs, hepatic cell lines Huh7 and HepG2, and iPSC derived hepatocyte like cells.  Confluently cultured Huh7s exhibited an improved CYP3A4 expression and were inducible by up to 4.9-fold, and hepatocytes differentiated from human iPSCs displayed a 3.3-fold CYP3A4 induction.  In addn., an increase in PXR expression levels was obsd. in both hepatic cell lines and iPSC derived hepatocytes upon rifampicin treatment, whereas a reproducible increase in PXR expression was not achieved in PHHs.  Our results indicate that both hepatoma originated cell lines and iPSCs may provide alternative sources to primary hepatocytes, providing reliable and reproducible results for CYP3A4/PXR metab., upon in vitro maturation.  This study may serve as a guide for the selection of suitable and feasible in vitro platforms for drug-drug interaction and toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcd_UbsGj877Vg90H21EOLACvtfcHk0ljWQBu_GOPIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVKmtbg%253D&md5=ba869e6337d8d3e1a5d2e72f47f752a4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0229106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0229106%26sid%3Dliteratum%253Aachs%26aulast%3DBulutoglu%26aufirst%3DB.%26aulast%3DRey-Bedon%26aufirst%3DC.%26aulast%3DMert%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DY.%2BY.%26aulast%3DYarmush%26aufirst%3DM.%2BL.%26aulast%3DUsta%26aufirst%3DO.%2BB.%26atitle%3DA%2520comparison%2520of%2520hepato-cellular%2520in%2520vitro%2520platforms%2520to%2520study%2520CYP3A4%2520induction%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26issue%3D2%26doi%3D10.1371%2Fjournal.pone.0229106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafagh, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, D. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">3D Primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: Emerging culture paradigms and applications</span>. <i>Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">1800347</span> <span class="refDoi"> DOI: 10.1002/biot.201800347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbiot.201800347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=7&author=V.+M.+Lauschkeauthor=R.+Z.+Shafaghauthor=D.+F.+G.+Hendriksauthor=M.+Ingelman-Sundberg&title=3D+Primary+hepatocyte+culture+systems+for+analyses+of+liver+diseases%2C+drug+metabolism%2C+and+toxicity%3A+Emerging+culture+paradigms+and+applications&doi=10.1002%2Fbiot.201800347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fbiot.201800347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.201800347%26sid%3Dliteratum%253Aachs%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DShafagh%26aufirst%3DR.%2BZ.%26aulast%3DHendriks%26aufirst%3DD.%2BF.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3D3D%2520Primary%2520hepatocyte%2520culture%2520systems%2520for%2520analyses%2520of%2520liver%2520diseases%252C%2520drug%2520metabolism%252C%2520and%2520toxicity%253A%2520Emerging%2520culture%2520paradigms%2520and%2520applications%26jtitle%3DBiotechnol.%2520J.%26date%3D2019%26volume%3D14%26issue%3D7%26doi%3D10.1002%2Fbiot.201800347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span> <span> </span><span class="NLM_article-title">Bioengineered liver models for drug testing and cell differentiation studies</span>. <i>Cell Mol Gastroenterol Hepatol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.jcmgh.2017.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jcmgh.2017.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29675458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=426-439&issue=3&author=G.+H.+Underhillauthor=S.+R.+Khetani&title=Bioengineered+liver+models+for+drug+testing+and+cell+differentiation+studies&doi=10.1016%2Fj.jcmgh.2017.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span></div><div class="casAuthors">Underhill Gregory H; Khetani Salman R</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-439.e1</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic.  Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix-coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli.  The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell-derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non-liver-derived nonparenchymal cell types.  In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types.  Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function.  Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed.  Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_LbJGsVkC5cyail4HZd-ifW6udTcc2ebf8FkDVO6BxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D&md5=ab67813eb483dfbfe5d5e799b065b40d</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2017.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2017.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DUnderhill%26aufirst%3DG.%2BH.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26atitle%3DBioengineered%2520liver%2520models%2520for%2520drug%2520testing%2520and%2520cell%2520differentiation%2520studies%26jtitle%3DCell%2520Mol%2520Gastroenterol%2520Hepatol%26date%3D2018%26volume%3D5%26issue%3D3%26spage%3D426%26epage%3D439%26doi%3D10.1016%2Fj.jcmgh.2017.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berridge, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vleet, T. R.</span></span> <span> </span><span class="NLM_article-title">Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications</span>. <i>Lab Chip</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1039/C9LC01168D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FC9LC01168D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32073020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BB387js1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1049-1057&issue=6&author=K.+Fabreauthor=B.+Berridgeauthor=W.+R.+Proctorauthor=S.+Ralstonauthor=Y.+Willauthor=S.+W.+Baranauthor=G.+Yoderauthor=T.+R.+Van+Vleet&title=Introduction+to+a+manuscript+series+on+the+characterization+and+use+of+microphysiological+systems+%28MPS%29+in+pharmaceutical+safety+and+ADME+applications&doi=10.1039%2FC9LC01168D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications</span></div><div class="casAuthors">Fabre Kristin; Berridge Brian; Proctor William R; Ralston Sherry; Van Vleet Terry R; Will Yvonne; Baran Szczepan W; Yoder Gorm</div><div class="citationInfo"><span class="NLM_cas:title">Lab on a chip</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1049-1057</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Safety related drug failures continue to be a challenge for pharmaceutical companies despite the numerous complex and lengthy in vitro assays and in vivo studies that make up the typical safety screening funnel.  A lack of complete translation of animal data to humans can explain some of those shortcomings.  Differences in sensitivity and drug disposition between animals and humans may also play a role.  Many gaps exist for potential target tissues of drugs that cannot be adequately modeled in vitro.  Microphysiological systems (MPS) may help to better model these target tissues and provide an opportunity to better assess some aspects of human safety prior to clinical studies.  There is hope that these systems can supplement current preclinical drug safety and disposition evaluations, filling gaps and enhancing our ability to predict and understand human relevant toxicities.  The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) MPS Affiliate is a group of pharmaceutical industry scientists who seek to expedite appropriate characterization and incorporation of MPS to potentially improve drug safety assessment and provide safer and more effective medicines to patients.  In keeping with this mission, the IQ MPS Affiliate scientists have prepared a series of organotypic manuscripts for several key drug safety and disposition target tissues (lung, liver, kidney, skin, gastrointestinal, cardiovascular, and blood brain barrier/central nervous system).  The goal of these manuscripts is to provide key information related to likely initial contexts of use (CoU) and key characterization data needed for incorporation of MPS in pharmaceutical safety screening including a list of characteristic functions, cell types, toxicities, and test agents (representing major mechanisms of toxicity) that can be used by MPS developers.  Additional manuscripts focusing on testing biologically based therapeutics and ADME considerations have been prepared as part of this effort.  These manuscripts focus on general needs for assessing biologics and ADME endpoints and include similar information to the tissue specific manuscripts where appropriate.  The current manuscript is an introduction to several general concepts related to pharmaceutical industry needs with regard to MPS application and other MPS concepts that apply across the organ specific manuscripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8is6LjALEtyzdcP07UmufW6udTcc2ebf8FkDVO6BxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387js1Sgsg%253D%253D&md5=ed9bd55146d9f9e5184e3f8870e5b466</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2FC9LC01168D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9LC01168D%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DK.%26aulast%3DBerridge%26aufirst%3DB.%26aulast%3DProctor%26aufirst%3DW.%2BR.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DBaran%26aufirst%3DS.%2BW.%26aulast%3DYoder%26aufirst%3DG.%26aulast%3DVan%2BVleet%26aufirst%3DT.%2BR.%26atitle%3DIntroduction%2520to%2520a%2520manuscript%2520series%2520on%2520the%2520characterization%2520and%2520use%2520of%2520microphysiological%2520systems%2520%2528MPS%2529%2520in%2520pharmaceutical%2520safety%2520and%2520ADME%2520applications%26jtitle%3DLab%2520Chip%26date%3D2020%26volume%3D20%26issue%3D6%26spage%3D1049%26epage%3D1057%26doi%3D10.1039%2FC9LC01168D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronxhi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodella, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropolis, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubins, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conegliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karalis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span> <span> </span><span class="NLM_article-title">Reproducing human and cross-species drug toxicities using a Liver-Chip</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">517</span>), <span class="NLM_elocation-id">eaax5516</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aax5516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1126%2Fscitranslmed.aax5516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31694927" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&issue=517&author=K.+J.+Jangauthor=M.+A.+Otienoauthor=J.+Ronxhiauthor=H.+K.+Limauthor=L.+Ewartauthor=K.+R.+Kodellaauthor=D.+B.+Petropolisauthor=G.+Kulkarniauthor=J.+E.+Rubinsauthor=D.+Coneglianoauthor=J.+Nawrothauthor=D.+Simicauthor=W.+Lamauthor=M.+Singerauthor=E.+Baraleauthor=B.+Singhauthor=M.+Soneeauthor=A.+J.+Streeterauthor=C.+Mantheyauthor=B.+Jonesauthor=A.+Srivastavaauthor=L.+C.+Anderssonauthor=D.+Williamsauthor=H.+Parkauthor=R.+Barrileauthor=J.+Slizauthor=A.+Herlandauthor=S.+Haneyauthor=K.+Karalisauthor=D.+E.+Ingberauthor=G.+A.+Hamilton&title=Reproducing+human+and+cross-species+drug+toxicities+using+a+Liver-Chip&doi=10.1126%2Fscitranslmed.aax5516"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5516%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DK.%2BJ.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DRonxhi%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DKodella%26aufirst%3DK.%2BR.%26aulast%3DPetropolis%26aufirst%3DD.%2BB.%26aulast%3DKulkarni%26aufirst%3DG.%26aulast%3DRubins%26aufirst%3DJ.%2BE.%26aulast%3DConegliano%26aufirst%3DD.%26aulast%3DNawroth%26aufirst%3DJ.%26aulast%3DSimic%26aufirst%3DD.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DBarale%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DSonee%26aufirst%3DM.%26aulast%3DStreeter%26aufirst%3DA.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DBarrile%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DJ.%26aulast%3DHerland%26aufirst%3DA.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DKaralis%26aufirst%3DK.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26atitle%3DReproducing%2520human%2520and%2520cross-species%2520drug%2520toxicities%2520using%2520a%2520Liver-Chip%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26issue%3D517%26doi%3D10.1126%2Fscitranslmed.aax5516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Ven, A. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdt, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahteenmaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multicenter study</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Ftoxsci%2Fkfx289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29329425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=655-666&issue=2&author=C.+C.+Bellauthor=A.+C.+A.+Dankersauthor=V.+M.+Lauschkeauthor=R.+Sison-Youngauthor=R.+Jenkinsauthor=C.+Roweauthor=C.+E.+Goldringauthor=K.+Parkauthor=S.+L.+Reganauthor=T.+Walkerauthor=C.+Schofieldauthor=A.+Bazeauthor=A.+J.+Fosterauthor=D.+P.+Williamsauthor=A.+W.+M.+van+de%0AVenauthor=F.+Jacobsauthor=J.+V.+Houdtauthor=T.+Lahteenmakiauthor=J.+Snoeysauthor=S.+Juhilaauthor=L.+Richertauthor=M.+Ingelman-Sundberg&title=Comparison+of+hepatic+2D+sandwich+cultures+and+3D+spheroids+for+long-term+toxicity+applications%3A+A+multicenter+study&doi=10.1093%2Ftoxsci%2Fkfx289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study</span></div><div class="casAuthors">Bell, Catherine C.; Dankers, Anita C. A.; Lauschke, Volker M.; Sison-Young, Rowena; Jenkins, Roz; Rowe, Cliff; Goldring, Chris E.; Park, Kevin; Regan, Sophie L.; Walker, Tracy; Schofield, Chris; Baze, Audrey; Foster, Alison J.; Williams, Dominic P.; van de Ven, Amy W. M.; Jacobs, Frank; Van Houdt, Jos; Laehteenmaeki, Tuula; Snoeys, Jan; Juhila, Satu; Richert, Lysiane; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-666</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced liver injury.  However, when cultured as 2D monolayers, PHH lose crucial hepatic functions within hours.  This dedifferentiation can be ameliorated when PHHs are cultured in sandwich configuration (2Dsw), particularly when cultures are regularly re-overlaid with extracellular matrix, or as 3D spheroids.  In this study, the 6 participating labs. evaluated the robustness of these 2 model systems made from cryopreserved PHH from the same donors considering both inter-donor and inter-lab. variability and compared their suitability for use in repeated-dose toxicity studies using 5 different hepatotoxins with different toxicity mechanisms.  We found that expression levels of proteins involved in drug absorption, distribution, metab., and excretion, as well as catalytic activities of 5 different CYPs, were significantly higher in 3D spheroid cultures, potentially affecting the exposure of the cells to drugs and their metabolites.  Furthermore, global proteomic analyses revealed that PHH in 3D spheroid configuration were temporally stable whereas proteomes from the same donors in 2Dsw cultures showed substantial alterations in protein expression patterns over the 14 days in culture.  Overall, spheroid cultures were more sensitive to the hepatotoxic compds. investigated, particularly upon long-term exposures, across testing sites with little inter-lab. or inter-donor variability.  The data presented here suggest that repeated-dosing regimens improve the predictivity of in vitro toxicity assays, and that PHH spheroids provide a sensitive and robust system for long-term mechanistic studies of drug-induced hepatotoxicity, whereas the 2Dsw system has a more dedifferentiated phenotype and lower sensitivity to detect hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigGHJ8Vmu_7Vg90H21EOLACvtfcHk0lhXip-I7Hrvwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF&md5=4154ee24a1a0c93374e00f0e7cc50e35</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx289%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DSison-Young%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DSchofield%26aufirst%3DC.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DA.%2BW.%2BM.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DLahteenmaki%26aufirst%3DT.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DComparison%2520of%2520hepatic%25202D%2520sandwich%2520cultures%2520and%25203D%2520spheroids%2520for%2520long-term%2520toxicity%2520applications%253A%2520A%2520multicenter%2520study%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26issue%3D2%26spage%3D655%26epage%3D666%26doi%3D10.1093%2Ftoxsci%2Fkfx289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crogan-Grundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">e0158674</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0158674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0158674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27387377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&issue=7&author=D.+G.+Nguyenauthor=J.+Funkauthor=J.+B.+Robbinsauthor=C.+Crogan-Grundyauthor=S.+C.+Presnellauthor=T.+Singerauthor=A.+B.+Roth&title=Bioprinted+3D+primary+liver+tissues+allow+assessment+of+organ-level+response+to+clinical+drug+induced+toxicity+in+vitro&doi=10.1371%2Fjournal.pone.0158674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span></div><div class="casAuthors">Nguyen, Deborah G.; Funk, Juergen; Robbins, Justin B.; Crogan-Grundy, Candace; Presnell, Sharon C.; Singer, Thomas; Roth, Adrian B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158674/1-e0158674/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modeling clin. relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI).  This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicol.  In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and nonparenchymal cells in a defined architecture.  Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histol. anal. that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin pos., smooth muscle actin neg. quiescent stellates.  Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 wk in culture.  To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by std. pre-clin. models, were compared to the structurally related non-toxic drug Levofloxacin.  Trovafloxacin induced significant, dosedependent toxicity at clin. relevant doses (≤ 4uM).  Interestingly, Trovafloxacin toxicity was obsd. without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports.  Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compds. with differential profile.  Thus, the combination of patient-derived primary cells with bioprinting technol. here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYl7I6xmS4qrVg90H21EOLACvtfcHk0lhXip-I7Hrvwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI&md5=3444083b1e6affcca18ae9063c66ae90</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158674%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DRobbins%26aufirst%3DJ.%2BB.%26aulast%3DCrogan-Grundy%26aufirst%3DC.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26atitle%3DBioprinted%25203D%2520primary%2520liver%2520tissues%2520allow%2520assessment%2520of%2520organ-level%2520response%2520to%2520clinical%2520drug%2520induced%2520toxicity%2520in%2520vitro%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D7%26doi%3D10.1371%2Fjournal.pone.0158674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">FDA.</span> <i>In vitro drug interaction studies —
Cytochrome P450
enzyme- and transporter-mediated drug interactions guidance for industry</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+In+vitro+drug+interaction+studies+%E2%80%94%0ACytochrome+P450%0Aenzyme-+and+transporter-mediated+drug+interactions+guidance+for+industry.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DIn%2520vitro%2520drug%2520interaction%2520studies%2520%25E2%2580%2594%250ACytochrome%2520P450%250Aenzyme-%2520and%2520transporter-mediated%2520drug%2520interactions%2520guidance%2520for%2520industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">EMA.</span> <i>Guideline on the investigation of drug interactions</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EMA.+Guideline+on+the+investigation+of+drug+interactions.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGuideline%2520on%2520the%2520investigation%2520of%2520drug%2520interactions" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamanda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, P. D.</span></span> <span> </span><span class="NLM_article-title">Considerations from the Innovation and Quality Induction working group in response to drug-drug Interaction guidance from regulatory agencies: Guidelines on model fitting and recommendations on time course for in vitro cytochrome P450 induction studies including impact on drug interaction risk assessment</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1124/dmd.120.000055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.120.000055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=33139460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3MXpslCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2021&pages=94-110&issue=1&author=S.+G.+Wongauthor=D.+Ramsdenauthor=S.+Dallasauthor=C.+Fungauthor=H.+J.+Einolfauthor=J.+Palamandaauthor=L.+Chenauthor=T.+C.+Goosenauthor=Y.+A.+Siuauthor=G.+Zhangauthor=D.+Tweedieauthor=N.+Hariparsadauthor=B.+Jonesauthor=P.+D.+Yates&title=Considerations+from+the+Innovation+and+Quality+Induction+working+group+in+response+to+drug-drug+Interaction+guidance+from+regulatory+agencies%3A+Guidelines+on+model+fitting+and+recommendations+on+time+course+for+in+vitro+cytochrome+P450+induction+studies+including+impact+on+drug+interaction+risk+assessment&doi=10.1124%2Fdmd.120.000055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidance from regulatory agencies: guidelines on model fitting and recommendations on time course for in vitro cytochrome p450 induction studies including impact on drug interaction risk assessment</span></div><div class="casAuthors">Wong, Simon G.; Ramsden, Diane; Dallas, Shannon; Fung, Conrad; Einolf, Heidi J.; Palamanda, Jairam; Chen, Liangfu; Goosen, Theunis C.; Siu, Y. Amy; Zhang, George; Tweedie, Donald; Hariparsad, Niresh; Jones, Barry; Yates, Phillip D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-110</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Translational and ADME Sciences Leadership Group Induction Working Group (IWG) presents an anal. on the time course for cytochrome P 450 induction in primary human hepatocytes.  Despite variability in induction response across hepatocyte donors, the following recommendations are proposed: 1) 48 h should be the primary time point for in vitro assessment of induction based on mRNA level or activity, with no further benefit from 72 h; 2) when using mRNA, 24-h incubations provide reliable assessment of induction and DDI risk; 3) if validated using prototypical inducers (>10-fold induction), 12-h incubations may provide an est. of induction potential, including characterization as neg. if <2-fold induction of mRNA and no concn. dependence; 4) atypical dose-response ("bell-shaped") curves can be addressed by removing points outside an established confidence interval and %CV; 5) when max. fold induction is well defined, the choice of nonlinear regression model has limited impact on estd. induction parameters; 6) when the max. fold induction is not well defined, conservative DDI risk assessment can be obtained using sigmoidal three-parameter fit or constraining logistic three- or four-parameter fits to the max. obsd. fold induction; 7) preliminary data suggest initial slope of the fold induction curve can be used to est. Emax/EC50 and for induction risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfsRW2nVVz9LVg90H21EOLACvtfcHk0lhSqs5yR_6-sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXpslCgug%253D%253D&md5=3be1f92d0f30bd645fb1a4011cac0b96</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fdmd.120.000055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.120.000055%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DDallas%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DC.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DPalamanda%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DSiu%26aufirst%3DY.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DYates%26aufirst%3DP.%2BD.%26atitle%3DConsiderations%2520from%2520the%2520Innovation%2520and%2520Quality%2520Induction%2520working%2520group%2520in%2520response%2520to%2520drug-drug%2520Interaction%2520guidance%2520from%2520regulatory%2520agencies%253A%2520Guidelines%2520on%2520model%2520fitting%2520and%2520recommendations%2520on%2520time%2520course%2520for%2520in%2520vitro%2520cytochrome%2520P450%2520induction%2520studies%2520including%2520impact%2520on%2520drug%2520interaction%2520risk%2520assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2021%26volume%3D49%26issue%3D1%26spage%3D94%26epage%3D110%26doi%3D10.1124%2Fdmd.120.000055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A. M.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 and xenobiotic receptor humanized mice</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.100007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1146%2Fannurev.pharmtox.45.120403.100007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16402898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=41-64&author=F.+J.+Gonzalezauthor=A.+M.+Yu&title=Cytochrome+P450+and+xenobiotic+receptor+humanized+mice&doi=10.1146%2Fannurev.pharmtox.45.120403.100007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P 450 and xenobiotic receptor humanized mice</span></div><div class="casAuthors">Gonzalez, Frank J.; Yu, Ai-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-64, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Most xenobiotics that enter the body are subjected to metab. that functions primarily to facilitate their elimination.  Metab. of certain xenobiotics can also result in the prodn. of electrophilic derivs. that can cause cell toxicity and transformation.  Many xenobiotics can also activate receptors that in turn induce the expression of genes encoding xenobiotic-metabolizing enzymes and xenobiotic transporters.  However, there are marked species differences in the way mammals respond to xenobiotics, which are due in large part to mol. differences in receptors and xenobiotic-metabolizing enzymes.  This presents a problem in extrapolating data obtained with rodent model systems to humans.  There are also polymorphisms in xenobiotic-metabolizing enzymes that can impact drug therapy and cancer susceptibility.  In an effort to generate more reliable in vivo systems to study and predict human response to xenobiotics, humanized mice are under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIudUG0AjU7Vg90H21EOLACvtfcHk0lhSqs5yR_6-sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFKltLo%253D&md5=a464c6f1ffb30917630b1740d5877cbe</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.100007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.100007%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DYu%26aufirst%3DA.%2BM.%26atitle%3DCytochrome%2520P450%2520and%2520xenobiotic%2520receptor%2520humanized%2520mice%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D41%26epage%3D64%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.100007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinchuk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orcutt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoeckler, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmermacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulac, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.029637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19833845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=16-24&issue=1&author=S.+Kimauthor=J.+E.+Dinchukauthor=M.+N.+Anthonyauthor=T.+Orcuttauthor=M.+E.+Zoecklerauthor=M.+B.+Sauerauthor=K.+W.+Mosureauthor=R.+Vuppugallaauthor=J.+E.+Graceauthor=J.+Simmermacherauthor=H.+A.+Dulacauthor=J.+Pizzanoauthor=M.+Sinz&title=Evaluation+of+cynomolgus+monkey+pregnane+X+receptor%2C+primary+hepatocyte%2C+and+in+vivo+pharmacokinetic+changes+in+predicting+human+CYP3A4+induction&doi=10.1124%2Fdmd.109.029637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction</span></div><div class="casAuthors">Kim, Sean; Dinchuk, Joseph E.; Anthony, Monique N.; Orcutt, Tami; Zoeckler, Mary E.; Sauer, Mary B.; Mosure, Kathleen W.; Vuppugalla, Ragini; Grace, James E., Jr.; Simmermacher, Jean; Dulac, Heidi A.; Pizzano, Jennifer; Sinz, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Monkeys have been proposed as an animal model to predict the magnitude of human clin. drug-drug interactions caused by CYP3A4 enzyme induction.  To evaluate whether the cynomolgus monkey can be an effective in vivo model, human CYP3A4 inducers were evaluated both in vitro and in vivo.  First, a full-length pregnane X receptor (PXR) was cloned from the cynomolgus monkey, and the sequence was compared with those of rhesus monkey and human PXR.  Cynomolgus and rhesus monkey PXR differed by only one amino acid (A68V), and both were highly homologous to human PXR (∼96%).  When the transactivation profiles of 30 compds., including known inducers of CYP3A4, were compared between cynomolgus and human PXR, a high degree of correlation with EC50 values was obsd.  These results suggest that cynomolgus and human PXR respond in a similar fashion to these ligands.  Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes.  Both monkey and human hepatocytes responded similarly to the inducers and resulted in increased RNA and enzyme activity changes of CYP3A8 and CYP3A4, resp.  Lastly, in vivo induction of CYP3A8 by rifampicin and hyperforin was shown by significant redns. of midazolam exposure that were comparable with those in humans.  These results show that the cynomolgus monkey can be a predictive in vivo animal model of PXR-mediated induction of human CYP3A4 and can provide a useful assessment of the resulting pharmacokinetic changes of affected drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJLEhuCwoAr7Vg90H21EOLACvtfcHk0lhsFAi-mcx4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fF&md5=ef8c7ec7bc2470d6bd4774d0323319b3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029637%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDinchuk%26aufirst%3DJ.%2BE.%26aulast%3DAnthony%26aufirst%3DM.%2BN.%26aulast%3DOrcutt%26aufirst%3DT.%26aulast%3DZoeckler%26aufirst%3DM.%2BE.%26aulast%3DSauer%26aufirst%3DM.%2BB.%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DSimmermacher%26aufirst%3DJ.%26aulast%3DDulac%26aufirst%3DH.%2BA.%26aulast%3DPizzano%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520cynomolgus%2520monkey%2520pregnane%2520X%2520receptor%252C%2520primary%2520hepatocyte%252C%2520and%2520in%2520vivo%2520pharmacokinetic%2520changes%2520in%2520predicting%2520human%2520CYP3A4%2520induction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D1%26spage%3D16%26epage%3D24%26doi%3D10.1124%2Fdmd.109.029637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Strategy for CYP3A induction risk assessment from preclinical signal to human: a case example of a late-stage discovery compound</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2403</span>– <span class="NLM_lpage">2414</span>, <span class="refDoi"> DOI: 10.1007/s11095-017-2246-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-017-2246-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28815392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2403-2414&issue=11&author=J.+Maoauthor=P.+Fanauthor=S.+Wongauthor=J.+Wangauthor=M.+H.+A.+Ismailiauthor=B.+Deanauthor=C.+Hopauthor=M.+Wrightauthor=Y.+Chen&title=Strategy+for+CYP3A+induction+risk+assessment+from+preclinical+signal+to+human%3A+a+case+example+of+a+late-stage+discovery+compound&doi=10.1007%2Fs11095-017-2246-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound</span></div><div class="casAuthors">Mao, Jialin; Fan, Peter; Wong, Susan; Wang, Jianshuang; Ismaili, Moulay Hicham Alaoui; Dean, Brian; Hop, Cornelis E. C. A.; Wright, Matthew; Chen, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2403-2414</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The exposure of G2917 decreased by four-fold at oral doses of 100 mg/kg twice daily for seven days in cynomolgus monkeys.  Addnl. investigative work was conducted to understand: (1) the causes for the significant redn. in G2917 exposure in monkeys; (2) the extrapolation of in vitro induction data to in vivo findings in monkeys, and (3) the relevance of this preclin. finding to humans at the projected human efficacious dose.  Methods: Pharmacokinetic and induction potency (in vitro and in vivo) of G2917 in monkeys, and the in vitro human induction potency were studied.  The hepatic CYP3A biomarkers 4β-hydroxycholesterol (4β-HC) and 6β-hydroxycortisol/cortisol ratio (6β-OHC/C) were monitored in in vivo studies.  The static mechanistic model was used to quant. understand the in vitro-in vivo extrapolation (IVIVE) on the magnitude of induction retrospectively.  Physiol. based pharmacokinetic (PBPK) modeling was used to predict the human pharmacokinetics and induction-based drug-drug interactions (DDI).  Results: All in vitro and in vivo data indicate that the significant redn. in exposure of G2917 in monkeys is caused by auto-induction of CYP3A.  The mechanistic understanding of IVIVE of G2917 induction in monkey provides higher confidence in the induction risk prediction in human using the PBPK modeling.  PBPK model anal. predicted min. auto-induction and DDI liability in humans at the predicted efficacious dose.  Conclusions: The learning of this example provided a strategy to address the human CYP3A induction risk prospectively when there is an auto-induction finding in preclin. toxicol. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMEWS1xkiQLbVg90H21EOLACvtfcHk0lhsFAi-mcx4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCntLjK&md5=35d5813fe13fd95ba7164a85be4b0868</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs11095-017-2246-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-017-2246-8%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DHop%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DStrategy%2520for%2520CYP3A%2520induction%2520risk%2520assessment%2520from%2520preclinical%2520signal%2520to%2520human%253A%2520a%2520case%2520example%2520of%2520a%2520late-stage%2520discovery%2520compound%26jtitle%3DPharm.%2520Res.%26date%3D2017%26volume%3D34%26issue%3D11%26spage%3D2403%26epage%3D2414%26doi%3D10.1007%2Fs11095-017-2246-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span> <span> </span><span class="NLM_article-title">A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1002/bdd.2173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbdd.2173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30724384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVyqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=81-93&issue=2&author=H.+Taharaauthor=M.+Watanabeauthor=M.+Hasegawa&title=A+comparative+study+for+detecting+CYP3A+induction+by+CYP3A+probe+drugs+and+endogenous+markers+in+cynomolgus+monkeys&doi=10.1002%2Fbdd.2173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys</span></div><div class="casAuthors">Tahara, Harunobu; Watanabe, Miwa; Hasegawa, Maki</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-93</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">CYP3A probe drugs such as midazolam and endogenous markers, and plasma 4β-hydroxycholesterol (4β-OHC) and urinary 6β-hydroxycortisol-to-cortisol ratios (6β-OHC/C) have been used as markers of CYP3A induction in cynomolgus monkeys, as with humans.  However, there is limited information on their sensitivity and ability to detect CYP3A induction, as most studies were evaluated only at a high dose of the inducer, rifampicin (RIF; 20 mg/kg).  In the present study, the CYP3A induction by RIF over a range doses of 0.2, 2 and 20 mg/kg (n = 4) was examd. using CYP3A probe drugs (midazolam, triazolam and alprazolam) and the plasma and urinary endogenous CYP3A markers (4β-OHC and 6β-OHC/C).  The sensitivity and relationship for detecting CYP3A induction was compared among the markers.  Four days repeated oral administration of rifampicin to cynomolgus monkeys reduced the area under the plasma concn.-time curve of all CYP3A probe drugs in a rifampicin dose-dependent manner.  Although the endogenous CYP3A markers (4β-OHC and 6β-OHC/C) were also changed for the middle (2 mg/kg) and high (20 mg/kg) doses of rifampicin, the fold-changes were relatively small, and CYP3A induction could not be detected at the lowest dose of rifampicin (0.2 mg/kg).  In conclusion, CYP3A probe drugs are more sensitive for detecting CYP3A induction than endogenous CYP3A markers in cynomolgus monkeys, even for a short exptl. period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfMwlDdujOR7Vg90H21EOLACvtfcHk0lgRqh5grD3UFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVyqsLk%253D&md5=a656dc22e1ed7977b644bae204e8cc52</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2173%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26atitle%3DA%2520comparative%2520study%2520for%2520detecting%2520CYP3A%2520induction%2520by%2520CYP3A%2520probe%2520drugs%2520and%2520endogenous%2520markers%2520in%2520cynomolgus%2520monkeys%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2019%26volume%3D40%26issue%3D2%26spage%3D81%26epage%3D93%26doi%3D10.1002%2Fbdd.2173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapelyukh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheer, N.</span></span> <span> </span><span class="NLM_article-title">Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.111.071845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21628639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ektbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=518-528&issue=3&author=M.+Hasegawaauthor=Y.+Kapelyukhauthor=H.+Taharaauthor=J.+Seiblerauthor=A.+Rodeauthor=S.+Kruegerauthor=D.+N.+Leeauthor=C.+R.+Wolfauthor=N.+Scheer&title=Quantitative+prediction+of+human+pregnane+X+receptor+and+cytochrome+P450+3A4+mediated+drug-drug+interaction+in+a+novel+multiple+humanized+mouse+line&doi=10.1124%2Fmol.111.071845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line</span></div><div class="casAuthors">Hasegawa, Maki; Kapelyukh, Yury; Tahara, Harunobu; Seibler, Jost; Rode, Anja; Krueger, Sylvia; Lee, Dongtao N.; Wolf, C. Roland; Scheer, Nico</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">518-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochrome P 450 (P 450) 3A4 is the predominant P 450 enzyme expressed in human liver and intestine, and it is involved in the metab. of approx. 50% of clin. used drugs.  Because of the differences in the multiplicity of CYP3A genes and the poor correlation of substrate specificity of CYP3A proteins between species, the extrapolation of CYP3A-mediated metab. of a drug from animals to man is difficult.  This situation is further complicated by the fact that the predictability of the clin. common drug-drug interaction of pregnane X receptor (PXR)-mediated CYP3A4 induction by animal studies is limited as a result of marked species differences in the interaction of many drugs with this receptor.  Here we describe a novel multiple humanized mouse line that combines a humanization for PXR, the closely related constitutive androstane receptor, and a replacement of the mouse Cyp3a cluster with a large human genomic region carrying CYP3A4 and CYP3A7.  We provide evidence that this model shows a human-like CYP3A4 induction response to different PXR activators, that it allows the ranking of these activators according to their potency to induce CYP3A4 expression in the human liver, and that it provides an exptl. approach to quant. predict PXR/CYP3A4-mediated drug-drug interactions in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvOIptc2dOTrVg90H21EOLACvtfcHk0lgRqh5grD3UFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ektbzM&md5=bf75370b920edd055adef7aab79eb753</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071845%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DKapelyukh%26aufirst%3DY.%26aulast%3DTahara%26aufirst%3DH.%26aulast%3DSeibler%26aufirst%3DJ.%26aulast%3DRode%26aufirst%3DA.%26aulast%3DKrueger%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%2BN.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26aulast%3DScheer%26aufirst%3DN.%26atitle%3DQuantitative%2520prediction%2520of%2520human%2520pregnane%2520X%2520receptor%2520and%2520cytochrome%2520P450%25203A4%2520mediated%2520drug-drug%2520interaction%2520in%2520a%2520novel%2520multiple%2520humanized%2520mouse%2520line%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D3%26spage%3D518%26epage%3D528%26doi%3D10.1124%2Fmol.111.071845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapelyukh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span> <span> </span><span class="NLM_article-title">An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.086397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.119.086397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30910785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=601-615&issue=6&author=C.+J.+Hendersonauthor=Y.+Kapelyukhauthor=N.+Scheerauthor=A.+Rodeauthor=A.+W.+McLarenauthor=A.+K.+MacLeodauthor=D.+Linauthor=J.+Wrightauthor=L.+A.+Stanleyauthor=C.+R.+Wolf&title=An+extensively+humanized+mouse+model+to+predict+pathways+of+drug+disposition+and+drug%2Fdrug+interactions%2C+and+to+facilitate+design+of+clinical+trials&doi=10.1124%2Fdmd.119.086397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials</span></div><div class="casAuthors">Henderson, C. J.; Kapelyukh, Y.; Scheer, N.; Rode, A.; McLaren, A. W.; MacLeod, A. K.; Lin, D.; Wright, J.; Stanley, L. A.; Wolf, C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-615</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species differences in drug metab. and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often pharmacol. active), and in differential activation of the transcription factors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), which regulate the expression of such enzymes as P450s and drug transporters.  These differences have gained addnl. importance as a consequence of the use of genetically modified mouse models for drug-efficacy testing and also patient-derived xenografts to predict individual patient responses to anticancer drugs.  A no. of humanized mouse models for cytochrome P450s, CAR, and PXR have been reported.  However, the utility of these models has been compromised by the redundancy in P 450 reactions across gene families, whereby the remaining murine P450s can metabolize the compds. being tested.  To remove this confounding factor and create a mouse model that more closely reflects human pathways of drug disposition, we substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A7.  We also created a mouse line in which 34 P450s were deleted from the mouse genome.  Using model compds. and anticancer drugs, we demonstrated how these mouse lines can be applied to predict drug-drug interactions in patients and discuss here their potential application in the more informed design of clin. trials and the personalized treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BHkJ_rwhl7Vg90H21EOLACvtfcHk0lgRqh5grD3UFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbjK&md5=2a44f88a1e897f06f4de8dfc9874a052</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.086397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.086397%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DC.%2BJ.%26aulast%3DKapelyukh%26aufirst%3DY.%26aulast%3DScheer%26aufirst%3DN.%26aulast%3DRode%26aufirst%3DA.%26aulast%3DMcLaren%26aufirst%3DA.%2BW.%26aulast%3DMacLeod%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DStanley%26aufirst%3DL.%2BA.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26atitle%3DAn%2520extensively%2520humanized%2520mouse%2520model%2520to%2520predict%2520pathways%2520of%2520drug%2520disposition%2520and%2520drug%252Fdrug%2520interactions%252C%2520and%2520to%2520facilitate%2520design%2520of%2520clinical%2520trials%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D601%26epage%3D615%26doi%3D10.1124%2Fdmd.119.086397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span> <span> </span><span class="NLM_article-title">Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug-drug interactions</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1754</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1754-1759&issue=5&author=J.+Q.+Lyauthor=K.+Messickauthor=A.+Qinauthor=R.+H.+Takahashiauthor=E.+F.+Choo&title=Utility+of+CYP3A4+and+PXR-CAR-CYP3A4%2F3A7+transgenic+mouse+models+to+assess+the+magnitude+of+CYP3A4+mediated+drug-drug+interactions&doi=10.1021%2Facs.molpharmaceut.7b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions</span></div><div class="casAuthors">Ly, Justin Q.; Messick, Kirsten; Qin, Ann; Takahashi, Ryan H.; Choo, Edna F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1754-1759</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Species differences in the expression, activity, regulation, and substrate specificity of metabolizing enzymes preclude the use of animal models to predict clin. drug-drug interactions (DDIs).  The objective of this work is to det. if the transgenic (Tg) Cyp3a-/-Tg-3A4Hep/Int and Nr1i2/Nr1i3-/--Cyp3a-/-Tg-PXR-CAR-3A4/3A7Hep/Int (PXR-CAR-CYP3A4/3A7) mouse models could be used to predict in vivo DDI of 10 drugs; alprazolam, bosutinib, crizotinib, dasatinib, gefitinib, ibrutinib, regorafenib, sorafenib, triazolam, and vandetinib (as victims); with varying magnitudes of reported CYP3A4 clin. DDI.  As an assessment of the effect of CYP3A4 inhibition, these drugs were coadministered to Cyp3a-/-Tg-3A4Hep/Int mice with the CYP3A inhibitor, itraconazole.  For crizotinib, regorafenib, sorafenib, and vandetanib, there was no significant increase of AUC obsd.; with alprazolam, bosutinib, ibrutinib, dasatinib, and triazolam, pretreatment with itraconazole resulted in a 2-, 4-, 17-, 7-, and 15-fold increase in AUC, resp.  With the exception of gefinitib for which the DDI effect was overpredicted (12-fold in Tg-mice vs 2-fold in the clinic), the magnitude of AUC increase obsd. in this study was consistent (within 2-fold) with the clin. DDI obsd. following administration with itraconazole/ketoconazole.  As an assessment of CYP3A4 induction, following rifampin pretreatment to PXR-CAR-3A4/3A7Hep/Int mice, an 8% decrease in vandetanib mean AUC was obsd.; 39-52% redn. in AUC were obsd. for dasatinib, ibrutinib, regorafenib, and sorafenib compared to vehicle treated mice.  The greatest effect of rifampin induction was obsd. with alprazolam, bosutinib, crizotinib, gefitinib, and triazolam where 72-91% decrease in AUC were obsd.  With the exception of vandetanib for which rifampin induction was under-predicted, the magnitude of induction obsd. in this study was consistent (within 2-fold) with clin. observations.  These data sets suggest that, with two exceptions, these transgenic mice models were able to exclude or capture the magnitude of CYP3A4 clin. inhibition and induction.  Data generated in transgenic mice may be used to gain confidence and complement in vitro and in silico methods for assessing DDI potential/liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDm24uLLulOLVg90H21EOLACvtfcHk0lgRixnBiMn0Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7s%253D&md5=4e756fcf505d921292062c23f3ac24eb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00006%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DJ.%2BQ.%26aulast%3DMessick%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DR.%2BH.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26atitle%3DUtility%2520of%2520CYP3A4%2520and%2520PXR-CAR-CYP3A4%252F3A7%2520transgenic%2520mouse%2520models%2520to%2520assess%2520the%2520magnitude%2520of%2520CYP3A4%2520mediated%2520drug-drug%2520interactions%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26issue%3D5%26spage%3D1754%26epage%3D1759%26doi%3D10.1021%2Facs.molpharmaceut.7b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umesono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of target gene specificity for steroid/thyroid hormone receptors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(89)90051-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2F0092-8674%2889%2990051-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=2500251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL1MXltFWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1989&pages=1139-1146&issue=7&author=K.+Umesonoauthor=R.+M.+Evans&title=Determinants+of+target+gene+specificity+for+steroid%2Fthyroid+hormone+receptors&doi=10.1016%2F0092-8674%2889%2990051-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of target gene specificity for steroid/thyroid hormone receptors</span></div><div class="casAuthors">Umesono, Kazuhiko; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-46</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The mol. specificity of the receptors for steroid and thyroid hormones is achieved by their selective interaction with DNA binding sites referred to as hormone response elements (HREs).  HREs can differ in primary nucleotide sequence as well as in the spacing of their dyadic half-sites.  The target gene specificity of the glucocorticoid receptor can be converted to that of the estrogen receptor by changing 3 amino acids clustered in the first zinc finger.  Remarkably, a single Gly to Glu change in this region produces a receptor that recognizes both glucocorticoid and estrogen response elements.  Further replacement of 5 amino acids in the stem of the second zinc finger transforms the specificity to that of the thyroid hormone receptor.  These findings localize structural determinants required for discrimination of HRE sequence and half-site spacing, resp., and suggest a simple pathway for the coevolution of receptor DNA binding domains and hormone-responsive gene networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5aEI2AU4Q2rVg90H21EOLACvtfcHk0lgRixnBiMn0Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFWhs78%253D&md5=cee05e62afb5953c97423a761fbabdb3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2889%2990051-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252889%252990051-2%26sid%3Dliteratum%253Aachs%26aulast%3DUmesono%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DDeterminants%2520of%2520target%2520gene%2520specificity%2520for%2520steroid%252Fthyroid%2520hormone%2520receptors%26jtitle%3DCell%26date%3D1989%26volume%3D57%26issue%3D7%26spage%3D1139%26epage%3D1146%26doi%3D10.1016%2F0092-8674%2889%2990051-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>331</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1016/S0022-2836(03)00795-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0022-2836%2803%2900795-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12909012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFGgu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2003&pages=815-828&issue=4&author=R.+E.+Watkinsauthor=P.+R.+Davis-Searlesauthor=M.+H.+Lambertauthor=M.+R.+Redinbo&title=Coactivator+binding+promotes+the+specific+interaction+between+ligand+and+the+pregnane+X+receptor&doi=10.1016%2FS0022-2836%2803%2900795-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Coactivator Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor</span></div><div class="casAuthors">Watkins, Ryan E.; Davis-Searles, Paula R.; Lambert, Mill H.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">815-828</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) detects the presence of a wide variety of endogenous and xenobiotic compds., and is a master regulator of the expression of genes central to drug metab. and excretion.  We present the 2.0 Å crystal structure of the human PXR ligand-binding domain (LBD) in complex with the cholesterol-lowering compd. SR12813 and a 25 amino acid residue fragment of the human steroid receptor coactivator-1 (SRC-1) contg. one LXXLL motif.  PXR crystallizes as a homodimer in the asym. unit in this structure and possesses a novel α2 helix adjacent to its ligand-binding cavity.  The SRC-1 peptide forms two distinct helixes and binds adjacent to the ligand-dependent transactivation AF-2 helix on the surface of PXR.  In contrast with previous PXR structures, in which SR12813 bound in multiple orientations, the small SR12813 agonist in this structure binds in a single, unique orientation within the receptor's ligand-binding pocket and contacts the AF-2 helix.  Thermal denaturation studies reveal that the SR12813 ligand and SRC-1 coactivator peptide each stabilize the LBD of PXR, and that together they exert an additive effect on the stability of the receptor.  These results indicate that the binding of coactivator to the surface of PXR limits the ability of this promiscuous receptor to "breathe" and helps to trap a single, active conformation of SR12813.  They further reveal that specificity is required for PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbb0Scjx9ALVg90H21EOLACvtfcHk0lgRixnBiMn0Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFGgu7k%253D&md5=ec6080e6e361daa2e5f5f08135cc1d3f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900795-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900795-2%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DCoactivator%2520binding%2520promotes%2520the%2520specific%2520interaction%2520between%2520ligand%2520and%2520the%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D331%26issue%3D4%26spage%3D815%26epage%3D828%26doi%3D10.1016%2FS0022-2836%2803%2900795-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luntz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittoop, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimmel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Human PXR forms a tryptophan zipper-mediated homodimer</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">8579</span>– <span class="NLM_lpage">8589</span>, <span class="refDoi"> DOI: 10.1021/bi0602821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0602821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=8579-8589&issue=28&author=S.+M.+Nobleauthor=V.+E.+Carnahanauthor=L.+B.+Mooreauthor=T.+Luntzauthor=H.+Wangauthor=O.+R.+Ittoopauthor=J.+B.+Stimmelauthor=P.+R.+Davis-Searlesauthor=R.+E.+Watkinsauthor=G.+B.+Wiselyauthor=E.+LeCluyseauthor=A.+Tripathyauthor=D.+P.+McDonnellauthor=M.+R.+Redinbo&title=Human+PXR+forms+a+tryptophan+zipper-mediated+homodimer&doi=10.1021%2Fbi0602821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Human PXR Forms a Tryptophan Zipper-Mediated Homodimer</span></div><div class="casAuthors">Noble, Schroeder M.; Carnahan, Virginia E.; Moore, Linda B.; Luntz, Tom; Wang, Hongbing; Ittoop, Olivia R.; Stimmel, Julie B.; Davis-Searles, Paula R.; Watkins, Ryan E.; Wisely, G. Bruce; LeCluyse, Ed; Tripathy, Ashutosh; McDonnell, Donald P.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">8579-8589</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human nuclear receptor pregnane X receptor (PXR) responds to a wide variety of potentially harmful chems. and coordinates the expression of genes central to xenobiotic and endobiotic metab.  Structural studies reveal that the PXR ligand binding domain (LBD) uses a novel sequence insert to form a homodimer unique to the nuclear receptor superfamily.  Terminal β-strands from each monomeric LBD interact in an ideal antiparallel fashion to bury potentially exposed surface β-strands, generating a 10-stranded intermol. β-sheet.  Conserved tryptophan and tyrosine residues lock across the dimer interface and provide the first tryptophan-zipper (Trp-Zip) interaction obsd. in a native protein.  We show using anal. ultracentrifugation that the PXR LBD forms a homodimer in soln.  We further find that removal of the interlocking arom. residues eliminates dimer formation but does not affect PXR's ability to interact with DNA, RXRα, or ligands.  Disruption of the homodimer significantly reduces receptor activity in transient transfection expts., however, and effectively eliminates the receptor's recruitment of the transcriptional coactivator SRC-1 both in vitro and in vivo.  Taken together, these results suggest that the unique Trp-Zip-mediated PXR homodimer plays a role in the function of this nuclear xenobiotic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE2ERjHL1Mb7Vg90H21EOLACvtfcHk0lhHpawaUURZig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFKgu78%253D&md5=3ce717647887ec0fc5f537c69720f07c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fbi0602821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0602821%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DS.%2BM.%26aulast%3DCarnahan%26aufirst%3DV.%2BE.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DLuntz%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DIttoop%26aufirst%3DO.%2BR.%26aulast%3DStimmel%26aufirst%3DJ.%2BB.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DTripathy%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DHuman%2520PXR%2520forms%2520a%2520tryptophan%2520zipper-mediated%2520homodimer%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26issue%3D28%26spage%3D8579%26epage%3D8589%26doi%3D10.1021%2Fbi0602821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastinejad, F.</span></span> <span> </span><span class="NLM_article-title">Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>456</i></span> (<span class="NLM_issue">7220</span>),  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nature07413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnature07413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19043829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BD1cjnsFSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2008&pages=350-356&issue=7220&author=V.+Chandraauthor=P.+Huangauthor=Y.+Hamuroauthor=S.+Raghuramauthor=Y.+Wangauthor=T.+P.+Burrisauthor=F.+Rastinejad&title=Structure+of+the+intact+PPAR-gamma-RXR-+nuclear+receptor+complex+on+DNA&doi=10.1038%2Fnature07413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA</span></div><div class="casAuthors">Chandra Vikas; Huang Pengxiang; Hamuro Yoshitomo; Raghuram Srilatha; Wang Yongjun; Burris Thomas P; Rastinejad Fraydoon</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">7220</span>),
    <span class="NLM_cas:pages">350-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nuclear receptors are multi-domain transcription factors that bind to DNA elements from which they regulate gene expression.  The peroxisome proliferator-activated receptors (PPARs) form heterodimers with the retinoid X receptor (RXR), and PPAR-gamma has been intensively studied as a drug target because of its link to insulin sensitization.  Previous structural studies have focused on isolated DNA or ligand-binding segments, with no demonstration of how multiple domains cooperate to modulate receptor properties.  Here we present structures of intact PPAR-gamma and RXR-alpha as a heterodimer bound to DNA, ligands and coactivator peptides.  PPAR-gamma and RXR-alpha form a non-symmetric complex, allowing the ligand-binding domain (LBD) of PPAR-gamma to contact multiple domains in both proteins.  Three interfaces link PPAR-gamma and RXR-alpha, including some that are DNA dependent.  The PPAR-gamma LBD cooperates with both DNA-binding domains (DBDs) to enhance response-element binding.  The A/B segments are highly dynamic, lacking folded substructures despite their gene-activation properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBfyLNYQMJfwwxfk_AGB-EfW6udTcc2ea4-Tev3yyuA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjnsFSjsg%253D%253D&md5=bb1b4cd7744a353431c7b575d7f5df50</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnature07413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07413%26sid%3Dliteratum%253Aachs%26aulast%3DChandra%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DHamuro%26aufirst%3DY.%26aulast%3DRaghuram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26aulast%3DRastinejad%26aufirst%3DF.%26atitle%3DStructure%2520of%2520the%2520intact%2520PPAR-gamma-RXR-%2520nuclear%2520receptor%2520complex%2520on%2520DNA%26jtitle%3DNature%26date%3D2008%26volume%3D456%26issue%3D7220%26spage%3D350%26epage%3D356%26doi%3D10.1038%2Fnature07413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastinejad, F.</span></span> <span> </span><span class="NLM_article-title">Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>495</i></span> (<span class="NLM_issue">7441</span>),  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature11966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnature11966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23485969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlClurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=495&publication_year=2013&pages=394-398&issue=7441&author=V.+Chandraauthor=P.+Huangauthor=N.+Potluriauthor=D.+Wuauthor=Y.+Kimauthor=F.+Rastinejad&title=Multidomain+integration+in+the+structure+of+the+HNF-4alpha+nuclear+receptor+complex&doi=10.1038%2Fnature11966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Multidomain integration in the structure of the HNF-4α nuclear receptor complex</span></div><div class="casAuthors">Chandra, Vikas; Huang, Pengxiang; Potluri, Nalini; Wu, Dalei; Kim, Youngchang; Rastinejad, Fraydoon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">495</span>
        (<span class="NLM_cas:issue">7441</span>),
    <span class="NLM_cas:pages">394-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hepatocyte nuclear factor 4α (HNF-4α; also known as NR2A1) is a member of the nuclear receptor (NR) family of transcription factors, which have conserved DNA-binding domains and ligand-binding domains.  HNF-4α is the most abundant DNA-binding protein in the liver, where some 40% of the actively transcribed genes have a HNF-4α response element.  These regulated genes are largely involved in the hepatic gluconeogenic program and lipid metab.  In the pancreas HNF-4α is also a master regulator, controlling an estd. 11% of islet genes.  HNF-4α protein mutations are linked to maturity-onset diabetes of the young, type 1 (MODY1) and hyperinsulinemic hypoglycemia.  Previous structural analyses of NRs, although productive in elucidating the structure of individual domains, have lagged behind in revealing the connectivity patterns of NR domains.  Here we describe the 2.9 Å crystal structure of the multidomain human HNF-4α homodimer bound to its DNA response element and coactivator-derived peptides.  A convergence zone connects multiple receptor domains in an asym. fashion, joining distinct elements from each monomer.  An arginine target of PRMT1 methylation protrudes directly into this convergence zone and sustains its integrity.  A serine target of protein kinase C is also responsible for maintaining domain-domain interactions.  These post-translational modifications lead to changes in DNA binding by communicating through the tightly connected surfaces of the quaternary fold.  We find that some MODY1 mutations, positioned on the ligand-binding domain and hinge regions of the receptor, compromise DNA binding at a distance by communicating through the interjunctional surfaces of the complex.  The overall domain representation of the HNF-4α homodimer is different from that of the PPAR-γ-RXR-α heterodimer, even when both NR complexes are assembled on the same DNA element.  Our findings suggest that unique quaternary folds and interdomain connections in NRs could be exploited by small-mol. allosteric modulators that affect distal functions in these polypeptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eKjjrFa-h7Vg90H21EOLACvtfcHk0lhHpawaUURZig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlClurk%253D&md5=13c1241ad16ef93ac40d16e0b9123591</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnature11966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11966%26sid%3Dliteratum%253Aachs%26aulast%3DChandra%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DPotluri%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DRastinejad%26aufirst%3DF.%26atitle%3DMultidomain%2520integration%2520in%2520the%2520structure%2520of%2520the%2520HNF-4alpha%2520nuclear%2520receptor%2520complex%26jtitle%3DNature%26date%3D2013%26volume%3D495%26issue%3D7441%26spage%3D394%26epage%3D398%26doi%3D10.1038%2Fnature11966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toresson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Structure of the retinoid X receptor alpha-liver X receptor beta (RXRalpha-LXRbeta) heterodimer on DNA</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnsmb.2778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24561505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=277-281&issue=3&author=X.+Louauthor=G.+Toressonauthor=C.+Benodauthor=J.+H.+Suhauthor=K.+J.+Philipsauthor=P.+Webbauthor=J.+A.+Gustafsson&title=Structure+of+the+retinoid+X+receptor+alpha-liver+X+receptor+beta+%28RXRalpha-LXRbeta%29+heterodimer+on+DNA&doi=10.1038%2Fnsmb.2778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on DNA</span></div><div class="casAuthors">Lou, Xiaohua; Toresson, Gudrun; Benod, Cindy; Suh, Ji Ho; Philips, Kevin J.; Webb, Paul; Gustafsson, Jan-Ake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) are conditional transcription factors with common multidomain organization that bind diverse DNA elements.  How DNA sequences influence NR conformation is poorly understood.  Here we report the crystal structure of the human retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on its cognate element, an AGGTCA direct repeat spaced by 4 nt.  The complex has an extended X-shaped arrangement, with DNA- and ligand-binding domains crossed, in contrast to the parallel domain arrangement of other NRs that bind an AGGTCA direct repeat spaced by 1 nt.  The LXRβ core binds DNA via canonical contacts and auxiliary DNA contacts that enhance affinity for the response element.  Comparisons of RXRα-LXRβs in the crystal asym. unit and with previous NR structures reveal flexibility in NR organization and suggest a role for RXRα in adaptation of heterodimeric complexes to DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocO-YqDoHi_rVg90H21EOLACvtfcHk0lhyyhsSMPOqJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFagtbs%253D&md5=aba55f18cb3e885f56e8e0de825137bb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2778%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DX.%26aulast%3DToresson%26aufirst%3DG.%26aulast%3DBenod%26aufirst%3DC.%26aulast%3DSuh%26aufirst%3DJ.%2BH.%26aulast%3DPhilips%26aufirst%3DK.%2BJ.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DStructure%2520of%2520the%2520retinoid%2520X%2520receptor%2520alpha-liver%2520X%2520receptor%2520beta%2520%2528RXRalpha-LXRbeta%2529%2520heterodimer%2520on%2520DNA%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D3%26spage%3D277%26epage%3D281%26doi%3D10.1038%2Fnsmb.2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">5525</span>),  <span class="NLM_fpage">2329</span>– <span class="NLM_lpage">2333</span>, <span class="refDoi"> DOI: 10.1126/science.1060762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1126%2Fscience.1060762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11408620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2001&pages=2329-2333&issue=5525&author=R.+E.+Watkinsauthor=G.+B.+Wiselyauthor=L.+B.+Mooreauthor=J.+L.+Collinsauthor=M.+H.+Lambertauthor=S.+P.+Williamsauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=The+human+nuclear+xenobiotic+receptor+PXR%3A+structural+determinants+of+directed+promiscuity&doi=10.1126%2Fscience.1060762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity</span></div><div class="casAuthors">Watkins, Ryan E.; Wisely, G. Bruce; Moore, Linda B.; Collins, Jon L.; Lambert, Millard H.; Williams, Shawn P.; Willson, Timothy M.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5525</span>),
    <span class="NLM_cas:pages">2329-2333</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The human nuclear pregnane X receptor (hPXR) activates cytochrome P 450-3A expression in response to a wide variety of xenobiotics and plays a crit. role in mediating dangerous drug-drug interactions.  The authors present the crystal structures of the ligand-binding domain of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolns. of 2.5 and 2.75 angstroms, resp.  The hydrophobic ligand-binding cavity of hPXR contains a small no. of polar residues, permitting SR12813 to bind-in three distinct orientations.  The position and nature of these polar residues were found to be crit. for establishing the precise pharmacol. activation profile of PXR.  The findings provide important insights into how hPXR detects xenobiotics and may prove useful in predicting and avoiding drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGros5DlMM1w9rVg90H21EOLACvtfcHk0lhyyhsSMPOqJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslSht7c%253D&md5=f78d0d3e742427fc771a3c958b07be5a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1126%2Fscience.1060762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1060762%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DThe%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%253A%2520structural%2520determinants%2520of%2520directed%2520promiscuity%26jtitle%3DScience%26date%3D2001%26volume%3D292%26issue%3D5525%26spage%3D2329%26epage%3D2333%26doi%3D10.1126%2Fscience.1060762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">2.1 A crystal structure of human PXR in complex with the St. John’s wort compound hyperforin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1021/bi0268753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0268753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1430-1438&issue=6&author=R.+E.+Watkinsauthor=J.+M.+Maglichauthor=L.+B.+Mooreauthor=G.+B.+Wiselyauthor=S.+M.+Nobleauthor=P.+R.+Davis-Searlesauthor=M.+H.+Lambertauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=2.1+A+crystal+structure+of+human+PXR+in+complex+with+the+St.+John%E2%80%99s+wort+compound+hyperforin&doi=10.1021%2Fbi0268753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">2.1 Å Crystal Structure of Human PXR in Complex with the St. John's Wort Compound Hyperforin</span></div><div class="casAuthors">Watkins, Ryan E.; Maglich, Jodi M.; Moore, Linda B.; Wisely, G. Bruce; Noble, Schroeder M.; Davis-Searles, Paula R.; Lambert, Mill H.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nuclear xenobiotic receptor PXR is activated by a wide variety of clin. used drugs and serves as a master regulator of drug metab. and excretion gene expression in mammals. St. John's wort is used widely in Europe and the United States to treat depression.  This unregulated herbal remedy leads to dangerous drug-drug interactions, however, in patients taking oral contraceptives, antivirals, or immunosuppressants.  Such interactions are caused by the activation of the human PXR by hyperforin, the psychoactive agent in St. John's wort.  In this study, we show that hyperforin induces the expression of numerous drug metab. and excretion genes in primary human hepatocytes.  We present the 2.1 Å crystal structure of hyperforin in complex with the ligand binding domain of human PXR.  Hyperforin induces conformational changes in PXR's ligand binding pocket relative to structures of human PXR elucidated previously and increases the size of the pocket by 250 Å3.  We find that the mutation of individual arom. residues within the ligand binding cavity changes PXR's response to particular ligands.  Taken together, these results demonstrate that PXR employs structural flexibility to expand the chem. space it samples and that the mutation of specific residues within the ligand binding pocket of PXR tunes the receptor's response to ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNQeEM-jnDbVg90H21EOLACvtfcHk0lgormC33yhvKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFaktQ%253D%253D&md5=f88f83a7ad885528a3a2bf0ab93214ae</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fbi0268753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0268753%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DMaglich%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DNoble%26aufirst%3DS.%2BM.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3D2.1%2520A%2520crystal%2520structure%2520of%2520human%2520PXR%2520in%2520complex%2520with%2520the%2520St.%2520John%25E2%2580%2599s%2520wort%2520compound%2520hyperforin%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26issue%3D6%26spage%3D1430%26epage%3D1438%26doi%3D10.1021%2Fbi0268753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1210/me.2004-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fme.2004-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15705662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1125-1134&issue=5&author=J.+E.+Chrencikauthor=J.+Oransauthor=L.+B.+Mooreauthor=Y.+Xueauthor=L.+Pengauthor=J.+L.+Collinsauthor=G.+B.+Wiselyauthor=M.+H.+Lambertauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=Structural+disorder+in+the+complex+of+human+pregnane+X+receptor+and+the+macrolide+antibiotic+rifampicin&doi=10.1210%2Fme.2004-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin</span></div><div class="casAuthors">Chrencik, Jill E.; Orans, Jillian; Moore, Linda B.; Xue, Yu; Peng, Li; Collins, Jon L.; Wisely, G. Bruce; Lambert, Millard H.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1125-1134</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The human nuclear xenobiotic receptor, pregnane X receptor (PXR), detects a variety of structurally distinct endogenous and xenobiotic compds. and controls expression of genes central to drug and cholesterol metab.  The macrolide antibiotic rifampicin, a front-line treatment for tuberculosis, is an established PXR agonist and, at 823 Da, is one of the largest known ligands for the receptor.  The authors present the 2.8 Å crystal structure of the ligand-binding domain of human PXR in complex with rifampicin.  The authors also use structural and mutagenesis data to examine the origins of the directed promiscuity exhibited by the PXRs across species.  Three structurally flexible loops adjacent to the ligand-binding pocket of PXR are disordered in this crystal structure, including the 200-210 region that is part of a sequence insert novel to the promiscuous PXRs relative to other members of the nuclear receptor superfamily.  The 4-methyl-1-piperazinyl ring of rifampicin, which would lie adjacent to the disordered protein regions, is also disordered and not obsd. in the structure.  Taken together, the results indicate that one wall of the PXR ligand-binding cavity can remain flexible even when the receptor is in complex with an activating ligand.  These observations highlight the key role that structural flexibility plays in PXR's promiscuous response to xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgc19c4Tdl7Vg90H21EOLACvtfcHk0lgormC33yhvKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFensbs%253D&md5=0a3f5e3a62477a68b8019c4d827c4e9c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1210%2Fme.2004-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2004-0346%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DOrans%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520disorder%2520in%2520the%2520complex%2520of%2520human%2520pregnane%2520X%2520receptor%2520and%2520the%2520macrolide%2520antibiotic%2520rifampicin%26jtitle%3DMol.%2520Endocrinol.%26date%3D2005%26volume%3D19%26issue%3D5%26spage%3D1125%26epage%3D1134%26doi%3D10.1210%2Fme.2004-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2156</span>– <span class="NLM_lpage">2166</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmc.2006.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17215127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=2156-2166&issue=5&author=Y.+Xueauthor=E.+Chaoauthor=W.+J.+Zuercherauthor=T.+M.+Willsonauthor=J.+L.+Collinsauthor=M.+R.+Redinbo&title=Crystal+structure+of+the+PXR-T1317+complex+provides+a+scaffold+to+examine+the+potential+for+receptor+antagonism&doi=10.1016%2Fj.bmc.2006.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism</span></div><div class="casAuthors">Xue, Yu; Chao, Esther; Zuercher, William J.; Willson, Timothy M.; Collins, Jon L.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2156-2166</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) recognizes a range of structurally and chem. distinct ligands and plays a key role in regulating the expression of protective gene products involved in the metab. and excretion of potentially harmful compds.  The identification and development of PXR antagonists is desirable as a potential way to control the up-regulation of drug metab. pathways during the therapeutic treatment of disease.  The authors present the 2.8 Å resoln. crystal structure of the PXR ligand binding domain (LBD) in complex with T0901317 (T1317), which is also an agonist of another member of the orphan class of the nuclear receptor superfamily, the liver X receptor (LXR).  In spite of differences in the size and shape of the receptors' ligand binding pockets, key interactions with this ligand are conserved between human PXR and human LXR.  Based on the PXR-T1317 structure, analogs of T1317 were generated with the goal of designing an PXR antagonist effective via the receptor's ligand binding pocket.  The authors find that selectivity in activating PXR vs. LXR was achieved; such compds. may be useful in addressing neurodegenerative diseases like Niemann-Pick C.  The authors were not successful, however, in producing a PXR antagonist.  Based on these observations, the authors conclude that the generation of PXR antagonists targeted to the ligand binding pocket may be difficult due to the promiscuity and structural conformability of this xenobiotic sensor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0FzLaTf8t7Vg90H21EOLACvtfcHk0lgormC33yhvKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOnt7o%253D&md5=69424ea9a1d044be36bf2fbdcbb5f8df</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520PXR-T1317%2520complex%2520provides%2520a%2520scaffold%2520to%2520examine%2520the%2520potential%2520for%2520receptor%2520antagonism%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26issue%3D5%26spage%3D2156%26epage%3D2166%26doi%3D10.1016%2Fj.bmc.2006.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischof, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural basis of human pregnane X receptor activation by the hops constituent colupulone</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1520</span>, <span class="refDoi"> DOI: 10.1124/mol.108.050732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.108.050732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18768384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGls7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1512-1520&issue=6&author=D.+G.+Teoticoauthor=J.+J.+Bischofauthor=L.+Pengauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=Structural+basis+of+human+pregnane+X+receptor+activation+by+the+hops+constituent+colupulone&doi=10.1124%2Fmol.108.050732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of human pregnane X receptor activation by the hops constituent colupulone</span></div><div class="casAuthors">Teotico, Denise G.; Bischof, Jason J.; Peng, Li; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1512-1520</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hops exts. are used to alleviate menopausal symptoms and as an alternative to hormone replacement therapy, but they can produce potentially harmful drug-drug interactions.  The nuclear xenobiotic receptor pregnane X receptor (PXR) is promiscuously activated by a range of structurally distinct chems.  It has a key role in the transcriptional regulation of genes that encode xenobiotic metab. enzymes.  In this study, hops exts. are shown to induce the expression of numerous drug metab. and excretion proteins.  The β-bitter acid colupulone is demonstrated to be a bioactive component and direct activator of human PXR.  The 2.8-Å resoln. crystal structure of the ligand binding domain of human PXR in complex with colupulone was elucidated, and colupulone was obsd. to bind in a single orientation stabilized by both van der Waals and hydrogen bonding contacts.  The crystal structure also indicates that related α- and β-bitter acids have the capacity to serve as PXR agonists as well.  Taken together, these results reveal the structural basis for drug-drug interactions mediated by colupulone and related constituents of hops exts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkNovjK7bNo7Vg90H21EOLACvtfcHk0lgqh7s2Moz5cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGls7zF&md5=5a2bbd34a55cfd4cbdc719126b42d3d8</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.050732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.050732%26sid%3Dliteratum%253Aachs%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DBischof%26aufirst%3DJ.%2BJ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520basis%2520of%2520human%2520pregnane%2520X%2520receptor%2520activation%2520by%2520the%2520hops%2520constituent%2520colupulone%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26issue%3D6%26spage%3D1512%26epage%3D1520%26doi%3D10.1124%2Fmol.108.050732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosise, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taremi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span> <span> </span><span class="NLM_article-title">Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1093/protein/gzn017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fprotein%2Fgzn017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18456871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=425-433&issue=7&author=W.+Wangauthor=W.+W.+Prosiseauthor=J.+Chenauthor=S.+S.+Taremiauthor=H.+V.+Leauthor=V.+Madisonauthor=X.+Cuiauthor=A.+Thomasauthor=K.+C.+Chengauthor=C.+A.+Lesburg&title=Construction+and+characterization+of+a+fully+active+PXR%2FSRC-1+tethered+protein+with+increased+stability&doi=10.1093%2Fprotein%2Fgzn017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability</span></div><div class="casAuthors">Wang, Wenyan; Prosise, Winifred W.; Chen, Jun; Taremi, S. Shane; Le, Hung V.; Madison, Vincent; Cui, Xiaoming; Thomas, Ann; Cheng, K.-C.; Lesburg, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">425-433</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The nuclear xenobiotic receptor PXR is a ligand-inducible transcription factor regulating drug-metabolizing enzymes and transporters and a master switch mediating potentially adverse drug-drug interactions.  In addn. to binding a coactivator protein such as SRC-1, the C-terminal ligand-binding domain (LBD) is solely responsible for ligand recognition and thus the ligand-dependent downstream effects.  In an effort to facilitate structural studies of PXR to understand and abolish the interactions between PXR and its ligands, several recombinant PXR/SRC-1 constructs were designed and evaluated for expression, stability and activity.  Expression strategies employing either dual expression or translationally coupled bicistronic expression were found to be unsuitable for producing stable PXR in a stoichiometric complex with a peptide derived from SRC-1 (SRC-1p).  A single polypeptide chain encompassing PXR and SRC-1p tethered with a peptidyl linker was designed to promote intramol. complex formation.  This tethered protein was overexpressed as a sol. protein and required no addnl. SRC-1p for further stabilization.  X-ray crystal structures in the presence and absence of the known PXR agonist SR-12813 were detd. to high resoln.  In addn., a CD-based binding assay was developed to allow rapid evaluation of PXR ligand affinity, making this tethered protein a convenient and effective reagent for the rational attenuation of drug-induced PXR-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaIAHYXZGyYLVg90H21EOLACvtfcHk0lgqh7s2Moz5cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sks7s%253D&md5=87a30decb4445d6b713b55eedc2b7038</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzn017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzn017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DProsise%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaremi%26aufirst%3DS.%2BS.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26atitle%3DConstruction%2520and%2520characterization%2520of%2520a%2520fully%2520active%2520PXR%252FSRC-1%2520tethered%2520protein%2520with%2520increased%2520stability%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2008%26volume%3D21%26issue%3D7%26spage%3D425%26epage%3D433%26doi%3D10.1093%2Fprotein%2Fgzn017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1002/pro.706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fpro.706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21805522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2isrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1713-1719&issue=10&author=Y.+Chengauthor=M.+R.+Redinbo&title=Activation+of+the+human+nuclear+xenobiotic+receptor+PXR+by+the+reverse+transcriptase-targeted+anti-HIV+drug+PNU-142721&doi=10.1002%2Fpro.706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721</span></div><div class="casAuthors">Cheng, Yuan; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1713-1719</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a member of the nuclear receptor superfamily of ligand-regulated transcription factors.  PXR responds to a structurally diverse variety of endogenous and xenobiotic compds., and coordinates the expression of genes central to the metab. and excretion of potentially harmful chems., including human therapeutics.  The reverse transcriptase inhibitor PNU-142721 has been designed to treat human immunodeficiency virus (HIV) infection.  Although this compd. has anti-HIV activity, it was established using cell-based assays that PNU-142721 is an efficacious PXR agonist.  We present here the 2.8 Å resoln. crystal structure of the human PXR ligand-binding domain in complex with PNU-142721.  PXR employs one hydrogen bond and fourteen van der Waals contacts to interact with the ligand, but allows two loops adjacent to the ligand-binding pocket to remain disordered in the structure.  These observations highlight the role structural flexibility plays in PXR's promiscuous responses to xenobiotics.  The crystal structure also explains why PNU-173575, a thiomethyl metabolite of PNU-142721, exhibits enhanced PXR activation relative to the unmodified compd. and why PNU-142721 can also activate rat PXR.  Taken together, the results presented here elucidate the structural basis for PXR activation by PNU-142721 and related chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5Vb_GQVVVLVg90H21EOLACvtfcHk0lgqh7s2Moz5cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2isrjJ&md5=c28e70e9ec58b599b9f4279ecfc88f74</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fpro.706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.706%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DActivation%2520of%2520the%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%2520by%2520the%2520reverse%2520transcriptase-targeted%2520anti-HIV%2520drug%2520PNU-142721%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26issue%3D10%26spage%3D1713%26epage%3D1719%26doi%3D10.1002%2Fpro.706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J. B.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grafstrom, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7550</span>– <span class="NLM_lpage">7564</span>, <span class="refDoi"> DOI: 10.1021/jm5003167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7550-7564&issue=18&author=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=J.+V.+Dunciaauthor=H.+Wuauthor=M.+Dharauthor=C.+Cavallaroauthor=A.+J.+Tebbenauthor=P.+H.+Carterauthor=J.+C.+Barrishauthor=M.+Yardeauthor=S.+W.+Bricenoauthor=M.+E.+Cvijicauthor=R.+R.+Grafstromauthor=R.+Liuauthor=S.+R.+Patelauthor=A.+J.+Watsonauthor=G.+Yangauthor=A.+V.+Roseauthor=R.+D.+Vickeryauthor=J.+Caceres-Cortesauthor=C.+Caporuscioauthor=D.+M.+Camacauthor=J.+A.+Khanauthor=Y.+Anauthor=W.+R.+Fosterauthor=P.+Daviesauthor=J.+Hynes&title=Discovery+of+the+CCR1+antagonist%2C+BMS-817399%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm5003167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Santella, Joseph B.; Gardner, Daniel S.; Duncia, John V.; Wu, Hong; Dhar, Murali; Cavallaro, Cullen; Tebben, Andrew J.; Carter, Percy H.; Barrish, Joel C.; Yarde, Melissa; Briceno, Stephanie W.; Cvijic, Mary Ellen; Grafstrom, R. Robert; Liu, Richard; Patel, Sima R.; Watson, Andrew J.; Yang, Guchen; Rose, Anne V.; Vickery, Rodney D.; Caceres-Cortes, Janet; Caporuscio, Christian; Camac, Daniel M.; Khan, Javed A.; An, Yongmi; Foster, William R.; Davies, Paul; Hynes, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7550-7564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered.  Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 I, which entered clin. trials for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB85zyhe5Qr7Vg90H21EOLACvtfcHk0lhU4YsEbaE-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fO&md5=33610179f9bcef718507168a5b82ab6f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm5003167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003167%26sid%3Dliteratum%253Aachs%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDhar%26aufirst%3DM.%26aulast%3DCavallaro%26aufirst%3DC.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DS.%2BW.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DGrafstrom%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRose%26aufirst%3DA.%2BV.%26aulast%3DVickery%26aufirst%3DR.%2BD.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DCaporuscio%26aufirst%3DC.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DFoster%26aufirst%3DW.%2BR.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520the%2520CCR1%2520antagonist%252C%2520BMS-817399%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D18%26spage%3D7550%26epage%3D7564%26doi%3D10.1021%2Fjm5003167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenny, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhire, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Developing adnectins that target SRC co-activator binding to PXR: A structural approach toward understanding promiscuity of PXR</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>427</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jmb.2014.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25579995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2015&pages=924-942&issue=4&author=J.+A.+Khanauthor=D.+M.+Camacauthor=S.+Lowauthor=A.+J.+Tebbenauthor=D.+L.+Wenselauthor=M.+C.+Wrightauthor=J.+Suauthor=V.+Jennyauthor=R.+D.+Guptaauthor=M.+Ruzanovauthor=K.+A.+Russoauthor=A.+Bellauthor=Y.+Anauthor=J.+W.+Brysonauthor=M.+Gaoauthor=P.+Gambhireauthor=E.+T.+Baldwinauthor=D.+Gardnerauthor=C.+L.+Cavallaroauthor=J.+V.+Dunciaauthor=J.+Hynes&title=Developing+adnectins+that+target+SRC+co-activator+binding+to+PXR%3A+A+structural+approach+toward+understanding+promiscuity+of+PXR&doi=10.1016%2Fj.jmb.2014.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Adnectins That Target SRC Co-Activator Binding to PXR: A Structural Approach toward Understanding Promiscuity of PXR</span></div><div class="casAuthors">Khan, Javed A.; Camac, Daniel M.; Low, Simon; Tebben, Andrew J.; Wensel, David L.; Wright, Martin C.; Su, Julie; Jenny, Victoria; Das Gupta, Ruchira; Ruzanov, Max; Russo, Katie A.; Bell, Aneka; An, Yongmi; Bryson, James W.; Gao, Mian; Gambhire, Pallavi; Baldwin, Eric T.; Gardner, Daniel; Cavallaro, Cullen L.; Duncia, John; Hynes, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">427</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">924-942</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a promiscuous nuclear receptor that functions as a sensor to a wide variety of xenobiotics and regulates expression of several drug metabolizing enzymes and transporters.  We have generated "Adnectins", derived from 10th fibronectin type III domain (10Fn3), that target the PXR ligand binding domain (LBD) interactions with the steroid receptor co-activator-1 (SRC-1) peptide, displacing SRC-1 binding.  Adnectins are structurally homologous to the Ig superfamily.  Three different co-crystal structures of PXR LBD with Adnectin-1 and CCR1 (CC chemokine receptor-1) antagonist Compd.-1 were detd.  This structural information was used to modulate PXR affinity for a related CCR1 antagonist compd. that entered into clin. trials for rheumatoid arthritis.  The structures of PXR with Adnectin-1 reveal specificity of Adnectin-1 in not only targeting the interface of the SRC-1 interactions but also engaging the same set of residues that are involved in binding of SRC-1 to PXR.  Substituting SRC-1 with Adnectin-1 does not alter the binding conformation of Compd.-1 in the ligand binding pocket.  The structure also reveals the possibility of using Adnectins as crystn. chaperones to generate structures of PXR with compds. of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHClQpf22lALVg90H21EOLACvtfcHk0lhU4YsEbaE-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVCmsg%253D%253D&md5=84634f9ee24a93b583f1bf1c99e0b2e3</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DWensel%26aufirst%3DD.%2BL.%26aulast%3DWright%26aufirst%3DM.%2BC.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DJenny%26aufirst%3DV.%26aulast%3DGupta%26aufirst%3DR.%2BD.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DK.%2BA.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DBryson%26aufirst%3DJ.%2BW.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGambhire%26aufirst%3DP.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DDeveloping%2520adnectins%2520that%2520target%2520SRC%2520co-activator%2520binding%2520to%2520PXR%253A%2520A%2520structural%2520approach%2520toward%2520understanding%2520promiscuity%2520of%2520PXR%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D427%26issue%3D4%26spage%3D924%26epage%3D942%26doi%3D10.1016%2Fj.jmb.2014.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delfosse, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendele, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavailles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daujat-Chavanieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8089</span>, <span class="refDoi"> DOI: 10.1038/ncomms9089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fncomms9089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26333997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC287ptVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8089&author=V.+Delfosseauthor=B.+Dendeleauthor=T.+Huetauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=S.+Gerbal-Chaloinauthor=B.+Beucherauthor=D.+Roecklinauthor=C.+Mullerauthor=R.+Rahmaniauthor=V.+Cavaillesauthor=M.+Daujat-Chavanieuauthor=V.+Vivatauthor=J.+M.+Pascussiauthor=P.+Balaguerauthor=W.+Bourguet&title=Synergistic+activation+of+human+pregnane+X+receptor+by+binary+cocktails+of+pharmaceutical+and+environmental+compounds&doi=10.1038%2Fncomms9089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds</span></div><div class="casAuthors">Delfosse Vanessa; Huet Tiphaine; Bourguet William; Delfosse Vanessa; Huet Tiphaine; Bourguet William; Delfosse Vanessa; Dendele Beatrice; Huet Tiphaine; Grimaldi Marina; Boulahtouf Abdelhay; Gerbal-Chaloin Sabine; Beucher Bertrand; Cavailles Vincent; Daujat-Chavanieu Martine; Pascussi Jean-Marc; Balaguer Patrick; Bourguet William; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Gerbal-Chaloin Sabine; Daujat-Chavanieu Martine; Beucher Bertrand; Pascussi Jean-Marc; Beucher Bertrand; Pascussi Jean-Marc; Roecklin Dominique; Muller Christina; Vivat Valerie; Rahmani Roger; Daujat-Chavanieu Martine</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Humans are chronically exposed to multiple exogenous substances, including environmental pollutants, drugs and dietary components.  Many of these compounds are suspected to impact human health, and their combination in complex mixtures could exacerbate their harmful effects.  Here we demonstrate that a pharmaceutical oestrogen and a persistent organochlorine pesticide, both exhibiting low efficacy when studied separately, cooperatively bind to the pregnane X receptor, leading to synergistic activation.  Biophysical analysis shows that each ligand enhances the binding affinity of the other, so the binary mixture induces a substantial biological response at doses at which each chemical individually is inactive.  High-resolution crystal structures reveal the structural basis for the observed cooperativity.  Our results suggest that the formation of 'supramolecular ligands' within the ligand-binding pocket of nuclear receptors contributes to the synergistic toxic effect of chemical mixtures, which may have broad implications for the fields of endocrine disruption, toxicology and chemical risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPLYllG1trW2mbXvSEQle5fW6udTcc2eYyqsuFWqPvcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287ptVWhsw%253D%253D&md5=2416828dd3854d2dea6727fbf0b1f8ed</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Fncomms9089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9089%26sid%3Dliteratum%253Aachs%26aulast%3DDelfosse%26aufirst%3DV.%26aulast%3DDendele%26aufirst%3DB.%26aulast%3DHuet%26aufirst%3DT.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DBeucher%26aufirst%3DB.%26aulast%3DRoecklin%26aufirst%3DD.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DRahmani%26aufirst%3DR.%26aulast%3DCavailles%26aufirst%3DV.%26aulast%3DDaujat-Chavanieu%26aufirst%3DM.%26aulast%3DVivat%26aufirst%3DV.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DBourguet%26aufirst%3DW.%26atitle%3DSynergistic%2520activation%2520of%2520human%2520pregnane%2520X%2520receptor%2520by%2520binary%2520cocktails%2520of%2520pharmaceutical%2520and%2520environmental%2520compounds%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8089%26doi%3D10.1038%2Fncomms9089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castriotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamhi, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of benzimidazole sulfonamides as orally bioavailable sphingosine 1-phosphate receptor 1 antagonists with in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7057</span>– <span class="NLM_lpage">7075</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7057-7075&issue=17&author=E.+J.+Hennessyauthor=V.+Ozaauthor=A.+Adamauthor=K.+Bythauthor=L.+Castriottaauthor=G.+Grewalauthor=G.+A.+Hamiltonauthor=V.+M.+Kamhiauthor=P.+Lewisauthor=D.+Liauthor=P.+Lyneauthor=L.+Osterauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=L.+Shaauthor=Q.+Suauthor=S.+Wenauthor=Y.+Xueauthor=B.+Yang&title=Identification+and+optimization+of+benzimidazole+sulfonamides+as+orally+bioavailable+sphingosine+1-phosphate+receptor+1+antagonists+with+in+vivo+activity&doi=10.1021%2Facs.jmedchem.5b01078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity</span></div><div class="casAuthors">Hennessy, Edward J.; Oza, Vibha; Adam, Ammar; Byth, Kate; Castriotta, Lillian; Grewal, Gurmit; Hamilton, Geraldine A.; Kamhi, Victor M.; Lewis, Paula; Li, Danyang; Lyne, Paul; Oster, Linda; Rooney, Michael T.; Saeh, Jamal C.; Sha, Li; Su, Qibin; Wen, Shengua; Xue, Yafeng; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7057-7075</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compds. described previously.  Lead compd. 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor phys. properties and metabolic stability.  Evolution of this compd. through structure-activity relationship development and property optimization led to in vivo probes such as 4.  However, this compd. was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chem. efforts were directed at addressing this liability.  By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compds. for further testing in human hepatocytes, we identified lipophilicity as a key mol. property influencing the likelihood of P 450 induction.  Ultimately, we have identified compds. such as 46 and 47, which demonstrate the desired S1P1 antagonist activity while having greatly reduced risk of CYP3A induction in humans.  These compds. have excellent oral bioavailability in preclin. species and exhibit pharmacodynamic effects of S1P1 antagonism in several in vivo models following oral dosing.  Relatively modest antitumor activity was obsd. in multiple xenograft models, however, suggesting that selective S1P1 antagonists would have limited utility as anticancer therapeutics as single agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNi1iJjQfobVg90H21EOLACvtfcHk0lg_xCNNSMR76w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7%252FE&md5=28b0841316d6e02b852341ebe9944ef8</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01078%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DCastriotta%26aufirst%3DL.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLewis%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DOster%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520benzimidazole%2520sulfonamides%2520as%2520orally%2520bioavailable%2520sphingosine%25201-phosphate%2520receptor%25201%2520antagonists%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D7057%26epage%3D7075%26doi%3D10.1021%2Facs.jmedchem.5b01078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemagiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudzianowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORgamma/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2017.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29233651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCqtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=85-93&issue=2&author=H.+Gongauthor=D.+S.+Weinsteinauthor=Z.+Luauthor=J.+J.+Duanauthor=S.+Stachuraauthor=L.+Haqueauthor=A.+Karmakarauthor=H.+Hemagiriauthor=D.+K.+Rautauthor=A.+K.+Guptaauthor=J.+Khanauthor=D.+Camacauthor=J.+S.+Sackauthor=A.+Pudzianowskiauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=V.+Borowskiauthor=J.+H.+Xieauthor=H.+Sunauthor=C.+D%E2%80%99Arienzoauthor=M.+Dabrosauthor=M.+A.+Galellaauthor=F.+Wangauthor=C.+A.+Weigeltauthor=Q.+Zhaoauthor=W.+Fosterauthor=J.+E.+Somervilleauthor=L.+M.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Identification+of+bicyclic+hexafluoroisopropyl+alcohol+sulfonamides+as+retinoic+acid+receptor-related+orphan+receptor+gamma+%28RORgamma%2FRORc%29+inverse+agonists.+Employing+structure-based+drug+design+to+improve+pregnane+X+receptor+%28PXR%29+selectivity&doi=10.1016%2Fj.bmcl.2017.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity</span></div><div class="casAuthors">Gong, Hua; Weinstein, David S.; Lu, Zhonghui; Duan, James J.-W.; Stachura, Sylwia; Haque, Lauren; Karmakar, Ananta; Hemagiri, Hemalatha; Raut, Dhanya Kumar; Gupta, Arun Kumar; Khan, Javed; Camac, Dan; Sack, John S.; Pudzianowski, Andrew; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Borowski, Virna; Xie, Jenny H.; Sun, Huadong; D'Arienzo, Celia; Dabros, Marta; Galella, Michael A.; Wang, Faye; Weigelt, Carolyn A.; Zhao, Qihong; Foster, William; Somerville, John E.; Salter-Cid, Luisa M.; Barrish, Joel C.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists.  However, a majority of these compds. showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα).  Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR.  Pharmacodynamic (PD) data for compd. 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclin. pharmacokinetic (PK) studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosFyMm8wpiSbVg90H21EOLACvtfcHk0lg_xCNNSMR76w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCqtr%252FJ&md5=be0dfef2d7494dca1979711a03ac7878</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DHemagiri%26aufirst%3DH.%26aulast%3DRaut%26aufirst%3DD.%2BK.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DCamac%26aufirst%3DD.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DPudzianowski%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFoster%26aufirst%3DW.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DIdentification%2520of%2520bicyclic%2520hexafluoroisopropyl%2520alcohol%2520sulfonamides%2520as%2520retinoic%2520acid%2520receptor-related%2520orphan%2520receptor%2520gamma%2520%2528RORgamma%252FRORc%2529%2520inverse%2520agonists.%2520Employing%2520structure-based%2520drug%2520design%2520to%2520improve%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D85%26epage%3D93%26doi%3D10.1016%2Fj.bmcl.2017.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chellaraj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzweiler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosley, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3194</span>– <span class="NLM_lpage">3196</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30146095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wiu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3194-3196&issue=19&author=R.+J.+Vazauthor=Y.+Liauthor=V.+Chellarajauthor=S.+Reilingauthor=T.+Kuntzweilerauthor=D.+Yangauthor=H.+Shenauthor=J.+D.+Batchelorauthor=Y.+Zhangauthor=X.+Chenauthor=L.+R.+McLeanauthor=R.+Kosley&title=Amelioration+of+PXR-mediated+CYP3A4+induction+by+mGluR2+modulators&doi=10.1016%2Fj.bmcl.2018.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators</span></div><div class="casAuthors">Vaz, Roy J.; Li, Yi; Chellaraj, Vinolia; Reiling, Stephan; Kuntzweiler, Theresa; Yang, Donglai; Shen, Hong; Batchelor, Joseph D.; Zhang, Ying; Chen, Xin; McLean, Larry R.; Kosley, Raymond Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3194-3196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This work describes the rational amelioration of Cytochrome P 450 4/5 (CYP3A4/5) induction through the Pregnane-X Receptor (PXR) pathway in a series of compds. that modulate the metabotropic glutamate Receptor 2 (mGluR2) via an allosteric mechanism.  The compds. were initially shown to induce CYP3A4/5 via the gold-std. induction assay measured in primary human hepatocytes.  This was followed up by testing the compds. in a PXR assay which correlated well with the assay in primary cells.  Further, one of the compds. was crystd. with PXR (pdb code 6DUP).  Anal. of this co-crystal structure, together with previously published PXR co-crystal structures, lead to modification ideas.  The compds. synthesized based on these ideas were shown not to be CYP3A4/5 inducers.  The mGluR2 activity of the resulting compds. was maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZvB8bb2rNg7Vg90H21EOLACvtfcHk0ljqywHs9rb1QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wiu7vF&md5=82d75ed0dce08ab5b62827e9a522e463</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChellaraj%26aufirst%3DV.%26aulast%3DReiling%26aufirst%3DS.%26aulast%3DKuntzweiler%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DBatchelor%26aufirst%3DJ.%2BD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcLean%26aufirst%3DL.%2BR.%26aulast%3DKosley%26aufirst%3DR.%26atitle%3DAmelioration%2520of%2520PXR-mediated%2520CYP3A4%2520induction%2520by%2520mGluR2%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D19%26spage%3D3194%26epage%3D3196%26doi%3D10.1016%2Fj.bmcl.2018.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Focken, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofstrand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodchild, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldbrook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkenbrecher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sojo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Empfield, J. R.</span></span> <span> </span><span class="NLM_article-title">Identification of CNS-penetrant aryl sulfonamides as isoform-selective NaV1.6 inhibitors with efficacy in mouse models of epilepsy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9618</span>– <span class="NLM_lpage">9641</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyjsrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9618-9641&issue=21&author=T.+Fockenauthor=K.+Burfordauthor=M.+E.+Grimwoodauthor=A.+Zenovaauthor=J.+C.+Andrezauthor=W.+Gongauthor=M.+Wilsonauthor=M.+Taronauthor=S.+Deckerauthor=V.+Lofstrandauthor=S.+Chowdhuryauthor=N.+Shuartauthor=S.+Linauthor=S.+J.+Goodchildauthor=C.+Youngauthor=M.+Sorianoauthor=P.+K.+Tariauthor=M.+Waldbrookauthor=K.+Nelkenbrecherauthor=R.+Kwanauthor=A.+Lindgrenauthor=G.+de+Boerauthor=S.+Leeauthor=L.+Sojoauthor=R.+J.+DeVitaauthor=C.+J.+Cohenauthor=S.+S.+Wesolowskiauthor=J.+P.+Johnsonauthor=C.+M.+Dehnhardtauthor=J.+R.+Empfield&title=Identification+of+CNS-penetrant+aryl+sulfonamides+as+isoform-selective+NaV1.6+inhibitors+with+efficacy+in+mouse+models+of+epilepsy&doi=10.1021%2Facs.jmedchem.9b01032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy</span></div><div class="casAuthors">Focken, Thilo; Burford, Kristen; Grimwood, Michael E.; Zenova, Alla; Andrez, Jean-Christophe; Gong, Wei; Wilson, Michael; Taron, Matt; Decker, Shannon; Lofstrand, Verner; Chowdhury, Sultan; Shuart, Noah; Lin, Sophia; Goodchild, Samuel J.; Young, Clint; Soriano, Maegan; Tari, Parisa K.; Waldbrook, Matthew; Nelkenbrecher, Karen; Kwan, Rainbow; Lindgren, Andrea; de Boer, Gina; Lee, Stephanie; Sojo, Luis; DeVita, Robert J.; Cohen, Charles J.; Wesolowski, Steven S.; Johnson, J. P.; Dehnhardt, Christoph M.; Empfield, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9618-9641</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonselective antagonists of voltage-gated sodium (NaV) channels have been long used for the treatment of epilepsies.  The efficacy of these drugs is thought to be due to the block of sodium channels on excitatory neurons, primarily NaV1.6 and NaV1.2.  However, these currently marketed drugs require high drug exposure and suffer from narrow therapeutic indexes.  Selective inhibition of NaV1.6, while sparing NaV1.1, is anticipated to provide a more effective and better tolerated treatment for epilepsies.  In addn., block of NaV1.2 may complement the anticonvulsant activity of NaV1.6 inhibition.  We discovered a novel series of aryl sulfonamides as CNS-penetrant, isoform-selective NaV1.6 inhibitors, which also displayed potent block of NaV1.2.  Optimization focused on increasing selectivity over NaV1.1, improving metabolic stability, reducing active efflux, and addressing a pregnane X-receptor liability.  We obtained compds. 30-32, which produced potent anticonvulsant activity in mouse seizure models, including a d.c. maximal electroshock seizure assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIs_b1ouzZDbVg90H21EOLACvtfcHk0ljqywHs9rb1QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyjsrnM&md5=aecc63b693edbbd19fa88b0696e0f123</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01032%26sid%3Dliteratum%253Aachs%26aulast%3DFocken%26aufirst%3DT.%26aulast%3DBurford%26aufirst%3DK.%26aulast%3DGrimwood%26aufirst%3DM.%2BE.%26aulast%3DZenova%26aufirst%3DA.%26aulast%3DAndrez%26aufirst%3DJ.%2BC.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DWilson%26aufirst%3DM.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DS.%26aulast%3DLofstrand%26aufirst%3DV.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DShuart%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DGoodchild%26aufirst%3DS.%2BJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DM.%26aulast%3DTari%26aufirst%3DP.%2BK.%26aulast%3DWaldbrook%26aufirst%3DM.%26aulast%3DNelkenbrecher%26aufirst%3DK.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DLindgren%26aufirst%3DA.%26aulast%3Dde%2BBoer%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DSojo%26aufirst%3DL.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BP.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DEmpfield%26aufirst%3DJ.%2BR.%26atitle%3DIdentification%2520of%2520CNS-penetrant%2520aryl%2520sulfonamides%2520as%2520isoform-selective%2520NaV1.6%2520inhibitors%2520with%2520efficacy%2520in%2520mouse%2520models%2520of%2520epilepsy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D21%26spage%3D9618%26epage%3D9641%26doi%3D10.1021%2Facs.jmedchem.9b01032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Laak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klint, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neagoe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux-Biehlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahllof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puetter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nubbemeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmeyer, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of the potent and selective P2 × 4 inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11194</span>– <span class="NLM_lpage">11217</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01304</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01304" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11194-11217&issue=24&author=S.+Wernerauthor=S.+Meschauthor=R.+C.+Hilligauthor=A.+Ter+Laakauthor=J.+Klintauthor=I.+Neagoeauthor=A.+Laux-Biehlmannauthor=H.+Dahllofauthor=N.+Brauerauthor=V.+Puetterauthor=R.+Nubbemeyerauthor=S.+Schulzauthor=M.+Bairleinauthor=T.+M.+Zollnerauthor=A.+Steinmeyer&title=Discovery+and+characterization+of+the+potent+and+selective+P2+%C3%97+4+inhibitor+N-%5B4-%283-Chlorophenoxy%29-3-sulfamoylphenyl%5D-2-phenylacetamide+%28BAY-1797%29+and+structure-guided+amelioration+of+its+CYP3A4+induction+profile&doi=10.1021%2Facs.jmedchem.9b01304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile</span></div><div class="casAuthors">Werner, Stefan; Mesch, Stefanie; Hillig, Roman C.; ter Laak, Antonius; Klint, Julie; Neagoe, Ioana; Laux-Biehlmann, Alexis; Dahlloef, Henrik; Braeuer, Nico; Puetter, Vera; Nubbemeyer, Reinhard; Schulz, Simone; Bairlein, Michaela; Zollner, Thomas M.; Steinmeyer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11194-11217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The P2X4 receptor is a ligand-gated ion channel that is expressed on a variety of cell types, esp. those involved in inflammatory and immune processes.  High-throughput screening led to a new class of P2X4 inhibitors with substantial CYP 3A4 induction in human hepatocytes.  A structure-guided optimization with respect to decreased pregnane X receptor (PXR) binding was started.  It was found that the introduction of larger and more polar substituents on the ether linker led to less PXR binding while maintaining the P2X4 inhibitory potency.  This translated into significantly reduced CYP 3A4 induction for compds. 71 and 73.  Unfortunately, the in vivo pharmacokinetic (PK) profiles of these compds. were insufficient for the desired profile in humans.  However, BAY-1797 (10) was identified and characterized as a potent and selective P2X4 antagonist.  This compd. is suitable for in vivo studies in rodents, and the anti-inflammatory and anti-nociceptive effects of BAY-1797 were demonstrated in a mouse complete Freund's adjuvant (CFA) inflammatory pain model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob3M_JZ6IYi7Vg90H21EOLACvtfcHk0ljJHI4y7knspA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nt7bL&md5=412d7541969d82bdb8afcc9fc1030e25</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01304%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DMesch%26aufirst%3DS.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DTer%2BLaak%26aufirst%3DA.%26aulast%3DKlint%26aufirst%3DJ.%26aulast%3DNeagoe%26aufirst%3DI.%26aulast%3DLaux-Biehlmann%26aufirst%3DA.%26aulast%3DDahllof%26aufirst%3DH.%26aulast%3DBrauer%26aufirst%3DN.%26aulast%3DPuetter%26aufirst%3DV.%26aulast%3DNubbemeyer%26aufirst%3DR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DBairlein%26aufirst%3DM.%26aulast%3DZollner%26aufirst%3DT.%2BM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520the%2520potent%2520and%2520selective%2520P2%2520%25C3%2597%25204%2520inhibitor%2520N-%255B4-%25283-Chlorophenoxy%2529-3-sulfamoylphenyl%255D-2-phenylacetamide%2520%2528BAY-1797%2529%2520and%2520structure-guided%2520amelioration%2520of%2520its%2520CYP3A4%2520induction%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11194%26epage%3D11217%26doi%3D10.1021%2Facs.jmedchem.9b01304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanteru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of phenyl (3-phenylpyrrolidin-3-yl)sulfones as selective, orally active RORgamm inverse agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVyltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367-373&issue=3&author=J.+J.+Duanauthor=Z.+Luauthor=B.+Jiangauthor=S.+Stachuraauthor=C.+A.+Weigeltauthor=J.+S.+Sackauthor=J.+Khanauthor=M.+Ruzanovauthor=M.+A.+Galellaauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=D.+J.+Shusterauthor=V.+Borowskiauthor=J.+H.+Xieauthor=L.+Zhangauthor=S.+Vanteruauthor=A.+K.+Guptaauthor=A.+Mathurauthor=Q.+Zhaoauthor=W.+Fosterauthor=L.+M.+Salter-Cidauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Structure-based+discovery+of+phenyl+%283-phenylpyrrolidin-3-yl%29sulfones+as+selective%2C+orally+active+RORgamm+inverse+agonists&doi=10.1021%2Facsmedchemlett.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists</span></div><div class="casAuthors">Duan, James J.-W.; Lu, Zhonghui; Jiang, Bin; Stachura, Sylwia; Weigelt, Carolyn A.; Sack, John S.; Khan, Javed; Ruzanov, Max; Galella, Michael A.; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Shuster, David J.; Borowski, Virna; Xie, Jenny H.; Zhang, Lisa; Vanteru, Sridhar; Gupta, Arun Kumar; Mathur, Arvind; Zhao, Qihong; Foster, William; Salter-Cid, Luisa M.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new Ph (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1.  Through a combination of structure-based design and structure-activity relationship studies, a polar set of amides at N1-position of the pyrrolidine ring and perfluoroisopropyl group at para-position of the 3-Ph group were identified as crit. structural elements to achieve high selectivity against PXR, LXRα, and LXRβ.  Further optimization led to the discovery of (1R,4r)-4-((R)-3-((4-fluorophenyl)sulfonyl)-3-(4-(perfluoropropan-2-yl)phenyl)pyrrolidine-1-carbonyl)cyclohexane-1-carboxylic acid (26), which displayed excellent selectivity, desirable liability and pharmacokinetic properties in vitro, and a good pharmacokinetic profile in mouse.  Oral administration of 26 demonstrated dose-dependent inhibition of IL-17 prodn. in a mouse IL-2/IL-23-induced pharmacodynamic model and biol.-like efficacy in an IL-23-induced mouse acanthosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZBJUkp-y6zbVg90H21EOLACvtfcHk0ljJHI4y7knspA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVyltLw%253D&md5=16114ce5cec852904e038f8d33be67a1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DVanteru%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFoster%26aufirst%3DW.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DStructure-based%2520discovery%2520of%2520phenyl%2520%25283-phenylpyrrolidin-3-yl%2529sulfones%2520as%2520selective%252C%2520orally%2520active%2520RORgamm%2520inverse%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D3%26spage%3D367%26epage%3D373%26doi%3D10.1021%2Facsmedchemlett.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torquato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellezza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, F.</span></span> <span> </span><span class="NLM_article-title">Garcinoic acid is a natural and selective agonist of pregnane X receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3701</span>– <span class="NLM_lpage">3712</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3701-3712&issue=7&author=D.+Bartoliniauthor=F.+De+Francoauthor=P.+Torquatoauthor=R.+Marinelliauthor=B.+Cerraauthor=R.+Ronchettiauthor=A.+Schonauthor=F.+Fallarinoauthor=A.+De+Lucaauthor=G.+Bellezzaauthor=I.+Ferriauthor=A.+Sidoniauthor=W.+G.+Waltonauthor=S.+J.+Pellockauthor=M.+R.+Redinboauthor=S.+Maniauthor=R.+Pellicciariauthor=A.+Gioielloauthor=F.+Galli&title=Garcinoic+acid+is+a+natural+and+selective+agonist+of+pregnane+X+receptor&doi=10.1021%2Facs.jmedchem.0c00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor</span></div><div class="casAuthors">Bartolini, Desiree; De Franco, Francesca; Torquato, Pierangelo; Marinelli, Rita; Cerra, Bruno; Ronchetti, Riccardo; Schon, Arne; Fallarino, Francesca; De Luca, Antonella; Bellezza, Guido; Ferri, Ivana; Sidoni, Angelo; Walton, William G.; Pellock, Samuel J.; Redinbo, Matthew R.; Mani, Sridhar; Pellicciari, Roberto; Gioiello, Antimo; Galli, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3701-3712</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) is a master xenobiotic-sensing transcription factor and a validated target for immune and inflammatory diseases.  The identification of chem. probes to investigate the therapeutic relevance of the receptor is still highly desired.  In fact, currently available PXR ligands are not highly selective and can exhibit toxicity and/or potential off-target effects.  In this study, we have identified garcinoic acid as a selective and efficient PXR agonist.  The properties of this natural mol. as a specific PXR agonist were demonstrated by the screening on a panel of nuclear receptors, the assessment of the phys. and thermodn. binding affinity, and the detn. of the PXR-garcinoic acid complex crystal structure.  Cytotoxicity, transcriptional, and functional properties were investigated in human liver cells, and compd. activity and target engagement were confirmed in vivo in mouse liver and gut tissue.  In conclusion, garcinoic acid is a selective natural agonist of PXR and a promising lead compd. toward the development of new PXR-regulating modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpzvQ2Jz97SbVg90H21EOLACvtfcHk0ljBZETFLFh1Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWkuro%253D&md5=1ece939693aca922c4cf745fe1fb9664</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00012%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DD.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DTorquato%26aufirst%3DP.%26aulast%3DMarinelli%26aufirst%3DR.%26aulast%3DCerra%26aufirst%3DB.%26aulast%3DRonchetti%26aufirst%3DR.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DBellezza%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DI.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DWalton%26aufirst%3DW.%2BG.%26aulast%3DPellock%26aufirst%3DS.%2BJ.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DGioiello%26aufirst%3DA.%26aulast%3DGalli%26aufirst%3DF.%26atitle%3DGarcinoic%2520acid%2520is%2520a%2520natural%2520and%2520selective%2520agonist%2520of%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D7%26spage%3D3701%26epage%3D3712%26doi%3D10.1021%2Facs.jmedchem.0c00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klakouski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discotto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peese, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhulu Naidu, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">127531</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32890685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127531&issue=22&author=P.+Sivaprakasamauthor=Z.+Wangauthor=N.+A.+Meanwellauthor=J.+A.+Khanauthor=D.+R.+Langleyauthor=S.+R.+Johnsonauthor=G.+Liauthor=A.+Pendriauthor=T.+P.+Connollyauthor=M.+Gaoauthor=D.+M.+Camacauthor=C.+Klakouskiauthor=T.+Zvyagaauthor=C.+Cianciauthor=B.+McAuliffeauthor=B.+Dingauthor=L.+Discottoauthor=M.+R.+Krystalauthor=S.+Jenkinsauthor=K.+M.+Peeseauthor=B.+Narasimhulu+Naidu&title=Structure-based+amelioration+of+PXR+transactivation+in+a+novel+series+of+macrocyclic+allosteric+inhibitors+of+HIV-1+integrase&doi=10.1016%2Fj.bmcl.2020.127531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Wang, Zhongyu; Meanwell, Nicholas A.; Khan, Javed A.; Langley, David R.; Johnson, Stephen R.; Li, Guo; Pendri, Annapurna; Connolly, Timothy P.; Gao, Mian; Camac, Daniel M.; Klakouski, Cheryl; Zvyaga, Tatyana; Cianci, Christopher; McAuliffe, Brian; Ding, Bo; Discotto, Linda; Krystal, Mark R.; Jenkins, Susan; Peese, Kevin M.; Narasimhulu Naidu, B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">127531</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivs. as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture.  However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition pathways.  In an attempt to modify PXR activity without affecting anti-HIV-1 activity, rational structure-based design and modeling approaches were used.  An X-ray cocrystal structure of (S,S)-1 in the PXR ligand binding domain (LBD) allowed an examn. of the potential of rational structural modifications designed to abrogate PXR.  The introduction of bulky basic amines at the C-8 position provided macrocyclic IZP derivs. that displayed potent HIV-1 inhibitory activity in cell culture with no detectable PXR transactivation at the highest concn. tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iQTZwxuzbLVg90H21EOLACvtfcHk0ljBZETFLFh1Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsbzF&md5=6c5aa7db7e553e2fea5cf9c4da1c25b2</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127531%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DKlakouski%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DB.%26aulast%3DDiscotto%26aufirst%3DL.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DPeese%26aufirst%3DK.%2BM.%26aulast%3DNarasimhulu%2BNaidu%26aufirst%3DB.%26atitle%3DStructure-based%2520amelioration%2520of%2520PXR%2520transactivation%2520in%2520a%2520novel%2520series%2520of%2520macrocyclic%2520allosteric%2520inhibitors%2520of%2520HIV-1%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127531%26doi%3D10.1016%2Fj.bmcl.2020.127531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roehrig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnoth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puetter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitmeier, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological characterization of a neutral, non-prodrug thrombin inhibitor with good oral pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12574</span>– <span class="NLM_lpage">12594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKlsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12574-12594&issue=21&author=A.+Hillischauthor=K.+M.+Gerickeauthor=S.+Allerheiligenauthor=S.+Roehrigauthor=M.+Schaeferauthor=A.+Tersteegenauthor=S.+Schulzauthor=P.+Lienauauthor=M.+Gnothauthor=V.+Puetterauthor=R.+C.+Hilligauthor=S.+Heitmeier&title=Design%2C+synthesis%2C+and+pharmacological+characterization+of+a+neutral%2C+non-prodrug+thrombin+inhibitor+with+good+oral+pharmacokinetics&doi=10.1021%2Facs.jmedchem.0c01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics</span></div><div class="casAuthors">Hillisch, Alexander; Gericke, Kersten M.; Allerheiligen, Swen; Roehrig, Susanne; Schaefer, Martina; Tersteegen, Adrian; Schulz, Simone; Lienau, Philip; Gnoth, Mark; Puetter, Vera; Hillig, Roman C.; Heitmeier, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12574-12594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite extensive research on small mol. thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug.  We have undertaken major efforts to identify neutral, non-prodrug inhibitors.  Using a holistic anal. of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability.  In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochem. properties to balance absorption and metabolic stability.  Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P 450 3A4 induction problem.  The selected compd. series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivs.  The resulting optimized compd., BAY1217224, has reached first clin. trials, which have confirmed the desired pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH5c8QWf1cdrVg90H21EOLACvtfcHk0ljBZETFLFh1Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKlsbfL&md5=d1230b8fb189a2b3d5164d49637f77b3</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01035%26sid%3Dliteratum%253Aachs%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DGericke%26aufirst%3DK.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DRoehrig%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DTersteegen%26aufirst%3DA.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DGnoth%26aufirst%3DM.%26aulast%3DPuetter%26aufirst%3DV.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DHeitmeier%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%2520of%2520a%2520neutral%252C%2520non-prodrug%2520thrombin%2520inhibitor%2520with%2520good%2520oral%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D21%26spage%3D12574%26epage%3D12594%26doi%3D10.1021%2Facs.jmedchem.0c01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toporova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">Assessing the selectivity of FXR, LXRs, CAR, and RORgamma pharmaceutical ligands with reporter cell lines</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1122</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.01122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3389%2Ffphar.2020.01122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32792956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlSitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1122&author=L.+Toporovaauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=P.+Balaguer&title=Assessing+the+selectivity+of+FXR%2C+LXRs%2C+CAR%2C+and+RORgamma+pharmaceutical+ligands+with+reporter+cell+lines&doi=10.3389%2Ffphar.2020.01122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the selectivity of FXR, LXRs, CAR, and RORγ pharmaceutical ligands with reporter cell lines</span></div><div class="casAuthors">Toporova, Lucia; Grimaldi, Marina; Boulahtouf, Abdelhay; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1122</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">To characterize human nuclear receptor (NR) specificity of synthetic pharmaceutical chems. we established stable cell lines expressing the ligand binding domains (LBDs) of human FXR, LXRa, LXRb, CAR, and RORγ fused to the yeast GAL4 DNA binding domain (DBD).  As we have already done for human PXR, a two-step transfection procedure was used.  HeLa cells stably expressing a Gal4 responsive gene (HG5LN cell line) were transfected by Gal4-NRs expressing plasmids.  At first, using these cell lines as well as the HG5LN PXR cells, we demonstrated that the basal activities varied from weak (FXR and LXRs), intermediate (PXR), to strong (CAR and RORγ), reflecting the recruitment of HeLa co-regulators in absence of ligand.  Secondly, we finely characterized the activities of com. available FXR, LXRa, LXRb, CAR, RORγ, and PXR agonists/antagonists GW4064, feraxamine, DY268, T0901317, GW3965, WAY252623, SR9238, SR9243, GSK2033, CITCO, CINPA1, PK11195, S07662, SR1078, SR0987, SR1001, SR2211, XY018, clotrimazole, dabrafenib, SR12813, and SPA70, resp.  Among these compds. we revealed both, receptor specific agonists/antagonists, as well as less selective ligands, activating or inhibiting several nuclear receptors.  FXR ligands manifested high receptor selectivity.  Vice versa, LXR ligands behaved in non-selective manner, all activating at least PXR.  CAR was selectively influenced by their ligands, while it also responded to several LXR ligands.  Finally, although PXR was quite selectively activated or antagonized by its own ligands, it responded to several NRs ligands as well.  Thus, using these reporter cell lines enabled us to precisely characterize the selectivity of pharmaceutical ligands for different nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPsrgA4IC48rVg90H21EOLACvtfcHk0liEA5DO_bi1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlSitbvF&md5=5990f8dc695e3c448125bb66f680ba77</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.01122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.01122%26sid%3Dliteratum%253Aachs%26aulast%3DToporova%26aufirst%3DL.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DAssessing%2520the%2520selectivity%2520of%2520FXR%252C%2520LXRs%252C%2520CAR%252C%2520and%2520RORgamma%2520pharmaceutical%2520ligands%2520with%2520reporter%2520cell%2520lines%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D1122%26doi%3D10.3389%2Ffphar.2020.01122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span> <span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&issue=2&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0liEA5DO_bi1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D2%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngan, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudnitskaya, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">The structural basis of pregnane X receptor binding promiscuity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">11572</span>– <span class="NLM_lpage">11581</span>, <span class="refDoi"> DOI: 10.1021/bi901578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKrsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=11572-11581&issue=48&author=C.+H.+Nganauthor=D.+Beglovauthor=A.+N.+Rudnitskayaauthor=D.+Kozakovauthor=D.+J.+Waxmanauthor=S.+Vajda&title=The+structural+basis+of+pregnane+X+receptor+binding+promiscuity&doi=10.1021%2Fbi901578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The Structural Basis of Pregnane X Receptor Binding Promiscuity</span></div><div class="casAuthors">Ngan, Chi-Ho; Beglov, Dmitri; Rudnitskaya, Aleksandra N.; Kozakov, Dima; Waxman, David J.; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">11572-11581</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The steroid and xenobiotic-responsive human pregnane X receptor (PXR) binds a broad range of structurally diverse compds.  The structures of the apo and ligand-bound forms of PXR are very similar, in contrast to most promiscuous proteins that generally adapt their shape to different ligands.  The authors investigated the structural origins of PXR's recognition promiscuity using computational solvent mapping, a technique developed for the identification and characterization of hot spots, i.e., regions of the protein surface that are major contributors to the binding free energy.  Results reveal that the smooth and nearly spherical binding site of PXR has a well-defined hot spot structure, with four hot spots located on four different sides of the pocket and a fifth close to its center.  Three of these hot spots are already present in the ligand-free protein.  The most important hot spot is defined by three structurally and sequentially conserved residues, W299, F288, and Y306.  This largely hydrophobic site is not very specific and interacts with all known PXR ligands.  Depending on their sizes and shapes, individual PXR ligands extend into two, three, or four more hot spot regions.  The large no. of potential arrangements within the binding site explains why PXR is able to accommodate a large variety of compds.  All five hot spots include at least one important residue, which is conserved in all mammalian PXRs, suggesting that the hot spot locations have remained largely invariant during mammalian evolution.  The same side chains also show a high level of structural conservation across hPXR structures.  However, each of the hPXR hot spots also includes residues with moveable side chains, further increasing the size variation in ligands that PXR can bind.  Results also suggest a unique signal transduction mechanism between the PXR homodimerization interface and its coactivator binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9monJ4ISxxrVg90H21EOLACvtfcHk0lhZue0_wmLdPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKrsb3E&md5=6d5d3c85fd1cffedc4e6610cb3c4914a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Fbi901578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901578n%26sid%3Dliteratum%253Aachs%26aulast%3DNgan%26aufirst%3DC.%2BH.%26aulast%3DBeglov%26aufirst%3DD.%26aulast%3DRudnitskaya%26aufirst%3DA.%2BN.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DThe%2520structural%2520basis%2520of%2520pregnane%2520X%2520receptor%2520binding%2520promiscuity%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26issue%3D48%26spage%3D11572%26epage%3D11581%26doi%3D10.1021%2Fbi901578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani Tagliabue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonati, L.</span></span> <span> </span><span class="NLM_article-title">Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16207</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-34373-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fs41598-018-34373-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30385820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BB3cvlslOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=16207&author=S.+Mottaauthor=L.+Calleaauthor=S.+Giani+Tagliabueauthor=L.+Bonati&title=Exploring+the+PXR+ligand+binding+mechanism+with+advanced+Molecular+Dynamics+methods&doi=10.1038%2Fs41598-018-34373-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods</span></div><div class="casAuthors">Motta Stefano; Callea Lara; Giani Tagliabue Sara; Bonati Laura</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16207</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Pregnane X Receptor (PXR) is a ligand-activated transcription factor belonging to the nuclear receptor family.  PXR can bind diverse drugs and environmental toxicants with different binding modes, making it an intriguing target for drug discovery.  Here we investigated the binding mechanism of the SR12813 ligand to elucidate the significant steps, from the ligand entrance pathway into the binding cavity, to the ligand-induced conformational changes, and to the exploration of its alternative binding geometries.  We used the advanced Molecular Dynamics-based methods implemented in the BiKi suite and developed specific methodological approaches to overcome the complexity induced by the buried and flexible binding cavity.  The adopted methods provided a full dynamic description of the binding event and allowed rationalization of the observed multiple binding modes.  These results suggest that the same approach could be exploited for the study of other binding processes with similar characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDjtJBTMU9EAHqQV89nF-2fW6udTcc2eaDOyeCElW-17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvlslOntg%253D%253D&md5=6a528d82c22cc7296caf74d2cde4e68c</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-34373-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-34373-z%26sid%3Dliteratum%253Aachs%26aulast%3DMotta%26aufirst%3DS.%26aulast%3DCallea%26aufirst%3DL.%26aulast%3DGiani%2BTagliabue%26aufirst%3DS.%26aulast%3DBonati%26aufirst%3DL.%26atitle%3DExploring%2520the%2520PXR%2520ligand%2520binding%2520mechanism%2520with%2520advanced%2520Molecular%2520Dynamics%2520methods%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D16207%26doi%3D10.1038%2Fs41598-018-34373-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulators of PXR and CAR</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1859</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2016.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bbagrm.2016.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12nt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1859&publication_year=2016&pages=1141-1154&issue=9&author=S.+C.+Chaiauthor=M.+T.+Cherianauthor=Y.+M.+Wangauthor=T.+Chen&title=Small-molecule+modulators+of+PXR+and+CAR&doi=10.1016%2Fj.bbagrm.2016.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulators of PXR and CAR</span></div><div class="casAuthors">Chai, Sergio C.; Cherian, Milu T.; Wang, Yue-Ming; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1859</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1141-1154</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two nuclear receptors, the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR), participate in the xenobiotic detoxification system by regulating the expression of drug-metabolizing enzymes and transporters in order to degrade and excrete foreign chems. or endogenous metabolites.  This review aims to expand the perceived relevance of PXR and CAR beyond their established role as master xenosensors to disease-oriented areas, emphasizing their modulation by small mols.  Structural studies of these receptors have provided much-needed insight into the nature of their binding promiscuity and the important elements that lead to ligand binding.  Reports of species- and isoform-selective activation highlight the need for further scrutiny when extrapolating from animal data to humans, as animal models are at the forefront of early drug discovery.  This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr.  Wen Xie.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDuudq7xVhrVg90H21EOLACvtfcHk0lhZue0_wmLdPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12nt7c%253D&md5=9caac4ee368cff75ae6201f383bb0332</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2016.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2016.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DCherian%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DSmall-molecule%2520modulators%2520of%2520PXR%2520and%2520CAR%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2016%26volume%3D1859%26issue%3D9%26spage%3D1141%26epage%3D1154%26doi%3D10.1016%2Fj.bbagrm.2016.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">PXR antagonists and implication in drug metabolism</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.3109/03602532.2012.746363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F03602532.2012.746363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23330542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=60-72&issue=1&author=S.+Maniauthor=W.+Douauthor=M.+R.+Redinbo&title=PXR+antagonists+and+implication+in+drug+metabolism&doi=10.3109%2F03602532.2012.746363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">PXR antagonists and implication in drug metabolism</span></div><div class="casAuthors">Mani, Sridhar; Dou, Wei; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-72</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Adopted orphan nuclear receptor (NR), pregnane X receptor (PXR), plays a central role in the regulation of xeno- and endobiotic metab.  Since the discovery of the functional role of PXR in 1998, there is evolving evidence for the role of PXR agonists in abrogating metabolic pathophysiol. (e.g., cholestasis, hypercholesterolemia, and inflammation).  However, more recently, it is clear that PXR is also an important mediator of adverse xeno- (e.g., enhances acetaminophen toxicity) and endobiotic (e.g., hepatic steatosis) metabolic phenotypes.  Moreover, in cancer therapeutics, PXR activation can induce drug resistance, and there is growing evidence for tissue-specific enhancement of the malignant phenotype.  Thus, in these instances, there may be a role for PXR antagonists.  However, as opposed to the discovery efforts for PXR agonists, there are only a few antagonists described.  The mode of action of these antagonists (e.g., sulforaphane) remains less clear.  Our lab. efforts have focused on this question.  Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.  In this review, we describe our published and unpublished findings on recent structure-function studies involving the azole chem. scaffold.  Further work in the future is needed to fully define potent, more-selective PXR antagonists that may be useful in clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxOh0MSugxrVg90H21EOLACvtfcHk0lgh07u3C8KDKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaksL4%253D&md5=52e26d69dddea8827caa8d71b3e8c659</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.3109%2F03602532.2012.746363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2012.746363%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DS.%26aulast%3DDou%26aufirst%3DW.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DPXR%2520antagonists%2520and%2520implication%2520in%2520drug%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2013%26volume%3D45%26issue%3D1%26spage%3D60%26epage%3D72%26doi%3D10.3109%2F03602532.2012.746363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Elucidating the ‘Jekyll and Hyde’ nature of PXR: the case for discovering antagonists or allosteric antagonists</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9901-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-009-9901-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19415465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlyls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1807-1815&issue=8&author=A.+Biswasauthor=S.+Maniauthor=M.+R.+Redinboauthor=M.+D.+Krasowskiauthor=H.+Liauthor=S.+Ekins&title=Elucidating+the+%E2%80%98Jekyll+and+Hyde%E2%80%99+nature+of+PXR%3A+the+case+for+discovering+antagonists+or+allosteric+antagonists&doi=10.1007%2Fs11095-009-9901-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the 'Jekyll and Hyde' Nature of PXR: The Case for Discovering Antagonists or Allosteric Antagonists</span></div><div class="casAuthors">Biswas, Arunima; Mani, Sridhar; Redinbo, Matthew R.; Krasowski, Matthew D.; Li, Hao; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1807-1815</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The pregnane X receptor belongs to the nuclear hormone receptor superfamily and is involved in the transcriptional control of numerous genes.  It was originally thought that it was a xenobiotic sensor controlling detoxification pathways.  Recent studies have shown an increasingly important role in inflammation and cancer, supporting its function in abrogating tissue damage.  PXR orthologs and PXR-like pathways have been identified in several non-mammalian species which corroborate a conserved role for PXR in cellular detoxification.  In summary, PXR has a multiplicity of roles in vivo and is being revealed as behaving like a "Jekyll and Hyde" nuclear hormone receptor.  The importance of this review is to elucidate the need for discovery of antagonists of PXR to further probe its biol. and therapeutic applications.  Although several PXR agonists are already reported, virtually nothing is known about PXR antagonists.  Here, we propose the development of PXR antagonists through chem., genetic and mol. modeling approaches.  Based on this review it will be clear that antagonists of PXR and PXR-like pathways will have widespread utility in PXR biol. and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJN0vcXp3bVrVg90H21EOLACvtfcHk0lgh07u3C8KDKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlyls7o%253D&md5=b1e19595ac79f661f55faeff53a8515a</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9901-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9901-7%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DA.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DElucidating%2520the%2520%25E2%2580%2598Jekyll%2520and%2520Hyde%25E2%2580%2599%2520nature%2520of%2520PXR%253A%2520the%2520case%2520for%2520discovering%2520antagonists%2520or%2520allosteric%2520antagonists%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26issue%3D8%26spage%3D1807%26epage%3D1815%26doi%3D10.1007%2Fs11095-009-9901-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchman, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Mutation of a single amino acid of pregnane X receptor switches an antagonist to agonist by altering AF-2 helix positioning</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1007/s00018-020-03505-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00018-020-03505-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32232515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFKhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2021&pages=317-335&author=A.+D.+Huberauthor=W.+C.+Wrightauthor=W.+Linauthor=K.+Majumderauthor=J.+A.+Lowauthor=J.+Wuauthor=C.+D.+Buchmanauthor=D.+J.+Pintelauthor=T.+Chen&title=Mutation+of+a+single+amino+acid+of+pregnane+X+receptor+switches+an+antagonist+to+agonist+by+altering+AF-2+helix+positioning&doi=10.1007%2Fs00018-020-03505-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of a single amino acid of pregnane X receptor switches an antagonist to agonist by altering AF-2 helix positioning</span></div><div class="casAuthors">Huber, Andrew D.; Wright, William C.; Lin, Wenwei; Majumder, Kinjal; Low, Jonathan A.; Wu, Jing; Buchman, Cameron D.; Pintel, David J.; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">317-335</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) is activated by chems. to transcriptionally regulate drug disposition and possibly decrease drug efficacy and increase resistance, suggesting therapeutic value for PXR antagonists.  We previously reported the antagonist SPA70 and its analog SJB7, which unexpectedly is an agonist.  Here, we describe another unexpected observation: mutating a single residue (W299A) within the PXR ligand-binding domain converts SPA70 to an agonist.  After characterizing wild-type and W299A PXR activity profiles, we used mol. dynamics simulations to reveal that in wild-type PXR, agonists stabilize the activation function 2 (AF-2) helix in an "inward" position, but SPA70 displaces the AF-2.  In W299A, however, SPA70 stabilizes the AF-2 "inward", like agonists.  We validated our model by predicting the antagonist SJC2 to be a W299A agonist, which was confirmed exptl.  Our work correlates previously unobserved ligand-induced conformational changes to PXR cellular activity and, for the first time, reveals how PXR antagonists work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6taSvgJPjrVg90H21EOLACvtfcHk0lgh07u3C8KDKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFKhsL8%253D&md5=a56ffd0d65fdac5dcfbd50cbf6da6ad2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs00018-020-03505-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-020-03505-y%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%2BD.%26aulast%3DWright%26aufirst%3DW.%2BC.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DMajumder%26aufirst%3DK.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBuchman%26aufirst%3DC.%2BD.%26aulast%3DPintel%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DMutation%2520of%2520a%2520single%2520amino%2520acid%2520of%2520pregnane%2520X%2520receptor%2520switches%2520an%2520antagonist%2520to%2520agonist%2520by%2520altering%2520AF-2%2520helix%2520positioning%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2021%26volume%3D78%26spage%3D317%26epage%3D335%26doi%3D10.1007%2Fs00018-020-03505-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fauber, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon Boenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rene, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6604</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2013.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24239186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslygtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6604-6609&issue=24&author=B.+P.+Fauberauthor=G.+de+Leon+Boenigauthor=B.+Burtonauthor=C.+Eidenschenkauthor=C.+Everettauthor=A.+Gobbiauthor=S.+G.+Hymowitzauthor=A.+R.+Johnsonauthor=M.+Liimattaauthor=P.+Lockeyauthor=M.+Normanauthor=W.+Ouyangauthor=O.+Reneauthor=H.+Wong&title=Structure-based+design+of+substituted+hexafluoroisopropanol-arylsulfonamides+as+modulators+of+RORc&doi=10.1016%2Fj.bmcl.2013.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc</span></div><div class="casAuthors">Fauber, Benjamin P.; de Leon Boenig, Gladys; Burton, Brenda; Eidenschenk, Celine; Everett, Christine; Gobbi, Alberto; Hymowitz, Sarah G.; Johnson, Adam R.; Liimatta, Marya; Lockey, Peter; Norman, Maxine; Ouyang, Wenjun; Rene, Olivier; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6604-6609</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of T0901317 analogs were explored as RORc inverse agonists using the principles of property- and structure-based drug design.  An X-ray co-crystal structure of T0901317 and RORc was obtained and provided mol. insight into why T0901317 functioned as an inverse agonist of RORc; whereas, the same ligand functioned as an agonist of FXR, LXR, and PXR.  The structural data was also used to design inhibitors with improved RORc biochem. and cellular activities.  The improved inhibitors possessed enhanced selectivity profiles (rationalized using the X-ray crystallog. data) against other nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxTcPky8JCMbVg90H21EOLACvtfcHk0lgxN_2wSkiacw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslygtrzL&md5=fb0331ebb12017c746f1a4f791e21637</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLockey%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DRene%26aufirst%3DO.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DStructure-based%2520design%2520of%2520substituted%2520hexafluoroisopropanol-arylsulfonamides%2520as%2520modulators%2520of%2520RORc%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D24%26spage%3D6604%26epage%3D6609%26doi%3D10.1016%2Fj.bmcl.2013.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T.G.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert
Grafstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span> <span> </span><span class="NLM_article-title">The discovery of BMS-457, a potent and selective CCR1 antagonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3833</span>– <span class="NLM_lpage">3840</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2013.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23707259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Cks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3833-3840&issue=13&author=D.+S.+Gardnerauthor=J.+B.+Santellaauthor=J.+V.+Dunciaauthor=P.+H.+Carterauthor=T.G.M.+Dharauthor=H.+Wuauthor=W.+Guoauthor=C.+Cavallaroauthor=K.+Van+Kirkauthor=M.+Yardeauthor=S.+W.+Bricenoauthor=R.+Robert%0AGrafstromauthor=R.+Liuauthor=S.+R.+Patelauthor=A.+J.+Tebbenauthor=D.+Camacauthor=J.+Khanauthor=A.+Watsonauthor=G.+Yangauthor=A.+Roseauthor=W.+R.+Fosterauthor=M.+E.+Cvijicauthor=P.+Daviesauthor=J.+Hynes&title=The+discovery+of+BMS-457%2C+a+potent+and+selective+CCR1+antagonist&doi=10.1016%2Fj.bmcl.2013.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of BMS-457, a potent and selective CCR1 antagonist</span></div><div class="casAuthors">Gardner, Daniel S.; Santella, Joseph B.; Duncia, John V.; Carter, Percy H.; Dhar, T. G. Murali; Wu, Hong; Guo, Weiwei; Cavallaro, Cullen; Van Kirk, Katy; Yarde, Melissa; Briceno, Stephanie W.; Robert Grafstrom, R.; Liu, Richard; Patel, Sima R.; Tebben, Andrew J.; Camac, Dan; Khan, Javed; Watson, Andrew; Yang, Guchen; Rose, Anne; Foster, William R.; Cvijic, Mary Ellen; Davies, Paul; Hynes, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3833-3840</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor.  Issues of PXR activity, ion-channel potency, and poor metabolic stability were addressed by the addn. of a hydroxyl group to an otherwise lipophilic area in the mol. resulting in the discovery of preclin. candidate BMS-457 for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwglrqThzB7Vg90H21EOLACvtfcHk0lgxN_2wSkiacw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Cks7g%253D&md5=0edb8fb8e1d1a8fd2579a360dee50f47</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.G.M.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DCavallaro%26aufirst%3DC.%26aulast%3DVan%2BKirk%26aufirst%3DK.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DS.%2BW.%26aulast%3DRobert%2BGrafstrom%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCamac%26aufirst%3DD.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DW.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DThe%2520discovery%2520of%2520BMS-457%252C%2520a%2520potent%2520and%2520selective%2520CCR1%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3833%26epage%3D3840%26doi%3D10.1016%2Fj.bmcl.2013.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. F.</span></span> <span> </span><span class="NLM_article-title">CXIX.—The formation and stability of spiro-compounds. Part I. spiro-Compounds from cyclohexane</span>. <i>J. Chem. Soc., Trans.</i> <span class="NLM_year" style="font-weight: bold;">1915</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1106</span>, <span class="refDoi"> DOI: 10.1039/CT9150701080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FCT9150701080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaC2MXhvVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=1915&pages=1080-1106&author=R.+M.+Beesleyauthor=C.+K.+Ingoldauthor=J.+F.+Thorpe&title=CXIX.%E2%80%94The+formation+and+stability+of+spiro-compounds.+Part+I.+spiro-Compounds+from+cyclohexane&doi=10.1039%2FCT9150701080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Formation and stability of spiro-compounds. I. Spiro-compounds from cyclohexano</span></div><div class="casAuthors">Beesley, Richard M.; Ingold, Christopher K.; Thorpe, Jocelyn F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Transactions</span>
        (<span class="NLM_cas:date">1915</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1080-1106</span>CODEN:
                <span class="NLM_cas:coden">JCHTA3</span>;
        ISSN:<span class="NLM_cas:issn">0368-1645</span>.
    </div><div class="casAbstract">A series of investigations has been undertaken with the object of ascertaining "the effect produced by the alteration of the tetrahedral angle consequent on ring formation, on the formation and stability of a 2nd ring joined to the existing ring by a quaternary C atom common to both."  The hypothesis was advanced that the angle formed by the 2 side chains attached to any 1 C atom of the cyclohexane ring will be altered in proportion to any change in angle between those valencies which participate in ring formation; i. e., the groups attached to 2 side chains emanating from the same C atom of a cyclohexane deriv., type (I), will be closer together than in a corresponding compd. having the open chain structure, type (II).  Expts. show that this hypothesis is probably correct.  For example a trans-spiro-acid, derived from a compd. of type (I) is more stable than trans-caronic acid, derived from a compd. of type (II).  The above hypothesis and another untenable one are presented and discussed in some detail and diagrammatically represented by showing the effect of "strain" on the angles between the valencies (represented by the apices of an inscribed tetrahedron) of a (spherical) C atom.  The bromination of CH2(CH2)4C(CH2CO2H)2 by means of PBr5 and Br led to the formation of a mixt. containing an acid product, probably C5H10>C(CHBrCO2H)(CH2CO2Et) (A), and a neutral product (B).  The latter was shown to be a mixt. of cis-diethyl α,α'-dibromocyclohexane-1,1-diacetate (C) (not obtained in the pure state) and the trans-lactone (D), C5H10>C.CH(CO2Et).O.CO.CHBr, prisms from petroleum or alc., m. 96°, b20 225-30°. (D) was sepd. from the mixt. (B) by the addition of an equal vol. of petroleum (b. 60-70°) and was also synthesized by boiling (C) with C5H5N [whereby only the trans-form of (C) was converted into (D)] or by distg. (C), whereby both the cis- and trans-forms were converted.  The isomeric cis-lactone (D'), microneedles, m. 69-70°, was formed in 25% yield upon distg. (C) from which (D) had been previously removed by means of C5H5N.  α-Hydroxycyclohexane-1,1-diacetic acid lactone (E), C5H10>C.CH(CO2H).O.CO.CH2, b13 240-1°, crystg. after long standing and seeding, microneedles, m. 91-2° (silver salt, amorphous), was formed from (A) by the action of boiling Na2CO3.  The free acid (F) corresponding to (E) could not be isolated and was found to be stable only in the form of its salts.  The amorphous silver salt and cryst. sodium salt of (F) were prepd.  The dianilide of (F), C5H10>C(CH2CONHPh)CH(OH)CONHPh, needles, m. 97°.  The aniline salt of (E), silky needles, m. 104°.  When (A) was added to boiling concd. KOH and the reaction mixt. cooled and acidified, trans-cyclohexane-spiro-cyclopropane-1,2-dicarboxylic acid (G), C5H10>C.CH(CO2H).CHCO2H, flattened needles, m. 237°, was formed.  Its silver salt sepd. in the form of a cryst. powder: its dianilide, needles, m. 292°.  The filtrate from (G) after extn. with Et2O and fractionation under reduced pressure yielded the cis-isomer (H) of (G), needles, m. 198°, more readily formed by distg. (G) which is first converted into the anhydride (J), C5H10>C.CH.CO.O.CO.CH, needles, m. 102°, which on treatment with alkali and subsequent acidification yields (H).  (J) was also readily prepd. by the interaction of (H) and AcCl, whereas (G) is not acted upon by this reagent.  The anilic acid, C5H10>C.CH(CO2H).CHCONHPh, derived from (J), small needles,m. 207° (decompn.); the corresponding anil, m. 119°.  When heated in a sealed tube with 50% concd. HCl at 180° for 5 hrs., (H) is partially reconverted into (G).  On attempting to replace the Br in (D) by an OH group, by means of moist Ag2O, ethyl α-hydroxycyclohexane-1,1-diacetate lactone, C5H10> C.CH2CO.O.CHCO2Et, b21 210°, was obtained and yielded (E) on hydrolysis.  The following hydrolysis products were formed when (D) was treated with boiling 15% aq. NaOH:C5H10>C:CHCO2H (K), m. 92° (identical with Wallach's acid as shown by the formation of the dibromide, m. 135-6°; ref. not given), and the trans-lactonic acid of α,α'-dihydroxycyclohexane-1,1-diacetic acid (L), C5H10>C.CH(OH).CO.O.CHCO2H.H2O, prisms, 100°, anhydrous, m. 145°.  (D') when subjected to a similar hydrolysis gave rise to a mixt. of (K), the cis-isomer (M) of (L), prisms, m. 168°, and cyclohexane-spiro-cyclopropanol-2,3-dicarboxylic acid (N), C5H10>C.C(OH)(CO2H).CHCO2H, pearly plates, m. 217°.  Boiling alc. KOH, reacting with (D), yielded (K), (L) and (N).  The action of 64% aq. KOH on (D) gave rise to a mixt. of (L), (N) and Δ1-cyclohexeneacetic acid, (O), CH2(CH2)3CH:C.CH2CO2H, m. 38° (identical with Wallach's compd.; also quant. formed by boiling (K) with 64% KOH, thus indicating that it was a byproduct in the above reaction).  The Et ester of (O), b25 118-2° (cf. Auwers and Ellinger, C. A. 6, 1147).  A similar reaction between 64% KOH and (D') gave rise to (O), (M) and (N).  (K) and (N) were sepd. by treatment with dry Et2O in which (N) is insol.  (L) was ordinarily sepd. from hydrolysis mixts. by esterifying and fractionating the ethyl ester, b25 206-10°.  The following derivs. of (L) are described: disodium salt, cryst.; disilver salt, powder; aniline salt, microcrystals, m. 133-4°; dianilide, C5H10>C[CH(OH)CONHPh]2, short needles, m. 169°.  (L) does not react with AcCl, is not reduced by AgOH, and when heated with H2O in a sealed tube or when distd., passes into (M).  The isolation of (M) was effected by esterifying hydrolysis mixts. and collecting the fraction of highest b. p., which was subsequently hydrolyzed with HCl.  (M) was readily acetylated.  The following derivs. of (M) were prepd.: disilver salt; dianilide, needles, m. 169° (not identical with the dianilide derived from (L)); acetate, C5H10>CH(OAc).CO.O.CHCO2H, m. 156° (silver salt of the acetate, cryst. powder).  The spiro-acid (N), which like (L) could not be acetylated, which is not converted into the lactone on heating and is otherwise stable, gave rise to the following compds.: silver salt, cryst. powder; anilide, needles, m. 202°.  Concd. H2SO4 acting upon (L) at 95-100°, gave rise to small amts. of cyclohexane-spiro-cyclopentanone, oil (forming a semicarbazone, needles, m. 175°), and an unidentified compd., m. 105°.  When heated with an equal amt. of H2O in a sealed tube at 240° for 0.5 hr., (L) yielded the lactonic acid of α-hydroxy-α'-cyclohexan-1-olsuccinic acid, C5H10>C.O.CO.CH(OH).CHCO2H, cubical prisms, m. 131°, whose disodium salt, disilver salt and aniline salt, m. 123°, were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLfaoba7kGULVg90H21EOLACvtfcHk0ljqs13ceJskzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaC2MXhvVGiuw%253D%253D&md5=de4306fddc79f71809a8556525abc983</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2FCT9150701080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FCT9150701080%26sid%3Dliteratum%253Aachs%26aulast%3DBeesley%26aufirst%3DR.%2BM.%26aulast%3DIngold%26aufirst%3DC.%2BK.%26aulast%3DThorpe%26aufirst%3DJ.%2BF.%26atitle%3DCXIX.%25E2%2580%2594The%2520formation%2520and%2520stability%2520of%2520spiro-compounds.%2520Part%2520I.%2520spiro-Compounds%2520from%2520cyclohexane%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Trans.%26date%3D1915%26volume%3D107%26spage%3D1080%26epage%3D1106%26doi%3D10.1039%2FCT9150701080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Cortez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truillet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbecker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletterick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, P. M.</span></span> <span> </span><span class="NLM_article-title">Development of 5N-bicalutamide, a high-affinity reversible covalent antiandrogen</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2934</span>– <span class="NLM_lpage">2939</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sksr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2934-2939&issue=12&author=F.+de+Jesus+Cortezauthor=P.+Nguyenauthor=C.+Truilletauthor=B.+Tianauthor=K.+M.+Kuchenbeckerauthor=M.+J.+Evansauthor=P.+Webbauthor=M.+P.+Jacobsonauthor=R.+J.+Fletterickauthor=P.+M.+England&title=Development+of+5N-bicalutamide%2C+a+high-affinity+reversible+covalent+antiandrogen&doi=10.1021%2Facschembio.7b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen</span></div><div class="casAuthors">de Jesus Cortez, Felipe; Nguyen, Phuong; Truillet, Charles; Tian, Boxue; Kuchenbecker, Kristopher M.; Evans, Michael J.; Webb, Paul; Jacobson, Matthew P.; Fletterick, Robert J.; England, Pamela M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2934-2939</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to clin. antiandrogens has plagued the evolution of effective therapeutics for advanced prostate cancer.  As with the first-line therapeutic bicalutamide (Casodex), resistance to newer antiandrogens (enzalutamide, ARN-509) develops quickly in patients, despite the fact that these drugs have ∼10-fold better affinity for androgen receptor than bicalutamide.  Improving affinity alone is often not sufficient to prevent resistance and alternative strategies are needed to improve antiandrogen efficacy.  Covalent and reversible covalent drugs are being used to thwart drug resistance in other contexts, and activated aryl nitriles are among the moieties being exploited for this purpose.  The authors capitalized on the presence of an aryl nitrile in bicalutamide, and the existence of a native cysteine residue (Cys784) in the androgen receptor ligand binding pocket, to develop 5N-bicalutamide I, a cysteine-reactive antiandrogen.  I exhibits a 150-fold improvement in Ki and 20-fold improvement in IC50 over the parent compd.  The authors attribute the marked improvement in affinity and activity to the formation of a covalent adduct with Cys784, a residue that is not among the more than 160 androgen receptor point mutations assocd. with prostate cancer.  Increasing the residence time of bound antiandrogen via formation of a covalent adduct may forestall the drug resistance seen with current clin. antiandrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNOswnQtRSebVg90H21EOLACvtfcHk0ljqs13ceJskzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sksr%252FP&md5=3871dfbf0cd53790a8e63f84a1157416</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00702%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJesus%2BCortez%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DP.%26aulast%3DTruillet%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DKuchenbecker%26aufirst%3DK.%2BM.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFletterick%26aufirst%3DR.%2BJ.%26aulast%3DEngland%26aufirst%3DP.%2BM.%26atitle%3DDevelopment%2520of%25205N-bicalutamide%252C%2520a%2520high-affinity%2520reversible%2520covalent%2520antiandrogen%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D12%26spage%3D2934%26epage%3D2939%26doi%3D10.1021%2Facschembio.7b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/ml400489b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400489b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=501-505&issue=5&author=A.+Berteottiauthor=F.+Vacondioauthor=A.+Lodolaauthor=M.+Bassiauthor=C.+Silvaauthor=M.+Morauthor=A.+Cavalli&title=Predicting+the+reactivity+of+nitrile-carrying+compounds+with+cysteine%3A+a+combined+computational+and+experimental+study&doi=10.1021%2Fml400489b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study</span></div><div class="casAuthors">Berteotti, Anna; Vacondio, Federica; Lodola, Alessio; Bassi, Michele; Silva, Claudia; Mor, Marco; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-505</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we report on a mechanistic investigation based on DFT calcns. and kinetic measures aimed at detg. the energetics related to the cysteine nucleophilic attack on nitrile-carrying compds.  Activation energies were found to correlate well with exptl. kinetic measures of reactivity with cysteine in phosphate buffer.  The agreement between computations and expts. points to this DFT-based approach as a tool for predicting both nitrile reactivity toward cysteines and the toxicity of nitriles as electrophile agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow33svQfComrVg90H21EOLACvtfcHk0ljqs13ceJskzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqs7k%253D&md5=8ccf41d312457a209f372d99e7f88910</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Fml400489b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400489b%26sid%3Dliteratum%253Aachs%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DBassi%26aufirst%3DM.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DPredicting%2520the%2520reactivity%2520of%2520nitrile-carrying%2520compounds%2520with%2520cysteine%253A%2520a%2520combined%2520computational%2520and%2520experimental%2520study%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D5%26spage%3D501%26epage%3D505%26doi%3D10.1021%2Fml400489b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oballa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthelette, C.</span></span> <span> </span><span class="NLM_article-title">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2006.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17157022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=998-1002&issue=4&author=R.+M.+Oballaauthor=J.+F.+Truchonauthor=C.+I.+Baylyauthor=N.+Chauretauthor=S.+Dayauthor=S.+Craneauthor=C.+Berthelette&title=A+generally+applicable+method+for+assessing+the+electrophilicity+and+reactivity+of+diverse+nitrile-containing+compounds&doi=10.1016%2Fj.bmcl.2006.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span></div><div class="casAuthors">Oballa, Renata M.; Truchon, Jean-Francois; Bayly, Christopher I.; Chauret, Nathalie; Day, Stephen; Crane, Sheldon; Berthelette, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">998-1002</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrile-based inhibitors of cathepsin K have been known for some time and mechanism-of-action studies have demonstrated that cysteinyl proteases interact with nitriles in a reversible fashion.  Three main classes of nitrile-contg. inhibitors have been published in the cathepsin K field: (i) cyanamides, (ii) arom. nitriles, and (iii) aminoacetonitriles.  A computational approach was used to calc. the theor. reactivities of diverse nitriles and this was found to correlate with their extent of reactivity with free cysteine.  Moreover, there is a tentative link between high reactivity with cysteine and the potential to lead to irreversible covalent binding to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFCCd4sSYvbVg90H21EOLACvtfcHk0lgbkBRK2xy8wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D&md5=b8fff00bdd6a746753f8f244d25b0cc8</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DBerthelette%26aufirst%3DC.%26atitle%3DA%2520generally%2520applicable%2520method%2520for%2520assessing%2520the%2520electrophilicity%2520and%2520reactivity%2520of%2520diverse%2520nitrile-containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D4%26spage%3D998%26epage%3D1002%26doi%3D10.1016%2Fj.bmcl.2006.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Irizarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starr, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uccello, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A.</span></span> <span> </span><span class="NLM_article-title">Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-l-lysine as an amine nucleophile</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1039/C6MD00017G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FC6MD00017G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=864-872&issue=5&author=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=R.+S.+Obachauthor=M.+E.+Flanaganauthor=J.+M.+Chenauthor=C.+Garcia-Irizarryauthor=J.+T.+Starrauthor=B.+Schuffauthor=D.+P.+Uccelloauthor=J.+A.+Young&title=Intrinsic+reactivity+profile+of+electrophilic+moieties+to+guide+covalent+drug+design%3A+N-%CE%B1-acetyl-l-lysine+as+an+amine+nucleophile&doi=10.1039%2FC6MD00017G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-L-lysine as an amine nucleophile</span></div><div class="casAuthors">Dahal, Upendra P.; Gilbert, Adam M.; Obach, R. Scott; Flanagan, Mark E.; Chen, Jinshan M.; Garcia-Irizarry, Carmen; Starr, Jeremy T.; Schuff, Brandon; Uccello, Daniel P.; Young, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">864-872</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent drugs contain a reactive electrophilic moiety or covalent reactive group (CRG), which forms an irreversible bond between the drug and a biol. target.  Consequently, the intrinsic reactivity of the CRG is an important consideration in the design of irreversible inhibitors.  Although reactivity assessments of CRGs with sulfur nucleophiles, such as glutathione and cysteine have been reported, reactivity of these moieties with amine-contg. nucleophiles is not well described.  In this study, intrinsic reactivities were detd. for a series of electrophiles (acrylamides, nitriles, cyanamides, sulfones, and sulfonamides) using N-α-acetyl-L-lysine as a model amine-based nucleophile and compared with results using glutathione (GSH).  Since the ε-amine of N-α-acetyl-L-lysine is protonated at neutral pH, reactions were carried out at pH 10.2.  In addn. to reporting rate data for reactions of CRGs with N-α-acetyl-L-lysine, elements of selectivity relative to thiol-contg. nucleophiles are also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofuy3ICddAE7Vg90H21EOLACvtfcHk0lgbkBRK2xy8wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFyjtrk%253D&md5=08e681ea8dfb353f89d8cdedba685694</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1039%2FC6MD00017G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00017G%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Irizarry%26aufirst%3DC.%26aulast%3DStarr%26aufirst%3DJ.%2BT.%26aulast%3DSchuff%26aufirst%3DB.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%26atitle%3DIntrinsic%2520reactivity%2520profile%2520of%2520electrophilic%2520moieties%2520to%2520guide%2520covalent%2520drug%2520design%253A%2520N-%25CE%25B1-acetyl-l-lysine%2520as%2520an%2520amine%2520nucleophile%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D864%26epage%3D872%26doi%3D10.1039%2FC6MD00017G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zeeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popplestone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span> <span> </span><span class="NLM_article-title">4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4507</span>– <span class="NLM_lpage">4510</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.06.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20580231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4507-4510&issue=15&author=J.+Caiauthor=X.+Fraderaauthor=M.+van+Zeelandauthor=M.+Dempsterauthor=K.+S.+Cameronauthor=D.+J.+Bennettauthor=J.+Robinsonauthor=L.+Popplestoneauthor=M.+Baughauthor=P.+Westwoodauthor=J.+Bruinauthor=W.+Hamiltonauthor=E.+Kinghornauthor=C.+Longauthor=J.+C.+Uitdehaag&title=4-%283-Trifluoromethylphenyl%29-pyrimidine-2-carbonitrile+as+cathepsin+S+inhibitors%3A+N3%2C+not+N1+is+critically+important&doi=10.1016%2Fj.bmcl.2010.06.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important</span></div><div class="casAuthors">Cai, Jiaqiang; Fradera, Xavier; van Zeeland, Mario; Dempster, Maureen; Cameron, Kenneth S.; Bennett, D. Jonathan; Robinson, John; Popplestone, Lucy; Baugh, Mark; Westwood, Paul; Bruin, John; Hamilton, William; Kinghorn, Emma; Long, Clive; Uitdehaag, Joost C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4507-4510</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using computer aided modeling studies, a new extended P2/S2 interaction was identified.  This extended region can accommodate a variety of functional groups, such as aryls and basic amines.  It was discovered that the N3 nitrogen of the pyrimidine-2-carbonitrile is crit. for its cathepsin cysteine protease inhibition.  N1 nitrogen also contributes to the inhibitory activity, but to a very limited degree.  An in situ double activation' mechanism was proposed to explain these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8NO3F-fwoJrVg90H21EOLACvtfcHk0lgbkBRK2xy8wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSktL8%253D&md5=c4f3a722e29616dca5e47b0c8cbcadef</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.043%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3Dvan%2BZeeland%26aufirst%3DM.%26aulast%3DDempster%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DK.%2BS.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DPopplestone%26aufirst%3DL.%26aulast%3DBaugh%26aufirst%3DM.%26aulast%3DWestwood%26aufirst%3DP.%26aulast%3DBruin%26aufirst%3DJ.%26aulast%3DHamilton%26aufirst%3DW.%26aulast%3DKinghorn%26aufirst%3DE.%26aulast%3DLong%26aufirst%3DC.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26atitle%3D4-%25283-Trifluoromethylphenyl%2529-pyrimidine-2-carbonitrile%2520as%2520cathepsin%2520S%2520inhibitors%253A%2520N3%252C%2520not%2520N1%2520is%2520critically%2520important%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D15%26spage%3D4507%26epage%3D4510%26doi%3D10.1016%2Fj.bmcl.2010.06.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+inhibitors%3A+Applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0liCqsHU54h82A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520inhibitors%253A%2520Applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism of decyanation of GDC-0425 by cytochrome P450</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.116.074336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28188299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=430-440&issue=5&author=R.+H.+Takahashiauthor=J.+S.+Halladayauthor=M.+Siuauthor=Y.+Chenauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=S.+Ma&title=Novel+mechanism+of+decyanation+of+GDC-0425+by+cytochrome+P450&doi=10.1124%2Fdmd.116.074336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism of decyanation of GDC-0425 by cytochrome P450</span></div><div class="casAuthors">Takahashi, Ryan H.; Halladay, Jason S.; Siu, Michael; Chen, Yuan; Hop, Cornelis E. C. A.; Khojasteh, S. Cyrus; Ma, Shuguang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GDC-0425 [5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile] is an orally bioavailable small-mol. inhibitor of checkpoint kinase 1 that was investigated as a novel cotherapy to potentiate chemotherapeutic drugs, such as gemcitabine.  In a radiolabeled absorption, distribution, metab., and excretion study in Sprague-Dawley rats, trace-level but long-lived 14C-labeled thiocyanate was obsd. in circulation.  This thiocyanate originated from metabolic decyanation of GDC-0425 and rapid conversion of cyanide to thiocyanate.  Excretion studies indicated decyanation was a minor metabolic pathway, but placing 14C at nitrile magnified its observation.  Cytochrome P450s catalyzed the oxidative decyanation reaction in vitro when tested with liver microsomes, and in the presence of 18O2, one atom of 18O was incorporated into the decyanated product.  To translate this finding to a clin. risk assessment, the total circulating levels of thiocyanate (endogenous plus drug-derived) were measured following repeated administration of GDC-0425 to rats and cynomolgus monkeys.  No overt increases were obsd. with thiocyanate concns. of 121-154 μM in rats and 71-110 μM in monkeys receiving vehicle and all tested doses of GDC-0425.  These findings were consistent with results from the radiolabel rat study where decyanation accounted for conversion of <1% of the administered GDC-0425 and contributed less than 1 μM thiocyanate to systemic levels.  Further, in vitro studies showed only trace oxidative decyanation for humans.  These data indicated that, although cyanide was metabolically released from GDC-0425 and formed low levels of thiocyanate, this pathway was a minor route of metab., and GDC-0425-related increases in systemic thiocyanate were unlikely to pose safety concerns for subjects of clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRG6UnL6fnKrVg90H21EOLACvtfcHk0liCqsHU54h82A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjJ&md5=d971d1844f8a12b17ebed60c50a45e56</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074336%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%2BH.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DS.%26atitle%3DNovel%2520mechanism%2520of%2520decyanation%2520of%2520GDC-0425%2520by%2520cytochrome%2520P450%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D430%26epage%3D440%26doi%3D10.1124%2Fdmd.116.074336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvakumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunath, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanteru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrichelvan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Rationally designed, conformationally constrained inverse agonists of RORgammat-identification of a potent, selective series with biologic-like in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9931</span>– <span class="NLM_lpage">9946</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9931-9946&issue=21&author=D.+Marcouxauthor=J.+J.+Duanauthor=Q.+Shiauthor=R.+J.+Cherneyauthor=A.+S.+Srivastavaauthor=L.+Corneliusauthor=D.+G.+Battauthor=Q.+Liuauthor=M.+Beaudoin-Bertrandauthor=C.+A.+Weigeltauthor=P.+Khandelwalauthor=S.+Vishwakrishnanauthor=K.+Selvakumarauthor=A.+Karmakarauthor=A.+K.+Guptaauthor=M.+Bashaauthor=S.+Ramlingamauthor=N.+Manjunathauthor=S.+Vanteruauthor=S.+Karmakarauthor=N.+Maddalaauthor=M.+Vetrichelvanauthor=A.+Guptaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=S.+Yipauthor=P.+Liauthor=D.+R.+Wuauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+S.+Sackauthor=J.+Wangauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=S.+Liauthor=D.+J.+Shusterauthor=V.+Borowskiauthor=J.+H.+Xieauthor=K.+W.+McIntyreauthor=M.+T.+Obermeierauthor=A.+Furaauthor=K.+Stefanskiauthor=G.+Corneliusauthor=J.+Hynesauthor=J.+A.+Tinoauthor=J.+E.+Macorauthor=L.+Salter-Cidauthor=R.+Dentonauthor=Q.+Zhaoauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Rationally+designed%2C+conformationally+constrained+inverse+agonists+of+RORgammat-identification+of+a+potent%2C+selective+series+with+biologic-like+in+vivo+efficacy&doi=10.1021%2Facs.jmedchem.9b01369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy</span></div><div class="casAuthors">Marcoux, David; Duan, James J.-W.; Shi, Qing; Cherney, Robert J.; Srivastava, Anurag S.; Cornelius, Lyndon; Batt, Douglas G.; Liu, Qingjie; Beaudoin-Bertrand, Myra; Weigelt, Carolyn A.; Khandelwal, Purnima; Vishwakrishnan, Sureshbabu; Selvakumar, Kumaravel; Karmakar, Ananta; Gupta, Arun Kumar; Basha, Mushkin; Ramlingam, Sridharan; Manjunath, Naveen; Vanteru, Sridhar; Karmakar, Sukhen; Maddala, Nageswara; Vetrichelvan, Muthalagu; Gupta, Anuradha; Rampulla, Richard A.; Mathur, Arvind; Yip, Shiuhang; Li, Peng; Wu, Dauh-Rurng; Khan, Javed; Ruzanov, Max; Sack, John S.; Wang, Jinhong; Yarde, Melissa; Cvijic, Mary Ellen; Li, Sha; Shuster, David J.; Borowski, Virna; Xie, Jenny H.; McIntyre, Kim W.; Obermeier, Mary T.; Fura, Aberra; Stefanski, Kevin; Cornelius, Georgia; Hynes, John; Tino, Joseph A.; Macor, John E.; Salter-Cid, Luisa; Denton, Rex; Zhao, Qihong; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9931-9946</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RORγt is an important nuclear receptor that regulates the prodn. of several pro-inflammatory cytokines such as IL-17 and IL-22.  As a result, RORγt has been identified as a potential target for the treatment of various immunol. disorders such as psoriasis, psoriatic arthritis and inflammatory bowel diseases.  Structure and computer assisted drug design led to the identification of a novel series of tricyclic RORγt inverse agonists with significantly improved in vitro activity in the reporter (Gal4) and human whole blood assays compared to the previous chemotype.  Through careful SAR, several potent and selective RORγt inverse agonists have been identified.  Pharmacokinetic studies allowed the identification of the lead mol. I with a low peak-to-trough ratio.  This mol. showed excellent activity in an IL-2/IL-23-induced mouse pharmacodynamic study and demonstrated biol.-like efficacy in an IL-23-induced preclin. model of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopLftyCaracbVg90H21EOLACvtfcHk0lh_HuaiFj5F7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7jI&md5=f96792289cff2eed2d072476a160630c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01369%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DKhandelwal%26aufirst%3DP.%26aulast%3DVishwakrishnan%26aufirst%3DS.%26aulast%3DSelvakumar%26aufirst%3DK.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DBasha%26aufirst%3DM.%26aulast%3DRamlingam%26aufirst%3DS.%26aulast%3DManjunath%26aufirst%3DN.%26aulast%3DVanteru%26aufirst%3DS.%26aulast%3DKarmakar%26aufirst%3DS.%26aulast%3DMaddala%26aufirst%3DN.%26aulast%3DVetrichelvan%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DRationally%2520designed%252C%2520conformationally%2520constrained%2520inverse%2520agonists%2520of%2520RORgammat-identification%2520of%2520a%2520potent%252C%2520selective%2520series%2520with%2520biologic-like%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D21%26spage%3D9931%26epage%3D9946%26doi%3D10.1021%2Facs.jmedchem.9b01369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-986251: A clinically viable, potent, and selective RORgammat inverse agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1221-1227&issue=6&author=R.+J.+Cherneyauthor=L.+A.+M.+Corneliusauthor=A.+Srivastavaauthor=C.+A.+Weigeltauthor=D.+Marcouxauthor=J.+J.+Duanauthor=Q.+Shiauthor=D.+G.+Battauthor=Q.+Liuauthor=S.+Yipauthor=D.+R.+Wuauthor=M.+Ruzanovauthor=J.+Sackauthor=J.+Khanauthor=J.+Wangauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=A.+Mathurauthor=S.+Liauthor=D.+Shusterauthor=P.+Khandelwalauthor=V.+Borowskiauthor=J.+Xieauthor=M.+Obermeierauthor=A.+Furaauthor=K.+Stefanskiauthor=G.+Corneliusauthor=J.+A.+Tinoauthor=J.+E.+Macorauthor=L.+Salter-Cidauthor=R.+Dentonauthor=Q.+Zhaoauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Discovery+of+BMS-986251%3A+A+clinically+viable%2C+potent%2C+and+selective+RORgammat+inverse+agonist&doi=10.1021%2Facsmedchemlett.0c00063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist</span></div><div class="casAuthors">Cherney, Robert J.; Cornelius, Lyndon A. M.; Srivastava, Anurag; Weigelt, Carolyn A.; Marcoux, David; Duan, James J.-W.; Shi, Qing; Batt, Douglas G.; Liu, Qingjie; Yip, Shiuhang; Wu, Dauh-Rurng; Ruzanov, Max; Sack, John; Khan, Javed; Wang, Jinhong; Yarde, Melissa; Cvijic, Mary Ellen; Mathur, Arvind; Li, Sha; Shuster, David; Khandelwal, Purnima; Borowski, Virna; Xie, Jenny; Obermeier, Mary; Fura, Aberra; Stefanski, Kevin; Cornelius, Georgia; Tino, Joseph A.; Macor, John E.; Salter-Cid, Luisa; Denton, Rex; Zhao, Qihong; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1221-1227</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel tricyclic analogs were designed, synthesized, and evaluated as RORγt inverse agonists.  Several of these compds. were potent in an IL-17 human whole blood assay and exhibited excellent oral bioavailability in mouse pharmacokinetic studies.  This led to the identification of compd. 5 (I), which displayed dose-dependent inhibition of IL-17F prodn. in a mouse IL-2/IL-23 stimulated pharmacodynamic model.  In addn., compd. 5 was studied in mouse acanthosis and imiquimod-induced models of skin inflammation, where it demonstrated robust efficacy comparable to a pos. control.  As a result of this excellent overall profile, compd. 5 (BMS-986251) was selected as a clin. viable developmental candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVYYYYm5tXnLVg90H21EOLACvtfcHk0lh_HuaiFj5F7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFOjtbY%253D&md5=564e4b778fb70ac5d05acc6f1d205306</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00063%26sid%3Dliteratum%253Aachs%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DKhandelwal%26aufirst%3DP.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DDiscovery%2520of%2520BMS-986251%253A%2520A%2520clinically%2520viable%252C%2520potent%252C%2520and%2520selective%2520RORgammat%2520inverse%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1221%26epage%3D1227%26doi%3D10.1021%2Facsmedchemlett.0c00063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Ligand- and structure-based pregnane X receptor models</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-050-2_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2F978-1-62703-050-2_15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23007437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2012&pages=359-375&author=S.+Kortagereauthor=M.+D.+Krasowskiauthor=S.+Ekins&title=Ligand-+and+structure-based+pregnane+X+receptor+models&doi=10.1007%2F978-1-62703-050-2_15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand- and structure-based pregnane X receptor models</span></div><div class="casAuthors">Kortagere, Sandhya; Krasowski, Matthew D.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Computational Toxicology, Volume I</span>),
    <span class="NLM_cas:pages">359-375</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a ligand dependent transcription factor that can be activated by structurally diverse agonists including steroid hormones, bile acids, herbal drugs, and prescription medications.  PXR regulates the transcription of several genes involved in xenobiotic detoxification and apoptosis.  Activation of PXR has the potential to initiate adverse effects by altering drug pharmacokinetics or perturbing physiol. processes.  Hence, more reliable prediction of PXR activators would be valuable for pharmaceutical drug discovery to avoid potential toxic effects.  Ligand- and protein structure-based computational models for PXR activation have been developed in several studies.  There has been limited success with structure-based modeling approaches to predict human PXR activators, which can be attributed to the large and promiscuous site of this protein.  Slightly better success has been achieved with ligand-based modeling methods including quant. structure-activity relationship (QSAR) anal., pharmacophore modeling and machine learning that use appropriate descriptors to account for the diversity of the ligand classes that bind to PXR.  These combined computational approaches using mol. shape information may assist scientists to more confidently identify PXR activators.  This chapter reviews the various ligand and structure based methods undertaken to date and their results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqJD7yRO3KbVg90H21EOLACvtfcHk0lj2Lb1S1K1fnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2htrw%253D&md5=34f0180db44e223a19e735535be1dcc8</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-050-2_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-050-2_15%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLigand-%2520and%2520structure-based%2520pregnane%2520X%2520receptor%2520models%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D929%26spage%3D359%26epage%3D375%26doi%3D10.1007%2F978-1-62703-050-2_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batayneh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambucetti, L.</span></span> <span> </span><span class="NLM_article-title">PXR and the regulation of apoA1 and HDL-cholesterol in rodents</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2004.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.phrs.2004.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15225665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1agt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=237-246&issue=3&author=K.+Bachmannauthor=H.+Patelauthor=Z.+Bataynehauthor=J.+Slamaauthor=D.+Whiteauthor=J.+Poseyauthor=S.+Ekinsauthor=D.+Goldauthor=L.+Sambucetti&title=PXR+and+the+regulation+of+apoA1+and+HDL-cholesterol+in+rodents&doi=10.1016%2Fj.phrs.2004.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">PXR and the regulation of apoA1 and HDL-cholesterol in rodents</span></div><div class="casAuthors">Bachmann, Kenneth; Patel, Hiral; Batayneh, Zaid; Slama, James; White, Donald; Posey, Julie; Ekins, Sean; Gold, David; Sambucetti, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-246</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Orphan nuclear receptors (ONRs) have been implicated in the regulation of lipids.  Several clin. studies conducted either prospectively or epidemiol. have pointed to a link between the regulation of hepatic CYP enzymes and HDL-cholesterol (HDL-C) and/or apolipoprotein A1 (apoA1).  The treatment of rats with a series of imidazole inducers of CYP3A yielded correlations between in vitro CYP3A activity measured as erythromycin demethylase activity and plasma HDL-C and hepatic apoA1 mRNA.  Similarly, a correlation was established between in vivo CYP3A activity, measured as ethosuximide clearance, and plasma HDL-C and hepatic apoA1 mRNA.  The treatment of wild-type (WT) mice with PXR agonists elicited increases in serum HDL-C and serum apoA1 levels.  On the other hand, the treatment of PXR-knockout mice (PXR-KOs) with the same PXR agonists failed to elicit increases in either serum HDL-C or serum apoA1 levels.  Superposition of the structures of three imidazoles known to be active CYP3A inducers in rats with the human PXR pharmacophore demonstrated a partial fit and predicted EC50 values typical of weak-moderate hPXR inducers in humans.  These imidazoles have been shown to increase apoA1 and HDL-C in rats and mice.  Taken together, these data suggest that PXR plays an important role in the regulation of apoA1 and HDL-C in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3BApfwdjzeLVg90H21EOLACvtfcHk0lj2Lb1S1K1fnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1agt7g%253D&md5=96ed41c10c1a27aa5248ebcdd2ce0014</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2004.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2004.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DBatayneh%26aufirst%3DZ.%26aulast%3DSlama%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DD.%26aulast%3DPosey%26aufirst%3DJ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DGold%26aufirst%3DD.%26aulast%3DSambucetti%26aufirst%3DL.%26atitle%3DPXR%2520and%2520the%2520regulation%2520of%2520apoA1%2520and%2520HDL-cholesterol%2520in%2520rodents%26jtitle%3DPharmacol.%2520Res.%26date%3D2004%26volume%3D50%26issue%3D3%26spage%3D237%26epage%3D246%26doi%3D10.1016%2Fj.phrs.2004.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirny, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span> <span> </span><span class="NLM_article-title">A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1788</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1023/A:1021429105173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1023%2FA%3A1021429105173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12523656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVSjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1788-1800&issue=12&author=S.+Ekinsauthor=L.+Mirnyauthor=E.+G.+Schuetz&title=A+ligand-based+approach+to+understanding+selectivity+of+nuclear+hormone+receptors+PXR%2C+CAR%2C+FXR%2C+LXRalpha%2C+and+LXRbeta&doi=10.1023%2FA%3A1021429105173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">A Ligand-Based Approach to Understanding Selectivity of Nuclear Hormone Receptors PXR, CAR, FXR, LXRα, and LXRβ</span></div><div class="casAuthors">Ekins, Sean; Mirny, Leonid; Schuetz, Erin G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1788-1800</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">A review.  In recent years discussion of nuclear hormone receptors, transporters, and drug-metabolizing enzymes has begun to take place as our knowledge of the overlapping ligand specificity of each of these proteins has deepened.  This ligand specificity is potentially valuable information for influencing future drug design, as it is important to avoid certain enzymes or transporters in order to circumvent potential drug-drug interactions.  Similarly, it is crit. that the induction of these same proteins via nuclear hormone receptors is avoided, as this can result in further toxicities.  Using a ligand-based approach in this review we describe new and previously published computational models for PXR, CAR, FXR, LXRα, and LXRβ that may help in understanding the complexity of interactions between transporters and enzymes.  The value of these types of models is that they may enable us to design mols. to selectively modulate pathways for therapeutic effect and in addn. predict the potential for drug interactions more reliably.  Simultaneously, we might learn which came first: the transporter, the enzyme, or the nuclear hormone receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo352_uBuNwELVg90H21EOLACvtfcHk0lhJ48xK30TiFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVSjsL0%253D&md5=73ec4700ce545b7fa1b0caed95c9e08c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1023%2FA%3A1021429105173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1021429105173%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DMirny%26aufirst%3DL.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26atitle%3DA%2520ligand-based%2520approach%2520to%2520understanding%2520selectivity%2520of%2520nuclear%2520hormone%2520receptors%2520PXR%252C%2520CAR%252C%2520FXR%252C%2520LXRalpha%252C%2520and%2520LXRbeta%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26issue%3D12%26spage%3D1788%26epage%3D1800%26doi%3D10.1023%2FA%3A1021429105173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span> <span> </span><span class="NLM_article-title">A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.108.020701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18505790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1689-1697&issue=8&author=K.+Yasudaauthor=A.+Ranadeauthor=R.+Venkataramananauthor=S.+Stromauthor=J.+Chupkaauthor=S.+Ekinsauthor=E.+Schuetzauthor=K.+Bachmann&title=A+comprehensive+in+vitro+and+in+silico+analysis+of+antibiotics+that+activate+pregnane+X+receptor+and+induce+CYP3A4+in+liver+and+intestine&doi=10.1124%2Fdmd.108.020701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine</span></div><div class="casAuthors">Yasuda, Kazuto; Ranade, Aarati; Venkataramanan, Raman; Strom, Stephen; Chupka, Jonathan; Ekins, Sean; Schuetz, Erin; Bachmann, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1689-1697</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have investigated several in silico and in vitro methods to improve our ability to predict potential drug interactions of antibiotics.  Our focus was to identify those antibiotics that activate pregnane X receptor (PXR) and induce CYP3A4 in human hepatocytes and intestinal cells.  Human PXR activation was screened using reporter assays in HepG2 cells, kinetic measurements of PXR activation were made in DPX-2 cells, and induction of CYP3A4 expression and activity was verified by quant. polymerase chain reaction, immunoblotting, and testosterone 6β-hydroxylation in primary human hepatocytes and LS180 cells.  We found that in HepG2 cells CYP3A4 transcription was activated strongly (>10-fold) by rifampin and troleandomycin; moderately (≥7-fold) by dicloxacillin, tetracycline, clindamycin, griseofulvin, and (≥4-fold) erythromycin; and weakly (>2.4-fold) by nafcillin, cefaclor, sulfisoxazole, and (>2-fold) cefadroxil and penicillin V.  Similar although not identical results were obtained in DPX-2 cells.  CYP3A4 mRNA and protein expression were induced by these antibiotics to differing extents in both liver and intestinal cells.  CYP3A4 activity was significantly increased by rifampin (9.7-fold), nafcillin and dicloxacillin (5.9-fold), and weakly induced (2-fold) by tetracycline, sufisoxazole, troleandomycin, and clindamycin.  Multiple pharmacophore models and docking indicated a good fit for dicloxacillin and nafcillin in PXR.  These results suggest that in vitro and in silico methods can help to prioritize and identify antibiotics that are most likely to reduce exposures of medications (such as oral contraceptive agents) which interact with enzymes and transporters regulated by PXR.  In summary, nafcillin, dicloxacillin, cephradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin exhibit a clear propensity to induce CYP3A4 and warrant further clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5qr3K9SkNbVg90H21EOLACvtfcHk0lhJ48xK30TiFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlams70%253D&md5=cd828b4967af1761264391538a8afbc5</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020701%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DRanade%26aufirst%3DA.%26aulast%3DVenkataramanan%26aufirst%3DR.%26aulast%3DStrom%26aufirst%3DS.%26aulast%3DChupka%26aufirst%3DJ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DE.%26aulast%3DBachmann%26aufirst%3DK.%26atitle%3DA%2520comprehensive%2520in%2520vitro%2520and%2520in%2520silico%2520analysis%2520of%2520antibiotics%2520that%2520activate%2520pregnane%2520X%2520receptor%2520and%2520induce%2520CYP3A4%2520in%2520liver%2520and%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D8%26spage%3D1689%26epage%3D1697%26doi%3D10.1124%2Fdmd.108.020701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">The identification of ligand features essential for PXR activation by pharmacophore modeling</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1021/ci049722q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049722q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsVSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=431-439&issue=2&author=D.+Schusterauthor=T.+Langer&title=The+identification+of+ligand+features+essential+for+PXR+activation+by+pharmacophore+modeling&doi=10.1021%2Fci049722q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling</span></div><div class="casAuthors">Schuster, Daniela; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-439</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug metabolizing enzymes and transporters are often involved in clin. relevant drug-drug interactions.  These functional proteins can be induced by a wide range of xenobiotics.  The induction is mediated by a group of receptors known as orphan nuclear receptors.  The pregnane X receptor (PXR) is a member of this receptor family and regulates the expression of multiple Cytochrome P 450 enzyme families (e.g. CYP3A and 2B), phase II enzymes (e.g. UDP glucuronosyl transferases), and transporters (e.g. Multidrug resistance protein 1).  The software package Catalyst was employed to derive pharmacophore models for PXR activation.  A structure based pharmacophore hypothesis and several ligand based ones were compared in order to identify ligand receptor interactions essential for receptor activation.  The results suggest that hydrogen bonding to Gln285 is indispensable for PXR activation.  Most ligands were found to form a second hydrogen bond to His407.  Hydrophobic interactions are not essential for receptor activation but contribute to ligand affinity.  Highly active compds. share up to five hydrophobic features that allow the ligand to occupy large areas of the predominantly hydrophobic binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyN4cEgMvr7Vg90H21EOLACvtfcHk0lgGaZqI4aRJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsVSksQ%253D%253D&md5=e3f3105881379b3f1768b094d718a3b8</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fci049722q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049722q%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DThe%2520identification%2520of%2520ligand%2520features%2520essential%2520for%2520PXR%2520activation%2520by%2520pharmacophore%2520modeling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26issue%3D2%26spage%3D431%26epage%3D439%26doi%3D10.1021%2Fci049722q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahoum, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussioux, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavanieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1124/mol.106.033415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.106.033415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17573484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=572-581&issue=3&author=G.+Lemaireauthor=C.+Benodauthor=V.+Nahoumauthor=A.+Pillonauthor=A.+M.+Boussiouxauthor=J.+F.+Guichouauthor=G.+Subraauthor=J.+M.+Pascussiauthor=W.+Bourguetauthor=A.+Chavanieuauthor=P.+Balaguer&title=Discovery+of+a+highly+active+ligand+of+human+pregnane+x+receptor%3A+a+case+study+from+pharmacophore+modeling+and+virtual+screening+to+%E2%80%9Cin+vivo%E2%80%9D+biological+activity&doi=10.1124%2Fmol.106.033415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity</span></div><div class="casAuthors">Lemaire, Geraldine; Benod, Cindy; Nahoum, Virginie; Pillon, Arnaud; Boussioux, Anne-Marie; Guichou, Jean-Francois; Subra, Guy; Pascussi, Jean-Marc; Bourguet, William; Chavanieu, Alain; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-581</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) is a nuclear receptor that regulates the expression of phase I and II drug-metabolizing enzymes as well as that of drug transporters.  In addn., this receptor plays a crit. role in cholesterol homeostasis and in protecting tissues from potentially toxic endobiotics.  HPXR is activated by a broad spectrum of low-affinity compds. including xenobiotics and endobiotics such as bile acids and their precursors.  Crystallog. studies revealed a ligand binding domain (LBD) with a large and conformable binding pocket that is likely to contribute to the ability of hPXR to respond to compds. of varying size and shape.  Here, we describe an in silico method that allowed the identification of nine novel hPXR agonists.  We further characterize the compd. 1-(2-chlorophenyl)-N-[1-(1-phenylethyl)- 1H-benzimidazol-5-yl]methanesulfonamide (C2BA-4), a methanesulfonamide that activates PXR specifically and more potently than does the ref. compd. 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butyl-phenol (SR12813) in our stable cell line expressing a Gal4-PXR and a GAL4 driven luciferase reporter gene.  Furthermore treatment of primary human hepatocytes with C2BA-4 results in a marked induction of the mRNA expression of hPXR target genes, such as cytochromes P 450 3A4 and 2B6.  Finally, C2BA-4 is also able to induce hPXR-mediated in vivo luciferase expression in HGPXR stable bioluminescent cells implanted in mice.  The study suggests new directions for the rational design of selective hPXR agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGory5EF3Mx4UbVg90H21EOLACvtfcHk0lgGaZqI4aRJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfM&md5=43de9126ad28627951b2a5b04d0bb410</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.033415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.033415%26sid%3Dliteratum%253Aachs%26aulast%3DLemaire%26aufirst%3DG.%26aulast%3DBenod%26aufirst%3DC.%26aulast%3DNahoum%26aufirst%3DV.%26aulast%3DPillon%26aufirst%3DA.%26aulast%3DBoussioux%26aufirst%3DA.%2BM.%26aulast%3DGuichou%26aufirst%3DJ.%2BF.%26aulast%3DSubra%26aufirst%3DG.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DBourguet%26aufirst%3DW.%26aulast%3DChavanieu%26aufirst%3DA.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520active%2520ligand%2520of%2520human%2520pregnane%2520x%2520receptor%253A%2520a%2520case%2520study%2520from%2520pharmacophore%2520modeling%2520and%2520virtual%2520screening%2520to%2520%25E2%2580%259Cin%2520vivo%25E2%2580%259D%2520biological%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D572%26epage%3D581%26doi%3D10.1124%2Fmol.106.033415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahaye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagury, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M.</span></span> <span> </span><span class="NLM_article-title">Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13321-016-0154-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1186%2Fs13321-016-0154-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=43&author=N.+Lagardeauthor=S.+Delahayeauthor=J.+F.+Zaguryauthor=M.+Montes&title=Discriminating+agonist+and+antagonist+ligands+of+the+nuclear+receptors+using+3D-pharmacophores&doi=10.1186%2Fs13321-016-0154-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores</span></div><div class="casAuthors">Lagarde, Nathalie; Delahaye, Solenne; Zagury, Jean-Francois; Montes, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/18</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) constitute an important class of therapeutic targets.  We evaluated the performance of 3D structure-based and ligand-based pharmacophore models in predicting the pharmacol. profile of NRs ligands using the NRLiSt BDB database.  We could generate selective pharmacophores for agonist and antagonist ligands and we found that the best performances were obtained by combining the structure-based and the ligand-based approaches.  The combination of pharmacophores that were generated allowed to cover most of the chem. space of the NRLiSt BDB datasets.  By screening the whole NRLiSt BDB on our 3D pharmacophores, we demonstrated their selectivity towards their dedicated NRs ligands.  The 3D pharmacophores herein presented can thus be used as a predictor of the pharmacol. activity of NRs ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS5Wkx5Jr5vLVg90H21EOLACvtfcHk0lgGaZqI4aRJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvF2kt78%253D&md5=7fa0ac5226a55070052478782b46ef8d</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0154-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0154-2%26sid%3Dliteratum%253Aachs%26aulast%3DLagarde%26aufirst%3DN.%26aulast%3DDelahaye%26aufirst%3DS.%26aulast%3DZagury%26aufirst%3DJ.%2BF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DDiscriminating%2520agonist%2520and%2520antagonist%2520ligands%2520of%2520the%2520nuclear%2520receptors%2520using%25203D-pharmacophores%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D43%26doi%3D10.1186%2Fs13321-016-0154-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Nasr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jérémie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laville, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labib, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagury, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M.</span></span> <span> </span><span class="NLM_article-title">NRLiSt BDB, the manually curated nuclear receptors ligands and structures benchmarking database</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3117</span>– <span class="NLM_lpage">3125</span>, <span class="refDoi"> DOI: 10.1021/jm500132p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500132p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlens7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3117-3125&issue=7&author=N.+Lagardeauthor=N.+Ben+Nasrauthor=A.+J%C3%A9r%C3%A9mieauthor=H.+Guillemainauthor=V.+Lavilleauthor=T.+Labibauthor=J.+F.+Zaguryauthor=M.+Montes&title=NRLiSt+BDB%2C+the+manually+curated+nuclear+receptors+ligands+and+structures+benchmarking+database&doi=10.1021%2Fjm500132p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">NRLiSt BDB, the Manually Curated Nuclear Receptors Ligands and Structures Benchmarking Database</span></div><div class="casAuthors">Lagarde, Nathalie; Ben Nasr, Nesrine; Jeremie, Aurore; Guillemain, Helene; Laville, Vincent; Labib, Taoufik; Zagury, Jean-Francois; Montes, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3117-3125</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) constitute an important class of drug targets.  We created the most exhaustive NR-focused benchmarking database to date, the NRLiSt BDB (NRs ligands and structures benchmarking database).  The 9905 compds. and 339 structures of the NRLiSt BDB are ready for structure-based and ligand-based virtual screening.  In the present study, we detail the protocol used to generate the NRLiSt BDB and its features.  We also give some examples of the errors that we found in ChEMBL that convinced us to manually review all original papers.  Since extensive and manually curated exptl. data about NR ligands and structures are provided in the NRLiSt BDB, it should become a powerful tool to assess the performance of virtual screening methods on NRs, to assist the understanding of NR's function and modulation, and to support the discovery of new drugs targeting NRs.  NRLiSt BDB is freely available online at http://nrlist.drugdesign.fr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxrFfpq27WbVg90H21EOLACvtfcHk0lgu7mMBJTquKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlens7g%253D&md5=d495ead29255e6944983527ba3d05416</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm500132p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500132p%26sid%3Dliteratum%253Aachs%26aulast%3DLagarde%26aufirst%3DN.%26aulast%3DBen%2BNasr%26aufirst%3DN.%26aulast%3DJ%25C3%25A9r%25C3%25A9mie%26aufirst%3DA.%26aulast%3DGuillemain%26aufirst%3DH.%26aulast%3DLaville%26aufirst%3DV.%26aulast%3DLabib%26aufirst%3DT.%26aulast%3DZagury%26aufirst%3DJ.%2BF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DNRLiSt%2520BDB%252C%2520the%2520manually%2520curated%2520nuclear%2520receptors%2520ligands%2520and%2520structures%2520benchmarking%2520database%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D7%26spage%3D3117%26epage%3D3125%26doi%3D10.1021%2Fjm500132p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torimoto-Katori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">In silico prediction of hPXR activators using structure-based pharmacophore modeling</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.xphs.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28315689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=1752-1759&issue=7&author=N.+Torimoto-Katoriauthor=R.+Huangauthor=H.+Katoauthor=R.+Ohashiauthor=M.+Xia&title=In+silico+prediction+of+hPXR+activators+using+structure-based+pharmacophore+modeling&doi=10.1016%2Fj.xphs.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Prediction of hPXR Activators Using Structure-Based Pharmacophore Modeling</span></div><div class="casAuthors">Torimoto-Katori, Nao; Huang, Ruili; Kato, Harutoshi; Ohashi, Rikiya; Xia, Menghang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1752-1759</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The activation of pregnane X receptor (PXR), a member of the nuclear receptor superfamily, can mediate potential drug-drug interactions by regulating the expression of several drug-mediated enzymes and transporters, resulting in reduced therapeutic efficacy or increased toxicity by producing reactive metabolites.  Therefore, in the early stage of drug development, it is important to predict these risks using an in silico approach.  The authors constructed a human PXR (hPXR) pharmacophore model based on known structural information of compds. that activate PXR.  The authors evaluated the prediction accuracy of the model using data sets generated on 68 original synthetic compds. from the Mitsubishi Tanabe Pharma Corporation and over 2500 drugs from the National Institutes of Health Chem. Genomics Center Pharmaceutical Collection for their ability to activate hPXR.  The prediction accuracies of the PXR pharmacophore model were 0.78 and 0.86 for the Mitsubishi Tanabe Pharma Corporation and National Institutes of Health Chem. Genomics Center Pharmaceutical Collection, resp.  The compds. resulting in the smallest root-mean square deviation hit by pharmacophore search were the well-known PXR inducers such as Bosentan.  These results suggest that using the in silico approach developed in this study is useful to identify potential hPXR activators and modify the drug design during the early stage of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9DxsCLSwFtbVg90H21EOLACvtfcHk0lgu7mMBJTquKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVaqtb8%253D&md5=36e6f7390ec7030ae1b6f337fa8d8710</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DTorimoto-Katori%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26atitle%3DIn%2520silico%2520prediction%2520of%2520hPXR%2520activators%2520using%2520structure-based%2520pharmacophore%2520modeling%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26issue%3D7%26spage%3D1752%26epage%3D1759%26doi%3D10.1016%2Fj.xphs.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. N.</span></span> <span> </span><span class="NLM_article-title">In silico tools to aid risk assessment of endocrine disrupting chemicals</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>205</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2004.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tox.2004.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15458789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2004&pages=43-53&issue=1%E2%80%932&author=M.+N.+Jacobs&title=In+silico+tools+to+aid+risk+assessment+of+endocrine+disrupting+chemicals&doi=10.1016%2Fj.tox.2004.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">In silico tools to aid risk assessment of endocrine disrupting chemicals</span></div><div class="casAuthors">Jacobs, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In silico or computational tools could be used more effectively in endocrine disruptor risk assessment for prescreening potential endocrine disruptors, improving exptl. in vitro screening assay design and facilitating more thorough data analyses.  The in silico tools reviewed here are three-fold and include the use of: (1) nuclear receptor (NR) crystal structures and homol. models to examine potential modes of ligand binding by different representative compds.; (2) multivariate principal component analyses (PCA) techniques to select best predicted cell lines for endocrine disrupting chems. (EDC) risk assessment purposes; (3) NR quant. structure-activity relationships (QSARs) that can be constructed from varied biol. data sources, using multivariate partial least squares (PLS) techniques and specific descriptors.  The cytosolic and NR examples discussed here include the Ah receptor, (AhR), the human estrogen receptor α (hERα) and the human pregnane X receptor (PXR).  The varied biol. data sets can be compared to give a more integrated dimension to receptor cross talk mechanisms, with further support from mol. modeling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogY_tV_NpBwbVg90H21EOLACvtfcHk0lgu7mMBJTquKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2msbc%253D&md5=3bc6f6019beee6c288153d7e6c48c7db</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2004.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2004.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%2BN.%26atitle%3DIn%2520silico%2520tools%2520to%2520aid%2520risk%2520assessment%2520of%2520endocrine%2520disrupting%2520chemicals%26jtitle%3DToxicology%26date%3D2004%26volume%3D205%26issue%3D1%25E2%2580%25932%26spage%3D43%26epage%3D53%26doi%3D10.1016%2Fj.tox.2004.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirillov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhmatulin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorokina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugrim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span> <span> </span><span class="NLM_article-title">A combined approach to drug metabolism and toxicity assessment</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.008458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.105.008458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16381662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=495-503&issue=3&author=S.+Ekinsauthor=S.+Andreyevauthor=A.+Ryabovauthor=E.+Kirillovauthor=E.+A.+Rakhmatulinauthor=S.+Sorokinaauthor=A.+Bugrimauthor=T.+Nikolskaya&title=A+combined+approach+to+drug+metabolism+and+toxicity+assessment&doi=10.1124%2Fdmd.105.008458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">A combined approach to drug metabolism and toxicity assessment</span></div><div class="casAuthors">Ekins, Sean; Andreyev, Sergey; Ryabov, Andy; Kirillov, Eugene; Rakhmatulin, Eugene A.; Sorokina, Svetlana; Bugrim, Andrej; Nikolskaya, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-503</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The challenge of predicting the metab. or toxicity of a drug in humans has been approached using in vivo animal models, in vitro systems, high throughput genomics and proteomics methods, and, more recently, computational approaches.  Understanding the complexity of biol. systems requires a broader perspective rather than focusing on just one method in isolation for prediction.  Multiple methods may therefore be necessary and combined for a more accurate prediction.  In the field of drug metab. and toxicol., we have seen the growth, in recent years, of computational quant. structure-activity relationships (QSARs), as well as empirical data from microarrays.  In the current study we have further developed a novel computational approach, Meta-Drug, that (1) predicts metabolites for mols. based on their chem. structure, (2) predicts the activity of the original compd. and its metabolites with various absorption, distribution, metab., excretion, and toxicity models, (3) incorporates the predictions with human cells signaling and metabolic pathways and networks, and (4) integrates networks and metabolites, with relevant toxicogenomic or other high throughput data.  We have demonstrated the utility of such an approach using recently published data from in vitro metab. and microarray studies for aprepitant, 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)phenyl-4-((3-oxo-1,2,4- triazol-5-yl)methyl)morpholine (L-742694), trovafloxacin, 4-hydroxytamoxifen, and artemisinin and other artemisinin analogs to show the predicted interactions with cytochromes P 450, pregnane X receptor, and P-glycoprotein, and the metabolites and the networks of genes that are affected.  As a comparison, we used a second computational approach, MetaCore, to generate statistically significant gene networks with the available expression data.  These case studies demonstrate the combination of QSARs and systems biol. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Kh8B58qO9LVg90H21EOLACvtfcHk0ljrJACwblPL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7c%253D&md5=0c6a510ad01cd2fba49132f84e313949</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008458%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DAndreyev%26aufirst%3DS.%26aulast%3DRyabov%26aufirst%3DA.%26aulast%3DKirillov%26aufirst%3DE.%26aulast%3DRakhmatulin%26aufirst%3DE.%2BA.%26aulast%3DSorokina%26aufirst%3DS.%26aulast%3DBugrim%26aufirst%3DA.%26aulast%3DNikolskaya%26aufirst%3DT.%26atitle%3DA%2520combined%2520approach%2520to%2520drug%2520metabolism%2520and%2520toxicity%2520assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D3%26spage%3D495%26epage%3D503%26doi%3D10.1124%2Fdmd.105.008458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Machine learning methods and docking for predicting human pregnane X receptor activation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1021/tx800102e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800102e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntVygsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1457-1467&issue=7&author=A.+Khandelwalauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+W.+Sinzauthor=P.+W.+Swaanauthor=S.+Ekins&title=Machine+learning+methods+and+docking+for+predicting+human+pregnane+X+receptor+activation&doi=10.1021%2Ftx800102e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Machine Learning Methods and Docking for Predicting Human Pregnane X Receptor Activation</span></div><div class="casAuthors">Khandelwal, Akash; Krasowski, Matthew D.; Reschly, Erica J.; Sinz, Michael W.; Swaan, Peter W.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1457-1467</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) regulates the expression of genes involved in xenobiotic metab. and transport.  In vitro methods to screen for PXR agonists are used widely.  In the current study, computational models for human PXR activators and PXR nonactivators were developed using recursive partitioning (RP), random forest (RF), and support vector machine (SVM) algorithms with VolSurf descriptors.  Following 10-fold randomization, the models correctly predicted 82.6-98.9% of activators and 62.0-88.6% of nonactivators.  The models were validated using sep. test sets.  The overall (n = 15) test set prediction accuracy for PXR activators with RP, RF, and SVM PXR models is 80-93.3%, representing an improvement over models previously reported.  All models were tested with a second test set (n = 145), and the prediction accuracy ranged from 63 to 67% overall.  These test set mols. were found to cover the same area in a principal component anal. plot as the training set, suggesting that the predictions were within the applicability domain.  The FlexX docking method combined with logistic regression performed poorly in classifying this PXR test set as compared with RP, RF, and SVM but may be useful for qual. interpretion of interactions within the LBD.  From this anal., VolSurf descriptors and machine learning methods had good classification accuracy and made reliable predictions within the model applicability domain.  These methods could be used for high throughput virtual screening to assess for PXR activation, prior to in vitro testing to predict potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo94faSaQs9LVg90H21EOLACvtfcHk0ljrJACwblPL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntVygsbk%253D&md5=3e84ea13c5eae46e90f16b4980212d9a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Ftx800102e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800102e%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DMachine%2520learning%2520methods%2520and%2520docking%2520for%2520predicting%2520human%2520pregnane%2520X%2520receptor%2520activation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26issue%3D7%26spage%3D1457%26epage%3D1467%26doi%3D10.1021%2Ftx800102e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anger, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giegerich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussregen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span> <span> </span><span class="NLM_article-title">Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5352</span>– <span class="NLM_lpage">5365</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmc.2012.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22560839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms12rsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5352-5365&issue=18&author=H.+Matterauthor=L.+T.+Angerauthor=C.+Giegerichauthor=S.+Gussregenauthor=G.+Hesslerauthor=K.+H.+Baringhaus&title=Development+of+in+silico+filters+to+predict+activation+of+the+pregnane+X+receptor+%28PXR%29+by+structurally+diverse+drug-like+molecules&doi=10.1016%2Fj.bmc.2012.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules</span></div><div class="casAuthors">Matter, Hans; Anger, Lennart T.; Giegerich, Clemens; Guessregen, Stefan; Hessler, Gerhard; Baringhaus, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5352-5365</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR), a member of the nuclear hormone superfamily, regulates the expression of several enzymes and transporters involved in metabolically relevant processes.  The significant induction of CYP450 enzymes by PXR, in particular CYP3A4, might significantly alter the metab. of prescribed drugs.  In order to early identify mols. in drug discovery with a potential to activate PXR as antitarget, we developed fast and reliable in silico filters by ligand-based QSAR techniques.  Two classification models were established on a diverse dataset of 434 drug-like mols.  A second augmented set allowed focusing on interesting regions in chem. space.  These classifiers are based on decision trees combined with a genetic algorithm based variable selection to arrive at predictive models.  The classifier for the first dataset on 29 descriptors showed good performance on a test set with a correct classification of both 100% for PXR activators and non-activators plus 87% for activators and 83% for non-activators in an external dataset.  The second classifier then correctly predicts 97% activators and 91% non-activators in a test set and 94% for activators and 64% non-activators in an external set of 50 mols., which still qualifies for application as a filter focusing on PXR activators.  Finally a quant. model for PXR activation for a subset of these mols. was derived using a regression-tree approach combined with GA variable selection.  This final model shows a predictive r2 of 0.774 for the test set and 0.452 for an external set of 33 mols.  Thus, the combination of these filters consistently provide guidelines for lowering PXR activation in novel candidate mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFIMqHB3fyKbVg90H21EOLACvtfcHk0lgnmOpWIoxXgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms12rsr4%253D&md5=9f2ce599c60a3290670ce53eedab0ed7</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DMatter%26aufirst%3DH.%26aulast%3DAnger%26aufirst%3DL.%2BT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DGussregen%26aufirst%3DS.%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26atitle%3DDevelopment%2520of%2520in%2520silico%2520filters%2520to%2520predict%2520activation%2520of%2520the%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520by%2520structurally%2520diverse%2520drug-like%2520molecules%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D18%26spage%3D5352%26epage%3D5365%26doi%3D10.1016%2Fj.bmc.2012.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekmarev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid scoring and classification approaches to predict human pregnane X receptor activators</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1007/s11095-008-9809-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-008-9809-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19115096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCmtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1001-1011&issue=4&author=S.+Kortagereauthor=D.+Chekmarevauthor=W.+J.+Welshauthor=S.+Ekins&title=Hybrid+scoring+and+classification+approaches+to+predict+human+pregnane+X+receptor+activators&doi=10.1007%2Fs11095-008-9809-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Scoring and Classification Approaches to Predict Human Pregnane X Receptor Activators</span></div><div class="casAuthors">Kortagere, Sandhya; Chekmarev, Dmitriy; Welsh, William J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a transcriptional regulator of many genes involved in xenobiotic metab. and excretion.  Reliable prediction of high affinity binders with this receptor would be valuable for pharmaceutical drug discovery to predict potential toxicol. responses.  Computational models were developed and validated for a dataset consisting of human PXR activators and non-activators.  The authors used support vector machine (SVM) algorithms with mol. descriptors derived from two sources, Shape Signatures and the Mol. Operating Environment (MOE) application software.  The authors also employed the mol. docking program GOLD in which the GoldScore method was supplemented with other scoring functions to improve docking results.  The overall test set prediction accuracy for PXR activators with SVM was 72% to 81%.  This indicates that mol. shape descriptors are useful in classification of compds. binding to this receptor.  The best docking prediction accuracy (61%) was obtained using 1D Shape Signature descriptors as a weighting factor to the GoldScore.  By pooling the available human PXR data sets the authors revealed those mol. features that are assocd. with human PXR activators.  These combined computational approaches using mol. shape information may assist scientists to more confidently identify PXR activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3B-l1nbBOe7Vg90H21EOLACvtfcHk0lgnmOpWIoxXgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCmtrfO&md5=e2e15b9655cdb73f0ff1ab1da41f8df7</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs11095-008-9809-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-008-9809-7%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DChekmarev%26aufirst%3DD.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DHybrid%2520scoring%2520and%2520classification%2520approaches%2520to%2520predict%2520human%2520pregnane%2520X%2520receptor%2520activators%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26issue%3D4%26spage%3D1001%26epage%3D1011%26doi%3D10.1007%2Fs11095-008-9809-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">In silico prediction of pregnane X receptor activators by machine learning approaches</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1124/mol.106.027623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.106.027623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17003167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2007&pages=158-168&issue=1&author=C.+Y.+Ungauthor=H.+Liauthor=C.+W.+Yapauthor=Y.+Z.+Chen&title=In+silico+prediction+of+pregnane+X+receptor+activators+by+machine+learning+approaches&doi=10.1124%2Fmol.106.027623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">In silico prediction of pregnane X receptor activators by machine learning approaches</span></div><div class="casAuthors">Ung, C. Y.; Li, H.; Yap, C. W.; Chen, Y. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) regulates drug metab. and is involved in drug-drug interactions.  Prediction of PXR activators is important for evaluating drug metab. and toxicity.  Computational pharmacophore and quant. structure-activity relationship models have been developed for predicting PXR activators.  Because of the structural diversity of PXR activators, more efforts are needed for exploring methods applicable to a broader spectrum of compds.  The authors explored three machine learning methods (MLMs) for predicting PXR activators, which were trained and tested by using significantly higher no. of compds., 128 PXR activators (98 human) and 77 PXR nonactivators, than those of previous studies.  The recursive feature-selection method was used to select mol. descriptors relevant to PXR activator prediction, which are consistent with conclusions from other computational and structural studies.  In a 10-fold cross-validation test, our MLM systems correctly predicted 81.2 to 84.0% of PXR activators, 80.8 to 85.0% of hPXR activators, 61.2 to 70.3% of PXR nonactivators, and 67.7 to 73.6% of hPXR nonactivators.  Our systems also correctly predicted 73.3 to 86.7% of 15 newly published hPXR activators.  MLMs seem to be useful for predicting PXR activators and for providing clues to physicochem. features of PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtf9BO0pCK5LVg90H21EOLACvtfcHk0lgnmOpWIoxXgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Grug%253D%253D&md5=258c12724e390d9c616e280f77ed181a</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.027623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.027623%26sid%3Dliteratum%253Aachs%26aulast%3DUng%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DIn%2520silico%2520prediction%2520of%2520pregnane%2520X%2520receptor%2520activators%2520by%2520machine%2520learning%2520approaches%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D71%26issue%3D1%26spage%3D158%26epage%3D168%26doi%3D10.1124%2Fmol.106.027623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches</span>. <i>Chemom. Intell. Lab. Syst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.chemolab.2012.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.chemolab.2012.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=271-279&author=H.+Raoauthor=Y.+Wangauthor=X.+Zengauthor=X.+Wangauthor=Y.+Liuauthor=J.+Yinauthor=H.+Heauthor=F.+Zhuauthor=Z.+Li&title=In+silico+identification+of+human+pregnane+X+receptor+activators+from+molecular+descriptors+by+machine+learning+approaches&doi=10.1016%2Fj.chemolab.2012.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches</span></div><div class="casAuthors">Rao, Hanbing; Wang, Yanying; Zeng, Xianyin; Wang, Xianxiang; Liu, Yong; Yin, Jiajian; He, Hua; Zhu, Feng; Li, Zerong</div><div class="citationInfo"><span class="NLM_cas:title">Chemometrics and Intelligent Laboratory Systems</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">CILSEN</span>;
        ISSN:<span class="NLM_cas:issn">0169-7439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the current study, computational models for hPXR activators and hPXR non-activators were developed using support vector machine (SVM), k-nearest neighbor (k-NN), and artificial neural networks (ANN) algorithms. 73 mol. descriptors used for hPXR activator and hPXR non-activator prediction were selected from a pool of 548 descriptors by using a multi-step hybrid feature selection method combining Fischer's score and Monte Carlo simulated annealing method.  The y-scrambling method was used to test if there is a chance correlation in the developed SVM model.  In the meantime, five-fold cross validation of these machine learning methods results in the prediction accuracies of 87.2-92.5% for hPXR activators and 73.8-87.8% for hPXR non-activators, and the prediction accuracies for external test set are 93.8-95.8% for hPXR activators and 86.7-92.8% for hPXR non-activators.  Our study suggested that the tested machine learning methods are potentially useful for hPXR activators identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr1gGOaS3QirVg90H21EOLACvtfcHk0lj40-lg4OlXmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnt73O&md5=b4d68deab6b184d7c356bf145b451282</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.chemolab.2012.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemolab.2012.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DIn%2520silico%2520identification%2520of%2520human%2520pregnane%2520X%2520receptor%2520activators%2520from%2520molecular%2520descriptors%2520by%2520machine%2520learning%2520approaches%26jtitle%3DChemom.%2520Intell.%2520Lab.%2520Syst.%26date%3D2012%26volume%3D118%26spage%3D271%26epage%3D279%26doi%3D10.1016%2Fj.chemolab.2012.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span> <span> </span><span class="NLM_article-title">Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e1000594</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1000594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pcbi.1000594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20011107" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&issue=12&author=S.+Ekinsauthor=S.+Kortagereauthor=M.+Iyerauthor=E.+J.+Reschlyauthor=M.+A.+Lillauthor=M.+R.+Redinboauthor=M.+D.+Krasowski&title=Challenges+predicting+ligand-receptor+interactions+of+promiscuous+proteins%3A+the+nuclear+receptor+PXR&doi=10.1371%2Fjournal.pcbi.1000594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1000594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1000594%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DM.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DLill%26aufirst%3DM.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26atitle%3DChallenges%2520predicting%2520ligand-receptor%2520interactions%2520of%2520promiscuous%2520proteins%253A%2520the%2520nuclear%2520receptor%2520PXR%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D12%26doi%3D10.1371%2Fjournal.pcbi.1000594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span> <span> </span><span class="NLM_article-title">Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.110.035808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21068194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=337-344&issue=2&author=Y.+Panauthor=L.+Liauthor=G.+Kimauthor=S.+Ekinsauthor=H.+Wangauthor=P.+W.+Swaan&title=Identification+and+validation+of+novel+human+pregnane+X+receptor+activators+among+prescribed+drugs+via+ligand-based+virtual+screening&doi=10.1124%2Fdmd.110.035808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening</span></div><div class="casAuthors">Pan, Yongmei; Li, Linhao; Kim, Gregory; Ekins, Sean; Wang, Hongbing; Swaan, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human pregnane X receptor (hPXR) plays a key role in regulating metab. and clearance of endogenous and exogenous substances.  Identification of novel hPXR activators among com. drugs may aid in avoiding drug-drug interactions during coadministration.  We applied ligand-based computational approaches for virtual screening of a commonly prescribed drug database (SCUT).  Bayesian classification models were generated with a training set comprising 177 compds. using Fingerprints and 117 structural descriptors.  A cell-based luciferase reporter assay was used for evaluation of chem.-mediated hPXR activation in HepG2 cells.  All compds. were tested at 10 μM concn. with rifampicin and DMSO as pos. and neg. controls, resp.  The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compds.  Screening the SCUT database with this model retrieved 105 hits and 17 compds. from the top 25 hits were chosen for in vitro testing.  The reporter assay confirmed that nine drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, megestrol, secobarbital, and aminoglutethimide, were previously unidentified hPXR activators.  Thus, the present study demonstrates that novel hPXR activators can be efficiently identified among U.S. Food and Drug Administration-approved and commonly prescribed drugs, which should lead to detection and prevention of potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsnBrsWk1drVg90H21EOLACvtfcHk0lj40-lg4OlXmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKmtrg%253D&md5=90ff1f16993d3697e6b35ac70457e0eb</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035808%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26atitle%3DIdentification%2520and%2520validation%2520of%2520novel%2520human%2520pregnane%2520X%2520receptor%2520activators%2520among%2520prescribed%2520drugs%2520via%2520ligand-based%2520virtual%2520screening%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D2%26spage%3D337%26epage%3D344%26doi%3D10.1124%2Fdmd.110.035808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-McLeod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1021/tx900417f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900417f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFWgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=664-676&issue=3&author=M.+Zientekauthor=C.+Stonerauthor=R.+Ayscueauthor=J.+Klug-McLeodauthor=Y.+Jiangauthor=M.+Westauthor=C.+Collinsauthor=S.+Ekins&title=Integrated+in+silico-in+vitro+strategy+for+addressing+cytochrome+P450+3A4+time-dependent+inhibition&doi=10.1021%2Ftx900417f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated in Silico-in Vitro Strategy for Addressing Cytochrome P450 3A4 Time-Dependent Inhibition</span></div><div class="casAuthors">Zientek, Michael; Stoner, Chad; Ayscue, Robyn; Klug-McLeod, Jacquelyn; Jiang, Ying; West, Michael; Collins, Claire; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">664-676</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Throughout the past decade, the expectations from the regulatory agencies for safety, drug-drug interactions (DDIs), pharmacokinetic, and disposition characterization of new chem. entities (NCEs) by pharmaceutical companies seeking registration have increased.  DDIs are frequently assessed using in silico, in vitro, and in vivo methodologies.  However, a key gap in this screening paradigm is a full structural understanding of time-dependent inhibition (TDI) on the cytochrome P 450 systems, particularly P 450 3A4.  To address this, a no. of high-throughput in vitro assays have been developed.  This work describes an automated assay for TDI using two concns. at two time points (2 + 2 assay).  Data generated with this assay for over 2000 compds. from multiple therapeutic programs were used to generate in silico Bayesian classification models of P 450 3A4-mediated TDI.  These in silico models were validated using several external test sets and multiple random group testing (receiver operator curve value >0.847).  We identified a no. of substructures that were likely to elicit TDI, the majority contg. indazole rings.  These in vitro and in silico approaches have been implemented as a part of the Pfizer screening paradigm.  The Bayesian models are available on the intranet to guide synthetic strategy, predict whether a NCE is likely to cause a TDI via P 450 3A4, filter for in vitro testing, and identify substructures important for TDI as well as those that do not cause TDI.  This represents an integrated in silico-in vitro strategy for addressing P 450 3A4 TDI and improving the efficiency of screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJqcGKVUJZLVg90H21EOLACvtfcHk0lhDB5G0tlIn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFWgtLc%253D&md5=97bb12a82e0f445e629b5241c6ead119</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Ftx900417f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900417f%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DStoner%26aufirst%3DC.%26aulast%3DAyscue%26aufirst%3DR.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DIntegrated%2520in%2520silico-in%2520vitro%2520strategy%2520for%2520addressing%2520cytochrome%2520P450%25203A4%2520time-dependent%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26issue%3D3%26spage%3D664%26epage%3D676%26doi%3D10.1021%2Ftx900417f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AbdulHameed, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Predicting rat and human pregnane X receptor activators using bayesian classification models</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1729-1740&issue=10&author=M.+D.+AbdulHameedauthor=D.+L.+Ippolitoauthor=A.+Wallqvist&title=Predicting+rat+and+human+pregnane+X+receptor+activators+using+bayesian+classification+models&doi=10.1021%2Facs.chemrestox.6b00227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Rat and Human Pregnane X Receptor Activators Using Bayesian Classification Models</span></div><div class="casAuthors">AbdulHameed, Mohamed Diwan M.; Ippolito, Danielle L.; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1729-1740</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a ligand-activated transcription factor that acts as a master regulator of metabolizing enzymes and transporters.  To avoid adverse drug-drug interactions and diseases such as steatosis and cancers assocd. with PXR activation, identifying drugs and chems. that activate PXR is of crucial importance.  The authors developed ligand-based predictive computational models for both rat and human PXR activation, which allowed the authors to identify potentially harmful chems. and evaluate species-specific effects of a given compd.  The authors utilized a large publicly available dataset of nearly 2000 compds. screened in cell-based reporter gene assays to develop Bayesian quant. structure-activity relationship models using physicochem. properties and structural descriptors.  The authors' anal. showed that PXR activators tend to be hydrophobic and significantly different from non-activators in terms of their physicochem. properties such as mol. wt., logP, no. of rings, and soly.  The authors' Bayesian models, evaluated by using five-fold cross validation, displayed a sensitivity of 75% (76%), specificity of 76% (75%), and accuracy of 89% for human (rat) PXR activation.  The authors identified structural features shared by rat and human PXR activators as well as those unique to each species.  The authors compared rat in vitro PXR activation data to in vivo data by using DrugMatrix, a large toxicogenomics database with gene expression data obtained from rats after exposure to diverse chems.  Although in vivo gene expression data pointed to cross-talk between nuclear receptor activators that is captured only by in vivo assays, overall the authors found broad agreement between in vitro and in vivo PXR activation.  Thus, the models developed here serve primarily as efficient initial high-throughput in silico screens of in vitro activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAUUcToXfeALVg90H21EOLACvtfcHk0lhDB5G0tlIn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOitrzK&md5=c215fd0adad8ebc93bf10c714fc25c11</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00227%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulHameed%26aufirst%3DM.%2BD.%26aulast%3DIppolito%26aufirst%3DD.%2BL.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DPredicting%2520rat%2520and%2520human%2520pregnane%2520X%2520receptor%2520activators%2520using%2520bayesian%2520classification%2520models%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D10%26spage%3D1729%26epage%3D1740%26doi%3D10.1021%2Facs.chemrestox.6b00227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism, excretion, and toxicity evaluation in drug discovery. 14. Prediction of human pregnane X receptor activators by using naive bayesian classification technique</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1021/tx500389q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500389q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=116-125&issue=1&author=H.+Shiauthor=S.+Tianauthor=Y.+Liauthor=D.+Liauthor=H.+Yuauthor=X.+Zhenauthor=T.+Hou&title=Absorption%2C+distribution%2C+metabolism%2C+excretion%2C+and+toxicity+evaluation+in+drug+discovery.+14.+Prediction+of+human+pregnane+X+receptor+activators+by+using+naive+bayesian+classification+technique&doi=10.1021%2Ftx500389q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique</span></div><div class="casAuthors">Shi, Huali; Tian, Sheng; Li, Youyong; Li, Dan; Yu, Huidong; Zhen, Xuechu; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-125</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The activation of pregnane X receptor (PXR), a member of the nuclear receptor (NR) superfamily, can mediate potential drug-drug interactions, and therefore, prediction of PXR activation is of great importance for evaluating drug metab. and toxicity.  In this study, based on 532 structurally diverse compds., we present a comprehensive anal. with the aim to build accurate classification models for distinguishing PXR activators from nonactivators by using a naive Bayesian classification technique.  First, the distributions of eight important mol. physicochem. properties of PXR activators vs. nonactivators were compared, illustrating that the hydrophobicity-related mol. descriptors (AlogP and log D) show slightly better capability to discriminate PXR activators from nonactivators than the others.  Then, based on mol. physicochem. properties, VolSurf descriptors, and mol. fingerprints, naive Bayesian classifiers were developed to sep. PXR activators from nonactivators.  The results demonstrate that the introduction of mol. fingerprints is quite essential to enhance the prediction accuracy of the classifiers.  The best Bayesian classifier based on the 21 physicochem. properties, VolSurf descriptors, and LCFC_10 fingerprints descriptors yields a prediction accuracy of 92.7% for the training set based on leave-one-out (LOO) cross-validation and of 85.2% for the test set.  Moreover, by exploring the important structural fragments derived from the best Bayesian classifier, we obsd. that flexibility is an important structural pattern for PXR activation.  In addn., chem. compds. contg. more halogen atoms, unsatd. alkanes chains relevant to π-π stacking, and fewer nitrogen atoms tend to be PXR activators.  We believe that the naive Bayesian classifier can be used as a reliable virtual screening tool to predict PXR activation in the drug design and discovery pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobB6jA90OqW7Vg90H21EOLACvtfcHk0lgWq2gzNz9nzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfF&md5=37931968857ae6808944195d9b57cf17</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Ftx500389q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500389q%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZhen%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%252C%2520and%2520toxicity%2520evaluation%2520in%2520drug%2520discovery.%252014.%2520Prediction%2520of%2520human%2520pregnane%2520X%2520receptor%2520activators%2520by%2520using%2520naive%2520bayesian%2520classification%2520technique%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26issue%3D1%26spage%3D116%26epage%3D125%26doi%3D10.1021%2Ftx500389q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dybdahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolov, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedebye, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsdottir, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J. R.</span></span> <span> </span><span class="NLM_article-title">QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>262</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2012.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.taap.2012.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22627063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=2012&pages=301-309&issue=3&author=M.+Dybdahlauthor=N.+G.+Nikolovauthor=E.+B.+Wedebyeauthor=S.+O.+Jonsdottirauthor=J.+R.+Niemela&title=QSAR+model+for+human+pregnane+X+receptor+%28PXR%29+binding%3A+screening+of+environmental+chemicals+and+correlations+with+genotoxicity%2C+endocrine+disruption+and+teratogenicity&doi=10.1016%2Fj.taap.2012.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR model for human pregnane X receptor (PXR) binding: Screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity</span></div><div class="casAuthors">Dybdahl, Marianne; Nikolov, Nikolai G.; Wedebye, Eva Bay; Jonsdottir, Svava Osk; Niemela, Jay R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) has a key role in regulating the metab. and transport of structurally diverse endogenous and exogenous compds.  Activation of PXR has the potential to initiate adverse effects, causing drug-drug interactions, and perturbing normal physiol. functions.  Therefore, identification of PXR ligands would be valuable information for pharmaceutical and toxicol. research.  In the present study, we developed a quant. structure-activity relationship (QSAR) model for the identification of PXR ligands using data based on a human PXR binding assay.  A total of 631 mols., representing a variety of chem. structures, constituted the training set of the model.  Cross-validation of the model showed a sensitivity of 82%, a specificity of 85%, and a concordance of 84%.  The developed model provided knowledge about mol. descriptors that may influence the binding of mols. to PXR.  The model was used to screen a large inventory of environmental chems., of which 47% was found to be within domain of the model.  Approx. 35% of the chems. within domain were predicted to be PXR ligands.  The predicted PXR ligands were found to be overrepresented among chems. predicted to cause adverse effects, such as genotoxicity, teratogenicity, estrogen receptor activation and androgen receptor antagonism compared to chems. not causing these effects.  The developed model may be useful as a tool for predicting potential PXR ligands and for providing mechanistic information of toxic effects of chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGTM7-zx2iobVg90H21EOLACvtfcHk0lgWq2gzNz9nzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nsrk%253D&md5=50d00b71e17120507c517950f7f84f54</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2012.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2012.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DDybdahl%26aufirst%3DM.%26aulast%3DNikolov%26aufirst%3DN.%2BG.%26aulast%3DWedebye%26aufirst%3DE.%2BB.%26aulast%3DJonsdottir%26aufirst%3DS.%2BO.%26aulast%3DNiemela%26aufirst%3DJ.%2BR.%26atitle%3DQSAR%2520model%2520for%2520human%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520binding%253A%2520screening%2520of%2520environmental%2520chemicals%2520and%2520correlations%2520with%2520genotoxicity%252C%2520endocrine%2520disruption%2520and%2520teratogenicity%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2012%26volume%3D262%26issue%3D3%26spage%3D301%26epage%3D309%26doi%3D10.1016%2Fj.taap.2012.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagome, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaotsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional quantitative structure-activity relationship analysis for human pregnane X receptor for the prediction of CYP3A4 induction in human hepatocytes: structure-based comparative molecular field analysis</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1002/jps.24235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjps.24235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25381754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyhsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=223-232&issue=1&author=K.+Handaauthor=I.+Nakagomeauthor=N.+Yamaotsuauthor=H.+Goudaauthor=S.+Hirono&title=Three-dimensional+quantitative+structure-activity+relationship+analysis+for+human+pregnane+X+receptor+for+the+prediction+of+CYP3A4+induction+in+human+hepatocytes%3A+structure-based+comparative+molecular+field+analysis&doi=10.1002%2Fjps.24235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Dimensional Quantitative Structure-Activity Relationship Analysis for Human Pregnane X Receptor for the Prediction of CYP3A4 induction in Human Hepatocytes: Structure-Based Comparative Molecular Field Analysis</span></div><div class="casAuthors">Handa, Koichi; Nakagome, Izumi; Yamaotsu, Noriyuki; Gouda, Hiroaki; Hirono, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The pregnane X receptor [PXR (NR1I2)] induces the expression of xenobiotic metabolic genes and transporter genes.  In this study, we aimed to establish a computational method for quantifying the enzyme-inducing potencies of different compds. via their ability to activate PXR, for the application in drug discovery and development.  To achieve this purpose, we developed a three-dimensional quant. structure-activity relationship (3D-QSAR) model using comparative mol. field anal. (CoMFA) for predicting enzyme-inducing potencies, based on computer-ligand docking to multiple PXR protein structures sampled from the trajectory of a mol. dynamics simulation.  Mol. mechanics-generalized born/surface area scores representing the ligand-protein-binding free energies were calcd. for each ligand.  As a result, the predicted enzyme-inducing potencies for compds. generated by the CoMFA model were in good agreement with the exptl. values.  Finally, we concluded that this 3D-QSAR model has the potential to predict the enzyme-inducing potencies of novel compds. with high precision and therefore has valuable applications in the early stages of the drug discovery process. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp876yp57PFFrVg90H21EOLACvtfcHk0lgWq2gzNz9nzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyhsbvI&md5=396cb725f1ec541a9a7b1e495c1187e7</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2Fjps.24235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24235%26sid%3Dliteratum%253Aachs%26aulast%3DHanda%26aufirst%3DK.%26aulast%3DNakagome%26aufirst%3DI.%26aulast%3DYamaotsu%26aufirst%3DN.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26atitle%3DThree-dimensional%2520quantitative%2520structure-activity%2520relationship%2520analysis%2520for%2520human%2520pregnane%2520X%2520receptor%2520for%2520the%2520prediction%2520of%2520CYP3A4%2520induction%2520in%2520human%2520hepatocytes%253A%2520structure-based%2520comparative%2520molecular%2520field%2520analysis%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26issue%3D1%26spage%3D223%26epage%3D232%26doi%3D10.1002%2Fjps.24235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myatt, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blower, P. E.,  Jr.</span></span> <span> </span><span class="NLM_article-title">LeadScope: software for exploring large sets of screening data</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/ci0000631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0000631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlalt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=1302-1314&issue=6&author=G.+Robertsauthor=G.+J.+Myattauthor=W.+P.+Johnsonauthor=K.+P.+Crossauthor=P.+E.+Blower&title=LeadScope%3A+software+for+exploring+large+sets+of+screening+data&doi=10.1021%2Fci0000631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">LeadScope: Software for Exploring Large Sets of Screening Data</span></div><div class="casAuthors">Roberts, Gulsevin; Myatt, Glenn J.; Johnson, Wayne P.; Cross, Kevin P.; Blower, Paul E. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1302-1314</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern approaches to drug discovery have dramatically increased the speed and quantity of compds. that are made and tested for potential potency.  The task of collecting, organizing, and assimilating this information is a major bottleneck in the discovery of new drugs.  We have developed LeadScope a novel, interactive computer program for visualizing, browsing, and interpreting chem. and biol. screening data that can assist pharmaceutical scientists in finding promising drug candidates.  The software organizes the chem. data by structural features familiar to medicinal chemists.  Graphs are used to summarize the data, and structural classes are highlighted that are statistically correlated with biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZfT6LgmN8LVg90H21EOLACvtfcHk0lg4BXzZkGmIrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlalt7g%253D&md5=7d95b14d7b5ff89706ee724425aeff2b</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1021%2Fci0000631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0000631%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DG.%26aulast%3DMyatt%26aufirst%3DG.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BP.%26aulast%3DCross%26aufirst%3DK.%2BP.%26aulast%3DBlower%26aufirst%3DP.%2BE.%26atitle%3DLeadScope%253A%2520software%2520for%2520exploring%2520large%2520sets%2520of%2520screening%2520data%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2000%26volume%3D40%26issue%3D6%26spage%3D1302%26epage%3D1314%26doi%3D10.1021%2Fci0000631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span> <span> </span><span class="NLM_article-title">Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2010.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tox.2010.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21115097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2011&pages=77-87&issue=3&author=H.+Kojimaauthor=F.+Sataauthor=S.+Takeuchiauthor=T.+Sueyoshiauthor=T.+Nagai&title=Comparative+study+of+human+and+mouse+pregnane+X+receptor+agonistic+activity+in+200+pesticides+using+in+vitro+reporter+gene+assays&doi=10.1016%2Fj.tox.2010.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays</span></div><div class="casAuthors">Kojima, Hiroyuki; Sata, Fumihiro; Takeuchi, Shinji; Sueyoshi, Tatsuya; Nagai, Tadanori</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">77-87</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The nuclear receptor, pregnane X receptor (PXR), is a ligand-dependent transcription factor that regulates genes involved in xenobiotic metab.  Recent studies have shown that PXR activation may affect energy metab. as well as the endocrine and immune systems.  In this study, the authors characterized and compared the agonistic activities of a variety of pesticides against human PXR (hPXR) and mouse PXR (mPXR).  The hPXR and mPXR agonistic activity of 200 pesticides (29 organochlorines, 11 di-Ph ethers, 56 organophosphorus pesticides, 12 pyrethroids, 22 carbamates, 12 acid amides, 7 triazines, 7 ureas, and 44 others) was tested by reporter gene assays using COS-7 simian kidney cells.  Of the 200 pesticides tested, 106 and 93 activated hPXR and mPXR, resp., and a total of 111 had hPXR and(or) mPXR agonistic activity with greater or lesser interspecies differences.  Although all of the pyrethroids and most of the organochlorines and acid amides acted as PXR agonists, a wide range of pesticides with diverse structures also showed hPXR and(or) mPXR agonistic activity.  Among the 200 pesticides, pyributicarb, pretilachlor, piperophos, and butamifos for hPXR, and phosalone, prochloraz, pendimethalin, and butamifos for mPXR, acted as particularly potent activators at low concns. in the order of 10-8-10-7M.  In addn., several organophosphorus oxon- and pyributicarb oxon-metabolites decreased PXR activation potency compared to their parent compds.  These results suggest that a large no. of structurally diverse pesticides and their metabolites possess PXR-mediated transcriptional activity, and their ability to do so varies in a species-dependent manner in humans and mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmLQNlWlAQY7Vg90H21EOLACvtfcHk0lg4BXzZkGmIrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaktLg%253D&md5=4823bd6aef9afcac088b8ad360ccfee3</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2010.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2010.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DSata%26aufirst%3DF.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DSueyoshi%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DT.%26atitle%3DComparative%2520study%2520of%2520human%2520and%2520mouse%2520pregnane%2520X%2520receptor%2520agonistic%2520activity%2520in%2520200%2520pesticides%2520using%2520in%2520vitro%2520reporter%2520gene%2520assays%26jtitle%3DToxicology%26date%3D2011%26volume%3D280%26issue%3D3%26spage%3D77%26epage%3D87%26doi%3D10.1016%2Fj.tox.2010.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of random forest and Pipeline Pilot Naive Bayes in prospective QSAR predictions</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/ci200615h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200615h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XislajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=792-803&issue=3&author=B.+Chenauthor=R.+P.+Sheridanauthor=V.+Hornakauthor=J.+H.+Voigt&title=Comparison+of+random+forest+and+Pipeline+Pilot+Naive+Bayes+in+prospective+QSAR+predictions&doi=10.1021%2Fci200615h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Random Forest and Pipeline Pilot Naive Bayes in Prospective QSAR Predictions</span></div><div class="casAuthors">Chen, Bin; Sheridan, Robert P.; Hornak, Viktor; Voigt, Johannes H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">792-803</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Random forest is currently considered one of the best QSAR methods available in terms of accuracy of prediction.  However, it is computationally intensive.  Naive Bayes is a simple, robust classification method.  The Laplacian-modified Naive Bayes implementation is the preferred QSAR method in the widely used com. chemoinformatics platform Pipeline Pilot.  We made a comparison of the ability of Pipeline Pilot Naive Bayes (PLPNB) and random forest to make accurate predictions on 18 large, diverse inhouse QSAR data sets.  These include on-target and ADME-related activities.  These data sets were set up as classification problems with either binary or multicategory activities.  We used a time-split method of dividing training and test sets, as we feel this is a realistic way of simulating prospective prediction.  PLPNB is computationally efficient.  However, random forest predictions are at least as good and in many cases significantly better than those of PLPNB on our data sets.  PLPNB performs better with ECFP4 and ECFP6 descriptors, which are native to Pipeline Pilot, and more poorly with other descriptors we tried.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopM-mDzNRvcLVg90H21EOLACvtfcHk0lg4BXzZkGmIrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislajtbY%253D&md5=63488794c7eebebed1f34c2e6989e104</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fci200615h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200615h%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DR.%2BP.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26atitle%3DComparison%2520of%2520random%2520forest%2520and%2520Pipeline%2520Pilot%2520Naive%2520Bayes%2520in%2520prospective%2520QSAR%2520predictions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D3%26spage%3D792%26epage%3D803%26doi%3D10.1021%2Fci200615h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoufir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">eMolTox: Prediction of molecular toxicity with confidence</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/bty135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fbioinformatics%2Fbty135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29522123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFCmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=2508-2509&issue=14&author=C.+Jiauthor=F.+Svenssonauthor=A.+Zoufirauthor=A.+Bender&title=eMolTox%3A+Prediction+of+molecular+toxicity+with+confidence&doi=10.1093%2Fbioinformatics%2Fbty135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">eMolTox: prediction of molecular toxicity with confidence</span></div><div class="casAuthors">Ji, Changge; Svensson, Fredrik; Zoufir, Azedine; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2508-2509</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4811</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Summary: In this work, we present eMolTox, a web server for the prediction of potential toxicity assocd. with a given mol.  A total of 174 toxicol.-related in vitro/vivo exptl. datasets were used for model construction and Mondrian conformal prediction was used to est. the confidence of the resulting predictions.  Toxic substructure anal. is also implemented in eMolTox. eMolTox predicts and displays a wealth of information of potential mol. toxicities for safety anal. in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_aaES1i5cZrVg90H21EOLACvtfcHk0liZjq-IbmT1jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFCmtL4%253D&md5=1f0f8c08e396e45109bfbc6fa1ced3fb</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbty135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbty135%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DF.%26aulast%3DZoufir%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DeMolTox%253A%2520Prediction%2520of%2520molecular%2520toxicity%2520with%2520confidence%26jtitle%3DBioinformatics%26date%3D2018%26volume%3D34%26issue%3D14%26spage%3D2508%26epage%3D2509%26doi%3D10.1093%2Fbioinformatics%2Fbty135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleifer, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsiedel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span> <span> </span><span class="NLM_article-title">KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/s13321-020-00422-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1186%2Fs13321-020-00422-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=24&author=A.+Morgerauthor=M.+Matheaauthor=J.+H.+Achenbachauthor=A.+Wolfauthor=R.+Buesenauthor=K.-J.+Schleiferauthor=R.+Landsiedelauthor=A.+Volkamer&title=KnowTox%3A+pipeline+and+case+study+for+confident+prediction+of+potential+toxic+effects+of+compounds+in+early+phases+of+development&doi=10.1186%2Fs13321-020-00422-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development</span></div><div class="casAuthors">Morger, Andrea; Mathea, Miriam; Achenbach, Janosch H.; Wolf, Antje; Buesen, Roland; Schleifer, Klaus-Juergen; Landsiedel, Robert; Volkamer, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">SpringerOpen</span>)
        </div><div class="casAbstract">Abstr.: Risk assessment of newly synthesized chems. is a prerequisite for regulatory approval.  In this context, in silico methods have great potential to reduce time, cost, and ultimately animal testing as they make use of the ever-growing amt. of available toxicity data.  Here, KnowTox is presented, a novel pipeline that combines three different in silico toxicol. approaches to allow for confident prediction of potentially toxic effects of query compds., i.e. machine learning models for 88 endpoints, alerts for 919 toxic substructures, and computational support for read-across.  Therefore, first, the conformal prediction technique was deployed, comprising an addnl. calibration step and per definition creating internally valid predictors at a given significance level.  Second, to further improve validity and information efficiency, two adaptations are suggested, exemplified at the androgen receptor antagonism endpoint.  This increase in validity comes at the cost of efficiency, which could again be improved by 20% for the initial ToxCast model by balancing the dataset during model training.  Finally, the value of the developed pipeline for risk assessment is discussed using two inhouse triazole mols.  Compared to a single toxicity prediction method, complementing the outputs of different approaches can have a higher impact on guiding toxicity testing and de-selecting most likely harmful development-candidate compds. early in the development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFOlJUVmwH3rVg90H21EOLACvtfcHk0liZjq-IbmT1jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVOlu74%253D&md5=49acdc1fad1e28857f3d7511121c0c1e</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1186%2Fs13321-020-00422-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-020-00422-x%26sid%3Dliteratum%253Aachs%26aulast%3DMorger%26aufirst%3DA.%26aulast%3DMathea%26aufirst%3DM.%26aulast%3DAchenbach%26aufirst%3DJ.%2BH.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DBuesen%26aufirst%3DR.%26aulast%3DSchleifer%26aufirst%3DK.-J.%26aulast%3DLandsiedel%26aufirst%3DR.%26aulast%3DVolkamer%26aufirst%3DA.%26atitle%3DKnowTox%253A%2520pipeline%2520and%2520case%2520study%2520for%2520confident%2520prediction%2520of%2520potential%2520toxic%2520effects%2520of%2520compounds%2520in%2520early%2520phases%2520of%2520development%26jtitle%3DJ.%2520Cheminf.%26date%3D2020%26volume%3D12%26spage%3D24%26doi%3D10.1186%2Fs13321-020-00422-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grulke, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volarath, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainadarajah, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wambaugh, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kancherla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patlewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crofton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. S.</span></span> <span> </span><span class="NLM_article-title">ToxCast chemical landscape: Paving the road to 21st century toxicology</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00135</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00135" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2it77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1225-1251&issue=8&author=A.+M.+Richardauthor=R.+S.+Judsonauthor=K.+A.+Houckauthor=C.+M.+Grulkeauthor=P.+Volarathauthor=I.+Thillainadarajahauthor=C.+Yangauthor=J.+Rathmanauthor=M.+T.+Martinauthor=J.+F.+Wambaughauthor=T.+B.+Knudsenauthor=J.+Kancherlaauthor=K.+Mansouriauthor=G.+Patlewiczauthor=A.+J.+Williamsauthor=S.+B.+Littleauthor=K.+M.+Croftonauthor=R.+S.+Thomas&title=ToxCast+chemical+landscape%3A+Paving+the+road+to+21st+century+toxicology&doi=10.1021%2Facs.chemrestox.6b00135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology</span></div><div class="casAuthors">Richard, Ann M.; Judson, Richard S.; Houck, Keith A.; Grulke, Christopher M.; Volarath, Patra; Thillainadarajah, Inthirany; Yang, Chihae; Rathman, James; Martin, Matthew T.; Wambaugh, John F.; Knudsen, Thomas B.; Kancherla, Jayaram; Mansouri, Kamel; Patlewicz, Grace; Williams, Antony J.; Little, Stephen B.; Crofton, Kevin M.; Thomas, Russell S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1225-1251</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The U.S. Environmental Protection Agency's (EPA) ToxCast program is testing a large library of Agency-relevant chems. using in vitro high-throughput screening (HTS) approaches to support the development of improved toxicity prediction models.  Launched in 2007, Phase I of the program screened 310 chems., mostly pesticides, across hundreds of ToxCast assay end points.  In Phase II, the ToxCast library was expanded to 1878 chems., culminating in the public release of screening data at the end of 2013.  Subsequent expansion in Phase III has resulted in more than 3800 chems. actively undergoing ToxCast screening, 96% of which are also being screened in the multi-Agency Tox21 project.  The chem. library unpinning these efforts plays a central role in defining the scope and potential application of ToxCast HTS results.  The history of the phased construction of EPA's ToxCast library is reviewed, followed by a survey of the library contents from several different vantage points.  CAS Registry Nos. are used to assess ToxCast library coverage of important toxicity, regulatory, and exposure inventories.  Structure-based representations of ToxCast chems. are then used to compute physicochem. properties, substructural features, and structural alerts for toxicity and biotransformation.  Cheminformatics approaches using these varied representations are applied to defining the boundaries of HTS testability, evaluating chem. diversity, and comparing the ToxCast library to potential target application inventories, such as used in EPA's Endocrine Disruption Screening Program (EDSP).  Through several examples, the ToxCast chem. library is demonstrated to provide comprehensive coverage of the knowledge domains and target inventories of potential interest to EPA.  Furthermore, the varied representations and approaches presented here define local chem. domains potentially worthy of further investigation (e.g., not currently covered in the testing library or defined by toxicity "alerts") to strategically support data mining and predictive toxicol. modeling moving forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7PtwfIqvibVg90H21EOLACvtfcHk0lg2a4oJL_HpgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2it77J&md5=d3a11c36e02ef799785702d93344bf42</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00135%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DA.%2BM.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DHouck%26aufirst%3DK.%2BA.%26aulast%3DGrulke%26aufirst%3DC.%2BM.%26aulast%3DVolarath%26aufirst%3DP.%26aulast%3DThillainadarajah%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRathman%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DWambaugh%26aufirst%3DJ.%2BF.%26aulast%3DKnudsen%26aufirst%3DT.%2BB.%26aulast%3DKancherla%26aufirst%3DJ.%26aulast%3DMansouri%26aufirst%3DK.%26aulast%3DPatlewicz%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DLittle%26aufirst%3DS.%2BB.%26aulast%3DCrofton%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DR.%2BS.%26atitle%3DToxCast%2520chemical%2520landscape%253A%2520Paving%2520the%2520road%2520to%252021st%2520century%2520toxicology%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D8%26spage%3D1225%26epage%3D1251%26doi%3D10.1021%2Facs.chemrestox.6b00135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Creusot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gassiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaterre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiavarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toporova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daujat-Chavanieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evrard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">The anti-cancer drug dabrafenib is a potent activator of the human pregnane X receptor</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1641</span>, <span class="refDoi"> DOI: 10.3390/cells9071641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3390%2Fcells9071641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1ymtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1641&issue=7&author=N.+Creusotauthor=M.+Gassiotauthor=E.+Alaterreauthor=B.+Chiavarinaauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=L.+Toporovaauthor=S.+Gerbal-Chaloinauthor=M.+Daujat-Chavanieuauthor=A.+Matheuxauthor=R.+Rahmaniauthor=C.+Gongoraauthor=A.+Evrardauthor=P.+Pourquierauthor=P.+Balaguer&title=The+anti-cancer+drug+dabrafenib+is+a+potent+activator+of+the+human+pregnane+X+receptor&doi=10.3390%2Fcells9071641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-cancer drug dabrafenib is a potent activator of the human pregnane X receptor</span></div><div class="casAuthors">Creusot, Nicolas; Gassiot, Matthieu; Alaterre, Elina; Chiavarina, Barbara; Grimaldi, Marina; Boulahtouf, Abdelhay; Toporova, Lucia; Gerbal-Chaloin, Sabine; Daujat-Chavanieu, Martine; Matheux, Alice; Rahmani, Roger; Gongora, Celine; Evrard, Alexandre; Pourquier, Philippe; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1641</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) is activated by a large set of endogenous and exogenous compds. and plays a crit. role in the control of detoxifying enzymes and transporters regulating liver and gastrointestinal drug metab. and clearance. hPXR is also involved in both the development of multidrug resistance and enhanced cancer cells aggressiveness.  Moreover, its unintentional activation by pharmaceutical drugs can mediate drug-drug interactions and cause severe adverse events.  In that context, the potential of the anticancer BRAF inhibitor dabrafenib suspected to activate hPXR and the human constitutive androstane receptor (hCAR) has not been thoroughly investigated yet.  Using different reporter cellular assays, we demonstrate that dabrafenib can activate hPXR as efficiently as its ref. agonist SR12813, whereas it does not activate mouse or zebrafish PXR nor hCAR.We also showed that dabrafenib binds to recombinant hPXR, induces the expression of hPXR responsive genes in colon LS174T-hPXR cancer cells and human hepatocytes and finally increases the proliferation in LS174T-hPXR cells.  Our study reveals that by using a panel of different cellular techniques it is possible to improve the assessment of hPXR agonist activity for new developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjivaoeQRdPLVg90H21EOLACvtfcHk0lg2a4oJL_HpgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1ymtb3J&md5=46d8bab509ceff1fa9d157864984bd72</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.3390%2Fcells9071641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9071641%26sid%3Dliteratum%253Aachs%26aulast%3DCreusot%26aufirst%3DN.%26aulast%3DGassiot%26aufirst%3DM.%26aulast%3DAlaterre%26aufirst%3DE.%26aulast%3DChiavarina%26aufirst%3DB.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DToporova%26aufirst%3DL.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DDaujat-Chavanieu%26aufirst%3DM.%26aulast%3DMatheux%26aufirst%3DA.%26aulast%3DRahmani%26aufirst%3DR.%26aulast%3DGongora%26aufirst%3DC.%26aulast%3DEvrard%26aufirst%3DA.%26aulast%3DPourquier%26aufirst%3DP.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DThe%2520anti-cancer%2520drug%2520dabrafenib%2520is%2520a%2520potent%2520activator%2520of%2520the%2520human%2520pregnane%2520X%2520receptor%26jtitle%3DCells%26date%3D2020%26volume%3D9%26issue%3D7%26spage%3D1641%26doi%3D10.3390%2Fcells9071641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database</span>. <i>Environ. Health Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1289/ehp.1001930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1289%2Fehp.1001930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20558333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyjtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=1412-1417&issue=10&author=S.+Kortagereauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+Venkateshauthor=S.+Maniauthor=S.+Ekins&title=Evaluation+of+computational+docking+to+identify+pregnane+X+receptor+agonists+in+the+ToxCast+database&doi=10.1289%2Fehp.1001930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database</span></div><div class="casAuthors">Kortagere, Sandhya; Krasowski, Matthew D.; Reschly, Erica J.; Venkatesh, Madhukumar; Mani, Sridhar; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Health Perspectives</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1412-1417</span>CODEN:
                <span class="NLM_cas:coden">EVHPAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-6765</span>.
    
            (<span class="NLM_cas:orgname">U. S. Department of Health and Human Services, Public Health Services</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a key transcriptional regulator of many genes [e.g., cytochrome P450s (CYP2C9, CYP3A4, CYP2B6), MDR1] involved in xenobiotic metab. and excretion.  As part of an evaluation of different approaches to predict compd. affinity for nuclear hormone receptors, we used the mol. docking program GOLD and a hybrid scoring scheme based on similarity weighted GoldScores to predict potential PXR agonists in the ToxCast database of pesticides and other industrial chems.  We present some of the limitations of different in vitro systems, as well as docking and ligand-based computational models.  Each ToxCast compd. was docked into the five published crystallog. structures of human PXR (hPXR), and 15 compds. were selected based on their consensus docking scores for testing.  In addn., we used a Bayesian model to classify the ToxCast compds. into PXR agonists and nonagonists.  HPXR activation was detd. by luciferase-based reporter assays in the HepG2 and DPX-2 human liver cell lines.  We tested 11 compds., of which 6 were strong agonists and 2 had weak agonist activity.  Docking results of addnl. compds. were compared with data reported in the literature.  The prediction sensitivity of PXR agonists in our sample ToxCast data set (n = 28) using docking and the GoldScore was higher than with the hybrid score at 66.7%.  The prediction sensitivity for PXR agonists using GoldScore for the entire ToxCast data set (n = 308) compared with data from the NIH (National Institutes of Health) Chem. Genomics Center data was 73.8%.  Docking and the GoldScore may be useful for prioritizing large data sets prior to in vitro testing with good sensitivity across the sample and entire ToxCast data set for hPXR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1lXdlLX7jzLVg90H21EOLACvtfcHk0lggXC5M-bPI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyjtrbO&md5=d9906fc4eb0f1eade813b79d66cc3163</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1289%2Fehp.1001930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.1001930%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520computational%2520docking%2520to%2520identify%2520pregnane%2520X%2520receptor%2520agonists%2520in%2520the%2520ToxCast%2520database%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D2010%26volume%3D118%26issue%3D10%26spage%3D1412%26epage%3D1417%26doi%3D10.1289%2Fehp.1001930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span> <span> </span><span class="NLM_article-title">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1080/00498250601050412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F00498250601050412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17484516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=124-138&issue=2&author=Y.+D.+Gaoauthor=S.+H.+Olsonauthor=J.+M.+Balkovecauthor=Y.+Zhuauthor=I.+Royoauthor=J.+Yabutauthor=R.+Eversauthor=E.+Y.+Tanauthor=W.+Tangauthor=D.+P.+Hartleyauthor=R.+T.+Mosley&title=Attenuating+pregnane+X+receptor+%28PXR%29+activation%3A+a+molecular+modelling+approach&doi=10.1080%2F00498250601050412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span></div><div class="casAuthors">Gao, Y.-D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that the pregnane X receptor (PXR) is a key regulator of cytochromes P 450 3A (e.g. CYP3A4 in human) gene expression.  As a result, activation of PXR may lead to CYP3A4 protein over-expression.  Because induction of CYP3A4 could result in clin. important drug-drug interactions, there has been a great interest in reducing the possibility of PXR activation by drug candidates in drug-discovery programs.  In order to provide structural insight for attenuating drug candidate-mediated PXR activation, we used a docking approach to study the structure-activity relationship for PXR activators.  Based on our docking models, it is proposed that introducing polar groups to the end of an activator should reduce its human PXR (hPXR) activity via destabilizing interactions in the hydrophobic areas of the PXR ligand-binding pocket.  A no. of analogs that incorporate these structural features then were designed and synthesized, and they exhibited significantly lower hPXR activation in a transactivation assay and decreased CYP3A4 induction in a human hepatocytes-based assay.  In addn., an example in which attenuating hPXR activation was achieved by sterically destabilizing the helixes 11 and 12 of the receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBZSC0secQoLVg90H21EOLACvtfcHk0lggXC5M-bPI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D&md5=400688510dd165a4a9632b6ba10bf267</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1080%2F00498250601050412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250601050412%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRoyo%26aufirst%3DI.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DE.%2BY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26atitle%3DAttenuating%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520activation%253A%2520a%2520molecular%2520modelling%2520approach%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26issue%3D2%26spage%3D124%26epage%3D138%26doi%3D10.1080%2F00498250601050412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span> <span> </span><span class="NLM_article-title">Insights from a three-dimensional model into ligand binding to constitutive active receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.9.951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.30.9.951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12167558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=951-956&issue=9&author=L.+Xiaoauthor=X.+Cuiauthor=V.+Madisonauthor=R.+E.+Whiteauthor=K.+C.+Cheng&title=Insights+from+a+three-dimensional+model+into+ligand+binding+to+constitutive+active+receptor&doi=10.1124%2Fdmd.30.9.951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Insights from a three-dimensional model into ligand binding to constitutive active receptor</span></div><div class="casAuthors">Xiao, Li; Cui, Xiaoming; Madison, Vincent; White, Ronald E.; Cheng, K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">951-956</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two orphan nuclear receptors, constitutive active (or androstane) receptor (CAR) and pregnane X receptor (PXR), are among the most important mediators of ligand-activated transcriptional induction of liver microsomal cytochrome P 450 drug-metabolizing enzymes.  CAR and PXR belong to the same NR1I receptor subfamily and show high sequence homol. to each other.  The vitamin D receptor (VDR) also belongs to the NR1I subfamily and has the second highest homol. to CAR in the ligand binding domain.  A 3D model of the ligand binding domain of human CAR (hCAR) was constructed based on the available x-ray structures of human PXR (hPXR) and VDR (hVDR).  The model shows that the size of the ligand binding cavities of hCAR and hPXR are similar, but larger than that of hVDR.  HPXR's capability of binding to extremely large ligands, such as rifampicin, implies that its binding cavity may be able to expand further through the flexibility of a surface loop.  In contrast, hCAR does not have this loop so that its cavity cannot expand, suggesting that hCAR would not bind to the largest hPXR ligands.  Docking calcns. of selected ligands to hCAR, based on the structural model, are consistent with previously reported receptor binding data.  The results from this study indicate that structural modeling will be a useful tool for understanding ligand binding to hCAR and for design of drugs free of hCAR-mediated enzyme induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMVoVyEEGrnLVg90H21EOLACvtfcHk0lggXC5M-bPI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVShur4%253D&md5=e1bf7beb49daf4e496f216d9f6899baf</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.9.951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.9.951%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26atitle%3DInsights%2520from%2520a%2520three-dimensional%2520model%2520into%2520ligand%2520binding%2520to%2520constitutive%2520active%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26issue%3D9%26spage%3D951%26epage%3D956%26doi%3D10.1124%2Fdmd.30.9.951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Molecular insights into the promiscuous interaction of human pregnane X receptor (hPXR) with diverse environmental chemicals and drug compounds</span>. <i>Chemosphere</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.chemosphere.2013.09.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.chemosphere.2013.09.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24182399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ksrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=138-145&author=S.+Chenauthor=N.+Heauthor=W.+Chenauthor=F.+Sunauthor=L.+Liauthor=R.+Dengauthor=Y.+Hu&title=Molecular+insights+into+the+promiscuous+interaction+of+human+pregnane+X+receptor+%28hPXR%29+with+diverse+environmental+chemicals+and+drug+compounds&doi=10.1016%2Fj.chemosphere.2013.09.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular insights into the promiscuous interaction of human pregnane X receptor (hPXR) with diverse environmental chemicals and drug compounds</span></div><div class="casAuthors">Chen, Sheng; He, Nianhai; Chen, Wensheng; Sun, Fengjun; Li, Luquan; Deng, Rui; Hu, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Chemosphere</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-145</span>CODEN:
                <span class="NLM_cas:coden">CMSHAF</span>;
        ISSN:<span class="NLM_cas:issn">0045-6535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The nuclear receptor member human pregnane X receptor (hPXR) regulates enzymes and transporters involved in xenobiotic detoxification as well as maintains homeostatic balance of bile acids, thyroid and steroid hormones.  HPXR can be recognized and activated by a structurally diverse array of environmental chems. and drug compds. to initiate adverse biol. effects, such as perturbing normal physiol. functions and causing dangerous drug-drug interactions and exhibiting a high promiscuity in its ligand spectrum.  Understanding of the mol. mechanism and biol. implication underlying the promiscuous interaction of hPXR with its diverse ligands is fundamentally important for toxicol. and pharmaceutical researches.  In the current study, mol. docking and hybrid quantum mechanics/mol. mechanics (QM/MM) were employed to investigate the binding mode, structural basis and energetic property of hPXR interactions with various activators and non-activators.  It was found that, as compared to non-activators, the activators adopt few dominant modes to tightly interact with hPXR, which are specified by few polar spots located on the hydrophobic surface of hPXR active pocket.  Based on the findings, a novel method called multiple binding mode-based quant. structure-activity relationship (MBMB-QSAR) that characterizes the nonbonded interaction profile of hPXR with its ligand in multiple binding modes was proposed to model and predict the activating potency of small-mol. compds. on hPXR.  Several partial least square (PLS) predictors derived from the MBMB-QSAR modeling were demonstrated to be effective for quant. characterization of the biol. behavior of exptl. confirmed activators, and for qual. differentiating the activators from a large no. of non-activators.  From the predictor models it is suggested that the hydrophobic force and electrostatic interaction play an important role in hPXR-ligand binding, while steric factor contributes moderately to the binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mRzy_7rpRLVg90H21EOLACvtfcHk0lgSd8ztk2GyUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ksrvO&md5=998e892317253d03527593cbf0bb627c</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.chemosphere.2013.09.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemosphere.2013.09.084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DMolecular%2520insights%2520into%2520the%2520promiscuous%2520interaction%2520of%2520human%2520pregnane%2520X%2520receptor%2520%2528hPXR%2529%2520with%2520diverse%2520environmental%2520chemicals%2520and%2520drug%2520compounds%26jtitle%3DChemosphere%26date%3D2014%26volume%3D96%26spage%3D138%26epage%3D145%26doi%3D10.1016%2Fj.chemosphere.2013.09.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaquiquzzaman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular interactions of dioxins and DLCs with the xenosensors (PXR and CAR): An in silico risk assessment approach</span>. <i>J. Mol. Recognit.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e2651</span> <span class="refDoi"> DOI: 10.1002/jmr.2651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjmr.2651" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&issue=12&author=G.+Vermaauthor=M.+F.+Khanauthor=M.+Shaquiquzzamanauthor=W.+Akhtarauthor=M.+Akhterauthor=S.+M.+Hasanauthor=M.+M.+Alam&title=Molecular+interactions+of+dioxins+and+DLCs+with+the+xenosensors+%28PXR+and+CAR%29%3A+An+in+silico+risk+assessment+approach&doi=10.1002%2Fjmr.2651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1002%2Fjmr.2651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.2651%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DM.%2BF.%26aulast%3DShaquiquzzaman%26aufirst%3DM.%26aulast%3DAkhtar%26aufirst%3DW.%26aulast%3DAkhter%26aufirst%3DM.%26aulast%3DHasan%26aufirst%3DS.%2BM.%26aulast%3DAlam%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520interactions%2520of%2520dioxins%2520and%2520DLCs%2520with%2520the%2520xenosensors%2520%2528PXR%2520and%2520CAR%2529%253A%2520An%2520in%2520silico%2520risk%2520assessment%2520approach%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2017%26volume%3D30%26issue%3D12%26doi%3D10.1002%2Fjmr.2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Screening ingredients from herbs against pregnane X receptor in the study of inductive herb-drug interactions: Combining pharmacophore and docking-based rank aggregation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">657159</span>, <span class="refDoi"> DOI: 10.1155/2015/657159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1155%2F2015%2F657159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26339628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC287psVOrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=657159&author=Z.+Cuiauthor=H.+Kangauthor=K.+Tangauthor=Q.+Liuauthor=Z.+Caoauthor=R.+Zhu&title=Screening+ingredients+from+herbs+against+pregnane+X+receptor+in+the+study+of+inductive+herb-drug+interactions%3A+Combining+pharmacophore+and+docking-based+rank+aggregation&doi=10.1155%2F2015%2F657159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Screening Ingredients from Herbs against Pregnane X Receptor in the Study of Inductive Herb-Drug Interactions: Combining Pharmacophore and Docking-Based Rank Aggregation</span></div><div class="casAuthors">Cui Zhijie; Kang Hong; Tang Kailin; Liu Qi; Cao Zhiwei; Zhu Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">657159</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The issue of herb-drug interactions has been widely reported.  Herbal ingredients can activate nuclear receptors and further induce the gene expression alteration of drug-metabolizing enzyme and/or transporter.  Therefore, the herb-drug interaction will happen when the herbs and drugs are coadministered.  This kind of interaction is called inductive herb-drug interactions.  Pregnane X Receptor (PXR) and drug-metabolizing target genes are involved in most of inductive herb-drug interactions.  To predict this kind of herb-drug interaction, the protocol could be simplified to only screen agonists of PXR from herbs because the relations of drugs with their metabolizing enzymes are well studied.  Here, a combinational in silico strategy of pharmacophore modelling and docking-based rank aggregation (DRA) was employed to identify PXR's agonists.  Firstly, 305 ingredients were screened out from 820 ingredients as candidate agonists of PXR with our pharmacophore model.  Secondly, DRA was used to rerank the result of pharmacophore filtering.  To validate our prediction, a curated herb-drug interaction database was built, which recorded 380 herb-drug interactions.  Finally, among the top 10 herb ingredients from the ranking list, 6 ingredients were reported to involve in herb-drug interactions.  The accuracy of our method is higher than other traditional methods.  The strategy could be extended to studies on other inductive herb-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFWR8GWePJMynGiHuhFGv8fW6udTcc2ebzPO8Js141vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287psVOrtA%253D%253D&md5=98b18daf73aebe11f776a2c7eec7321a</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1155%2F2015%2F657159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F657159%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DScreening%2520ingredients%2520from%2520herbs%2520against%2520pregnane%2520X%2520receptor%2520in%2520the%2520study%2520of%2520inductive%2520herb-drug%2520interactions%253A%2520Combining%2520pharmacophore%2520and%2520docking-based%2520rank%2520aggregation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D657159%26doi%3D10.1155%2F2015%2F657159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avolio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paonessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, F.</span></span> <span> </span><span class="NLM_article-title">Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4547</span>– <span class="NLM_lpage">4557</span>, <span class="refDoi"> DOI: 10.1021/jm050056+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050056%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4547-4557&issue=14&author=S.+Harperauthor=S.+Avolioauthor=B.+Paciniauthor=M.+Di+Filippoauthor=S.+Altamuraauthor=L.+Tomeiauthor=G.+Paonessaauthor=S.+Di+Marcoauthor=A.+Carfiauthor=C.+Giulianoauthor=J.+Padronauthor=F.+Bonelliauthor=G.+Migliaccioauthor=R.+De+Francescoauthor=R.+Lauferauthor=M.+Rowleyauthor=F.+Narjes&title=Potent+inhibitors+of+subgenomic+hepatitis+C+virus+RNA+replication+through+optimization+of+indole-N-acetamide+allosteric+inhibitors+of+the+viral+NS5B+polymerase&doi=10.1021%2Fjm050056%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase</span></div><div class="casAuthors">Harper, Steven; Avolio, Salvatore; Pacini, Barbara; Di Filippo, Marcello; Altamura, Sergio; Tomei, Licia; Paonessa, Giacomo; Di Marco, Stefania; Carfi, Andrea; Giuliano, Claudio; Padron, Julio; Bonelli, Fabio; Migliaccio, Giovanni; De Francesco, Raffaele; Laufer, Ralph; Rowley, Michael; Narjes, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4547-4557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand.  Compds. that block replication of subgenomic HCV RNA in liver cells are of interest because of their demonstrated antiviral effect in the clinic.  In followup to a recent report that indole-N-acetamides were potent allosteric inhibitors of the HCV NS5B polymerase enzyme, the optimization as cell-based inhibitors are described.  The crystal structure of I bound to NS5B was a guide in the design of a two-dimensional compd. array that highlighted that formally zwitterionic inhibitors have strong intracellular potency and that pregnane X receptor (PXR) activation (an undesired off-target activity) was linked to a structural feature of the inhibitor.  Optimized analogs devoid of PXR activation (EC50 = 127 nM) retain strong cell-based efficacy under high serum conditions and showed acceptable pharmacokinetics parameters in rat and dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPuXP6GW8l7bVg90H21EOLACvtfcHk0lgSd8ztk2GyUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVSltb8%253D&md5=eda6f08c07dd89cc20360c555a860bdf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjm050056%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050056%252B%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DAvolio%26aufirst%3DS.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DPaonessa%26aufirst%3DG.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DCarfi%26aufirst%3DA.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPadron%26aufirst%3DJ.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DPotent%2520inhibitors%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520through%2520optimization%2520of%2520indole-N-acetamide%2520allosteric%2520inhibitors%2520of%2520the%2520viral%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D14%26spage%3D4547%26epage%3D4557%26doi%3D10.1021%2Fjm050056%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes-Seeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiselle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacci-Daniel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3979</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2014.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24986660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jt7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3979-3985&issue=16&author=D.+Barnes-Seemanauthor=C.+Boiselleauthor=C.+Capacci-Danielauthor=R.+Chopraauthor=K.+Hoffmasterauthor=C.+T.+Jonesauthor=M.+Katoauthor=K.+Linauthor=S.+Maauthor=G.+Panauthor=L.+Shuauthor=J.+Wangauthor=L.+Whitemanauthor=M.+Xuauthor=R.+Zhengauthor=J.+Fu&title=Design+and+synthesis+of+lactam-thiophene+carboxylic+acids+as+potent+hepatitis+C+virus+polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors</span></div><div class="casAuthors">Barnes-Seeman, David; Boiselle, Carri; Capacci-Daniel, Christina; Chopra, Rajiv; Hoffmaster, Keith; Jones, Christopher T.; Kato, Mitsunori; Lin, Kai; Ma, Sue; Pan, Guoyu; Shu, Lei; Wang, Jianling; Whiteman, Leah; Xu, Mei; Zheng, Rui; Fu, Jiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3979-3985</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors.  Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor I.  This lead compd. has a favorable pharmacokinetic profile in rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYh3RQ4DmSFrVg90H21EOLACvtfcHk0lj2_PGesLNpiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jt7zM&md5=441c6d42d6947272b185499ab33ad64b</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DBoiselle%26aufirst%3DC.%26aulast%3DCapacci-Daniel%26aufirst%3DC.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DHoffmaster%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DC.%2BT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DShu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWhiteman%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520lactam-thiophene%2520carboxylic%2520acids%2520as%2520potent%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3979%26epage%3D3985%26doi%3D10.1016%2Fj.bmcl.2014.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilimoria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selliah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawgo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waal, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allosteric HCV NS5B inhibitors. 2. Lactam-containing thiophene carboxylates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=251-255&issue=2&author=P.+Liauthor=W.+Dorschauthor=D.+J.+Laufferauthor=D.+Bilimoriaauthor=N.+Chauretauthor=J.+J.+Courtauthor=S.+K.+Dasauthor=F.+Denisauthor=N.+Maniauthor=S.+Nanthakumarauthor=O.+Nicolasauthor=B.+G.+Raoauthor=S.+Ronkinauthor=S.+Selliahauthor=R.+S.+Shawgoauthor=R.+Stearnsauthor=Q.+Tangauthor=N.+D.+Waalauthor=J.+Green&title=Discovery+of+novel+allosteric+HCV+NS5B+inhibitors.+2.+Lactam-containing+thiophene+carboxylates&doi=10.1021%2Facsmedchemlett.6b00479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates</span></div><div class="casAuthors">Li, Pan; Dorsch, Warren; Lauffer, David J.; Bilimoria, Darius; Chauret, Nathalie; Court, John J.; Das, Sanjoy Kumar; Denis, Francois; Mani, Nagraj; Nanthakumar, Suganthini; Nicolas, Olivier; Rao, B. Govinda; Ronkin, Steven; Selliah, Subajini; Shawgo, Rebecca S.; Stearns, Ralph; Tang, Qing; Waal, Nathan D.; Green, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-255</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lomibuvir is a nonnucleoside, allosteric inhibitor of the hepatitis C virus NS5B polymerase with demonstrated clin. efficacy.  Further development efforts within this class of inhibitor focused on improving the antiviral activity and physicochem. and pharmacokinetic properties.  Recently, the authors reported the development of this series, leading to a compd. with comparable potency and an improved physicochem. profile relative.  Further exploration of the amino amide-derived side chain led to a series of lactam derivs., inspired by the x-ray crystal structure of related thiophene carboxylate inhibitors.  This series, exemplified by 12f, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[[(3S)-hexahydro-1-methyl-2-oxo-1H-azepin-3-yl][(trans-4-methylcyclohexyl)carbonyl]amino]-2-thiophenecarboxylic acid [1355038-54-8], provided 3-5-fold improvement in potency against HCV replication, as measured by replicon assays.  The synthesis, structure-activity relationships, in vitro ADME characterization, and in vivo evaluation of this novel series are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojwI0P91VScLVg90H21EOLACvtfcHk0lj2_PGesLNpiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSqsrg%253D&md5=6e9026adde8c5f5ca7e432da136c6992</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00479%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DDorsch%26aufirst%3DW.%26aulast%3DLauffer%26aufirst%3DD.%2BJ.%26aulast%3DBilimoria%26aufirst%3DD.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DDenis%26aufirst%3DF.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DNicolas%26aufirst%3DO.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DRonkin%26aufirst%3DS.%26aulast%3DSelliah%26aufirst%3DS.%26aulast%3DShawgo%26aufirst%3DR.%2BS.%26aulast%3DStearns%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DWaal%26aufirst%3DN.%2BD.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520allosteric%2520HCV%2520NS5B%2520inhibitors.%25202.%2520Lactam-containing%2520thiophene%2520carboxylates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D2%26spage%3D251%26epage%3D255%26doi%3D10.1021%2Facsmedchemlett.6b00479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanowski-Vosatka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieringer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3405</span>– <span class="NLM_lpage">3411</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2008.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18440811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3405-3411&issue=11&author=Y.+Zhuauthor=S.+H.+Olsonauthor=A.+Hermanowski-Vosatkaauthor=S.+Mundtauthor=K.+Shahauthor=M.+Springerauthor=R.+Thieringerauthor=S.+Wrightauthor=J.+Xiaoauthor=H.+Zokianauthor=J.+M.+Balkovec&title=4-Methyl-5-phenyl+triazoles+as+selective+inhibitors+of+11beta-hydroxysteroid+dehydrogenase+type+I&doi=10.1016%2Fj.bmcl.2008.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I</span></div><div class="casAuthors">Zhu, Yuping; Olson, Steven H.; Hermanowski-Vosatka, Anne; Mundt, Steven; Shah, Kashmira; Springer, Marty; Thieringer, Rolf; Wright, Samuel; Xiao, Jianying; Zokian, Hratch; Balkovec, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3405-3411</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">4-Methyl-5-phenyl-(1,2,4)-triazoles were identified as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).  They were active in vitro and in an in vivo mouse pharmacodynamic (PD) model.  The synthesis and structure activity relationships are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohs8pGTNpvTbVg90H21EOLACvtfcHk0lg31ldcCLvNfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yhsbY%253D&md5=321b69d6467e3fc67d1359f5edfd78cb</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DHermanowski-Vosatka%26aufirst%3DA.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSpringer%26aufirst%3DM.%26aulast%3DThieringer%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZokian%26aufirst%3DH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26atitle%3D4-Methyl-5-phenyl%2520triazoles%2520as%2520selective%2520inhibitors%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%2520I%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D11%26spage%3D3405%26epage%3D3411%26doi%3D10.1016%2Fj.bmcl.2008.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maletic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J.</span></span> <span> </span><span class="NLM_article-title">Substituted phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase Type 1</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2141</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2011.01.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21334894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFCkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2141-2145&issue=7&author=W.+Sunauthor=M.+Maleticauthor=S.+S.+Mundtauthor=K.+Shahauthor=H.+Zokianauthor=K.+Lyonsauthor=S.+T.+Waddellauthor=J.+Balkovec&title=Substituted+phenyl+triazoles+as+selective+inhibitors+of+11beta-hydroxysteroid+dehydrogenase+Type+1&doi=10.1016%2Fj.bmcl.2011.01.125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1</span></div><div class="casAuthors">Sun, Wanying; Maletic, Milana; Mundt, Steven S.; Shah, Kashmira; Zokian, Hratch; Lyons, Kathy; Waddell, Sherman T.; Balkovec, James</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2141-2145</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3-(Phenylcyclobutyl)-1,2,4-triazoles were identified as inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD1).  They were shown to be active in the mouse in vivo pharmacodynamic model (PD) for HSD1 but exhibited a potent off-target activation of the Pregnane X Receptor (PXR).  SAR studies and synthesis of analogs that led to the discovery of a selective HSD1 inhibitor are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfIHxLo32eC7Vg90H21EOLACvtfcHk0lg31ldcCLvNfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFCkurs%253D&md5=8711f6f6bc517ecd508b33ca8e303205</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.125%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DMaletic%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%2BS.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DZokian%26aufirst%3DH.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DWaddell%26aufirst%3DS.%2BT.%26aulast%3DBalkovec%26aufirst%3DJ.%26atitle%3DSubstituted%2520phenyl%2520triazoles%2520as%2520selective%2520inhibitors%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520Type%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D2141%26epage%3D2145%26doi%3D10.1016%2Fj.bmcl.2011.01.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercot, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guram, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komorowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veniant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7953</span>– <span class="NLM_lpage">7967</span>, <span class="refDoi"> DOI: 10.1021/jm801073z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801073z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7953-7967&issue=24&author=C.+Fotschauthor=M.+D.+Bartbergerauthor=E.+A.+Bercotauthor=M.+Chenauthor=R.+Cupplesauthor=M.+Emeryauthor=J.+Fretlandauthor=A.+Guramauthor=C.+Haleauthor=N.+Hanauthor=D.+Hickmanauthor=R.+W.+Hungateauthor=M.+Hayashiauthor=R.+Komorowskiauthor=Q.+Liuauthor=G.+Matsumotoauthor=D.+J.+St.+Jeanauthor=S.+Ursuauthor=M.+Veniantauthor=G.+Xuauthor=Q.+Yeauthor=C.+Yuanauthor=J.+Zhangauthor=X.+Zhangauthor=H.+Tuauthor=M.+Wang&title=Further+studies+with+the+2-amino-1%2C3-thiazol-4%285H%29-one+class+of+11beta-hydroxysteroid+dehydrogenase+type+1+inhibitors%3A+reducing+pregnane+X+receptor+activity+and+exploring+activity+in+a+monkey+pharmacodynamic+model&doi=10.1021%2Fjm801073z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model</span></div><div class="casAuthors">Fotsch, Christopher; Bartberger, Michael D.; Bercot, Eric A.; Chen, Michelle; Cupples, Rod; Emery, Maury; Fretland, Jenne; Guram, Anil; Hale, Clarence; Han, Nianhe; Hickman, Dean; Hungate, Randall W.; Hayashi, Michael; Komorowski, Renee; Liu, Qingyian; Matsumoto, Guy; St. Jean, David J.; Ursu, Stefania; Veniant, Murielle; Xu, Guifen; Ye, Qiuping; Yuan, Chester; Zhang, Jiandong; Zhang, Xiping; Tu, Hua; Wang, Minghan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7953-7967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. contg. the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).  One of our lead compds. from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR).  To try and mitigate the PXR activity, we prepd. analogs of our lead series that contained polar groups on the right-hand side of the thiazolone.  Several analogs contg. amides or alcs. appended to the C-5 position of the thiazolone showed a significant redn. in PXR activity.  Through these structure-activity efforts, a compd. contg. a tert-alc. group off the C-5 position, analog (S)-33a, was found to have an 11β-HSD1 Ki = 35 nM and negligible PXR activity.  Compd. (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11β-HSD1 activity after being orally administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRKNSaUFCaPrVg90H21EOLACvtfcHk0ljbn9-S_QUkiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb%252FK&md5=282c537175cf7d06a3dd99ddd73924aa</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fjm801073z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801073z%26sid%3Dliteratum%253Aachs%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBercot%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGuram%26aufirst%3DA.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DN.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHungate%26aufirst%3DR.%2BW.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DKomorowski%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMatsumoto%26aufirst%3DG.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DUrsu%26aufirst%3DS.%26aulast%3DVeniant%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DFurther%2520studies%2520with%2520the%25202-amino-1%252C3-thiazol-4%25285H%2529-one%2520class%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520inhibitors%253A%2520reducing%2520pregnane%2520X%2520receptor%2520activity%2520and%2520exploring%2520activity%2520in%2520a%2520monkey%2520pharmacodynamic%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7953%26epage%3D7967%26doi%3D10.1021%2Fjm801073z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villemure, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1801</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2009.01.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19217779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1797-1801&issue=6&author=Y.+Rewauthor=D.+L.+McMinnauthor=Z.+Wangauthor=X.+Heauthor=R.+W.+Hungateauthor=J.+C.+Jaenauthor=A.+Sudomauthor=D.+Sunauthor=H.+Tuauthor=S.+Ursuauthor=E.+Villemureauthor=N.+P.+Walkerauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+and+optimization+of+piperidyl+benzamide+derivatives+as+a+novel+class+of+11beta-HSD1+inhibitors&doi=10.1016%2Fj.bmcl.2009.01.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors</span></div><div class="casAuthors">Rew, Yosup; McMinn, Dustin L.; Wang, Zhulun; He, Xiao; Hungate, Randall W.; Jaen, Juan C.; Sudom, Athena; Sun, Daqing; Tu, Hua; Ursu, Stefania; Villemure, Elisia; Walker, Nigel P. C.; Yan, Xuelei; Ye, Qiuping; Powers, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1797-1801</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Discovery and optimization of a piperidyl benzamide series of 11β-HSD1 inhibitors is described.  This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor soly., limited in vivo exposure, and in vitro cytotoxicity issues obsd. with the cyclohexyl benzamide structures.  These efforts led to the discovery of piperidyl benzamide 15 which features improved properties over the cyclohexyl benzamide derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaYVcvPuFyJLVg90H21EOLACvtfcHk0ljctA84qaBGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltbw%253D&md5=3ffc3c0dadf23d90cc91a247a0e97bb4</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.058%26sid%3Dliteratum%253Aachs%26aulast%3DRew%26aufirst%3DY.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHungate%26aufirst%3DR.%2BW.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTu%26aufirst%3DH.%26aulast%3DUrsu%26aufirst%3DS.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DWalker%26aufirst%3DN.%2BP.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520piperidyl%2520benzamide%2520derivatives%2520as%2520a%2520novel%2520class%2520of%252011beta-HSD1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D6%26spage%3D1797%26epage%3D1801%26doi%3D10.1016%2Fj.bmcl.2009.01.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayeem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrity, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponticiello, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 1,2,4-triazolopyridines as inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1021/ml500144h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500144h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=803-808&issue=7&author=J.+Liauthor=L.+J.+Kennedyauthor=H.+Wangauthor=J.+J.+Liauthor=S.+J.+Walkerauthor=Z.+Hongauthor=S.+P.+O%E2%80%99Connorauthor=A.+Nayeemauthor=D.+M.+Camacauthor=P.+E.+Morinauthor=S.+Sheriffauthor=M.+Wangauthor=T.+Harperauthor=R.+Gollaauthor=R.+Seethalaauthor=T.+Harrityauthor=R.+P.+Ponticielloauthor=N.+N.+Morganauthor=J.+R.+Taylorauthor=R.+Zeboauthor=D.+A.+Gordonauthor=J.+A.+Robl&title=Optimization+of+1%2C2%2C4-triazolopyridines+as+inhibitors+of+human+11beta-hydroxysteroid+dehydrogenase+type+1+%2811beta-HSD-1%29&doi=10.1021%2Fml500144h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)</span></div><div class="casAuthors">Li, Jun; Kennedy, Lawrence J.; Wang, Haixia; Li, James J.; Walker, Steven J.; Hong, Zhenqiu; O'Connor, Stephen P.; Nayeem, Akbar; Camac, Daniel M.; Morin, Paul E.; Sheriff, Steven; Wang, Mengmeng; Harper, Timothy; Golla, Rajasree; Seethala, Ramakrishna; Harrity, Thomas; Ponticiello, Randolph P.; Morgan, Nathan N.; Taylor, Joseph R.; Zebo, Rachel; Gordon, David A.; Robl, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small alkyl groups and spirocyclic-arom. rings directly attached to the left side and right side of the 1,2,4-triazolopyridines (TZP), resp., were found to be potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase-type 1 (11β-HSD-1) enzyme. 3-(1-(4-Chlorophenyl)cyclopropyl)-8-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridine (9f) was identified as a potent inhibitor of the 11β-HSD-1 enzyme with reduced Pregnane-X receptor (PXR) transactivation activity.  The binding orientation of this TZP series was revealed by X-ray crystallog. structure studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8M6fo9BKqH7Vg90H21EOLACvtfcHk0ljctA84qaBGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOgu7o%253D&md5=0a64d071b7a7c0e0c6d54d91d740f427</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fml500144h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500144h%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DL.%2BJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%2BJ.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BP.%26aulast%3DNayeem%26aufirst%3DA.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DT.%26aulast%3DGolla%26aufirst%3DR.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DHarrity%26aufirst%3DT.%26aulast%3DPonticiello%26aufirst%3DR.%2BP.%26aulast%3DMorgan%26aufirst%3DN.%2BN.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DZebo%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26atitle%3DOptimization%2520of%25201%252C2%252C4-triazolopyridines%2520as%2520inhibitors%2520of%2520human%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520%252811beta-HSD-1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D7%26spage%3D803%26epage%3D808%26doi%3D10.1021%2Fml500144h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sa, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-((R)-4-(2-fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A highly potent, selective, and orally bioavailable inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10189</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01122</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01122" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10176-10189&issue=22&author=J.+H.+Ryuauthor=J.+A.+Leeauthor=S.+Kimauthor=Y.+A.+Shinauthor=J.+Yangauthor=H.+Y.+Hanauthor=H.+J.+Sonauthor=Y.+H.+Kimauthor=J.+H.+Saauthor=J.+S.+Kimauthor=J.+Leeauthor=J.+Leeauthor=H.+G.+Park&title=Discovery+of+2-%28%28R%29-4-%282-fluoro-4-%28methylsulfonyl%29phenyl%29-2-methylpiperazin-1-yl%29-N-%28%281R%2C2s%2C3S%2C5S%2C7S%29-5-hydroxyadamantan-2-yl%29pyrimidine-4-carboxamide+%28SKI2852%29%3A+A+highly+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+11beta-hydroxysteroid+dehydrogenase+type+1+%2811beta-HSD1%29&doi=10.1021%2Facs.jmedchem.6b01122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</span></div><div class="casAuthors">Ryu, Je Ho; Lee, Jung A.; Kim, Shinae; Shin, Young Ah; Yang, Jewon; Han, Hye Young; Son, Hyun Joo; Kim, Yong Hyuk; Sa, Joon Ho; Kim, Jae-Sun; Lee, Jungeun; Lee, Jeeyeon; Park, Hyeung-geun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10176-10189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of picolinamide- and pyrimidine-4-carboxamide-based inhibitors of 11β-hydroxysteroid dehydrogenase type 1 was synthesized and evaluated to optimize the lead compd.  The combination of the replacement of a pyridine ring of the lead compd with a pyrimidine ring and the introduction of an addnl. fluorine substituent at the 2-position of the Ph ring resulted in the discovery of a potent, selective, and orally bioavailable inhibitor, SKI2852, which demonstrated no CYP and PXR liabilities, excellent PK profiles across species, and highly potent and sustainable PD activity.  Repeated oral administration of SKI2852 significantly reduced blood glucose and HbA1c levels and improved the lipid profiles in ob/ob mice.  Moreover, the HbA1c-lowering effect of metformin was synergistically enhanced in combination with SKI2852.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqgyIMAhNv7rVg90H21EOLACvtfcHk0liujJLE1MamMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgtrzI&md5=9ecc2500a3f4ab996d0416395765a7bf</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01122%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%2BY.%26aulast%3DSon%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSa%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DH.%2BG.%26atitle%3DDiscovery%2520of%25202-%2528%2528R%2529-4-%25282-fluoro-4-%2528methylsulfonyl%2529phenyl%2529-2-methylpiperazin-1-yl%2529-N-%2528%25281R%252C2s%252C3S%252C5S%252C7S%2529-5-hydroxyadamantan-2-yl%2529pyrimidine-4-carboxamide%2520%2528SKI2852%2529%253A%2520A%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520%252811beta-HSD1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10176%26epage%3D10189%26doi%3D10.1021%2Facs.jmedchem.6b01122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPardo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span> <span> </span><span class="NLM_article-title">A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2007.11.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18240388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=682-687&issue=2&author=D.+M.+Fengauthor=R.+M.+DiPardoauthor=J.+M.+Waiauthor=R.+K.+Changauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bockauthor=S.+D.+Kuduk&title=A+new+class+of+bradykinin+B1+receptor+antagonists+with+high+oral+bioavailability+and+minimal+PXR+activity&doi=10.1016%2Fj.bmcl.2007.11.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity</span></div><div class="casAuthors">Feng, Dong-Mei; DiPardo, Robert M.; Wai, Jenny M.; Chang, Ronald K.; Di Marco, Christina N.; Murphy, Kathy L.; Ransom, Richard W.; Reiss, Duane R.; Tang, Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas J.; Bock, Mark G.; Kuduk, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and synthesis of a novel class of human bradykinin B1 antagonists featuring difluoroethyl ether and isoxazole carboxamide moieties are disclosed.  Compd. I displayed excellent pharmacokinetic properties, efficient ex vivo receptor occupancy, and low potential for P 450 induction via PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGlnJu6rHabVg90H21EOLACvtfcHk0liujJLE1MamMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWltQ%253D%253D&md5=0935638967e236a493bb58690625a313</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.057%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26atitle%3DA%2520new%2520class%2520of%2520bradykinin%2520B1%2520receptor%2520antagonists%2520with%2520high%2520oral%2520bioavailability%2520and%2520minimal%2520PXR%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D2%26spage%3D682%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2007.11.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reger, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondiskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmick
Graufelds, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uebele, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renger, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,4-disubstituted quinazolin-2-ones as T-type calcium channel antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1021/ml100004r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100004r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=75-79&issue=2&author=J.+C.+Barrowauthor=K.+E.+Rittleauthor=T.+S.+Regerauthor=Z.+Q.+Yangauthor=P.+Bondiskeyauthor=G.+B.+McGaugheyauthor=M.+G.+Bockauthor=G.+D.+Hartmanauthor=C.+Tangauthor=J.+Ballardauthor=Y.+Kuoauthor=T.+Prueksaritanontauthor=C.+E.+Nussauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=R.+L.+Krausauthor=Y.+Liauthor=M.+J.+Marinoauthor=V.+Kuzmick%0AGraufeldsauthor=V.+N.+Uebeleauthor=J.+J.+Renger&title=Discovery+of+4%2C4-disubstituted+quinazolin-2-ones+as+T-type+calcium+channel+antagonists&doi=10.1021%2Fml100004r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists</span></div><div class="casAuthors">Barrow, James C.; Rittle, Kenneth E.; Reger, Thomas S.; Yang, Zhi-Qiang; Bondiskey, Phung; McGaughey, Georgia B.; Bock, Mark G.; Hartman, George D.; Tang, Cuyue; Ballard, Jeanine; Kuo, Yuhsin; Prueksaritanont, Thomayant; Nuss, Cindy E.; Doran, Scott M.; Fox, Steven V.; Garson, Susan L.; Kraus, Richard L.; Li, Yuxing; Marino, Michael J.; Graufelds, Valerie Kuzmick; Uebele, Victor N.; Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-79</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of quinazolinone T-type calcium channel antagonists have been prepd. and evaluated using in vitro and in vivo assays.  Optimization of the screening hit 3 (I) by modifications of the 3- and 4-positions of the quinazolinone ring afforded potent and selective antagonists that displayed in vivo central nervous system efficacy in epilepsy and tremor models, as well as significant effects on rat active wake as measured by electrocorticogram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4CrnH3JZ9dbVg90H21EOLACvtfcHk0liujJLE1MamMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlt74%253D&md5=5a5a073bcadfd16f2c80c56b4a077b82</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Fml100004r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100004r%26sid%3Dliteratum%253Aachs%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DReger%26aufirst%3DT.%2BS.%26aulast%3DYang%26aufirst%3DZ.%2BQ.%26aulast%3DBondiskey%26aufirst%3DP.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DNuss%26aufirst%3DC.%2BE.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DKraus%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DKuzmick%2BGraufelds%26aufirst%3DV.%26aulast%3DUebele%26aufirst%3DV.%2BN.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%25204%252C4-disubstituted%2520quinazolin-2-ones%2520as%2520T-type%2520calcium%2520channel%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26issue%3D2%26spage%3D75%26epage%3D79%26doi%3D10.1021%2Fml100004r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reger, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondiskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uebele, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renger, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5147</span>– <span class="NLM_lpage">5152</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20673719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5147-5152&issue=17&author=K.+A.+Schlegelauthor=Z.+Q.+Yangauthor=T.+S.+Regerauthor=Y.+Shuauthor=R.+Cubeauthor=K.+E.+Rittleauthor=P.+Bondiskeyauthor=M.+G.+Bockauthor=G.+D.+Hartmanauthor=C.+Tangauthor=J.+Ballardauthor=Y.+Kuoauthor=T.+Prueksaritanontauthor=C.+E.+Nussauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=R.+L.+Krausauthor=Y.+Liauthor=V.+N.+Uebeleauthor=J.+J.+Rengerauthor=J.+C.+Barrow&title=Discovery+and+expanded+SAR+of+4%2C4-disubstituted+quinazolin-2-ones+as+potent+T-type+calcium+channel+antagonists&doi=10.1016%2Fj.bmcl.2010.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists</span></div><div class="casAuthors">Schlegel, Kelly-Ann S.; Yang, Zhi-Qiang; Reger, Thomas S.; Shu, Youheng; Cube, Rowena; Rittle, Kenneth E.; Bondiskey, Phung; Bock, Mark G.; Hartman, George D.; Tang, Cuyue; Ballard, Jeanine; Kuo, Yuhsin; Prueksaritanont, Thomayant; Nuss, Cindy E.; Doran, Scott M.; Fox, Steven V.; Garson, Susan L.; Kraus, Richard L.; Li, Yuxing; Uebele, Victor N.; Renger, John J.; Barrow, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5147-5152</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported.  Based on lead compds. I and II, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified III as a potent T-type Ca2+ channel antagonist with minimized PXR activation.  In vivo, III suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptfwYqPK3qq7Vg90H21EOLACvtfcHk0lgGn1gK0Xr-Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr7P&md5=d557eccc05fcb93de8d2d59c9bcea1a8</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DSchlegel%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DZ.%2BQ.%26aulast%3DReger%26aufirst%3DT.%2BS.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DCube%26aufirst%3DR.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DBondiskey%26aufirst%3DP.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DNuss%26aufirst%3DC.%2BE.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DKraus%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DUebele%26aufirst%3DV.%2BN.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520expanded%2520SAR%2520of%25204%252C4-disubstituted%2520quinazolin-2-ones%2520as%2520potent%2520T-type%2520calcium%2520channel%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D17%26spage%3D5147%26epage%3D5152%26doi%3D10.1016%2Fj.bmcl.2010.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frennesson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span> <span> </span><span class="NLM_article-title">SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.01.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20153189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitleht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1744-1748&issue=5&author=K.+Zimmermannauthor=M.+D.+Wittmanauthor=M.+G.+Saulnierauthor=U.+Velaparthiauthor=X.+Sangauthor=D.+B.+Frennessonauthor=C.+Struzynskiauthor=S.+P.+Seitzauthor=L.+Heauthor=J.+M.+Carboniauthor=A.+Liauthor=A.+F.+Greerauthor=M.+Gottardisauthor=R.+M.+Attarauthor=Z.+Yangauthor=P.+Balimaneauthor=L.+N.+Discenzaauthor=F.+Y.+Leeauthor=M.+Sinzauthor=S.+Kimauthor=D.+Vyas&title=SAR+of+PXR+transactivation+in+benzimidazole-based+IGF-1R+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors</span></div><div class="casAuthors">Zimmermann, Kurt; Wittman, Mark D.; Saulnier, Mark G.; Velaparthi, Upender; Sang, Xiaopeng; Frennesson, David B.; Struzynski, Charles; Seitz, Steven P.; He, Liqi; Carboni, Joan M.; Li, Aixin; Greer, Ann F.; Gottardis, Marco; Attar, Ricardo M.; Yang, Zheng; Balimane, Praveen; Discenza, Lorell N.; Lee, Francis Y.; Sinz, Michael; Kim, Sean; Vyas, Dolatrai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1744-1748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SAR of PXR transactivation by 3-(benzimidazol-2-yl)-pyridine-2-one based ATP competitive inhibitors of Insulin-like Growth Factor 1 Receptor kinase (IGF-1R) is discussed.  Compds. without PXR transactivation, with in vivo antitumor activity, reduced protein binding and improved oral exposure are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWYqNCYfwPbVg90H21EOLACvtfcHk0lgGn1gK0Xr-Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitleht7s%253D&md5=ea60b27acff314cef6744d8b496c45cd</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.087%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DFrennesson%26aufirst%3DD.%2BB.%26aulast%3DStruzynski%26aufirst%3DC.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%2BF.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DSAR%2520of%2520PXR%2520transactivation%2520in%2520benzimidazole-based%2520IGF-1R%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D5%26spage%3D1744%26epage%3D1748%26doi%3D10.1016%2Fj.bmcl.2010.01.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5897</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/jm800832q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&issue=19&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperidin-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity&doi=10.1021%2Fjm800832q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity</span></div><div class="casAuthors">Velaparthi, Upender; Wittman, Mark; Liu, Peiying; Carboni, Joan M.; Lee, Francis Y.; Attar, Ricardo; Balimane, Praveen; Clarke, Wendy; Sinz, Michael W.; Hurlburt, Warren; Patel, Karishma; Discenza, Lorell; Kim, Sean; Gottardis, Marco; Greer, Ann; Li, Aixin; Saulnier, Mark; Yang, Zheng; Zimmermann, Kurt; Trainor, George; Vyas, Dolatrai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5897-5900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity.  This lead compd. was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PXR transactivation, poor aq. soly., and high plasma protein binding.  Herein we disclose the evolution of this chemotype to address these issues.  This effort led to 10 (BMS-695735, I), which exhibits improved ADME properties, a low risk for drug-drug interactions, and in vivo efficacy in multiple xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMOvd77Lq3rVg90H21EOLACvtfcHk0lgIZ654PMfTkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3I&md5=524b5a89b9e550d7871d462843224194</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperidin-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D19%26spage%3D5897%26epage%3D5900%26doi%3D10.1021%2Fjm800832q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercovici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfmacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torhan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2519</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2009.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19339177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslyiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2519-2523&issue=9&author=G.+D.+Hoauthor=J.+Anthesauthor=A.+Bercoviciauthor=J.+P.+Caldwellauthor=K.+C.+Chengauthor=X.+Cuiauthor=A.+Fawziauthor=X.+Fernandezauthor=W.+J.+Greenleeauthor=J.+Heyauthor=W.+Korfmacherauthor=S.+X.+Luauthor=R.+L.+McLeodauthor=F.+Ngauthor=A.+S.+Torhanauthor=Z.+Tanauthor=D.+Tulshianauthor=G.+B.+Vartyauthor=X.+Xuauthor=H.+Zhang&title=The+discovery+of+tropane+derivatives+as+nociceptin+receptor+ligands+for+the+management+of+cough+and+anxiety&doi=10.1016%2Fj.bmcl.2009.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety</span></div><div class="casAuthors">Ho, Ginny D.; Anthes, John; Bercovici, Ana; Caldwell, John P.; Cheng, Kuo-Chi; Cui, Xiaoming; Fawzi, Ahmad; Fernandez, Xiomara; Greenlee, William J.; Hey, John; Korfmacher, Walter; Lu, Sherry X.; McLeod, Robbie L.; Ng, Fay; Torhan, April Smith; Tan, Zheng; Tulshian, Deen; Varty, Geoffrey B.; Xu, Xiaoying; Zhang, Hongtao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2519-2523</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter, we present the synthesis and highlight the structure-activity relationship of tropane (8-methyl-8-azabicyclo[3.2.1]octane) derivs. culminating in the identification of I (Ar = phenyl) and I (Ar = 4-fluorophenyl) as potent and orally active antitussive and anxiolytic agents.  The in vitro and in vivo activities, pharmacokinetic profile, and the hPXR activity, which predicts the potential 3A4 induction in human, are disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqeKhX1PcTALVg90H21EOLACvtfcHk0lgIlfLLzMCjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslyiur4%253D&md5=46923d57e072bb7e55c64107986df87f</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DG.%2BD.%26aulast%3DAnthes%26aufirst%3DJ.%26aulast%3DBercovici%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DFawzi%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DX.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHey%26aufirst%3DJ.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DMcLeod%26aufirst%3DR.%2BL.%26aulast%3DNg%26aufirst%3DF.%26aulast%3DTorhan%26aufirst%3DA.%2BS.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520tropane%2520derivatives%2520as%2520nociceptin%2520receptor%2520ligands%2520for%2520the%2520management%2520of%2520cough%2520and%2520anxiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D9%26spage%3D2519%26epage%3D2523%26doi%3D10.1016%2Fj.bmcl.2009.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aaron, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toteva, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4607</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20594845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4607-4610&issue=15&author=J.+A.+Kaizermanauthor=W.+Aaronauthor=S.+Anauthor=R.+Austinauthor=M.+Brownauthor=A.+Chongauthor=T.+Huangauthor=R.+Hungateauthor=B.+Jiangauthor=M.+G.+Johnsonauthor=G.+Leeauthor=B.+S.+Lucasauthor=J.+Orfauthor=M.+Rongauthor=M.+M.+Totevaauthor=D.+Wickramasingheauthor=G.+Xuauthor=Q.+Yeauthor=W.+Zhongauthor=D.+L.+McMinn&title=Addressing+PXR+liabilities+of+phthalazine-based+hedgehog%2Fsmoothened+antagonists+using+novel+pyridopyridazines&doi=10.1016%2Fj.bmcl.2010.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines</span></div><div class="casAuthors">Kaizerman, Jacob A.; Aaron, Wade; An, Songzhu; Austin, Richard; Brown, Matt; Chong, Angela; Huang, Tom; Hungate, Randall; Jiang, Ben; Johnson, Michael G.; Lee, Gary; Lucas, Brian S.; Orf, Jessica; Rong, Minqing; Toteva, Maria M.; Wickramasinghe, Dineli; Xu, Guifen; Ye, Qiuping; Zhong, Wendy; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4607-4610</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyridopyridazine antagonists of the hedgehog signaling pathway are described.  Designed to optimize our previously described phthalazine smoothened antagonists, a representative compd. eliminates a PXR liability while retaining potency and in vitro metabolic stability.  Moreover, the compd. has improved efficacy in a hedgehog/smoothened signaling mouse pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXaldfRtLH7Vg90H21EOLACvtfcHk0lgIlfLLzMCjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSkur0%253D&md5=6927105e59b3859aea28cccefe464c3a</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DKaizerman%26aufirst%3DJ.%2BA.%26aulast%3DAaron%26aufirst%3DW.%26aulast%3DAn%26aufirst%3DS.%26aulast%3DAustin%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DChong%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLucas%26aufirst%3DB.%2BS.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DM.%26aulast%3DToteva%26aufirst%3DM.%2BM.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DAddressing%2520PXR%2520liabilities%2520of%2520phthalazine-based%2520hedgehog%252Fsmoothened%2520antagonists%2520using%2520novel%2520pyridopyridazines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D15%26spage%3D4607%26epage%3D4610%26doi%3D10.1016%2Fj.bmcl.2010.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMauro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feric Bojic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornecook, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngblood, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Sulfonamides as selective Na<sub>V</sub>1.7 inhibitors: Optimizing potency and pharmacokinetics while mitigating metabolic liabilities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5969</span>– <span class="NLM_lpage">5989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01851</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01851" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5969-5989&issue=14&author=M.+M.+Weissauthor=T.+A.+Dineenauthor=I.+E.+Marxauthor=S.+Altmannauthor=A.+Boezioauthor=H.+Bregmanauthor=M.+Chu-Moyerauthor=E.+F.+DiMauroauthor=E.+Feric+Bojicauthor=R.+S.+Fotiauthor=H.+Gaoauthor=R.+Graceffaauthor=H.+Gunaydinauthor=A.+Guzman-Perezauthor=H.+Huangauthor=L.+Huangauthor=M.+Jaroshauthor=T.+Kornecookauthor=C.+R.+Kreimanauthor=J.+Liguttiauthor=D.+S.+Laauthor=M.+J.+Linauthor=D.+Liuauthor=B.+D.+Moyerauthor=H.+N.+Nguyenauthor=E.+A.+Petersonauthor=P.+E.+Roseauthor=K.+Tabornauthor=B.+D.+Youngbloodauthor=V.+Yuauthor=R.+T.+Fremeau&title=Sulfonamides+as+selective+NaV1.7+inhibitors%3A+Optimizing+potency+and+pharmacokinetics+while+mitigating+metabolic+liabilities&doi=10.1021%2Facs.jmedchem.6b01851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities</span></div><div class="casAuthors">Weiss, Matthew M.; Dineen, Thomas A.; Marx, Isaac E.; Altmann, Steven; Boezio, Alessandro; Bregman, Howard; Chu-Moyer, Margaret; DiMauro, Erin F.; Feric Bojic, Elma; Foti, Robert S.; Gao, Hua; Graceffa, Russell; Gunaydin, Hakan; Guzman-Perez, Angel; Huang, Hongbing; Huang, Liyue; Jarosh, Michael; Kornecook, Thomas; Kreiman, Charles R.; Ligutti, Joseph; La, Daniel S.; Lin, Min-Hwa Jasmine; Liu, Dong; Moyer, Bryan D.; Nguyen, Hanh N.; Peterson, Emily A.; Rose, Paul E.; Taborn, Kristin; Youngblood, Beth D.; Yu, Violeta; Fremeau, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5969-5989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several reports have recently emerged regarding the identification of heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms.  The optimization of a series of internal NaV1.7 leads that address a no. of metabolic liabilities including bioactivation, PXR activation, as well as CYP3A4 induction and inhibition led to the identification of potent and selective inhibitors that demonstrated favorable pharmacokinetic profiles and were devoid of the aforementioned liabilities.  The key to achieving this within a series prone to transporter-mediated clearance was the identification of a small range of optimal cLogD values and the discovery of subtle PXR SAR that was not lipophilicity dependent.  This enabled the identification of compd. 20, which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal of histamine-induced scratching bouts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovsPC2UZpxsbVg90H21EOLACvtfcHk0liQJ_1T8aJ9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtbw%253D&md5=6333a6b936e48f9d18cf9df10ea12853</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01851%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DAltmann%26aufirst%3DS.%26aulast%3DBoezio%26aufirst%3DA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DChu-Moyer%26aufirst%3DM.%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DFeric%2BBojic%26aufirst%3DE.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DJarosh%26aufirst%3DM.%26aulast%3DKornecook%26aufirst%3DT.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DTaborn%26aufirst%3DK.%26aulast%3DYoungblood%26aufirst%3DB.%2BD.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26atitle%3DSulfonamides%2520as%2520selective%2520NaV1.7%2520inhibitors%253A%2520Optimizing%2520potency%2520and%2520pharmacokinetics%2520while%2520mitigating%2520metabolic%2520liabilities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5969%26epage%3D5989%26doi%3D10.1021%2Facs.jmedchem.6b01851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Able, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMauro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feric
Bojic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornecook, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milgram, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescourio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparling, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeoman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span> <span> </span><span class="NLM_article-title">Sulfonamides as selective Na<sub>V</sub>1.7 inhibitors: Optimizing potency, pharmacokinetics, and metabolic properties to obtain atropisomeric quinolinone (AM-0466) that affords robust in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5990</span>– <span class="NLM_lpage">6017</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5990-6017&issue=14&author=R.+F.+Graceffaauthor=A.+A.+Boezioauthor=J.+Ableauthor=S.+Altmannauthor=L.+M.+Berryauthor=C.+Boezioauthor=J.+R.+Butlerauthor=M.+Chu-Moyerauthor=M.+Cookeauthor=E.+F.+DiMauroauthor=T.+A.+Dineenauthor=E.+Feric%0ABojicauthor=R.+S.+Fotiauthor=R.+T.+Fremeauauthor=A.+Guzman-Perezauthor=H.+Gaoauthor=H.+Gunaydinauthor=H.+Huangauthor=L.+Huangauthor=C.+Ilchauthor=M.+Jaroshauthor=T.+Kornecookauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=J.+Liguttiauthor=B.+C.+Milgramauthor=M.+J.+Linauthor=I.+E.+Marxauthor=H.+N.+Nguyenauthor=E.+A.+Petersonauthor=G.+Rescourioauthor=J.+Robertsauthor=L.+Schenkelauthor=R.+Shimanovichauthor=B.+A.+Sparlingauthor=J.+Stellwagenauthor=K.+Tabornauthor=K.+R.+Vaidaauthor=J.+Wangauthor=J.+Yeomanauthor=V.+Yuauthor=D.+Zhuauthor=B.+D.+Moyerauthor=M.+M.+Weiss&title=Sulfonamides+as+selective+NaV1.7+inhibitors%3A+Optimizing+potency%2C+pharmacokinetics%2C+and+metabolic+properties+to+obtain+atropisomeric+quinolinone+%28AM-0466%29+that+affords+robust+in+vivo+activity&doi=10.1021%2Facs.jmedchem.6b01850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity</span></div><div class="casAuthors">Graceffa, Russell F.; Boezio, Alessandro A.; Able, Jessica; Altmann, Steven; Berry, Loren M.; Boezio, Christiane; Butler, John R.; Chu-Moyer, Margaret; Cooke, Melanie; DiMauro, Erin F.; Dineen, Thomas A.; Feric Bojic, Elma; Foti, Robert S.; Fremeau, Robert T.; Guzman-Perez, Angel; Gao, Hua; Gunaydin, Hakan; Huang, Hongbing; Huang, Liyue; Ilch, Christopher; Jarosh, Michael; Kornecook, Thomas; Kreiman, Charles R.; La, Daniel S.; Ligutti, Joseph; Milgram, Benjamin C.; Lin, Min-Hwa Jasmine; Marx, Isaac E.; Nguyen, Hanh N.; Peterson, Emily A.; Rescourio, Gwen; Roberts, John; Schenkel, Laurie; Shimanovich, Roman; Sparling, Brian A.; Stellwagen, John; Taborn, Kristin; Vaida, Karina R.; Wang, Jean; Yeoman, John; Yu, Violeta; Zhu, Dawn; Moyer, Bryan D.; Weiss, Matthew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5990-6017</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of its strong genetic validation, NaV1.7 has attracted significant interest as a target for the treatment of pain.  We have previously reported on a no. of structurally distinct bicyclic heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms.  Herein, we report the discovery and optimization of a series of atropisomeric quinolinone sulfonamide inhibitors [Bicyclic sulfonamide compds. as sodium channel inhibitors and their prepn. WO 2014201206, 2014] of NaV1.7, which demonstrate nanomolar inhibition of NaV1.7 and exhibit high levels of selectivity over other sodium channel isoforms.  After optimization of metabolic and pharmacokinetic properties, including PXR activation, CYP2C9 inhibition, and CYP3A4 TDI, several compds. were advanced into in vivo target engagement and efficacy models.  When tested in mice, compd. 39 (AM-0466) demonstrated robust pharmacodynamic activity in a NaV1.7-dependent model of histamine-induced pruritus (itch) and addnl. in a capsaicin-induced nociception model of pain without any confounding effect in open-field activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ofeMhgMFqbVg90H21EOLACvtfcHk0liQJ_1T8aJ9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKltr4%253D&md5=5b48afe24a97290ea5e44a71deaa0303</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01850%26sid%3Dliteratum%253Aachs%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAble%26aufirst%3DJ.%26aulast%3DAltmann%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DButler%26aufirst%3DJ.%2BR.%26aulast%3DChu-Moyer%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DM.%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DFeric%2BBojic%26aufirst%3DE.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DIlch%26aufirst%3DC.%26aulast%3DJarosh%26aufirst%3DM.%26aulast%3DKornecook%26aufirst%3DT.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DMilgram%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DRescourio%26aufirst%3DG.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DSchenkel%26aufirst%3DL.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSparling%26aufirst%3DB.%2BA.%26aulast%3DStellwagen%26aufirst%3DJ.%26aulast%3DTaborn%26aufirst%3DK.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYeoman%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26atitle%3DSulfonamides%2520as%2520selective%2520NaV1.7%2520inhibitors%253A%2520Optimizing%2520potency%252C%2520pharmacokinetics%252C%2520and%2520metabolic%2520properties%2520to%2520obtain%2520atropisomeric%2520quinolinone%2520%2528AM-0466%2529%2520that%2520affords%2520robust%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5990%26epage%3D6017%26doi%3D10.1021%2Facs.jmedchem.6b01850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&issue=4&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cuiauthor=P.+Chenauthor=K.+Straleyauthor=E.+Tobinauthor=F.+Wangauthor=M.+D.+Davidauthor=V.+Penard-Lacroniqueauthor=C.+Quivoronauthor=V.+Saadaauthor=S.+de+Bottonauthor=S.+Grossauthor=L.+Dangauthor=H.+Yangauthor=L.+Utleyauthor=Y.+Chenauthor=H.+Kimauthor=S.+Jinauthor=Z.+Guauthor=G.+Yaoauthor=Z.+Luoauthor=X.+Lvauthor=C.+Fangauthor=L.+Yanauthor=A.+Olaharskiauthor=L.+Silvermanauthor=S.+Billerauthor=S.+M.+Suauthor=K.+Yen&title=Discovery+of+AG-120+%28Ivosidenib%29%3A+A+first-in-class+mutant+IDH1+inhibitor+for+the+treatment+of+IDH1+mutant+cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0liU3zpCvlA99w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DTobin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DUtley%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DOlaharski%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520AG-120%2520%2528Ivosidenib%2529%253A%2520A%2520first-in-class%2520mutant%2520IDH1%2520inhibitor%2520for%2520the%2520treatment%2520of%2520IDH1%2520mutant%2520cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1007/s00280-020-04064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00280-020-04064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32296873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=959-968&issue=5&author=B.+Fanauthor=D.+Daiauthor=C.+D.+DiNardoauthor=E.+Steinauthor=S.+de+Bottonauthor=E.+C.+Attarauthor=H.+Liuauthor=G.+Liuauthor=I.+Lemieuxauthor=S.+V.+Agrestaauthor=H.+Yang&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+ivosidenib+in+patients+with+advanced+hematologic+malignancies+with+an+IDH1+mutation&doi=10.1007%2Fs00280-020-04064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation</span></div><div class="casAuthors">Fan, Bin; Dai, David; DiNardo, Courtney D.; Stein, Eytan; de Botton, Stephane; Attar, Eyal C.; Liu, Hua; Liu, Guowen; Lemieux, Ian; Agresta, Samuel V.; Yang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Isocitrate dehydrogenase (IDH) mutations lead to formation of the oncometabolite 2-hydroxyglutarate (2-HG), which is elevated in several solid and liq. tumors.  Ivosidenib (AG-120) is a targeted, potent, oral inhibitor of the mutant IDH1 protein.  We describe detailed pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematol. malignancies with an IDH1 mutation treated in a phase I study (ClinicalTrials.gov NCT02074839).  Methods: Patients received single and multiple oral doses of ivosidenib from 100 mg twice daily to 1200 mg once daily (QD) in 28-day continuous cycles.  Concns. of ivosidenib and 2-HG in plasma, and 2-HG in bone marrow, were assessed at routine intervals.  Plasma 4β-hydroxycholesterol/cholesterol ratios were assessed as a marker of CYP3A activity.  Results: Ivosidenib was rapidly absorbed and slowly eliminated (half-life 72-138 h) after single and multiple dosing.  Ivosidenib exhibited dose- and time-dependent pharmacokinetics, with exposure increasing sub-proportionally to dose, and clearance increasing with increasing dose.  Plasma 2-HG concns. were maximally and persistently inhibited in the majority of patients receiving 500-mg QD ivosidenib, to concns. close to those obsd. in healthy subjects.  Ivosidenib pharmacokinetics were not affected by mild or moderate renal impairment, mild hepatic impairment, age, wt., sex, race, or co-administration of weak CYP3A4 inhibitors or inducers.  Moderate-to-strong CYP3A4 inhibitors decreased ivosidenib clearance.  Ivosidenib also induced CYP3A enzyme activity, with increases in 4β-hydroxycholesterol/cholesterol ratios of 119-168% at 500-mg QD ivosidenib.  Conclusions: Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematol. malignancies with an IDH1 mutation.  Clin. trial registration: ClinicalTrials.gov NCT02074839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS-BnXjEPoPrVg90H21EOLACvtfcHk0ljO1U737mcziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOrtb4%253D&md5=87a108f5c5bbb9086c3d58f3b1a295e7</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1007%2Fs00280-020-04064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-020-04064-6%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DStein%26aufirst%3DE.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLemieux%26aufirst%3DI.%26aulast%3DAgresta%26aufirst%3DS.%2BV.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520ivosidenib%2520in%2520patients%2520with%2520advanced%2520hematologic%2520malignancies%2520with%2520an%2520IDH1%2520mutation%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26issue%3D5%26spage%3D959%26epage%3D968%26doi%3D10.1007%2Fs00280-020-04064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginnetti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segerdell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anquandah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calamari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillgrove, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Identification of second-generation P2 × 3 antagonists for treatment of pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1396</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.02.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29548573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1392-1396&issue=8&author=A.+T.+Ginnettiauthor=D.+V.+Paoneauthor=S.+R.+Staufferauthor=C.+M.+Potteigerauthor=A.+W.+Shawauthor=J.+Dengauthor=J.+J.+Mulhearnauthor=D.+N.+Nguyenauthor=C.+Segerdellauthor=J.+Anquandahauthor=A.+Calamariauthor=G.+Chengauthor=M.+D.+Leitlauthor=A.+Liangauthor=E.+Mooreauthor=J.+Panigelauthor=M.+Urbanauthor=J.+Wangauthor=K.+Fillgroveauthor=C.+Tangauthor=S.+Cookauthor=S.+Kaneauthor=C.+A.+Salvatoreauthor=S.+L.+Grahamauthor=C.+S.+Burgey&title=Identification+of+second-generation+P2+%C3%97+3+antagonists+for+treatment+of+pain&doi=10.1016%2Fj.bmcl.2018.02.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of second-generation P2X3 antagonists for treatment of pain</span></div><div class="casAuthors">Ginnetti, Anthony T.; Paone, Daniel V.; Stauffer, Shaun R.; Potteiger, Craig M.; Shaw, Anthony W.; Deng, James; Mulhearn, James J.; Nguyen, Diem N.; Segerdell, Carolyn; Anquandah, Juliana; Calamari, Amy; Cheng, Gong; Leitl, Michael D.; Liang, Annie; Moore, Eric; Panigel, Jacqueline; Urban, Mark; Wang, Jixin; Fillgrove, Kerry; Tang, Cuyue; Cook, Sean; Kane, Stefanie; Salvatore, Christopher A.; Graham, Samuel L.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1392-1396</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A second-generation small mol. P2X3 receptor antagonist has been developed.  The lead optimization strategy to address shortcomings of the first-generation preclin. lead compd. is described herein.  These studies were directed towards the identification and amelioration of preclin. hepatobiliary findings, reducing potential for drug-drug interactions, and decreasing the projected human dose of the first-generation lead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGgzmlO0F8bVg90H21EOLACvtfcHk0ljO1U737mcziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslWqsLY%253D&md5=96b6cb25c0cee2ddb671cd624ea6c138</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.039%26sid%3Dliteratum%253Aachs%26aulast%3DGinnetti%26aufirst%3DA.%2BT.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BW.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DMulhearn%26aufirst%3DJ.%2BJ.%26aulast%3DNguyen%26aufirst%3DD.%2BN.%26aulast%3DSegerdell%26aufirst%3DC.%26aulast%3DAnquandah%26aufirst%3DJ.%26aulast%3DCalamari%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DLiang%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DPanigel%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFillgrove%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DS.%26aulast%3DKane%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DIdentification%2520of%2520second-generation%2520P2%2520%25C3%2597%25203%2520antagonists%2520for%2520treatment%2520of%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D8%26spage%3D1392%26epage%3D1396%26doi%3D10.1016%2Fj.bmcl.2018.02.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngblood, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavva, N. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of TRPM8 antagonist (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoy l)nicotinic acid (AMG 333), a clinical candidate for the treatment of migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8186</span>– <span class="NLM_lpage">8201</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8186-8201&issue=18&author=D.+B.+Horneauthor=K.+Biswasauthor=J.+Brownauthor=M.+D.+Bartbergerauthor=J.+Clarineauthor=C.+D.+Davisauthor=V.+K.+Goreauthor=S.+Harriedauthor=M.+Hornerauthor=M.+R.+Kallerauthor=S.+G.+Lehtoauthor=Q.+Liuauthor=V.+V.+Maauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=C.+C.+Yuanauthor=B.+D.+Youngbloodauthor=M.+Zhangauthor=W.+Zhongauthor=J.+R.+Allenauthor=J.+J.+Chenauthor=N.+R.+Gavva&title=Discovery+of+TRPM8+antagonist+%28S%29-6-%28%28%283-fluoro-4-%28trifluoromethoxy%29phenyl%29%283-fluoropyridin-2-yl%29methyl%29carbamoy+l%29nicotinic+acid+%28AMG+333%29%2C+a+clinical+candidate+for+the+treatment+of+migraine&doi=10.1021%2Facs.jmedchem.8b00518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine</span></div><div class="casAuthors">Horne, Daniel B.; Biswas, Kaustav; Brown, James; Bartberger, Michael D.; Clarine, Jeffrey; Davis, Carl D.; Gore, Vijay K.; Harried, Scott; Horner, Michelle; Kaller, Matthew R.; Lehto, Sonya G.; Liu, Qingyian; Ma, Vu V.; Monenschein, Holger; Nguyen, Thomas T.; Yuan, Chester C.; Youngblood, Beth D.; Zhang, Maosheng; Zhong, Wenge; Allen, Jennifer R.; Chen, Jian Jeffrey; Gavva, Narender R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8186-8201</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Transient-receptor-potential melastatin 8 (TRPM8), the predominant mammalian cold-temp. thermosensor, is a nonselective cation channel expressed in a subpopulation of sensory neurons in the peripheral nervous system, including nerve circuitry implicated in migraine pathogenesis: the trigeminal and pterygopalatine ganglia.  Genome-wide assocn. studies have identified an assocn. between TRPM8 and reduced risk of migraine.  This disclosure focuses on medicinal-chem. efforts to improve the druglike properties of initial leads, particularly removal of CYP3A4-induction liability and improvement of pharmacokinetic properties.  A novel series of biarylmethanamide TRPM8 antagonists was developed, and a subset of leads were evaluated in preclin. toxicol. studies to identify a clin. candidate with an acceptable preclin. safety profile leading to clin. candidate AMG 333, a potent and highly selective antagonist of TRPM8 that was evaluated in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL2alekBC2xbVg90H21EOLACvtfcHk0liLTD2B2iX3JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbvI&md5=6b251d0823e6f5a3a7f393d2aeeb5b38</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00518%26sid%3Dliteratum%253Aachs%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DBiswas%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DC.%2BD.%26aulast%3DGore%26aufirst%3DV.%2BK.%26aulast%3DHarried%26aufirst%3DS.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DLehto%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DV.%2BV.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DYoungblood%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DGavva%26aufirst%3DN.%2BR.%26atitle%3DDiscovery%2520of%2520TRPM8%2520antagonist%2520%2528S%2529-6-%2528%2528%25283-fluoro-4-%2528trifluoromethoxy%2529phenyl%2529%25283-fluoropyridin-2-yl%2529methyl%2529carbamoy%2520l%2529nicotinic%2520acid%2520%2528AMG%2520333%2529%252C%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D18%26spage%3D8186%26epage%3D8201%26doi%3D10.1021%2Facs.jmedchem.8b00518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greszler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vortherms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kym, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid (ABBV/GLPG-2222), a potent cystic fibrosis transmembrane conductance regulator (CFTR) corrector for the treatment of cystic fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1449</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01339</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01339" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2gsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1436-1449&issue=4&author=X.+Wangauthor=B.+Liuauthor=X.+Searleauthor=C.+Yeungauthor=A.+Bogdanauthor=S.+Greszlerauthor=A.+Singhauthor=Y.+Fanauthor=A.+M.+Swensenauthor=T.+Vorthermsauthor=C.+Balutauthor=Y.+Jiaauthor=K.+Desinoauthor=W.+Gaoauthor=H.+Yongauthor=C.+Tseauthor=P.+Kym&title=Discovery+of+4-%5B%282R%2C4R%29-4-%28%7B%5B1-%282%2C2-Difluoro-1%2C3-benzodioxol-5-yl%29cyclopropyl%5Dcarbonyl%7Damino%29-7-%28difluoromethoxy%29-3%2C4-dihydro-2H-chromen-2-yl%5Dbenzoic+acid+%28ABBV%2FGLPG-2222%29%2C+a+potent+cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29+corrector+for+the+treatment+of+cystic+fibrosis&doi=10.1021%2Facs.jmedchem.7b01339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis</span></div><div class="casAuthors">Wang, Xueqing; Liu, Bo; Searle, Xenia; Yeung, Clinton; Bogdan, Andrew; Greszler, Stephen; Singh, Ashvani; Fan, Yihong; Swensen, Andrew M.; Vortherms, Timothy; Balut, Corina; Jia, Ying; Desino, Kelly; Gao, Wenqing; Yong, Hong; Tse, Chris; Kym, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1436-1449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed.  To effectively treat the most prevalent patient population (F508del mutation), two biomol. modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel.  Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors.  Herein, the authors disclose the discovery of a highly potent series of CFTR correctors and the structure-activity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222, which is currently in clin. trials in patients harboring the F508del CFTR mutation on at least one allele.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4J11loTFmPLVg90H21EOLACvtfcHk0lh2OxJKY2Y1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2gsbzI&md5=34bea6adb0b8696288fedce258a661fd</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01339%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSearle%26aufirst%3DX.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DBogdan%26aufirst%3DA.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DDesino%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DKym%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25204-%255B%25282R%252C4R%2529-4-%2528%257B%255B1-%25282%252C2-Difluoro-1%252C3-benzodioxol-5-yl%2529cyclopropyl%255Dcarbonyl%257Damino%2529-7-%2528difluoromethoxy%2529-3%252C4-dihydro-2H-chromen-2-yl%255Dbenzoic%2520acid%2520%2528ABBV%252FGLPG-2222%2529%252C%2520a%2520potent%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%2520corrector%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1436%26epage%3D1449%26doi%3D10.1021%2Facs.jmedchem.7b01339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. K.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 3A4 induction: Lumacaftor versus Ivacaftor potentially resulting in significantly reduced plasma concentration of Ivacaftor</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.2174/1872312812666180328105259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2174%2F1872312812666180328105259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29595119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=71-74&issue=1&author=E.+K.+Schneider&title=Cytochrome+P450+3A4+induction%3A+Lumacaftor+versus+Ivacaftor+potentially+resulting+in+significantly+reduced+plasma+concentration+of+Ivacaftor&doi=10.2174%2F1872312812666180328105259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor</span></div><div class="casAuthors">Schneider, Elena K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-74</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Since the release of ivacaftor-lumacaftor, several red-flags have been raised that highlight the clin. efficacy of this combination strategy that may be limited due to antagonistic drug-drug interactions.  The effect of ivacaftor, its major metabolites M1 and M6, lumacaftor and the novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator tezacaftor at 10 g/mL on the enzymic activity of the major xenobiotic metabolizing enzymes CYP1A2 and CYP3A4 as well as the minor enzymes CYP2B6 and CYP2C9 was assayed.  Lumacaftor (3.74 x 105 ± 3.11 × 104 RLU), and ivacaftor-M6 (3.43 × 105 ± 7.61 × 103 RLU) markedly induced the activity of CYP3A4.  Ivacaftor (2.22 x 105 ± 3.94 × 104 RLU) showed a lower relative ratio of luminescence units compared to chloramphenicol (3.17 × 105 ± 1.55 x 104 RLU).  Interestingly, ivacaftor-M1 (6.74 × 104 ± 3.09 × 104 RLU) and the novel CFTR modulator tezacaftor (2.40 × 104 ± 8.14 × 104 RLU) did not show CYP3A4 induction.  In the CYP1A2 and CYP2C9 assay, all metabolites showed a decrease in the ratio of luminescence units compared to the controls.  Ivacaftor, its major metabolites, lumacaftor and tezacaftor all showed a slight increase in the ratio of luminescence units compared to the control rifampin with CYP2B6.  All in all, present findings would suggest that lumacaftor and ivacaftor-M6 are strong inducers of CYP3A4, potentially reducing ivacaftor concns.; ivacaftor itself induces CYP3A4 to some extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Pg98lMvTxLVg90H21EOLACvtfcHk0lh2OxJKY2Y1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtLbL&md5=a6b6b0840adcc707fc3a47ff371a39e4</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.2174%2F1872312812666180328105259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1872312812666180328105259%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DE.%2BK.%26atitle%3DCytochrome%2520P450%25203A4%2520induction%253A%2520Lumacaftor%2520versus%2520Ivacaftor%2520potentially%2520resulting%2520in%2520significantly%2520reduced%2520plasma%2520concentration%2520of%2520Ivacaftor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2018%26volume%3D12%26issue%3D1%26spage%3D71%26epage%3D74%26doi%3D10.2174%2F1872312812666180328105259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scanio, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altenbach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gfesser, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greszler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vortherms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrimpf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kym, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of ABBV/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVGks7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1543-1548&issue=11&author=M.+J.+C.+Scanioauthor=X.+B.+Searleauthor=B.+Liuauthor=J.+R.+Koenigauthor=R.+Altenbachauthor=G.+A.+Gfesserauthor=A.+Bogdanauthor=S.+Greszlerauthor=G.+Zhaoauthor=A.+Singhauthor=Y.+Fanauthor=A.+M.+Swensenauthor=T.+Vorthermsauthor=A.+Manelliauthor=C.+Balutauthor=Y.+Jiaauthor=W.+Gaoauthor=H.+Yongauthor=M.+Schrimpfauthor=C.+Tseauthor=P.+Kymauthor=X.+Wang&title=Discovery+of+ABBV%2FGLPG-3221%2C+a+potent+corrector+of+CFTR+for+the+treatment+of+cystic+fibrosis&doi=10.1021%2Facsmedchemlett.9b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABBV/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis</span></div><div class="casAuthors">Scanio, Marc J. C.; Searle, Xenia B.; Liu, Bo; Koenig, John R.; Altenbach, Robert; Gfesser, Gregory A.; Bogdan, Andrew; Greszler, Stephen; Zhao, Gang; Singh, Ashvani; Fan, Yihong; Swensen, Andrew M.; Vortherms, Timothy; Manelli, Arlene; Balut, Corina; Jia, Ying; Gao, Wenqing; Yong, Hong; Schrimpf, Michael; Tse, Chris; Kym, Philip; Wang, Xueqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a genetic disorder that affects multiple tissues and organs.  CF is caused by mutations in the CFTR gene, resulting in insufficient or impaired cystic fibrosis transmembrane conductance regulator (CFTR) protein.  The deletion of phenylalanine at position 508 of the protein (F508del-CFTR) is the most common mutation obsd. in CF patients.  The most effective treatments of these patients employ two CFTR modulator classes, correctors and potentiators.  CFTR correctors increase protein levels at the cell surface; CFTR potentiators enable the functional opening of CFTR channels at the cell surface.  Triple-combination therapies utilize two distinct corrector mols. (C1 and C2) to further improve the overall efficacy.  We identified the need to develop a C2 corrector series that had the potential to be used in conjunction with our existing C1 corrector series and provide robust clin. efficacy for CF patients.  The identification of a pyrrolidine series of CFTR C2 correctors and the structure-activity relationship of this series is described.  This work resulted in the discovery and selection of (2S,3R,4S,5S)-3-(tert-butyl)-4-((2-methoxy-5-(trifluoromethyl)pyridin-3-yl)methoxy)-1-((S)-tetrahydro-2H-pyran-2-carbonyl)-5-(o-tolyl)pyrrolidine-2-carboxylic acid (ABBV/GLPG-3221), which was advanced to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB4FeR_QyZBrVg90H21EOLACvtfcHk0lhZFedv__9ZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVGks7rK&md5=9894641a51117b34921b7a886a4ab1d0</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00377%26sid%3Dliteratum%253Aachs%26aulast%3DScanio%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DSearle%26aufirst%3DX.%2BB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DKoenig%26aufirst%3DJ.%2BR.%26aulast%3DAltenbach%26aufirst%3DR.%26aulast%3DGfesser%26aufirst%3DG.%2BA.%26aulast%3DBogdan%26aufirst%3DA.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DSchrimpf%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DKym%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520ABBV%252FGLPG-3221%252C%2520a%2520potent%2520corrector%2520of%2520CFTR%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1543%26epage%3D1548%26doi%3D10.1021%2Facsmedchemlett.9b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelen, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurlino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Identification and biological evaluation of thiazole-based inverse agonists of RORgammat</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29631962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1446-1455&issue=9&author=C.+Gegeauthor=M.+D.+Cummingsauthor=M.+Albersauthor=O.+Kinzelauthor=G.+Kleymannauthor=T.+Schluterauthor=C.+Steeneckauthor=M.+I.+Nelenauthor=C.+Milliganauthor=J.+Spurlinoauthor=X.+Xueauthor=K.+Leonardauthor=J.+P.+Edwardsauthor=A.+Fourieauthor=S.+D.+Goldbergauthor=T.+Hoffmann&title=Identification+and+biological+evaluation+of+thiazole-based+inverse+agonists+of+RORgammat&doi=10.1016%2Fj.bmcl.2018.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological evaluation of thiazole-based inverse agonists of RORγt</span></div><div class="casAuthors">Gege, Christian; Cummings, Maxwell D.; Albers, Michael; Kinzel, Olaf; Kleymann, Gerald; Schlueter, Thomas; Steeneck, Christoph; Nelen, Marina I.; Milligan, Cindy; Spurlino, John; Xue, Xiaohua; Leonard, Kristi; Edwards, James P.; Fourie, Anne; Goldberg, Steven D.; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1446-1455</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear receptor retinoic acid receptor-related orphan receptor gamma t (RORγt) is a transcription factor that drives Th17 cell differentiation and IL-17 prodn. in both innate and adaptive immune cells.  The IL-23/IL-17 pathway is implicated in major autoimmune and inflammatory diseases.  RORγt lies at the core of this pathway and represents an attractive opportunity for intervention with a small mol.  Despite diverse chem. series having been reported, combining high potency and nuclear receptor selectivity with good physicochem. properties remains a challenging endeavor in the field of RORγt drug discovery.  The authors describe the discovery and evaluation of a new class of potent and selective RORγt inverse agonists based on a thiazole core.  Acid analog 1j (Et 5-[4-[N-(tert-butyl)sulfamoyl]naphthalen-1-yl]-4-(cyclohexylmethyl)thiazole-2-carboxylate) demonstrated oral bioavailability in rats and was potent in a human whole blood assay, suggesting potential utility in treating autoimmune and inflammatory diseases such as psoriasis.  X-ray crystallog. data helped to elucidate the mol. mechanism for RORγt inhibition with this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8APFwgPE97Vg90H21EOLACvtfcHk0lhZFedv__9ZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejtLg%253D&md5=5eb11be2492120db73c94733d56ae126</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DNelen%26aufirst%3DM.%2BI.%26aulast%3DMilligan%26aufirst%3DC.%26aulast%3DSpurlino%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DIdentification%2520and%2520biological%2520evaluation%2520of%2520thiazole-based%2520inverse%2520agonists%2520of%2520RORgammat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D9%26spage%3D1446%26epage%3D1455%26doi%3D10.1016%2Fj.bmcl.2018.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of new oxadiazole substituted thiazole RORgammat inverse agonists through a bioisosteric amide replacement approach</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127174</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32334912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127174&issue=12&author=C.+Steeneckauthor=C.+Gegeauthor=O.+Kinzelauthor=M.+Albersauthor=G.+Kleymannauthor=T.+Schluterauthor=A.+Schulzauthor=X.+Xueauthor=M.+D.+Cummingsauthor=A.+M.+Fourieauthor=K.+A.+Leonardauthor=B.+Scottauthor=J.+P.+Edwardsauthor=T.+Hoffmannauthor=S.+D.+Goldberg&title=Discovery+and+optimization+of+new+oxadiazole+substituted+thiazole+RORgammat+inverse+agonists+through+a+bioisosteric+amide+replacement+approach&doi=10.1016%2Fj.bmcl.2020.127174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach</span></div><div class="casAuthors">Steeneck, Christoph; Gege, Christian; Kinzel, Olaf; Albers, Michael; Kleymann, Gerald; Schlueter, Thomas; Schulz, Andreas; Xue, Xiaohua; Cummings, Maxwell D.; Fourie, Anne M.; Leonard, Kristi A.; Scott, Brian; Edwards, James P.; Hoffmann, Thomas; Goldberg, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127174</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from previously identified thiazole-2-carboxamides exemplified by compd. I, two new series of RORγt inverse agonists with significantly improved aq. soly., ADME parameters and oral PK properties were discovered.  These scaffolds were identified from a bioisosteric amide replacement approach.  Amongst the variety of heterocycles explored, a 1,3,4-oxadiazole led to compds. with the best overall profile for SAR development and in vivo exploration.  In an ex vivo mouse PD model, concn. dependent efficacy was demonstrated and compds. II and III were profiled in a 5-day rat tolerability study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb8R3FUJDRdrVg90H21EOLACvtfcHk0lgtwutO5lkV7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb4%253D&md5=e853db68a306e4424a143003e54db5b4</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127174%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DGege%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DLeonard%26aufirst%3DK.%2BA.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520new%2520oxadiazole%2520substituted%2520thiazole%2520RORgammat%2520inverse%2520agonists%2520through%2520a%2520bioisosteric%2520amide%2520replacement%2520approach%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127174%26doi%3D10.1016%2Fj.bmcl.2020.127174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurlino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORgammat</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127205</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32336498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127205&issue=12&author=C.+Gegeauthor=M.+Albersauthor=O.+Kinzelauthor=G.+Kleymannauthor=T.+Schluterauthor=C.+Steeneckauthor=T.+Hoffmannauthor=X.+Xueauthor=M.+D.+Cummingsauthor=J.+Spurlinoauthor=C.+Milliganauthor=A.+M.+Fourieauthor=J.+P.+Edwardsauthor=K.+Leonardauthor=K.+Coeauthor=B.+Scottauthor=D.+Pippelauthor=S.+D.+Goldberg&title=Optimization+and+biological+evaluation+of+thiazole-bis-amide+inverse+agonists+of+RORgammat&doi=10.1016%2Fj.bmcl.2020.127205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt</span></div><div class="casAuthors">Gege, Christian; Albers, Michael; Kinzel, Olaf; Kleymann, Gerald; Schlueter, Thomas; Steeneck, Christoph; Hoffmann, Thomas; Xue, Xiaohua; Cummings, Maxwell D.; Spurlino, John; Milligan, Cynthia; Fourie, Anne M.; Edwards, James P.; Leonard, Kristi; Coe, Kevin; Scott, Brian; Pippel, Dan; Goldberg, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127205</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear receptor retinoic acid receptor-related orphan receptor gamma t (RORγt) is a transcription factor that drives Th17 cell differentiation and IL-17 prodn. in both innate and adaptive immune cells.  The IL-23/IL-17 pathway is implicated in major autoimmune and inflammatory diseases.  RORγt lies at the core of this pathway and represents an attractive opportunity for intervention with small mol. therapeutics.  Despite diverse chem. series having been reported, combining high potency and nuclear receptor selectivity with good physicochem. properties remains a challenging endeavor in the field of RORγt drug discovery.  We recently described the discovery and evaluation of a new class of potent and selective RORγt inverse agonists based on a thiazole scaffold.  Herein we describe the successful optimization of this class by incorporation of an addnl. amide moiety at the 4-position of the thiazole core.  In several optimization cycles, we have reduced human PXR activation, improved soly., and increased potency while maintaining nuclear receptor selectivity.  X-ray crystallog. anal. of compd. 1g bound in the sterol binding site of the ligand binding domain of RORγt was largely consistent with an earlier structure, guiding further insight into the mol. mechanism for RORγt inhibition with this series.  Compd. 1g is orally bioavailable, potent in a human whole blood assay and proved to be efficacious in an ex-vivo IL-17A assay, and was selected for preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlRppte3yxrVg90H21EOLACvtfcHk0ljH7sgtr86dbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSnur4%253D&md5=f2bc572a7452257eaa29260df1a6837b</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127205%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DSpurlino%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DC.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DCoe%26aufirst%3DK.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DPippel%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DOptimization%2520and%2520biological%2520evaluation%2520of%2520thiazole-bis-amide%2520inverse%2520agonists%2520of%2520RORgammat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127205%26doi%3D10.1016%2Fj.bmcl.2020.127205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemagiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2- yl)phenyl)pyrrolidines as novel RORgammat inverse agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">127392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32738966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127392&issue=17&author=B.+Jiangauthor=J.+J.+Duanauthor=S.+Stachuraauthor=A.+Karmakarauthor=H.+Hemagiriauthor=D.+K.+Rautauthor=A.+K.+Guptaauthor=C.+A.+Weigeltauthor=J.+Khanauthor=J.+S.+Sackauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=M.+A.+Galellaauthor=A.+Mathurauthor=Q.+Zhaoauthor=L.+M.+Salter-Cidauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Discovery+of+%283S%2C4S%29-3-methyl-3-%284-fluorophenyl%29-4-%284-%281%2C1%2C1%2C3%2C3%2C3-hexafluoro-2-hydroxyprop-2-+yl%29phenyl%29pyrrolidines+as+novel+RORgammat+inverse+agonists&doi=10.1016%2Fj.bmcl.2020.127392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists</span></div><div class="casAuthors">Jiang, Bin; Duan, James J.-W.; Stachura, Sylwia; Karmakar, Ananta; Hemagiri, Hemalatha; Raut, Dhanya Kumar; Gupta, Arun Kumar; Weigelt, Carolyn A.; Khan, Javed; Sack, John S.; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Galella, Michael A.; Mathur, Arvind; Zhao, Qihong; Salter-Cid, Luisa M.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">127392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of cis-3,4-diphenylpyrrolidines were designed as RORγt inverse agonists based on the binding conformation of previously reported bicyclic sulfonamide I.  Preliminary synthesis and structure-activity relationship (SAR) study established (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidine as the most effective scaffold.  Subsequent SAR optimization led to identification of a piperidinyl carboxamide II, which was potent against RORγt (EC50 of 61 nM in an inverse agonist assay), selective relative to RORα, RORβ, LXRα and LXRβ, and stable in human and mouse liver microsomes.  Furthermore, compd. II exhibited considerably lower PXR Ymax (46%) and emerged as a promising lead.  The binding mode of the diphenylpyrrolidine series was established with an X-ray co-crystal structure of III/RORγt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonLsaq8L7Su7Vg90H21EOLACvtfcHk0ljH7sgtr86dbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrt77P&md5=a3a584c64a9b19d1d09685366dcd3616</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127392%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DHemagiri%26aufirst%3DH.%26aulast%3DRaut%26aufirst%3DD.%2BK.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DDiscovery%2520of%2520%25283S%252C4S%2529-3-methyl-3-%25284-fluorophenyl%2529-4-%25284-%25281%252C1%252C1%252C3%252C3%252C3-hexafluoro-2-hydroxyprop-2-%2520yl%2529phenyl%2529pyrrolidines%2520as%2520novel%2520RORgammat%2520inverse%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127392%26doi%3D10.1016%2Fj.bmcl.2020.127392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiffe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eerdenbrugh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span> <span> </span><span class="NLM_article-title">New potent DOT1L inhibitors for in vivo evaluation in mouse</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00452</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00452" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1OhurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1655-1660&issue=12&author=F.+Staufferauthor=A.+Weissauthor=C.+Scheuflerauthor=H.+Mobitzauthor=C.+Ragotauthor=K.+S.+Beyerauthor=K.+Calkinsauthor=D.+Guthyauthor=M.+Kiffeauthor=B.+Van+Eerdenbrughauthor=R.+Tiedtauthor=C.+Gaul&title=New+potent+DOT1L+inhibitors+for+in+vivo+evaluation+in+mouse&doi=10.1021%2Facsmedchemlett.9b00452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse</span></div><div class="casAuthors">Stauffer, Frederic; Weiss, Andreas; Scheufler, Clemens; Mobitz, Henrik; Ragot, Christian; Beyer, Kim S.; Calkins, Keith; Guthy, Daniel; Kiffe, Michael; Van Eerdenbrugh, Bernard; Tiedt, Ralph; Gaul, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1660</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes.  A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclin. mouse tumor xenograft model.  Compds. displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKjK-qoNQ0bVg90H21EOLACvtfcHk0ljf5q6Rbeenjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1OhurnM&md5=2d51f814db9aded229a51fda1e9d2213</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00452%26sid%3Dliteratum%253Aachs%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DRagot%26aufirst%3DC.%26aulast%3DBeyer%26aufirst%3DK.%2BS.%26aulast%3DCalkins%26aufirst%3DK.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DKiffe%26aufirst%3DM.%26aulast%3DVan%2BEerdenbrugh%26aufirst%3DB.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DGaul%26aufirst%3DC.%26atitle%3DNew%2520potent%2520DOT1L%2520inhibitors%2520for%2520in%2520vivo%2520evaluation%2520in%2520mouse%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1655%26epage%3D1660%26doi%3D10.1021%2Facsmedchemlett.9b00452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">A new approach of mitigating CYP3A4 induction led to the discovery of potent hepatitis B virus (HBV) capsid inhibitor with optimal ADMET profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10352</span>– <span class="NLM_lpage">10361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10352-10361&issue=22&author=X.+Linauthor=H.+Shiauthor=W.+Zhangauthor=Z.+Qiuauthor=Z.+Zhouauthor=F.+Deyauthor=S.+Zhongauthor=H.+Qiuauthor=J.+Xieauthor=X.+Zhouauthor=G.+Yangauthor=G.+Tangauthor=H.+C.+Shenauthor=W.+Zhu&title=A+new+approach+of+mitigating+CYP3A4+induction+led+to+the+discovery+of+potent+hepatitis+B+virus+%28HBV%29+capsid+inhibitor+with+optimal+ADMET+profiles&doi=10.1021%2Facs.jmedchem.9b01421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles</span></div><div class="casAuthors">Lin, Xianfeng; Shi, Houguang; Zhang, Weixing; Qiu, Zongxing; Zhou, Zheng; Dey, Fabian; Zhong, Sheng; Qiu, Hongxia; Xie, Jianxun; Zhou, Xue; Yang, Guang; Tang, Guozhi; Shen, Hong C.; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10352-10361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein is a new approach to mitigate CYP3A4 induction.  In this unconventional approach, a fine-tuning of the dihedral angle between the C4 Ph and the dihydropyrimidine core of the heteroaryldihydropyrimidine (HAP) class of capsid inhibitors successfully altered the structure-activity-relationships (SARs) of the unwanted CYP3A4 induction and the desired HBV capsid inhibition to more favorable values.  This eventually led to the discovery of a new capsid inhibitor with significantly reduced CYP3A4 induction, excellent anti-HBV activity, favorable preclin. PK/PD profiles, and no early safety flags.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNfHXvhTVCabVg90H21EOLACvtfcHk0ljf5q6Rbeenjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7rK&md5=21f92e9b739581463229d5bf46d47c3d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01421%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDey%26aufirst%3DF.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DA%2520new%2520approach%2520of%2520mitigating%2520CYP3A4%2520induction%2520led%2520to%2520the%2520discovery%2520of%2520potent%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitor%2520with%2520optimal%2520ADMET%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10352%26epage%3D10361%26doi%3D10.1021%2Facs.jmedchem.9b01421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruderek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of second generation EZH2 inhibitors with long residence time</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1205-1212&issue=6&author=A.+Khannaauthor=A.+Coteauthor=S.+Aroraauthor=L.+Moineauthor=V.+S.+Gehlingauthor=J.+Brennemanauthor=N.+Cantoneauthor=J.+I.+Stuckeyauthor=S.+Apteauthor=A.+Ramakrishnanauthor=K.+Bruderekauthor=W.+D.+Bradleyauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=R.+J.+Simsauthor=P.+Trojerauthor=J.+R.+Levell&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+second+generation+EZH2+inhibitors+with+long+residence+time&doi=10.1021%2Facsmedchemlett.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time</span></div><div class="casAuthors">Khanna, Avinash; Cote, Alexandre; Arora, Shilpi; Moine, Ludivine; Gehling, Victor S.; Brenneman, Jehrod; Cantone, Nico; Stuckey, Jacob I.; Apte, Shruti; Ramakrishnan, Ashwin; Bruderek, Kamil; Bradley, William D.; Audia, James E.; Cummings, Richard T.; Sims, Robert J.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1212</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM).  EZH2 is commonly mutated in hematol. malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis.  First generation EZH2 inhibitors are beginning to show clin. benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition.  During our medicinal chem. campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time.  Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochem. properties, which have the potential to expand the clin. use of EZH2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx-ixCY_R5KrVg90H21EOLACvtfcHk0liYUlWdAL4JuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D&md5=e54bac34b75f41d6b82666016df08c1f</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DBrenneman%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DApte%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DBruderek%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%2520second%2520generation%2520EZH2%2520inhibitors%2520with%2520long%2520residence%2520time%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1205%26epage%3D1212%26doi%3D10.1021%2Facsmedchemlett.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndifor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugovic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shireman, B. T.</span></span> <span> </span><span class="NLM_article-title">Substituted azabicyclo[2.2.1]heptanes as selective orexin-1 antagonists: Discovery of JNJ-54717793</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2002</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1Wmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2002-2009&issue=10&author=C.+Previlleauthor=P.+Bonaventureauthor=T.+Koudriakovaauthor=B.+Lordauthor=D.+Nepomucenoauthor=M.+Rizzolioauthor=N.+Maniauthor=K.+J.+Coeauthor=A.+Ndiforauthor=C.+Dugovicauthor=C.+A.+Dvorakauthor=H.+Coateauthor=D.+J.+Pippelauthor=A.+Fitzgeraldauthor=B.+Allisonauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=B.+T.+Shireman&title=Substituted+azabicyclo%5B2.2.1%5Dheptanes+as+selective+orexin-1+antagonists%3A+Discovery+of+JNJ-54717793&doi=10.1021%2Facsmedchemlett.0c00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793</span></div><div class="casAuthors">Preville, Cathy; Bonaventure, Pascal; Koudriakova, Tatiana; Lord, Brian; Nepomuceno, Diane; Rizzolio, Michele; Mani, Neelakandha; Coe, Kevin J.; Ndifor, Anthony; Dugovic, Christine; Dvorak, Curt A.; Coate, Heather; Pippel, Daniel J.; Fitzgerald, Anne; Allison, Brett; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Shireman, Brock T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2002-2009</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The orexin system consists of two neuropeptides (orexin-A and orexin-B) that exert their mode of action on two receptors (orexin-1 and orexin-2).  While the role of the orexin-2 receptor is established as an important modulator of sleep wake states, the role of the orexin-1 receptor is believed to play a role in addiction, panic, or anxiety.  In this manuscript, we describe the optimization of a nonselective substituted azabicyclo[2.2.1]heptane dual orexin receptor antagonist (DORA) into orally bioavailable, brain penetrating, selective orexin-1 receptor (OX1R) antagonists.  This resulted in the discovery of our first candidate for clin. development, JNJ-54717793.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp66G0rIU1vJbVg90H21EOLACvtfcHk0liYUlWdAL4JuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1Wmtbs%253D&md5=0dccbf0362cfd6ba9dbaee0a40031064</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00085%26sid%3Dliteratum%253Aachs%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DNdifor%26aufirst%3DA.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCoate%26aufirst%3DH.%26aulast%3DPippel%26aufirst%3DD.%2BJ.%26aulast%3DFitzgerald%26aufirst%3DA.%26aulast%3DAllison%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26atitle%3DSubstituted%2520azabicyclo%255B2.2.1%255Dheptanes%2520as%2520selective%2520orexin-1%2520antagonists%253A%2520Discovery%2520of%2520JNJ-54717793%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D2002%26epage%3D2009%26doi%3D10.1021%2Facsmedchemlett.0c00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delfosse, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardia-Parège, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiavarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Mével, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruszczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeneix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianférani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fini, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into the synergistic activation of the RXR-PXR heterodimer by endocrine disruptor mixtures</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e2020551118</span> <span class="refDoi"> DOI: 10.1073/pnas.2020551118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1073%2Fpnas.2020551118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=33361153" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2021&issue=1&author=V.+Delfosseauthor=T.+Huetauthor=D.+Harrusauthor=M.+Granellauthor=M.+Bourguetauthor=C.+Gardia-Par%C3%A8geauthor=B.+Chiavarinaauthor=M.+Grimaldiauthor=S.+Le+M%C3%A9velauthor=P.+Blancauthor=D.+Huangauthor=J.+Gruszczykauthor=B.+Demeneixauthor=S.+Cianf%C3%A9raniauthor=J.+B.+Finiauthor=P.+Balaguerauthor=W.+Bourguet&title=Mechanistic+insights+into+the+synergistic+activation+of+the+RXR-PXR+heterodimer+by+endocrine+disruptor+mixtures&doi=10.1073%2Fpnas.2020551118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2020551118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2020551118%26sid%3Dliteratum%253Aachs%26aulast%3DDelfosse%26aufirst%3DV.%26aulast%3DHuet%26aufirst%3DT.%26aulast%3DHarrus%26aufirst%3DD.%26aulast%3DGranell%26aufirst%3DM.%26aulast%3DBourguet%26aufirst%3DM.%26aulast%3DGardia-Par%25C3%25A8ge%26aufirst%3DC.%26aulast%3DChiavarina%26aufirst%3DB.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DLe%2BM%25C3%25A9vel%26aufirst%3DS.%26aulast%3DBlanc%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DGruszczyk%26aufirst%3DJ.%26aulast%3DDemeneix%26aufirst%3DB.%26aulast%3DCianf%25C3%25A9rani%26aufirst%3DS.%26aulast%3DFini%26aufirst%3DJ.%2BB.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DBourguet%26aufirst%3DW.%26atitle%3DMechanistic%2520insights%2520into%2520the%2520synergistic%2520activation%2520of%2520the%2520RXR-PXR%2520heterodimer%2520by%2520endocrine%2520disruptor%2520mixtures%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2021%26volume%3D118%26issue%3D1%26doi%3D10.1073%2Fpnas.2020551118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0141.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0141.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of ligand activation of PXR through the formation of a heterodimer with RXR and subsequent gene expression via binding to the PXR response element. Adapted from Tebbens et al. (ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>). Copyright 2018 MDPI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of the heterotetrameric complex formed by PXR in orange, RXRα in cyan, SRC-1 in dark blue, and the cocrystallized activator SR12813 in green. The AF-2 domain is highlighted in red (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Main residues delineating the PXR binding pocket. The residues corresponding to the hydrophobic cage (on the left), the polar rim (on the top), the hydrophobic side (on the right), and the polar channel (on the bottom) are represented, respectively, in green, blue, orange, and magenta. (B) Binding site description using the SiteMap (Schrodinger) representation.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Hydrophobic areas are represented in yellow, HB acceptor areas are in red, and HB donor areas are in blue. Small white dots cover the region where chemical matter can bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Residues involved in the five hot spots described by Ngan et al. (a) Residues belonging to the first hot spot are colored in light green. (b) Residues belonging to the second hot spot are colored in cyan. (c) Residues corresponding to the third hot spot are colored in faded red. (d) Residues corresponding to the fourth hot spot are colored in faded orange. (e) Residues corresponding to the fifth hot spot are colored in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of the hPXR-LBD in complex with rifampicin (<b>1</b>) (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX">1SKX</a>) and chemical structure of rifampicin (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of the hPXR-LBD in complex with the PNU-142721 (<b>65</b>) (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R8D">3R8D</a>) and chemical structure of PNU-142721 (<b>65</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of the hPXR-LBD in complex with the synthetic estrogen 17α-ethinylestradiol (<b>42</b>) and the pesticide trans-nonachlor (TNC, <b>68</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G">4X1G</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Five binding modes observed in the PXR-LBD for SR12813 (<b>62</b>) (in gray): (a–c) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH">1ILH</a> crystal structure, and three alternate binding modes were observed; (d) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL">1NRL</a> crystal structure; and (e) in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X">4J5X</a> crystal structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Putative distinct binding site for antagonists (molecular surface in cyan). The AF-2 region is represented in red and the SRC-1 coactivator in dark blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of the closely related agonist <b>70</b> (SJB7) and antagonist <b>79</b> (SPA70).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (Left) T0901317 (<b>63</b>) bound to PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I">2O9I</a>). (Right) T0901317 bound to LXRβ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQC">1PQC</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. PXR SAR versus LXRβ SAR for analogues of T0901317 (<b>63</b>), described by GSK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PXR SAR for a series of T0901317 (<b>63</b>) analogues as RORγ inverse agonists from Genentech and Argenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. CCR1 antagonists from BMS showing the initial compound, <b>88</b>, and two analogues with polar groups, <b>89</b> and <b>90</b>, on the right-hand side phenyl ring, which reduces PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cyclopentyl amide CCR1 antagonist <b>91</b>, from BMS, with the four hydroxylated isomers <b>92</b>–<b>95</b>, showing differing effects on PXR activity. NB for <b>92</b> two sets of data are reported in the same paper, i.e., CCR1 IC<sub>50</sub> 1.7 nM and Chemotaxis IC<sub>50</sub> 4.6 nM also listed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures and profiles of CCR1 antagonists <b>66</b> and <b>67</b> from BMS that were successfully crystallized with PXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Crystal structure of <b>66</b> in complex with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9">4NY9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. First binding mode of <b>67</b> showing overall similarity to that of <b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD">4XHD</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Second binding mode of <b>67</b> showing the different conformation of the cyclopropylmethyl group relative to the pose shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S0T">4S0T</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Profile of optimized CCR1 antagonist and development candidate BMS-817399 (<b>101</b>) from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of two tool S1P<sub>1</sub> antagonists, <b>69</b> and <b>102</b>, from AstraZeneca that <i>in vivo</i> profiling revealed CYP3A4 induction, which was ultimately discovered to be caused by PXR induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Optimized compounds from AZ S1P<sub>1</sub> antagonist series (<b>103</b> and <b>104</b>) with significantly reduced PXR induction potential.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structure of PXR in complex with <b>69</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. mGluR2 PAMs (<b>105</b> and <b>72</b>) from Sanofi which identified PXR induction as an issue for the series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structure of PXR in complex with <b>72</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP">6DUP</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Regions highlighted to target and associated molecular modifications based on the crystal structure of <b>72</b> with PXR. N/A = not available.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structure and pharmacological profile of BMS RORγ inverse agonist hit <b>109</b> alongside related literature reference T0901317 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. RORγ inverse agonists from BMS with substitution α-to the thioether, <b>110</b>–<b>112</b> and <b>71</b>, showing the effect of the amide and the different effects on RORγ and PXR for the enantiomers <b>71</b> and <b>112</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structure of RORγ inverse agonist <b>71</b> (in gray) from BMS in complex with (a) PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS">6BNS</a>) and (b) RORγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BN6">6BN6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Optimized RORγ inverse agonists from BMS, <b>113</b>–<b>115</b>, that were designed based on the information gleaned from the structure of <b>71</b> with PXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Evolution of BMS RORγ inverse agonist series from initial design (<b>75</b>) through <b>116</b> and <b>117</b> to compounds with enhanced PXR selectivity (<b>118</b>–<b>120</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structure of PXR with <b>75</b>, pose a in gray and pose b in cyan (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1">6NX1</a>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. SAR around the HFIPA group of <b>75</b>, highlighting the importance of the CF<sub>3</sub> groups (<b>121</b>) and the hydrogen bond donating interaction with PXR (<b>122</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Combination of the heptafluoro isopropyl group on the left-hand side with the polar right-hand side groups resulted in an optimal balance between on target activity and PXR selectivity, including efficacy at PXR, <b>123</b>–<b>126</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Locking the conformation of <b>126</b> resulted in a substantial increase in activity (<b>127</b>). Optimization of other properties while maintaining PXR selectivity resulted in compounds such as <b>128</b> and ultimately the development compound BMS-986251 (<b>129</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Selected examples from Xenon Na<sub>V</sub>1.6 project highlighting lack of correlation between measured log <i>D</i> and PXR activity (EC<sub>50</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Na<sub>V</sub>1.6 blocker <b>73</b> (XPC-4755) bound to PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41">6S41</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of <b>133</b> and <b>134</b> highlighting the differences in PXR induction and MDR1 ER for substitution at the <i>meta</i> (<b>133</b>) versus <i>ortho</i> (<b>134</b>) positions of the benzylic phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures and summary data for optimized compounds <b>135</b>–<b>137</b> from the Xenon Na<sub>V</sub>1.6 inhibitor project.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Phenylsulfonamide P2X4 inhibitors from Bayer, highlighting starting point <b>138</b> (BAY-1797) and selected SAR examples, including substitution of the phenyl acetamide moiety at the <i>ortho</i>-position (<b>139</b>–<b>141</b>), <i>para</i>-position (<b>142</b> and <b>143</b>), and the benzylic position (<b>74</b>). MEC = minimum efficacious concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure of P2X4 antagonist <b>74</b> with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY">6HTY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Overlay of the crystal structures of PXR LBD bound to <b>73</b> (in gray) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S41">4S41</a>) and to <b>74</b> (in cyan) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HTY">4HTY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Summary of substituted phenolic ethers from Bayer P2X4 antagonist series designed using the PXR crystal structure in complex with <b>74</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Further P2X4 inhibitors from Bayer designed with the use of PXR crystallography to reduce PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures and PXR activity of HIV-1 integrase allosteric inhibitors from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. (a) Crystal structure of PXR LBD in interaction with <b>77</b> (left) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9">6XP9</a>) and (b) crystal structure of HIV-1 integrase in interaction with <b>77</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UM8">6UM8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. PXR SAR from a series of thrombin inhibitors from Bayer, showing attempts to weaken PXR activity by increasing polarity in the hydrophobic cage, <b>160</b>, and decreasing the strength of the H-bond interaction with Gln285 on the polar rim, <b>161</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Crystal structure of thrombin inhibitor <b>78</b> from Bayer with PXR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI">6TFI</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0049.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Summary profiles of key thrombin inhibitors from Bayer showing the best balance between PXR activation and overall profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. SAR around the amide of HCV NS5B inhibitors from Merck showing that replacement of the flexible amide group in <b>167</b> and <b>169</b> by a more rigid piperidine, as found in <b>168</b> and <b>170</b>, reduces PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0051.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. SAR from a series of carboxylic acid HCV NS5B inhibitors from Novartis, highlighting the positive impact of adding an alcohol and the impact a methyl group may have.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0052.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. HCV NS5B inhibitors from Vertex showing the impact of chirality on PXR activity and that adding carbon atoms can be beneficial in certain cases. PXR activation is relative to 20 μM rifampicin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0053.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. SAR on PXR activation for a series of 11β-HSD1 inhibitors from Merck (<b>184</b>–<b>187</b>), showing the positive impact of the <i>meta</i>- and <i>para</i>-ethylsulfone on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0054.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. 11β-HSD1 inhibitors from Merck showing attempts to diminish PXR activation by reducing lipophilicity via replacement of the outer phenyl ring of <b>184</b> by aromatic heterocycles (<b>188</b>–<b>192</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0055.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Further variation of the outer phenyl ring of <b>184</b> with heteroaromatic ring systems showing polar groups such as pyrimidine (<b>193</b>), pyrazine (<b>194</b>), and isoxazole (<b>195</b> and <b>196</b>) have a beneficial effect on PXR activation, whereas lipophilic systems such as thiophene (<b>197</b>) do not.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0056.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Divergent SAR for Cl-replacements from a series of 11β-HSD1 inhibitors from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0057.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Effect on PXR activation of replacement of the outer phenyl ring on the right-hand side by polar groups (<b>201</b>–<b>203</b>) or removal (<b>204</b>) from a series of 11β-HSD1 inhibitors from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0058.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Reduction of clearance by addition of a fluorine atom to the cyclobutyl ring of <b>194</b> resulted in the identification of <b>205</b>, which maintained low PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0059.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. SAR of PXR activation from a series of aminothiazolone 11β-HSD1 inhibitors from Amgen, showing that polar groups attached to the highlighted phenyl ring can reduce PXR activity, <b>208</b> and <b>209</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0060.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Alkyl alcohol derivatives <b>210</b> and <b>211</b> and the beneficial effect of fluorination of the left-hand side phenyl ring (<b>210</b>, <b>212</b>, <b>213</b>, and <b>214</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0061.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. PXR SAR for a series of amide 11β-HSD1 inhibitors from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0062.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. PXR SAR for aryl ether modification from a series of BMS 11β-HSD1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0063.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. PXR SAR for alkyl ether derivatives (<b>229</b> and <b>230</b>) and directly linked alkyl groups (<b>231</b>–<b>233</b>) from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0064.jpeg" id="rightTab-gr64" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Subtle structural modification of <b>234</b> resulted in <b>235</b>, with significant diminution of PXR activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0065.jpeg" id="rightTab-gr65" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. B1 antagonists from Merck showing that replacement of a trifluoromethyl amide (<b>236</b>) by more polar groups (<b>237</b>–<b>239</b>) can have a beneficial effect on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0066.jpeg" id="rightTab-gr66" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. SAR for PXR activation from a series of T-type Ca<sup>2+</sup> antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0067.jpeg" id="rightTab-gr67" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Further PXR SAR from Merck T-type Ca<sup>2+</sup> channel blockers showing the benefit of polarity (N-oxide) and removing fluorine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0068.jpeg" id="rightTab-gr68" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Summary showing the structural modification from BSM-536924 (<b>248</b>) to BMS-695735 (<b>249</b>) to overcome PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig69" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Figure 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0069.jpeg" id="rightTab-gr69" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 69. <b>267</b> and <b>268</b> showing the two-point SAR combination still has low PXR activation in the IGF-1R inhibitor series from BMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig69"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig70" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Figure 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0070.jpeg" id="rightTab-gr70" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 70. SAR of PXR activation within a series of NOP agonists from Schering-Plough showing the SAR for substitution on the phenyl ring (<b>269</b>–<b>272</b>) and the amide (<b>269</b>, <b>273</b>–<b>276</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig70"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig71" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Figure 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0071.jpeg" id="rightTab-gr71" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 71. SAR of PXR activation in a series of smoothened antagonists (<b>277</b>–<b>281</b>) from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig71"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig72" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Figure 72</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0072.jpeg" id="rightTab-gr72" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 72. Minimal impact on PXR activity by replacing the left-hand side phenyl ring (<b>278</b>) by pyridine (<b>281</b>–<b>283</b>) for smoothened antagonists from Amgen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig72"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig73" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Figure 73</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0073.jpeg" id="rightTab-gr73" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 73. Effect of aza-phthalazine analogues (<b>284</b>–<b>287</b>) on PXR activity from Amgen smoothened antagonists, resulting in the optimal derivative <b>288</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig73"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig74" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Figure 74</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0074.jpeg" id="rightTab-gr74" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 74. Na<sub>v</sub>1.7 inhibitors from Amgen, showing reduction in CYP3A4 induction by replacing a trifluoromethyl group (<b>290</b>) by a fluoro-phenyl ring (<b>291</b>) and subsequent modulation of the aromatic amine of the sulfonamide, showing the beneficial effect of thiadiazole (<b>294</b>) and oxadiazole (<b>295</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig74"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig75" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Figure 75</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0075.jpeg" id="rightTab-gr75" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 75. Na<sub>v</sub>1.7 inhibitors from Amgen showing that subtle changes in structure can have a large impact on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig75"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig76" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Figure 76</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0076.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0076.jpeg" id="rightTab-gr76" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 76. Two further matched airs from Amgen Na<sub>v</sub>1.7 inhibitors showing the beneficial effect of the <i>meta</i>-trifluoromethyl group in reducing PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig76"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig77" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Figure 77</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0077.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0077.jpeg" id="rightTab-gr77" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 77. PXR activation SAR from Amgen Na<sub>v</sub>1.7 antagonists showing effects of substitution <i>para</i>-to the methoxy group on the inner ring and the beneficial effect of substitution at the <i>para</i>-position on the outer phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0077.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig77"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig78" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Figure 78</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0078.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0078.jpeg" id="rightTab-gr78" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 78. Na<sub>v</sub>1.7 inhibitors from Amgen showing the variation of PXR activation versus trifluoromethyl substitution, <b>312</b>–<b>314</b>, the effect of alternative bulky <i>meta</i>-substituents (<b>315</b>) and combinations of <i>meta</i>- and <i>para</i>-substituents (<b>316</b> and <b>317</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0078.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig78"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig79" data-index="79" class="article__inlineFigure"><h2 class="fig-label">Figure 79</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0079.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0079.jpeg" id="rightTab-gr79" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 79. Further Na<sub>v</sub>1.7 inhibitors from Amgen showing the beneficial effect of 3,4-disubstitution on PXR activation, along with AM-0466 (<b>321</b>) which had the overall best balance of properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0079.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig79"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig80" data-index="80" class="article__inlineFigure"><h2 class="fig-label">Figure 80</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0080.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0080.jpeg" id="rightTab-gr80" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 80. PXR activation SAR from a series of IDH1 inhibitors from Agios.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0080.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig80"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig81" data-index="81" class="article__inlineFigure"><h2 class="fig-label">Figure 81</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0081.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0081.jpeg" id="rightTab-gr81" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 81. SAR of MK-3901 (<b>327</b>) analogues versus PXR activation for a series of P2X3 antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0081.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig81"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig82" data-index="82" class="article__inlineFigure"><h2 class="fig-label">Figure 82</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0082.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0082.jpeg" id="rightTab-gr82" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 82. Final PXR SAR optimization of P2X3 antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0082.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig82"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig83" data-index="83" class="article__inlineFigure"><h2 class="fig-label">Figure 83</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0083.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0083.jpeg" id="rightTab-gr83" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 83. SAR from the Amgen TRPM8 antagonist project showing attempts to reduce lipophilicity in order to ameliorate CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0083.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig83"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig84" data-index="84" class="article__inlineFigure"><h2 class="fig-label">Figure 84</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0084.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0084.jpeg" id="rightTab-gr84" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 84. Compounds with the best CYP3A4 induction profiles from the Amgen TRPM8 antagonist project.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0084.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig84"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig85" data-index="85" class="article__inlineFigure"><h2 class="fig-label">Figure 85</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0085.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0085.jpeg" id="rightTab-gr85" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 85. SAR from a series of CFTR correctors from AbbVie showing that slight modifications of <b>340</b> were able to reduce (<b>341</b>) or increase (<b>342</b> and <b>343</b>) CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0085.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig85"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig86" data-index="86" class="article__inlineFigure"><h2 class="fig-label">Figure 86</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0086.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0086.jpeg" id="rightTab-gr86" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 86. Further SAR from a series of CFTR correctors from AbbVie, showing the beneficial effect of moving the carboxylic acid group on potency and CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0086.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig86"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig87" data-index="87" class="article__inlineFigure"><h2 class="fig-label">Figure 87</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0087.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0087.jpeg" id="rightTab-gr87" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 87. SAR from a series of CFTR correctors from AbbVie showing simple modification of the southern amide can greatly diminish CYP3A4 induction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0087.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig87"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig88" data-index="88" class="article__inlineFigure"><h2 class="fig-label">Figure 88</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0088.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0088.jpeg" id="rightTab-gr88" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 88. SAR for CYP3A4 induction for a series of CFTR correctors from AbbVie showing the effect of <i>ortho</i>-substitution of the eastern phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0088.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig88"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig89" data-index="89" class="article__inlineFigure"><h2 class="fig-label">Figure 89</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0089.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0089.jpeg" id="rightTab-gr89" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 89. Prototypical RORγ inverse agonist from Phenex and Janssen (<b>352</b>) and related derivatives <b>353</b> and <b>354</b>, designed to increase polarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0089.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig89"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig90" data-index="90" class="article__inlineFigure"><h2 class="fig-label">Figure 90</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0090.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0090.jpeg" id="rightTab-gr90" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 90. SAR for PXR activation via modulation of the naphthyl moiety in a series of RORγ inverse agonists from Phenex and Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0090.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig90"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig91" data-index="91" class="article__inlineFigure"><h2 class="fig-label">Figure 91</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0091.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0091.jpeg" id="rightTab-gr91" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 91. SAR for PXR activation from a series of RORγ inverse agonists from Janssen and Phenex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0091.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig91"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig92" data-index="92" class="article__inlineFigure"><h2 class="fig-label">Figure 92</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0092.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0092.jpeg" id="rightTab-gr92" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 92. PXR activation SAR from a series of amide RORγ inverse agonists from Phenex and Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0092.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig92"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig93" data-index="93" class="article__inlineFigure"><h2 class="fig-label">Figure 93</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0093.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0093.jpeg" id="rightTab-gr93" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 93. Highlights of PXR SAR from left-hand side amide modifications from Janssen/Phenex RORγ inverse agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0093.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig93"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig94" data-index="94" class="article__inlineFigure"><h2 class="fig-label">Figure 94</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0094.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0094.jpeg" id="rightTab-gr94" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 94. Effect of replacing the acetamide group in RORγ inverse agonist <b>374</b> on PXR activation and effect of moving the methyl group on the pyrrolidine ring (<b>376</b> vs <b>377</b>). Compounds are racemic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0094.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig94"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig95" data-index="95" class="article__inlineFigure"><h2 class="fig-label">Figure 95</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0095.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0095.jpeg" id="rightTab-gr95" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 95. Addition of polar groups to the <i>para</i>-position of the benzyl moiety in the RORγ inverse agonist <b>379</b> increases PXR activation. Compounds are single enantiomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0095.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig95"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig96" data-index="96" class="article__inlineFigure"><h2 class="fig-label">Figure 96</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0096.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0096.jpeg" id="rightTab-gr96" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 96. Fluorination of the HFIPA moiety in <b>382</b> drastically reduced PXR activation (<b>383</b>), whereas addition of polar groups to the acetamide on the piperidine in <b>384</b> and <b>385</b> had little impact on PXR activation. Compounds are single enantiomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0096.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig96"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig97" data-index="97" class="article__inlineFigure"><h2 class="fig-label">Figure 97</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0097.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0097.jpeg" id="rightTab-gr97" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 97. DOT1L inhibitors from Novartis (<b>386</b>–<b>389</b>) highlighting <i>in vivo</i> SAR on autoinduction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0097.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig97"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig98" data-index="98" class="article__inlineFigure"><h2 class="fig-label">Figure 98</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0098.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0098.jpeg" id="rightTab-gr98" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 98. Structures and profiles of Roche HBV capsid inhibitors HAP_R10 (<b>390</b>) and HAP_R01 (<b>391</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0098.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig98"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig99" data-index="99" class="article__inlineFigure"><h2 class="fig-label">Figure 99</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0099.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0099.jpeg" id="rightTab-gr99" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 99. Conformations of <b>391</b> in gray (HAP_R01) bound to Cp149, showing the conformation of the molecule, in particular the halogenated phenyl ring is perpendicular to that of the dihydropyrimidine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WRE">5WRE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0099.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig99"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig100" data-index="100" class="article__inlineFigure"><h2 class="fig-label">Figure 100</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0100.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0100.jpeg" id="rightTab-gr100" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 100. Final optimization of HBV capsid inhibitors from Roche resulting in <b>398</b> and, ultimately, <b>399</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0100.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig100"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig101" data-index="101" class="article__inlineFigure"><h2 class="fig-label">Figure 101</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0101.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0101.jpeg" id="rightTab-gr101" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 101. Summary of structural modification undertaken by Roche with a very subtle change ultimately having a big impact on PXR activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0101.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig101"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig102" data-index="102" class="article__inlineFigure"><h2 class="fig-label">Figure 102</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0102.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0102.jpeg" id="rightTab-gr102" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 102. CYP induction SAR from a series of EZH2 inhibitors from Constellation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0102.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig102"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig103" data-index="103" class="article__inlineFigure"><h2 class="fig-label">Figure 103</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0103.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0103.jpeg" id="rightTab-gr103" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 103. Effect of varying the methyl ether of azetidine derivative <b>405</b> on CYP3A4 induction for a series of EZH2 inhibitors from Constellation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0103.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig103"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig104" data-index="104" class="article__inlineFigure"><h2 class="fig-label">Figure 104</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0104.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0104.jpeg" id="rightTab-gr104" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 104. SAR from Constellation EZH2 inhibitors showing the effect of azaindole substitution on CYP3A4 upregulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0104.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig104"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig105" data-index="105" class="article__inlineFigure"><h2 class="fig-label">Figure 105</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0105.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0105.jpeg" id="rightTab-gr105" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 105. PXR SAR for a series of OX1 antagonists from Janssen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0105.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig105"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig106" data-index="106" class="article__inlineFigure"><h2 class="fig-label">Figure 106</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0106.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0106.jpeg" id="rightTab-gr106" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 106. Summary of some key recurrent/general pharmacophoric alerts for PXR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0106.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig106"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig107" data-index="107" class="article__inlineFigure"><h2 class="fig-label">Figure 107</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0107.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0107.jpeg" id="rightTab-gr107" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 107. (a) Structure of PXR with clotrimazole (<b>417</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXA">7AXA</a>). (b) Structure of PXR with clotrimazole (<b>417</b>) and estradiol (<b>425</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXJ">7AXJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0107.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig107"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig108" data-index="108" class="article__inlineFigure"><h2 class="fig-label">Figure 108</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0108.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0108.jpeg" id="rightTab-gr108" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 108. Structure of PXR with covalent ligands. (a) Fipronil (<b>420</b>) in gray showing a covalent bond between Cys284 and the nitrile group (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXD">7AXD</a>). (b) Structure of PXR with pretilachlor showing two copies of the ligand (black and gray) in the binding pocket, one of which forms a covalent bond between Cys207 and the chloro-acetamide (<b>422</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF">7AXF</a>). (c) Rotated view of PXR with pretilachlor showing two copies of the ligand (black and gray) in the binding pocket, one of which forms a covalent bond between Cys207 and the chloro-acetamide (<b>422</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF">7AXF</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0108.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig108"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig109" data-index="109" class="article__inlineFigure"><h2 class="fig-label">Figure 109</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/medium/jm0c02245_0109.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0109.jpeg" id="rightTab-gr109" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 109. Structure of PXR with (a) ferutinin (<b>419</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXC">7AXC</a>). (b) Oxadiazon (<b>421</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXE">7AXE</a>). (c) α-Zearalanol (<b>424</b>) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXH">7AXH</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c02245/20210520/images/large/jm0c02245_0109.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02245&amp;id=fig109"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 258 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterström, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. M.</span></span> <span> </span><span class="NLM_article-title">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80900-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0092-8674%2800%2980900-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9489701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=73-82&issue=1&author=S.+A.+Kliewerauthor=J.+T.+Mooreauthor=L.+Wadeauthor=J.+L.+Staudingerauthor=M.+A.+Watsonauthor=S.+A.+Jonesauthor=D.+D.+McKeeauthor=B.+B.+Oliverauthor=T.+M.+Willsonauthor=R.+H.+Zetterstr%C3%B6mauthor=T.+Perlmannauthor=J.+M.+Lehmann&title=An+orphan+nuclear+receptor+activated+by+pregnanes+defines+a+novel+steroid+signaling+pathway&doi=10.1016%2FS0092-8674%2800%2980900-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span></div><div class="casAuthors">Kliewer, Steven A.; Moore, John T.; Wade, Laura; Staudinger, Jeff L.; Watson, Michael A.; Jones, Stacey A.; McKee, David D.; Oliver, Beverly B.; Willson, Timothy M.; Zetterstrom, Rolf H.; Perlmann, Thomas; Lehmann, Jurgen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors.  We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids.  PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids.  Notably, PXR.1 is efficaciously activated by pregnenolone 16α-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo.  Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcj-Q4c6TTLVg90H21EOLACvtfcHk0lha60K9bm-Nww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D&md5=1c24d97b161b497c4d2503e7b7adb778</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980900-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980900-9%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DL.%26aulast%3DStaudinger%26aufirst%3DJ.%2BL.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZetterstr%25C3%25B6m%26aufirst%3DR.%2BH.%26aulast%3DPerlmann%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520orphan%2520nuclear%2520receptor%2520activated%2520by%2520pregnanes%2520defines%2520a%2520novel%2520steroid%2520signaling%2520pathway%26jtitle%3DCell%26date%3D1998%26volume%3D92%26issue%3D1%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0092-8674%2800%2980900-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span> <span> </span><span class="NLM_article-title">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1023</span>, <span class="refDoi"> DOI: 10.1172/JCI3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1172%2FJCI3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9727070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1016-1023&issue=5&author=J.+M.+Lehmannauthor=D.+D.+McKeeauthor=M.+A.+Watsonauthor=T.+M.+Willsonauthor=J.+T.+Mooreauthor=S.+A.+Kliewer&title=The+human+orphan+nuclear+receptor+PXR+is+activated+by+compounds+that+regulate+CYP3A4+gene+expression+and+cause+drug+interactions&doi=10.1172%2FJCI3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span></div><div class="casAuthors">Lehmann, Jurgen M.; McKee, David D.; Watson, Michael A.; Willson, Timothy M.; Moore, John T.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the oxidative metab. of a wide variety of xenobiotics including an estd. 60% of all clin. used drugs.  Although expression of the CYP3A4 gene is known to be induced in response to a variety of compds., the mechanism underlying this induction, which represents a basis for drug interactions in patients, has remained unclear.  The authors report the identification of a human (h) orphan nuclear receptor, termed the pregnane X receptor (PXR), that binds to a response element in the CYP3A4 promoter and is activated by a range of drugs known to induce CYP3A4 expression.  Comparison of hPXR with the recently cloned mouse PXR reveals marked differences in their activation by certain drugs, which may account in part for the species-specific effects of compds. on CYP3A gene expression.  These findings provide a mol. explanation for the ability of disparate chems. to induce CYP3A4 levels and, furthermore, provide a basis for developing in vitro assays to aid in predicting whether drugs will interact in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7B4VVObDCH7Vg90H21EOLACvtfcHk0lha60K9bm-Nww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D&md5=536bd0a0a80d2d6b36cdc7747a8e0fd0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1172%2FJCI3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3703%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DThe%2520human%2520orphan%2520nuclear%2520receptor%2520PXR%2520is%2520activated%2520by%2520compounds%2520that%2520regulate%2520CYP3A4%2520gene%2520expression%2520and%2520cause%2520drug%2520interactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26issue%3D5%26spage%3D1016%26epage%3D1023%26doi%3D10.1172%2FJCI3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juguilon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolado, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Meter, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">SXR, a novel steroid and xenobiotic-sensing nuclear receptor</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3195</span>– <span class="NLM_lpage">3205</span>, <span class="refDoi"> DOI: 10.1101/gad.12.20.3195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1101%2Fgad.12.20.3195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9784494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVSnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=3195-3205&issue=20&author=B.+Blumbergauthor=W.+Sabbaghauthor=H.+Juguilonauthor=J.+Boladoauthor=C.+M.+van%0AMeterauthor=E.+S.+Ongauthor=R.+M.+Evans&title=SXR%2C+a+novel+steroid+and+xenobiotic-sensing+nuclear+receptor&doi=10.1101%2Fgad.12.20.3195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">SXR, a novel steroid and xenobiotic-sensing nuclear receptor</span></div><div class="casAuthors">Blumberg, Bruce; Sabbagh, Walid, Jr.; Juguilon, Henry; Bolado, Jack, Jr.; Van Meter, Casey M.; Ong, Estelita S.; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3195-3205</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">An important requirement for physiol. homeostasis is the detoxification and removal of endogenous hormones and xenobiotic compds. with biol. activity.  Much of the detoxification is performed by cytochrome P 450 enzymes, many of which have broad substrate specificity and are inducible by hundreds of different compds., including steroids.  The ingestion of dietary steroids and lipids induces the same enzymes; therefore, they would appear to be integrated into a coordinated metabolic pathway.  Instead of possessing hundreds of receptors, one for each inducing compd., we propose the existence of a few broad specificity, low-affinity sensing receptors that would monitor aggregate levels of inducers to trigger prodn. of metabolizing enzymes.  In support of this model, we have isolated a novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), which activates transcription in response to a diversity of natural and synthetic compds.  SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P 450 genes and is expressed in tissues in which these catabolic enzymes are expressed.  These results strongly support the steroid sensor hypothesis and suggest that broad specificity sensing receptors may represent a novel branch of the nuclear receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe45GV6SpF3rVg90H21EOLACvtfcHk0li-gSTBvpfi6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVSnsb8%253D&md5=cd22f265a573af0102e47d412172c499</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.20.3195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.20.3195%26sid%3Dliteratum%253Aachs%26aulast%3DBlumberg%26aufirst%3DB.%26aulast%3DSabbagh%26aufirst%3DW.%26aulast%3DJuguilon%26aufirst%3DH.%26aulast%3DBolado%26aufirst%3DJ.%26aulast%3Dvan%2BMeter%26aufirst%3DC.%2BM.%26aulast%3DOng%26aufirst%3DE.%2BS.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DSXR%252C%2520a%2520novel%2520steroid%2520and%2520xenobiotic-sensing%2520nuclear%2520receptor%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26issue%3D20%26spage%3D3195%26epage%3D3205%26doi%3D10.1101%2Fgad.12.20.3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertilsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendeberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydow-Bäckman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postlind, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenstam, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12208</span>– <span class="NLM_lpage">12213</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.21.12208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1073%2Fpnas.95.21.12208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=9770465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1cXmsl2rs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12208-12213&issue=21&author=G.+Bertilssonauthor=J.+Heidrichauthor=K.+Svenssonauthor=M.+Asmanauthor=L.+Jendebergauthor=M.+Sydow-B%C3%A4ckmanauthor=R.+Ohlssonauthor=H.+Postlindauthor=P.+Blomquistauthor=A.+Berkenstam&title=Identification+of+a+human+nuclear+receptor+defines+a+new+signaling+pathway+for+CYP3A+induction&doi=10.1073%2Fpnas.95.21.12208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction</span></div><div class="casAuthors">Bertilsson, Goran; Heidrich, Jessica; Svensson, Kristian; Asman, Michael; Jendeberg, Lena; Sydow-Backman, Mona; Ohlsson, Rolf; Postlind, Hans; Blomquist, Patrik; Berkenstam, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12208-12213</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nuclear receptors regulate metabolic pathways in response to changes in the environment by appropriate alterations in gene expression of key metabolic enzymes.  Here, a computational search approach based on iteratively built hidden Markov models of nuclear receptors was used to identify a human nuclear receptor, termed hPAR, that is expressed in liver and intestines.  HPAR was efficiently activated by pregnanes and by clin. used drugs including rifampicin, an antibiotic known to selectively induce human but not murine CYP3A expression.  The CYP3A drug-metabolizing enzymes are expressed in gut and liver in response to environmental chems. and clin. used drugs.  Interestingly, hPAR is not activated by pregnenolone 16α-carbonitrile, which is a potent inducer of murine CYP3A genes and an activator of the mouse receptor PXR.1.  Furthermore, hPAR was found to bind to and trans-activate through a conserved regulatory sequence present in human but not murine CYP3A genes.  These results provide evidence that hPAR and PXR.1 may represent orthologous genes from different species that have evolved to regulate overlapping target genes in response to pharmacol. distinct CYP3A activators, and have potential implications for the in vitro identification of drug interactions important to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6lbkuDG1xyLVg90H21EOLACvtfcHk0li-gSTBvpfi6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsl2rs7w%253D&md5=d53e043b07c6aff3de4c5d4204def3bc</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.21.12208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.21.12208%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DG.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DSvensson%26aufirst%3DK.%26aulast%3DAsman%26aufirst%3DM.%26aulast%3DJendeberg%26aufirst%3DL.%26aulast%3DSydow-B%25C3%25A4ckman%26aufirst%3DM.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DPostlind%26aufirst%3DH.%26aulast%3DBlomquist%26aufirst%3DP.%26aulast%3DBerkenstam%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520human%2520nuclear%2520receptor%2520defines%2520a%2520new%2520signaling%2520pathway%2520for%2520CYP3A%2520induction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D21%26spage%3D12208%26epage%3D12213%26doi%3D10.1073%2Fpnas.95.21.12208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>345</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fjpet.112.201863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23536316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=473-482&issue=3&author=W.+Douauthor=J.+Zhangauthor=E.+Zhangauthor=A.+Sunauthor=L.+Dingauthor=G.+Chouauthor=Z.+Wangauthor=S.+Mani&title=Chrysin+ameliorates+chemically+induced+colitis+in+the+mouse+through+modulation+of+a+PXR%2FNF-%CE%BAB+signaling+pathway&doi=10.1124%2Fjpet.112.201863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway</span></div><div class="casAuthors">Dou, Wei; Zhang, Jingjing; Zhang, Eryun; Sun, Aning; Ding, Lili; Chou, Guixin; Wang, Zhengtao; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted activation of pregnane X receptor (PXR) in recent years has become a therapeutic strategy for inflammatory bowel disease.  Chrysin is a naturally occurring flavonoid with anti-inflammation activity.  The current study investigated the role of chrysin as a putative mouse PXR agonist in preventing exptl. colitis.  Pre-administration of chrysin ameliorated inflammatory symptoms in mouse models of colitis (dextran sodium sulfate- and 2,4,6-trinitrobenzene sulfonic acid-induced) and resulted in down-regulation of nuclear transcription factor κB (NF-κB) target genes (inducible NO synthase, intercellular adhesion mol.-1, monocyte chemotactic protein-1, cyclooxygenase 2, tumor necrosis factor-α, and interleukin 6) in the colon mucosa.  Chrysin inhibited the phosphorylation/degrdn. of inhibitor κBα (IκBα), which correlated with the decrease in the activity of myeloperoxidase and the levels of tumor necrosis factor-κ and interleukin 6 in the colon.  Consistent with the in vivo results, chrysin blocked lipopolysaccharide -stimulated nuclear translocation of NF-κB p65 in mouse macrophage RAW264.7.  Furthermore, chrysin dose-dependently activated human/mouse PXR in reporter gene assays and up-regulated xenobiotic detoxification genes in the colon mucosa, but not in the liver.  Silencing of PXR by RNA interference demonstrated necessity of PXR in mediating chrysin's ability to induce xenobiotic detoxification genes and NF-κB inactivation.  The repression of NF-κB transcription activity by chrysin was confirmed by in vitro PXR transduction.  These findings suggest that the effect of chrysin in preventing chem. induced colitis is mediated in large part by a PXR/NF-κB pathway.  The data also suggest that chrysin or chrysin-like flavonoids could be further developed as intestine-specific PXR activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozsbOWiIBkibVg90H21EOLACvtfcHk0li-gSTBvpfi6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL8%253D&md5=bb07302041857fc39100674b245ed48d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201863%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DChou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DChrysin%2520ameliorates%2520chemically%2520induced%2520colitis%2520in%2520the%2520mouse%2520through%2520modulation%2520of%2520a%2520PXR%252FNF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26issue%3D3%26spage%3D473%26epage%3D482%26doi%3D10.1124%2Fjpet.112.201863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gironella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garambois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudhomme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgaux, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollande, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannequin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span> <span> </span><span class="NLM_article-title">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">56558</span>– <span class="NLM_lpage">56573</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.18632%2Foncotarget.10646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27448961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ktVyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=56558-56573&issue=35&author=C.+Planqueauthor=F.+Rajabiauthor=F.+Grilletauthor=P.+Finettiauthor=F.+Bertucciauthor=M.+Gironellaauthor=J.+J.+Lozanoauthor=B.+Beucherauthor=J.+Giraudauthor=V.+Garamboisauthor=C.+Vincentauthor=D.+Brownauthor=L.+Cailloauthor=J.+Kantarauthor=A.+Pelegrinauthor=M.+Prudhommeauthor=J.+Ripocheauthor=J.+F.+Bourgauxauthor=C.+Ginestierauthor=A.+Castellsauthor=F.+Hollandeauthor=J.+Pannequinauthor=J.+M.+Pascussi&title=Pregnane+X-receptor+promotes+stem+cell-mediated+colon+cancer+relapse&doi=10.18632%2Foncotarget.10646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnane X-receptor promotes stem cell-mediated colon cancer relapse</span></div><div class="casAuthors">Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Planque Chris; Rajabi Fatemeh; Grillet Fanny; Beucher Bertrand; Giraud Julie; Caillo Ludovic; Hollande Frederic; Pannequin Julie; Pascussi Jean Marc; Finetti Pascal; Bertucci Francois; Gironella Meritxell; Lozano Juan Jose; Castells Antoni; Garambois Veronique; Vincent Charles; Pelegrin Andre; Brown Daniel; Hollande Frederic; Kantar Jovana; Prudhomme Michel; Ripoche Jeremie; Bourgaux Jean Francois; Ginestier Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">56558-56573</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs).  Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence.  First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance.  Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy.  This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpvV4km2DSQK2q3xNe7a7QfW6udTcc2ebsh-4YoyMqtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ktVyqsg%253D%253D&md5=00ab1dd5dbf30db9dddfc20c28964a63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10646%26sid%3Dliteratum%253Aachs%26aulast%3DPlanque%26aufirst%3DC.%26aulast%3DRajabi%26aufirst%3DF.%26aulast%3DGrillet%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DGironella%26aufirst%3DM.%26aulast%3DLozano%26aufirst%3DJ.%2BJ.%26aulast%3DBeucher%26aufirst%3DB.%26aulast%3DGiraud%26aufirst%3DJ.%26aulast%3DGarambois%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DCaillo%26aufirst%3DL.%26aulast%3DKantar%26aufirst%3DJ.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DPrudhomme%26aufirst%3DM.%26aulast%3DRipoche%26aufirst%3DJ.%26aulast%3DBourgaux%26aufirst%3DJ.%2BF.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DCastells%26aufirst%3DA.%26aulast%3DHollande%26aufirst%3DF.%26aulast%3DPannequin%26aufirst%3DJ.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26atitle%3DPregnane%2520X-receptor%2520promotes%2520stem%2520cell-mediated%2520colon%2520cancer%2520relapse%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D35%26spage%3D56558%26epage%3D56573%26doi%3D10.18632%2Foncotarget.10646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.2011.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21832990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=575-581&issue=4&author=K.+Maedaauthor=Y.+Ikedaauthor=T.+Fujitaauthor=K.+Yoshidaauthor=Y.+Azumaauthor=Y.+Haruyamaauthor=N.+Yamaneauthor=Y.+Kumagaiauthor=Y.+Sugiyama&title=Identification+of+the+rate-determining+process+in+the+hepatic+clearance+of+atorvastatin+in+a+clinical+cassette+microdosing+study&doi=10.1038%2Fclpt.2011.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study</span></div><div class="casAuthors">Maeda, K.; Ikeda, Y.; Fujita, T.; Yoshida, K.; Azuma, Y.; Haruyama, Y.; Yamane, N.; Kumagai, Y.; Sugiyama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clearance of atorvastatin occurs through hepatic uptake by org. anion transporting polypeptides (OATPs) and subsequent metab. by cytochrome P 450 (CYP) 3A4.  To demonstrate the relative importance of OATPs and CYP3A4 in the hepatic elimination of atorvastatin in vivo, a clin. cassette microdose study was performed.  A cocktail consisting of a microdose of atorvastatin along with probe substrates for OATPs (pravastatin) and CYP3A4 (midazolam) was orally administered to eight healthy volunteers.  The pharmacokinetics of this cocktail was obsd. at baseline, after an oral dose of 600 mg rifampicin (an inhibitor of OATPs), and after an i.v. dose of 200 mg itraconazole (a CYP3A4 inhibitor).  Rifampicin increased the pravastatin dose-normalized area under the plasma concn.-time curve (AUC) (4.6-fold), and itraconazole significantly increased the midazolam dose-normalized AUC (1.7-fold).  The atorvastatin dose-normalized AUC increased 12-fold when coadministered with rifampicin but did not change when coadministered with itraconazole.  These results indicate that hepatic uptake via OATPs makes the dominant contribution to the hepatic elimination of atorvastatin at a subtherapeutic microdose.  Clin. Pharmacol. & Therapeutics (2011) 90 4, 575-581. doi:10.1038/clpt.2011.142.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RhNvYVyyPLVg90H21EOLACvtfcHk0lil3fHr9ECS7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqtbbM&md5=8bcac4f57a99151af0aee27d96370525</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.142%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DY.%26aulast%3DHaruyama%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DN.%26aulast%3DKumagai%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520the%2520rate-determining%2520process%2520in%2520the%2520hepatic%2520clearance%2520of%2520atorvastatin%2520in%2520a%2520clinical%2520cassette%2520microdosing%2520study%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D90%26issue%3D4%26spage%3D575%26epage%3D581%26doi%3D10.1038%2Fclpt.2011.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">14581</span>– <span class="NLM_lpage">14587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010173200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M010173200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11297522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=14581-14587&issue=18&author=A.+Geickauthor=M.+Eichelbaumauthor=O.+Burk&title=Nuclear+receptor+response+elements+mediate+induction+of+intestinal+MDR1+by+rifampin&doi=10.1074%2Fjbc.M010173200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span></div><div class="casAuthors">Geick, Anke; Eichelbaum, Michel; Burk, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">14581-14587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intestinal P-glycoprotein, which is encoded by the MDR1 gene, plays an important role in the absorption and presystemic elimination of many xenobiotics.  Hence, an understanding of the factors regulating its expression and function is of substantial interest.  In addn. to genetic factors, exposure to drugs such as rifampin can profoundly affect its expression.  So far, the mechanisms by which rifampin induces MDR1 expression are poorly understood.  Recent studies demonstrate that the nuclear receptor PXR (pregnane X receptor) is involved in xenobiotic induction of CYP3A4.  Because CYP3A4 and MDR1 are often co-induced, we investigated whether a similar mechanism is also involved in MDR1 induction.  The human colon carcinoma cell line LS174T was used as an intestinal model to study induction because in these cells the endogenous MDR1 gene is highly inducible by rifampin.  The 5'-upstream region of human MDR1 was examd. for the presence of potential PXR response elements.  Several binding sites were identified that form a complex regulatory cluster at about -8 kilobase pairs.  Only one DR4 motif within this cluster is necessary for induction by rifampin.  We conclude that induction of MDR1 is mediated by a DR4 motif in the upstream enhancer at about -8 kilobase pairs, to which PXR binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDciMSSWDvqbVg90H21EOLACvtfcHk0lg-GQwjuB2IuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D&md5=756631447fee46a9a89df3bb5a263ea5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010173200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010173200%26sid%3Dliteratum%253Aachs%26aulast%3DGeick%26aufirst%3DA.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBurk%26aufirst%3DO.%26atitle%3DNuclear%2520receptor%2520response%2520elements%2520mediate%2520induction%2520of%2520intestinal%2520MDR1%2520by%2520rifampin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D18%26spage%3D14581%26epage%3D14587%26doi%3D10.1074%2Fjbc.M010173200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kast, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anisfeld, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontonoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2908</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109326200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M109326200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11706036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=2908-2915&issue=4&author=H.+R.+Kastauthor=B.+Goodwinauthor=P.+T.+Tarrauthor=S.+A.+Jonesauthor=A.+M.+Anisfeldauthor=C.+M.+Stoltzauthor=P.+Tontonozauthor=S.+Kliewerauthor=T.+M.+Willsonauthor=P.+A.+Edwards&title=Regulation+of+multidrug+resistance-associated+protein+2+%28ABCC2%29+by+the+nuclear+receptors+pregnane+X+receptor%2C+farnesoid+X-activated+receptor%2C+and+constitutive+androstane+receptor&doi=10.1074%2Fjbc.M109326200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor</span></div><div class="casAuthors">Kast, Heidi R.; Goodwin, Bryan; Tarr, Paul T.; Jones, Stacey A.; Anisfeld, Andrew M.; Stoltz, Catherine M.; Tontonoz, Peter; Kliewer, Steve; Willson, Timothy M.; Edwards, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2908-2915</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The multidrug resistance-assocd. protein 2 (MRP2, ABCC2), mediates the efflux of several conjugated compds. across the apical membrane of the hepatocyte into the bile canaliculi.  We identified MRP2 in a screen designed to isolate genes that are regulated by the farnesoid X-activated receptor (FXR, NR1H4).  MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands.  In addn., we have shown that MRP2 expression is regulated by the pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3).  Thus, treatment of rodent hepatocytes with PXR or CAR agonists results in a robust induction of MRP2 mRNA levels.  The dexamethasone- and pregnenolone 16α-carbonitrile-dependent induction of MRP2 expression was not evident in hepatocytes derived from PXR null mice.  In contrast, induction of MRP2 by phenobarbital, an activator of CAR, was comparable in wild-type and PXR null mice.  An unusual 26-bp sequence was identified 440 bp upstream of the MRP2 transcription initiation site that contains an everted repeat of the AGTTCA hexad sepd. by 8 nucleotides (ER-8).  PXR, CAR, and FXR bound with high affinity to this element as heterodimers with the retinoid X receptor α (RXRα, NR2B1).  Luciferase reporter gene constructs contg. 1 kb of the rat MRP2 promoter were prepd. and transiently transfected into HepG2 cells.  Luciferase activity was induced in a PXR-, CAR-, or FXR-dependent manner.  Furthermore, the isolated ER-8 element was capable of conferring PXR, CAR, and FXR responsiveness on a heterologous thymidine kinase promoter.  Mutation of the ER-8 element abolished the nuclear receptor response.  These studies demonstrate that MRP2 is regulated by three distinct nuclear receptor signaling pathways that converge on a common response element in the 5'-flanking region of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVkHAzOXsXVrVg90H21EOLACvtfcHk0lg-GQwjuB2IuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVSgt7c%253D&md5=4695a74d9fe74de16c078ef355c33af4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109326200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109326200%26sid%3Dliteratum%253Aachs%26aulast%3DKast%26aufirst%3DH.%2BR.%26aulast%3DGoodwin%26aufirst%3DB.%26aulast%3DTarr%26aufirst%3DP.%2BT.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DAnisfeld%26aufirst%3DA.%2BM.%26aulast%3DStoltz%26aufirst%3DC.%2BM.%26aulast%3DTontonoz%26aufirst%3DP.%26aulast%3DKliewer%26aufirst%3DS.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DEdwards%26aufirst%3DP.%2BA.%26atitle%3DRegulation%2520of%2520multidrug%2520resistance-associated%2520protein%25202%2520%2528ABCC2%2529%2520by%2520the%2520nuclear%2520receptors%2520pregnane%2520X%2520receptor%252C%2520farnesoid%2520X-activated%2520receptor%252C%2520and%2520constitutive%2520androstane%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D4%26spage%3D2908%26epage%3D2915%26doi%3D10.1074%2Fjbc.M109326200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squires, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negishi, M.</span></span> <span> </span><span class="NLM_article-title">Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">49307</span>– <span class="NLM_lpage">49314</span>, <span class="refDoi"> DOI: 10.1074/jbc.M407281200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M407281200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15347657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslKis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=49307-49314&issue=47&author=E.+J.+Squiresauthor=T.+Sueyoshiauthor=M.+Negishi&title=Cytoplasmic+localization+of+pregnane+X+receptor+and+ligand-dependent+nuclear+translocation+in+mouse+liver&doi=10.1074%2Fjbc.M407281200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoplasmic Localization of Pregnane X Receptor and Ligand-dependent Nuclear Translocation in Mouse Liver</span></div><div class="casAuthors">Squires, E. James; Sueyoshi, Tatsuya; Negishi, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">49307-49314</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) plays an important role in the response to xenobiotics and endogenous toxins.  We have used a specific anti-PXR antibody in the Western blotting of mouse liver nuclear exts. to show that PXR is accumulated in the nucleus after treatment with 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN), followed by an increase in Cyp3a11 mRNA.  Expression of wild type PXR and various mutants as green fluorescent fusion proteins in mouse livers showed that PXR was retained in the cytoplasm from where PCN treatment translocated PXR into the nucleus.  Furthermore, the xenochem. response signal, the nuclear translocation signal, and the activation function 2 domain were all required for the nuclear translocation to occur.  Immunopptn. expts. using the hsp90 antibody demonstrated the presence of PXR in a complex with the endogenous cytoplasmic constitutive active/androstane receptor retention protein (CCRP) in HepG2 cells.  Fluorescence resonance energy transfer anal. of mouse liver sections after co-expression of cyan fluorescent protein-CCRP and yellow fluorescent protein-PXR also indicated that CCRP and PXR were closely assocd. in vivo.  Overexpression of exogenous CCRP increased the cytoplasmic level of the PXR·CCRP·hsp90 complex, whereas a decrease in endogenous CCRP by treatment with small interfering RNA for CCRP repressed the PXR-mediated reporter activity in HepG2 cells.  We conclude that the CCRP mediates the retention of PXR in the cytosol and modulates the activation of PXR in response to PCN treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkTHaprvFNEbVg90H21EOLACvtfcHk0lg-GQwjuB2IuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslKis7c%253D&md5=b2999e9f5af168accfc3d7be4749f58f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M407281200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M407281200%26sid%3Dliteratum%253Aachs%26aulast%3DSquires%26aufirst%3DE.%2BJ.%26aulast%3DSueyoshi%26aufirst%3DT.%26aulast%3DNegishi%26aufirst%3DM.%26atitle%3DCytoplasmic%2520localization%2520of%2520pregnane%2520X%2520receptor%2520and%2520ligand-dependent%2520nuclear%2520translocation%2520in%2520mouse%2520liver%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D47%26spage%3D49307%26epage%3D49314%26doi%3D10.1074%2Fjbc.M407281200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. D.</span></span> <span> </span><span class="NLM_article-title">Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT)</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1124/mol.105.013375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.105.013375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16219912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlWgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=99-108&issue=1&author=D.+R.+Johnsonauthor=C.+W.+Liauthor=L.+Y.+Chenauthor=J.+C.+Ghoshauthor=J.+D.+Chen&title=Regulation+and+binding+of+pregnane+X+receptor+by+nuclear+receptor+corepressor+silencing+mediator+of+retinoid+and+thyroid+hormone+receptors+%28SMRT%29&doi=10.1124%2Fmol.105.013375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT)</span></div><div class="casAuthors">Johnson, David R.; Li, Chia-Wei; Chen, Liuh-Yow; Ghosh, Jagadish C.; Chen, J. Don</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-108</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is an orphan nuclear receptor predominantly expressed in liver and intestine.  PXR coordinates hepatic responses to prevent liver injury induced by environmental toxins.  PXR activates cytochrome P 450 3A4 gene expression upon binding to rifampicin (Rif) and clotrimazole (CTZ) by recruiting transcriptional coactivators.  It remains unclear whether and how PXR regulates gene expression in the absence of ligand.  In this study, the authors analyzed interactions between PXR and the silencing mediator of retinoid and thyroid hormone receptors (SMRT) and detd. the role of SMRT in regulating PXR activity.  The authors show that SMRT interacts with PXR in glutathione S-transferase pull-down, yeast two-hybrid, and mammalian two-hybrid assays.  The interaction is mediated through the ligand-binding domain of PXR and the SMRT's nuclear receptor-interacting domain 2.  The PXR-SMRT interaction is sensitive to species-specific ligands, and Rif causes an exchange of the corepressor SMRT with the p160 coactivator known as receptor-assocd. coactivator 3 (RAC3).  Deletion of the PXR's activation function 2 helix enhances SMRT binding and abolishes ligand-dependent dissocn. of SMRT.  Coexpression of PXR with SMRT results in colocalization at discrete nuclear foci.  Finally, transient transfection assays show that overexpression of SMRT inhibits PXR's transactivation of the Cyp3A4 promoter, whereas silencing of SMRT enhances the reporter expression.  Taken together, the authors' results suggest that the corepressor SMRT may bind to and regulate the transcriptional activity of PXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCt76NaFMaEbVg90H21EOLACvtfcHk0lhiKtodhdt54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlWgtg%253D%253D&md5=9d68053e214e7abcbdd3fe0ad4f30721</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.013375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.013375%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DL.%2BY.%26aulast%3DGhosh%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DJ.%2BD.%26atitle%3DRegulation%2520and%2520binding%2520of%2520pregnane%2520X%2520receptor%2520by%2520nuclear%2520receptor%2520corepressor%2520silencing%2520mediator%2520of%2520retinoid%2520and%2520thyroid%2520hormone%2520receptors%2520%2528SMRT%2529%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D69%26issue%3D1%26spage%3D99%26epage%3D108%26doi%3D10.1124%2Fmol.105.013375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labhart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span> <span> </span><span class="NLM_article-title">Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn1047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fnar%2Fgkn1047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19129222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivFSgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1160-1173&issue=4&author=N.+Hariparsadauthor=X.+Chuauthor=J.+Yabutauthor=P.+Labhartauthor=D.+P.+Hartleyauthor=X.+Daiauthor=R.+Evers&title=Identification+of+pregnane-X+receptor+target+genes+and+coactivator+and+corepressor+binding+to+promoter+elements+in+human+hepatocytes&doi=10.1093%2Fnar%2Fgkn1047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes</span></div><div class="casAuthors">Hariparsad, Niresh; Chu, Xiaoyan; Yabut, Jocelyn; Labhart, Paul; Hartley, Dylan P.; Dai, Xudong; Evers, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1160-1173</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Chromatin immunopptn. (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes.  Genes, both previously known to be involved and not known to be involved in drug disposition, with PXR response elements (PXREs) located upstream, within or downstream from their potentially assocd. genes, were identified.  Validation expts. identified several new drug disposition genes with PXR binding sites.  Of these, only CYP4F12 demonstrated increased binding in the presence of rifampicin.  The role of PXR in the basal and inductive response of CYP4F12 was confirmed in hepatocytes in which PXR was silenced.  We also assessed the assocn. of PXR-coactivators and -corepressors with known and newly identified PXREs.  Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.  Promoter-dependent patterns were obsd. with respect to the binding of various coactivators and corepressors involved in the regulation of CYP4F12, CYP3A4, CYP2B6, UGT1A1 and P-glycoprotein.  In conclusion, these findings indicate that PXR is involved in the regulation of CYP4F12 and that PXR along with SRC1 binds to a broad range of promoters but that many of these are not inducible by rifampicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn_9fDtL602LVg90H21EOLACvtfcHk0lhiKtodhdt54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivFSgtr0%253D&md5=4d857deb5a6ba9519ad7d9f3d1d76df4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn1047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn1047%26sid%3Dliteratum%253Aachs%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DLabhart%26aufirst%3DP.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DEvers%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520pregnane-X%2520receptor%2520target%2520genes%2520and%2520coactivator%2520and%2520corepressor%2520binding%2520to%2520promoter%2520elements%2520in%2520human%2520hepatocytes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2009%26volume%3D37%26issue%3D4%26spage%3D1160%26epage%3D1173%26doi%3D10.1093%2Fnar%2Fgkn1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talmage, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollet, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural and functional analysis of the human nuclear xenobiotic receptor PXR in complex with RXRalpha</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>425</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2561</span>– <span class="NLM_lpage">2577</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2013.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jmb.2013.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23602807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1altL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2013&pages=2561-2577&issue=14&author=B.+D.+Wallaceauthor=L.+Bettsauthor=G.+Talmageauthor=R.+M.+Polletauthor=N.+S.+Holmanauthor=M.+R.+Redinbo&title=Structural+and+functional+analysis+of+the+human+nuclear+xenobiotic+receptor+PXR+in+complex+with+RXRalpha&doi=10.1016%2Fj.jmb.2013.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of the Human Nuclear Xenobiotic Receptor PXR in Complex with RXRα</span></div><div class="casAuthors">Wallace, Bret D.; Betts, Laurie; Talmage, Garrick; Pollet, Rebecca M.; Holman, Natalie S.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2561-2577</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human nuclear xenobiotic receptor PXR recognizes a range of potentially harmful drugs and endobiotic chems. but must complex with the nuclear receptor RXRα to control the expression of numerous drug metab. genes.  To date, the structural basis and functional consequences of this interaction have remained unclear.  Here, we present 2.8-Å-resoln. crystal structures of the heterodimeric complex formed between the ligand-binding domains of human PXR and RXRα.  These structures establish that PXR and RXRα form a heterotetramer unprecedented in the nuclear receptor family of ligand-regulated transcription factors.  We further show that both PXR and RXRα bind to the transcriptional coregulator SRC-1 with higher affinity when they are part of the PXR/RXRα heterotetramer complex than they do when each ligand-binding domain is examd. alone.  Furthermore, we purify the full-length forms of each receptor from recombinant bacterial expression systems and characterize their interactions with a range of direct and everted repeat DNA elements.  Taken together, these data advance our understanding of PXR, the master regulator of drug metab. gene expression in humans, in its functional partnership with RXRα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGo2ung3hwFbVg90H21EOLACvtfcHk0lhiKtodhdt54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1altL8%253D&md5=4e9381bfb79f59d050f26f3e3ce6c77f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DB.%2BD.%26aulast%3DBetts%26aufirst%3DL.%26aulast%3DTalmage%26aufirst%3DG.%26aulast%3DPollet%26aufirst%3DR.%2BM.%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520and%2520functional%2520analysis%2520of%2520the%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%2520in%2520complex%2520with%2520RXRalpha%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D425%26issue%3D14%26spage%3D2561%26epage%3D2577%26doi%3D10.1016%2Fj.jmb.2013.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkinson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span> <span> </span><span class="NLM_article-title">The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1210/mend.14.1.0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fmend.14.1.0409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10628745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=27-39&issue=1&author=S.+A.+Jonesauthor=L.+B.+Mooreauthor=J.+L.+Shenkauthor=G.+B.+Wiselyauthor=G.+A.+Hamiltonauthor=D.+D.+McKeeauthor=N.+C.+Tomkinsonauthor=E.+L.+LeCluyseauthor=M.+H.+Lambertauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=J.+T.+Moore&title=The+pregnane+X+receptor%3A+a+promiscuous+xenobiotic+receptor+that+has+diverged+during+evolution&doi=10.1210%2Fmend.14.1.0409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution</span></div><div class="casAuthors">Jones, Stacey A.; Moore, Linda B.; Shenk, Jennifer L.; Wisely, G. Bruce; Hamilton, Geraldine A.; McKee, David D.; Tomkinson, Nicholas C. O.; LeCluyse, Edward L.; Lambert, Millard H.; Willson, Timothy M.; Kliewer, Steven A.; Moore, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transcription of genes encoding cytochrome P 450 3A (CYP3A) monooxygenases is induced by a variety of xenobiotics and natural steroids.  There are marked differences in the compds. that induce CYP3A gene expression between species.  Recently, the mouse and human pregnane X receptor (PXR) were shown to be activated by compds. that induce CYP3A expression.  However, most studies of CYP3A regulation have been performed using rabbit and rat hepatocytes.  Here, the authors report the cloning and characterization of PXR from these two species.  PXR is remarkably divergent between species, with the rabbit, rat, and human receptors sharing only approx. 80% amino acid identity in their ligand-binding domains.  This sequence divergence is reflected by marked pharmacol. differences in PXR activation profiles.  For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.  Conversely, pregnane 16α-carbonitrile is a more potent activator of the rat and mouse PXR than the human and rabbit receptor.  The activities of xenobiotics in PXR activation assays correlate well with their ability to induce CYP3A expression in primary hepatocytes.  Through the use of a novel scintillation proximity binding assay, the authors demonstrate that many of the compds. that induce CYP3A expression bind directly to human PXR.  These data establish PXR as a promiscuous xenobiotic receptor that has diverged during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cu4x3jOH8rVg90H21EOLACvtfcHk0lhlqWutw8vAkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D&md5=50bbd39e3285b9293b8a452798b5cffd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fmend.14.1.0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.14.1.0409%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DShenk%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DTomkinson%26aufirst%3DN.%2BC.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520pregnane%2520X%2520receptor%253A%2520a%2520promiscuous%2520xenobiotic%2520receptor%2520that%2520has%2520diverged%2520during%2520evolution%26jtitle%3DMol.%2520Endocrinol.%26date%3D2000%26volume%3D14%26issue%3D1%26spage%3D27%26epage%3D39%26doi%3D10.1210%2Fmend.14.1.0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tebbens, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanzendorfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavek, P.</span></span> <span> </span><span class="NLM_article-title">Mathematical models in the description of pregnane X receptor (PXR)-regulated cytochrome P450 enzyme induction</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1785</span>, <span class="refDoi"> DOI: 10.3390/ijms19061785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3390%2Fijms19061785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1785&issue=6&author=J.+D.+Tebbensauthor=M.+Azarauthor=E.+Friedmannauthor=M.+Lanzendorferauthor=P.+Pavek&title=Mathematical+models+in+the+description+of+pregnane+X+receptor+%28PXR%29-regulated+cytochrome+P450+enzyme+induction&doi=10.3390%2Fijms19061785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mathematical models in the description of pregnane X receptor (PXR)-regulated cytochrome P450 enzyme induction</span></div><div class="casAuthors">Tebbens, Jurjen Duintjer; Azar, Malek; Friedmann, Elfriede; Lanzendorfer, Martin; Pavek, Petr</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1785/1-1785/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The pregnane X receptor (PXR) is a drug/xenobiotic-activated transcription factor of crucial importance for major cytochrome P 450 xenobiotic-metabolizing enzymes (CYP) expression and regulation in the liver and the intestine.  One of the major target genes regulated by PXR is the cytochrome P 450 enzyme (CYP3A4), which is the most important human drug-metabolizing enzyme.  In addn., PXR is supposed to be involved both in basal and/or inducible expression of many other CYPs, such as CYP2B6, CYP2C8, 2C9 and 2C19, CYP3A5, CYP3A7, and CYP2A6.  Interestingly, the dynamics of PXR-mediated target genes regulation has not been systematically studied and we have only a few mechanistic math. and biol. based models describing gene expression dynamics after PXR activation in cellular models.  Furthermore, few indirect math. PKPD models for prediction of CYP3A metabolic activity in vivo have been built based on compartmental models with respect to drug-drug interactions or hormonal crosstalk.  Importantly, several neg. feedback loops have been described in PXR regulation.  Although current math. models propose these adaptive mechanisms, a comprehensive math. model based on sufficient exptl. data is still missing.  In the current review, we summarize and compare these models and address some issues that should be considered for the improvement of PXR-mediated gene regulation modeling as well as for our better understanding of the quant. and spatial dynamics of CYPs expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBUJxLhKakwLVg90H21EOLACvtfcHk0lhlqWutw8vAkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmt7rM&md5=0a5256ce321c39f19b475e635601c5c4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3390%2Fijms19061785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061785%26sid%3Dliteratum%253Aachs%26aulast%3DTebbens%26aufirst%3DJ.%2BD.%26aulast%3DAzar%26aufirst%3DM.%26aulast%3DFriedmann%26aufirst%3DE.%26aulast%3DLanzendorfer%26aufirst%3DM.%26aulast%3DPavek%26aufirst%3DP.%26atitle%3DMathematical%2520models%2520in%2520the%2520description%2520of%2520pregnane%2520X%2520receptor%2520%2528PXR%2529-regulated%2520cytochrome%2520P450%2520enzyme%2520induction%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D6%26spage%3D1785%26doi%3D10.3390%2Fijms19061785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.2133/dmpk.19.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2133%2Fdmpk.19.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15499180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=135-149&issue=2&author=M.+Nishimuraauthor=S.+Naitoauthor=T.+Yokoi&title=Tissue-specific+mRNA+expression+profiles+of+human+nuclear+receptor+subfamilies&doi=10.2133%2Fdmpk.19.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies</span></div><div class="casAuthors">Nishimura, Masuhiro; Naito, Shinsaku; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-149</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Pairs of forward and reverse primers and TaqMan probes specific to each human nuclear receptor were prepd.  Anal. of the mRNA expression level of each target of 43 nuclear receptors in total RNA from single and pooled specimens of various human organs (liver, kidney, adrenal gland, lung, heart, brain, cerebellum, skeletal muscle, spleen, thymus, thyroid gland, prostate, testis, uterus, placenta, bone marrow, trachea, and salivary gland) was performed by real-time reverse transcription PCR using an ABI PRISM 7700 sequence detector system.  The mRNA expression of 33 nuclear receptors (NR1A1, 1A2, 1B1, 1B2, 1B3, 1C1, 1C2, 1C3, 1D1, 1D2, 1F1, 1F2, 1F3, 1H2, 1H3, 1I1, 1I2, 2B1, 2B2, 2B3, 2C1, 2C2, 2F1, 2F2, 3A2, 3B1, 3C1, 3C2, 3C4, 4A1, 4A2, 4A3, and 6A1) was successfully detected in all of the tissues by this method.  NR1H4, 2A1, and 3C3 mRNAs were not detectable in the heart, heart, and liver, resp.  NR5A2 mRNA was not detectable in either the brain or cerebellum.  NR3A1 mRNA was not detectable in the small intestine, colon, brain, and cerebellum.  NR5A1 mRNA was not detectable in the kidney, stomach, small intestine, and colon.  NR1I3 mRNA was detected in the liver, kidney, stomach, small intestine, adrenal gland, lung, brain, skeletal muscle, thymus, thyroid gland, prostate, testis, placenta, and trachea.  NR2A2 mRNA was detected in the liver, kidney, prostate, testis, uterus, and trachea.  NR2E1 mRNA was detected in the adrenal gland, brain, cerebellum, testis, placenta, and bone marrow.  NR2E3 mRNA was detected in the adrenal gland, thyroid gland, prostate, testis, uterus, trachea, and salivary gland.  This study provides information concerning the tissue distribution of the mRNA expression of 43 human nuclear receptors.  The mRNA expression profiles of CYP3A4, CYP3A5 and ABC-transporters are also shown.  These results are valuable for establishing a nuclear receptor-mediated screening system for new chem. entities in new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLCRH2amGMZbVg90H21EOLACvtfcHk0lhlqWutw8vAkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKjs7Y%253D&md5=e6df59832fc0ae5e0d57846d40eec10a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.19.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.19.135%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DS.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DTissue-specific%2520mRNA%2520expression%2520profiles%2520of%2520human%2520nuclear%2520receptor%2520subfamilies%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2004%26volume%3D19%26issue%3D2%26spage%3D135%26epage%3D149%26doi%3D10.2133%2Fdmpk.19.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">FDA</span>.  <i>Clinical drug interaction studies—Cytochrome
P450
enzyme- and transporter-mediated drug interactions guidance for industry</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Clinical+drug+interaction+studies%E2%80%94Cytochrome%0AP450%0Aenzyme-+and+transporter-mediated+drug+interactions+guidance+for+industry.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DClinical%2520drug%2520interaction%2520studies%25E2%2580%2594Cytochrome%250AP450%250Aenzyme-%2520and%2520transporter-mediated%2520drug%2520interactions%2520guidance%2520for%2520industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laaksovirta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1996.tb00021.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1528-1157.1996.tb00021.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8598183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK28XitV2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=253-257&issue=3&author=J.+T.+Backmanauthor=K.+T.+Olkkolaauthor=M.+Ojalaauthor=H.+Laaksovirtaauthor=P.+J.+Neuvonen&title=Concentrations+and+effects+of+oral+midazolam+are+greatly+reduced+in+patients+treated+with+carbamazepine+or+phenytoin&doi=10.1111%2Fj.1528-1157.1996.tb00021.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin</span></div><div class="casAuthors">Backman, Janne T.; Olkkola, Klaus T.; Ojala, Mikael; Laaksovirta, Hannu; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-7</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Midazolam is a short-acting benzodiazepine which is used as an oral hypnotic agent in several countries.  We studied the pharmacokinetic and pharmacodynamic aspects of an oral 15-mg dose of midazolam in 6 patients with epilepsy who are also taking carbamazepine (CBZ) or phenytoin (PHT).  We compared results with those obtained in 7 noninduced control subjects.  Plasma concns. and effects of midazolam were measured for 10 h.  In patients with epilepsy, the area under the plasma concn.-time curve (AUC) of midazolam (mean ± SEM) was only 5.7% (0.60 ± 0.16 vs. 10.5 ± 0.6 μg .sum. min/mL), and the peak midazolam concn. was 7.4% (5.2 ± 1.2 vs. 70.4 ± 9.0 ng/mL) of its value in control subjects (p < 0.001).  The elimination half-life (t1/2) of midazolam was 1.3 ± 0.2 h in patients and 3.1 ± 0.1 h in controls (p < 0.001).  The low plasma midazolam concns. in the patient group were assocd. with reduced pharmacodynamic effects as compared with control subjects [e.g., the Crit. Flicker Fusion Test (CFFT), p < 0.05].  Induction of CYP3A (cytochrome P-450IIIA) enzymes by CBZ and PHT is the most likely explanation of the great difference in the pharmacokinetic and pharmacodynamic profiles of oral midazolam in the two groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGHtYt08VebVg90H21EOLACvtfcHk0lg2pwGaMyOf_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitV2nt78%253D&md5=a58e249913a7637724e54a19604398aa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1996.tb00021.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1996.tb00021.x%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DOjala%26aufirst%3DM.%26aulast%3DLaaksovirta%26aufirst%3DH.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DConcentrations%2520and%2520effects%2520of%2520oral%2520midazolam%2520are%2520greatly%2520reduced%2520in%2520patients%2520treated%2520with%2520carbamazepine%2520or%2520phenytoin%26jtitle%3DEpilepsia%26date%3D1996%26volume%3D37%26issue%3D3%26spage%3D253%26epage%3D257%26doi%3D10.1111%2Fj.1528-1157.1996.tb00021.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffels, P.</span></span> <span> </span><span class="NLM_article-title">Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2004.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15536460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=452-466&issue=5&author=E.+D.+Kharaschauthor=A.+Walkerauthor=C.+Hofferauthor=P.+Sheffels&title=Intravenous+and+oral+alfentanil+as+in+vivo+probes+for+hepatic+and+first-pass+cytochrome+P450+3A+activity%3A+noninvasive+assessment+by+use+of+pupillary+miosis&doi=10.1016%2Fj.clpt.2004.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis</span></div><div class="casAuthors">Kharasch, Evan D.; Walker, Alysa; Hoffer, Christine; Sheffels, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">452-466</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Systemic clearance of i.v. (IV) alfentanil (ALF) is an in vivo probe for hepatic cytochrome P 450 (CYP) 3A activity, miosis is a surrogate for plasma ALF concns., and IV ALF miosis is a noninvasive probe for hepatic CYP3A.  This investigation characterized the bioavailability and first-pass metab. of oral ALF and tested the hypotheses that (1) first-pass ALF clearance reflects first-pass CYP3A activity, (2) miosis after oral ALF will reflect intestinal and hepatic CYP3A activity, and (3) miosis can approx. plasma concn.-based pharmacokinetic measures for IV and oral ALF as a noninvasive in vivo probe for hepatic and first-pass CYP3A activity and drug interactions.  Results were compared with those for midazolam (MDZ), an alternative CYP3A probe.  Ten volunteers were studied by use of a randomized, 9-way, crossover design after administration of rifampin (INN, rifampicin) (hepatic and intestinal CYP3A induction), troleandomycin (TAO) (hepatic and intestinal CYP3A inhibition), grapefruit juice (selective intestine CYP3A inhibition), or nothing (control).  For each condition, they received 1 mg IV MDZ and then 15 μg/kg IV ALF, as well as 3 mg oral MDZ and then oral ALF (23 or 60 μg/kg) on another day.  Plasma concns. were detd. by liq. chromatog.-mass spectrometry.  Dark-adapted pupil diams. were measured coincident with blood sampling.  ALF effect was analyzed similarly to concn. to yield an effect "clearance" (Dose/Area under the pupil diam. change vs. time curve).  Bioavailability (Foral), hepatic extn. (EH), and intestinal availability (FG) were 0.26 ± 0.08, 0.52 ± 0.09, and 0.56 ± 0.20, resp., for MDZ and 0.42 ± 0.15, 0.28 ± 0.09, and 0.56 ± 0.18, resp., for ALF.  Oral clearance (CL/F) was 34.7 ± 12.8 and 10.9 ± 3.5 mL · kg-1 · min-1, resp., for MDZ and ALF.  After rifampin, TAO, and grapefruit juice, ALF Foral was 0.04 ± 0.02 (P < .05, vs. control), 0.99 ± 0.18 (P < .05, vs. control), and 0.62 ± 0.18 (P < .05, vs. control), resp.; EH was 0.69 ± 0.14 (P < .05, vs. control), 0.04 ± 0.01 (P < .05, vs. control), and 0.26 ± 0.08, resp.; FG was 0.16 ± 0.10 (P < .05, vs. control), 1.0 ± 0.2 (P < .05, vs. control), and 0.85 ± 0.30 (P < .05, vs. control), resp.; CL/F was 339 ± 233 (P < .05, vs. control), 0.62 ± 0.26 (P < .05, vs. control), and 6.7 ± 2.5 (P < .05, vs. control), resp., and effect clearance was 2.1 ± 1.1 (P < .05, vs. control), 0.087 ± 0.056 (P < .05, vs. control), and 0.54 ± 0.30 (0.73 ± 0.43 mg · mm-1 · h-1 in controls), resp.  There were significant correlations between ALF and MDZ systemic clearances (r2 = 0.92), EH (r2 = 0.93), and CL/F (r2 = 0.97), as well as between oral ALF effect (miosis) clearance and oral clearance (r2 = 0.59).  ALF and MDZ have similar intestinal extn. but low and intermediate hepatic extn., resp.  Systemic and oral clearances of ALF are excellent in vivo probes for hepatic and first-pass CYP3A activities and drug interactions.  Miosis was an acceptable surrogate for plasma ALF.  ALF miosis may be a suitable noninvasive in vivo probe for both hepatic and first-pass CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEwLXDAh9aLVg90H21EOLACvtfcHk0lg2pwGaMyOf_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWntL4%253D&md5=754fbcb7a0cf7588f8c83b868cb5051d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DHoffer%26aufirst%3DC.%26aulast%3DSheffels%26aufirst%3DP.%26atitle%3DIntravenous%2520and%2520oral%2520alfentanil%2520as%2520in%2520vivo%2520probes%2520for%2520hepatic%2520and%2520first-pass%2520cytochrome%2520P450%25203A%2520activity%253A%2520noninvasive%2520assessment%2520by%2520use%2520of%2520pupillary%2520miosis%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D76%26issue%3D5%26spage%3D452%26epage%3D466%26doi%3D10.1016%2Fj.clpt.2004.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Link, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grignaschi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmann, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krähenbühl, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2008.03201.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2008.03201.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18537963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSgur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2008&pages=473-484&issue=4&author=B.+Linkauthor=M.+Haschkeauthor=N.+Grignaschiauthor=M.+Bodmerauthor=Y.+Z.+Aschmannauthor=M.+Wenkauthor=S.+Kr%C3%A4henb%C3%BChl&title=Pharmacokinetics+of+intravenous+and+oral+midazolam+in+plasma+and+saliva+in+humans%3A+usefulness+of+saliva+as+matrix+for+CYP3A+phenotyping&doi=10.1111%2Fj.1365-2125.2008.03201.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping</span></div><div class="casAuthors">Link, Bettina; Haschke, Manuel; Grignaschi, Nathalie; Bodmer, Michael; Aschmann, Yvonne Zysset; Wenk, Markus; Krahenbuhl, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-484</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suitable for CYP3A phenotyping.  This was a two way cross-over study in eight subjects treated with 2 mg midazolam IV or 7.5 mg orally under basal conditions and after CYP3A induction with rifampicin.  Under basal conditions and IV administration, midazolam and 1'-hydroxymidazolam (plasma, saliva), 4-hydroxymidazolam and 1'-hydroxymidazolam-glucuronide (plasma) were detectable.  After rifampicin, the AUC of midazolam [mean differences plasma 53.7 (95% CI 4.6, 102.9) and saliva 0.83 (95% CI 0.52, 1.14) ng ml-1 h] and 1'-hydroxymidazolam [mean difference plasma 11.8 (95% CI 7.9, 15.7) ng ml-1 h] had decreased significantly.  There was a significant correlation between the midazolam concns. in plasma and saliva (basal conditions: r = 0.864, P<0.0001; after rifampicin: r = 0.842, P < 0.0001).  After oral administration and basal conditions, midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam were detectable in plasma and saliva.  After treatment with rifampicin, the AUC of midazolam [mean difference plasma 104.5 (95% CI 74.1, 134.9) ng/mL-1/h] and 1'-hydroxymidazolam [mean differences plasma 51.9 (95% CI 34.8, 69.1) and saliva 2.3 (95% CI 1.9, 2.7) ng/mL-1/h] had decreased significantly.  The parameters sepg. best between basal conditions and post-rifampicin were: (1'-hydroxymidazolam + 1'-hydroxymidazolam-glucuronide)/midazolam at 20-30 min (plasma) and the AUC of midazolam (saliva) after IV, and the AUC of midazolam (plasma) and of 1'-hydroxymidazolam (plasma and saliva) after oral administration.  Saliva appears to be a suitable matrix for non-invasive CYP3A phenotyping using midazolam as a probe drug, but sensitive anal. methods are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0tF4kmcSBYrVg90H21EOLACvtfcHk0lisWQlbaFC1mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSgur%252FL&md5=b4f2efb5b97bc43f1799eef5448f6bea</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2008.03201.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2008.03201.x%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DB.%26aulast%3DHaschke%26aufirst%3DM.%26aulast%3DGrignaschi%26aufirst%3DN.%26aulast%3DBodmer%26aufirst%3DM.%26aulast%3DAschmann%26aufirst%3DY.%2BZ.%26aulast%3DWenk%26aufirst%3DM.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520intravenous%2520and%2520oral%2520midazolam%2520in%2520plasma%2520and%2520saliva%2520in%2520humans%253A%2520usefulness%2520of%2520saliva%2520as%2520matrix%2520for%2520CYP3A%2520phenotyping%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D66%26issue%3D4%26spage%3D473%26epage%3D484%26doi%3D10.1111%2Fj.1365-2125.2008.03201.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannaprasaht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosius, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haehner-Daniels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(03)00187-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0009-9236%2803%2900187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12966371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVKmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=275-287&issue=3&author=J.+C.+Gorskiauthor=S.+Vannaprasahtauthor=M.+A.+Hammanauthor=W.+T.+Ambrosiusauthor=M.+A.+Bruceauthor=B.+Haehner-Danielsauthor=S.+D.+Hall&title=The+effect+of+age%2C+sex%2C+and+rifampin+administration+on+intestinal+and+hepatic+cytochrome+P450+3A+activity&doi=10.1016%2FS0009-9236%2803%2900187-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity</span></div><div class="casAuthors">Gorski, J. Christopher; Vannaprasaht, Suda; Hamman, Mitchell A.; Ambrosius, Walter T.; Bruce, Melissa A.; Haehner-Daniels, Barbara; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-287</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">The relative susceptibility of intestinal and hepatic cytochrome P 450 (CYP) 3A to induction by rifampin (INN, rifampicin), as a function of age and sex, was investigated with the CYP3A substrate midazolam.  Fourteen young women (mean age, 26±4 yr), 14 young men (mean age, 27±4 yr), 14 elderly women (mean age, 72±5 yr), and 10 elderly men (mean age, 70±4 yr) received simultaneous i.v. doses (0.05 mg/kg over a 30-min period) and oral doses of midazolam (3-8 mg of a stable isotope, 15N3-midazolam) before and after 7 days of rifampin dosing (600 mg once daily in the evening).  Serum and urine samples were assayed for midazolam, 15N3-midazolam, and metabolites by liq. chromatog.-mass spectrometry.  No significant difference (P ≥.05) in the baseline systemic and oral clearance of midazolam was obsd. between male and female or young and old volunteers.  Rifampin significantly (P <.0001) increased the systemic and oral clearance of midazolam from 0.44±0.2 L · h/kg and 1.56±0.8 L · h/kg to 0.96±0.3 L · h/kg and 34.4±21.2 L · h/kg, resp.  Likewise, the oral clearance of midazolam was significantly (P <.0001) increased in women and men, from 1.64±0.87 L · kg/h and 1.46±0.7 L · kg/h to 28.4±13.2 L · kg/h and 41.6±26.5 L · kg/h, resp.  A significant (P =.0023) effect of sex was noted in the extent of induction of the oral clearance of midazolam, being greater in men than in women.  In contrast, the extent of midazolam systemic clearance induction was greater in women than in men (P =.0107).  Age did not influence the extent of intestinal and hepatic CYP3A induction as detd. by the oral and systemic clearance of midazolam.  Rifampin dosing significantly (P <.0001) reduced the oral availability by 88%, from 0.32±0.13 to 0.04±0.02.  Correspondingly, hepatic and intestinal availabilities were significantly (P <.0001) reduced after rifampin administration.  After rifampin, the correlation coeff. for the relationship between oral availability and intestinal availability was significantly (P <.0001) reduced from 0.96 to 0.67, which reflects the increasing contribution of hepatic extn. to the detn. of midazolam oral availability.  A significant nonlinear inverse relationship was obsd. between the percent change in systemic clearance of midazolam and the initial baseline midazolam systemic clearance (r = -0.68, N = 52, P <.0001).  Likewise, a significant inverse relationship was obsd. between the percent change in oral clearance and the baseline oral clearance (r = -0.39, N = 52, P =.0041).  A significant inverse relationship between the ratio of hepatic intrinsic clearance in the presence of rifampin to that in the absence of rifampin and the corresponding ratio of intestinal intrinsic clearance was obsd. (Spearman correlation coeff. [r] = -0.68, P <.0001) and indicates that in a given individual the extent of induction was high at either the hepatic or the intestinal site but not both.  Sex-related differences exist in the extent of intestinal and hepatic CYP3A induction by rifampin.  The extent of induction at hepatic and intestinal sites was inversely dependent and reflected the independent regulation of CYP3A expression at these sites.  The large interindividual variation in the extent of induction is explained in part by the variation in baseline expression of CYP3A.  Sex-related differences in response to CYP3A inducers will be substrate-dependent and reflect the relative contribution of hepatic and intestinal sites of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWH-YrwUmxRLVg90H21EOLACvtfcHk0lisWQlbaFC1mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVKmtr8%253D&md5=25d07c6b4a27d3d88327de58d2e52629</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2803%2900187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252803%252900187-5%26sid%3Dliteratum%253Aachs%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DVannaprasaht%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DM.%2BA.%26aulast%3DAmbrosius%26aufirst%3DW.%2BT.%26aulast%3DBruce%26aufirst%3DM.%2BA.%26aulast%3DHaehner-Daniels%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effect%2520of%2520age%252C%2520sex%252C%2520and%2520rifampin%2520administration%2520on%2520intestinal%2520and%2520hepatic%2520cytochrome%2520P450%25203A%2520activity%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D74%26issue%3D3%26spage%3D275%26epage%3D287%26doi%3D10.1016%2FS0009-9236%2803%2900187-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafziger, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazierad, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. S.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Comparison of midazolam and simvastatin as cytochrome P450 3A probes</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2005.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16580903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFaiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2006&pages=350-361&issue=4&author=E.+Chungauthor=A.+N.+Nafzigerauthor=D.+J.+Kazieradauthor=J.+S.+Bertino&title=Comparison+of+midazolam+and+simvastatin+as+cytochrome+P450+3A+probes&doi=10.1016%2Fj.clpt.2005.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of midazolam and simvastatin as cytochrome P450 3A probes</span></div><div class="casAuthors">Chung, Ellen; Nafziger, Anne N.; Kazierad, David J.; Bertino, Joseph S., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">350-361</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The objective was to compare simvastatin with the validated probe midazolam in the assessment of cytochrome P 450 (CYP) 3A activity.  This study used an open-label, fixed-sequential, 3-way crossover study design.  Nineteen subjects received oral doses of 0.075 mg/kg midazolam and 40 mg simvastatin during 3 phases (baseline, after inhibition with 400 mg ketoconazole for 10 days, and after induction with 600 mg rifampin [INN, rifampicin] for 9 days).  Serial plasma concns. of midazolam and simvastatin were obtained.  Oral clearances of midazolam and simvastatin were compared.  Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL-min-1-kg-1 [range, 12-57 mL-min-1-kg-1] to 2.7 mL-min-1-kg-1 [range, 1.2-8.5 mL-min-1-kg-1], P <0.001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL-min-1-kg-1 [range, 125-371 mL-min-1-kg-1], P <0.001).  Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL-min-1-kg-1 [range, 151-1478 mL-min-1-kg-1] to 25 mL-min-1-kg-1 [range, 8.0-147 mL-min-1-kg-1], P <0.001) and increased after rifampin (to a geometric mean of 3536 mL-min-1-kg-1 [range, 413-10,329 mL-min-1-kg-1], P <0.001).  The change in simvastatin clearance was highly variable from baseline to inhibition (6- to 33-fold decrease) and from baseline to induction (2- to 39-fold increase) compared with midazolam (7- to 18-fold decrease during inhibition and 4- to 12-fold increase during induction).  Midazolam and simvastatin oral clearances were correlated for all study phases (r = 0.5 and P = .03 for baseline and r = 0.53 and P = .02 for inhibition) but were weakest for induction (r = -0.031, P = .22).  The area under the concn.-time curve inhibitory ratio for midazolam was 9.4 vs. 12.4 for simvastatin (r = 0.3, P = .03).  Compared with midazolam, simvastatin is a nonvalidated, suboptimal probe for studying CYP3A drug interactions because of its lack of CYP3A specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQIWqkhAoKLVg90H21EOLACvtfcHk0lisWQlbaFC1mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFaiurs%253D&md5=24127314b6d2fa174c8267b0b376eec7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DE.%26aulast%3DNafziger%26aufirst%3DA.%2BN.%26aulast%3DKazierad%26aufirst%3DD.%2BJ.%26aulast%3DBertino%26aufirst%3DJ.%2BS.%26atitle%3DComparison%2520of%2520midazolam%2520and%2520simvastatin%2520as%2520cytochrome%2520P450%25203A%2520probes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D79%26issue%3D4%26spage%3D350%26epage%3D361%26doi%3D10.1016%2Fj.clpt.2005.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieniaszek, H. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammaitoni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahdieh, H.</span></span> <span> </span><span class="NLM_article-title">Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1177/0091270004271969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F0091270004271969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15703368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=337-345&issue=3&author=M.+Adamsauthor=H.+J.+Pieniaszekauthor=A.+R.+Gammaitoniauthor=H.+Ahdieh&title=Oxymorphone+extended+release+does+not+affect+CYP2C9+or+CYP3A4+metabolic+pathways&doi=10.1177%2F0091270004271969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways</span></div><div class="casAuthors">Adams, Michael; Pieniaszek, Henry J.; Gammaitoni, Arnold R.; Ahdieh, Harry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-345</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two 14-day, randomized, open-label, parallel-group studies examd. the effects of extended-release (ER) oxymorphone on CYP2C9 or CYP3A4 metabolic activities in healthy subjects.  On days -1, 7, and 14, subjects received either a CYP2C9 probe (tolbutamide 500 mg) or CYP3A4 probes (midazolam and [14C N-methyl]-erythromycin for the erythromycin breath test).  Subjects were randomized to 5 groups: high-dose oxymorphone ER (3 × 20 mg q12h) + naltrexone (50 mg q24h); low-dose oxymorphone ER (10-20 mg q12h); rifampin (2 × 300 mg q24h), an inducer of CYP2C9 and CYP3A4 activities; naltrexone (50 mg q24h); or CYP probes alone (controls).  Probe metab. was significantly altered by rifampin on days 7 and 14 (P < .05), whereas probe metab. was not significantly affected by low-dose oxymorphone ER or by high-dose oxymorphone ER plus naltrexone.  Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJL3BWGW4DbVg90H21EOLACvtfcHk0li1dzKDJzGSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Sltr0%253D&md5=2dc48bf668df1c3a905158cdd588c7f7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1177%2F0091270004271969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270004271969%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DPieniaszek%26aufirst%3DH.%2BJ.%26aulast%3DGammaitoni%26aufirst%3DA.%2BR.%26aulast%3DAhdieh%26aufirst%3DH.%26atitle%3DOxymorphone%2520extended%2520release%2520does%2520not%2520affect%2520CYP2C9%2520or%2520CYP3A4%2520metabolic%2520pathways%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D45%26issue%3D3%26spage%3D337%26epage%3D345%26doi%3D10.1177%2F0091270004271969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masica, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. R.</span></span> <span> </span><span class="NLM_article-title">Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women</span>. <i>Pharmacogenetics</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1097/00008571-200310000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F00008571-200310000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=14515058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1arurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=595-606&issue=10&author=M.+D.+Floydauthor=G.+Gervasiniauthor=A.+L.+Masicaauthor=G.+Mayoauthor=A.+L.+Georgeauthor=K.+Bhatauthor=R.+B.+Kimauthor=G.+R.+Wilkinson&title=Genotype-phenotype+associations+for+common+CYP3A4+and+CYP3A5+variants+in+the+basal+and+induced+metabolism+of+midazolam+in+European-+and+African-American+men+and+women&doi=10.1097%2F00008571-200310000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women</span></div><div class="casAuthors">Floyd, Michael D.; Gervasini, Guillermo; Masica, Andrew L.; Mayo, Gail; George, Alfred L., Jr.; Bhat, Kolari; Kim, Richard B.; Wilkinson, Grant R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">595-606</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">CYP3A activity in adults varies between individuals and it has been suggested that this has a genetic basis, possibly related to variant alleles in CYP3A4 and CYP3A5 genes.  Accordingly, genotype-phenotype assocns. were investigated under constitutive and induced conditions.  Midazolam's systemic and oral clearances, and the erythromycin breath test (ERBT) were detd. in 57 healthy subjects: 23 (11 men, 12 women) European- and 34 (14 men, 20 women) African-Americans.  Studies were undertaken in the basal state and after 14-15 days pretreatment with rifampin.  DNA was characterized for the common polymorphisms CYP3A4*1B, CYP3A5*3, CYP3A5*6 and CYP3A5*7 by direct sequencing, and for exon 21 and exon 26 variants of MDR1 by allele-specific, real-time polymerase chain reaction.  In 95% of subjects, the basal systemic clearance of midazolam was unimodally distributed and variability was less than four-fold whereas, in 98% of the study population, oral clearance varied five-fold.  No population or sex-related differences were apparent.  Similar findings were obsd. with the ERBT.  Rifampin pretreatment markedly increased the systemic (two-fold) and oral clearance (16-fold) of midazolam, and the ERBT (two-fold) but the variabilities were unchanged.  No assocns. were noted between these phenotypic measures and any of the studied genotypes, except for oral clearance and its fold-increase after rifampin.  These were related to the presence of CYP3A4*1B and the inversely linked CYP3A5*3 polymorphism, with the extent of induction being approx. 50% greater in CYP3A5*3 homozygotes compared to wild-type subjects.  In most healthy subjects, variability in intestinal and hepatic CYP3A activity, using midazolam as an in-vivo probe, is modest and common polymorphisms in CYP3A4 and CYP3A5 do not appear to have important functional significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94c27EOq4fLVg90H21EOLACvtfcHk0li1dzKDJzGSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1arurw%253D&md5=7d9bb419ac29b71b8f511c801d6552b5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00008571-200310000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200310000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DFloyd%26aufirst%3DM.%2BD.%26aulast%3DGervasini%26aufirst%3DG.%26aulast%3DMasica%26aufirst%3DA.%2BL.%26aulast%3DMayo%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DA.%2BL.%26aulast%3DBhat%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DWilkinson%26aufirst%3DG.%2BR.%26atitle%3DGenotype-phenotype%2520associations%2520for%2520common%2520CYP3A4%2520and%2520CYP3A5%2520variants%2520in%2520the%2520basal%2520and%2520induced%2520metabolism%2520of%2520midazolam%2520in%2520European-%2520and%2520African-American%2520men%2520and%2520women%26jtitle%3DPharmacogenetics%26date%3D2003%26volume%3D13%26issue%3D10%26spage%3D595%26epage%3D606%26doi%3D10.1097%2F00008571-200310000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gashaw, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudny-Klöppel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höchel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, C.</span></span> <span> </span><span class="NLM_article-title">The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1002/cpt.1848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpt.1848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32275771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFegsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=798-807&author=H.+Wiesingerauthor=S.+Kleinauthor=A.+Rottmannauthor=B.+Nowotnyauthor=K.+Rieckeauthor=I.+Gashawauthor=M.+Brudny-Kl%C3%B6ppelauthor=R.+Frickeauthor=J.+H%C3%B6chelauthor=C.+Friedrich&title=The+effects+of+weak+and+strong+CYP3A+induction+by+rifampicin+on+the+pharmacokinetics+of+five+progestins+and+ethinylestradiol+compared+to+midazolam&doi=10.1002%2Fcpt.1848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam</span></div><div class="casAuthors">Wiesinger, Herbert; Klein, Stefan; Rottmann, Antje; Nowotny, Bettina; Riecke, Kai; Gashaw, Isabella; Brudny-Kloeppel, Margarete; Fricke, Robert; Hoechel, Joachim; Friedrich, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">798-807</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">It is known that co-administration of CYP3A inducers may decrease the effectiveness of oral contraceptives contg. progestins as mono-prepns. or combined with ethinylestradiol.  Rifampicin was used to induce CYP3A.  The progestins chosen as victim drugs were levonorgestrel, norethindrone, desogestrel, and dienogest as mono-products, and drospirenone combined with ethinylestradiol.  Postmenopausal women (n = 12-14 per treatment group) received, in fixed sequence, a single dose of the victim drug plus midazolam without rifampicin, with rifampicin 10 mg/day and with rifampicin 600 mg/day.  The effects on progestin exposure were compared with the effects on midazolam exposure.  Weak CYP3A induction, as confirmed by a mean decrease in midazolam exposure by 46%, resulted in minor changes in progestin exposure (mean decreases: 15-37%).  Strong CYP3A induction, in contrast, resulted in mean decreases by 57-90% (mean decrease in midazolam exposure 86%).  Our data might provide an impetus to revisit the currently applied clin. recommendations for oral contraceptives, esp. for levonorgestrel and norethindrone-contg. products, and they might give an indication as to which progestin could be used, if requested, by women taking weak CYP3A inducers-although it is acknowledged that the exact exposure-response relationship for contraceptive efficacy is currently unclear for most progestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9zztv3A-QvbVg90H21EOLACvtfcHk0li1dzKDJzGSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFegsb7P&md5=aef222a027f40ed3defda0b263c355a1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1848%26sid%3Dliteratum%253Aachs%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DRottmann%26aufirst%3DA.%26aulast%3DNowotny%26aufirst%3DB.%26aulast%3DRiecke%26aufirst%3DK.%26aulast%3DGashaw%26aufirst%3DI.%26aulast%3DBrudny-Kl%25C3%25B6ppel%26aufirst%3DM.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DH%25C3%25B6chel%26aufirst%3DJ.%26aulast%3DFriedrich%26aufirst%3DC.%26atitle%3DThe%2520effects%2520of%2520weak%2520and%2520strong%2520CYP3A%2520induction%2520by%2520rifampicin%2520on%2520the%2520pharmacokinetics%2520of%2520five%2520progestins%2520and%2520ethinylestradiol%2520compared%2520to%2520midazolam%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D798%26epage%3D807%26doi%3D10.1002%2Fcpt.1848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. G.</span></span> <span> </span><span class="NLM_article-title">Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2003.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2003.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15001966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslenur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=157-162&issue=3&author=J.+Y.+Parkauthor=K.+A.+Kimauthor=M.+H.+Kangauthor=S.+L.+Kimauthor=J.+G.+Shin&title=Effect+of+rifampin+on+the+pharmacokinetics+of+rosiglitazone+in+healthy+subjects&doi=10.1016%2Fj.clpt.2003.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects</span></div><div class="casAuthors">Park, Ji-Young; Kim, Kyoung-Ah; Kang, Mun-Ho; Kim, Su-Lyun; Shin, Jae-Gook</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-162</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background and objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs.  Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone.  Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans.  Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo.  On day 7, a single dose of 8 mg rosiglitazone was administered orally.  Plasma rosiglitazone concns. were measured.  Results: Rifampin significantly decreased the mean area under the plasma concn.-time curve for rosiglitazone by 65% (2947.9 ng · h/mL vs. 991.5 ng · h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 h (P < .001).  The peak plasma concn. of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL vs. 362.3 ng/mL, P < .01).  The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h vs. 8.5 L/h, P < .001).  Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P 450 (CYP) 2C8 and, to a lesser extent, CYP2C9.  Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUpZwrbrEVP7Vg90H21EOLACvtfcHk0lg_8zNLmiCmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslenur8%253D&md5=08b2974d5e193e8b7a0cba297a8fc5bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2003.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2003.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BA.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BL.%26aulast%3DShin%26aufirst%3DJ.%2BG.%26atitle%3DEffect%2520of%2520rifampin%2520on%2520the%2520pharmacokinetics%2520of%2520rosiglitazone%2520in%2520healthy%2520subjects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D75%26issue%3D3%26spage%3D157%26epage%3D162%26doi%3D10.1016%2Fj.clpt.2003.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höjer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterloh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, A.</span></span> <span> </span><span class="NLM_article-title">Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/clpt.1980.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.1980.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=7351120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADyaL3c%252FptVOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1980&pages=83-88&issue=1&author=L.+Bertilssonauthor=B.+H%C3%B6jerauthor=G.+Tybringauthor=J.+Osterlohauthor=A.+Rane&title=Autoinduction+of+carbamazepine+metabolism+in+children+examined+by+a+stable+isotope+technique&doi=10.1038%2Fclpt.1980.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique</span></div><div class="casAuthors">Bertilsson L; Hojer B; Tybring G; Osterloh J; Rane A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-8</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Autoinduction of carbamazepine (CBZ) metabolism was investigated in 3 children (10 to 13 yr old) using tetradeuterium-labeled CBZ (CBZ-D4).  Prior to treatment, CBZ and CBZ-D4 given as a mixture had almost identical kinetics in each patient.  During maintenance therapy with CBZ, part of the CBZ was exchanged for CBZ-D4 on 3 occasions.  The clearance of CBZ-D4 given on the second day of therapy was 0.036 +/- 0.003 1 . kg-1 . hr-1, whereas it had been 0.028 +/- 0.003 before treatment.  After 17 to 32 days of treatment, clearance doubled (0.056 +/- 0.010) but during the next 4 mo there was no further increase, indicating that the autoinduction was complete within 1 mo.  As a corollary there was a decrease in steady-state plasma levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGB0Nwy1WbIcNIRw0GKUoEfW6udTcc2eYM0nDkjr9bprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c%252FptVOitQ%253D%253D&md5=5623f7a43881f44514fb361048d14833</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1980.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1980.13%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DL.%26aulast%3DH%25C3%25B6jer%26aufirst%3DB.%26aulast%3DTybring%26aufirst%3DG.%26aulast%3DOsterloh%26aufirst%3DJ.%26aulast%3DRane%26aufirst%3DA.%26atitle%3DAutoinduction%2520of%2520carbamazepine%2520metabolism%2520in%2520children%2520examined%2520by%2520a%2520stable%2520isotope%2520technique%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1980%26volume%3D27%26issue%3D1%26spage%3D83%26epage%3D88%26doi%3D10.1038%2Fclpt.1980.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwater, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lademacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammelsberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects</span>. <i>Clin Pharmacol Drug Dev</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1002/cpdd.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpdd.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27273149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=54-65&issue=1&author=T.+Yamazakiauthor=A.+Desaiauthor=R.+Goldwaterauthor=D.+Hanauthor=C.+Howiesonauthor=S.+Akhtarauthor=D.+Kowalskiauthor=C.+Lademacherauthor=H.+Pearlmanauthor=D.+Rammelsbergauthor=R.+Townsend&title=Pharmacokinetic+effects+of+isavuconazole+coadministration+with+the+cytochrome+P450+enzyme+substrates+bupropion%2C+repaglinide%2C+caffeine%2C+dextromethorphan%2C+and+methadone+in+healthy+subjects&doi=10.1002%2Fcpdd.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects</span></div><div class="casAuthors">Yamazaki, Takao; Desai, Amit; Goldwater, Ronald; Han, David; Howieson, Corrie; Akhtar, Shahzad; Kowalski, Donna; Lademacher, Christopher; Pearlman, Helene; Rammelsberg, Diane; Townsend, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-65</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This report describes phase 1 clin. trials performed to assess interactions of oral isavuconazole at the clin. targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P 450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n = 24), and methadone (CYP2B6/CYP2C19/CYP3A4; 10 mg; n = 23).  Compared with each drug alone, coadministration with isavuconazole changed the area under the concn.-time curves (AUC∞) and max. concns. (Cmax) as follows: bupropion, AUC∞ reduced 42%, Cmax reduced 31%; repaglinide, AUC∞ reduced 8%, Cmax reduced 14%; caffeine, AUC∞ increased 4%, Cmax reduced 1%; dextromethorphan, AUC∞ increased 18%, Cmax increased 17%; R-methadone, AUC∞ reduced 10%, Cmax increased 3%; S-methadone, AUC∞ reduced 35%, Cmax increased 1%.  In all studies, there were no deaths, 1 serious adverse event (dextromethorphan study; perioral numbness, numbness of right arm and leg), and adverse events leading to study discontinuation were rare.  Thus, isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2-, CYP2C8-, or CYP2D6-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-9FdRdpH2bVg90H21EOLACvtfcHk0lg_8zNLmiCmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhtb0%253D&md5=6f05bf602e3aa7f8a63f6653df9d0719</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.281%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DD.%26aulast%3DHowieson%26aufirst%3DC.%26aulast%3DAkhtar%26aufirst%3DS.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3DLademacher%26aufirst%3DC.%26aulast%3DPearlman%26aufirst%3DH.%26aulast%3DRammelsberg%26aufirst%3DD.%26aulast%3DTownsend%26aufirst%3DR.%26atitle%3DPharmacokinetic%2520effects%2520of%2520isavuconazole%2520coadministration%2520with%2520the%2520cytochrome%2520P450%2520enzyme%2520substrates%2520bupropion%252C%2520repaglinide%252C%2520caffeine%252C%2520dextromethorphan%252C%2520and%2520methadone%2520in%2520healthy%2520subjects%26jtitle%3DClin%2520Pharmacol%2520Drug%2520Dev%26date%3D2017%26volume%3D6%26issue%3D1%26spage%3D54%26epage%3D65%26doi%3D10.1002%2Fcpdd.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay-Sontheimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragueneau-Majlessi, I.</span></span> <span> </span><span class="NLM_article-title">Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.117.078691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29572333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWlsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=835-845&issue=6&author=J.+Yuauthor=Z.+Zhouauthor=J.+Tay-Sontheimerauthor=R.+H.+Levyauthor=I.+Ragueneau-Majlessi&title=Risk+of+clinically+relevant+pharmacokinetic-based+drug-drug+interactions+with+drugs+approved+by+the+U.S.+Food+and+Drug+Administration+between+2013+and+2016&doi=10.1124%2Fdmd.117.078691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016</span></div><div class="casAuthors">Yu, Jingjing; Zhou, Zhu; Tay-Sontheimer, Jessica; Levy, Rene H.; Ragueneau-Majlessi, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">835-845</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A total of 103 drugs (including 14 combination drugs)were approved by the U.S.  Food and Drug Administration from 2013 to 2016.  Pharmacokineticbased drug interaction profiles were analyzed using the University of Washington Drug Interaction Database, and the clin. relevance of these observations was characterized based on information from new drug application reviews.CYP3Awas involved in approx. two-thirds of all drug-drug interactions (DDIs).  Transporters (alone or with enzymes) participated in about half of all interactions, but most of these were weak-to-moderate interactions.When considered as victims, eight new mol. entities (NMEs; cobimetinib, ibrutinib, isavuconazole, ivabradine, naloxegol, paritaprevir, simeprevir, and venetoclax)were identified as sensitive substrates of CYP3A, two NMEs (pirfenidone and tasimelteon) were sensitive substratesofCYP1A2, oneNME(dasabuvir)was a sensitive substrate of CYP2C8, one NME (eliglustat) was a sensitive substrate of CYP2D6, and one NME (grazoprevir) was a sensitive substrate of OATP1B1/3 (with changes in exposure greater than 5-fold when coadministered with a strong inhibitor).  Approx. 75%of identified CYP3A substrates were also substrates of P-glycoprotein.  As perpetrators, most clin. DDIs involved weak-to-moderate inhibition or induction.  Only idelalisib showed strong inhibition of CYP3A, and lumacaftor behaved as a strong CYP3A inducer.  Among drugs with large changes in exposure (5-fold),whether as victim or perpetrator, the mostrepresented therapeutic classes were antivirals and oncol. drugs, suggesting a significant risk of clin. DDIs in these patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopgUFlZcyDRLVg90H21EOLACvtfcHk0lhFKTnRQU6Rdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWlsLnE&md5=fd09c08cc94f829a16f6b07225e25da4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078691%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DTay-Sontheimer%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DR.%2BH.%26aulast%3DRagueneau-Majlessi%26aufirst%3DI.%26atitle%3DRisk%2520of%2520clinically%2520relevant%2520pharmacokinetic-based%2520drug-drug%2520interactions%2520with%2520drugs%2520approved%2520by%2520the%2520U.S.%2520Food%2520and%2520Drug%2520Administration%2520between%25202013%2520and%25202016%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D6%26spage%3D835%26epage%3D845%26doi%3D10.1124%2Fdmd.117.078691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeg, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span> <span> </span><span class="NLM_article-title">No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1002/hep.20568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fhep.20568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15726657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=595-602&issue=3&author=K.+Dilgerauthor=A.+Denkauthor=M.+H.+Heegauthor=U.+Beuers&title=No+relevant+effect+of+ursodeoxycholic+acid+on+cytochrome+P450+3A+metabolism+in+primary+biliary+cirrhosis&doi=10.1002%2Fhep.20568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis</span></div><div class="casAuthors">Dilger, Karin; Denk, Annette; Heeg, Malte H. J.; Beuers, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis.  CYP3A is of key importance in human drug metab., being involved in presystemic extn. of more than 50% of all drugs currently available and of various endogenous compds.  Therefore, we compared the induction potential of UDCA with that of the prototypical inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol.  Twelve patients with early-stage primary biliary cirrhosis and eight healthy volunteers were treated with UDCA (15 mg/kg daily) for 3 wk and subsequently with rifampicin (600 mg/d) for 1 wk.  Extensive pharmacokinetic profiling of oral budesonide (3 mg) was performed by detn. of budesonide and phase I metabolites (6β-hydroxybudesonide, 16α-hydroxyprednisolone) in plasma and urine at baseline and at the end of each treatment.  In parallel, urinary 6β-hydroxycortisol, a validated marker of CYP3A induction, was detd.  UDCA did not affect biotransformation of budesonide and urinary excretion of 6β-hydroxycortisol either in patients or in healthy volunteers.  Ratios of areas under plasma concn.-time curves (AUC0-12 h during UDCA/AUC0-12 h before UDCA) of both metabolites were not higher than those of budesonide itself.  In contrast, administration of rifampicin markedly induced CYP3A metab., resulting in abolished budesonide plasma levels and high urinary excretion of 6β-hydroxycortisol.  Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC16α-hydroxyprednisolone/AUCbudesonide in patients: baseline, 8.6 ± 3.9; UDCA, 10.7 ± 7.1; rifampicin, 527.0 ± 248.7).  In conclusion, UDCA is not a relevant inducer of CYP3A enzymes in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwI3pysXls_7Vg90H21EOLACvtfcHk0lhFKTnRQU6Rdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFCrs70%253D&md5=3cd18b1f7a644a2bf1c6f6618e32e0ee</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fhep.20568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.20568%26sid%3Dliteratum%253Aachs%26aulast%3DDilger%26aufirst%3DK.%26aulast%3DDenk%26aufirst%3DA.%26aulast%3DHeeg%26aufirst%3DM.%2BH.%26aulast%3DBeuers%26aufirst%3DU.%26atitle%3DNo%2520relevant%2520effect%2520of%2520ursodeoxycholic%2520acid%2520on%2520cytochrome%2520P450%25203A%2520metabolism%2520in%2520primary%2520biliary%2520cirrhosis%26jtitle%3DHepatology%26date%3D2005%26volume%3D41%26issue%3D3%26spage%3D595%26epage%3D602%26doi%3D10.1002%2Fhep.20568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Erp, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guchelaar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploeger, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romijn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span> <span> </span><span class="NLM_article-title">Mitotane has a strong and a durable inducing effect on CYP3A4 activity</span>. <i>Eur. J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1530/EJE-10-0956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1530%2FEJE-10-0956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21220434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=621-626&issue=4&author=N.+P.+van%0AErpauthor=H.+J.+Guchelaarauthor=B.+A.+Ploegerauthor=J.+A.+Romijnauthor=J.+Hartighauthor=H.+Gelderblom&title=Mitotane+has+a+strong+and+a+durable+inducing+effect+on+CYP3A4+activity&doi=10.1530%2FEJE-10-0956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotane has a strong and a durable inducing effect on CYP3A4 activity</span></div><div class="casAuthors">van Erp, Nielka P.; Guchelaar, Henk-Jan; Ploeger, Bart A.; Romijn, Johannes A.; den Hartigh, Jan; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">621-626</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">The effects of mitotane on the pharmacokinetics (PK) of co-administered drugs are mostly unknown.  The aim of the present study was to describe the effects of mitotane on the PK of the phenotypic probe midazolam and of the tyrosine kinase inhibitor sunitinib.  A serendipitous observation was made in two of nine patients who volunteered in a sunitinib pharmacokinetic study.  Both patients were diagnosed with adrenocortical carcinoma (ACC) and were exposed to mitotane.  The sunitinib PK study was designed to det. the relationship between CYP3A4 activity and sunitinib exposure using 7.5 mg midazolam orally as a phenotypic probe.  Serial blood samples for PK anal. of midazolam, 1-hydroxy-midazolam, and sunitinib were collected at steady-state sunitinib PK (between days 14 and 20).  To confirm this observation in the mitotane-exposed patients, midazolam PK was evaluated in two addnl. patients with ACC and mitotane treatment.  The 4 mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC0-12h (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg × h/l resp. P = 0.001) and increased 1-hydroxy-midazolam exposure (mean AUC0-12h (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg × h/l, P = 0.008).  Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg × h/l vs. 1344 (1079-1609) (mean (95% CI)) μg × h/l).  Mitotane has a strong and long-lasting inducing effect on CYP3A4 activity, which will result in clin. relevant interactions with multiple drugs since many drugs are metabolized by this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlCXR5puxBArVg90H21EOLACvtfcHk0lhFKTnRQU6Rdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGhsLk%253D&md5=b7360167aa432627a6645d08c3c34735</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1530%2FEJE-10-0956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEJE-10-0956%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BErp%26aufirst%3DN.%2BP.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26aulast%3DPloeger%26aufirst%3DB.%2BA.%26aulast%3DRomijn%26aufirst%3DJ.%2BA.%26aulast%3DHartigh%26aufirst%3DJ.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DMitotane%2520has%2520a%2520strong%2520and%2520a%2520durable%2520inducing%2520effect%2520on%2520CYP3A4%2520activity%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2011%26volume%3D164%26issue%3D4%26spage%3D621%26epage%3D626%26doi%3D10.1530%2FEJE-10-0956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milad, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span> <span> </span><span class="NLM_article-title">Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.050526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fjpet.103.050526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12766253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=1027-1034&issue=3&author=J.+Sahiauthor=M.+A.+Miladauthor=X.+Zhengauthor=K.+A.+Roseauthor=H.+Wangauthor=L.+Stilgenbauerauthor=D.+Gilbertauthor=S.+Jolleyauthor=R.+H.+Sternauthor=E.+L.+LeCluyse&title=Avasimibe+induces+CYP3A4+and+multiple+drug+resistance+protein+1+gene+expression+through+activation+of+the+pregnane+X+receptor&doi=10.1124%2Fjpet.103.050526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor</span></div><div class="casAuthors">Sahi, Jasminder; Milad, Mark A.; Zheng, Xianxian; Rose, Kelly A.; Wang, Hongbing; Stilgenbauer, Linda; Gilbert, Darryl; Jolley, Summer; Stern, Ralph H.; Lecluyse, Edward L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro and clin. studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions.  Clin., 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were obsd. after 50 and 750 mg of avasimibe daily for 7 days, resp.  A 40% decrease in digoxin (P-glycoprotein substrate) area under the curve was obsd. with 750 mg of avasimibe daily for 10 days.  In vitro studies were conducted to define the mechanisms of these interactions.  Induction was obsd. in CYP3A4 activity and immunoreactive protein (EC50 of 200-400 nM) in primary human hepatocytes treated with avasimibe.  Rifampin treatment yielded similar results.  Microarray anal. revealed avasimibe (1 μM) increased CYP3A4 mRNA 20-fold, compared with a 23-fold increase with 50 μM rifampin.  Avasimibe induced P-glycoprotein mRNA by about 2-fold and immunoreactive protein in a dose-dependent manner.  Transient transfection assays showed that avasimibe is a potent activator of the human pregnane X receptor (hPXR) and more active than rifampin on an equimolar basis.  Drug-drug interaction studies for CYP3A4 using pooled human hepatic microsomes and avasimibe at various concns., revealed IC50 values of 20.7, 1.6, and 3.1 μM using testosterone, midazolam, and felodipine as probe substrates, resp.  Our results indicate that avasimibe causes clin. significant drug-drug interactions through direct activation of hPXR and the subsequent induction of its target genes CYP3A4 and multiple drug resistance protein 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFlGRnInRzLVg90H21EOLACvtfcHk0ljszdekyx4EVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVeht7s%253D&md5=7d74f67f0192f2c7de913d1995328479</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.050526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.050526%26sid%3Dliteratum%253Aachs%26aulast%3DSahi%26aufirst%3DJ.%26aulast%3DMilad%26aufirst%3DM.%2BA.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DRose%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DStilgenbauer%26aufirst%3DL.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DStern%26aufirst%3DR.%2BH.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26atitle%3DAvasimibe%2520induces%2520CYP3A4%2520and%2520multiple%2520drug%2520resistance%2520protein%25201%2520gene%2520expression%2520through%2520activation%2520of%2520the%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26issue%3D3%26spage%3D1027%26epage%3D1034%26doi%3D10.1124%2Fjpet.103.050526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulat, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitselos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug-drug interaction of apalutamide, Part 1: Clinical studies in healthy men and patients with castration-resistant prostate cancer</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00882-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs40262-020-00882-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32338345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1ajsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=1135-1148&author=I.+Duranauthor=J.+Carlesauthor=I.+Bulatauthor=P.+Hellemansauthor=A.+Mitselosauthor=P.+Wardauthor=J.+Jiaoauthor=D.+Armasauthor=C.+Chien&title=Pharmacokinetic+drug-drug+interaction+of+apalutamide%2C+Part+1%3A+Clinical+studies+in+healthy+men+and+patients+with+castration-resistant+prostate+cancer&doi=10.1007%2Fs40262-020-00882-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer</span></div><div class="casAuthors">Duran, Ignacio; Carles, Joan; Bulat, Iurie; Hellemans, Peter; Mitselos, Anna; Ward, Peter; Jiao, James; Armas, Danielle; Chien, Caly</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1135-1148</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background and Objectives: Two phase I studies assessed the drug-drug interaction potential of apalutamide as a substrate and perpetrator.  Methods: Study A randomized 45 healthy men to single-dose apalutamide 240 mg alone or with strong inhibitors of cytochrome P 450 (CYP)3A4 (itraconazole) or CYP2C8 (gemfibrozil).  In study B, 23 patients with castration-resistant prostate cancer received probes for CYP3A4 (midazolam), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP2C8 (pioglitazone), and transporter substrates for P-glycoprotein (P-gp) (fexofenadine) and breast cancer resistance protein (BCRP)/org. anion transporting polypeptide (OATP) 1B1 (rosuvastatin) at baseline and after repeat once-daily administration of apalutamide 240 mg to steady state.  Results: Systemic exposure (area under the plasma concn.-time curve) to single-dose apalutamide increased 68% with gemfibrozil but was relatively unchanged with itraconazole (study A).  Apalutamide reduced systemic exposure to midazolam 92%, omeprazole 85%, S-warfarin 46%, fexofenadine 30%, rosuvastatin 41%, and pioglitazone 18% (study B).  After a single dose, apalutamide is predominantly metabolized by CYP2C8, and less by CYP3A4.  Conclusions: Co-administration of apalutamide with CYP3A4, CYP2C19, CYP2C9, P-gp, BCRP or OATP1B1 substrates may cause loss of activity for these medications.  Therefore, appropriate mitigation strategies are recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGChlL7246C7Vg90H21EOLACvtfcHk0ljszdekyx4EVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1ajsLc%253D&md5=851e4bc001eab4d352b104d8e0551093</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00882-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00882-2%26sid%3Dliteratum%253Aachs%26aulast%3DDuran%26aufirst%3DI.%26aulast%3DCarles%26aufirst%3DJ.%26aulast%3DBulat%26aufirst%3DI.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DMitselos%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DJiao%26aufirst%3DJ.%26aulast%3DArmas%26aufirst%3DD.%26aulast%3DChien%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520drug-drug%2520interaction%2520of%2520apalutamide%252C%2520Part%25201%253A%2520Clinical%2520studies%2520in%2520healthy%2520men%2520and%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D1135%26epage%3D1148%26doi%3D10.1007%2Fs40262-020-00882-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majcher-Peszynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehleke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klammt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundkowski, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miekisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewelow, B.</span></span> <span> </span><span class="NLM_article-title">The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1007/s00228-005-0061-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00228-005-0061-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16341856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=29-36&issue=1&author=S.+C.+Muellerauthor=J.+Majcher-Peszynskaauthor=B.+Uehlekeauthor=S.+Klammtauthor=R.+G.+Mundkowskiauthor=W.+Miekischauthor=H.+Sieversauthor=S.+Bauerauthor=B.+Frankauthor=G.+Kundtauthor=B.+Drewelow&title=The+extent+of+induction+of+CYP3A+by+St.+John%E2%80%99s+wort+varies+among+products+and+is+linked+to+hyperforin+dose&doi=10.1007%2Fs00228-005-0061-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose</span></div><div class="casAuthors">Mueller, Silke C.; Majcher-Peszynska, Jolanta; Uehleke, Bernhard; Klammt, Sebastian; Mundkowski, Ralf G.; Miekisch, Wolfram; Sievers, Hartwig; Bauer, Steffen; Frank, Bruno; Kundt, Guenther; Drewelow, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective: Induction of CYP3A by St.  John's wort (SJW) exts. with high hyperforin (HYF) content is well described.  Since SJW products vary in the amt. of HYF and other main constituents, the aim of the study was to evaluate the effect on CYP3A function of SJW prepns. with a range from very low to high HYF content.  Methods: Forty-two male, healthy volunteers were randomized into six parallel SJW medication groups with varying compn. esp. with regard to HYF content.  Midazolam plasma concn. profiles were characterized after a single oral dose of 7.5 mg midazolam on the day before and on the 14th day of SJW medication.  Results: All SJW prepns. tested resulted in a decrease in midazolam AUC, although the extent of the effect differed.  The ext. LI 160 (HYF 41 mg/day) decreased midazolam AUC0-12h by 79.4% (95% CI -88.6; -70.1), which was significantly greater than the effect by any other medication (p<0.05).  SJW powder tablets 2.7 g/day (HYF 12 mg/day) resulted in a midazolam AUC0-12h decrease of 47.9% (95% CI -59.7;-36.2), while 2.7 g/day SJW powder tablets that were almost devoid of HYF (0.13 mg/day) reduced midazolam AUC0-12h by only 21.1% (95% CI -33.9; -8.3).  Considering all six SJW medications tested, the extent of midazolam AUC decrease correlated significantly with increasing HYF dose (r=-0.765, p<0.001), but not with hypericin dose (r=-0.067; p=0.673).  Conclusion: The extent of induction of CYP3A varies among St.  John's wort products and depends on hyperforin dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIIqMLdwDZbrVg90H21EOLACvtfcHk0ljszdekyx4EVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVOlug%253D%253D&md5=0490b22cfb82f02e54d09ea0c8b91089</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00228-005-0061-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-005-0061-3%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DS.%2BC.%26aulast%3DMajcher-Peszynska%26aufirst%3DJ.%26aulast%3DUehleke%26aufirst%3DB.%26aulast%3DKlammt%26aufirst%3DS.%26aulast%3DMundkowski%26aufirst%3DR.%2BG.%26aulast%3DMiekisch%26aufirst%3DW.%26aulast%3DSievers%26aufirst%3DH.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DB.%26aulast%3DKundt%26aufirst%3DG.%26aulast%3DDrewelow%26aufirst%3DB.%26atitle%3DThe%2520extent%2520of%2520induction%2520of%2520CYP3A%2520by%2520St.%2520John%25E2%2580%2599s%2520wort%2520varies%2520among%2520products%2520and%2520is%2520linked%2520to%2520hyperforin%2520dose%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D1%26spage%3D29%26epage%3D36%26doi%3D10.1007%2Fs00228-005-0061-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtbecker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnhaus, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidemann, H.</span></span> <span> </span><span class="NLM_article-title">The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8894514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=1121-1123&issue=10&author=N.+Holtbeckerauthor=M.+F.+Frommauthor=H.+K.+Kroemerauthor=E.+E.+Ohnhausauthor=H.+Heidemann&title=The+nifedipine-rifampin+interaction.+Evidence+for+induction+of+gut+wall+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism</span></div><div class="casAuthors">Holtbecker, Norbert; Fromm, Martin F.; Kroemer, Heyo K.; Ohnhaus, Edgar E.; Heidemann, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1121-1123</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The calcium channel blocker nifedipine is metabolized by cytochrome P 450 3A4, which is present in liver and mucosa of the small bowel.  Cytochrome P 450 3A4 is inducible by the tuberculostatic rifampin in liver and the small bowel.  The contribution of gut wall metab. to total clearance of nifedipine before and during induction has not been detd. in detail.  We therefore investigated the nifedipine-rifampin interaction, with special emphasis on the contribution of gut wass metab. to total metab. of nifedipine before and during administration of rifampin.  Pharmacokinetics of nifedipine were studied in six healthy volunteers on sep. days by administration of 20 μg/kg body wt. nifedipine i.v. and 20 mg nifedipine orally before and after 7 days of rifampin treatment (600 mg/day).  Enzyme induction did not significantly alter pharmacokinetics of nifedipine after i.v. administration.  In contrast, oral clearance of nifedipine increased from 1.5 ± 0.2 L/min to 20.9 ± 8.3 L/min (p < 0.01) and bioavailability decreased from 41.2 ± 5.4% to 5.3 ± 2.7% (p < 0.001).  Although hepatic extn. of nifedipine was not significantly altered during induction (47.4 ± 6.6% vs. 67.4 ± 20.2%; ns), the calcd. extn. of nifedipine in gut wall mucosa increased from 21.8 ± 13.3% to 75.8 ± 28.2% (p < 0.05).  We conclude that there is a relevant interaction between nifedipine and rifampin.  The redn. of nifedipine bioavailability during enzyme induction is most likely due to rifampin-induced gut wall metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcYR_QVFyE2LVg90H21EOLACvtfcHk0lgIeFNiggBbRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeit7s%253D&md5=0ba33026eb6458617bb21b47b7fe3093</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoltbecker%26aufirst%3DN.%26aulast%3DFromm%26aufirst%3DM.%2BF.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DOhnhaus%26aufirst%3DE.%2BE.%26aulast%3DHeidemann%26aufirst%3DH.%26atitle%3DThe%2520nifedipine-rifampin%2520interaction.%2520Evidence%2520for%2520induction%2520of%2520gut%2520wall%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26issue%3D10%26spage%3D1121%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">FDA</span>.  <i>Lumacaftor NDA No. 206038</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Lumacaftor+NDA+No.+206038."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLumacaftor%2520NDA%2520No.%2520206038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayan-Oshodi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Peña, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.112.046060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22789530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1945-1952&issue=10&author=M.+A.+Ayan-Oshodiauthor=B.+A.+Willisauthor=W.+F.+Annesauthor=S.+L.+Loweauthor=S.+Friedrichauthor=A.+de+la+Pe%C3%B1aauthor=W.+Zhangauthor=T.+Brownauthor=S.+D.+Wiseauthor=S.+D.+Hall&title=The+effects+on+metabolic+clearance+when+administering+a+potent+CYP3A+autoinducer+with+the+prototypic+CYP3A+inhibitor%2C+ketoconazole&doi=10.1124%2Fdmd.112.046060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole</span></div><div class="casAuthors">Ayan-Oshodi, Mosun A.; Willis, Brian A.; Annes, William F.; Lowe, Stephen L.; Friedrich, Stuart; de la Pena, Amparo; Zhang, Wei; Brown, Thomas; Wise, Stephen D.; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1945-1952</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ketoconazole is recognized as the prototypical CYP3A inhibitor and is often used to det. the metabolic CYP3A liabilities of new chem. entities in preclin. and clin. studies.  Ketoconazole has been com. available for approx. 30 years and was marketed before drug-metabolizing enzymes were well characterized; consequently, little is known about its metabolic profile.  Semagacestat, a γ-secretase inhibitor investigated as a potential therapy for Alzheimer's disease, was detd. to be a potent CYP3A autoinducer in human hepatocytes.  Two human studies were conducted to assess the induction potential of semagacestat.  In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.  In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.  Ketoconazole decreased semagacestat CL/F by 32% after a single dose of semagacestat [geometric means ratio est., 0.68; 90% confidence interval (CI). 0.64, 0.73] and 46% at steady state (geometric means ratio est. 0.54; 90% CI, 0.51, 0.58).  Ketoconazole area under the concn.-time curve over 8 h decreased 49% from first to last day of semagacestat dosing.  Semagacestat significantly increases the oral clearance of CYP3A substrates, confirming its inducer designation.  More importantly, when administered with a potent CYP3A inducer at steady state, ketoconazole's plasma exposure decreased, indicating that it may also be cleared by CYP3A, other inducible enzymes or transporters, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSbL34aQEaCbVg90H21EOLACvtfcHk0lgIeFNiggBbRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmsbvE&md5=2ae359568d90f744509be521e8e7adaa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046060%26sid%3Dliteratum%253Aachs%26aulast%3DAyan-Oshodi%26aufirst%3DM.%2BA.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DAnnes%26aufirst%3DW.%2BF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3Dde%2Bla%2BPe%25C3%25B1a%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DT.%26aulast%3DWise%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DThe%2520effects%2520on%2520metabolic%2520clearance%2520when%2520administering%2520a%2520potent%2520CYP3A%2520autoinducer%2520with%2520the%2520prototypic%2520CYP3A%2520inhibitor%252C%2520ketoconazole%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D10%26spage%3D1945%26epage%3D1952%26doi%3D10.1124%2Fdmd.112.046060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">FDA.</span> <i>Dabrafenib NDA No. 202806</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Dabrafenib+NDA+No.+202806."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DDabrafenib%2520NDA%2520No.%2520202806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">FDA.</span> <i>Cenobamate NDA No. 212839</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Cenobamate+NDA+No.+212839."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DCenobamate%2520NDA%2520No.%2520212839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">FDA.</span> <i>Lorlatinib NDA No. 210868</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Lorlatinib+NDA+No.+210868."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLorlatinib%2520NDA%2520No.%2520210868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosset, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terra, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidsey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: Integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.116.074476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28254951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=501-511&issue=5&author=J.+Q.+Dongauthor=J.+R.+Gossetauthor=O.+A.+Fahmiauthor=Z.+Linauthor=J.+R.+Chabotauthor=S.+G.+Terraauthor=V.+Leauthor=K.+Chidseyauthor=P.+Nouriauthor=A.+Kimauthor=L.+Buckbinderauthor=A.+S.+Kalgutkar&title=Examination+of+the+human+cytochrome+P4503A4+induction+potential+of+PF-06282999%2C+an+irreversible+myeloperoxidase+inactivator%3A+Integration+of+preclinical%2C+in+silico%2C+and+biomarker+methodologies+in+the+prediction+of+the+clinical+outcome&doi=10.1124%2Fdmd.116.074476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome</span></div><div class="casAuthors">Dong, Jennifer Q.; Gosset, James R.; Fahmi, Odette A.; Lin, Zhiwu; Chabot, Jeffrey R.; Terra, Steven G.; Le, Vu; Chidsey, Kristin; Nouri, Parya; Kim, Albert; Buckbinder, Leonard; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-511</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The propensity for CYP3A4 induction by 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999), an irreversible inactivator of myeloperoxidase, was examd. in the present study.  Studies using human hepatocytes revealed moderate increases in CYP3A4 mRNA and midazolam-1'-hydroxylase activity in a PF-06282999 dose-dependent fashion.  At the highest tested concn. of 300 μM, PF-06282999 caused maximal induction in CYP3A4 mRNA and enzyme activity ranging from 56% to 86% and 47% t0 72%, resp., of rifampicin response across the three hepatocyte donor pools.  In a clin. drug-drug interaction (DDI) study, the mean midazolam Cmax and area under the curve (AUC) values following 14-day treatment with PF-06282999 decreased in a dose-dependent fashion with a max. decrease in midazolam AUC0-inf and Cmax of ∼57.2% and 41.1% obsd. at the 500 mg twice daily dose.  The moderate impact on midazolam pharmacokinetics at the 500 mg twice daily dose of PF-06282999 was also reflected in statistically significant changes in plasma 4β-hydroxycholesterol/cholesterol and urinary 6β-hydroxycortisol/cortisol ratios.  Changes in plasma and urinary CYP3A4 biomarkers did not reach statistical significance at the 125 mg three times daily dose of PF-06282999, despite a modest decrease in midazolam systemic exposure.  Predicted DDI magnitude based on the in vitro induction parameters and simulated pharmacokinetics of perpetrator (PF-06282999) and victim (midazolam) using the Simcyp (Simcyp Ltd., Sheffield, United Kingdom) population-based simulator were in reasonable agreement with the obsd. clin. data.  Since the magnitude of the 4β-hydroxycholesterol or 6β-hydroxycortisol ratio change was generally smaller than the magnitude of the midazolam AUC change with PF-06282999, a pharmacokinetic interaction study with midazolam ultimately proved important for assessment of DDI via CYP3A4 induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyuhKk0yzrgrVg90H21EOLACvtfcHk0li9FALBYEaFWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjP&md5=e824db495a6cd97c20bd4de48e4d5cc9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074476%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%2BQ.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DChabot%26aufirst%3DJ.%2BR.%26aulast%3DTerra%26aufirst%3DS.%2BG.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DChidsey%26aufirst%3DK.%26aulast%3DNouri%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DExamination%2520of%2520the%2520human%2520cytochrome%2520P4503A4%2520induction%2520potential%2520of%2520PF-06282999%252C%2520an%2520irreversible%2520myeloperoxidase%2520inactivator%253A%2520Integration%2520of%2520preclinical%252C%2520in%2520silico%252C%2520and%2520biomarker%2520methodologies%2520in%2520the%2520prediction%2520of%2520the%2520clinical%2520outcome%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D501%26epage%3D511%26doi%3D10.1124%2Fdmd.116.074476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shebley, M.</span></span> <span> </span><span class="NLM_article-title">Quantitative assessment of elagolix enzyme-transporter interplay and drug-drug interactions using physiologically based pharmacokinetic modeling</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1007/s40262-019-00833-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs40262-019-00833-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31713224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=617-627&issue=5&author=M.+S.+Chineyauthor=J.+Ngauthor=J.+P.+Gibbsauthor=M.+Shebley&title=Quantitative+assessment+of+elagolix+enzyme-transporter+interplay+and+drug-drug+interactions+using+physiologically+based+pharmacokinetic+modeling&doi=10.1007%2Fs40262-019-00833-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling</span></div><div class="casAuthors">Chiney, Manoj S.; Ng, Juki; Gibbs, John P.; Shebley, Mohamad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-627</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Elagolix is approved for the management of moderate-to-severe pain assocd. with endometriosis.  The aim of this anal. was to develop a physiol. based pharmacokinetic (PBPK) model that describes the enzyme-transporter interplay involved in the disposition of elagolix and to predict the magnitude of drug-drug interaction (DDI) potential of elagolix as an inhibitor of P-glycoprotein (P-gp) and inducer of cytochrome P 450 (CYP) 3A4.  Methods: A PBPK model (SimCYP version 15.0.86.0) was developed using elagolix data from in vitro, clin. PK and DDI studies.  Data from DDI studies were used to quantify contributions of the uptake transporter org. anion transporting polypeptide (OATP) 1B1 and CYP3A4 in the disposition of elagolix, and to quant. assess the perpetrator potential of elagolix as a CYP3A4 inducer and P-gp inhibitor.  Results: After accounting for the interplay between elagolix metab. by CYP3A4 and uptake by OATP1B1, the model-predicted PK parameters of elagolix along with the DDI AUC∞ and Cmax ratios, were within 1.5-fold of the obsd. data.  Based on model simulations, elagolix 200 mg administered twice daily is a moderate inducer of CYP3A4 (approx. 56% redn. in midazolam AUC∞).  Simulations of elagolix 150 mg administered once daily with digoxin predicted an increase in digoxin Cmax and AUC∞ by 68% and 19%, resp.  Conclusions: A PBPK model of elagolix was developed, verified, and applied to characterize the disposition interplay between CYP3A4 and OATP1B1, and to predict the DDI potential of elagolix as a perpetrator under dosing conditions that were not tested clin.  PBPK model-based predictions were used to support labeling language for DDI recommendations of elagolix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-QsvPuSLgbVg90H21EOLACvtfcHk0li9FALBYEaFWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemu7rF&md5=7cc7a8e23faa0f6ca13f7ad80bc8ba15</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40262-019-00833-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-019-00833-6%26sid%3Dliteratum%253Aachs%26aulast%3DChiney%26aufirst%3DM.%2BS.%26aulast%3DNg%26aufirst%3DJ.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DShebley%26aufirst%3DM.%26atitle%3DQuantitative%2520assessment%2520of%2520elagolix%2520enzyme-transporter%2520interplay%2520and%2520drug-drug%2520interactions%2520using%2520physiologically%2520based%2520pharmacokinetic%2520modeling%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26issue%3D5%26spage%3D617%26epage%3D627%26doi%3D10.1007%2Fs40262-019-00833-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langdon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndongo, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vourvahis, M.</span></span> <span> </span><span class="NLM_article-title">The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1572</span>, <span class="refDoi"> DOI: 10.1007/s00228-012-1287-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00228-012-1287-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22527351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyhsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=1567-1572&issue=11&author=J.+Davisauthor=G.+Langdonauthor=G.+Laytonauthor=C.+L.+Chongauthor=M.+N.+Ndongoauthor=M.+Vourvahis&title=The+effect+of+lersivirine%2C+a+next-generation+NNRTI%2C+on+the+pharmacokinetics+of+midazolam+and+oral+contraceptives+in+healthy+subjects&doi=10.1007%2Fs00228-012-1287-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects</span></div><div class="casAuthors">Davis, John; Langdon, Grant; Layton, Gary; Chong, Chew Lan; Ndongo, Marie-Noella; Vourvahis, Manoli</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1567-1572</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a unique resistance profile that exhibits potent antiretroviral activity against wild-type human immunodeficiency virus and clin. relevant NNRTI-resistant strains.  Results from in vitro and in vivo investigations suggest that lersivirine is a cytochrome P 450 (CYP3A4) inducer that is metabolized by CYP3A4 and uridine diphosphate glucuronosyltransferase (UGT) 2B7.  In order to formally assess the effects of lersivirine on CYP3A4 metab. and/or glucuronidation, we performed studies aimed at investigating the effects of lersivirine co-administration on the pharmacokinetics (PK) of midazolam, ethinylestradiol and levonorgestrel.  Methods: Two drug-drug interaction studies were performed.  Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein.  The effects of co-administration on the PK parameters of midazolam and OCs were assessed.  Results: At clin. relevant lersivirine doses (500-1,000 mg total daily dose), the mean plasma exposure of midazolam was reduced in a dose-dependent manner by 20-36 %.  Co-administration of lersivirine 1,000 mg QD with OCs had minor PK effects, increasing ethinylestradiol exposure by 10 % and reducing levonorgestrel exposure by 13 %.  Conclusions: These data further support previous observations that lersivirine is a weak CYP3A4 inducer, a weak inhibitor of glucuronidation, and a P-glycoprotein inhibitor.  In both studies, lersivirine appeared to have a good safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH6AneMpZs4rVg90H21EOLACvtfcHk0lgi-HOZpltqrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyhsr7O&md5=f8574ca6b7efe7c4f87455af54ece715</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs00228-012-1287-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-012-1287-5%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLangdon%26aufirst%3DG.%26aulast%3DLayton%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DC.%2BL.%26aulast%3DNdongo%26aufirst%3DM.%2BN.%26aulast%3DVourvahis%26aufirst%3DM.%26atitle%3DThe%2520effect%2520of%2520lersivirine%252C%2520a%2520next-generation%2520NNRTI%252C%2520on%2520the%2520pharmacokinetics%2520of%2520midazolam%2520and%2520oral%2520contraceptives%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D68%26issue%3D11%26spage%3D1567%26epage%3D1572%26doi%3D10.1007%2Fs00228-012-1287-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">FDA.</span> <i>Telotristat ethyl NDA No. 208794</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Telotristat+ethyl+NDA+No.+208794."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTelotristat%2520ethyl%2520NDA%2520No.%2520208794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensign, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedynek, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span> <span> </span><span class="NLM_article-title">Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fclpt.2011.276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22398970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=673-684&issue=4&author=E.+D.+Kharaschauthor=D.+Whittingtonauthor=D.+Ensignauthor=C.+Hofferauthor=P.+S.+Bedynekauthor=S.+Campbellauthor=K.+Stubbertauthor=A.+Craffordauthor=A.+Londonauthor=T.+Kim&title=Mechanism+of+efavirenz+influence+on+methadone+pharmacokinetics+and+pharmacodynamics&doi=10.1038%2Fclpt.2011.276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics</span></div><div class="casAuthors">Kharasch, E. D.; Whittington, D.; Ensign, D.; Hoffer, C.; Bedynek, P. S.; Campbell, S.; Stubbert, K.; Crafford, A.; London, A.; Kim, T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">673-684</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mechanisms by which efavirenz diminishes methadone plasma concns. are unknown.  This investigation detd. efavirenz influence on clin. methadone disposition and miosis, i.v. and oral alfentanil clearance (hepatic and intestinal cytochrome P 450 3A4/5 (CYP3A4/5) activity), fexofenadine disposition (intestinal transporters activity), and efavirenz clearance and 8-hydroxylation (CYP2B6 activity), and human hepatocyte effects.  Efavirenz induced systemic and oral alfentanil clearances two- to fivefold and induced efavirenz 8-hydroxylation.  Efavirenz stereoselectively decreased methadone plasma concns. 50-70%.  Methadone systemic and oral clearances, hepatic clearance and extn. ratio, N-demethylation, and metabolite formation clearance were stereoselectively increased two- to threefold.  Bioavailability decreased.  Efavirenz shifted methadone concn.-miosis curves leftward and upward.  Efavirenz induced hepatocyte CYP2B6 and CYP3A4 expression, activity, and methadone N-demethylation.  Results show that efavirenz coinduced hepatic CYP2B6 and CYP3A4/5, coinduced hepatic and intestinal CYP3A4/5, and coinduced gastrointestinal CYP3A4/5 and efflux transporters.  Methadone disposition was most consistent with efavirenz induction of hepatic CYP2B6-mediated methadone N-demethylation.  Efavirenz may alter methadone pharmacodynamics.  Clin. Pharmacol. & Therapeutics (2012); 91 4, 673-684. doi:10.1038/clpt.2011.276.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZt1GVs-Ga7Vg90H21EOLACvtfcHk0lgi-HOZpltqrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOkurY%253D&md5=36c71279d00ba733ec5c6aa389d726e0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.276%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DEnsign%26aufirst%3DD.%26aulast%3DHoffer%26aufirst%3DC.%26aulast%3DBedynek%26aufirst%3DP.%2BS.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DStubbert%26aufirst%3DK.%26aulast%3DCrafford%26aufirst%3DA.%26aulast%3DLondon%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DT.%26atitle%3DMechanism%2520of%2520efavirenz%2520influence%2520on%2520methadone%2520pharmacokinetics%2520and%2520pharmacodynamics%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D91%26issue%3D4%26spage%3D673%26epage%3D684%26doi%3D10.1038%2Fclpt.2011.276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates sildenafil, amlodipine, tolbutamide, and repaglinide</span>. <i>Clin Pharmacol Drug Dev</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1002/cpdd.324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fcpdd.324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28067999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=363-376&issue=4&author=M.+Gillenauthor=C.+Yangauthor=D.+Wilsonauthor=S.+Valdezauthor=C.+Leeauthor=B.+Kerrauthor=Z.+Shen&title=Evaluation+of+pharmacokinetic+interactions+between+lesinurad%2C+a+new+selective+urate+reabsorption+inhibitor%2C+and+CYP+enzyme+substrates+sildenafil%2C+amlodipine%2C+tolbutamide%2C+and+repaglinide&doi=10.1002%2Fcpdd.324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide</span></div><div class="casAuthors">Gillen, Michael; Yang, Chun; Wilson, David; Valdez, Shakti; Lee, Caroline; Kerr, Bradley; Shen, Zancong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-376</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Lesinurad is a selective uric acid reabsorption inhibitor approved for the treatment of hyperuricemia assocd. with gout in combination with xanthine oxidase inhibitors.  In vitro assays indicate that lesinurad is an inducer of CYPs in the order CYP3A > CYP2C8 > CYP2C9 > CYP2C19 > CYP2B6 and an inhibitor of CYP2C8 and CYP2C9.  To investigate the drug interaction potential of lesinurad, clin. drug interaction studies were conducted.  Open-label studies in volunteers investigated the effects of single-/multiple-dose lesinurad on the pharmacokinetics of sildenafil and amlodipine (CYP3A4 induction), tolbutamide (CYP2C9 inhibition/induction), and repaglinide (CYP2C8 inhibition/induction).  There was no apparent induction of CYP2C8 and CYP2C9 following repeated lesinurad administration, although no inhibition of CYP2C9 and modest inhibition of CYP2C8 were obsd. following single-dose lesinurad.  Consistent with in vitro observations, lesinurad (200 mg once daily) was an inducer of CYP3A based on the effects on sildenafil exposure.  Sildenafil exposure decreased by approx. 34% for Cmax and AUC when administered with multiple-dose lesinurad 200 mg and allopurinol 300 mg, relative to sildenafil alone.  During lesinurad therapy, the possibility of reduced efficacy of concomitant drugs that are CYP3A substrates should be considered and their efficacy monitored because of induction of CYP3A by lesinurad.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo__JbrBf2wLVg90H21EOLACvtfcHk0lgi-HOZpltqrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbrE&md5=a5b4c42e2433f60af3d87cc0a8f7008d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.324%26sid%3Dliteratum%253Aachs%26aulast%3DGillen%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DValdez%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKerr%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interactions%2520between%2520lesinurad%252C%2520a%2520new%2520selective%2520urate%2520reabsorption%2520inhibitor%252C%2520and%2520CYP%2520enzyme%2520substrates%2520sildenafil%252C%2520amlodipine%252C%2520tolbutamide%252C%2520and%2520repaglinide%26jtitle%3DClin%2520Pharmacol%2520Drug%2520Dev%26date%3D2017%26volume%3D6%26issue%3D4%26spage%3D363%26epage%3D376%26doi%3D10.1002%2Fcpdd.324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2005.02383.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2005.02383.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15963102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2ktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2005&pages=107-112&issue=1&author=G.+A.+Paulauthor=J.+S.+Gibbsauthor=A.+R.+Boobisauthor=A.+Abbasauthor=M.+R.+Wilkins&title=Bosentan+decreases+the+plasma+concentration+of+sildenafil+when+coprescribed+in+pulmonary+hypertension&doi=10.1111%2Fj.1365-2125.2005.02383.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension</span></div><div class="casAuthors">Paul, Gideon A.; Gibbs, J. Simon R.; Boobis, Alan R.; Abbas, Allifia; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To det. whether bosentan decreases the plasma concn. of sildenafil in patients with pulmonary arterial hypertension.  Ten patients (aged 39-77 years) with pulmonary arterial hypertension in WHO functional class III received bosentan 62.5 mg twice daily for 1 mo, then 125 mg twice daily for a second month.  Sildenafil 100 mg was given as a single dose before starting bosentan (visit 1) and at the end of each month of bosentan treatment (visits 2 and 3).  Sildenafil and its primary metabolite, desmethylsildenafil, were measured in plasma at 0 h and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h using liq. chromatog.-tandem mass spectrometry.  Statistical anal. was by repeated measures ANOVA, using log transformed data where appropriate.  Treatment with bosentan 62.5 mg twice daily for 4 wk was assocd. with a two-fold increase in sildenafil clearance/F and a 50% decrease in the AUC (P < 0.001).  Increasing the dose of bosentan to 125 mg twice daily led to a further increase in sildenafil oral clearance and decrease in the AUC (P < 0.001 vs. 62.5 mg bosentan).  The ratio of AUC on bosentan treatment relative to that of visit 1 was 0.47 [95% confidence interval (Cl) 0.36, 0.61] for visit 2 and 0.31 (95% Cl 0.23, 0.41) for visit 3 (P < 0.001).  Sildenafil Cmax fell from 759 ng ml-1 on visit 1 to 333 ng ml-1 on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).  The AUC and plasma half-life of desmethylsildenafil was also decreased by bosentan in a dose-dependent manner (P < 0.01).  Bosentan significantly decreases the plasma concn. of sildenafil when coadministered to patients with pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr36c2mn71LT7Vg90H21EOLACvtfcHk0ljUyO9Lva-MLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2ktrc%253D&md5=34df20f64b356bb1585f3543cca2d3d3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02383.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02383.x%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DG.%2BA.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%26aulast%3DBoobis%26aufirst%3DA.%2BR.%26aulast%3DAbbas%26aufirst%3DA.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DBosentan%2520decreases%2520the%2520plasma%2520concentration%2520of%2520sildenafil%2520when%2520coprescribed%2520in%2520pulmonary%2520hypertension%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D60%26issue%3D1%26spage%3D107%26epage%3D112%26doi%3D10.1111%2Fj.1365-2125.2005.02383.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöller-Gyüre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetelmans, R. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between etravirine and non-antiretroviral drugs</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2165/11534740-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2165%2F11534740-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21142266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=25-39&issue=1&author=T.+N.+Kakudaauthor=M.+Sch%C3%B6ller-Gy%C3%BCreauthor=R.+M.+Hoetelmans&title=Pharmacokinetic+interactions+between+etravirine+and+non-antiretroviral+drugs&doi=10.2165%2F11534740-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interactions between etravirine and non-antiretroviral drugs</span></div><div class="casAuthors">Kakuda, Thomas N.; Scholler-Gyure, Monika; Hoetelmans, Richard M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.  Etravirine has been approved in several countries for use as part of highly active antiretroviral therapy in treatment-experienced patients.  In vivo, etravirine is a substrate for, and weak inducer of, the hepatic cytochrome P 450 (CYP) isoenzyme 3A4 and a substrate and weak inhibitor of CYP2C9 and CYP2C19.  Etravirine is also a weak inhibitor of P-glycoprotein.  An extensive drug-drug interaction program in HIV-neg. subjects has been carried out to assess the potential for pharmacokinetic interactions between etravirine and a variety of non-antiretroviral drugs.  Effects of atorvastatin, clarithromycin, methadone, omeprazole, oral contraceptives, paroxetine, ranitidine and sildenafil on the pharmacokinetic disposition of etravirine were of no clin. relevance.  Likewise, etravirine had no clin. significant effect on the pharmacokinetics of fluconazole, methadone, oral contraceptives, paroxetine or voriconazole.  No clin. relevant interactions are expected between etravirine and azithromycin or ribavirin, therefore, etravirine can be combined with these agents without dose adjustment.  Fluconazole and voriconazole increased etravirine exposure 1.9- and 1.4-fold, resp., in healthy subjects, however, no increase in the incidence of adverse effects was obsd. in patients receiving etravirine and fluconazole during clin. trials, therefore, etravirine can be combined with these antifungals although caution is advised.  Digoxin plasma exposure was slightly increased when co-administered with etravirine.  No dose adjustments of digoxin are needed when used in combination with etravirine, however, it is recommended that digoxin levels should be monitored.  Caution should be exercised in combining rifabutin with etravirine in the presence of certain boosted HIV protease inhibitors due to the risk of decreased exposure to etravirine.  Although adjustments to the dose of clarithromycin are unnecessary for the treatment of most infections, the use of an alternative macrolide (e.g. azithromycin) is recommended for the treatment of Mycobacterium avium complex infection since the overall activity of clarithromycin against this pathogen may be altered when co-administered with etravirine.  Dosage adjustments based on clin. response are recommended for clopidogrel, HMG-CoA reductase inhibitors (e.g. atorvastatin) and for phosphodiesterase type-5 inhibitors (e.g. sildenafil) because changes in the exposure of these medications in the presence of co-administered etravirine may occur.  When co-administered with etravirine, a dose redn. or alternative to diazepam is recommended.  When combining etravirine with warfarin, the international normalized ratio (INR) should be monitored.  Systemic dexamethasone should be co-administered with caution, or an alternative to dexamethasone be found as dexamethasone induces CYP3A4.  Caution is also warranted when co-administering etravirine with some antiarrhythmics, calcineurin inhibitors (e.g. ciclosporin) and antidepressants (e.g. citalopram).  Co-administration of etravirine with some antiepileptics (e.g. carbamazepine and phenytoin), rifampicin (rifampin), rifapentine or prepns. contg. St John's wort (Hypericum perforatum) is currently not recommended as these are potent inducers of CYP3A and/or CYP2C and may potentially decrease etravirine exposure.  Antiepileptics that are less likely to interact based on their known pharmacol. properties include gabapentin, lamotrigine, levetiracetam and pregabalin.  Overall, pharmacokinetic and clin. data show etravirine to be well tolerated and generally safe when given in combination with non-antiretroviral agents, with minimal clin. significant drug interactions and no need for dosage adjustments of etravirine in any of the cases, or of the non-antiretroviral agent in the majority of cases studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s-3t6TAjlbVg90H21EOLACvtfcHk0ljUyO9Lva-MLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKitbc%253D&md5=9ef064f3dbba198d7a267f7058a452ae</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2165%2F11534740-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11534740-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DSch%25C3%25B6ller-Gy%25C3%25BCre%26aufirst%3DM.%26aulast%3DHoetelmans%26aufirst%3DR.%2BM.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520etravirine%2520and%2520non-antiretroviral%2520drugs%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26issue%3D1%26spage%3D25%26epage%3D39%26doi%3D10.2165%2F11534740-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. H.</span></span> <span> </span><span class="NLM_article-title">Combined therapy with thioridazine decreases plasma levels of quetiapine in Taiwanese schizophrenic patients</span>. <i>Ther. Drug Monit.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1097/FTD.0b013e31825479cc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2FFTD.0b013e31825479cc" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22569350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1ant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=345-348&issue=3&author=S.+C.+Changauthor=M.+L.+Luauthor=Y.+C.+Wangauthor=F.+W.+Linauthor=S.+H.+Huangauthor=P.+H.+Kuoauthor=H.+O.+Hoauthor=T.+H.+Wu&title=Combined+therapy+with+thioridazine+decreases+plasma+levels+of+quetiapine+in+Taiwanese+schizophrenic+patients&doi=10.1097%2FFTD.0b013e31825479cc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Therapy With Thioridazine Decreases Plasma Levels of Quetiapine in Taiwanese Schizophrenic Patients</span></div><div class="casAuthors">Chang, Shen-Chieh; Lu, Mong-Liang; Wang, Yue-Chi; Lin, Fang-Wei; Huang, Shu-Huei; Kuo, Pei-Hsin; Ho, Hsiu-O.; Wu, Tzu-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Drug Monitoring</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-348</span>CODEN:
                <span class="NLM_cas:coden">TDMODV</span>;
        ISSN:<span class="NLM_cas:issn">0163-4356</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia.  Methods: Sixteen subjects with schizophrenia were recruited for this study.  The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study.  QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week.  On day 15, blood samples were collected at 12 time points within an 8-h interval.  The authors assayed the plasma levels of QTP with a high-performance liq. chromatog. system coupled with UV detector.  Results: Significantly decreased plasma levels of QTP after oral administration were obsd. in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 h, and the P values were 0.046, 0.001, and 0.005, resp.  The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 vs. 1452.3 ± 707.5 ng/mL; P = 0.002).  The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 vs. 60.3 ± 28.5 L/h; P = 0.03).  Other pharmacokinetic parameters were not significantly different.  Conclusions: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP.  Although TDZ is switched to QTP, choosing larger doses of QTP for titrn. may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9M_UF7rQxv7Vg90H21EOLACvtfcHk0lh8gWL3ggmY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1ant70%253D&md5=59af5b2d7d00e6a00606765566373919</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1097%2FFTD.0b013e31825479cc&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFTD.0b013e31825479cc%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DLu%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DLin%26aufirst%3DF.%2BW.%26aulast%3DHuang%26aufirst%3DS.%2BH.%26aulast%3DKuo%26aufirst%3DP.%2BH.%26aulast%3DHo%26aufirst%3DH.%2BO.%26aulast%3DWu%26aufirst%3DT.%2BH.%26atitle%3DCombined%2520therapy%2520with%2520thioridazine%2520decreases%2520plasma%2520levels%2520of%2520quetiapine%2520in%2520Taiwanese%2520schizophrenic%2520patients%26jtitle%3DTher.%2520Drug%2520Monit.%26date%3D2012%26volume%3D34%26issue%3D3%26spage%3D345%26epage%3D348%26doi%3D10.1097%2FFTD.0b013e31825479cc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. C.</span></span> <span> </span><span class="NLM_article-title">Evidence of an interaction between nifedipine and nafcillin in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2003.01789.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1046%2Fj.1365-2125.2003.01789.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12814453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=588-590&issue=6&author=C.+C.+Langauthor=S.+K.+Jamalauthor=Z.+Mohamedauthor=M.+R.+Mustafaauthor=A.+M.+Mustafaauthor=T.+C.+Lee&title=Evidence+of+an+interaction+between+nifedipine+and+nafcillin+in+humans&doi=10.1046%2Fj.1365-2125.2003.01789.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of an interaction between nifedipine and nafcillin in humans</span></div><div class="casAuthors">Lang, C. C.; Jamal, S. K.; Mohamed, Z.; Mustafa, M. R.; Mustafa, A. M.; Lee, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">588-590</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Aims: Nafcillin (Wyeth Labs., Philadelphia, PA, USA) has been reported to induce the metab. of cyclosporin and warfarin, which are known substrates of cytochrome P 450 (CYP).  However, there has not been any report to date on its possible interaction with nifedipine, an index substrate of the enzyme, CYP3A4.  Methods: Nine healthy normotensive subjects participated in this randomized placebo-controlled two-way crossover study examg. the effects of 5 days' pretreatment of nafcillin 500 mg or placebo four times daily on the pharmacokinetics of an oral dose of nifedipine 10 mg.  Plasma nifedipine concns. were measured by gas chromatog.-mass spectrometry.  Results: The area under the plasma nifedipine concn.-time curve (AUC0-α) in nafcillin-pretreated subjects (80.9±32.9 μg l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4±93.2 μg l-1 h-1) (P < 0.001).  Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5±42.01 h-1 vs. 56.5±32.01 h-1) (P < 0.002).  Conclusions: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjh7_0u5Y9F7Vg90H21EOLACvtfcHk0lh8gWL3ggmY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFaitL4%253D&md5=922736f107886edf88882b47f4a137ff</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2003.01789.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2003.01789.x%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DC.%2BC.%26aulast%3DJamal%26aufirst%3DS.%2BK.%26aulast%3DMohamed%26aufirst%3DZ.%26aulast%3DMustafa%26aufirst%3DM.%2BR.%26aulast%3DMustafa%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DEvidence%2520of%2520an%2520interaction%2520between%2520nifedipine%2520and%2520nafcillin%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2003%26volume%3D55%26issue%3D6%26spage%3D588%26epage%3D590%26doi%3D10.1046%2Fj.1365-2125.2003.01789.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span> <span> </span><span class="NLM_article-title">Drug interactions with fluconazole</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">Suppl 3</span>),  <span class="NLM_fpage">S327</span>, <span class="refDoi"> DOI: 10.1093/clinids/12.Supplement_3.S327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fclinids%2F12.Supplement_3.S327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1990&pages=S327&issue=Suppl+3&author=J.+D.+Lazarauthor=K.+D.+Wilner&title=Drug+interactions+with+fluconazole&doi=10.1093%2Fclinids%2F12.Supplement_3.S327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F12.Supplement_3.S327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F12.Supplement_3.S327%26sid%3Dliteratum%253Aachs%26aulast%3DLazar%26aufirst%3DJ.%2BD.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26atitle%3DDrug%2520interactions%2520with%2520fluconazole%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1990%26volume%3D12%26issue%3DSuppl%25203%26spage%3DS327%26doi%3D10.1093%2Fclinids%2F12.Supplement_3.S327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayesekera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayewardene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevanayagam, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aweeka, F.</span></span> <span> </span><span class="NLM_article-title">Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1177/00912709922011746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F00912709922011746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10516944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=1085-1093&issue=10&author=S.+Hayashiauthor=D.+Jayesekeraauthor=A.+Jayewardeneauthor=A.+Shahauthor=L.+Thevanayagamauthor=F.+Aweeka&title=Altered+pharmacokinetics+of+indinavir+by+a+novel+nonnucleoside+reverse+transcriptase+inhibitor+%28HBY-097%29%3A+a+pharmacokinetic+evaluation+in+HIV-positive+patients&doi=10.1177%2F00912709922011746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients</span></div><div class="casAuthors">Hayashi, Sandra; Jayesekera, Deepthi; Jayewardene, Anura; Shah, Anita; Thevanayagam, Lourdes; Aweeka, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1085-1093</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">HBY-097 (HBY), an investigational nonnucleoside reverse transcriptase inhibitor (NNRTI), and indinavir (IDV) share a common metabolic pathway, cytochrome P 4503A4 (CYP3A4), and may clin. be used together as well as with zidovudine (ZDV).  Thus, the potential pharmacokinetic (PK) interaction between these drugs was evaluated.  HBY (500 mg Q8H), IDV (800 mg Q8H), and ZDV (200 mg Q8H) were given to 8 HIV-infected subjects.  Serial plasma samples were collected at baseline (ZDV and IDV alone) and day 11 (all 3 drugs) to det. PK parameters using noncompartmental anal.  PK parameters for ZDV in the presence and absence of HBY were not appreciably different.  However, both the max. (Cmax) and min. (Cmin) concns. of IDV were significantly reduced, from a mean of 7514 ± 1636 and 146 ± 81 mcg/L to 4725 ± 2494 mcg/L and 54 ± 24 mcg/L (p < .05) after addn. of HBY.  Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 ± 0.14 to 1.94 ± 0.63 L/h/kg (p < .05) with an assocd. redn. in area under the curve (AUC0-8) from 16,034 ± 4903 to 6134 ± 2701 mg/L/h (p < .05).  The increase in IDV CL/F is consistent with the obsd. metabolic induction effects of other NNRTIs.  The results of this trial showed that HBY significantly alters the pharmacokinetic parameters of IDV at the dose studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyw-i9VefTbVg90H21EOLACvtfcHk0lh8gWL3ggmY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFWrsw%253D%253D&md5=37b1e0744e3677b2ca82e4b8fcb4bcd8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1177%2F00912709922011746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912709922011746%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DJayesekera%26aufirst%3DD.%26aulast%3DJayewardene%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DThevanayagam%26aufirst%3DL.%26aulast%3DAweeka%26aufirst%3DF.%26atitle%3DAltered%2520pharmacokinetics%2520of%2520indinavir%2520by%2520a%2520novel%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520%2528HBY-097%2529%253A%2520a%2520pharmacokinetic%2520evaluation%2520in%2520HIV-positive%2520patients%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1999%26volume%3D39%26issue%3D10%26spage%3D1085%26epage%3D1093%26doi%3D10.1177%2F00912709922011746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taburet, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiec, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morand-Joubert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chêne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clavel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, P. M.</span></span> <span> </span><span class="NLM_article-title">Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clpt.2003.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15060509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVKgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=310-323&issue=4&author=A.+M.+Taburetauthor=G.+Raguinauthor=C.+Le+Tiecauthor=C.+Drozauthor=A.+Barrailauthor=I.+Vincentauthor=L.+Morand-Joubertauthor=G.+Ch%C3%AAneauthor=F.+Clavelauthor=P.+M.+Girard&title=Interactions+between+amprenavir+and+the+lopinavir-ritonavir+combination+in+heavily+pretreated+patients+infected+with+human+immunodeficiency+virus&doi=10.1016%2Fj.clpt.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus</span></div><div class="casAuthors">Taburet, Anne-Marie; Raguin, Gilles; Le Tiec, Clotilde; Droz, Cecile; Barrail, Aurelie; Vincent, Isabelle; Morand-Joubert, Laurence; Chene, Genevieve; Clavel, Francois; Girard, Pierre-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">310-323</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: This pharmacokinetic study was designed to characterize interactions between amprenavir and the lopinavir-ritonavir combination in patients infected with human immunodeficiency virus in whom previous antiretroviral therapy had failed.  Methods: Twenty-seven patients included in a randomized clin. trial (ANRS [National Agency for AIDS Research] Protocol 104) participated in this study.  They were randomized to receive ritonavir at a dose of either 100 mg twice daily or 200 mg twice daily.  For the first 2 wk of therapy, they were randomly assigned to receive lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily), amprenavir (600 mg twice daily) plus ritonavir (100 mg twice daily), lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily) plus addnl. ritonavir (100 mg twice daily), or amprenavir (600 mg twice daily) plus ritonavir (200 mg twice daily).  From week 3 onward, all patients received amprenavir plus lopinavir-ritonavir with or without an addnl. ritonavir dose (100 mg twice daily).  The pharmacokinetics of the 3 drugs was studied in weeks 2 and 6 of therapy.  Results: Median amprenavir concns. decreased by 54% (P = .004) when lopinavir was added to the amprenavir-ritonavir regimen.  Lopinavir weakly displaced amprenavir from plasma proteins: The av. unbound fraction of amprenavir was 0.089 in week 2 and 0.114 in week 6 (P = .03), but this did not fully account for the obsd. interaction.  Increasing the ritonavir dose did not affect the amprenavir concn.  The relationship between lopinavir and ritonavir concns. fitted a max. effect (Emax) model;the av. concn. of ritonavir that yielded a lopinavir concn. of 8119 ng/mL (50% of Emax) was 602 ng/mL (coeff. of variation, 22%).  There was a significant relationship between the lopinavir inhibitory quotient and the virol. response in week 2 (P = .005).  Conclusion: Lopinavir markedly decreases the amprenavir concn. during amprenavir and lopinavir-ritonavir combination therapy.  The inhibitory quotients were more predictive of the short-term virol. response than was the level of drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThmGSjwIoPrVg90H21EOLACvtfcHk0lhFy4aP-HGsbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVKgurk%253D&md5=37a33196c0c7479cf11954b3aeaf84ab</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DTaburet%26aufirst%3DA.%2BM.%26aulast%3DRaguin%26aufirst%3DG.%26aulast%3DLe%2BTiec%26aufirst%3DC.%26aulast%3DDroz%26aufirst%3DC.%26aulast%3DBarrail%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DI.%26aulast%3DMorand-Joubert%26aufirst%3DL.%26aulast%3DCh%25C3%25AAne%26aufirst%3DG.%26aulast%3DClavel%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DP.%2BM.%26atitle%3DInteractions%2520between%2520amprenavir%2520and%2520the%2520lopinavir-ritonavir%2520combination%2520in%2520heavily%2520pretreated%2520patients%2520infected%2520with%2520human%2520immunodeficiency%2520virus%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D75%26issue%3D4%26spage%3D310%26epage%3D323%26doi%3D10.1016%2Fj.clpt.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellriegel, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span> <span> </span><span class="NLM_article-title">Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1067/mcp.2002.121217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1067%2Fmcp.2002.121217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11823757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=46-56&issue=1&author=P.+Robertsonauthor=E.+T.+Hellriegelauthor=S.+Aroraauthor=M.+Nelson&title=Effect+of+modafinil+on+the+pharmacokinetics+of+ethinyl+estradiol+and+triazolam+in+healthy+volunteers&doi=10.1067%2Fmcp.2002.121217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers</span></div><div class="casAuthors">Robertson, Philmore, Jr.; Hellriegel, Edward T.; Arora, Sanjay; Nelson, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Background: Modafinil was reported to produce a concn.-related induction of CYP3A4/5 activity in vitro in primary cultures of human hepatocytes.  Objective: The authors' objective was to det. whether the pharmacokinetics of steady-state ethinyl estradiol (INN, ethinylestradiol) and single-dose triazolam were altered after 4 wk of modafinil treatment in volunteers.  Methods: This was a placebo-controlled, single-blind, single-period study in 41 female subjects who were receiving long-term treatment with an oral contraceptive that contained ethinyl estradiol (0.035 mg) and norgestimate (0.180-0.250 mg).  Pharmacokinetic profiles for ethinyl estradiol and for a single oral dose of triazolam (0.125 mg) were obtained the day before initiation of treatment with modafinil (200 mg for 7 days, followed by 400 mg for 21 days) or placebo (28 days).  A 2nd dose of triazolam was administered with the final dose of modafinil, and pharmacokinetic profiling was repeated.  Results: The modafinil treatment group had a marked decrease in max. obsd. blood plasma concns. and areas under the plasma concn.-time curve for triazolam relative to placebo, with a much smaller decrease in these parameters for ethinyl estradiol.  The half-life of triazolam was also decreased, but the half-life of ethinyl estradiol did not appear to be affected by treatment with modafinil.  Conclusion: Modafinil induced CYP3A4/5 activity in humans in vivo, suggesting that there is potential for metabolic drug-drug interactions between modafinil and substrates of CYP3A4/5.  However, the induction appeared to be more gastrointestinal than hepatic in nature.  Therefore significant metabolic drug-drug interactions are most likely to occur with compds. (such as triazolam) that undergo significant gastrointestinal CYP3A4/5-mediated 1st-pass metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzAFw-4DlfLVg90H21EOLACvtfcHk0lhFy4aP-HGsbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFOgsL0%253D&md5=67f43c8ddfac778f23b1c79bd95576d4</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.121217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.121217%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DP.%26aulast%3DHellriegel%26aufirst%3DE.%2BT.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DM.%26atitle%3DEffect%2520of%2520modafinil%2520on%2520the%2520pharmacokinetics%2520of%2520ethinyl%2520estradiol%2520and%2520triazolam%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D71%26issue%3D1%26spage%3D46%26epage%3D56%26doi%3D10.1067%2Fmcp.2002.121217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusawake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Adel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenendaal-Van de Meent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katashima, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2466</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0634-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs12325-017-0634-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29076107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2466-2480&issue=11&author=T.+Kusawakeauthor=M.+den+Adelauthor=D.+Groenendaal-Van+de+Meentauthor=A.+Garcia-Hernandezauthor=A.+Takadaauthor=K.+Katoauthor=Y.+Ohtsuauthor=M.+Katashima&title=Pharmacokinetic+evaluation+of+the+interactions+of+amenamevir+%28ASP2151%29+with+ketoconazole%2C+rifampicin%2C+midazolam%2C+and+warfarin+in+healthy+adults&doi=10.1007%2Fs12325-017-0634-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults</span></div><div class="casAuthors">Kusawake, Tomohiro; den Adel, Martin; Groenendaal-van de Meent, Dorien; Garcia-Hernandez, Alberto; Takada, Akitsugu; Kato, Kota; Ohtsu, Yoshiaki; Katashima, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2466-2480</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Amenamevir is a nonnucleoside antiherpes virus compd. available for treating herpes zoster infections.  Four studies aimed to det. any potential interactions between amenamevir and ketoconazole, rifampicin, midazolam, or warfarin in healthy male participants.  Methods: Two studies were open-label studies that evaluated the effects of multiple doses of ketoconazole (400 mg) and rifampicin (600 mg) on the pharmacokinetics of a single oral dose of amenamevir.  The other two studies were randomized, double-blind, parallel-group studies that evaluated the effects of multiple doses of amenamevir on the pharmacokinetics of a single dose of midazolam (7.5 mg) and warfarin (25 mg).  A drug interaction was considered to occur if the 90% confidence interval (CI) of the least squares geometric mean ratio (GMR) of amenamevir to the comparator was outside the prespecified interval of 0.80-1.25.  Results: Interactions were obsd. between amenamevir and ketoconazole, rifampicin, and midazolam, but not between amenamevir and warfarin.  After a single 400-mg dose of amenamevir, the GMRs of amenamevir plus ketoconazole or rifampicin vs. amenamevir alone for Cmax and the area under the plasma concn.-time curve from time zero to infinity (AUCinf) were 1.30 (90% CI 1.17-1.45) and 2.58 (90% CI 2.32-2.87), resp., for ketoconazole and 0.42 (90% CI 0.37-0.49) and 0.17 (90% CI 0.15-0.19), resp., for rifampicin.  Following multiple doses of amenamevir (400 mg), the GMRs of midazolam plus amenamevir vs. midazolam alone for AUCinf and Cmax were 0.53 (90% CI 0.47-0.61) and 0.63 (90% CI 0.50-0.80), resp.  After a single dose of warfarin, the (S)-warfarin and (R)-warfarin mean Cmax increased and mean AUCinf decreased in the presence of amenamevir; however, the 90% CIs of the GMRs for these parameters remained within the predefined limits.  Conclusion: These findings confirm that amenamevir (as a cytochrome P 450 3A4 substrate) can interact with ketoconazole or rifampicin, and (as a cytochrome P 450 3A4 inducer) can interact with midazolam; however, no interaction between amenamevir and (S)-warfarin was obsd., indicating that amenamevir is not an inducer of cytochrome P 450 2C9.  Funding: Astellas Pharma.  Trial registration: EudraCT2007-002227-33 (study 15L-CL-008), EudraCT2007-002228-14 (study 15L-CL-009), EudraCT2007-002761-13 (study 15L-CL-010), and EudraCT2007-002779-14 (study 15L-CL-018).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqINGVtMLmb7Vg90H21EOLACvtfcHk0lhFy4aP-HGsbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgt7nP&md5=55908510ab40f9ca9ed5e8325d0947e2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0634-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0634-4%26sid%3Dliteratum%253Aachs%26aulast%3DKusawake%26aufirst%3DT.%26aulast%3Dden%2BAdel%26aufirst%3DM.%26aulast%3DGroenendaal-Van%2Bde%2BMeent%26aufirst%3DD.%26aulast%3DGarcia-Hernandez%26aufirst%3DA.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DOhtsu%26aufirst%3DY.%26aulast%3DKatashima%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520evaluation%2520of%2520the%2520interactions%2520of%2520amenamevir%2520%2528ASP2151%2529%2520with%2520ketoconazole%252C%2520rifampicin%252C%2520midazolam%252C%2520and%2520warfarin%2520in%2520healthy%2520adults%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26issue%3D11%26spage%3D2466%26epage%3D2480%26doi%3D10.1007%2Fs12325-017-0634-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">FDA.</span> <i>Vemurafenib NDA No. 202429</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Vemurafenib+NDA+No.+202429."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DVemurafenib%2520NDA%2520No.%2520202429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">FDA.</span> <i>Tazemetostat NDA No. 211723</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Tazemetostat+NDA+No.+211723."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTazemetostat%2520NDA%2520No.%2520211723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, K. T.</span></span> <span> </span><span class="NLM_article-title">PXR ligand classification model with SFED-weighted WHIM and CoMMA descriptors</span>. <i>SAR QSAR Environ Res</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1080/1062936X.2012.665385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F1062936X.2012.665385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22591167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XntF2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=485-504&issue=5%E2%80%936&author=S.+L.+Maauthor=J.+Y.+Joungauthor=S.+Leeauthor=K.+H.+Choauthor=K.+T.+No&title=PXR+ligand+classification+model+with+SFED-weighted+WHIM+and+CoMMA+descriptors&doi=10.1080%2F1062936X.2012.665385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PXR ligand classification model with SFED-weighted WHIM and CoMMA descriptors</span></div><div class="casAuthors">Ma, S. L.; Joung, J. Y.; Lee, S.; Cho, K. H.; No, K. T.</div><div class="citationInfo"><span class="NLM_cas:title">SAR and QSAR in Environmental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">485-504</span>CODEN:
                <span class="NLM_cas:coden">SQERED</span>;
        ISSN:<span class="NLM_cas:issn">1026-776X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Understanding which type of endogenous and exogenous compds. serve as agonists for the nuclear pregnane X receptor (PXR) would be valuable for drug discovery and development, because PXR regulates a large no. of genes related to xenobiotic metab.  Although several models have been proposed to classify human PXR activators and non-activators, models with better predictability are necessary for practical purposes in drug discovery.  Grid-weighted holistic invariant mol. (G-WHIM) and comparative mol. moment anal. (G-CoMMA) type 3D descriptors that contain information about the solvation free energy of target mols. were developed.  With these descriptors, prediction models built using decision tree (DT)-, support vector machine (SVM)-, and Kohonen neural network (KNN)-based models exhibited better predictability than previously proposed models.  Solvation free energy d.-weighted G-WHIM and G-CoMMA descriptors reveal new insights into PXR ligand classification, and incorporation with machine learning methods (DT, SVM, KNN) exhibits promising results, esp. SVM and KNN.  SVM- and KNN-based models exhibit accuracy around 0.90, and DT-based models exhibit accuracy around 0.8 for both the training and test sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolbTzawYi83rVg90H21EOLACvtfcHk0ljpfoNI89kbaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntF2msLw%253D&md5=2ce3c7862ac40b85c33519a0e84fd0aa</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1080%2F1062936X.2012.665385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1062936X.2012.665385%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%2BL.%26aulast%3DJoung%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DK.%2BH.%26aulast%3DNo%26aufirst%3DK.%2BT.%26atitle%3DPXR%2520ligand%2520classification%2520model%2520with%2520SFED-weighted%2520WHIM%2520and%2520CoMMA%2520descriptors%26jtitle%3DSAR%2520QSAR%2520Environ%2520Res%26date%3D2012%26volume%3D23%26issue%3D5%25E2%2580%25936%26spage%3D485%26epage%3D504%26doi%3D10.1080%2F1062936X.2012.665385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissung, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1345/aph.1P354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1345%2Faph.1P354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20959500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVynsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=1709-1717&issue=11&author=N.+F.+Smithauthor=S.+Maniauthor=E.+G.+Schuetzauthor=K.+Yasudaauthor=T.+M.+Sissungauthor=S.+E.+Batesauthor=W.+D.+Figgauthor=A.+Sparreboom&title=Induction+of+CYP3A4+by+vinblastine%3A+Role+of+the+nuclear+receptor+NR1I2&doi=10.1345%2Faph.1P354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2</span></div><div class="casAuthors">Smith, Nicola F.; Mani, Sridhar; Schuetz, Erin G.; Yasuda, Kazuto; Sissung, Tristan M.; Bates, Susan E.; Figg, William D.; Sparreboom, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1709-1717</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Harvey Whitney Books Co.</span>)
        </div><div class="casAbstract">BACKGROUND: Several microtubule targeting agents are capable of inducing CYP3A4 via activation of the pregnane X receptor (PXR; NR1I2).  OBJECTIVE: To evaluate the CYP3A4 induction potential of vinblastine both clin. and in vitro and det. the involvement of the nuclear receptors NR1I2 and the constitutive androstane receptor (NR1I3).  METHODS: Midazolam pharmacokinetics were evaluated in 6 patients who were enrolled in a Phase 1/2 study of infusional vinblastine given in combination with the ABCB1 (P-glycoprotein) antagonist valspodar (PSC 833) and received the CYP3A4 phenotyping probe midazolam on more than 1 occasion.  Genotyping was conducted in CYP3A4, CYP3A5, and ABCB1 to rule out potential pharmacogenetic influences.  Clin. data were followed-up by Western blotting and reporter assays in HepG2 and NIH3T3 cells treated with vinblastine over a dose range of 150-4800 ng/mL for 48 h.  RESULTS: In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).  No obvious effect of polymorphisms in CYP3A4, CYP3A5, and ABCB1 on midazolam clearance was obsd.  In vitro, vinblastine induced CYP3A4 protein.  Furthermore, cell-based reporter gene assays using transiently transfected HepG2 and NIH3T3 cells indicated that vinblastine (150-4800 ng/mL) weakly activated human and mouse full-length NR1I2, but had no influence on NR1I3.  CONCLUSIONS: Collectively, these findings suggest that vinblastine is able to induce CYP3A4, at least in part, via an NR1I2-dependent mechanism, and thus has the potential to facilitate its own elimination and cause interactions with other CYP3A4 substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYhdsLEZm5xLVg90H21EOLACvtfcHk0ljpfoNI89kbaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVynsr7L&md5=242798968c96f3d0c6a419558f520712</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1345%2Faph.1P354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1P354%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BF.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DSissung%26aufirst%3DT.%2BM.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DInduction%2520of%2520CYP3A4%2520by%2520vinblastine%253A%2520Role%2520of%2520the%2520nuclear%2520receptor%2520NR1I2%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2010%26volume%3D44%26issue%3D11%26spage%3D1709%26epage%3D1717%26doi%3D10.1345%2Faph.1P354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">FDA.</span> <i>Tecovirimat NDA No. 208627</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Tecovirimat+NDA+No.+208627."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTecovirimat%2520NDA%2520No.%2520208627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K.</span></span> <span> </span><span class="NLM_article-title">The effect of ticagrelor on the metabolism of midazolam in healthy volunteers</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2013.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.clinthera.2013.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23870610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFektr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=1025-1037&issue=7&author=R.+Tengauthor=K.+Butler&title=The+effect+of+ticagrelor+on+the+metabolism+of+midazolam+in+healthy+volunteers&doi=10.1016%2Fj.clinthera.2013.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Ticagrelor on the Metabolism of Midazolam in Healthy Volunteers</span></div><div class="casAuthors">Teng, Renli; Butler, Kathleen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vitro studies have demonstrated that ticagrelor, an oral antiplatelet agent, is a substrate, activator, and inhibitor of cytochrome P 450 (CYP) 3A.  Thus, potential CYP3A-mediated drug-drug interactions may occur.  The goal of this article was to report study results on the effect of ticagrelor on the pharmacokinetics of oral midazolam (oral midazolam study) and oral vs. i.v. (IV) midazolam (oral/IV midazolam study).  Secondary objectives included assessing the effect of midazolam on ticagrelor pharmacokinetic parameters, and the safety and tolerability of ticagrelor/midazolam coadministration.  Two randomized crossover studies were conducted in healthy volunteers (n = 28 in each) with ticagrelor and midazolam.  In the first study, volunteers received oral ticagrelor (400 mg daily) or placebo for 6 days, then oral midazolam (7.5 mg).  The second study regimen was a single dose of ticagrelor 270 mg, then ticagrelor 180 mg BID for 6 days with a single oral (7.5 mg) or IV (2.5 mg) dose of midazolam.  After oral midazolam administration, ticagrelor significantly reduced the AUC0-∞ of midazolam (30%-32%) and 4-hydroxymidazolam (42%-47%) but not 1-hydroxymidazolam.  After administration of IV midazolam, ticagrelor reduced the AUC0-∞ of midazolam (12%) and 4-hydroxymidazolam (23%) but not 1-hydroxymidazolam.  These results indicate that ticagrelor can weakly activate the metab. of midazolam to its major 1'-hydroxy metabolite, and at the same time, seems to weakly inhibit midazolam 4'-hydroxylation.  Furthermore, ticagrelor affects both hepatic and intestinal CYP3A activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-DTHVi2U0bVg90H21EOLACvtfcHk0liQ6wOqiheQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFektr7E&md5=6bc4d787cb3ab07257be3ba9c9250e41</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2013.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2013.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DK.%26atitle%3DThe%2520effect%2520of%2520ticagrelor%2520on%2520the%2520metabolism%2520of%2520midazolam%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Ther.%26date%3D2013%26volume%3D35%26issue%3D7%26spage%3D1025%26epage%3D1037%26doi%3D10.1016%2Fj.clinthera.2013.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span> <span> </span><span class="NLM_article-title">Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1002/jcph.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23585187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=642-653&issue=6&author=S.+Dhuriaauthor=H.+Einolfauthor=J.+Mangoldauthor=S.+Senauthor=H.+Guauthor=L.+Wangauthor=S.+Cameron&title=Time-dependent+inhibition+and+induction+of+human+cytochrome+P4503A4%2F5+by+an+oral+IAP+antagonist%2C+LCL161%2C+in+vitro+and+in+vivo+in+healthy+subjects&doi=10.1002%2Fjcph.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, In vitro and in vivo in healthy subjects</span></div><div class="casAuthors">Dhuria, Shyeilla; Einolf, Heidi; Mangold, James; Sen, Suman; Gu, Helen; Wang, Lai; Cameron, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642-653, 12</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tumor cells can evade programmed cell death via up-regulation of inhibitor of apoptosis proteins (IAPs).  LCL161 is a small mol. oral IAP antagonist in development for use in combination with cytotoxic agents.  The effect of LCL161 on CYP3A4/5 (CYP3A) activity was investigated in vitro and in a clin. study.  Results in human liver microsomes indicated LCL161 inhibited CYP3A in a concn.- and time-dependent manner (KI of 0.797 μM and kinact of 0.0803 min-1).  LCL161 activated human PXR in a reporter gene assay and induced CYP3A4 mRNA up to ∼5-fold in human hepatocytes.  In healthy subjects, the dual inhibitor and inductive effects of a single dose of LCL161 were characterized using single midazolam doses, given before and at three time points after the LCL161 dose.  Midazolam Cmax increased 3.22-fold and AUC(0-inf) increased 9.32-fold when administered four hours after LCL161.  Three days later, midazolam Cmax decreased by 27% andAUC(0-inf) decreased by 30%.  No drug interaction remained one week later.  The strong CYP3A inhibition by LCL161 was accurately predicted using dynamic physiol.-based pharmacokinetic (PBPK) modeling approaches in Simcyp.  However, the obsd. induction effect after the LCL161 dose could not be modeled; suggesting direct enzyme induction by LCL161 was not the underlying mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXYvIbAlEy9LVg90H21EOLACvtfcHk0liQ6wOqiheQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrL&md5=e677682940a7053eb24b6df9b221d59b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fjcph.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.79%26sid%3Dliteratum%253Aachs%26aulast%3DDhuria%26aufirst%3DS.%26aulast%3DEinolf%26aufirst%3DH.%26aulast%3DMangold%26aufirst%3DJ.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCameron%26aufirst%3DS.%26atitle%3DTime-dependent%2520inhibition%2520and%2520induction%2520of%2520human%2520cytochrome%2520P4503A4%252F5%2520by%2520an%2520oral%2520IAP%2520antagonist%252C%2520LCL161%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D6%26spage%3D642%26epage%3D653%26doi%3D10.1002%2Fjcph.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prien, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korjamo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graudenz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bühler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieschen, H.</span></span> <span> </span><span class="NLM_article-title">Drug-drug interaction potential of darolutamide: In vitro and clinical studies</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1007/s13318-019-00577-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs13318-019-00577-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31571146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=747-759&issue=6&author=C.+Zurthauthor=M.+Koskinenauthor=R.+Frickeauthor=O.+Prienauthor=T.+Korjamoauthor=K.+Graudenzauthor=K.+Dennerauthor=M.+Bairleinauthor=C.+J.+von+B%C3%BChlerauthor=G.+Wilkinsonauthor=H.+Gieschen&title=Drug-drug+interaction+potential+of+darolutamide%3A+In+vitro+and+clinical+studies&doi=10.1007%2Fs13318-019-00577-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies</span></div><div class="casAuthors">Zurth, Christian; Koskinen, Mikko; Fricke, Robert; Prien, Olaf; Korjamo, Timo; Graudenz, Kristina; Denner, Karsten; Bairlein, Michaela; von Buehler, Clemens-Jeremias; Wilkinson, Gary; Gieschen, Hille</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">747-759</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Drug-drug interaction potential of darolutamide was investigated in both nonclin. and clin. studies.  A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide.  Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, org. anion-transporting polypeptide (OATP)1B1, OATP1B3 and org. anion transporter (OAT)3].  In vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP.  In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity.  Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was obsd. in vitro.  Phase I data showed that darolutamide exposure increased 1.75-fold with co-administered itraconazole and decreased by 72% with rifampicin.  Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects.  Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7iTDqf-pvDrVg90H21EOLACvtfcHk0liQ6wOqiheQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlurbN&md5=2a32b72f53f0dd3c5dd76cd4692c2962</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs13318-019-00577-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-019-00577-5%26sid%3Dliteratum%253Aachs%26aulast%3DZurth%26aufirst%3DC.%26aulast%3DKoskinen%26aufirst%3DM.%26aulast%3DFricke%26aufirst%3DR.%26aulast%3DPrien%26aufirst%3DO.%26aulast%3DKorjamo%26aufirst%3DT.%26aulast%3DGraudenz%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DBairlein%26aufirst%3DM.%26aulast%3Dvon%2BB%25C3%25BChler%26aufirst%3DC.%2BJ.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DGieschen%26aufirst%3DH.%26atitle%3DDrug-drug%2520interaction%2520potential%2520of%2520darolutamide%253A%2520In%2520vitro%2520and%2520clinical%2520studies%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2019%26volume%3D44%26issue%3D6%26spage%3D747%26epage%3D759%26doi%3D10.1007%2Fs13318-019-00577-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekersky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolbert, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.2012.01028.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fj.1875-9114.2012.01028.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22422635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=340-353&issue=4&author=M.+Walzerauthor=I.+Bekerskyauthor=R.+A.+Blumauthor=D.+Tolbert&title=Pharmacokinetic+drug+interactions+between+clobazam+and+drugs+metabolized+by+cytochrome+P450+isoenzymes&doi=10.1002%2Fj.1875-9114.2012.01028.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug interations between clobazam and drugs metabolized by cytochrome P450 isoenzymes</span></div><div class="casAuthors">Walzer, Mark; Bekersky, Ihor; Blum, Robert A.; Tolbert, Dwain</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">340-353</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To investigate potential drug-drug interactions between clobazam and cytochrome P 450 (CYP) isoenzyme substrates, inhibitors, and inducers.  Two, prospective, open-label, single-center, drug-drug interaction (DDI) studies and a population pharmacokinetics anal. of seven multi-center phase II-III trials.  Fifty-four healthy adult volunteers were enrolled in the two drug-drug interaction studies; 53 completed the studies.  The population pharmacokinetics anal. evaluated data from 171 participants from five studies with healthy volunteers and two studies with patients with Lennox-Gastaut syndrome.  Participants in these studies received clobazam and stable dosages of the following antiepileptic drugs: phenobarbital, phenytoin, carbamazepine, valproic acid, lamotrigine, felbamate, or oxcarbazepine.  In the first drug-drug interaction study, 36 participants received a single oral dose of clobazam 10 mg on day 1, followed by either ketoconazole 400 mg once/day or omeprazole 40 mg once/day on days 17-22, with a single dose of clobazam 10 mg coadministered on day 22, to study the effects of CYP3A4 or CYP2C19 inhibition, resp., on clobazam and its active metabolite N-desmethylclobazam (N-CLB).  In the second study, 18 participants received a drug cocktail consisting of caffeine 200 mg, tolbutamide 500 mg, dextromethorphan 30 mg, and midazolam 4 mg on days 1 and 19, and clobazam 40 mg/day on days 4-19, to study clobazam's effects on CYP1A2, CYP2C9, CYP2D6, and CYP3A4.  Measurements and Main Results. In the first DDI study, coadministration of ketoconazole (a CYP3A4 inhibitor) and clobazam increased clobazam's area under the concn. time curve from time zero extrapolated to infinity (AUC0-∞) 54% and decreased clobazam's max. plasma concn. (Cmax) by 15% vs. administration of clobazam alone, but the combination affected these pharmacokinetic parameters for N-CLB to a lesser degree.  The CYP2C19 inhibitor omeprazole increased AUC0-∞ and Cmax of N-CLB by 36% and 15%, resp., but did not significantly affect the pharmacokinetics of clobazam.  At steady state, N-CLB has 3-4 times greater exposure than clobazam.  In the second DDI study, no clin. significant drug-drug interactions were obsd. between clobazam 40 mg and the CYP probe substrates caffeine or tolbutamide.  Exposure to midazolam and its 1-hydroxymidazolam metabolite, however, decreased by 27% and increased 4-fold, resp.  Clobazam increased dextromethorphan (CYP2D6) AUC0-∞ by 95% and Cmax by 59%.  In the population pharmacokinetics anal., stable dosages of common antiepileptic drugs that induce CYP3A4 or CYP2C19, or inhibit CYP2C19, had negligible effects on clobazam or N-CLB.  Clobazam did not affect valproic acid or lamotrigine exposures.  Conclusion. These findings suggest no clin. meaningful drug-drug interactions between clobazam and drugs metabolized by CYP3A4, CYP2C19, CYP1A2, or CYP2C9.  Concomitant use of drugs metabolized by CYP2D6 may require dosage adjustment.  Clobazam may be administered safely as adjunctive therapy in patients with Lennox-Gastaut syndrome, without meaningful changes in clobazam pharmacokinetics that would require dosage adjustment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcoJ7hptTrrVg90H21EOLACvtfcHk0liQ6wOqiheQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyms7w%253D&md5=82b3890f80ffddbe7ce49fb28d688104</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.2012.01028.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.2012.01028.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalzer%26aufirst%3DM.%26aulast%3DBekersky%26aufirst%3DI.%26aulast%3DBlum%26aufirst%3DR.%2BA.%26aulast%3DTolbert%26aufirst%3DD.%26atitle%3DPharmacokinetic%2520drug%2520interactions%2520between%2520clobazam%2520and%2520drugs%2520metabolized%2520by%2520cytochrome%2520P450%2520isoenzymes%26jtitle%3DPharmacotherapy%26date%3D2012%26volume%3D32%26issue%3D4%26spage%3D340%26epage%3D353%26doi%3D10.1002%2Fj.1875-9114.2012.01028.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enejosa, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisniku, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span> <span> </span><span class="NLM_article-title">Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: A study with the modified cooperstown 5 + 1 cocktail</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1002/jcph.1496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.1496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31378969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=86-95&issue=1&author=M.+F.+Mohamedauthor=T.+Fengauthor=J.+V.+Enejosaauthor=O.+Fisnikuauthor=A.+A.+Othman&title=Effects+of+upadacitinib+coadministration+on+the+pharmacokinetics+of+sensitive+cytochrome+P450+probe+substrates%3A+A+study+with+the+modified+cooperstown+5+%2B+1+cocktail&doi=10.1002%2Fjcph.1496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail</span></div><div class="casAuthors">Mohamed, Mohamed-Eslam F.; Feng, Tian; Enejosa, Jeffrey V.; Fisniku, Ogert; Othman, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P 450 (CYP) enzymes using a cocktail approach.  Healthy subjects (n = 20) received single oral doses of the modified Cooperstown 5+1 cocktail drugs (midazolam [CYP3A], caffeine [CYP1A2], warfarin + vitamin K [CYP2C9], omeprazole [CYP2C19], and dextromethorphan [CYP2D6]) without upadacitinib and on day 11 (midazolam) or 12 (all other probes) of a 15-day regimen of upadacitinib 30 mg once daily (extended-release formulation).  Serial blood samples and 12-h urine samples were collected for assays of the probe substrates and select metabolites.  The ratio (90%CI) of area under the plasma concn.-time curve from time 0 to infinity (AUCinf) central values when the cocktail drugs were administered with upadacitinib relative to when administered alone were 0.74 (0.68-0.80) for midazolam, 1.22 (1.15-1.29) for caffeine, 1.11 (1.07-1.15) for S-warfarin, 1.07 (0.95-1.22) for dextromethorphan, and 0.82 (0.72-0.94) for omeprazole.  The ratio (90%CI) was 1.09 (1.00-1.19) for 5-hydroxy-omeprazole to omeprazole AUCinf ratio and 1.17 (0.97-1.41) for dextromethorphan to dextrorphan 12-h molar urinary ratio.  Upadacitinib 30 mg once daily (a dose that is twice the optimal dose in rheumatoid arthritis based on phase 3 results) has a limited effect on CYP3A activity (26% decrease in exposure of midazolam, a sensitive CYP3A substrate) and no relevant effects on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 activity in vivo.  No clin. relevant changes in plasma exposures are expected for drugs that are substrates for the evaluated CYP enzymes when coadministered with upadacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoNYO5yLUz7Vg90H21EOLACvtfcHk0lgPXNGbPofEHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqt7bN&md5=00d87d40120c10962d1c028b66994c52</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1496%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DM.%2BF.%26aulast%3DFeng%26aufirst%3DT.%26aulast%3DEnejosa%26aufirst%3DJ.%2BV.%26aulast%3DFisniku%26aufirst%3DO.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26atitle%3DEffects%2520of%2520upadacitinib%2520coadministration%2520on%2520the%2520pharmacokinetics%2520of%2520sensitive%2520cytochrome%2520P450%2520probe%2520substrates%253A%2520A%2520study%2520with%2520the%2520modified%2520cooperstown%25205%2520%252B%25201%2520cocktail%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2020%26volume%3D60%26issue%3D1%26spage%3D86%26epage%3D95%26doi%3D10.1002%2Fjcph.1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">FDA.</span> <i>Actos Product Label</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Actos+Product+Label."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DActos%2520Product%2520Label" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. J.</span></span> <span> </span><span class="NLM_article-title">Effect of quercetin on CYP3A activity in Chinese healthy participants</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1177/0091270011406278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F0091270011406278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21680781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVKju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=940-946&issue=6&author=K.+M.+Duanauthor=S.+Y.+Wangauthor=W.+Ouyangauthor=Y.+M.+Maoauthor=L.+J.+Yang&title=Effect+of+quercetin+on+CYP3A+activity+in+Chinese+healthy+participants&doi=10.1177%2F0091270011406278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of quercetin on CYP3A activity in Chinese healthy piticipants</span></div><div class="casAuthors">Duan, Kai-Ming; Wang, Sai-Ying; Ouyang, Wen; Mao, Yan-Mei; Yang, Li-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">940-946</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aims of this study were to investigate the effect of quercetin on CYP3A activity in vivo.  An open, randomized, 2-period crossover expt. was performed in 18 healthy male volunteers.  Genotyped data were available from a total of 165 participants.  The allelic frequency was 52.5%.  Every volunteer ingested orally 500 mg quercetin or placebo once a day for 13 consecutive days.  On day 14, a single 7.5-mg midazolam tablet was administrated orally.  The plasma concns. of midazolam and 1-OH-midazolam were detd. over 24 h.  The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC0-12 h) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC0-∞ of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t1/2 (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased tmax significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), resp.  In conclusion, quercetin significantly induced CYP3A activity to substrate midazolam, and the induction was partly related to the CYP3A5 genotype, being more prominent in CYP3A5*1/*1 and CYP3A5*1/*3 individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoro5kEAympfbVg90H21EOLACvtfcHk0lgPXNGbPofEHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVKju7s%253D&md5=bc55d635d25e838b0f6ed8b5762bab7f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F0091270011406278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011406278%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DK.%2BM.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DY.%2BM.%26aulast%3DYang%26aufirst%3DL.%2BJ.%26atitle%3DEffect%2520of%2520quercetin%2520on%2520CYP3A%2520activity%2520in%2520Chinese%2520healthy%2520participants%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26issue%3D6%26spage%3D940%26epage%3D946%26doi%3D10.1177%2F0091270011406278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1995.tb00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.1995.tb00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=8527290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK2MXosl2ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1995&pages=270-272&issue=3&author=J.+Ahonenauthor=K.+T.+Olkkolaauthor=P.+J.+Neuvonen&title=Effect+of+itraconazole+and+terbinafine+on+the+pharmacokinetics+and+pharmacodynamics+of+midazolam+in+healthy+volunteers&doi=10.1111%2Fj.1365-2125.1995.tb00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers</span></div><div class="casAuthors">Ahonen, Jouni; Olkkola, Klaus T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">270-2</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">Twelve healthy volunteers were given orally placebo, itraconazole 100 mg or terbinafine 250 mg for 4 days.  Midazolam 7.5 mg was ingested on the fourth day, after which plasma samples were collected and psychomotor performance tests carried out for 17 h.  Itraconazole increased the area under the midazolam concn.-time curve 6-fold,, the peak concn. 2.5-fold and the elimination half-life 2-fold compared with placebo and terbinafine pretreatments.  The pharmacokinetic parameters did not differ between placebo and terbinafine phases.  The higher concns. of midazolam during the itraconazole phase were assocd. with increased effects.  In contrast to itraconazole, terbinafine had no effect on midazolam pharmacokinetics and psychomotor performance tests were unchanged from placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZRXHpFc5UbVg90H21EOLACvtfcHk0lgTuFIhVr1liQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosl2ltrw%253D&md5=e6ef77bc7afe344c5f6a139afba189bb</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1995.tb00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1995.tb00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DAhonen%26aufirst%3DJ.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffect%2520of%2520itraconazole%2520and%2520terbinafine%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520midazolam%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1995%26volume%3D40%26issue%3D3%26spage%3D270%26epage%3D272%26doi%3D10.1111%2Fj.1365-2125.1995.tb00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severynse-Stevens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3699</span>– <span class="NLM_lpage">3703</span>, <span class="refDoi"> DOI: 10.1128/AAC.02632-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1128%2FAAC.02632-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23689718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3699-3703&issue=8&author=H.+Winterauthor=E.+Egiziauthor=N.+Eronduauthor=A.+Ginsbergauthor=D.+J.+Rouseauthor=D.+Severynse-Stevensauthor=E.+Pauliauthor=D.+Everitt&title=Evaluation+of+pharmacokinetic+interaction+between+PA-824+and+midazolam+in+healthy+adult+subjects&doi=10.1128%2FAAC.02632-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Egizi, Erica; Erondu, Ngozi; Ginsberg, Ann; Rouse, Doris J.; Severynse-Stevens, Diana; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3699-3703</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects.  The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4.  Subjects received a single oral dose of midazolam (2 mg), followed by a 2-day washout.  After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days.  On day 14, all subjects received the final PA-824 dose coadministered with a 2-mg oral dose of midazolam.  The pharmacokinetic endpoints AUC0-t, AUC0-∞, and Cmax for midazolam and 1-hydroxy midazolam were compared between midazolam administered alone vs. midazolam coadministered with PA-824.  Statistical anal. demonstrated that the mean midazolam values of Cmax, AUC0-t, and AUC0-∞ parameters were reduced by ca. 16, 15, and 15%, resp., when PA-824 was coadministered with midazolam.  The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone.  The Cmax of 1-hydroxy midazolam was similar between treatments.  Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clin. meaningful extent and is not likely to markedly affect the pharmacokinetics of CYP3A4 metabolized drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYL4vjAgGRCrVg90H21EOLACvtfcHk0lgTuFIhVr1liQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L&md5=596e43ace93fca069a3d53ac661ab352</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.02632-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02632-12%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DSeverynse-Stevens%26aufirst%3DD.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interaction%2520between%2520PA-824%2520and%2520midazolam%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D8%26spage%3D3699%26epage%3D3703%26doi%3D10.1128%2FAAC.02632-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtenbaum, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alston, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brobst, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aberg, J. A.</span></span> <span> </span><span class="NLM_article-title">Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1097/01.qai.0000167156.44980.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F01.qai.0000167156.44980.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15980690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=307-312&issue=3&author=J.+G.+Gerberauthor=S.+L.+Rosenkranzauthor=C.+J.+Fichtenbaumauthor=J.+M.+Vegaauthor=A.+Yangauthor=B.+L.+Alstonauthor=S.+W.+Brobstauthor=Y.+Segalauthor=J.+A.+Aberg&title=Effect+of+efavirenz+on+the+pharmacokinetics+of+simvastatin%2C+atorvastatin%2C+and+pravastatin%3A+results+of+AIDS+Clinical+Trials+Group+5108+Study&doi=10.1097%2F01.qai.0000167156.44980.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study</span></div><div class="casAuthors">Gerber, John G.; Rosenkranz, Susan L.; Fichtenbaum, Carl J.; Vega, Jose M.; Yang, Amy; Alston, Beverly L.; Brobst, Susan W.; Segal, Yoninah; Aberg, Judith A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Efavirenz (EFV) is assocd. with hyperlipidemia when used in combination with other antiretroviral drugs.  EFV is a mixed inducer/inhibitor of cytochrome P 450 (CYP) 3A4 isoenzyme and may interact with hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4.  To assess the drug-drug interaction of EFV used in combination with simvastatin (SIM), atorvastatin (ATR), or pravastatin (PRA), an open-label trial was conducted in 52 healthy adult HIV-seroneg. subjects across AIDS Clin. Trials Group sites in the United States.  Subjects received 40 mg of SIM, 10 mg of ATR, or 40 mg of PRA daily on days 0 through 3 and days 15 through 18.  EFV was administered daily at a dose of 600 mg on days 4 through 18.  SIM, ATR, and PRA concns. were detd. before and after EFV, and EFV concns. were detd. before and after statins.  EFV reduced SIM acid exposure (area under the curve at 0 to 24 h [AUC0-24h]) by 58% (Wilcoxon signed rank test, P = 0.003) and active HMG-CoA reductase inhibitory activity by 60% (P < 0.001).  EFV reduced ATR exposure by 43% (P < 0.001) and the total active ATR exposure by 34% (P = 0.005).  EFV administration resulted in a 40% decrease in PRA exposure (P = 0.005).  SIM, ATR, and PRA had no effect on non-steady-state EFV concns.  In conclusion, EFV, when administered with SIM, ATR, or PRA, can result in significant induction of statin metab.  The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWde_DToHJxLVg90H21EOLACvtfcHk0lgTuFIhVr1liQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFantL8%253D&md5=a5f79c0ecbae37bab2490bf7347061f4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1097%2F01.qai.0000167156.44980.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.qai.0000167156.44980.33%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DJ.%2BG.%26aulast%3DRosenkranz%26aufirst%3DS.%2BL.%26aulast%3DFichtenbaum%26aufirst%3DC.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DAlston%26aufirst%3DB.%2BL.%26aulast%3DBrobst%26aufirst%3DS.%2BW.%26aulast%3DSegal%26aufirst%3DY.%26aulast%3DAberg%26aufirst%3DJ.%2BA.%26atitle%3DEffect%2520of%2520efavirenz%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%252C%2520atorvastatin%252C%2520and%2520pravastatin%253A%2520results%2520of%2520AIDS%2520Clinical%2520Trials%2520Group%25205108%2520Study%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2005%26volume%3D39%26issue%3D3%26spage%3D307%26epage%3D312%26doi%3D10.1097%2F01.qai.0000167156.44980.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">FDA.</span> <i>Safinamide NDA No. 207145</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Safinamide+NDA+No.+207145."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DSafinamide%2520NDA%2520No.%2520207145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">FDA.</span> <i>Oritavancin NDA No. 206334</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Oritavancin+NDA+No.+206334."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DOritavancin%2520NDA%2520No.%2520206334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribadeneira, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. W.</span></span> <span> </span><span class="NLM_article-title">A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.04155.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1365-2125.2011.04155.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22122233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Klur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2012&pages=98-108&issue=1&author=D.+Zhouauthor=M.+Sunzelauthor=M.+D.+Ribadeneiraauthor=M.+A.+Smithauthor=D.+Desaiauthor=J.+Linauthor=S.+W.+Grimm&title=A+clinical+study+to+assess+CYP1A2+and+CYP3A4+induction+by+AZD7325%2C+a+selective+GABA%28A%29+receptor+modulator+-+an+in+vitro+and+in+vivo+comparison&doi=10.1111%2Fj.1365-2125.2011.04155.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator - an in vitro and in vivo comparison</span></div><div class="casAuthors">Zhou, Diansong; Sunzel, Maria; Ribadeneira, Maria D.; Smith, Mark A.; Desai, Dhaval; Lin, Jianrong; Grimm, Scott W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-108</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To investigate the potential of AZD7325 to induce CYP1A2 and CYP3A4 enzyme activities.  Induction of CYP1A2 and CYP3A4 by AZD7325 was first evaluated using cultured human hepatocytes.  The effect of multiple doses of 10 mg AZD7325 on the pharmacokinetics of midazolam and caffeine was then examd. in healthy subjects.  The highest CYP1A2 and CYP3A4 induction responses were obsd. in human hepatocytes treated with 1 or 10 μM of AZD7325, in the range of 17.9%-54.9% and 76.9%-85.7% of the pos. control responses, resp.  The results triggered the further clin. evaluation of AZD7325 induction potential.  AZD7325 reached a plasma Cmax of 0.2 μM after 10 mg daily dosing to steady-state.  AZD7325 decreased midazolam geometric mean AUC by 19% (0.81-fold, 90% CI 0.77, 0.87), but had no effect on midazolam Cmax (90% CI 0.82, 0.97).  The mean CL/F of midazolam increased from 62 l h-1 (midazolam alone) to 76 l h-1 when co-administered with AZD7325.  The AUC and Cmax of caffeine were not changed after co-administration of AZD7325, with geometric mean ratios (90% CI) of 1.17 (1.12, 1.23) and 0.99 (0.95, 1.03), resp.  While AZD7325 appeared to be a potent CYP3A4 inducer and a moderate CYP1A2 inducer from in vitro studies, the expected efficacious dose of AZD7325 had no effect on CYP1A2 activity and only a weak inducing effect on CYP3A4 activity.  This comparison of in vitro and in vivo results demonstrates the crit. role that clin. exposure plays in evaluating the CYP induction risk of a drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos460HcEeQuLVg90H21EOLACvtfcHk0linVNTaEtiYfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Klur%252FJ&md5=c613cf8289d286c9a3b40b0e45c844fb</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.04155.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.04155.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSunzel%26aufirst%3DM.%26aulast%3DRibadeneira%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26atitle%3DA%2520clinical%2520study%2520to%2520assess%2520CYP1A2%2520and%2520CYP3A4%2520induction%2520by%2520AZD7325%252C%2520a%2520selective%2520GABA%2528A%2529%2520receptor%2520modulator%2520-%2520an%2520in%2520vitro%2520and%2520in%2520vivo%2520comparison%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D74%26issue%3D1%26spage%3D98%26epage%3D108%26doi%3D10.1111%2Fj.1365-2125.2011.04155.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">FDA.</span> <i>Pitolisant NDA No. 211150</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Pitolisant+NDA+No.+211150."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPitolisant%2520NDA%2520No.%2520211150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, A.</span></span> <span> </span><span class="NLM_article-title">Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1067/mcp.2001.120025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1067%2Fmcp.2001.120025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11753267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=518-524&issue=6&author=K.+Sugimotoauthor=M.+Ohmoriauthor=S.+Tsuruokaauthor=K.+Nishikiauthor=A.+Kawaguchiauthor=K.+Haradaauthor=M.+Arakawaauthor=K.+Sakamotoauthor=M.+Masadaauthor=I.+Miyamoriauthor=A.+Fujimura&title=Different+effects+of+St+John%E2%80%99s+wort+on+the+pharmacokinetics+of+simvastatin+and+pravastatin&doi=10.1067%2Fmcp.2001.120025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin</span></div><div class="casAuthors">Sugimoto, Koh-ichi; Ohmori, Masami; Tsuruoka, Shuichi; Nishiki, Kenta; Kawaguchi, Atsuhiro; Harada, Ken-ichi; Arakawa, Masashi; Sakamoto, Koh-ichi; Masada, Mikio; Miyamori, Isamu; Fujimura, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">518-524</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">The effects of St John's Wort on the pharmacokinetics of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors simvastatin (an inactive lactone prodrug) and pravastatin were detd.  Healthy male subjects took a St John's Wort caplet (300 mg) or matching placebo three times a day for 14 days in a double-blind, crossover study.  On day 14, a single oral dose of 10 mg simvastatin or 20 mg pravastatin was given.  Repeated St John's Wort treatment tended to lower plasma simvastatin concn. and significantly lowered concns. of simvastatin hydroxy acid, its active metabolite.  The peak concn. in plasma of simvastatin hydroxy acid tended to be decreased and its area under the plasma concn.-time curve between time zero and 24 h after administration was significantly decreased by St John's Wort.  On the other hand, St John's Wort did not influence plasma pravastatin concn.  St John's wort caused no significant differences in the elimination half-life of simvastatin or pravastatin.  Thus, Sr John's Wort decreases plasma concns. of simvastatin but not of pravastatin.  Because simvastatin is extensively metabolized by cytochrome P 4503A4 in the intestinal wall and liver, which is induced by St John's Wort, it is likely that this interaction is partly caused by the enhancement of the cytochrome P 4503A4-mediated 1st-pass metab. of simvastatin in the small intestine and liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGcpKjeXDo7Vg90H21EOLACvtfcHk0linVNTaEtiYfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVCkuw%253D%253D&md5=a43eebdefe27b8459ae09369b6d13b26</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.120025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.120025%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DS.%26aulast%3DNishiki%26aufirst%3DK.%26aulast%3DKawaguchi%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DK.%26aulast%3DMasada%26aufirst%3DM.%26aulast%3DMiyamori%26aufirst%3DI.%26aulast%3DFujimura%26aufirst%3DA.%26atitle%3DDifferent%2520effects%2520of%2520St%2520John%25E2%2580%2599s%2520wort%2520on%2520the%2520pharmacokinetics%2520of%2520simvastatin%2520and%2520pravastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D70%26issue%3D6%26spage%3D518%26epage%3D524%26doi%3D10.1067%2Fmcp.2001.120025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolan, P.</span></span> <span> </span><span class="NLM_article-title">Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1002/jcph.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjcph.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24386664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=1313-1321&issue=12&author=A.+Stockisauthor=P.+Rolan&title=Effect+of+brivaracetam+%28400+mg%2Fday%29+on+the+pharmacokinetics+and+pharmacodynamics+of+a+combination+oral+contraceptive+in+healthy+women&doi=10.1002%2Fjcph.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women</span></div><div class="casAuthors">Stockis, Armel; Rolan, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Brivaracetam is a high-affinity synaptic vesicle protein 2A ligand, in Phase III clin. development for epilepsy.  This study assessed the effect of brivaracetam 400 mg/day on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (OC) contg. 30 μg ethinylestradiol and 150 μg levonorgestrel, in healthy pre-menopausal women.  This open-label, single-center, randomized, two-way crossover, multiple oral dose study (N01080) included two consecutive 28-day cycles without (control) or with brivaracetam (test), and a 28-day follow-up.  OC was taken on Days 1-21 of every cycle and brivaracetam 200 mg twice daily was administered on Days 1-20 of the test cycle.  Ethinylestradiol and levonorgestrel pharmacokinetics were detd. on Day 20 and endogenous hormones were measured frequently during both control and test cycles.  Overall, 23/24 participants (age: 19-39 years) completed the study.  AUC ratio (90% confidence interval) for brivaracetam vs. control was 0.73 (0.69, 0.78) for ethinylestradiol and 0.78 (0.72, 0.83) for levonorgestrel, outside pre-defined bioequivalence limits (0.80-1.25).  Levels of endogenous hormones were similar and normal during brivaracetam and control cycles.  Brivaracetam in combination with OC was well tolerated.  Brivaracetam 400 mg/day co-administered with a combination OC in healthy women reduced ethinylestradiol and levonorgestrel plasma levels but did not result in ovulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJLfM0GAwMFLVg90H21EOLACvtfcHk0linVNTaEtiYfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurjN&md5=c8319a294e97ac6deabd57028c5cab0a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fjcph.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.187%26sid%3Dliteratum%253Aachs%26aulast%3DStockis%26aufirst%3DA.%26aulast%3DRolan%26aufirst%3DP.%26atitle%3DEffect%2520of%2520brivaracetam%2520%2528400%2520mg%252Fday%2529%2520on%2520the%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520a%2520combination%2520oral%2520contraceptive%2520in%2520healthy%2520women%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26issue%3D12%26spage%3D1313%26epage%3D1321%26doi%3D10.1002%2Fjcph.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span> <span> </span><span class="NLM_article-title">Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1046/j.1528-1157.2003.55602.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1046%2Fj.1528-1157.2003.55602.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12681003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFymu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=540-549&issue=4&author=D.+R.+Dooseauthor=S.+S.+Wangauthor=M.+Padmanabhanauthor=S.+Schwabeauthor=D.+Jacobsauthor=M.+Bialer&title=Effect+of+topiramate+or+carbamazepine+on+the+pharmacokinetics+of+an+oral+contraceptive+containing+norethindrone+and+ethinyl+estradiol+in+healthy+obese+and+nonobese+female+subjects&doi=10.1046%2Fj.1528-1157.2003.55602.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects</span></div><div class="casAuthors">Doose, Dennis R.; Wang, Shean-Sheng; Padmanabhan, Mukund; Schwabe, Stefan; Jacobs, David; Bialer, Meir</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-549</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) contg. norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure.  Methods: This randomized, open-label, five-group study included two 28-day cycles.  Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2).  The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day.  Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m2.  The BMI of the remaining four groups was ≥27 kg/m2.  Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, resp., compared with OC monotherapy.  A similar nonsignificant difference was obsd. with the plasma levels and AUC values of norethindrone (p > 0.05).  CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, resp., and increased their resp. oral clearance by 69% and 127% (p < 0.05).  Because CBZ induces CUP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated.  Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC contg. norethindrone and ethinyl estradiol.  The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6SnEfgJ2eM7Vg90H21EOLACvtfcHk0li_5uv_4sLozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFymu7o%253D&md5=64900949086ba7248ecf87b8cba150a5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1046%2Fj.1528-1157.2003.55602.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1528-1157.2003.55602.x%26sid%3Dliteratum%253Aachs%26aulast%3DDoose%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DS.%2BS.%26aulast%3DPadmanabhan%26aufirst%3DM.%26aulast%3DSchwabe%26aufirst%3DS.%26aulast%3DJacobs%26aufirst%3DD.%26aulast%3DBialer%26aufirst%3DM.%26atitle%3DEffect%2520of%2520topiramate%2520or%2520carbamazepine%2520on%2520the%2520pharmacokinetics%2520of%2520an%2520oral%2520contraceptive%2520containing%2520norethindrone%2520and%2520ethinyl%2520estradiol%2520in%2520healthy%2520obese%2520and%2520nonobese%2520female%2520subjects%26jtitle%3DEpilepsia%26date%3D2003%26volume%3D44%26issue%3D4%26spage%3D540%26epage%3D549%26doi%3D10.1046%2Fj.1528-1157.2003.55602.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Anaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span> <span> </span><span class="NLM_article-title">The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1007/s00280-011-1772-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00280-011-1772-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22057855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=563-571&issue=2&author=H.+A.+Wakeleeauthor=C.+H.+Takimotoauthor=A.+Lopez-Anayaauthor=Q.+Chuauthor=G.+Middletonauthor=D.+Dunlopauthor=R.+Ramlauauthor=N.+Leighlauthor=E.+K.+Rowinskyauthor=D.+Haoauthor=P.+Zatloukalauthor=C.+D.+Jacobsauthor=J.+Rodon&title=The+effect+of+bexarotene+on+atorvastatin+pharmacokinetics%3A+results+from+a+phase+I+trial+of+bexarotene+plus+chemotherapy+in+patients+with+advanced+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-011-1772-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Wakelee, Heather A.; Takimoto, Chris H.; Lopez-Anaya, Arturo; Chu, Quincy; Middleton, Gary; Dunlop, David; Ramlau, Rodryg; Leighl, Natasha; Rowinsky, Eric K.; Hao, Desiree; Zatloukal, Petr; Jacobs, Charlotte D.; Rodon, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">563-571</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bexarotene (Targretin capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metab.  This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate).  This trial was run in parallel with phase III trials of the combinations to det. whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.  Patients (n = 48) with advanced non-small cell lung cancer were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400 mg/m2/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5 days before chemotherapy due to hypertriglyceridemia induced by bexarotene.  Extensive plasma sampling to characterize the PK profiles of the lipid-lowering drugs, relevant chemotherapy agents was performed on day 1 (without bexarotene) and during chemotherapy cycles 2 or 3 (with bexarotene).  Here, we report the drug-drug interactions between the lipid-lowering agents and bexarotene.  Mean atorvastatin clearance and dose-cor. AUC values were reduced by nearly 50% with the addn. of concomitant bexarotene.  As fenofibrate was less effective at controlling hypertriglyceridemia, too few patients received this agent to make any meaningful conclusions about drug-drug interactions.  A drug-drug interaction was seen in this trial with bexarotene co-administration leading to a significant redn. in the AUC of atorvastatin.  The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metab. of atorvastatin.  Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprlFr1XJuh7rVg90H21EOLACvtfcHk0li_5uv_4sLozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOkur4%253D&md5=d26136e814972944d57b60e0b5d80222</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1772-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1772-z%26sid%3Dliteratum%253Aachs%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DTakimoto%26aufirst%3DC.%2BH.%26aulast%3DLopez-Anaya%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DMiddleton%26aufirst%3DG.%26aulast%3DDunlop%26aufirst%3DD.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DHao%26aufirst%3DD.%26aulast%3DZatloukal%26aufirst%3DP.%26aulast%3DJacobs%26aufirst%3DC.%2BD.%26aulast%3DRodon%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520bexarotene%2520on%2520atorvastatin%2520pharmacokinetics%253A%2520results%2520from%2520a%2520phase%2520I%2520trial%2520of%2520bexarotene%2520plus%2520chemotherapy%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26issue%3D2%26spage%3D563%26epage%3D571%26doi%3D10.1007%2Fs00280-011-1772-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergis, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eshleman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A. C.</span></span> <span> </span><span class="NLM_article-title">Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1097/00002030-200501280-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1097%2F00002030-200501280-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15668539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=145-152&issue=2&author=A.+D.+Kashubaauthor=C.+Tierneyauthor=G.+F.+Downeyauthor=E.+P.+Acostaauthor=E.+N.+Vergisauthor=K.+Klingmanauthor=J.+W.+Mellorsauthor=S.+H.+Eshlemanauthor=T.+R.+Scottauthor=A.+C.+Collier&title=Combining+fosamprenavir+with+lopinavir%2Fritonavir+substantially+reduces+amprenavir+and+lopinavir+exposure%3A+ACTG+protocol+A5143+results&doi=10.1097%2F00002030-200501280-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results</span></div><div class="casAuthors">Kashuba, Angela D. M.; Tierney, Camlin; Downey, Gerald F.; Acosta, Edward P.; Vergis, Emanuel N.; Klingman, Karin; Mellors, John W.; Eshleman, Susan H.; Scott, Trevor R.; Collier, Ann C.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients.  Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk.  Design: Multi-center, open-label, selectively randomized, steady-state pharmacokinetic study in HIV-infected subjects.  Methods: A planned independent interim review occurred after at least eight subjects were randomized to each arm.  Subjects received twice daily LPV/RTV 400/100 mg (arm A; n = 8); fosamprenavir/RTV 700/100 mg (arm B; n = 8) or LPV/RTV/fosamprenavir 400/100/700 mg (arm C; n = 17).  Plasma samples were collected over 12 h between study weeks 2 and 4.  Pharmacokinetic parameters were compared based on a one-sided t-test on log-transformed data with a Peto stopping boundary (P < 0.001).  Results: Amprenavir mean area under the curve over 12 h (AUC0-12 h) and concn. at 12 h (C12 h) (μg/mL) were, resp., 42.7 μg × h/mL (range, 33.1-55.1) and 2.4 μg/mL (range, 1.4-3.2) in arm B and 17.4 μg × h/mL (range, 4.6-41.3) and 0.9 μg/mL (range, 0.2-2.7) in arm C: geometric mean ratio (GMR) arm C:B was 0.36 [99.9% upper confidence boundary (UCB), 0.64] and 0.31 (99.9% h UCB, 0.61), resp. (P ≤ 0.0001).  Lopinavir AUC0-12 h and C12 h were, resp., 95.3 μg × h/mL (range, 60.3-119.3) and 6.3 μg/mL (range, 2.2-9.2) in arm A and 54.4 μg × h/mL (range, 23.5-112.2) and 3.0 μg/mL (range, 0.4-7.9) in arm C: GMR arm C:A of 0.52 (99.9% UCB, 0.89) and 0.39 (99.9% UCB, 0.98), resp. (P ≤ 0.0008).  Ritonavir exposure was not significantly different between arms.  Conclusion: APV and LPV exposures are significantly reduced using LPV/RTV/fosamprenavir, possibly increasing the risk of virol. failure.  Consequently, A5143 was closed to enrollment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDQz0DvFuoLVg90H21EOLACvtfcHk0li_5uv_4sLozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCrsg%253D%253D&md5=ed835481eadb971ede34d3a22e321f8f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2F00002030-200501280-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002030-200501280-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26aulast%3DTierney%26aufirst%3DC.%26aulast%3DDowney%26aufirst%3DG.%2BF.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26aulast%3DVergis%26aufirst%3DE.%2BN.%26aulast%3DKlingman%26aufirst%3DK.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DEshleman%26aufirst%3DS.%2BH.%26aulast%3DScott%26aufirst%3DT.%2BR.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26atitle%3DCombining%2520fosamprenavir%2520with%2520lopinavir%252Fritonavir%2520substantially%2520reduces%2520amprenavir%2520and%2520lopinavir%2520exposure%253A%2520ACTG%2520protocol%2520A5143%2520results%26jtitle%3DAIDS%26date%3D2005%26volume%3D19%26issue%3D2%26spage%3D145%26epage%3D152%26doi%3D10.1097%2F00002030-200501280-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meraviglia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landonio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boreggio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzardini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, E.</span></span> <span> </span><span class="NLM_article-title">Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.phrs.2011.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21958880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=198-203&issue=2&author=D.+Cattaneoauthor=C.+Gervasoniauthor=V.+Cozziauthor=S.+Baldelliauthor=S.+Fucileauthor=P.+Meravigliaauthor=S.+Landonioauthor=G.+Boreggioauthor=G.+Rizzardiniauthor=E.+Clementi&title=Co-administration+of+raltegravir+reduces+daily+darunavir+exposure+in+HIV-1+infected+patients&doi=10.1016%2Fj.phrs.2011.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients</span></div><div class="casAuthors">Cattaneo, Dario; Gervasoni, Cristina; Cozzi, Valeria; Baldelli, Sara; Fucile, Serena; Meraviglia, Paola; Landonio, Simona; Boreggio, Gabriella; Rizzardini, Giuliano; Clementi, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved.  In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration.  The assessment of trough plasma drug concns. was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients.  No significant differences on darunavir and ritonavir plasma trough levels were obsd. between patients receiving or not raltegravir.  Co-administration of raltegravir was, however, assocd. with a 40% redn. in darunavir C max and estd. AUC0-24, as well a 60% increase in the estd. darunavir clearance compared with values measured in patients not given raltegravir.  Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir.  These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, esp. considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9U-nlzDZ4xrVg90H21EOLACvtfcHk0lh-OxliVu9aLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ohu7k%253D&md5=a4357037f03cc7fb35c38cb6d28c5cd6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DD.%26aulast%3DGervasoni%26aufirst%3DC.%26aulast%3DCozzi%26aufirst%3DV.%26aulast%3DBaldelli%26aufirst%3DS.%26aulast%3DFucile%26aufirst%3DS.%26aulast%3DMeraviglia%26aufirst%3DP.%26aulast%3DLandonio%26aufirst%3DS.%26aulast%3DBoreggio%26aufirst%3DG.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DClementi%26aufirst%3DE.%26atitle%3DCo-administration%2520of%2520raltegravir%2520reduces%2520daily%2520darunavir%2520exposure%2520in%2520HIV-1%2520infected%2520patients%26jtitle%3DPharmacol.%2520Res.%26date%3D2012%26volume%3D65%26issue%3D2%26spage%3D198%26epage%3D203%26doi%3D10.1016%2Fj.phrs.2011.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milazzo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridolfo, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avolio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antinori, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2014.12.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.ijantimicag.2014.12.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25769784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Oms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=545-549&issue=5&author=L.+Milazzoauthor=D.+Cattaneoauthor=E.+Calviauthor=C.+Gervasoniauthor=C.+Mazzaliauthor=P.+Ronziauthor=A.+M.+Periauthor=A.+L.+Ridolfoauthor=A.+D%E2%80%99Avolioauthor=S.+Antinori&title=Pharmacokinetic+interactions+between+telaprevir+and+antiretroviral+drugs+in+HIV%2FHCV-coinfected+patients+with+advanced+liver+fibrosis+and+prior+HCV+non-responders&doi=10.1016%2Fj.ijantimicag.2014.12.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders</span></div><div class="casAuthors">Milazzo, Laura; Cattaneo, Dario; Calvi, Elisa; Gervasoni, Cristina; Mazzali, Cristina; Ronzi, Paola; Peri, Anna Maria; Ridolfo, Anna Lisa; D'Avolio, Antonio; Antinori, Spinello</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">545-549</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Complex drug-drug interactions have been reported with concurrent administration of telaprevir (TVR) and human immunodeficiency virus (HIV) protease inhibitors (PIs), leading to relevant limitations of the therapeutic options for patients coinfected with hepatitis C virus (HCV) and HIV.  However, little is known about the pharmacokinetics and drug interactions between TVR and antiretrovirals in HIV/HCV-coinfected patients with advanced liver fibrosis.  Here we report the pharmacokinetics of TVR and antiretrovirals in a cohort of HIV/HCV genotype 1-coinfected patients with advanced liver fibrosis treated with TVR-based triple anti-HCV therapy.  No significant differences were obsd. in the pharmacokinetics of atazanavir, amprenavir or tenofovir at baseline and at Day 15 of TVR, whereas the AUC0-4 h of darunavir was 36% lower in the presence of TVR (AUC0-4 h 15 007 ng h/mL and 9563 ng h/mL at baseline and at Day 15 of TVR administration, resp.).  Noteworthy, the AUC0-4 h, Cmin and Cmax of raltegravir were reduced by 61%, 50% and 64%, resp.  However, none of the patient's plasma levels of tenofovir, atazanavir, amprenavir or raltegravir declined below their min. effective concns. even in assocn. with TVR, and no HIV treatment failure occurred.  A non-significant trend for lower TVR exposure was seen in patients concomitantly given amprenavir vs. those given atazanavir (AUC0-4 h, 9840 ng h/mL and 13 345 ng h/mL, resp.).  In conclusion, this study highlighted the feasibility of maintaining the current antiretroviral regimen in HIV/HCV-coinfected patients, even when significant interactions with TVR are predictable, whenever a change of HIV PIs is not deemed appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBEdb-gcc7rVg90H21EOLACvtfcHk0lh-OxliVu9aLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Oms7o%253D&md5=c08f490621c83ff12a96c5af937b2a2a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2014.12.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2014.12.035%26sid%3Dliteratum%253Aachs%26aulast%3DMilazzo%26aufirst%3DL.%26aulast%3DCattaneo%26aufirst%3DD.%26aulast%3DCalvi%26aufirst%3DE.%26aulast%3DGervasoni%26aufirst%3DC.%26aulast%3DMazzali%26aufirst%3DC.%26aulast%3DRonzi%26aufirst%3DP.%26aulast%3DPeri%26aufirst%3DA.%2BM.%26aulast%3DRidolfo%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Avolio%26aufirst%3DA.%26aulast%3DAntinori%26aufirst%3DS.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520telaprevir%2520and%2520antiretroviral%2520drugs%2520in%2520HIV%252FHCV-coinfected%2520patients%2520with%2520advanced%2520liver%2520fibrosis%2520and%2520prior%2520HCV%2520non-responders%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2015%26volume%3D45%26issue%3D5%26spage%3D545%26epage%3D549%26doi%3D10.1016%2Fj.ijantimicag.2014.12.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulskotte, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zutven, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treitel, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngberg, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterton, J. R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1093/cid/cis968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fcid%2Fcis968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23155151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Wmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=718-726&issue=5&author=E.+G.+Hulskotteauthor=H.+P.+Fengauthor=F.+Xuanauthor=M.+G.+van+Zutvenauthor=M.+A.+Treitelauthor=E.+A.+Hughesauthor=E.+O%E2%80%99Maraauthor=S.+P.+Youngbergauthor=J.+A.+Wagnerauthor=J.+R.+Butterton&title=Pharmacokinetic+interactions+between+the+hepatitis+C+virus+protease+inhibitor+boceprevir+and+ritonavir-boosted+HIV-1+protease+inhibitors+atazanavir%2C+darunavir%2C+and+lopinavir&doi=10.1093%2Fcid%2Fcis968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir</span></div><div class="casAuthors">Hulskotte, Ellen G. J.; Feng, Hwa-Ping; Xuan, Fengjuan; van Zutven, Marga G. J. A.; Treitel, Michelle A.; Hughes, Eric A.; O'Mara, Edward; Youngberg, Stephen P.; Wagner, John A.; Butterton, Joan R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">718-726</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs.  Methods: A randomized, open-label study to assess the pharmacokinetic interactions between boceprevir and ritonavir-boosted protease inhibitors (PI/r) was conducted in 39 healthy adults.  Subjects received boceprevir (800 mg, 3 times daily) for 6 days and then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400 mg twice daily, or darunavir (DRV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant boceprevir on days 25-31.  Results: Boceprevir decreased the exposure of all PI/r, with area under the concn.-time curve [AUC] from time 0 to the time of the last measurable sample geometric mean ratios of 0.65 (90% confidence interval [CI], .55-.78) for ATV/r; 0.66 (90% CI, .60-.72) for LPV/r, and 0.56 (90% CI, .51-.61) for DRV/r.  Coadministration with boceprevir decreased RTV AUC during a dosing interval τ (AUCτ) by 22%-36%.  ATV/r did not significantly affect boceprevir exposure, but boceprevir AUCτ was reduced by 45% and 32% when coadministered with LPV/r and DRV/r, resp.  Overall, treatments were well tolerated with no unexpected adverse events.  Conclusions: Concomitant administration of boceprevir with PI/r resulted in reduced exposures of PI and boceprevir.  These drug-drug interactions may reduce the effectiveness of PI/r and/or boceprevir when coadministered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0dAeQ1vU3bVg90H21EOLACvtfcHk0ljj64z_jzkwkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Wmt74%253D&md5=7ec9df4458b14c660c1f59bbdedb8c90</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis968%26sid%3Dliteratum%253Aachs%26aulast%3DHulskotte%26aufirst%3DE.%2BG.%26aulast%3DFeng%26aufirst%3DH.%2BP.%26aulast%3DXuan%26aufirst%3DF.%26aulast%3Dvan%2BZutven%26aufirst%3DM.%2BG.%26aulast%3DTreitel%26aufirst%3DM.%2BA.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DE.%26aulast%3DYoungberg%26aufirst%3DS.%2BP.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26atitle%3DPharmacokinetic%2520interactions%2520between%2520the%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%2520boceprevir%2520and%2520ritonavir-boosted%2520HIV-1%2520protease%2520inhibitors%2520atazanavir%252C%2520darunavir%252C%2520and%2520lopinavir%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D718%26epage%3D726%26doi%3D10.1093%2Fcid%2Fcis968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roadcap, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilzer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasseter, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. D.</span></span> <span> </span><span class="NLM_article-title">Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1177/00912700122010311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1177%2F00912700122010311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11361054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvVaktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=573-581&issue=5&author=T.+Prueksaritanontauthor=J.+M.+Vegaauthor=J.+Zhaoauthor=K.+Gaglianoauthor=O.+Kuznetsovaauthor=B.+Musserauthor=R.+D.+Aminauthor=L.+Liuauthor=B.+A.+Roadcapauthor=S.+Dilzerauthor=K.+C.+Lasseterauthor=J.+D.+Rogers&title=Interactions+between+simvastatin+and+troglitazone+or+pioglitazone+in+healthy+subjects&doi=10.1177%2F00912700122010311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects</span></div><div class="casAuthors">Prueksaritanont, Thomayant; Vega, Jose M.; Zhao, Jamie; Gagliano, Kathleen; Kuznetsova, Olga; Musser, Bret; Amin, Raju D.; Liu, Lida; Roadcap, Brad A.; Dilzer, Stacy; Lasseter, K. C.; Rogers, J. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-581</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two randomized, two-period crossover studies were conducted to evaluate the effects of repeat oral dosing of troglitazone (Study I) and pioglitazone (Study II) on the pharmacokinetics of plasma HMG-CoA reductase inhibitors following multiple oral doses of simvastatin and of simvastatin on the plasma pharmacokinetics of troglitazone (Study I) in healthy subjects.  In both studies, each subject received two treatments.  Treatment A consisted of once-daily oral doses of troglitazone 400 mg (Study I) or pioglitazone 45 mg (Study II) for 24 days with coadministration of once-daily doses of simvastatin 40 mg (Study I) or 80 mg (Study II) on Days 15 through 24.  Treatment B consisted of once-daily oral doses of simvastatin 40 mg (Study I) or 80 mg (Study II) for 10 days.  In Study I, the area under the plasma concn.-time profiles (AUC) and max. plasma concns. (Cmax) of HMG-CoA reductase inhibitors in subjects who received both troglitazone and simvastatin were decreased modestly (by -30% for Cmax and ∼40% for AUC), but time to reach Cmax (tmax) did not change, as compared with those who received simvastatin alone.  Simvastatin, administered orally as a 40 mg tablet daily for 10 days, did not affect the AUC or tmax (p > 0.5) but caused a small but clin. insignificant increase (∼25%) in Cmax for troglitazone.  In Study II, pioglitazone, at the highest approved dose for clin. use, did not significantly alter any of the pharmacokinetic parameters (AUC, Cmax, and tmax) of simvastatin HMG-CoA reductase inhibitory activity.  For all treatment regimens, side effects were mild and transient, suggesting that coadministration of simvastatin with either troglitazone or pioglitazone was well tolerated.  The modest effect of troglitazone on simvastatin pharmacokinetics is in agreement with the suggestion that troglitazone is an inducer of CYP3A.  The insignificant effect of simvastatin on troglitazone pharmacokinetics is consistent with the conclusion that simvastatin is not a significant inhibitor for drug-metabolizing enzymes.  The lack of pharmacokinetic effect of pioglitazone on simvastatin supports the expectation that this combination may be used safely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSL5Nu3eJxLVg90H21EOLACvtfcHk0ljj64z_jzkwkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvVaktrw%253D&md5=890d0938b1e389f92ff329092a21801f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1177%2F00912700122010311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912700122010311%26sid%3Dliteratum%253Aachs%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGagliano%26aufirst%3DK.%26aulast%3DKuznetsova%26aufirst%3DO.%26aulast%3DMusser%26aufirst%3DB.%26aulast%3DAmin%26aufirst%3DR.%2BD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRoadcap%26aufirst%3DB.%2BA.%26aulast%3DDilzer%26aufirst%3DS.%26aulast%3DLasseter%26aufirst%3DK.%2BC.%26aulast%3DRogers%26aufirst%3DJ.%2BD.%26atitle%3DInteractions%2520between%2520simvastatin%2520and%2520troglitazone%2520or%2520pioglitazone%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D41%26issue%3D5%26spage%3D573%26epage%3D581%26doi%3D10.1177%2F00912700122010311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desar, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmer-Bonte, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Herpen, C. M.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fsj.bjc.6605777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21045832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=1637-1643&issue=11&author=I.+M.+Desarauthor=J.+N.+Timmer-Bonteauthor=D.+M.+Burgerauthor=W.+T.+van+der+Graafauthor=C.+M.+van+Herpen&title=A+phase+I+dose-escalation+study+to+evaluate+safety+and+tolerability+of+sorafenib+combined+with+sirolimus+in+patients+with+advanced+solid+cancer&doi=10.1038%2Fsj.bjc.6605777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer</span></div><div class="casAuthors">Desar, I. M. E.; Timmer-Bonte, J. N. H.; Burger, D. M.; van der Graaf, W. T. A.; van Herpen, C. M. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1637-1643</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically.  Methods: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was performed to det. the recommended dose of the combination in patients with solid tumors.  Secondary objectives were to det. the safety profile and max. tolerated dose (MTD), and to evaluate the pharmacokinetics (PK) of the combination.  Results: Dose-limiting toxicities were transaminitis and cutaneous toxicity.  The most frequently reported adverse events were elevated transaminases, hypophosphatemia, fatigue, anorexia, diarrhoea, nausea, rash and palmar-plantar erythrodysaesthesia.  Sirolimus did not change the PK of sorafenib; in contrast, sorafenib reduced the AUC(0-96) and Cmax of sirolimus.  No objective responses were obsd.; eight patients showed stable disease for a median of 16.3 wk (range 8-24).  The MTD of the combination was sorafenib 200 mg b.i.d. with sirolimus 1 mg q.d.  Conclusion: The combination of sorafenib and sirolimus showed enhanced toxicity, which could not be explained by the PK of both drugs.  The relative low doses at the MTD, in combination with the PK results, do not warrant further development of this combination.  British Journal of Cancer (2010) 103, 1637-1643. doi:10.1038/sj.bjc.6605777 www.bjcancer.com Published online 2 Nov. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsaC_41362rVg90H21EOLACvtfcHk0ljj64z_jzkwkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygsrvP&md5=d044f9072599d1b9898094582d8c80f2</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605777%26sid%3Dliteratum%253Aachs%26aulast%3DDesar%26aufirst%3DI.%2BM.%26aulast%3DTimmer-Bonte%26aufirst%3DJ.%2BN.%26aulast%3DBurger%26aufirst%3DD.%2BM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DW.%2BT.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520to%2520evaluate%2520safety%2520and%2520tolerability%2520of%2520sorafenib%2520combined%2520with%2520sirolimus%2520in%2520patients%2520with%2520advanced%2520solid%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26issue%3D11%26spage%3D1637%26epage%3D1643%26doi%3D10.1038%2Fsj.bjc.6605777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuseau, E.</span></span> <span> </span><span class="NLM_article-title">Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1167.2008.01665.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1528-1167.2008.01665.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18503564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1123-1141&issue=7&author=E.+Peruccaauthor=J.+Cloydauthor=D.+Critchleyauthor=E.+Fuseau&title=Rufinamide%3A+clinical+pharmacokinetics+and+concentration-response+relationships+in+patients+with+epilepsy&doi=10.1111%2Fj.1528-1167.2008.01665.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy</span></div><div class="casAuthors">Perucca, Emilio; Cloyd, James; Critchley, David; Fuseau, Eliane</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1123-1141</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Rufinamide is a new, orally active antiepileptic drug (AED), which has been found to be effective in the treatment of partial seizures and drop attacks assocd. with the Lennox-Gastaut syndrome.  When taken with food, rufinamide is relatively well absorbed in the lower dose range, with approx. dose-proportional plasma concns. up to 1,600 mg/day, but less than dose-proportional plasma concns. at higher doses due to reduced oral bioavailability.  Rufinamide is not extensively bound to plasma proteins.  During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.  The apparent vol. of distribution (Vd/F) and apparent oral clearance (CL/F) are related to body size, the best predictor being body surface area.  Rufinamide is not a substrate of cytochrome P 450 (CYP450) enzymes and is extensively metabolized via hydrolysis by carboxylesterases to a pharmacol. inactive carboxylic acid deriv., which is excreted in the urine.  Rufinamide pharmacokinetics are not affected by impaired renal function.  Potential differences in rufinamide pharmacokinetics between children and adults have not been investigated systematically in formal studies.  Although population pharmacokinetic modeling suggests that in the absence of interacting comedication rufinamide CL/F may be higher in children than in adults, a meaningful comparison of data across age groups is complicated by age-related differences in doses and in proportion of patients receiving drugs known to increase or to decrease rufinamide CL/F.  A study investigating the effect of rufinamide on the pharmacokinetics of the CYP3A4 substrate triazolam and an oral contraceptive interaction study showed that rufinamide has some enzyme-inducing potential in man.  Findings from population pharmacokinetic modeling indicate that rufinamide does not modify the CL/F of topiramate or valproic acid, but may slightly increase the CL/F of carbamazepine and lamotrigine and slightly decrease the CL/F of phenobarbital and phenytoin (all predicted changes were <20%).  These changes in the pharmacokinetics of assocd. AEDs are unlikely to make it necessary to change the dosages of these AEDs given concomitantly with rufinamide, with the exception that consideration should be given to reducing the dose of phenytoin.  Based on population pharmacokinetic modeling, lamotrigine, topiramate, or benzodiazepines do not affect the pharmacokinetics of rufinamide, but valproic acid may increase plasma rufinamide concns., esp. in children in whom plasma rufinamide concns. could be increased substantially.  Conversely, comedication with carbamazepine, vigabatrin, phenytoin, phenobarbital, and primidone was assocd. with a slight-to-moderate decrease in plasma rufinamide concns., ranging from a min. of -13.7% in female children comedicated with vigabatrin to a max. of -46.3% in female adults comedicated with phenytoin, phenobarbital, or primidone.  In population modeling using data from placebo-controlled trials, a pos. correlation has been identified between redn. in seizure frequency and steady-state plasma rufinamide concns.  The probability of adverse effects also appears to be concn.-related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu7yrQLFQJTrVg90H21EOLACvtfcHk0lga1sFPMxRFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWmtLw%253D&md5=de55ebfc30ead7320da5d1125b310939</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1167.2008.01665.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1167.2008.01665.x%26sid%3Dliteratum%253Aachs%26aulast%3DPerucca%26aufirst%3DE.%26aulast%3DCloyd%26aufirst%3DJ.%26aulast%3DCritchley%26aufirst%3DD.%26aulast%3DFuseau%26aufirst%3DE.%26atitle%3DRufinamide%253A%2520clinical%2520pharmacokinetics%2520and%2520concentration-response%2520relationships%2520in%2520patients%2520with%2520epilepsy%26jtitle%3DEpilepsia%26date%3D2008%26volume%3D49%26issue%3D7%26spage%3D1123%26epage%3D1141%26doi%3D10.1111%2Fj.1528-1167.2008.01665.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommadossi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusek, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>179</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1086/314703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1086%2F314703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10191212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFKgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1999&pages=1116-1123&issue=5&author=R.+L.+Murphyauthor=J.+P.+Sommadossiauthor=M.+Lamsonauthor=D.+B.+Hallauthor=M.+Myersauthor=A.+Dusek&title=Antiviral+effect+and+pharmacokinetic+interaction+between+nevirapine+and+indinavir+in+persons+infected+with+human+immunodeficiency+virus+type+1&doi=10.1086%2F314703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1</span></div><div class="casAuthors">Murphy, Robert L.; Sommadossi, Jean-Pierre; Lamson, Michael; Hall, David B.; Myers, Maureen; Dusek, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1116-1123</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Nevirapine and indinavir have the potential of affecting the pharmacokinetics of each other.  In a prospective trial, 24 human immunodeficiency virus (HIV)-infected subjects on stable nucleoside or no therapy were treated with 800 mg of indinavir every 8 h.  After 7 days, 200 mg of nevirapine a day was added for 14 days and then increased to 200 mg twice a day.  At day 7 (before nevirapine), there was a sevenfold difference among the subjects in indinavir area under the curve (AUC), and there was a significant correlation between indinavir AUC (r2 = 0.378, P =.019), min. plasma concn. (Cmin; r2 = 0.359, P =.023), max. plasma concn. (Cmax; r2 = 0.340, P =.028), and plasma HIV RNA decline.  Nevirapine significantly reduced median indinavir Cmin (47.5%) and AUC (27.4%) and, to a lesser extent, Cmax (11%).  Plasma HIV RNA values were ≤20 copies/mL in 10 of 17 (58.8%) subjects at 58 wk or last visit.  These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkg36iAGYlrrVg90H21EOLACvtfcHk0lga1sFPMxRFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFKgt7Y%253D&md5=0b19bb4c5f6fc267d8905d222595124d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1086%2F314703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F314703%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BL.%26aulast%3DSommadossi%26aufirst%3DJ.%2BP.%26aulast%3DLamson%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BB.%26aulast%3DMyers%26aufirst%3DM.%26aulast%3DDusek%26aufirst%3DA.%26atitle%3DAntiviral%2520effect%2520and%2520pharmacokinetic%2520interaction%2520between%2520nevirapine%2520and%2520indinavir%2520in%2520persons%2520infected%2520with%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D1999%26volume%3D179%26issue%3D5%26spage%3D1116%26epage%3D1123%26doi%3D10.1086%2F314703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aviles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matti
Vehaskari, V.</span></span> <span> </span><span class="NLM_article-title">Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients</span>. <i>Pediatr. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3046.2005.00263.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fj.1399-3046.2005.00263.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15787787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVGhtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=162-169&issue=2&author=J.+S.+Kimauthor=D.+H.+Avilesauthor=D.+M.+Silversteinauthor=P.+L.+Leblancauthor=V.+Matti%0AVehaskari&title=Effect+of+age%2C+ethnicity%2C+and+glucocorticoid+use+on+tacrolimus+pharmacokinetics+in+pediatric+renal+transplant+patients&doi=10.1111%2Fj.1399-3046.2005.00263.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients</span></div><div class="casAuthors">Kim, Jung Sue; Aviles, Diego H.; Silverstein, Douglas M.; LeBlanc, Pamela L.; Vehaskari, V. Matti</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Transplantation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">PETRF6</span>;
        ISSN:<span class="NLM_cas:issn">1397-3142</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Tacrolimus has become an effective alternative to cyclosporine as a component of primary immunosuppression in pediatric renal transplant patients, but the information on the pharmacokinetic characteristics of tacrolimus in young patients is still limited.  The primary objective of this study was to det. the effect of patient age, ethnicity, and concurrent steroid administration on tacrolimus pharmacokinetics in pediatric renal transplant patients.  The study population consisted of 30 pediatric patients, age 1.5-18.6 yr, who received a kidney transplant between July 1999 and Feb. 2004.  After twice daily dosing was stabilized based on clin. judgment, at least 5 days postoperatively, tacrolimus levels were drawn prior to, and 1, 2, 4, 8, and 12 h after the morning dose.  The mean dose of tacrolimus was 0.12 mg/kg/dose.  Mean trough level was 11.9 ± 5.0 ng/mL.  Mean area under the curve (AUC) was 192 ± 84 with a range of 78-360 h × (ng/mL).  The correlation between trough level and AUC was only fair (r = 0.74); later time points correlated better with AUC, and an excellent correlation (r = 0.96) was obtained between the mean of trough and 2-h level (C2) and AUC.  There was a neg. correlation between age and dose per body wt. (r = -0.68).  African-American patients had marginally lower drug exposure with similar dosing.  Three age groups (<5, 5-12, and > 12 yr) were compared with respect to dosing and AUC.  Despite similar AUC in all three groups, the mean dose per kg required to achieve the AUC was 2.7- and 1.9-fold higher in the <5 and 5-12-yr groups, resp., compared with the > 12-yr group.  Nine of the 30 patients were on a totally steroid-free regimen.  Their tacrolimus dose and trough levels were similar to those of steroid-exposed patients, but their mean AUC was 41% higher.  Our results show an inverse correlation between age and required tacrolimus dose, wide interindividual variation, and greater exposure with steroid-free regimen despite no change in trough level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4y7wCTJDA7Vg90H21EOLACvtfcHk0lga1sFPMxRFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVGhtb0%253D&md5=8beda4598949ade638687ff5a2e427b3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3046.2005.00263.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3046.2005.00263.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DAviles%26aufirst%3DD.%2BH.%26aulast%3DSilverstein%26aufirst%3DD.%2BM.%26aulast%3DLeblanc%26aufirst%3DP.%2BL.%26aulast%3DMatti%2BVehaskari%26aufirst%3DV.%26atitle%3DEffect%2520of%2520age%252C%2520ethnicity%252C%2520and%2520glucocorticoid%2520use%2520on%2520tacrolimus%2520pharmacokinetics%2520in%2520pediatric%2520renal%2520transplant%2520patients%26jtitle%3DPediatr.%2520Transplant.%26date%3D2005%26volume%3D9%26issue%3D2%26spage%3D162%26epage%3D169%26doi%3D10.1111%2Fj.1399-3046.2005.00263.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1002/med.21648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fmed.21648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31782213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlantbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=1061-1083&issue=3&author=S.+C.+Chaiauthor=W.+C.+Wrightauthor=T.+Chen&title=Strategies+for+developing+pregnane+X+receptor+antagonists%3A+Implications+from+metabolism+to+cancer&doi=10.1002%2Fmed.21648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer</span></div><div class="casAuthors">Chai, Sergio C.; Wright, William C.; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1061-1083</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Pregnane X receptor (PXR) is a ligand-activated nuclear receptor (NR) that was originally identified as a master regulator of xenobiotic detoxification.  It regulates the expression of drug-metabolizing enzymes and transporters to control the degrdn. and excretion of endobiotics and xenobiotics, including therapeutic agents.  The metab. and disposition of drugs might compromise their efficacy and possibly cause drug toxicity and/or drug resistance.  Because many drugs can promiscuously bind and activate PXR, PXR antagonists might have therapeutic value in preventing and overcoming drug-induced PXR-mediated drug toxicity and drug resistance.  Furthermore, PXR is now known to have broader cellular functions, including the regulation of cell proliferation, and glucose and lipid metab.  Thus, PXR might be involved in human diseases such as cancer and metabolic diseases.  This review focuses on the development of PXR antagonists, which has been hampered by the promiscuity of PXR ligand binding.  However, substantial progress has been made in recent years, suggesting that it is feasible to develop selective PXR antagonists.  We discuss the current status, challenges, and strategies in developing selective PXR antagonists.  The strategies are based on the mol. mechanisms of antagonism in related NRs that can be applied to the design of PXR antagonists, primarily driven by structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmoMgI_jgLdrVg90H21EOLACvtfcHk0liElNlD9ocavQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlantbk%253D&md5=2dae3977e2e2b600441e4e0ffff6a21e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fmed.21648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21648%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DWright%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520developing%2520pregnane%2520X%2520receptor%2520antagonists%253A%2520Implications%2520from%2520metabolism%2520to%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26issue%3D3%26spage%3D1061%26epage%3D1083%26doi%3D10.1002%2Fmed.21648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koibuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, Y.</span></span> <span> </span><span class="NLM_article-title">Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">32453</span>– <span class="NLM_lpage">32458</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111245200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M111245200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12072427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32453-32458&issue=36&author=A.+Takeshitaauthor=M.+Taguchiauthor=N.+Koibuchiauthor=Y.+Ozawa&title=Putative+role+of+the+orphan+nuclear+receptor+SXR+%28steroid+and+xenobiotic+receptor%29+in+the+mechanism+of+CYP3A4+inhibition+by+xenobiotics&doi=10.1074%2Fjbc.M111245200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition of xenobiotics</span></div><div class="casAuthors">Takeshita, Akira; Taguchi, Manabu; Koubuchi, Noriyuki; Ozawa, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">32453-32458</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the metab. of endogenous steroids and drugs in liver.  Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter. Conversely, it is not known whether SXR mediates the transcriptional repression. We thus examd. transcriptional repression of SXR and its interaction with corepressors, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) using reporter assays in the absence and presence of ligand.  Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.  Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1.  On the other hand, the anti-fungal agent ketoconazole decreased XSR interaction with both SRC-1 and sMRT.  Ketoconazole partially inhibited corticosterone-induced SXR-mediated transcription on the CYP3A4 promoter.  Taken together, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription.  Further, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8my6zcHy4z7Vg90H21EOLACvtfcHk0liElNlD9ocavQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVWhsb0%253D&md5=1989e2742d9fc6b1bceb24b2791f0bdc</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111245200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111245200%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DTaguchi%26aufirst%3DM.%26aulast%3DKoibuchi%26aufirst%3DN.%26aulast%3DOzawa%26aufirst%3DY.%26atitle%3DPutative%2520role%2520of%2520the%2520orphan%2520nuclear%2520receptor%2520SXR%2520%2528steroid%2520and%2520xenobiotic%2520receptor%2529%2520in%2520the%2520mechanism%2520of%2520CYP3A4%2520inhibition%2520by%2520xenobiotics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D36%26spage%3D32453%26epage%3D32458%26doi%3D10.1074%2Fjbc.M111245200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span> <span> </span><span class="NLM_article-title">Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">592</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1124/mol.107.038398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.107.038398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17576789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=592-603&issue=3&author=S.+Ekinsauthor=C.+Changauthor=S.+Maniauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+Iyerauthor=V.+Kholodovychauthor=N.+Aiauthor=W.+J.+Welshauthor=M.+Sinzauthor=P.+W.+Swaanauthor=R.+Patelauthor=K.+Bachmann&title=Human+pregnane+X+receptor+antagonists+and+agonists+define+molecular+requirements+for+different+binding+sites&doi=10.1124%2Fmol.107.038398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites</span></div><div class="casAuthors">Ekins, Sean; Chang, Cheng; Mani, Sridhar; Krasowski, Matthew D.; Reschly, Erica J.; Iyer, Manisha; Kholodovych, Vladyslav; Ai, Ni; Welsh, William J.; Sinz, Michael; Swaan, Peter W.; Patel, Rachana; Bachmann, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">592-603</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metab. and transporter genes.  The receptor is promiscuous, binding many structural classes of mols. that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metab. and excretion of therapeutic agents, and causing drug-drug interactions.  It has been suggested that human PXR antagonists represent a means to counteract such interactions.  Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain.  In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse mols. with exptl. PXR agonist binding data.  We have addnl. defined a novel pharmacophore for the steroidal agonist site.  All agonist pharmacophores showed that hydrophobic features are predominant.  In contrast, a qual. comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features.  Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping.  Combining computational and exptl. data for different classes of mols. provided strong evidence for agonists and antagonists binding distinct regions on PXR.  These observations bear significant implications for future discovery of mols. that are more selective and potent antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4MHwW1VExI7Vg90H21EOLACvtfcHk0liElNlD9ocavQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfO&md5=0a47c81ca4be5d3d6b1af2c455245819</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.038398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.038398%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DIyer%26aufirst%3DM.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DBachmann%26aufirst%3DK.%26atitle%3DHuman%2520pregnane%2520X%2520receptor%2520antagonists%2520and%2520agonists%2520define%2520molecular%2520requirements%2520for%2520different%2520binding%2520sites%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D592%26epage%3D603%26doi%3D10.1124%2Fmol.107.038398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Computational discovery of novel low micromolar human pregnane X receptor antagonists</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1124/mol.108.049437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.108.049437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18579710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVClt7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=662-672&issue=3&author=S.+Ekinsauthor=V.+Kholodovychauthor=N.+Aiauthor=M.+Sinzauthor=J.+Galauthor=L.+Geraauthor=W.+J.+Welshauthor=K.+Bachmannauthor=S.+Mani&title=Computational+discovery+of+novel+low+micromolar+human+pregnane+X+receptor+antagonists&doi=10.1124%2Fmol.108.049437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Computational discovery of novel low micromolar human pregnane X receptor antagonists</span></div><div class="casAuthors">Ekins, Sean; Kholodovych, Vladyslav; Ai, Ni; Sinz, Michael; Gal, Joseph; Gera, Lajos; Welsh, William J.; Bachmann, Kenneth; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">662-672</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Very few antagonists have been identified for the human pregnane X receptor (PXR).  These mols. may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compds. and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metab. and transporter genes.  A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features.  This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies.  Using computational approaches to search libraries of known drugs or com. available mols. is preferred over random screening.  The authors have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3',5-dimethyl-3,5'-biisoxazole-4'-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)].  The authors have also used the computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain.  The involvement of this domain was also suggested by further site-directed mutagenesis work.  The authors have addnl. described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro.  These observations are important for predicting whether further mols. may interact with PXR as antagonists in vivo with potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeljCOyj4ubVg90H21EOLACvtfcHk0ljhX0BmcV1uVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVClt7jK&md5=a34d583b7283fb5e6c367e26edb91c68</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049437%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DAi%26aufirst%3DN.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DGal%26aufirst%3DJ.%26aulast%3DGera%26aufirst%3DL.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DBachmann%26aufirst%3DK.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DComputational%2520discovery%2520of%2520novel%2520low%2520micromolar%2520human%2520pregnane%2520X%2520receptor%2520antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26issue%3D3%26spage%3D662%26epage%3D672%26doi%3D10.1124%2Fmol.108.049437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoeckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalpana, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fsj.onc.1209788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16819505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=258-268&issue=2&author=H.+Huangauthor=H.+Wangauthor=M.+Sinzauthor=M.+Zoecklerauthor=J.+Staudingerauthor=M.+R.+Redinboauthor=D.+G.+Teoticoauthor=J.+Lockerauthor=G.+V.+Kalpanaauthor=S.+Mani&title=Inhibition+of+drug+metabolism+by+blocking+the+activation+of+nuclear+receptors+by+ketoconazole&doi=10.1038%2Fsj.onc.1209788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole</span></div><div class="casAuthors">Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-268</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Individual variation in drug metab. is a major cause of unpredictable side effects during therapy.  Drug metab. is controlled by a class of orphan nuclear receptors (NRs), which regulate expression of genes such as CYP (cytochrome)3A4 and MDR-1 (multi-drug resistance-1), that are involved in this process.  We have found that xenobiotic-mediated induction of CYP3A4 and MDR-1 gene transcription was inhibited by ketoconazole, a commonly used antifungal drug.  Ketoconazole mediated its effect by inhibiting the activation of NRs, human pregnenolone X receptor and constitutive androstene receptor, involved in regulation of CYP3A4 and MDR-1.  The effect of ketoconazole was specific to the group of NRs that control xenobiotic metab.  Ketoconazole disrupted the interaction of the xenobiotic receptor PXR with the co-activator steroid receptor co-activator-1.  Ketoconazole treatment resulted in delayed metab. of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins.  These studies demonstrate for the first time that ketoconazole represses the coordinated activation of genes involved in drug metab., by blocking activation of a specific subset of NRs.  Our results suggest that ketoconazole can be used as a pan-antagonist of NRs involved in xenobiotic metab. in vivo, which may lead to novel strategies that improve drug effect and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZEHj1LOG88LVg90H21EOLACvtfcHk0ljhX0BmcV1uVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFOltw%253D%253D&md5=efc15e866bab4deae25bb301cb002b8b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209788%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DStaudinger%26aufirst%3DJ.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DLocker%26aufirst%3DJ.%26aulast%3DKalpana%26aufirst%3DG.%2BV.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520drug%2520metabolism%2520by%2520blocking%2520the%2520activation%2520of%2520nuclear%2520receptors%2520by%2520ketoconazole%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D2%26spage%3D258%26epage%3D268%26doi%3D10.1038%2Fsj.onc.1209788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalpana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Activated pregnenolone X-receptor is a target for ketoconazole and its analogs</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1158%2F1078-0432.CCR-06-1592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17438109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1emsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2488-2495&issue=8&author=H.+Wangauthor=H.+Huangauthor=H.+Liauthor=D.+G.+Teoticoauthor=M.+Sinzauthor=S.+D.+Bakerauthor=J.+Staudingerauthor=G.+Kalpanaauthor=M.+R.+Redinboauthor=S.+Mani&title=Activated+pregnenolone+X-receptor+is+a+target+for+ketoconazole+and+its+analogs&doi=10.1158%2F1078-0432.CCR-06-1592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Activated pregnenolone X-receptor is a target for ketoconazole and its analogs</span></div><div class="casAuthors">Wang, Hongwei; Huang, Haiyan; Li, Hao; Teotico, Denise G.; Sinz, Michael; Baker, Sharyn D.; Staudinger, Jeffrey; Kalpana, Ganjam; Redinbo, Matthew R.; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2488-2495</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Variations in biotransformation and elimination of microtubule-binding drugs are a major cause of unpredictable side effects during cancer therapy.  Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.  In vitro RNA-, protein-, and transcription-based assays in multiple cell lines derived from hepatocytes and PXR wild-type and null mouse studies were employed to show the effects of ketoconazole and its analogs on ligand-activated PXR-mediated gene transcription and translation.  The transcriptional activation of genes regulating biotransformation and transport by the liganded human nuclear xenobiotic receptor, PXR, was inhibited by the commonly used antifungal ketoconazole and related azole analogs.  Mutations at the AF-2 surface of the human PXR ligand-binding domain indicate that ketoconazole may interact with specific residues outside the ligand-binding pocket.  Furthermore, in contrast to that obsd. in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel.  These studies show that some azole compds. repress the coordinated activation of genes involved in drug metab. by blocking PXR activation.  Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogs may also serve to preserve paclitaxel blood levels on chronic dosing of drugs.  The observations may facilitate new strategies to improve the clin. efficacy of drugs and to reduce therapeutic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBWhTciBBQp7Vg90H21EOLACvtfcHk0ljhX0BmcV1uVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1emsrw%253D&md5=debab3778111b68a24d3d0912132ecd2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1592%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DStaudinger%26aufirst%3DJ.%26aulast%3DKalpana%26aufirst%3DG.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DActivated%2520pregnenolone%2520X-receptor%2520is%2520a%2520target%2520for%2520ketoconazole%2520and%2520its%2520analogs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D8%26spage%3D2488%26epage%3D2495%26doi%3D10.1158%2F1078-0432.CCR-06-1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvail, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.111.071787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21464197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=124-135&issue=1&author=M.+Venkateshauthor=H.+Wangauthor=J.+Cayerauthor=M.+Lerouxauthor=D.+Salvailauthor=B.+Dasauthor=J.+E.+Wrobelauthor=S.+Mani&title=In+vivo+and+in+vitro+characterization+of+a+first-in-class+novel+azole+analog+that+targets+pregnane+X+receptor+activation&doi=10.1124%2Fmol.111.071787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation</span></div><div class="casAuthors">Venkatesh, Madhukumar; Wang, Hongwei; Cayer, Julie; Leroux, Melissa; Salvail, Dany; Das, Bhaskar; Wrobel, Jay E.; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">124-135</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a master regulator of xenobiotic clearance and is implicated in deleterious drug interactions (e.g., acetaminophen hepatotoxicity) and cancer drug resistance.  However, small-mol. targeting of this receptor has been difficult; to date, directed synthesis of a relatively specific PXR inhibitor has remained elusive.  Here we report the development and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(2,4-difluorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethanone (FLB-12)] that antagonizes the activated state of PXR with limited effects on other related nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor α, peroxisome proliferator-activated receptor γ, and mouse constitutive androstane receptor).  We investigated the toxicity and PXR antagonist effect of FLB-12 in vivo.  Compared with ketoconazole, a prototypical PXR antagonist, FLB-12 is significantly less toxic to hepatocytes.  FLB-12 significantly inhibits the PXR-activated loss of righting reflex to 2,2,2-tribromoethanol (Avertin) in vivo, abrogates PXR-mediated resistance to 7-ethyl-10-hydroxycamptothecin (SN-38) in colon cancer cells in vitro, and attenuates PXR-mediated acetaminophen hepatotoxicity in vivo.  Thus, relatively selective targeting of PXR by antagonists is feasible and warrants further investigation.  This class of agents is suitable for development as chem. probes of PXR function as well as potential PXR-directed therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKnTEY7zfXbVg90H21EOLACvtfcHk0lhh6SqpdCipFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFajt7c%253D&md5=7839fb7bcb50ca6aa0199f8bc4431f2b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071787%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCayer%26aufirst%3DJ.%26aulast%3DLeroux%26aufirst%3DM.%26aulast%3DSalvail%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DWrobel%26aufirst%3DJ.%2BE.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520characterization%2520of%2520a%2520first-in-class%2520novel%2520azole%2520analog%2520that%2520targets%2520pregnane%2520X%2520receptor%2520activation%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D1%26spage%3D124%26epage%3D135%26doi%3D10.1124%2Fmol.111.071787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">SPA70 is a potent antagonist of human pregnane X receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">741</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00780-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fs41467-017-00780-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28963450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FjvVGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=741&author=W.+Linauthor=Y.+M.+Wangauthor=S.+C.+Chaiauthor=L.+Lvauthor=J.+Zhengauthor=J.+Wuauthor=Q.+Zhangauthor=Y.+D.+Wangauthor=P.+R.+Griffinauthor=T.+Chen&title=SPA70+is+a+potent+antagonist+of+human+pregnane+X+receptor&doi=10.1038%2Fs41467-017-00780-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">SPA70 is a potent antagonist of human pregnane X receptor</span></div><div class="casAuthors">Lin Wenwei; Wang Yue-Ming; Chai Sergio C; Wu Jing; Chen Taosheng; Lv Lili; Zhang Qijun; Zheng Jie; Griffin Patrick R; Wang Yong-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">741</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many drugs bind to and activate human pregnane X receptor (hPXR) to upregulate drug-metabolizing enzymes, resulting in decreased drug efficacy and increased resistance.  This suggests that hPXR antagonists have therapeutic value.  Here we report that SPA70 is a potent and selective hPXR antagonist.  SPA70 inhibits hPXR in human hepatocytes and humanized mouse models and enhances the chemosensitivity of cancer cells, consistent with the role of hPXR in drug resistance.  Unexpectedly, SJB7, a close analog of SPA70, is an hPXR agonist.  X-ray crystallography reveals that SJB7 resides in the ligand-binding domain (LBD) of hPXR, interacting with the AF-2 helix to stabilize the LBD for coactivator binding.  Differential hydrogen/deuterium exchange analysis demonstrates that SPA70 and SJB7 interact with the hPXR LBD.  Docking studies suggest that the lack of the para-methoxy group in SPA70 compromises its interaction with the AF-2, thus explaining its antagonism.  SPA70 is an hPXR antagonist and promising therapeutic tool.The xenobiotic-activated human pregnane X receptor (hPXR) regulates drug metabolism.  Here the authors develop hPXR modulators, which are of potential therapeutic interest and functionally and structurally characterize the antagonist SPA70 and the structurally related agonist SJB7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKzRlR5ipxKZotVjB3IRIyfW6udTcc2eaKr4P_4t1hO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FjvVGhsQ%253D%253D&md5=e337c9ea0bacbf140ad9e899dd0eb264</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00780-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00780-5%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DSPA70%2520is%2520a%2520potent%2520antagonist%2520of%2520human%2520pregnane%2520X%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D741%26doi%3D10.1038%2Fs41467-017-00780-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span> <span> </span><span class="NLM_article-title">Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5332</span>– <span class="NLM_lpage">5340</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1158%2F1078-0432.CCR-08-1033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18765524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5332-5340&issue=17&author=D.+Guptaauthor=M.+Venkateshauthor=H.+Wangauthor=S.+Kimauthor=M.+Sinzauthor=G.+L.+Goldbergauthor=K.+Whitneyauthor=C.+Longleyauthor=S.+Mani&title=Expanding+the+roles+for+pregnane+X+receptor+in+cancer%3A+proliferation+and+drug+resistance+in+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-08-1033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer</span></div><div class="casAuthors">Gupta, Divya; Venkatesh, Madhukumar; Wang, Hongwei; Kim, Sean; Sinz, Michael; Goldberg, Gary L.; Whitney, Kathleen; Longley, Clifford; Mani, Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5332-5340</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We examd. the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand.  SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quant. reverse transcription-PCR and Western blot.  Human ovarian cancer tissue was also analyzed for PXR expression by immunochem.  Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quant. reverse transcription-PCR.  SKOV-3 cell proliferation was assessed by MTT assay.  In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts.  PXR is expressed in ovarian cancer cells.  In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2.  PXR activation in SKOV-3 cells induces cell proliferation and drug resistance.  In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth.  PXR activation, regardless of the type of ligand agonist present, promotes the "malignant" phenotype of cancer cells.  These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUEdc9ePco7Vg90H21EOLACvtfcHk0lhh6SqpdCipFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsb3M&md5=b55a327dd9111dd3065bb153ccf97e92</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1033%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DG.%2BL.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DMani%26aufirst%3DS.%26atitle%3DExpanding%2520the%2520roles%2520for%2520pregnane%2520X%2520receptor%2520in%2520cancer%253A%2520proliferation%2520and%2520drug%2520resistance%2520in%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D17%26spage%3D5332%26epage%3D5340%26doi%3D10.1158%2F1078-0432.CCR-08-1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rigalli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocchetti, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold-Mende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span> <span> </span><span class="NLM_article-title">The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e0193242</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0193242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0193242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29470550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12qtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=2&author=J.+P.+Rigalliauthor=M.+Reichelauthor=T.+Reuterauthor=G.+N.+Tocchettiauthor=G.+Dyckhoffauthor=C.+Herold-Mendeauthor=D.+Theileauthor=J.+Weiss&title=The+pregnane+X+receptor+%28PXR%29+and+the+nuclear+receptor+corepressor+2+%28NCoR2%29+modulate+cell+growth+in+head+and+neck+squamous+cell+carcinoma&doi=10.1371%2Fjournal.pone.0193242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Rigalli, Juan Pablo; Reichel, Matthias; Reuter, Tasmin; Tocchetti, Guillermo Nicolas; Dyckhoff, Gerhard; Herold-Mende, Christel; Theile, Dirk; Weiss, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0193242/1-e0193242/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide.  The pregnane X receptor (PXR) is a nuclear receptor regulating several target genes assocd. with cancer malignancy.  We here demonstrated a significant effect of PXR on HNSCC cell growth, as evidenced in PXR knock-down expts.  PXR transcriptional activity is more importantly regulated by the presence of coactivators and corepressors than by PXR protein expression.  To date, there is scarce information on the regulation of PXR in HNSCC and on its role in the pathogenesis of this disease.  Coactivator and corepressor expression was screened through qRT-PCR in 8 HNSCC cell lines and correlated to PXR activity, detd. by using a reporter gene assay.  All cell lines considerably expressed all the cofactors assessed.  PXR activity neg. correlated with nuclear receptor corepressor 2 (NCoR2) expression, indicating a major role of this corepressor in PXR modulation and suggesting its potential as a surrogate for PXR activity in HNSCC.  To test the assocn. of NCoR2 with the malignant phenotype, a subset of three cell lines was transfected with an over-expression plasmid for this corepressor.  Subsequently, cell growth and chemoresistance assays were performed.  To elucidate the mechanisms underlying NCoR2 effects on cell growth, caspase 3/7 activity and protein levels of cleaved caspase 3 and PARP were evaluated.  In HNO97 cells, NCoR2 over-expression decreased cell growth, chemoresistance and increased cleaved caspase 3 levels, caspase activity and cleaved PARP levels.  On the contrary, in HNO124 and HNO210 cells, NCoR2 over-expression increased cell growth, drug resistance and decreased cleaved caspase 3 levels, caspase activity and cleaved PARP levels.  In conclusion, we demonstrated a role of PXR and NCoR2 in the modulation of cell growth in HNSCC.  This may contribute to a better understanding of the highly variable HNSCC therapeutic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GBIiOo3b07Vg90H21EOLACvtfcHk0lj9yevPXDKjdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12qtrnK&md5=d5713cab5808d1f9970e6a315c0cedc3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0193242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0193242%26sid%3Dliteratum%253Aachs%26aulast%3DRigalli%26aufirst%3DJ.%2BP.%26aulast%3DReichel%26aufirst%3DM.%26aulast%3DReuter%26aufirst%3DT.%26aulast%3DTocchetti%26aufirst%3DG.%2BN.%26aulast%3DDyckhoff%26aufirst%3DG.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DJ.%26atitle%3DThe%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520and%2520the%2520nuclear%2520receptor%2520corepressor%25202%2520%2528NCoR2%2529%2520modulate%2520cell%2520growth%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D2%26doi%3D10.1371%2Fjournal.pone.0193242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veech, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelboin, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span> <span> </span><span class="NLM_article-title">Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1210/mend-1-8-542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fmend-1-8-542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=3153476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL1cXjsFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1987&pages=542-547&issue=8&author=B.+J.+Songauthor=T.+Matsunagaauthor=J.+P.+Hardwickauthor=S.+S.+Parkauthor=R.+L.+Veechauthor=C.+S.+Yangauthor=H.+V.+Gelboinauthor=F.+J.+Gonzalez&title=Stabilization+of+cytochrome+P450j+messenger+ribonucleic+acid+in+the+diabetic+rat&doi=10.1210%2Fmend-1-8-542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat</span></div><div class="casAuthors">Song, Byung J.; Matsunaga, Tamihide; Hardwick, James P.; Park, Sang S.; Veech, Richard L.; Yang, Chung S.; Gelboin, Harry V.; Gonzalez, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">542-7</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    </div><div class="casAbstract">In streptozotocin-diabetic rats, marked increases in both cytochrome P 450j and its mRNA were obsd. in liver, lung, and kidney.  The increases in P 450j mRNA were due to specific mRNA stabilization, a mechanism which is clearly distinct from the induction mechanism elicited by either acetone or ethanol administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo53DtN2wFybVg90H21EOLACvtfcHk0lj9yevPXDKjdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXjsFOkuw%253D%253D&md5=968d99149e2cd9b2468fcb2a67ce3923</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1210%2Fmend-1-8-542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend-1-8-542%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DB.%2BJ.%26aulast%3DMatsunaga%26aufirst%3DT.%26aulast%3DHardwick%26aufirst%3DJ.%2BP.%26aulast%3DPark%26aufirst%3DS.%2BS.%26aulast%3DVeech%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BS.%26aulast%3DGelboin%26aufirst%3DH.%2BV.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26atitle%3DStabilization%2520of%2520cytochrome%2520P450j%2520messenger%2520ribonucleic%2520acid%2520in%2520the%2520diabetic%2520rat%26jtitle%3DMol.%2520Endocrinol.%26date%3D1987%26volume%3D1%26issue%3D8%26spage%3D542%26epage%3D547%26doi%3D10.1210%2Fmend-1-8-542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrighton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)84558-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0021-9258%2819%2984558-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=3486184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL28Xit1altLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=6264-2671&issue=14&author=P.+B.+Watkinsauthor=S.+A.+Wrightonauthor=E.+G.+Schuetzauthor=P.+Maurelauthor=P.+S.+Guzelian&title=Macrolide+antibiotics+inhibit+the+degradation+of+the+glucocorticoid-responsive+cytochrome+P-450p+in+rat+hepatocytes+in+vivo+and+in+primary+monolayer+culture&doi=10.1016%2FS0021-9258%2819%2984558-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture</span></div><div class="casAuthors">Watkins, Paul B.; Wrighton, Steven A.; Schuetz, Erin G.; Maurel, Patrick; Guzelian, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6264-71</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">To investigate the mechanism of induction of cytochrome P-450p, rats were treated for 4 days with the macrolide antibiotic triacetyloleandomycin (TAO) and dexamethasone (I).  I and TAO induced the synthesis of P-450p ≤70- and 35-fold over control values, resp., as estd. from measurements of P-450p mRNA translatable in a cell-free system.  However, the accumulation of P-450p holocytochrome (measured as the TAO-metabolite spectral complex) or P-450p protein (measured by quant. immunoblotting) was increased ≤150-fold by TAO but only 32-fold by I.  The possibility that TAO decreases the degrdn. of P-450p was supported by the observation that administration of TAO to I-treated rats labeled with NaH14CO3 and δ-[3H]aminolevulinic acid retarded the decay of radioactive immunoprecipitable P-450p protein (half-time = 60 vs. 14 h) and heme = 73 vs. 10 h).  To confirm these results, P-450p protein synthesis was measured as radioactivity incorporated into immunoprecipitable P-450p in primary monolayer cultures of adult rat hepatocytes incubated with [3H]leucine.  I treatment of the cultures stimulated P-450p synthesis by ≤30-fold, whereas macrolides were without effect.  However, macrolide antibiotics but not I inhibited the disappearance of radiolabeled P-450p from cultured hepatocytes similar to the results obtained in vivo.  Thus, macrolide antibiotics induced P-450p, the most rapidly turning over cytochrome yet reported by stimulating its synthesis indirectly and by blocking its degrdn. significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_PjmI9eH0rVg90H21EOLACvtfcHk0lj9yevPXDKjdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xit1altLk%253D&md5=fab2afd10b0e3d3a5c3176bbb829a754</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2984558-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252984558-1%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DMaurel%26aufirst%3DP.%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26atitle%3DMacrolide%2520antibiotics%2520inhibit%2520the%2520degradation%2520of%2520the%2520glucocorticoid-responsive%2520cytochrome%2520P-450p%2520in%2520rat%2520hepatocytes%2520in%2520vivo%2520and%2520in%2520primary%2520monolayer%2520culture%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26issue%3D14%26spage%3D6264%26epage%3D2671%26doi%3D10.1016%2FS0021-9258%2819%2984558-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2010.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.addr.2010.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20727377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGitr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=1238-1249&issue=13&author=A.+H.+Tolsonauthor=H.+Wang&title=Regulation+of+drug-metabolizing+enzymes+by+xenobiotic+receptors%3A+PXR+and+CAR&doi=10.1016%2Fj.addr.2010.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR</span></div><div class="casAuthors">Tolson, Antonia H.; Wang, Hongbing</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug-metabolizing enzymes (DMEs) and transporters play pivotal roles in the disposition and detoxification of numerous foreign and endogenous chems.  To accommodate chem. challenges, the expression of many DMEs and transporters is up-regulated by a group of ligand-activated transcription factors namely nuclear receptors (NRs).  The importance of NRs in xenobiotic metab. and clearance is best exemplified by the most promiscuous xenobiotic receptors: pregnane X receptor (PXR, NR1I2) and constitutive androstane/activated receptor (CAR, NR1I3).  Together, these 2 receptors govern the inductive expression of a largely overlapping array of target genes encoding phase I and II DMEs, and drug transporters.  Moreover, PXR and CAR also represent 2 distinctive mechanisms of NR activation, whereby CAR demonstrates both constitutive and ligand-independent activation.  In this review, recent advances in our understanding of PXR and CAR as xenosensors are discussed with emphasis placed on the differences rather than similarities of these 2 xenobiotic receptors in ligand recognition and target gene regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7BWMbiPTmTrVg90H21EOLACvtfcHk0lj-ehmblCQg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGitr7E&md5=facfa8122514e1535362784fa41156c6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DTolson%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520drug-metabolizing%2520enzymes%2520by%2520xenobiotic%2520receptors%253A%2520PXR%2520and%2520CAR%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2010%26volume%3D62%26issue%3D13%26spage%3D1238%26epage%3D1249%26doi%3D10.1016%2Fj.addr.2010.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hakkola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 induction and xeno-sensing receptors pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor alpha at the crossroads of toxicokinetics and toxicodynamics</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">S5</span>),  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1111/bcpt.13004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1111%2Fbcpt.13004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29527807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFWgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=42-50&issue=S5&author=J.+Hakkolaauthor=C.+Bernasconiauthor=S.+Coeckeauthor=L.+Richertauthor=T.+B.+Anderssonauthor=O.+Pelkonen&title=Cytochrome+P450+induction+and+xeno-sensing+receptors+pregnane+X+receptor%2C+constitutive+androstane+receptor%2C+aryl+hydrocarbon+receptor+and+peroxisome+proliferator-activated+receptor+alpha+at+the+crossroads+of+toxicokinetics+and+toxicodynamics&doi=10.1111%2Fbcpt.13004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics</span></div><div class="casAuthors">Hakkola, Jukka; Bernasconi, Camilla; Coecke, Sandra; Richert, Lysiane; Andersson, Tommy B.; Pelkonen, Olavi</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">S5</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pregnane X receptor (PXR), constitutive androstane receptor (CAR), aryl hydrocarbon receptor (AHR) and peroxisome proliferator-activated receptor α (PPARα) are ligand-activated transcription factors that regulate expression of many xenobiotic-metabolizing enzymes including several cytochrome P 450 (CYP) enzymes.  Many xenobiotics induce CYP enzymes through these intracellular receptors and consequently affect toxicokinetics and possible metabolic activation of the receptor ligands and other xenobiotics utilizing similar metabolic pathways.  However, it is now apparent that the xenobiotic receptors regulate also many endogenous functions and signalling pathways, and xenobiotic exposure thus may dysregulate an array of fundamental cell functions.  This MiniReview surveys and discusses the multifaceted roles of xenobiotic receptors, for which CYP induction may serve as the first alert and possibly a biomarker for exposure to xenobiotics.  With the current emergence of the adverse outcome pathway (AOP) concept, these receptors are being and will be assigned as mol. initiating events or key events in numerous discrete toxicity pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvRj8tUem0krVg90H21EOLACvtfcHk0lj-ehmblCQg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFWgu7o%253D&md5=d85ffb14d36b0566608bbd57cada812d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.13004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.13004%26sid%3Dliteratum%253Aachs%26aulast%3DHakkola%26aufirst%3DJ.%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DCoecke%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DPelkonen%26aufirst%3DO.%26atitle%3DCytochrome%2520P450%2520induction%2520and%2520xeno-sensing%2520receptors%2520pregnane%2520X%2520receptor%252C%2520constitutive%2520androstane%2520receptor%252C%2520aryl%2520hydrocarbon%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor%2520alpha%2520at%2520the%2520crossroads%2520of%2520toxicokinetics%2520and%2520toxicodynamics%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2018%26volume%3D123%26issue%3DS5%26spage%3D42%26epage%3D50%26doi%3D10.1111%2Fbcpt.13004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. S.</span></span> <span> </span><span class="NLM_article-title">Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10–11</span>),  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1080/00498250701534893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F00498250701534893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17968743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ahu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=1196-1224&issue=10%E2%80%9311&author=N.+J.+Hewittauthor=E.+L.+Lecluyseauthor=S.+S.+Ferguson&title=Induction+of+hepatic+cytochrome+P450+enzymes%3A+methods%2C+mechanisms%2C+recommendations%2C+and+in+vitro-in+vivo+correlations&doi=10.1080%2F00498250701534893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations</span></div><div class="casAuthors">Hewitt, N. J.; Lecluyse, E. L.; Ferguson, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10/11</span>),
    <span class="NLM_cas:pages">1196-1224</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Induction of drug-clearance pathways (Phase 1 and 2 enzymes and transporters) can have important clin. consequences.  Inducers can (1) increase the clearance of other drugs, resulting in a decreased therapeutic effect, (2) increase the activation of pro-drugs, causing an alteration in their efficacy and pharmacokinetics, and (3) increase the bioactivation of drugs that contribute to hepatotoxicity via reactive intermediates.  Nuclear receptors are key mediators of drug-induced changes in the expression of drug-clearance pathways.  However, species differences in nuclear receptor activation make the prediction of cytochrome P 450 (CYP) induction in humans from data derived from animal models problematic.  Thus, in vitro human-relevant model systems are increasingly used to evaluate enzyme induction.  In this review, the authors' current understanding of the mechanisms of enzyme induction and the in vitro methods for assessing the induction potential of new drugs will be discussed.  Relevant issues and considerations surrounding proper study design and the interpretation of in vitro results will be discussed in light of the current US Food and Drug Administration (FDA) recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhMI6NCTa3K7Vg90H21EOLACvtfcHk0lj-ehmblCQg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ahu7vL&md5=b663184b1d69bf228dc543f6df0a665e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1080%2F00498250701534893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701534893%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DN.%2BJ.%26aulast%3DLecluyse%26aufirst%3DE.%2BL.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26atitle%3DInduction%2520of%2520hepatic%2520cytochrome%2520P450%2520enzymes%253A%2520methods%252C%2520mechanisms%252C%2520recommendations%252C%2520and%2520in%2520vitro-in%2520vivo%2520correlations%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26issue%3D10%25E2%2580%259311%26spage%3D1196%26epage%3D1224%26doi%3D10.1080%2F00498250701534893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1002/bdd.2212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbdd.2212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31778578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvVWlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3-31&issue=1%E2%80%932&author=C.+Luauthor=L.+Di&title=In+vitro+and+in+vivo+methods+to+assess+pharmacokinetic+drug-+drug+interactions+in+drug+discovery+and+development&doi=10.1002%2Fbdd.2212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development</span></div><div class="casAuthors">Lu, Chuang; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-31</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-drug interactions (DDIs) caused by the co-administration of multiple drugs are major safety concerns in the clinic.  Several drugs have been withdrawn from the market due to perpetrator or victim DDIs.  Strategies have been developed to assess DDI risks early in drug discovery to reduce DDI liabilities.  High-to-medium throughput assays are available to identify undesirable scaffolds and to guide structural modifications to minimize DDIs.  Definitive methods are used at later stages of drug discovery and development to provide a more accurate measurement of DDI parameters and to enable clin. translations.  Physiol. based pharmacokinetic modeling and simulations are powerful tools to accurately predict DDIs and to assess risks in the clinic.  Although significant advances have been made over the years, many challenges remain for clin. DDI translations.  This includes DDIs involving non-cytochrome P 450 enzymes, transporters, enzyme-transporter interplay, indirect effects from biologics, and pharmacodynamic based DDI.  This review focuses on methods that are used to assess hepatic DDIs caused by enzyme inhibition and induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGre3eY_7Kg7Vg90H21EOLACvtfcHk0liDqzapGw7sgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvVWlsg%253D%253D&md5=9b07ed3f32112f7ae9393369a290ed2b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2212%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520methods%2520to%2520assess%2520pharmacokinetic%2520drug-%2520drug%2520interactions%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2020%26volume%3D41%26issue%3D1%25E2%2580%25932%26spage%3D3%26epage%3D31%26doi%3D10.1002%2Fbdd.2212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span> <span> </span><span class="NLM_article-title">Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1517/17460441003762717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17460441003762717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22823132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=491-511&issue=5&author=M.+Honmaauthor=M.+Kozawaauthor=H.+Suzuki&title=Methods+for+the+quantitative+evaluation+and+prediction+of+CYP+enzyme+induction+using+human+in+vitro+systems&doi=10.1517%2F17460441003762717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems</span></div><div class="casAuthors">Honma, Masashi; Kozawa, Masanari; Suzuki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">491-511</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  For successful drug development, it is important to investigate the potency of candidate drugs causing drug-drug interactions (DDI) during the early stages of development.  The most common mechanisms of DDIs are the inhibition and induction of CYP enzymes.  Therefore, it is important to develop compds. with lower potencies for CYP enzyme induction.  The aim of the present paper is to present an overview of the current knowledge of CYP induction mechanisms, particularly focusing on the transcriptional gene activation mediated by pregnane X receptor, aryl hydrocarbon receptor and constitutive androstane receptor.  The adoptable options of in vitro assay methods for evaluating CYP induction are also summarized.  Finally, we introduce a method for the quant. prediction of CYP3A4 induction considering the turnover of CYP3A4 mRNA and protein in hepatocytes based on the data obtained from a reporter gene assay.  In order to predict in vivo CYP enzyme induction quant. based on in vitro information, an understanding of the physiol. induction mechanisms and the features of each in vitro assay system is essential.  We also present the estn. method of in vivo CYP induction potency of each compd. based on the in vitro data which are routinely obtained but not necessarily utilized maximally in pharmaceutical companies.  It is desirable to select compds. with lower potencies for the inductive effect.  For this purpose, an accurate prioritization procedure to evaluate the induction potency of each compd. in a quant. manner considering the pharmacol. effective concn. of each compd. is necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcRC_9DT7Mw7Vg90H21EOLACvtfcHk0liDqzapGw7sgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFGktrc%253D&md5=c41f715a0b1a5b4ed3ca83d0f4746935</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1517%2F17460441003762717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441003762717%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DM.%26aulast%3DKozawa%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DMethods%2520for%2520the%2520quantitative%2520evaluation%2520and%2520prediction%2520of%2520CYP%2520enzyme%2520induction%2520using%2520human%2520in%2520vitro%2520systems%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26issue%3D5%26spage%3D491%26epage%3D511%26doi%3D10.1517%2F17460441003762717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.3109/03602532.2012.743560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F03602532.2012.743560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23330538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=3-14&issue=1&author=M.+W.+Sinz&title=Evaluation+of+pregnane+X+receptor+%28PXR%29-mediated+CYP3A4+drug-drug+interactions+in+drug+development&doi=10.3109%2F03602532.2012.743560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development</span></div><div class="casAuthors">Sinz, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The increased capacity to rapidly eliminate drugs can have a profound effect on the efficacious exposure of coadministered drugs, esp. in today's medical world of polypharmacy.  There are numerous drug-drug interactions (DDIs) related to a loss of therapeutic efficacy and many of these are caused by pregnane X receptor (PXR)-mediated transcriptional activation of drug-metabolizing enzymes or drug transporters.  Evaluation of PXR activation and subsequent induction of proteins involved in drug elimination and distribution have become routine in drug discovery and drug development.  The assays used to evaluate PXR directly are high throughput and provide useful information on the ability of a drug's potential to ppt. a DDI.  In addn., they may serve as useful tools to support structure-activity or structure-liability relationships to eliminate or minimize the potential of new drug candidates to cause induction and, ultimately, a DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdAO7aDGKoIrVg90H21EOLACvtfcHk0liDqzapGw7sgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaks7s%253D&md5=cd1309722b84b0e7781480a61258c329</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3109%2F03602532.2012.743560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2012.743560%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DEvaluation%2520of%2520pregnane%2520X%2520receptor%2520%2528PXR%2529-mediated%2520CYP3A4%2520drug-drug%2520interactions%2520in%2520drug%2520development%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2013%26volume%3D45%26issue%3D1%26spage%3D3%26epage%3D14%26doi%3D10.3109%2F03602532.2012.743560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1517/17425255.2013.754010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2013.754010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23327618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFehtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=253-266&issue=3&author=X.+Chaiauthor=S.+Zengauthor=W.+Xie&title=Nuclear+receptors+PXR+and+CAR%3A+implications+for+drug+metabolism+regulation%2C+pharmacogenomics+and+beyond&doi=10.1517%2F17425255.2013.754010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond</span></div><div class="casAuthors">Chai, Xiaojuan; Zeng, Su; Xie, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-266</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Orphan' nuclear receptors belong to the nuclear receptor (NR) superfamily of transcriptional factors.  Binding of ligands to these receptors results in the recruitment of the co-activators, thereby regulating the expression of cognate target genes.Areas covered: This review discusses the transcriptional regulation of P 450 genes by two major xenobiotic nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR).  Addnl. PXR and CAR target genes include those encoded for UDP-glucuronosyltransferases, glutathione S-transferases, sulfotransferases and drug transporters.  The authors discuss the involvement of PXR and CAR in endobiotic metab.  They also review the polymorphisms of PXR and CAR.Expert opinion: PXR and CAR are both xenobiotic and endobiotic receptors.  A remarkably diverse set of chems. can activate PXR and CAR.  There is significant cross-talk among xenobiotic receptors.  Future studies are needed to focus on the polymorphisms of the nuclear receptors and the complex regulatory networks among nuclear receptors.  Considerations should be given while designing PXR- or CAR-targeting pharmaceutics to avoid adverse drug effects.  In the meantime, due to the diverse functions of PXR and CAR, agonists or antagonists for these receptors may have therapeutic potentials in managing certain diseases and enhancing therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyEQ2FuTWDbVg90H21EOLACvtfcHk0liDqzapGw7sgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFehtL8%253D&md5=a78c158ec4e88e8eda90572259b1878e</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1517%2F17425255.2013.754010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2013.754010%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DW.%26atitle%3DNuclear%2520receptors%2520PXR%2520and%2520CAR%253A%2520implications%2520for%2520drug%2520metabolism%2520regulation%252C%2520pharmacogenomics%2520and%2520beyond%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3D253%26epage%3D266%26doi%3D10.1517%2F17425255.2013.754010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamuru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">Identification of clinically used drugs that activate pregnane X receptors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.110.035105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20966043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1eltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=151-159&issue=1&author=S.+J.+Shuklaauthor=S.+Sakamuruauthor=R.+Huangauthor=T.+A.+Moellerauthor=P.+Shinnauthor=D.+Vanleerauthor=D.+S.+Auldauthor=C.+P.+Austinauthor=M.+Xia&title=Identification+of+clinically+used+drugs+that+activate+pregnane+X+receptors&doi=10.1124%2Fdmd.110.035105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of clinically used drugs that activate pregnane X receptors</span></div><div class="casAuthors">Shukla, Sunita J.; Sakamuru, Srilatha; Huang, Ruili; Moeller, Timothy A.; Shinn, Paul; Van Leer, Danielle; Auld, Douglas S.; Austin, Christopher P.; Xia, Menghang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) binds xenobiotics and regulates the expression of several drug-metabolizing enzymes and transporters.  Human PXR (hPXR) activation and CYP3A4 induction can be involved in drug-drug interactions, resulting in reduced efficacy or increased toxicity.  However, there are known species-specific differences with regard to PXR activation that should be taken into account when animal PXR data are extrapolated to humans.  We profiled 2816 clin. used drugs from the National Institutes of Health Chem. Genomics Center Pharmaceutical Collection for their ability to activate hPXR and rat PXR (rPXR) at the cellular level, induce human CYP3A4 at the cellular level, and bind human PXR at the protein level.  From 6 to 11% of drugs were identified as active across the four assays, which included assay-specific and pan-active compds.  The lowest concordance was obsd. between the hPXR and rPXR assays, and many compds. active in both assays nonetheless demonstrated significant potency differences between species.  Anal. based on clustering potency values demonstrated the greatest activity correlation between the hPXR activation and CYP3A4 induction assays.  Structure-activity relationship anal. identified chem. scaffolds that were pan-active (e.g., dihydropyridine calcium channel blockers) and others that were uniquely active in individual assays (e.g., steroids and fatty acids).  These results provide important information on PXR activation by clin. used drugs, highlight the species specificity of PXR activation by xenobiotics, and provide a means of prioritizing compds. for follow-up studies and optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-L7_KIVyFbVg90H21EOLACvtfcHk0lj0XsaTeLg_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1eltQ%253D%253D&md5=a0798aafb8ecff60e0ce9de0aea2bfe3</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035105%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%2BJ.%26aulast%3DSakamuru%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DMoeller%26aufirst%3DT.%2BA.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DVanleer%26aufirst%3DD.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DXia%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520clinically%2520used%2520drugs%2520that%2520activate%2520pregnane%2520X%2520receptors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D1%26spage%3D151%26epage%3D159%26doi%3D10.1124%2Fdmd.110.035105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights of phenobarbital-mediated activation of human but not mouse Pregnane X Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1124/mol.119.116616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.119.116616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31436536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2019&pages=345-354&issue=3&author=L.+Liauthor=M.+A.+Welchauthor=Z.+Liauthor=B.+Mackowiakauthor=S.+Heywardauthor=P.+W.+Swaanauthor=H.+Wang&title=Mechanistic+insights+of+phenobarbital-mediated+activation+of+human+but+not+mouse+Pregnane+X+Receptor&doi=10.1124%2Fmol.119.116616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insights of phenobarbital-mediated activation of human but not mouse pregnane X receptor</span></div><div class="casAuthors">Li, Linhao; Welch, Matthew A.; Li, Zhihui; Mackowiak, Bryan; Heyward, Scott; Swaan, Peter W.; Wang, Hongbing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phenobarbital (PB), a broadly used antiseizure drug, was the first to be characterized as an inducer of cytochrome P 450 by activation of the constitutive androstane receptor (CAR).  Although PB is recognized as a conserved CAR activator among species via a well-documented indirect activation mechanism, conflicting results have been reported regarding PB regulation of the pregnane X receptor (PXR), a sister receptor of CAR, and the underlying mechanisms remain elusive.  Here, we show that in a human CAR (hCAR)-knockout (KO) HepaRG cell line, PB significantly induces the expression of CYP2B6 and CYP3A4, two shared target genes of hCAR and human PXR (hPXR).  In human primary hepatocytes and hCAR-KO HepaRG cells, PB-induced expression of CYP3A4 was markedly repressed by genetic knockdown or pharmacol. inhibition of hPXR.  Mechanistically, PB concn. dependently activates hPXR but not its mouse counterpart in cell-based luciferase assays.  Mammalian two-hybrid assays demonstrated that PB selectively increases the functional interaction between the steroid receptor coactivator-1 and hPXR but not mouse PXR.  Moreover, surface plasmon resonance binding affinity assay showed that PB directly binds to the ligand binding domain of hPXR (KD = 1.42 × 10-05).  Structure-activity anal. further revealed that the amino acid tryptophan-299 within the ligand binding pocket of hPXR plays a key role in the agonistic binding of PB and mutation of tryptophan-299 disrupts PB activation of hPXR.  Collectively, these data reveal that PB, a selective mouse CAR activator, activates both hCAR and hPXR, and provide novel mechanistic insights for PB-mediated activation of hPXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOWSbzsmNpObVg90H21EOLACvtfcHk0lj0XsaTeLg_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb3P&md5=29901e444d0457919178762d28521bf3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.116616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.116616%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWelch%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMackowiak%26aufirst%3DB.%26aulast%3DHeyward%26aufirst%3DS.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DMechanistic%2520insights%2520of%2520phenobarbital-mediated%2520activation%2520of%2520human%2520but%2520not%2520mouse%2520Pregnane%2520X%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2019%26volume%3D96%26issue%3D3%26spage%3D345%26epage%3D354%26doi%3D10.1124%2Fmol.119.116616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">30650</span>– <span class="NLM_lpage">30657</span>, <span class="refDoi"> DOI: 10.1074/jbc.M806132200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1074%2Fjbc.M806132200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18784074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWjtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=30650-30657&issue=45&author=W.+Linauthor=J.+Wuauthor=H.+Dongauthor=D.+Bouckauthor=F.+Y.+Zengauthor=T.+Chen&title=Cyclin-dependent+kinase+2+negatively+regulates+human+pregnane+X+receptor-mediated+CYP3A4+gene+expression+in+HepG2+liver+carcinoma+cells&doi=10.1074%2Fjbc.M806132200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent Kinase 2 Negatively Regulates Human Pregnane X Receptor-mediated CYP3A4 Gene Expression in HepG2 Liver Carcinoma Cells</span></div><div class="casAuthors">Lin, Wenwei; Wu, Jing; Dong, Hanqing; Bouck, David; Zeng, Fu-Yue; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">30650-30657</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) regulates the expression of crit. drug metab. enzymes.  One of such enzymes, cytochrome P 450 3A4 (CYP3A4), plays crit. roles in drug metab. in hepatocytes that are either quiescent or passing through the cell cycle.  It has been well established that the expression of P 450, such as CYP3A4, is markedly reduced during liver development or regeneration.  Numerous studies have implicated cellular signaling pathways in modulating the functions of nuclear receptors, including hPXR.  Here we report that inhibition of cyclin-dependent kinases (Cdks) by kenpaullone and roscovitine (two small mol. inhibitors of Cdks that we identified in a screen for compds. that activate hPXR) leads to activation of hPXR-mediated CYP3A4 gene expression in HepG2 human liver carcinoma cells.  Consistent with this finding, activation of Cdk2 attenuates the activation of CYP3A4 gene expression.  In vitro kinase assays revealed that Cdk2 directly phosphorylates hPXR.  A phosphomimetic mutation of a putative Cdk phosphorylation site, Ser350, significantly impairs the function of hPXR, whereas a phosphorylation-deficient mutation confers resistance to Cdk2.  Using HepG2 that has been stably transfected with hPXR and the CYP3A4-luciferase reporter, enriched in different phases of the cell cycle, we found that hPXR-mediated CYP3A4 expression is greatly reduced in the S phase.  Our results indicate for the first time that Cdk2 neg. regulates the activity of hPXR, and suggest an important role for Cdk2 in regulating hPXR activity and CYP3A4 expression in hepatocytes passing through the cell cycle, such as those in fetal or regenerating adult liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkgf2IueIC87Vg90H21EOLACvtfcHk0lj0XsaTeLg_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWjtL7N&md5=6251afac3aa0058f35e5cdce10892d42</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M806132200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M806132200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBouck%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DCyclin-dependent%2520kinase%25202%2520negatively%2520regulates%2520human%2520pregnane%2520X%2520receptor-mediated%2520CYP3A4%2520gene%2520expression%2520in%2520HepG2%2520liver%2520carcinoma%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D45%26spage%3D30650%26epage%3D30657%26doi%3D10.1074%2Fjbc.M806132200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.2174/138920006776873535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2174%2F138920006776873535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16724927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvV2mt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=375-388&issue=4&author=M.+Sinzauthor=S.+Kimauthor=Z.+Zhuauthor=T.+Chenauthor=M.+Anthonyauthor=K.+Dickinsonauthor=A.+D.+Rodrigues&title=Evaluation+of+170+xenobiotics+as+transactivators+of+human+pregnane+X+receptor+%28hPXR%29+and+correlation+to+known+CYP3A4+drug+interactions&doi=10.2174%2F138920006776873535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions</span></div><div class="casAuthors">Sinz, Michael; Kim, Sean; Zhu, Zhengrong; Chen, Taosheng; Anthony, Monique; Dickinson, Kenneth; Rodrigues, A. David</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-388</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The human transcription factor pregnane X receptor (hPXR) is a key regulator of enzyme expression, esp. cytochrome P 450 3A4 (CYP3A4).  Due to the prominence of CYP3A4 in the elimination of many drugs, the development of high throughput in vitro models to predict the effect of drugs on CYP3A4 expression have increased.  To better interpret and predict potential drug-drug interactions due to CYP3A4 enzyme induction, we evaluated 170 xenobiotics in a hPXR transactivation assay and compared these results to known clin. drug-drug interactions.  Of the 170 xenobiotics tested, 54% of them demonstrated some level of hPXR transactivation.  By taking into consideration cell culture conditions (soly., cytotoxicity, appropriate drug concn. in media), as well as in vivo pharmacokinetics (therapeutic plasma Cmax, distribution, route of administration, dosing regimen, liver exposure, potential to inhibit CYP3A4), the risk potential of CYP3A4 enzyme induction for most compds. reduced dramatically.  By employing this overall interpretation strategy, the final percentage of compds. predicted to significantly induce CYP3A4 reduced to 5%, all of which are known to cause drug-drug interactions.  Also, this is the first report that identifies several potent compds. that have the ability to transactivate hPXR that previously have not been identified, such as terbinafine, diclofenac, sildenafil, glimepiride, montelukast, and ticlopidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq33cLLzAqFhrVg90H21EOLACvtfcHk0ljFdAh0LWe_qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvV2mt7k%253D&md5=06bec83c4e3fdf78d19b7e636ff43694</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2174%2F138920006776873535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006776873535%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DAnthony%26aufirst%3DM.%26aulast%3DDickinson%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DEvaluation%2520of%2520170%2520xenobiotics%2520as%2520transactivators%2520of%2520human%2520pregnane%2520X%2520receptor%2520%2528hPXR%2529%2520and%2520correlation%2520to%2520known%2520CYP3A4%2520drug%2520interactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26issue%3D4%26spage%3D375%26epage%3D388%26doi%3D10.2174%2F138920006776873535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span> <span> </span><span class="NLM_article-title">Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bcp.2008.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18647599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSiur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=680-689&issue=5&author=X.+Cuiauthor=A.+Thomasauthor=V.+Gerlachauthor=R.+E.+Whiteauthor=R.+A.+Morrisonauthor=K.+C.+Cheng&title=Application+and+interpretation+of+hPXR+screening+data%3A+Validation+of+reporter+signal+requirements+for+prediction+of+clinically+relevant+CYP3A4+inducers&doi=10.1016%2Fj.bcp.2008.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers</span></div><div class="casAuthors">Cui, Xiaoming; Thomas, Ann; Gerlach, Valerie; White, Ronald E.; Morrison, Richard A.; Cheng, K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">680-689</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A human pregnane X receptor (PXR) reporter-gene assay was established and validated using 19 therapeutic agents known to be clin. CYP3A4 inducers, 5 clin. non-inducers, and 6 known inducers in human hepatocytes.  The extent of CYP3A4 induction (measured as RIF ratio in comparison to rifampicin) and EC50 was obtained from the dose-response curve.  All of the clin. inducers (19/19) and human hepatocyte inducers (6/6) showed pos. responses in the PXR assay.  One out of five clin. non-inducers, pioglitazone, also showed a pos. response.  An addnl. series of 18 commonly used drugs with no reports of clin. induction was also evaluated as putative neg. controls.  Sixteen of these were neg. (89%), whereas two of these, flutamide and haloperidol showed 16-fold (RIF ratio 0.79) and 10-fold (RIF ratio 0.48) maximal induction, resp. in the reporter-gene system.  Flutamide and haloperidol were further demonstrated to cause CYP3A4 induction in human cryopreserved hepatocytes based on testosterone 6β-hydroxylation activity.  The induction potential index calcd. based on the max. RIF ratio, EC50, and in vivo max. plasma concn. was used to predict the likelihood of CYP3A4 induction in humans.  When the induction potential index is greater than 0.08, the compd. is likely to cause induction in humans.  A high-throughput screening strategy was developed based on the validation results at 1 μM and 10 μM for the same set of drugs.  A RIF ratio of 0.4 was set as more practical screening cut-off to minimize the possibility of generating false positives.  Thus, a tiered approach was implemented to use the human PXR reporter-gene assay from early lead optimization to late lead characterization in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMv10iQqK5SrVg90H21EOLACvtfcHk0ljFdAh0LWe_qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSiur7N&md5=7f355b57cafc38b5348151d3d6a3bd2f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DX.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DGerlach%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26atitle%3DApplication%2520and%2520interpretation%2520of%2520hPXR%2520screening%2520data%253A%2520Validation%2520of%2520reporter%2520signal%2520requirements%2520for%2520prediction%2520of%2520clinically%2520relevant%2520CYP3A4%2520inducers%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26issue%3D5%26spage%3D680%26epage%3D689%26doi%3D10.1016%2Fj.bcp.2008.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span> <span> </span><span class="NLM_article-title">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.7.795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.30.7.795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12065438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=795-804&issue=7&author=G.+Luoauthor=M.+Cunninghamauthor=S.+Kimauthor=T.+Burnauthor=J.+Linauthor=M.+Sinzauthor=G.+Hamiltonauthor=C.+Rizzoauthor=S.+Jolleyauthor=D.+Gilbertauthor=A.+Downeyauthor=D.+Mudraauthor=R.+Grahamauthor=K.+Carrollauthor=J.+Xieauthor=A.+Madanauthor=A.+Parkinsonauthor=D.+Christauthor=B.+Sellingauthor=E.+LeCluyseauthor=L.+S.+Gan&title=CYP3A4+induction+by+drugs%3A+correlation+between+a+pregnane+X+receptor+reporter+gene+assay+and+CYP3A4+expression+in+human+hepatocytes&doi=10.1124%2Fdmd.30.7.795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span></div><div class="casAuthors">Luo, Gang; Cunningham, Mark; Kim, Sean; Burn, Tim; Lin, Jianrong; Sinz, Michael; Hamilton, Geraldine; Rizzo, Christopher; Jolley, Summer; Gilbert, Darryl; Downey, April; Mudra, Daniel; Graham, Richard; Carroll, Kathy; Xie, Jindong; Madan, Ajay; Parkinson, Andrew; Christ, Dave; Selling, Bernard; Lecluyse, Edward; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A4 (CYP3A4) is detd. typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity.  Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers.  To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR.  Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6β-hydroxylase activity.  Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technol./Northern blotting and Western blotting, resp.  In general, PXR activation correlated with the induction potential obsd. in human hepatocyte cultures.  Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.  Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity.  It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJw2uJawzuLVg90H21EOLACvtfcHk0lhAlvq_INSH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D&md5=0de8fb68ebce41eed8d634cff33fad20</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.7.795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.7.795%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DDowney%26aufirst%3DA.%26aulast%3DMudra%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DChrist%26aufirst%3DD.%26aulast%3DSelling%26aufirst%3DB.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DCYP3A4%2520induction%2520by%2520drugs%253A%2520correlation%2520between%2520a%2520pregnane%2520X%2520receptor%2520reporter%2520gene%2520assay%2520and%2520CYP3A4%2520expression%2520in%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26issue%3D7%26spage%3D795%26epage%3D804%26doi%3D10.1124%2Fdmd.30.7.795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otmani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.026526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.026526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19307295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslamu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1259-1268&issue=6&author=D.+F.+McGinnityauthor=G.+Zhangauthor=J.+R.+Kennyauthor=G.+A.+Hamiltonauthor=S.+Otmaniauthor=K.+R.+Stamsauthor=S.+Haneyauthor=P.+Brassilauthor=D.+M.+Stresserauthor=R.+J.+Riley&title=Evaluation+of+multiple+in+vitro+systems+for+assessment+of+CYP3A4+induction+in+drug+discovery%3A+human+hepatocytes%2C+pregnane+X+receptor+reporter+gene%2C+and+Fa2N-4+and+HepaRG+cells&doi=10.1124%2Fdmd.109.026526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells</span></div><div class="casAuthors">McGinnity, Dermot F.; Zhang, George; Kenny, Jane R.; Hamilton, Geraldine A.; Otmani, Sara; Stams, Karen R.; Haney, Suzzette; Brassil, Patrick; Stresser, David M.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prototypic CYP3A4 inducers were tested in a pregnane X receptor (PXR) reporter gene assay, Fa2N-4 cells, HepaRG cells, and primary human hepatocytes, along with neg. controls, using CYP3A4 mRNA and activity endpoints, where appropriate.  Over half of the compds. tested (14 of 24) were identified as time-dependent inhibitors of CYP3A4 and high mRNA/activity ratios (>10) were consistent with CYP3A4 time-dependent inhibition for compds. such as troleandomycin, ritonavir, and verapamil.  Induction response was compared between two human donors; there was an excellent correlation in the EC50 ests. (r2 = 0.89, p < 0.001), and a weak but statistically significant correlation was noted for max. obsd. induction at an optimum concn. (Emax) (r2 = 0.38, p = 0.001).  Emax and EC50 ests. detd. from the PXR reporter gene assay and Fa2N-4 and HepaRG cells were compared with those from hepatocytes.  Overall, EC50 values generated using hepatocytes agreed with those generated in the PXR reporter gene assay (r2 = 0.85, p < 0.001) and Fa2N-4 (r2 = 0.65, p < 0.001) and HepaRG (r2 = 0.99, p < 0.001) cells.  However, Emax values generated in hepatocytes were only significantly correlated to those detd. in Fa2N-4 (r2 = 0.33, p = 0.005) and HepaRG cells (r2 = 0.79, p < 0.001).  "Gold std." cytochrome P 450 induction data can be generated using primary human hepatocytes, but a restricted, erratic supply and interdonor variability somewhat restrict routine application within a drug discovery setting.  HepaRG cells are a valuable recent addn. to the armory of in vitro tools for assessing CYP3A4 induction and seem to be an excellent surrogate of primary cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_-PVv-4qN7Vg90H21EOLACvtfcHk0lhAlvq_INSH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslamu7k%253D&md5=206e3a4213127b750e7f27f2484eb082</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.026526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.026526%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DOtmani%26aufirst%3DS.%26aulast%3DStams%26aufirst%3DK.%2BR.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520multiple%2520in%2520vitro%2520systems%2520for%2520assessment%2520of%2520CYP3A4%2520induction%2520in%2520drug%2520discovery%253A%2520human%2520hepatocytes%252C%2520pregnane%2520X%2520receptor%2520reporter%2520gene%252C%2520and%2520Fa2N-4%2520and%2520HepaRG%2520cells%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26issue%3D6%26spage%3D1259%26epage%3D1268%26doi%3D10.1124%2Fdmd.109.026526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, Z.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1517/17425255.2016.1125881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2016.1125881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26612411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2rtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=169-174&issue=2&author=Z.+Dvorak&title=Opportunities+and+challenges+in+using+human+hepatocytes+in+cytochromes+P450+induction+assays&doi=10.1517%2F17425255.2016.1125881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays</span></div><div class="casAuthors">Dvorak, Zdenek</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-174</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Identification of inducers of xenobiotic-metabolizing cytochromes P 450 (CYP) is of topical interest.  The issue mainly concerns three sectors: (i) preclin. testing of drug candidates and testing existing drugs and their combinations; (ii) food safety applications with regard to additives, contaminants, and adulterants; (iii) environmental applications, comprising detection and identification of endocrine disruptors.: A literature search was performed using the PubMed database, covering state-of-the-art of human hepatocyte (HH) culture use, and their exploitation for the identification of P 450 inducers.  A list of CYP inducers identified by HHs is provided.: Primary cultures of HHs had long been considered as a gold std. for induction assays of xenobiotic-metabolizing enzymes.  Owing to several shortcomings of HHs, alternative approaches such as immortalization of HHs, use of cell lines, generation of clonal cell lines from HHs, use of induced pluripotent stem (iPS) cells, cells from humanized animals, etc., were employed.  While yielding particular advantage, overall, alternatives to HHs still remain an avenue for discrete applications or tech. situations.  Thus, HHs remain the most suitable model for complex CYP induction studies.  The summary may be effectively expressed by strength/weakness/opportunity/threats anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKOcaCfuyK7Vg90H21EOLACvtfcHk0lhAlvq_INSH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2rtLk%253D&md5=37e9415443b9abf65ad15c0452f4a311</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1517%2F17425255.2016.1125881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2016.1125881%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520using%2520human%2520hepatocytes%2520in%2520cytochromes%2520P450%2520induction%2520assays%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2016%26volume%3D12%26issue%3D2%26spage%3D169%26epage%3D174%26doi%3D10.1517%2F17425255.2016.1125881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of models for predicting drug-drug interactions due to induction</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1517/17425255.2010.516251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2010.516251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20955108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1399-1416&issue=11&author=O.+A.+Fahmiauthor=S.+L.+Ripp&title=Evaluation+of+models+for+predicting+drug-drug+interactions+due+to+induction&doi=10.1517%2F17425255.2010.516251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of models for predicting drug-drug interactions due to induction</span></div><div class="casAuthors">Fahmi, Odette A.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1399-1416</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs.  It is, therefore, important to understand a new compd.'s potential for enzyme induction and to understand how to use the induction data generated in vitro to predict potential for drug-drug interactions in vivo.  Areas covered in this review: Recent advances in methods for using in vitro data to predict potential for CYP3A induction in vivo are reviewed.  What the reader will gain: The reader will gain a comprehensive understanding of the advantages and disadvantages of various prediction methods for induction and be able to directly compare different methods using a common in vitro data set.  Take home message: The various methods for predicting clin. CYP3A induction from in vitro induction data all have demonstrated utility; it is the authors' opinion that the correlation-based approaches offer as good or better predictivity and have simpler input requirements than more complex approaches.  Of the different correlation approaches, the relatively simple unbound Cmax/EC50 or AUC/EC50 approaches are the simplest and yet show the best correlation to the obsd. clin. data.  While the approaches discussed herein represent an improvement in our understanding of the predictive value of in vitro induction data, it is important to recognize that there is still room for improvement in quant. prediction of magnitude of drug interactions due to induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLyowSf3OMrVg90H21EOLACvtfcHk0lhTEiRmRyNMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtbzN&md5=1b95f24bb423f019f8d2b349cc4af592</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.516251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.516251%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520models%2520for%2520predicting%2520drug-drug%2520interactions%2520due%2520to%2520induction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26issue%3D11%26spage%3D1399%26epage%3D1416%26doi%3D10.1517%2F17425255.2010.516251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohutsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyser, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span> <span> </span><span class="NLM_article-title">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.081927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.118.081927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29959133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGgt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1285-1303&issue=9&author=J.+R.+Kennyauthor=D.+Ramsdenauthor=D.+B.+Buckleyauthor=S.+Dallasauthor=C.+Fungauthor=M.+Mohutskyauthor=H.+J.+Einolfauthor=L.+Chenauthor=J.+G.+Dekeyserauthor=M.+Fitzgeraldauthor=T.+C.+Goosenauthor=Y.+A.+Siuauthor=R.+L.+Walskyauthor=G.+Zhangauthor=D.+Tweedieauthor=N.+Hariparsad&title=Considerations+from+the+innovation+and+quality+induction+working+group+in+response+to+drug-drug+interaction+guidances+from+regulatory+agencies%3A+focus+on+CYP3A4+mRNA+in+vitro+response+thresholds%2C+variability%2C+and+clinical+relevance&doi=10.1124%2Fdmd.118.081927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance</span></div><div class="casAuthors">Kenny, Jane R.; Ramsden, Diane; Buckley, David B.; Dallas, Shannon; Fung, Conrad; Mohutsky, Michael; Einolf, Heidi J.; Chen, Liangfu; Dekeyser, Joshua G.; Fitzgerald, Maria; Goosen, Theunis C.; Siu, Y. Amy; Walsky, Robert L.; Zhang, George; Tweedie, Donald; Hariparsad, Niresh</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1303,S1-S63</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Innovation and Quality Induction Working Group presents an assessment of best practice for data interpretation of in vitro induction, specifically, response thresholds, variability, application of controls, and translation to clin. risk assessment with focus on CYP3A4 mRNA.  Clin. CYP3A induction and in vitro data were gathered for 51 compds., 16 of which were proprietary.  A large degree of variability was obsd. in both the clin. and in vitro induction responses; however, anal. confirmed in vitro data are able to predict clin. induction risk.  Following extensive examn. of this large data set, the following recommendations are proposed. a) Cytochrome P 450 induction should continue to be evaluated in three sep. human donors in vitro. b) In light of empirically divergent responses in rifampicin control and most test inducers, normalization of data to percent pos. control appears to be of limited benefit. c) With concn. dependence, 2-fold induction is an acceptable threshold for pos. identification of in vitro CYP3A4 mRNA induction. d) To reduce the risk of false positives, in the absence of a concn.-dependent response, induction = 2-fold should be obsd. in more than one donor to classify a compd. as an in vitro inducer. e) If qualifying a compd. as neg. for CYP3A4 mRNA induction, the magnitude of maximal rifampicin response in that donor should be = 10-fold. f) Inclusion of a neg. control adds no value beyond that of the vehicle control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n28E_4a3zrVg90H21EOLACvtfcHk0lhTEiRmRyNMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGgt77P&md5=c81560dc8914cae6f51ef72216d4cc21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.081927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.081927%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DDallas%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DC.%26aulast%3DMohutsky%26aufirst%3DM.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDekeyser%26aufirst%3DJ.%2BG.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DSiu%26aufirst%3DY.%2BA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHariparsad%26aufirst%3DN.%26atitle%3DConsiderations%2520from%2520the%2520innovation%2520and%2520quality%2520induction%2520working%2520group%2520in%2520response%2520to%2520drug-drug%2520interaction%2520guidances%2520from%2520regulatory%2520agencies%253A%2520focus%2520on%2520CYP3A4%2520mRNA%2520in%2520vitro%2520response%2520thresholds%252C%2520variability%252C%2520and%2520clinical%2520relevance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D9%26spage%3D1285%26epage%3D1303%26doi%3D10.1124%2Fdmd.118.081927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. E.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1517/17425255.2015.1013095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1517%2F17425255.2015.1013095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25659570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFymt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=557-572&issue=4&author=R.+J.+Rileyauthor=C.+E.+Wilson&title=Cytochrome+P450+time-dependent+inhibition+and+induction%3A+advances+in+assays%2C+risk+analysis+and+modelling&doi=10.1517%2F17425255.2015.1013095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling</span></div><div class="casAuthors">Riley, Robert J.; Wilson, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">557-572</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: It is widely accepted that current practice of polypharmacy inevitably increases the incidence of drug-drug interactions (DDIs).  Serious DDIs are a major liability for new mol. entities entering the pharmaceutical market.  Various strategies are employed to avoid problematic compds. for clin. development.  Progress made with reversible CYP DDIs has prompted a switch to study and model time-dependent inhibition and induction interactions.  Areas covered: An overview of popular exptl. practices is presented with discussion of techniques and algorithms used to analyze the clin. DDI risk.  Emphasis is placed on the transition from early, simple static equations, via more complex net mechanistic, static models to dynamic approaches involving multiple perpetrators and metabolites, simultaneous inhibition and induction.  Expert opinion: Inclusion of the more conservative terms for parameters required for DDI evaluation may eliminate promising chem. space, encourages poor practice and hampers innovation.  Breakthroughs have originated from understanding of 'outliers' from such analyses where CYP enzyme-transporter interplay may be involved.  The role of key transporters in drug disposition is firmly established as the chem. required to address new targets deviates from traditional 'drug-like' space.  Attempts to model more complex interactions for substrates of both CYP enzymes and drug transporters are still in their infancy and will benefit from dynamic modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphH0w3CLvVl7Vg90H21EOLACvtfcHk0lhTEiRmRyNMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFymt7s%253D&md5=93a365fa067fe4da49442401bacc575f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1013095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1013095%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DWilson%26aufirst%3DC.%2BE.%26atitle%3DCytochrome%2520P450%2520time-dependent%2520inhibition%2520and%2520induction%253A%2520advances%2520in%2520assays%252C%2520risk%2520analysis%2520and%2520modelling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26issue%3D4%26spage%3D557%26epage%3D572%26doi%3D10.1517%2F17425255.2015.1013095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadie-Viollon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantion, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coassolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2009.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tiv.2009.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19497360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyktLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=346-356&issue=1&author=C.+Abadie-Viollonauthor=H.+Martinauthor=N.+Blanchardauthor=D.+Pekthongauthor=P.+Bachellierauthor=G.+Mantionauthor=B.+Heydauthor=F.+Schulerauthor=P.+Coassoloauthor=E.+Alexandreauthor=L.+Richert&title=Follow-up+to+the+pre-validation+of+a+harmonised+protocol+for+assessment+of+CYP+induction+responses+in+freshly+isolated+and+cryopreserved+human+hepatocytes+with+respect+to+culture+format%2C+treatment%2C+positive+reference+inducers+and+incubation+conditions&doi=10.1016%2Fj.tiv.2009.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions</span></div><div class="casAuthors">Abadie-Viollon, Catherine; Martin, Helene; Blanchard, Nadege; Pekthong, Dumrongsak; Bachellier, Philippe; Mantion, Georges; Heyd, Bruno; Schuler, Frantz; Coassolo, Philippe; Alexandre, Eliane; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology in Vitro</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">346-356</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors have compared induction responses of human hepatocytes to known inducers of CYP1A2, CYP2B6, CYP2C and CYP3A4/5 to det. whether the culture format, treatment regimen and/or substrate incubation conditions affected the outcome.  CYP induction responses to prototypical inducers were equiv. regardless of pre-culture time (24 h or 48 h), plate format (60 mm or 24-well plates) used or whether CYP activities were measured in microsomes or whole cell monolayers.  Fold-induction of CYP3A4/5 by 1000 μM PB and 10 μM RIF were equiv.  In contrast, the fold-induction of CYP2B6 by PB was 3-fold higher that by 10 μM RIF.  In addn. to inducing CYP1A2, 50 μM OME also induced CYP3A4/5 in 50% of the donors tested.  CYP2B6 was induced in 14 out of 21 donors by BNF; however CYP3A4/5 was unaffected by BNF in these donors.  To confirm that donor-to-donor variation was not due to inter-lab. differences, the induction responses of 5 different batches of cryopreserved human hepatocytes were compared in two different labs.  The induction of CYP1A2, CYP2B6 and CYP3A4 measured in the authors' lab. were equiv. to those obtained by the com. companies, proving good between-lab. reproducibility.  In conclusion, there is some flexibility in the treatment and incubation protocols for classical CYP induction assays on human hepatocytes.  Both RIF and PB are suitable pos. control inducers of CYP3A4/5 but PB may be more appropriate for CYP2B6 induction.  BNF may be more appropriate for CYP1A2 induction than OME since, in contrast to the latter, it does not induce CYP3A4.  Induction responses using hepatocytes from the same donor but in different labs can be expected to be similar.  The good reproducibility of induction responses between labs. using cryopreserved hepatocytes underlines the usefulness of these cells for these types of studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe9LzZ7UJbUbVg90H21EOLACvtfcHk0ljoHplRiit4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyktLrP&md5=7062b5e142fa391020b2af68287780fd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2009.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2009.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DAbadie-Viollon%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DH.%26aulast%3DBlanchard%26aufirst%3DN.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DMantion%26aufirst%3DG.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DFollow-up%2520to%2520the%2520pre-validation%2520of%2520a%2520harmonised%2520protocol%2520for%2520assessment%2520of%2520CYP%2520induction%2520responses%2520in%2520freshly%2520isolated%2520and%2520cryopreserved%2520human%2520hepatocytes%2520with%2520respect%2520to%2520culture%2520format%252C%2520treatment%252C%2520positive%2520reference%2520inducers%2520and%2520incubation%2520conditions%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2010%26volume%3D24%26issue%3D1%26spage%3D346%26epage%3D356%26doi%3D10.1016%2Fj.tiv.2009.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desbans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.676693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F00498254.2012.676693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22515431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=968-979&issue=10&author=E.+Alexandreauthor=A.+Bazeauthor=C.+Parmentierauthor=C.+Desbansauthor=D.+Pekthongauthor=B.+Gerinauthor=C.+Wackauthor=P.+Bachellierauthor=B.+Heydauthor=J.+C.+Weberauthor=L.+Richert&title=Plateable+cryopreserved+human+hepatocytes+for+the+assessment+of+cytochrome+P450+inducibility%3A+experimental+condition-related+variables+affecting+their+response+to+inducers&doi=10.3109%2F00498254.2012.676693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers</span></div><div class="casAuthors">Alexandre, Eliane; Baze, Audrey; Parmentier, Celine; Desbans, Coraline; Pekthong, Dumrongsak; Gerin, Brigitte; Wack, Claudine; Bachellier, Philippe; Heyd, Bruno; Weber, Jean-Christophe; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">968-979</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The aim of the present study was to assess the stability of cryopreserved human hepatocytes over 5 years and to explore exptl. condition-related variables such as seeding d., culture matrix and medium, start and duration of treatment that could potentially affect the quality of cultures and their response to cytochrome P 450 (CYP) inducers.  63/125 Batches of cryopreserved human hepatocytes were plateable after thawing.  Of those, 17 batches showed reproducible recovery, viability, and plateability (< 5% intra-batch variability) ≤ 5 years.  When cultured in collagen home-coated 48-well plates at a seeding d. allowing 70% confluence, cryopreserved human hepatocytes display activities equiv. to fresh counterparts.  Their response to CYP inducers is maximal and equiv. to fresh counterpart for an incubation of 72 h starting at Day 2 or Day 3 after plating when cultured in modified Hepatocyte Maintenance Medium (HMM).  The no. of cryopreserved human hepatocytes can be further reduced by a cocktail of CYP substrates for the assessment of their inducibility.  Exptl. condition-related variables, such as seeding d., culture matrix and medium, start and duration of treatment, affecting the response of plateable thawed cryopreserved human hepatocytes to cytochrome P 450 inducers can be reduced by optimizing crit. steps of the protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojL5_gs2uBlbVg90H21EOLACvtfcHk0ljoHplRiit4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhs7rP&md5=349fd39f0ab0a8f626db248dc275f399</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.676693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.676693%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DParmentier%26aufirst%3DC.%26aulast%3DDesbans%26aufirst%3DC.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DWack%26aufirst%3DC.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DWeber%26aufirst%3DJ.%2BC.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DPlateable%2520cryopreserved%2520human%2520hepatocytes%2520for%2520the%2520assessment%2520of%2520cytochrome%2520P450%2520inducibility%253A%2520experimental%2520condition-related%2520variables%2520affecting%2520their%2520response%2520to%2520inducers%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D10%26spage%3D968%26epage%3D979%26doi%3D10.3109%2F00498254.2012.676693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, T.</span></span> <span> </span><span class="NLM_article-title">A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.028613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20699409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1912-1916&issue=11&author=N.+Kamiguchiauthor=E.+Aoyamaauthor=T.+Okudaauthor=T.+Moriwaki&title=A+96-well+plate+assay+for+CYP4503A+induction+using+cryopreserved+human+hepatocytes&doi=10.1124%2Fdmd.109.028613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes</span></div><div class="casAuthors">Kamiguchi, Naomi; Aoyama, Eiji; Okuda, Teruaki; Moriwaki, Toshiya</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1912-1916</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A reliable and practical CYP3A induction assay with cryopreserved human hepatocytes in a 96-well format was developed.  Various 96-well plates with different basement membrane were evaluated using prototypical inducers, rifampicin, phenytoin, and carbamazepine.  Thin-layer (TL) Matrigel was found to yield the highest basal and induced levels of CYP3A activity as detd. by testosterone 6β-hydroxylation.  Concn.-dependent CYP3A induction of rifampicin was reproducible with the EC50 values of 0.36 ± 0.28 μM from four batches of human hepatocytes using the 96-well plate with TL Matrigel.  The rank order of induction potency for nine inducers or noninducers at a concn. of 10 μM were well comparable among the multiple donors, by expressing the results as percentage of change compared with the pos. control, 10 μM rifampicin.  Cotreatment of avasimibe or efavirenz with 10 μM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.  From a comparison of induced CYP3A activities and gene expression levels, there were compds. that would cause induction of CYP3A4 mRNA but not activity, presumably due to their inhibitory effect on CYP3A activity.  The cotreatment assay of test compd. with rifampicin allows us to exclude the false-neg. results caused by the cytotoxicity and/or the mechanism-based inactivation, when the drug candidate's ability for CYP3A induction is evaluating the enzyme activity.  This 96-well plate assay, which is robust, reproducible, and convenient, has demonstrated the paramount applicability to the early drug discovery stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBoBVfUJb69LVg90H21EOLACvtfcHk0lgn-kk0oajErw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurrN&md5=b6d2b306c423f874e04557c2d7f8c855</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028613%26sid%3Dliteratum%253Aachs%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DAoyama%26aufirst%3DE.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DMoriwaki%26aufirst%3DT.%26atitle%3DA%252096-well%2520plate%2520assay%2520for%2520CYP4503A%2520induction%2520using%2520cryopreserved%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D11%26spage%3D1912%26epage%3D1916%26doi%3D10.1124%2Fdmd.109.028613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell’Aiera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, H.</span></span> <span> </span><span class="NLM_article-title">Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.719088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F00498254.2012.719088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23153057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=320-335&issue=4&author=B.+Gerinauthor=S.+Dell%E2%80%99Aieraauthor=L.+Richertauthor=S.+Smithauthor=H.+Chanteux&title=Assessment+of+cytochrome+P450+%281A2%2C+2B6%2C+2C9+and+3A4%29+induction+in+cryopreserved+human+hepatocytes+cultured+in+48-well+plates+using+the+cocktail+strategy&doi=10.3109%2F00498254.2012.719088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy</span></div><div class="casAuthors">Gerin, Brigitte; Dell'Aiera, Sylvie; Richert, Lysiane; Smith, Steven; Chanteux, Hugues</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-335</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. A fast, straightforward and cost-effective assay was validated for the assessment of CYP induction in cryopreserved human hepatocytes cultured in 48-well plates.  The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, resp.2.  Cryopreserved human hepatocytes were treated for 72 h with prototypical ref. inducers, β-naphthoflavone (25 μM), phenobarbital (500 μM) and rifampicin (10 μM) as pos. controls for CYP induction.  The use of a cocktail strategy has been validated and compared to the classical approach (single incubation).  The need of using phase II inhibitor (salicylamide) in CYP induction assay was also investigated.3.  By using three different batches of cryopreserved human hepatocytes and our conditions of incubations, we showed that there was no relevant drug-drug interaction using the cocktail strategy.  The same conclusions were obsd. when a broad range of enzyme activity has to be assessed (wide range of ref. inducers, i.e. EC50-Emax expt.).  In addn., the interassay reproducibility assessment showed that the day-to-day variability was minimal.4.  In summary, the study showed that the conditions used (probe substrates, concn. of probe substrate and time of incubation) for the cocktail approach were appropriate for investigations of CYP induction potential of new chem. entities.  In addn., it was also clear that the use of salicylamide in the incubation media was not mandatory and could generate drug-drug interactions.  For this reason, we recommend to not use salicylamide in CYP induction assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob8cySbzrBjbVg90H21EOLACvtfcHk0lgn-kk0oajErw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWnuro%253D&md5=42e8e42b784fc430c0c7753bfec0be4a</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.719088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.719088%26sid%3Dliteratum%253Aachs%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DDell%25E2%2580%2599Aiera%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DChanteux%26aufirst%3DH.%26atitle%3DAssessment%2520of%2520cytochrome%2520P450%2520%25281A2%252C%25202B6%252C%25202C9%2520and%25203A4%2529%2520induction%2520in%2520cryopreserved%2520human%2520hepatocytes%2520cultured%2520in%252048-well%2520plates%2520using%2520the%2520cocktail%2520strategy%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26issue%3D4%26spage%3D320%26epage%3D335%26doi%3D10.3109%2F00498254.2012.719088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilk-Zasadna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asturiol, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Vieira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coecke, S.</span></span> <span> </span><span class="NLM_article-title">Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2019.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tiv.2019.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31158489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=212-228&author=C.+Bernasconiauthor=O.+Pelkonenauthor=T.+B.+Anderssonauthor=J.+Stricklandauthor=I.+Wilk-Zasadnaauthor=D.+Asturiolauthor=T.+Coleauthor=R.+Liskaauthor=A.+Worthauthor=U.+Muller-Vieiraauthor=L.+Richertauthor=C.+Chesneauthor=S.+Coecke&title=Validation+of+in+vitro+methods+for+human+cytochrome+P450+enzyme+induction%3A+Outcome+of+a+multi-laboratory+study&doi=10.1016%2Fj.tiv.2019.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study</span></div><div class="casAuthors">Bernasconi, Camilla; Pelkonen, Olavi; Andersson, Tommy B.; Strickland, Judy; Wilk-Zasadna, Iwona; Asturiol, David; Cole, Thomas; Liska, Roman; Worth, Andrew; Muller-Vieira, Ursula; Richert, Lysiane; Chesne, Christophe; Coecke, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-228</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event assocd. with thyroid disruption, and a biomarker for toxicol. relevant nuclear receptor-mediated pathways.  This paper summarizes the results of a multi-lab. validation study of two in vitro methods that assess the potential of chems. to induce cytochrome P 450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4.  The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells.  The validation study was coordinated by the European Union Ref. Lab. for Alternatives to Animal Testing of the European Commission's Joint Research Center and involved a ring trial among six labs.  The reproducibility was assessed within and between labs. using a validation set of 13 selected chems. (known human inducers and non-inducers) tested under blind conditions.  The ability of the two methods to predict human CYP induction potential was assessed.  Chem. space anal. confirmed that the selected chems. are broadly representative of a diverse range of chems.  The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing.  Recommendations for the practical application of the two methods are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovbDBq4KT3YbVg90H21EOLACvtfcHk0lgn-kk0oajErw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsLbM&md5=3e7abd48790f1a27f97fd5b01d5cae5c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2019.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2019.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DStrickland%26aufirst%3DJ.%26aulast%3DWilk-Zasadna%26aufirst%3DI.%26aulast%3DAsturiol%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DT.%26aulast%3DLiska%26aufirst%3DR.%26aulast%3DWorth%26aufirst%3DA.%26aulast%3DMuller-Vieira%26aufirst%3DU.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DChesne%26aufirst%3DC.%26aulast%3DCoecke%26aufirst%3DS.%26atitle%3DValidation%2520of%2520in%2520vitro%2520methods%2520for%2520human%2520cytochrome%2520P450%2520enzyme%2520induction%253A%2520Outcome%2520of%2520a%2520multi-laboratory%2520study%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2019%26volume%3D60%26spage%3D212%26epage%3D228%26doi%3D10.1016%2Fj.tiv.2019.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilmant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanteux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depelchin, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhalluin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atienzar, F. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins</span>. <i>Cell Biol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s10565-011-9208-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs10565-011-9208-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22258563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=69-87&issue=2&author=H.+H.+Geretsauthor=K.+Tilmantauthor=B.+Gerinauthor=H.+Chanteuxauthor=B.+O.+Depelchinauthor=S.+Dhalluinauthor=F.+A.+Atienzar&title=Characterization+of+primary+human+hepatocytes%2C+HepG2+cells%2C+and+HepaRG+cells+at+the+mRNA+level+and+CYP+activity+in+response+to+inducers+and+their+predictivity+for+the+detection+of+human+hepatotoxins&doi=10.1007%2Fs10565-011-9208-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins</span></div><div class="casAuthors">Gerets, H. H. J.; Tilmant, K.; Gerin, B.; Chanteux, H.; Depelchin, B. O.; Dhalluin, S.; Atienzar, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-87</span>CODEN:
                <span class="NLM_cas:coden">CBTOE2</span>;
        ISSN:<span class="NLM_cas:issn">0742-2091</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In the pharmaceutical industry, improving the early detection of drug-induced hepatotoxicity is essential as it is one of the most important reasons for attrition of candidate drugs during the later stages of drug development.  The first objective of this study was to better characterize different cellular models (i.e., HepG2, HepaRG cells, and fresh primary human hepatocytes) at the gene expression level and analyze their metabolic cytochrome P 450 capabilities.  The cellular models were exposed to three different CYP450 inducers; beta-naphthoflavone (BNF), phenobarbital (PB), and rifampicin (RIF).  HepG2 cells responded very weakly to the different inducers at the gene expression level, and this translated generally into low CYP450 activities in the induced cells compared with the control cells.  On the contrary, HepaRG cells and the three human donors were inducible after exposure to BNF, PB, and RIF according to gene expression responses and CYP450 activities.  Consequently, HepaRG cells could be used in screening as a substitute and/or in complement to primary hepatocytes for CYP induction studies.  The second objective was to investigate the predictivity of the different cellular models to detect hepatotoxins (16 hepatotoxic and 5 nonhepatotoxic compds.).  Specificity was 100% with the different cellular models tested.  Cryopreserved human hepatocytes gave the highest sensitivity, ranging from 31% to 44% (depending on the donor), followed by lower sensitivity (13%) for HepaRG and HepG2 cells (6.3%).  Overall, none of the models under study gave desirable sensitivities (80-100%).  Consequently, a high metabolic capacity and CYP inducibility in cell lines does not necessarily correlate with a high sensitivity for the detection of hepatotoxic drugs.  Further investigations are necessary to compare different cellular models and det. those that are best suited for the detection of hepatotoxic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w-GT2Vz3D7Vg90H21EOLACvtfcHk0lhIcBnwu1iR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOntr4%253D&md5=c934bdf740236466cb9885e0f4cb2502</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1007%2Fs10565-011-9208-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10565-011-9208-4%26sid%3Dliteratum%253Aachs%26aulast%3DGerets%26aufirst%3DH.%2BH.%26aulast%3DTilmant%26aufirst%3DK.%26aulast%3DGerin%26aufirst%3DB.%26aulast%3DChanteux%26aufirst%3DH.%26aulast%3DDepelchin%26aufirst%3DB.%2BO.%26aulast%3DDhalluin%26aufirst%3DS.%26aulast%3DAtienzar%26aufirst%3DF.%2BA.%26atitle%3DCharacterization%2520of%2520primary%2520human%2520hepatocytes%252C%2520HepG2%2520cells%252C%2520and%2520HepaRG%2520cells%2520at%2520the%2520mRNA%2520level%2520and%2520CYP%2520activity%2520in%2520response%2520to%2520inducers%2520and%2520their%2520predictivity%2520for%2520the%2520detection%2520of%2520human%2520hepatotoxins%26jtitle%3DCell%2520Biol.%2520Toxicol.%26date%3D2012%26volume%3D28%26issue%3D2%26spage%3D69%26epage%3D87%26doi%3D10.1007%2Fs10565-011-9208-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanebratt, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.107.017418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17954527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=137-145&issue=1&author=K.+P.+Kanebrattauthor=T.+B.+Andersson&title=HepaRG+cells+as+an+in+vitro+model+for+evaluation+of+cytochrome+P450+induction+in+humans&doi=10.1124%2Fdmd.107.017418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans</span></div><div class="casAuthors">Kanebratt, Kajsa P.; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-145</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">HepaRG is a highly differentiated cell line that displays several hepatocyte-like functions, including drug-metabolizing enzymes.  In this study, the HepaRG cells were characterized and evaluated as an in vitro model to predict cytochrome P 450 (P 450) enzyme induction of drugs in humans.  Exposure of HepaRG cells to prototypical inducers resulted in induction of CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 mRNA, as well as phenacetin O-dealkylase, bupropion hydroxylase, diclofenac 4'-hydroxylase, and midazolam 1'-hydroxylase activities.  The obsd. induction is consistent with the previously reported expression of the nuclear receptors pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor, which are necessary for a P 450 induction response.  To avoid problems with toxicity and soly., the induction potency of test compds. was evaluated by calcg. the concns. leading to a 2-fold increase of baseline mRNA or enzyme activity levels (F2 values) instead of EC50 values from full dose-response curves.  For CYP3A4 mRNA, the obtained F2 values were related to the in vivo exposure [area under the plasma concn. vs. time curve (AUC)] of the inducer (AUC/F2).  This score was then correlated with the decrease in AUC for a CYP3A probe drug, administered before and after treatment with the inducing agent.  By using this method an excellent correlation (R2 = 0.863) was obtained, which implies that the degree of CYP3A induction in vivo can be predicted from CYP3A4 mRNA induction in HepaRG cells.  The present study shows that HepaRG cells are a valuable model to be used for prediction of induction of drug-metabolizing P 450 enzymes in vivo in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYyE5u3pdNhrVg90H21EOLACvtfcHk0lhIcBnwu1iR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFGkug%253D%253D&md5=90adf2af9291a73b0f7ce90a84ee301a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017418%26sid%3Dliteratum%253Aachs%26aulast%3DKanebratt%26aufirst%3DK.%2BP.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DHepaRG%2520cells%2520as%2520an%2520in%2520vitro%2520model%2520for%2520evaluation%2520of%2520cytochrome%2520P450%2520induction%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D1%26spage%3D137%26epage%3D145%26doi%3D10.1124%2Fdmd.107.017418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lechon, M. J.</span></span> <span> </span><span class="NLM_article-title">Culture and functional characterization of human hepatoma HepG2 cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1250</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-2074-7_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2F978-1-4939-2074-7_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26272135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1250&publication_year=2015&pages=77-93&author=M.+T.+Donatoauthor=L.+Tolosaauthor=M.+J.+Gomez-Lechon&title=Culture+and+functional+characterization+of+human+hepatoma+HepG2+cells&doi=10.1007%2F978-1-4939-2074-7_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Culture and functional characterization of human hepatoma HepG2 cells</span></div><div class="casAuthors">Donato, Maria Teresa; Tolosa, Laia; Gomez-Lechon, Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1250</span>
        (<span class="NLM_cas:issue">Protocols in In Vitro Hepatocyte Research</span>),
    <span class="NLM_cas:pages">77-93</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Hepatoma cell lines are frequently used as in vitro alternatives to primary human hepatocytes.  Cell lines are characterized by their unlimited life span, stable phenotype, high availability, and easy handling.  However, their major limitation is the lower expression of some metabolic activities compared with hepatocytes.  HepG2 is a human hepatoma that is most commonly used in drug metab. and hepatotoxicity studies.  HepG2 cells are nontumorigenic cells with high proliferation rates and an epithelial-like morphol. that perform many differentiated hepatic functions.  In this chapter, freezing, thawing, and subculturing procedures for HepG2 cells are described.  We further provide protocols for evaluating lipid accumulation, glycogen storage, urea synthesis, and phase I and phase II drug metabolizing activities in HepG2 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJtIIBkq4ryrVg90H21EOLACvtfcHk0lhIcBnwu1iR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtb7F&md5=a6b158d9a18180387126ef445908431a</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2074-7_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-2074-7_5%26sid%3Dliteratum%253Aachs%26aulast%3DDonato%26aufirst%3DM.%2BT.%26aulast%3DTolosa%26aufirst%3DL.%26aulast%3DGomez-Lechon%26aufirst%3DM.%2BJ.%26atitle%3DCulture%2520and%2520functional%2520characterization%2520of%2520human%2520hepatoma%2520HepG2%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2015%26volume%3D1250%26spage%3D77%26epage%3D93%26doi%3D10.1007%2F978-1-4939-2074-7_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span> <span> </span><span class="NLM_article-title">Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.108.020677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18332078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1046-1055&issue=6&author=N.+Hariparsadauthor=B.+A.+Carrauthor=R.+Eversauthor=X.+Chu&title=Comparison+of+immortalized+Fa2N-4+cells+and+human+hepatocytes+as+in+vitro+models+for+cytochrome+P450+induction&doi=10.1124%2Fdmd.108.020677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction</span></div><div class="casAuthors">Hariparsad, Niresh; Carr, Brian A.; Evers, Raymond; Chu, Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1046-1055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fa2N-4 cells have been proposed as a tool to identify CYP3A4 inducers.  To evaluate whether Fa2N-4 cells are a reliable surrogate for cryopreserved human hepatocytes, the authors assessed the basal mRNA expression of 64 drug disposition genes in Fa2N-4 cells.  Significant differences were found in the expression of major drug-metabolizing enzymes, nuclear receptors, and transporters between both cell types.  Importantly, the expression of constitutive androstane receptor (CAR) and several hepatic uptake transporters was significantly lower (>50-fold) in Fa2N-4 cells, whereas the expression of pregnane X-receptor (PXR) and aryl hydrocarbon receptor (AhR) was similar between Fa2N-4 cells and human hepatocytes.  By using an optimized induction assay for Fa2N-4 cells, CYP3A4 induction by rifampicin, the prototypical PXR activator, increased from 1.5- to 7-fold at the level of functional activity.  With nine selected compds., which are known inducers of CYP3A4 either via activation of PXR, CAR, or both, the authors evaluated CYP3A4 and CYP2B6 mRNA induction using Fa2N-4 cells and human hepatocytes.  No response was obsd. in Fa2N-4 cells treated with the selective CAR activators 6-(4-chlorophenyl)imidazo[2,1-b][1,3]-thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime and artemisinin.  CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.  This finding was in agreement with the lack of expression of CAR.  The EC50 value for rifampicin-mediated CYP3A4 induction was 10-fold higher than that in human hepatocytes.  This result could be attributed to the low expression of hepatic org. anion-transporting polypeptides OATP1B1 and OATP1B3 in Fa2N-4 cells.  In summary, the findings identify limitations of Fa2N-4 cells as a predictive induction model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3DPpt6tkQ7Vg90H21EOLACvtfcHk0lgztQoyVA-TxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbk%253D&md5=30fb194a166481cea4cf9de0f20f3ac3</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020677%26sid%3Dliteratum%253Aachs%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DCarr%26aufirst%3DB.%2BA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DX.%26atitle%3DComparison%2520of%2520immortalized%2520Fa2N-4%2520cells%2520and%2520human%2520hepatocytes%2520as%2520in%2520vitro%2520models%2520for%2520cytochrome%2520P450%2520induction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D6%26spage%3D1046%26epage%3D1055%26doi%3D10.1124%2Fdmd.108.020677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulutoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Bedon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarmush, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usta, O. B.</span></span> <span> </span><span class="NLM_article-title">A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e0229106</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0229106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0229106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32106230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&issue=2&author=B.+Bulutogluauthor=C.+Rey-Bedonauthor=S.+Mertauthor=L.+Tianauthor=Y.+Y.+Jangauthor=M.+L.+Yarmushauthor=O.+B.+Usta&title=A+comparison+of+hepato-cellular+in+vitro+platforms+to+study+CYP3A4+induction&doi=10.1371%2Fjournal.pone.0229106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction</span></div><div class="casAuthors">Bulutoglu, Beyza; Rey-Bedon, Camilo; Mert, Safak; Tian, Lipeng; Jang, Yoon-Young; Yarmush, Martin L.; Usta, O. Berk</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0229106</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In vitro studies of drug toxicity and drug-drug interactions are crucial for drug development efforts.  Currently, the utilization of primary human hepatocytes (PHHs) is the de facto std. for this purpose, due to their functional xenobiotic response and drug metabolizing CYP450 enzyme metab.  However, PHHs are scarce, expensive, require laborious maintenance, and exhibit lot-to-lot heterogeneity.  Alternative human in vitro platforms include hepatic cell lines, which are easy to access and maintain, and induced pluripotent stem cell (iPSC) derived hepatocytes.  In this study, we provide a direct comparison of drug induced CYP3A4 and PXR expression levels of PHHs, hepatic cell lines Huh7 and HepG2, and iPSC derived hepatocyte like cells.  Confluently cultured Huh7s exhibited an improved CYP3A4 expression and were inducible by up to 4.9-fold, and hepatocytes differentiated from human iPSCs displayed a 3.3-fold CYP3A4 induction.  In addn., an increase in PXR expression levels was obsd. in both hepatic cell lines and iPSC derived hepatocytes upon rifampicin treatment, whereas a reproducible increase in PXR expression was not achieved in PHHs.  Our results indicate that both hepatoma originated cell lines and iPSCs may provide alternative sources to primary hepatocytes, providing reliable and reproducible results for CYP3A4/PXR metab., upon in vitro maturation.  This study may serve as a guide for the selection of suitable and feasible in vitro platforms for drug-drug interaction and toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcd_UbsGj877Vg90H21EOLACvtfcHk0lgztQoyVA-TxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVKmtbg%253D&md5=ba869e6337d8d3e1a5d2e72f47f752a4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0229106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0229106%26sid%3Dliteratum%253Aachs%26aulast%3DBulutoglu%26aufirst%3DB.%26aulast%3DRey-Bedon%26aufirst%3DC.%26aulast%3DMert%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DY.%2BY.%26aulast%3DYarmush%26aufirst%3DM.%2BL.%26aulast%3DUsta%26aufirst%3DO.%2BB.%26atitle%3DA%2520comparison%2520of%2520hepato-cellular%2520in%2520vitro%2520platforms%2520to%2520study%2520CYP3A4%2520induction%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26issue%3D2%26doi%3D10.1371%2Fjournal.pone.0229106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafagh, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, D. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">3D Primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: Emerging culture paradigms and applications</span>. <i>Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">1800347</span> <span class="refDoi"> DOI: 10.1002/biot.201800347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbiot.201800347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=7&author=V.+M.+Lauschkeauthor=R.+Z.+Shafaghauthor=D.+F.+G.+Hendriksauthor=M.+Ingelman-Sundberg&title=3D+Primary+hepatocyte+culture+systems+for+analyses+of+liver+diseases%2C+drug+metabolism%2C+and+toxicity%3A+Emerging+culture+paradigms+and+applications&doi=10.1002%2Fbiot.201800347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fbiot.201800347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.201800347%26sid%3Dliteratum%253Aachs%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DShafagh%26aufirst%3DR.%2BZ.%26aulast%3DHendriks%26aufirst%3DD.%2BF.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3D3D%2520Primary%2520hepatocyte%2520culture%2520systems%2520for%2520analyses%2520of%2520liver%2520diseases%252C%2520drug%2520metabolism%252C%2520and%2520toxicity%253A%2520Emerging%2520culture%2520paradigms%2520and%2520applications%26jtitle%3DBiotechnol.%2520J.%26date%3D2019%26volume%3D14%26issue%3D7%26doi%3D10.1002%2Fbiot.201800347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span> <span> </span><span class="NLM_article-title">Bioengineered liver models for drug testing and cell differentiation studies</span>. <i>Cell Mol Gastroenterol Hepatol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.jcmgh.2017.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jcmgh.2017.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29675458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=426-439&issue=3&author=G.+H.+Underhillauthor=S.+R.+Khetani&title=Bioengineered+liver+models+for+drug+testing+and+cell+differentiation+studies&doi=10.1016%2Fj.jcmgh.2017.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span></div><div class="casAuthors">Underhill Gregory H; Khetani Salman R</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-439.e1</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic.  Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix-coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli.  The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell-derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non-liver-derived nonparenchymal cell types.  In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types.  Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function.  Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed.  Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_LbJGsVkC5cyail4HZd-ifW6udTcc2ea5RsXK0q84G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D&md5=ab67813eb483dfbfe5d5e799b065b40d</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2017.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2017.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DUnderhill%26aufirst%3DG.%2BH.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26atitle%3DBioengineered%2520liver%2520models%2520for%2520drug%2520testing%2520and%2520cell%2520differentiation%2520studies%26jtitle%3DCell%2520Mol%2520Gastroenterol%2520Hepatol%26date%3D2018%26volume%3D5%26issue%3D3%26spage%3D426%26epage%3D439%26doi%3D10.1016%2Fj.jcmgh.2017.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berridge, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vleet, T. R.</span></span> <span> </span><span class="NLM_article-title">Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications</span>. <i>Lab Chip</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1039/C9LC01168D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FC9LC01168D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32073020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BB387js1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1049-1057&issue=6&author=K.+Fabreauthor=B.+Berridgeauthor=W.+R.+Proctorauthor=S.+Ralstonauthor=Y.+Willauthor=S.+W.+Baranauthor=G.+Yoderauthor=T.+R.+Van+Vleet&title=Introduction+to+a+manuscript+series+on+the+characterization+and+use+of+microphysiological+systems+%28MPS%29+in+pharmaceutical+safety+and+ADME+applications&doi=10.1039%2FC9LC01168D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications</span></div><div class="casAuthors">Fabre Kristin; Berridge Brian; Proctor William R; Ralston Sherry; Van Vleet Terry R; Will Yvonne; Baran Szczepan W; Yoder Gorm</div><div class="citationInfo"><span class="NLM_cas:title">Lab on a chip</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1049-1057</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Safety related drug failures continue to be a challenge for pharmaceutical companies despite the numerous complex and lengthy in vitro assays and in vivo studies that make up the typical safety screening funnel.  A lack of complete translation of animal data to humans can explain some of those shortcomings.  Differences in sensitivity and drug disposition between animals and humans may also play a role.  Many gaps exist for potential target tissues of drugs that cannot be adequately modeled in vitro.  Microphysiological systems (MPS) may help to better model these target tissues and provide an opportunity to better assess some aspects of human safety prior to clinical studies.  There is hope that these systems can supplement current preclinical drug safety and disposition evaluations, filling gaps and enhancing our ability to predict and understand human relevant toxicities.  The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) MPS Affiliate is a group of pharmaceutical industry scientists who seek to expedite appropriate characterization and incorporation of MPS to potentially improve drug safety assessment and provide safer and more effective medicines to patients.  In keeping with this mission, the IQ MPS Affiliate scientists have prepared a series of organotypic manuscripts for several key drug safety and disposition target tissues (lung, liver, kidney, skin, gastrointestinal, cardiovascular, and blood brain barrier/central nervous system).  The goal of these manuscripts is to provide key information related to likely initial contexts of use (CoU) and key characterization data needed for incorporation of MPS in pharmaceutical safety screening including a list of characteristic functions, cell types, toxicities, and test agents (representing major mechanisms of toxicity) that can be used by MPS developers.  Additional manuscripts focusing on testing biologically based therapeutics and ADME considerations have been prepared as part of this effort.  These manuscripts focus on general needs for assessing biologics and ADME endpoints and include similar information to the tissue specific manuscripts where appropriate.  The current manuscript is an introduction to several general concepts related to pharmaceutical industry needs with regard to MPS application and other MPS concepts that apply across the organ specific manuscripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8is6LjALEtyzdcP07UmufW6udTcc2ebTNlvfaSK5LLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387js1Sgsg%253D%253D&md5=ed9bd55146d9f9e5184e3f8870e5b466</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2FC9LC01168D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9LC01168D%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DK.%26aulast%3DBerridge%26aufirst%3DB.%26aulast%3DProctor%26aufirst%3DW.%2BR.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DBaran%26aufirst%3DS.%2BW.%26aulast%3DYoder%26aufirst%3DG.%26aulast%3DVan%2BVleet%26aufirst%3DT.%2BR.%26atitle%3DIntroduction%2520to%2520a%2520manuscript%2520series%2520on%2520the%2520characterization%2520and%2520use%2520of%2520microphysiological%2520systems%2520%2528MPS%2529%2520in%2520pharmaceutical%2520safety%2520and%2520ADME%2520applications%26jtitle%3DLab%2520Chip%26date%3D2020%26volume%3D20%26issue%3D6%26spage%3D1049%26epage%3D1057%26doi%3D10.1039%2FC9LC01168D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronxhi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodella, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropolis, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubins, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conegliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karalis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span> <span> </span><span class="NLM_article-title">Reproducing human and cross-species drug toxicities using a Liver-Chip</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">517</span>), <span class="NLM_elocation-id">eaax5516</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aax5516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1126%2Fscitranslmed.aax5516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=31694927" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&issue=517&author=K.+J.+Jangauthor=M.+A.+Otienoauthor=J.+Ronxhiauthor=H.+K.+Limauthor=L.+Ewartauthor=K.+R.+Kodellaauthor=D.+B.+Petropolisauthor=G.+Kulkarniauthor=J.+E.+Rubinsauthor=D.+Coneglianoauthor=J.+Nawrothauthor=D.+Simicauthor=W.+Lamauthor=M.+Singerauthor=E.+Baraleauthor=B.+Singhauthor=M.+Soneeauthor=A.+J.+Streeterauthor=C.+Mantheyauthor=B.+Jonesauthor=A.+Srivastavaauthor=L.+C.+Anderssonauthor=D.+Williamsauthor=H.+Parkauthor=R.+Barrileauthor=J.+Slizauthor=A.+Herlandauthor=S.+Haneyauthor=K.+Karalisauthor=D.+E.+Ingberauthor=G.+A.+Hamilton&title=Reproducing+human+and+cross-species+drug+toxicities+using+a+Liver-Chip&doi=10.1126%2Fscitranslmed.aax5516"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5516%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DK.%2BJ.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DRonxhi%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DKodella%26aufirst%3DK.%2BR.%26aulast%3DPetropolis%26aufirst%3DD.%2BB.%26aulast%3DKulkarni%26aufirst%3DG.%26aulast%3DRubins%26aufirst%3DJ.%2BE.%26aulast%3DConegliano%26aufirst%3DD.%26aulast%3DNawroth%26aufirst%3DJ.%26aulast%3DSimic%26aufirst%3DD.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DBarale%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DSonee%26aufirst%3DM.%26aulast%3DStreeter%26aufirst%3DA.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DBarrile%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DJ.%26aulast%3DHerland%26aufirst%3DA.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DKaralis%26aufirst%3DK.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26atitle%3DReproducing%2520human%2520and%2520cross-species%2520drug%2520toxicities%2520using%2520a%2520Liver-Chip%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26issue%3D517%26doi%3D10.1126%2Fscitranslmed.aax5516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Ven, A. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdt, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahteenmaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multicenter study</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Ftoxsci%2Fkfx289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29329425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=655-666&issue=2&author=C.+C.+Bellauthor=A.+C.+A.+Dankersauthor=V.+M.+Lauschkeauthor=R.+Sison-Youngauthor=R.+Jenkinsauthor=C.+Roweauthor=C.+E.+Goldringauthor=K.+Parkauthor=S.+L.+Reganauthor=T.+Walkerauthor=C.+Schofieldauthor=A.+Bazeauthor=A.+J.+Fosterauthor=D.+P.+Williamsauthor=A.+W.+M.+van+de%0AVenauthor=F.+Jacobsauthor=J.+V.+Houdtauthor=T.+Lahteenmakiauthor=J.+Snoeysauthor=S.+Juhilaauthor=L.+Richertauthor=M.+Ingelman-Sundberg&title=Comparison+of+hepatic+2D+sandwich+cultures+and+3D+spheroids+for+long-term+toxicity+applications%3A+A+multicenter+study&doi=10.1093%2Ftoxsci%2Fkfx289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study</span></div><div class="casAuthors">Bell, Catherine C.; Dankers, Anita C. A.; Lauschke, Volker M.; Sison-Young, Rowena; Jenkins, Roz; Rowe, Cliff; Goldring, Chris E.; Park, Kevin; Regan, Sophie L.; Walker, Tracy; Schofield, Chris; Baze, Audrey; Foster, Alison J.; Williams, Dominic P.; van de Ven, Amy W. M.; Jacobs, Frank; Van Houdt, Jos; Laehteenmaeki, Tuula; Snoeys, Jan; Juhila, Satu; Richert, Lysiane; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-666</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced liver injury.  However, when cultured as 2D monolayers, PHH lose crucial hepatic functions within hours.  This dedifferentiation can be ameliorated when PHHs are cultured in sandwich configuration (2Dsw), particularly when cultures are regularly re-overlaid with extracellular matrix, or as 3D spheroids.  In this study, the 6 participating labs. evaluated the robustness of these 2 model systems made from cryopreserved PHH from the same donors considering both inter-donor and inter-lab. variability and compared their suitability for use in repeated-dose toxicity studies using 5 different hepatotoxins with different toxicity mechanisms.  We found that expression levels of proteins involved in drug absorption, distribution, metab., and excretion, as well as catalytic activities of 5 different CYPs, were significantly higher in 3D spheroid cultures, potentially affecting the exposure of the cells to drugs and their metabolites.  Furthermore, global proteomic analyses revealed that PHH in 3D spheroid configuration were temporally stable whereas proteomes from the same donors in 2Dsw cultures showed substantial alterations in protein expression patterns over the 14 days in culture.  Overall, spheroid cultures were more sensitive to the hepatotoxic compds. investigated, particularly upon long-term exposures, across testing sites with little inter-lab. or inter-donor variability.  The data presented here suggest that repeated-dosing regimens improve the predictivity of in vitro toxicity assays, and that PHH spheroids provide a sensitive and robust system for long-term mechanistic studies of drug-induced hepatotoxicity, whereas the 2Dsw system has a more dedifferentiated phenotype and lower sensitivity to detect hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigGHJ8Vmu_7Vg90H21EOLACvtfcHk0lhxEvByLC0wIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF&md5=4154ee24a1a0c93374e00f0e7cc50e35</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx289%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DSison-Young%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DSchofield%26aufirst%3DC.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DA.%2BW.%2BM.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DLahteenmaki%26aufirst%3DT.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DComparison%2520of%2520hepatic%25202D%2520sandwich%2520cultures%2520and%25203D%2520spheroids%2520for%2520long-term%2520toxicity%2520applications%253A%2520A%2520multicenter%2520study%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26issue%3D2%26spage%3D655%26epage%3D666%26doi%3D10.1093%2Ftoxsci%2Fkfx289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crogan-Grundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">e0158674</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0158674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pone.0158674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=27387377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&issue=7&author=D.+G.+Nguyenauthor=J.+Funkauthor=J.+B.+Robbinsauthor=C.+Crogan-Grundyauthor=S.+C.+Presnellauthor=T.+Singerauthor=A.+B.+Roth&title=Bioprinted+3D+primary+liver+tissues+allow+assessment+of+organ-level+response+to+clinical+drug+induced+toxicity+in+vitro&doi=10.1371%2Fjournal.pone.0158674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span></div><div class="casAuthors">Nguyen, Deborah G.; Funk, Juergen; Robbins, Justin B.; Crogan-Grundy, Candace; Presnell, Sharon C.; Singer, Thomas; Roth, Adrian B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158674/1-e0158674/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modeling clin. relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI).  This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicol.  In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and nonparenchymal cells in a defined architecture.  Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histol. anal. that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin pos., smooth muscle actin neg. quiescent stellates.  Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 wk in culture.  To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by std. pre-clin. models, were compared to the structurally related non-toxic drug Levofloxacin.  Trovafloxacin induced significant, dosedependent toxicity at clin. relevant doses (≤ 4uM).  Interestingly, Trovafloxacin toxicity was obsd. without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports.  Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compds. with differential profile.  Thus, the combination of patient-derived primary cells with bioprinting technol. here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYl7I6xmS4qrVg90H21EOLACvtfcHk0li1X4mgyL6s0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI&md5=3444083b1e6affcca18ae9063c66ae90</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158674%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DRobbins%26aufirst%3DJ.%2BB.%26aulast%3DCrogan-Grundy%26aufirst%3DC.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26atitle%3DBioprinted%25203D%2520primary%2520liver%2520tissues%2520allow%2520assessment%2520of%2520organ-level%2520response%2520to%2520clinical%2520drug%2520induced%2520toxicity%2520in%2520vitro%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D7%26doi%3D10.1371%2Fjournal.pone.0158674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">FDA.</span> <i>In vitro drug interaction studies —
Cytochrome P450
enzyme- and transporter-mediated drug interactions guidance for industry</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+In+vitro+drug+interaction+studies+%E2%80%94%0ACytochrome+P450%0Aenzyme-+and+transporter-mediated+drug+interactions+guidance+for+industry.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DIn%2520vitro%2520drug%2520interaction%2520studies%2520%25E2%2580%2594%250ACytochrome%2520P450%250Aenzyme-%2520and%2520transporter-mediated%2520drug%2520interactions%2520guidance%2520for%2520industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">EMA.</span> <i>Guideline on the investigation of drug interactions</i>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EMA.+Guideline+on+the+investigation+of+drug+interactions.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fclinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGuideline%2520on%2520the%2520investigation%2520of%2520drug%2520interactions" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamanda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariparsad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, P. D.</span></span> <span> </span><span class="NLM_article-title">Considerations from the Innovation and Quality Induction working group in response to drug-drug Interaction guidance from regulatory agencies: Guidelines on model fitting and recommendations on time course for in vitro cytochrome P450 induction studies including impact on drug interaction risk assessment</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1124/dmd.120.000055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.120.000055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=33139460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3MXpslCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2021&pages=94-110&issue=1&author=S.+G.+Wongauthor=D.+Ramsdenauthor=S.+Dallasauthor=C.+Fungauthor=H.+J.+Einolfauthor=J.+Palamandaauthor=L.+Chenauthor=T.+C.+Goosenauthor=Y.+A.+Siuauthor=G.+Zhangauthor=D.+Tweedieauthor=N.+Hariparsadauthor=B.+Jonesauthor=P.+D.+Yates&title=Considerations+from+the+Innovation+and+Quality+Induction+working+group+in+response+to+drug-drug+Interaction+guidance+from+regulatory+agencies%3A+Guidelines+on+model+fitting+and+recommendations+on+time+course+for+in+vitro+cytochrome+P450+induction+studies+including+impact+on+drug+interaction+risk+assessment&doi=10.1124%2Fdmd.120.000055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations from the innovation and quality induction working group in response to drug-drug interaction guidance from regulatory agencies: guidelines on model fitting and recommendations on time course for in vitro cytochrome p450 induction studies including impact on drug interaction risk assessment</span></div><div class="casAuthors">Wong, Simon G.; Ramsden, Diane; Dallas, Shannon; Fung, Conrad; Einolf, Heidi J.; Palamanda, Jairam; Chen, Liangfu; Goosen, Theunis C.; Siu, Y. Amy; Zhang, George; Tweedie, Donald; Hariparsad, Niresh; Jones, Barry; Yates, Phillip D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-110</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Translational and ADME Sciences Leadership Group Induction Working Group (IWG) presents an anal. on the time course for cytochrome P 450 induction in primary human hepatocytes.  Despite variability in induction response across hepatocyte donors, the following recommendations are proposed: 1) 48 h should be the primary time point for in vitro assessment of induction based on mRNA level or activity, with no further benefit from 72 h; 2) when using mRNA, 24-h incubations provide reliable assessment of induction and DDI risk; 3) if validated using prototypical inducers (>10-fold induction), 12-h incubations may provide an est. of induction potential, including characterization as neg. if <2-fold induction of mRNA and no concn. dependence; 4) atypical dose-response ("bell-shaped") curves can be addressed by removing points outside an established confidence interval and %CV; 5) when max. fold induction is well defined, the choice of nonlinear regression model has limited impact on estd. induction parameters; 6) when the max. fold induction is not well defined, conservative DDI risk assessment can be obtained using sigmoidal three-parameter fit or constraining logistic three- or four-parameter fits to the max. obsd. fold induction; 7) preliminary data suggest initial slope of the fold induction curve can be used to est. Emax/EC50 and for induction risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfsRW2nVVz9LVg90H21EOLACvtfcHk0li1X4mgyL6s0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXpslCgug%253D%253D&md5=3be1f92d0f30bd645fb1a4011cac0b96</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fdmd.120.000055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.120.000055%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DDallas%26aufirst%3DS.%26aulast%3DFung%26aufirst%3DC.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DPalamanda%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DSiu%26aufirst%3DY.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHariparsad%26aufirst%3DN.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DYates%26aufirst%3DP.%2BD.%26atitle%3DConsiderations%2520from%2520the%2520Innovation%2520and%2520Quality%2520Induction%2520working%2520group%2520in%2520response%2520to%2520drug-drug%2520Interaction%2520guidance%2520from%2520regulatory%2520agencies%253A%2520Guidelines%2520on%2520model%2520fitting%2520and%2520recommendations%2520on%2520time%2520course%2520for%2520in%2520vitro%2520cytochrome%2520P450%2520induction%2520studies%2520including%2520impact%2520on%2520drug%2520interaction%2520risk%2520assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2021%26volume%3D49%26issue%3D1%26spage%3D94%26epage%3D110%26doi%3D10.1124%2Fdmd.120.000055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A. M.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 and xenobiotic receptor humanized mice</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.100007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1146%2Fannurev.pharmtox.45.120403.100007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16402898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=41-64&author=F.+J.+Gonzalezauthor=A.+M.+Yu&title=Cytochrome+P450+and+xenobiotic+receptor+humanized+mice&doi=10.1146%2Fannurev.pharmtox.45.120403.100007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P 450 and xenobiotic receptor humanized mice</span></div><div class="casAuthors">Gonzalez, Frank J.; Yu, Ai-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-64, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Most xenobiotics that enter the body are subjected to metab. that functions primarily to facilitate their elimination.  Metab. of certain xenobiotics can also result in the prodn. of electrophilic derivs. that can cause cell toxicity and transformation.  Many xenobiotics can also activate receptors that in turn induce the expression of genes encoding xenobiotic-metabolizing enzymes and xenobiotic transporters.  However, there are marked species differences in the way mammals respond to xenobiotics, which are due in large part to mol. differences in receptors and xenobiotic-metabolizing enzymes.  This presents a problem in extrapolating data obtained with rodent model systems to humans.  There are also polymorphisms in xenobiotic-metabolizing enzymes that can impact drug therapy and cancer susceptibility.  In an effort to generate more reliable in vivo systems to study and predict human response to xenobiotics, humanized mice are under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIudUG0AjU7Vg90H21EOLACvtfcHk0lgUZQTdFWXFgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFKltLo%253D&md5=a464c6f1ffb30917630b1740d5877cbe</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.100007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.100007%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DYu%26aufirst%3DA.%2BM.%26atitle%3DCytochrome%2520P450%2520and%2520xenobiotic%2520receptor%2520humanized%2520mice%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D41%26epage%3D64%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.100007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinchuk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orcutt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoeckler, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmermacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulac, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.109.029637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19833845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=16-24&issue=1&author=S.+Kimauthor=J.+E.+Dinchukauthor=M.+N.+Anthonyauthor=T.+Orcuttauthor=M.+E.+Zoecklerauthor=M.+B.+Sauerauthor=K.+W.+Mosureauthor=R.+Vuppugallaauthor=J.+E.+Graceauthor=J.+Simmermacherauthor=H.+A.+Dulacauthor=J.+Pizzanoauthor=M.+Sinz&title=Evaluation+of+cynomolgus+monkey+pregnane+X+receptor%2C+primary+hepatocyte%2C+and+in+vivo+pharmacokinetic+changes+in+predicting+human+CYP3A4+induction&doi=10.1124%2Fdmd.109.029637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction</span></div><div class="casAuthors">Kim, Sean; Dinchuk, Joseph E.; Anthony, Monique N.; Orcutt, Tami; Zoeckler, Mary E.; Sauer, Mary B.; Mosure, Kathleen W.; Vuppugalla, Ragini; Grace, James E., Jr.; Simmermacher, Jean; Dulac, Heidi A.; Pizzano, Jennifer; Sinz, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Monkeys have been proposed as an animal model to predict the magnitude of human clin. drug-drug interactions caused by CYP3A4 enzyme induction.  To evaluate whether the cynomolgus monkey can be an effective in vivo model, human CYP3A4 inducers were evaluated both in vitro and in vivo.  First, a full-length pregnane X receptor (PXR) was cloned from the cynomolgus monkey, and the sequence was compared with those of rhesus monkey and human PXR.  Cynomolgus and rhesus monkey PXR differed by only one amino acid (A68V), and both were highly homologous to human PXR (∼96%).  When the transactivation profiles of 30 compds., including known inducers of CYP3A4, were compared between cynomolgus and human PXR, a high degree of correlation with EC50 values was obsd.  These results suggest that cynomolgus and human PXR respond in a similar fashion to these ligands.  Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes.  Both monkey and human hepatocytes responded similarly to the inducers and resulted in increased RNA and enzyme activity changes of CYP3A8 and CYP3A4, resp.  Lastly, in vivo induction of CYP3A8 by rifampicin and hyperforin was shown by significant redns. of midazolam exposure that were comparable with those in humans.  These results show that the cynomolgus monkey can be a predictive in vivo animal model of PXR-mediated induction of human CYP3A4 and can provide a useful assessment of the resulting pharmacokinetic changes of affected drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJLEhuCwoAr7Vg90H21EOLACvtfcHk0lgUZQTdFWXFgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fF&md5=ef8c7ec7bc2470d6bd4774d0323319b3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029637%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDinchuk%26aufirst%3DJ.%2BE.%26aulast%3DAnthony%26aufirst%3DM.%2BN.%26aulast%3DOrcutt%26aufirst%3DT.%26aulast%3DZoeckler%26aufirst%3DM.%2BE.%26aulast%3DSauer%26aufirst%3DM.%2BB.%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DSimmermacher%26aufirst%3DJ.%26aulast%3DDulac%26aufirst%3DH.%2BA.%26aulast%3DPizzano%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520cynomolgus%2520monkey%2520pregnane%2520X%2520receptor%252C%2520primary%2520hepatocyte%252C%2520and%2520in%2520vivo%2520pharmacokinetic%2520changes%2520in%2520predicting%2520human%2520CYP3A4%2520induction%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D1%26spage%3D16%26epage%3D24%26doi%3D10.1124%2Fdmd.109.029637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Strategy for CYP3A induction risk assessment from preclinical signal to human: a case example of a late-stage discovery compound</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2403</span>– <span class="NLM_lpage">2414</span>, <span class="refDoi"> DOI: 10.1007/s11095-017-2246-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-017-2246-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28815392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=2403-2414&issue=11&author=J.+Maoauthor=P.+Fanauthor=S.+Wongauthor=J.+Wangauthor=M.+H.+A.+Ismailiauthor=B.+Deanauthor=C.+Hopauthor=M.+Wrightauthor=Y.+Chen&title=Strategy+for+CYP3A+induction+risk+assessment+from+preclinical+signal+to+human%3A+a+case+example+of+a+late-stage+discovery+compound&doi=10.1007%2Fs11095-017-2246-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound</span></div><div class="casAuthors">Mao, Jialin; Fan, Peter; Wong, Susan; Wang, Jianshuang; Ismaili, Moulay Hicham Alaoui; Dean, Brian; Hop, Cornelis E. C. A.; Wright, Matthew; Chen, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2403-2414</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The exposure of G2917 decreased by four-fold at oral doses of 100 mg/kg twice daily for seven days in cynomolgus monkeys.  Addnl. investigative work was conducted to understand: (1) the causes for the significant redn. in G2917 exposure in monkeys; (2) the extrapolation of in vitro induction data to in vivo findings in monkeys, and (3) the relevance of this preclin. finding to humans at the projected human efficacious dose.  Methods: Pharmacokinetic and induction potency (in vitro and in vivo) of G2917 in monkeys, and the in vitro human induction potency were studied.  The hepatic CYP3A biomarkers 4β-hydroxycholesterol (4β-HC) and 6β-hydroxycortisol/cortisol ratio (6β-OHC/C) were monitored in in vivo studies.  The static mechanistic model was used to quant. understand the in vitro-in vivo extrapolation (IVIVE) on the magnitude of induction retrospectively.  Physiol. based pharmacokinetic (PBPK) modeling was used to predict the human pharmacokinetics and induction-based drug-drug interactions (DDI).  Results: All in vitro and in vivo data indicate that the significant redn. in exposure of G2917 in monkeys is caused by auto-induction of CYP3A.  The mechanistic understanding of IVIVE of G2917 induction in monkey provides higher confidence in the induction risk prediction in human using the PBPK modeling.  PBPK model anal. predicted min. auto-induction and DDI liability in humans at the predicted efficacious dose.  Conclusions: The learning of this example provided a strategy to address the human CYP3A induction risk prospectively when there is an auto-induction finding in preclin. toxicol. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMEWS1xkiQLbVg90H21EOLACvtfcHk0lgUZQTdFWXFgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCntLjK&md5=35d5813fe13fd95ba7164a85be4b0868</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs11095-017-2246-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-017-2246-8%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DHop%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DStrategy%2520for%2520CYP3A%2520induction%2520risk%2520assessment%2520from%2520preclinical%2520signal%2520to%2520human%253A%2520a%2520case%2520example%2520of%2520a%2520late-stage%2520discovery%2520compound%26jtitle%3DPharm.%2520Res.%26date%3D2017%26volume%3D34%26issue%3D11%26spage%3D2403%26epage%3D2414%26doi%3D10.1007%2Fs11095-017-2246-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span> <span> </span><span class="NLM_article-title">A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1002/bdd.2173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fbdd.2173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30724384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVyqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=81-93&issue=2&author=H.+Taharaauthor=M.+Watanabeauthor=M.+Hasegawa&title=A+comparative+study+for+detecting+CYP3A+induction+by+CYP3A+probe+drugs+and+endogenous+markers+in+cynomolgus+monkeys&doi=10.1002%2Fbdd.2173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys</span></div><div class="casAuthors">Tahara, Harunobu; Watanabe, Miwa; Hasegawa, Maki</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-93</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">CYP3A probe drugs such as midazolam and endogenous markers, and plasma 4β-hydroxycholesterol (4β-OHC) and urinary 6β-hydroxycortisol-to-cortisol ratios (6β-OHC/C) have been used as markers of CYP3A induction in cynomolgus monkeys, as with humans.  However, there is limited information on their sensitivity and ability to detect CYP3A induction, as most studies were evaluated only at a high dose of the inducer, rifampicin (RIF; 20 mg/kg).  In the present study, the CYP3A induction by RIF over a range doses of 0.2, 2 and 20 mg/kg (n = 4) was examd. using CYP3A probe drugs (midazolam, triazolam and alprazolam) and the plasma and urinary endogenous CYP3A markers (4β-OHC and 6β-OHC/C).  The sensitivity and relationship for detecting CYP3A induction was compared among the markers.  Four days repeated oral administration of rifampicin to cynomolgus monkeys reduced the area under the plasma concn.-time curve of all CYP3A probe drugs in a rifampicin dose-dependent manner.  Although the endogenous CYP3A markers (4β-OHC and 6β-OHC/C) were also changed for the middle (2 mg/kg) and high (20 mg/kg) doses of rifampicin, the fold-changes were relatively small, and CYP3A induction could not be detected at the lowest dose of rifampicin (0.2 mg/kg).  In conclusion, CYP3A probe drugs are more sensitive for detecting CYP3A induction than endogenous CYP3A markers in cynomolgus monkeys, even for a short exptl. period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfMwlDdujOR7Vg90H21EOLACvtfcHk0lgRY0HCwYPU5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVyqsLk%253D&md5=a656dc22e1ed7977b644bae204e8cc52</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2173%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26atitle%3DA%2520comparative%2520study%2520for%2520detecting%2520CYP3A%2520induction%2520by%2520CYP3A%2520probe%2520drugs%2520and%2520endogenous%2520markers%2520in%2520cynomolgus%2520monkeys%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2019%26volume%3D40%26issue%3D2%26spage%3D81%26epage%3D93%26doi%3D10.1002%2Fbdd.2173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapelyukh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheer, N.</span></span> <span> </span><span class="NLM_article-title">Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.111.071845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21628639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ektbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=518-528&issue=3&author=M.+Hasegawaauthor=Y.+Kapelyukhauthor=H.+Taharaauthor=J.+Seiblerauthor=A.+Rodeauthor=S.+Kruegerauthor=D.+N.+Leeauthor=C.+R.+Wolfauthor=N.+Scheer&title=Quantitative+prediction+of+human+pregnane+X+receptor+and+cytochrome+P450+3A4+mediated+drug-drug+interaction+in+a+novel+multiple+humanized+mouse+line&doi=10.1124%2Fmol.111.071845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line</span></div><div class="casAuthors">Hasegawa, Maki; Kapelyukh, Yury; Tahara, Harunobu; Seibler, Jost; Rode, Anja; Krueger, Sylvia; Lee, Dongtao N.; Wolf, C. Roland; Scheer, Nico</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">518-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochrome P 450 (P 450) 3A4 is the predominant P 450 enzyme expressed in human liver and intestine, and it is involved in the metab. of approx. 50% of clin. used drugs.  Because of the differences in the multiplicity of CYP3A genes and the poor correlation of substrate specificity of CYP3A proteins between species, the extrapolation of CYP3A-mediated metab. of a drug from animals to man is difficult.  This situation is further complicated by the fact that the predictability of the clin. common drug-drug interaction of pregnane X receptor (PXR)-mediated CYP3A4 induction by animal studies is limited as a result of marked species differences in the interaction of many drugs with this receptor.  Here we describe a novel multiple humanized mouse line that combines a humanization for PXR, the closely related constitutive androstane receptor, and a replacement of the mouse Cyp3a cluster with a large human genomic region carrying CYP3A4 and CYP3A7.  We provide evidence that this model shows a human-like CYP3A4 induction response to different PXR activators, that it allows the ranking of these activators according to their potency to induce CYP3A4 expression in the human liver, and that it provides an exptl. approach to quant. predict PXR/CYP3A4-mediated drug-drug interactions in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvOIptc2dOTrVg90H21EOLACvtfcHk0lgRY0HCwYPU5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ektbzM&md5=bf75370b920edd055adef7aab79eb753</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071845%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DKapelyukh%26aufirst%3DY.%26aulast%3DTahara%26aufirst%3DH.%26aulast%3DSeibler%26aufirst%3DJ.%26aulast%3DRode%26aufirst%3DA.%26aulast%3DKrueger%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%2BN.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26aulast%3DScheer%26aufirst%3DN.%26atitle%3DQuantitative%2520prediction%2520of%2520human%2520pregnane%2520X%2520receptor%2520and%2520cytochrome%2520P450%25203A4%2520mediated%2520drug-drug%2520interaction%2520in%2520a%2520novel%2520multiple%2520humanized%2520mouse%2520line%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26issue%3D3%26spage%3D518%26epage%3D528%26doi%3D10.1124%2Fmol.111.071845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapelyukh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span> <span> </span><span class="NLM_article-title">An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.086397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.119.086397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30910785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=601-615&issue=6&author=C.+J.+Hendersonauthor=Y.+Kapelyukhauthor=N.+Scheerauthor=A.+Rodeauthor=A.+W.+McLarenauthor=A.+K.+MacLeodauthor=D.+Linauthor=J.+Wrightauthor=L.+A.+Stanleyauthor=C.+R.+Wolf&title=An+extensively+humanized+mouse+model+to+predict+pathways+of+drug+disposition+and+drug%2Fdrug+interactions%2C+and+to+facilitate+design+of+clinical+trials&doi=10.1124%2Fdmd.119.086397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials</span></div><div class="casAuthors">Henderson, C. J.; Kapelyukh, Y.; Scheer, N.; Rode, A.; McLaren, A. W.; MacLeod, A. K.; Lin, D.; Wright, J.; Stanley, L. A.; Wolf, C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-615</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species differences in drug metab. and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often pharmacol. active), and in differential activation of the transcription factors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), which regulate the expression of such enzymes as P450s and drug transporters.  These differences have gained addnl. importance as a consequence of the use of genetically modified mouse models for drug-efficacy testing and also patient-derived xenografts to predict individual patient responses to anticancer drugs.  A no. of humanized mouse models for cytochrome P450s, CAR, and PXR have been reported.  However, the utility of these models has been compromised by the redundancy in P 450 reactions across gene families, whereby the remaining murine P450s can metabolize the compds. being tested.  To remove this confounding factor and create a mouse model that more closely reflects human pathways of drug disposition, we substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A7.  We also created a mouse line in which 34 P450s were deleted from the mouse genome.  Using model compds. and anticancer drugs, we demonstrated how these mouse lines can be applied to predict drug-drug interactions in patients and discuss here their potential application in the more informed design of clin. trials and the personalized treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BHkJ_rwhl7Vg90H21EOLACvtfcHk0lgRY0HCwYPU5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbjK&md5=2a44f88a1e897f06f4de8dfc9874a052</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.086397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.086397%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DC.%2BJ.%26aulast%3DKapelyukh%26aufirst%3DY.%26aulast%3DScheer%26aufirst%3DN.%26aulast%3DRode%26aufirst%3DA.%26aulast%3DMcLaren%26aufirst%3DA.%2BW.%26aulast%3DMacLeod%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DStanley%26aufirst%3DL.%2BA.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26atitle%3DAn%2520extensively%2520humanized%2520mouse%2520model%2520to%2520predict%2520pathways%2520of%2520drug%2520disposition%2520and%2520drug%252Fdrug%2520interactions%252C%2520and%2520to%2520facilitate%2520design%2520of%2520clinical%2520trials%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D601%26epage%3D615%26doi%3D10.1124%2Fdmd.119.086397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span> <span> </span><span class="NLM_article-title">Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug-drug interactions</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1754</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1754-1759&issue=5&author=J.+Q.+Lyauthor=K.+Messickauthor=A.+Qinauthor=R.+H.+Takahashiauthor=E.+F.+Choo&title=Utility+of+CYP3A4+and+PXR-CAR-CYP3A4%2F3A7+transgenic+mouse+models+to+assess+the+magnitude+of+CYP3A4+mediated+drug-drug+interactions&doi=10.1021%2Facs.molpharmaceut.7b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions</span></div><div class="casAuthors">Ly, Justin Q.; Messick, Kirsten; Qin, Ann; Takahashi, Ryan H.; Choo, Edna F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1754-1759</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Species differences in the expression, activity, regulation, and substrate specificity of metabolizing enzymes preclude the use of animal models to predict clin. drug-drug interactions (DDIs).  The objective of this work is to det. if the transgenic (Tg) Cyp3a-/-Tg-3A4Hep/Int and Nr1i2/Nr1i3-/--Cyp3a-/-Tg-PXR-CAR-3A4/3A7Hep/Int (PXR-CAR-CYP3A4/3A7) mouse models could be used to predict in vivo DDI of 10 drugs; alprazolam, bosutinib, crizotinib, dasatinib, gefitinib, ibrutinib, regorafenib, sorafenib, triazolam, and vandetinib (as victims); with varying magnitudes of reported CYP3A4 clin. DDI.  As an assessment of the effect of CYP3A4 inhibition, these drugs were coadministered to Cyp3a-/-Tg-3A4Hep/Int mice with the CYP3A inhibitor, itraconazole.  For crizotinib, regorafenib, sorafenib, and vandetanib, there was no significant increase of AUC obsd.; with alprazolam, bosutinib, ibrutinib, dasatinib, and triazolam, pretreatment with itraconazole resulted in a 2-, 4-, 17-, 7-, and 15-fold increase in AUC, resp.  With the exception of gefinitib for which the DDI effect was overpredicted (12-fold in Tg-mice vs 2-fold in the clinic), the magnitude of AUC increase obsd. in this study was consistent (within 2-fold) with the clin. DDI obsd. following administration with itraconazole/ketoconazole.  As an assessment of CYP3A4 induction, following rifampin pretreatment to PXR-CAR-3A4/3A7Hep/Int mice, an 8% decrease in vandetanib mean AUC was obsd.; 39-52% redn. in AUC were obsd. for dasatinib, ibrutinib, regorafenib, and sorafenib compared to vehicle treated mice.  The greatest effect of rifampin induction was obsd. with alprazolam, bosutinib, crizotinib, gefitinib, and triazolam where 72-91% decrease in AUC were obsd.  With the exception of vandetanib for which rifampin induction was under-predicted, the magnitude of induction obsd. in this study was consistent (within 2-fold) with clin. observations.  These data sets suggest that, with two exceptions, these transgenic mice models were able to exclude or capture the magnitude of CYP3A4 clin. inhibition and induction.  Data generated in transgenic mice may be used to gain confidence and complement in vitro and in silico methods for assessing DDI potential/liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDm24uLLulOLVg90H21EOLACvtfcHk0ljNtM1ia-FIeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWju7s%253D&md5=4e756fcf505d921292062c23f3ac24eb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00006%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DJ.%2BQ.%26aulast%3DMessick%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DR.%2BH.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26atitle%3DUtility%2520of%2520CYP3A4%2520and%2520PXR-CAR-CYP3A4%252F3A7%2520transgenic%2520mouse%2520models%2520to%2520assess%2520the%2520magnitude%2520of%2520CYP3A4%2520mediated%2520drug-drug%2520interactions%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26issue%3D5%26spage%3D1754%26epage%3D1759%26doi%3D10.1021%2Facs.molpharmaceut.7b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umesono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">Determinants of target gene specificity for steroid/thyroid hormone receptors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(89)90051-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2F0092-8674%2889%2990051-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=2500251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaL1MXltFWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1989&pages=1139-1146&issue=7&author=K.+Umesonoauthor=R.+M.+Evans&title=Determinants+of+target+gene+specificity+for+steroid%2Fthyroid+hormone+receptors&doi=10.1016%2F0092-8674%2889%2990051-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of target gene specificity for steroid/thyroid hormone receptors</span></div><div class="casAuthors">Umesono, Kazuhiko; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-46</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The mol. specificity of the receptors for steroid and thyroid hormones is achieved by their selective interaction with DNA binding sites referred to as hormone response elements (HREs).  HREs can differ in primary nucleotide sequence as well as in the spacing of their dyadic half-sites.  The target gene specificity of the glucocorticoid receptor can be converted to that of the estrogen receptor by changing 3 amino acids clustered in the first zinc finger.  Remarkably, a single Gly to Glu change in this region produces a receptor that recognizes both glucocorticoid and estrogen response elements.  Further replacement of 5 amino acids in the stem of the second zinc finger transforms the specificity to that of the thyroid hormone receptor.  These findings localize structural determinants required for discrimination of HRE sequence and half-site spacing, resp., and suggest a simple pathway for the coevolution of receptor DNA binding domains and hormone-responsive gene networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5aEI2AU4Q2rVg90H21EOLACvtfcHk0ljNtM1ia-FIeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFWhs78%253D&md5=cee05e62afb5953c97423a761fbabdb3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2889%2990051-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252889%252990051-2%26sid%3Dliteratum%253Aachs%26aulast%3DUmesono%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DDeterminants%2520of%2520target%2520gene%2520specificity%2520for%2520steroid%252Fthyroid%2520hormone%2520receptors%26jtitle%3DCell%26date%3D1989%26volume%3D57%26issue%3D7%26spage%3D1139%26epage%3D1146%26doi%3D10.1016%2F0092-8674%2889%2990051-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>331</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1016/S0022-2836(03)00795-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2FS0022-2836%2803%2900795-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12909012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFGgu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2003&pages=815-828&issue=4&author=R.+E.+Watkinsauthor=P.+R.+Davis-Searlesauthor=M.+H.+Lambertauthor=M.+R.+Redinbo&title=Coactivator+binding+promotes+the+specific+interaction+between+ligand+and+the+pregnane+X+receptor&doi=10.1016%2FS0022-2836%2803%2900795-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Coactivator Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor</span></div><div class="casAuthors">Watkins, Ryan E.; Davis-Searles, Paula R.; Lambert, Mill H.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">815-828</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) detects the presence of a wide variety of endogenous and xenobiotic compds., and is a master regulator of the expression of genes central to drug metab. and excretion.  We present the 2.0 Å crystal structure of the human PXR ligand-binding domain (LBD) in complex with the cholesterol-lowering compd. SR12813 and a 25 amino acid residue fragment of the human steroid receptor coactivator-1 (SRC-1) contg. one LXXLL motif.  PXR crystallizes as a homodimer in the asym. unit in this structure and possesses a novel α2 helix adjacent to its ligand-binding cavity.  The SRC-1 peptide forms two distinct helixes and binds adjacent to the ligand-dependent transactivation AF-2 helix on the surface of PXR.  In contrast with previous PXR structures, in which SR12813 bound in multiple orientations, the small SR12813 agonist in this structure binds in a single, unique orientation within the receptor's ligand-binding pocket and contacts the AF-2 helix.  Thermal denaturation studies reveal that the SR12813 ligand and SRC-1 coactivator peptide each stabilize the LBD of PXR, and that together they exert an additive effect on the stability of the receptor.  These results indicate that the binding of coactivator to the surface of PXR limits the ability of this promiscuous receptor to "breathe" and helps to trap a single, active conformation of SR12813.  They further reveal that specificity is required for PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbb0Scjx9ALVg90H21EOLACvtfcHk0ljNtM1ia-FIeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFGgu7k%253D&md5=ec6080e6e361daa2e5f5f08135cc1d3f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900795-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900795-2%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DCoactivator%2520binding%2520promotes%2520the%2520specific%2520interaction%2520between%2520ligand%2520and%2520the%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D331%26issue%3D4%26spage%3D815%26epage%3D828%26doi%3D10.1016%2FS0022-2836%2803%2900795-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luntz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittoop, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimmel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Human PXR forms a tryptophan zipper-mediated homodimer</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">8579</span>– <span class="NLM_lpage">8589</span>, <span class="refDoi"> DOI: 10.1021/bi0602821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0602821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=8579-8589&issue=28&author=S.+M.+Nobleauthor=V.+E.+Carnahanauthor=L.+B.+Mooreauthor=T.+Luntzauthor=H.+Wangauthor=O.+R.+Ittoopauthor=J.+B.+Stimmelauthor=P.+R.+Davis-Searlesauthor=R.+E.+Watkinsauthor=G.+B.+Wiselyauthor=E.+LeCluyseauthor=A.+Tripathyauthor=D.+P.+McDonnellauthor=M.+R.+Redinbo&title=Human+PXR+forms+a+tryptophan+zipper-mediated+homodimer&doi=10.1021%2Fbi0602821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Human PXR Forms a Tryptophan Zipper-Mediated Homodimer</span></div><div class="casAuthors">Noble, Schroeder M.; Carnahan, Virginia E.; Moore, Linda B.; Luntz, Tom; Wang, Hongbing; Ittoop, Olivia R.; Stimmel, Julie B.; Davis-Searles, Paula R.; Watkins, Ryan E.; Wisely, G. Bruce; LeCluyse, Ed; Tripathy, Ashutosh; McDonnell, Donald P.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">8579-8589</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human nuclear receptor pregnane X receptor (PXR) responds to a wide variety of potentially harmful chems. and coordinates the expression of genes central to xenobiotic and endobiotic metab.  Structural studies reveal that the PXR ligand binding domain (LBD) uses a novel sequence insert to form a homodimer unique to the nuclear receptor superfamily.  Terminal β-strands from each monomeric LBD interact in an ideal antiparallel fashion to bury potentially exposed surface β-strands, generating a 10-stranded intermol. β-sheet.  Conserved tryptophan and tyrosine residues lock across the dimer interface and provide the first tryptophan-zipper (Trp-Zip) interaction obsd. in a native protein.  We show using anal. ultracentrifugation that the PXR LBD forms a homodimer in soln.  We further find that removal of the interlocking arom. residues eliminates dimer formation but does not affect PXR's ability to interact with DNA, RXRα, or ligands.  Disruption of the homodimer significantly reduces receptor activity in transient transfection expts., however, and effectively eliminates the receptor's recruitment of the transcriptional coactivator SRC-1 both in vitro and in vivo.  Taken together, these results suggest that the unique Trp-Zip-mediated PXR homodimer plays a role in the function of this nuclear xenobiotic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE2ERjHL1Mb7Vg90H21EOLACvtfcHk0lhPjrahx9a7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFKgu78%253D&md5=3ce717647887ec0fc5f537c69720f07c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fbi0602821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0602821%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DS.%2BM.%26aulast%3DCarnahan%26aufirst%3DV.%2BE.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DLuntz%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DIttoop%26aufirst%3DO.%2BR.%26aulast%3DStimmel%26aufirst%3DJ.%2BB.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DTripathy%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DHuman%2520PXR%2520forms%2520a%2520tryptophan%2520zipper-mediated%2520homodimer%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26issue%3D28%26spage%3D8579%26epage%3D8589%26doi%3D10.1021%2Fbi0602821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastinejad, F.</span></span> <span> </span><span class="NLM_article-title">Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>456</i></span> (<span class="NLM_issue">7220</span>),  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nature07413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnature07413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19043829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BD1cjnsFSjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2008&pages=350-356&issue=7220&author=V.+Chandraauthor=P.+Huangauthor=Y.+Hamuroauthor=S.+Raghuramauthor=Y.+Wangauthor=T.+P.+Burrisauthor=F.+Rastinejad&title=Structure+of+the+intact+PPAR-gamma-RXR-+nuclear+receptor+complex+on+DNA&doi=10.1038%2Fnature07413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA</span></div><div class="casAuthors">Chandra Vikas; Huang Pengxiang; Hamuro Yoshitomo; Raghuram Srilatha; Wang Yongjun; Burris Thomas P; Rastinejad Fraydoon</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">7220</span>),
    <span class="NLM_cas:pages">350-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nuclear receptors are multi-domain transcription factors that bind to DNA elements from which they regulate gene expression.  The peroxisome proliferator-activated receptors (PPARs) form heterodimers with the retinoid X receptor (RXR), and PPAR-gamma has been intensively studied as a drug target because of its link to insulin sensitization.  Previous structural studies have focused on isolated DNA or ligand-binding segments, with no demonstration of how multiple domains cooperate to modulate receptor properties.  Here we present structures of intact PPAR-gamma and RXR-alpha as a heterodimer bound to DNA, ligands and coactivator peptides.  PPAR-gamma and RXR-alpha form a non-symmetric complex, allowing the ligand-binding domain (LBD) of PPAR-gamma to contact multiple domains in both proteins.  Three interfaces link PPAR-gamma and RXR-alpha, including some that are DNA dependent.  The PPAR-gamma LBD cooperates with both DNA-binding domains (DBDs) to enhance response-element binding.  The A/B segments are highly dynamic, lacking folded substructures despite their gene-activation properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBfyLNYQMJfwwxfk_AGB-EfW6udTcc2eaMxNNl5VjM2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjnsFSjsg%253D%253D&md5=bb1b4cd7744a353431c7b575d7f5df50</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnature07413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07413%26sid%3Dliteratum%253Aachs%26aulast%3DChandra%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DHamuro%26aufirst%3DY.%26aulast%3DRaghuram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26aulast%3DRastinejad%26aufirst%3DF.%26atitle%3DStructure%2520of%2520the%2520intact%2520PPAR-gamma-RXR-%2520nuclear%2520receptor%2520complex%2520on%2520DNA%26jtitle%3DNature%26date%3D2008%26volume%3D456%26issue%3D7220%26spage%3D350%26epage%3D356%26doi%3D10.1038%2Fnature07413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastinejad, F.</span></span> <span> </span><span class="NLM_article-title">Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>495</i></span> (<span class="NLM_issue">7441</span>),  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature11966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnature11966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23485969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlClurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=495&publication_year=2013&pages=394-398&issue=7441&author=V.+Chandraauthor=P.+Huangauthor=N.+Potluriauthor=D.+Wuauthor=Y.+Kimauthor=F.+Rastinejad&title=Multidomain+integration+in+the+structure+of+the+HNF-4alpha+nuclear+receptor+complex&doi=10.1038%2Fnature11966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Multidomain integration in the structure of the HNF-4α nuclear receptor complex</span></div><div class="casAuthors">Chandra, Vikas; Huang, Pengxiang; Potluri, Nalini; Wu, Dalei; Kim, Youngchang; Rastinejad, Fraydoon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">495</span>
        (<span class="NLM_cas:issue">7441</span>),
    <span class="NLM_cas:pages">394-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hepatocyte nuclear factor 4α (HNF-4α; also known as NR2A1) is a member of the nuclear receptor (NR) family of transcription factors, which have conserved DNA-binding domains and ligand-binding domains.  HNF-4α is the most abundant DNA-binding protein in the liver, where some 40% of the actively transcribed genes have a HNF-4α response element.  These regulated genes are largely involved in the hepatic gluconeogenic program and lipid metab.  In the pancreas HNF-4α is also a master regulator, controlling an estd. 11% of islet genes.  HNF-4α protein mutations are linked to maturity-onset diabetes of the young, type 1 (MODY1) and hyperinsulinemic hypoglycemia.  Previous structural analyses of NRs, although productive in elucidating the structure of individual domains, have lagged behind in revealing the connectivity patterns of NR domains.  Here we describe the 2.9 Å crystal structure of the multidomain human HNF-4α homodimer bound to its DNA response element and coactivator-derived peptides.  A convergence zone connects multiple receptor domains in an asym. fashion, joining distinct elements from each monomer.  An arginine target of PRMT1 methylation protrudes directly into this convergence zone and sustains its integrity.  A serine target of protein kinase C is also responsible for maintaining domain-domain interactions.  These post-translational modifications lead to changes in DNA binding by communicating through the tightly connected surfaces of the quaternary fold.  We find that some MODY1 mutations, positioned on the ligand-binding domain and hinge regions of the receptor, compromise DNA binding at a distance by communicating through the interjunctional surfaces of the complex.  The overall domain representation of the HNF-4α homodimer is different from that of the PPAR-γ-RXR-α heterodimer, even when both NR complexes are assembled on the same DNA element.  Our findings suggest that unique quaternary folds and interdomain connections in NRs could be exploited by small-mol. allosteric modulators that affect distal functions in these polypeptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eKjjrFa-h7Vg90H21EOLACvtfcHk0lhPjrahx9a7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlClurk%253D&md5=13c1241ad16ef93ac40d16e0b9123591</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnature11966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11966%26sid%3Dliteratum%253Aachs%26aulast%3DChandra%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DPotluri%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DRastinejad%26aufirst%3DF.%26atitle%3DMultidomain%2520integration%2520in%2520the%2520structure%2520of%2520the%2520HNF-4alpha%2520nuclear%2520receptor%2520complex%26jtitle%3DNature%26date%3D2013%26volume%3D495%26issue%3D7441%26spage%3D394%26epage%3D398%26doi%3D10.1038%2Fnature11966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toresson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Structure of the retinoid X receptor alpha-liver X receptor beta (RXRalpha-LXRbeta) heterodimer on DNA</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fnsmb.2778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24561505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=277-281&issue=3&author=X.+Louauthor=G.+Toressonauthor=C.+Benodauthor=J.+H.+Suhauthor=K.+J.+Philipsauthor=P.+Webbauthor=J.+A.+Gustafsson&title=Structure+of+the+retinoid+X+receptor+alpha-liver+X+receptor+beta+%28RXRalpha-LXRbeta%29+heterodimer+on+DNA&doi=10.1038%2Fnsmb.2778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on DNA</span></div><div class="casAuthors">Lou, Xiaohua; Toresson, Gudrun; Benod, Cindy; Suh, Ji Ho; Philips, Kevin J.; Webb, Paul; Gustafsson, Jan-Ake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) are conditional transcription factors with common multidomain organization that bind diverse DNA elements.  How DNA sequences influence NR conformation is poorly understood.  Here we report the crystal structure of the human retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on its cognate element, an AGGTCA direct repeat spaced by 4 nt.  The complex has an extended X-shaped arrangement, with DNA- and ligand-binding domains crossed, in contrast to the parallel domain arrangement of other NRs that bind an AGGTCA direct repeat spaced by 1 nt.  The LXRβ core binds DNA via canonical contacts and auxiliary DNA contacts that enhance affinity for the response element.  Comparisons of RXRα-LXRβs in the crystal asym. unit and with previous NR structures reveal flexibility in NR organization and suggest a role for RXRα in adaptation of heterodimeric complexes to DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocO-YqDoHi_rVg90H21EOLACvtfcHk0lgraLFljN0_5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFagtbs%253D&md5=aba55f18cb3e885f56e8e0de825137bb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2778%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DX.%26aulast%3DToresson%26aufirst%3DG.%26aulast%3DBenod%26aufirst%3DC.%26aulast%3DSuh%26aufirst%3DJ.%2BH.%26aulast%3DPhilips%26aufirst%3DK.%2BJ.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DStructure%2520of%2520the%2520retinoid%2520X%2520receptor%2520alpha-liver%2520X%2520receptor%2520beta%2520%2528RXRalpha-LXRbeta%2529%2520heterodimer%2520on%2520DNA%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D3%26spage%3D277%26epage%3D281%26doi%3D10.1038%2Fnsmb.2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">5525</span>),  <span class="NLM_fpage">2329</span>– <span class="NLM_lpage">2333</span>, <span class="refDoi"> DOI: 10.1126/science.1060762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1126%2Fscience.1060762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=11408620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2001&pages=2329-2333&issue=5525&author=R.+E.+Watkinsauthor=G.+B.+Wiselyauthor=L.+B.+Mooreauthor=J.+L.+Collinsauthor=M.+H.+Lambertauthor=S.+P.+Williamsauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=The+human+nuclear+xenobiotic+receptor+PXR%3A+structural+determinants+of+directed+promiscuity&doi=10.1126%2Fscience.1060762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity</span></div><div class="casAuthors">Watkins, Ryan E.; Wisely, G. Bruce; Moore, Linda B.; Collins, Jon L.; Lambert, Millard H.; Williams, Shawn P.; Willson, Timothy M.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5525</span>),
    <span class="NLM_cas:pages">2329-2333</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The human nuclear pregnane X receptor (hPXR) activates cytochrome P 450-3A expression in response to a wide variety of xenobiotics and plays a crit. role in mediating dangerous drug-drug interactions.  The authors present the crystal structures of the ligand-binding domain of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolns. of 2.5 and 2.75 angstroms, resp.  The hydrophobic ligand-binding cavity of hPXR contains a small no. of polar residues, permitting SR12813 to bind-in three distinct orientations.  The position and nature of these polar residues were found to be crit. for establishing the precise pharmacol. activation profile of PXR.  The findings provide important insights into how hPXR detects xenobiotics and may prove useful in predicting and avoiding drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGros5DlMM1w9rVg90H21EOLACvtfcHk0lgraLFljN0_5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslSht7c%253D&md5=f78d0d3e742427fc771a3c958b07be5a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1126%2Fscience.1060762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1060762%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DThe%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%253A%2520structural%2520determinants%2520of%2520directed%2520promiscuity%26jtitle%3DScience%26date%3D2001%26volume%3D292%26issue%3D5525%26spage%3D2329%26epage%3D2333%26doi%3D10.1126%2Fscience.1060762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Searles, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">2.1 A crystal structure of human PXR in complex with the St. John’s wort compound hyperforin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1021/bi0268753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0268753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1430-1438&issue=6&author=R.+E.+Watkinsauthor=J.+M.+Maglichauthor=L.+B.+Mooreauthor=G.+B.+Wiselyauthor=S.+M.+Nobleauthor=P.+R.+Davis-Searlesauthor=M.+H.+Lambertauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=2.1+A+crystal+structure+of+human+PXR+in+complex+with+the+St.+John%E2%80%99s+wort+compound+hyperforin&doi=10.1021%2Fbi0268753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">2.1 Å Crystal Structure of Human PXR in Complex with the St. John's Wort Compound Hyperforin</span></div><div class="casAuthors">Watkins, Ryan E.; Maglich, Jodi M.; Moore, Linda B.; Wisely, G. Bruce; Noble, Schroeder M.; Davis-Searles, Paula R.; Lambert, Mill H.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nuclear xenobiotic receptor PXR is activated by a wide variety of clin. used drugs and serves as a master regulator of drug metab. and excretion gene expression in mammals. St. John's wort is used widely in Europe and the United States to treat depression.  This unregulated herbal remedy leads to dangerous drug-drug interactions, however, in patients taking oral contraceptives, antivirals, or immunosuppressants.  Such interactions are caused by the activation of the human PXR by hyperforin, the psychoactive agent in St. John's wort.  In this study, we show that hyperforin induces the expression of numerous drug metab. and excretion genes in primary human hepatocytes.  We present the 2.1 Å crystal structure of hyperforin in complex with the ligand binding domain of human PXR.  Hyperforin induces conformational changes in PXR's ligand binding pocket relative to structures of human PXR elucidated previously and increases the size of the pocket by 250 Å3.  We find that the mutation of individual arom. residues within the ligand binding cavity changes PXR's response to particular ligands.  Taken together, these results demonstrate that PXR employs structural flexibility to expand the chem. space it samples and that the mutation of specific residues within the ligand binding pocket of PXR tunes the receptor's response to ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNQeEM-jnDbVg90H21EOLACvtfcHk0lgraLFljN0_5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFaktQ%253D%253D&md5=f88f83a7ad885528a3a2bf0ab93214ae</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fbi0268753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0268753%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DR.%2BE.%26aulast%3DMaglich%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DNoble%26aufirst%3DS.%2BM.%26aulast%3DDavis-Searles%26aufirst%3DP.%2BR.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3D2.1%2520A%2520crystal%2520structure%2520of%2520human%2520PXR%2520in%2520complex%2520with%2520the%2520St.%2520John%25E2%2580%2599s%2520wort%2520compound%2520hyperforin%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26issue%3D6%26spage%3D1430%26epage%3D1438%26doi%3D10.1021%2Fbi0268753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1210/me.2004-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1210%2Fme.2004-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15705662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1125-1134&issue=5&author=J.+E.+Chrencikauthor=J.+Oransauthor=L.+B.+Mooreauthor=Y.+Xueauthor=L.+Pengauthor=J.+L.+Collinsauthor=G.+B.+Wiselyauthor=M.+H.+Lambertauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=Structural+disorder+in+the+complex+of+human+pregnane+X+receptor+and+the+macrolide+antibiotic+rifampicin&doi=10.1210%2Fme.2004-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin</span></div><div class="casAuthors">Chrencik, Jill E.; Orans, Jillian; Moore, Linda B.; Xue, Yu; Peng, Li; Collins, Jon L.; Wisely, G. Bruce; Lambert, Millard H.; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1125-1134</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The human nuclear xenobiotic receptor, pregnane X receptor (PXR), detects a variety of structurally distinct endogenous and xenobiotic compds. and controls expression of genes central to drug and cholesterol metab.  The macrolide antibiotic rifampicin, a front-line treatment for tuberculosis, is an established PXR agonist and, at 823 Da, is one of the largest known ligands for the receptor.  The authors present the 2.8 Å crystal structure of the ligand-binding domain of human PXR in complex with rifampicin.  The authors also use structural and mutagenesis data to examine the origins of the directed promiscuity exhibited by the PXRs across species.  Three structurally flexible loops adjacent to the ligand-binding pocket of PXR are disordered in this crystal structure, including the 200-210 region that is part of a sequence insert novel to the promiscuous PXRs relative to other members of the nuclear receptor superfamily.  The 4-methyl-1-piperazinyl ring of rifampicin, which would lie adjacent to the disordered protein regions, is also disordered and not obsd. in the structure.  Taken together, the results indicate that one wall of the PXR ligand-binding cavity can remain flexible even when the receptor is in complex with an activating ligand.  These observations highlight the key role that structural flexibility plays in PXR's promiscuous response to xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgc19c4Tdl7Vg90H21EOLACvtfcHk0li9vUwHX9DnFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFensbs%253D&md5=0a3f5e3a62477a68b8019c4d827c4e9c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1210%2Fme.2004-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2004-0346%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DOrans%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520disorder%2520in%2520the%2520complex%2520of%2520human%2520pregnane%2520X%2520receptor%2520and%2520the%2520macrolide%2520antibiotic%2520rifampicin%26jtitle%3DMol.%2520Endocrinol.%26date%3D2005%26volume%3D19%26issue%3D5%26spage%3D1125%26epage%3D1134%26doi%3D10.1210%2Fme.2004-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2156</span>– <span class="NLM_lpage">2166</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmc.2006.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17215127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=2156-2166&issue=5&author=Y.+Xueauthor=E.+Chaoauthor=W.+J.+Zuercherauthor=T.+M.+Willsonauthor=J.+L.+Collinsauthor=M.+R.+Redinbo&title=Crystal+structure+of+the+PXR-T1317+complex+provides+a+scaffold+to+examine+the+potential+for+receptor+antagonism&doi=10.1016%2Fj.bmc.2006.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism</span></div><div class="casAuthors">Xue, Yu; Chao, Esther; Zuercher, William J.; Willson, Timothy M.; Collins, Jon L.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2156-2166</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) recognizes a range of structurally and chem. distinct ligands and plays a key role in regulating the expression of protective gene products involved in the metab. and excretion of potentially harmful compds.  The identification and development of PXR antagonists is desirable as a potential way to control the up-regulation of drug metab. pathways during the therapeutic treatment of disease.  The authors present the 2.8 Å resoln. crystal structure of the PXR ligand binding domain (LBD) in complex with T0901317 (T1317), which is also an agonist of another member of the orphan class of the nuclear receptor superfamily, the liver X receptor (LXR).  In spite of differences in the size and shape of the receptors' ligand binding pockets, key interactions with this ligand are conserved between human PXR and human LXR.  Based on the PXR-T1317 structure, analogs of T1317 were generated with the goal of designing an PXR antagonist effective via the receptor's ligand binding pocket.  The authors find that selectivity in activating PXR vs. LXR was achieved; such compds. may be useful in addressing neurodegenerative diseases like Niemann-Pick C.  The authors were not successful, however, in producing a PXR antagonist.  Based on these observations, the authors conclude that the generation of PXR antagonists targeted to the ligand binding pocket may be difficult due to the promiscuity and structural conformability of this xenobiotic sensor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0FzLaTf8t7Vg90H21EOLACvtfcHk0li9vUwHX9DnFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOnt7o%253D&md5=69424ea9a1d044be36bf2fbdcbb5f8df</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520PXR-T1317%2520complex%2520provides%2520a%2520scaffold%2520to%2520examine%2520the%2520potential%2520for%2520receptor%2520antagonism%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26issue%3D5%26spage%3D2156%26epage%3D2166%26doi%3D10.1016%2Fj.bmc.2006.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teotico, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischof, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural basis of human pregnane X receptor activation by the hops constituent colupulone</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1520</span>, <span class="refDoi"> DOI: 10.1124/mol.108.050732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.108.050732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18768384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGls7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1512-1520&issue=6&author=D.+G.+Teoticoauthor=J.+J.+Bischofauthor=L.+Pengauthor=S.+A.+Kliewerauthor=M.+R.+Redinbo&title=Structural+basis+of+human+pregnane+X+receptor+activation+by+the+hops+constituent+colupulone&doi=10.1124%2Fmol.108.050732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of human pregnane X receptor activation by the hops constituent colupulone</span></div><div class="casAuthors">Teotico, Denise G.; Bischof, Jason J.; Peng, Li; Kliewer, Steven A.; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1512-1520</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hops exts. are used to alleviate menopausal symptoms and as an alternative to hormone replacement therapy, but they can produce potentially harmful drug-drug interactions.  The nuclear xenobiotic receptor pregnane X receptor (PXR) is promiscuously activated by a range of structurally distinct chems.  It has a key role in the transcriptional regulation of genes that encode xenobiotic metab. enzymes.  In this study, hops exts. are shown to induce the expression of numerous drug metab. and excretion proteins.  The β-bitter acid colupulone is demonstrated to be a bioactive component and direct activator of human PXR.  The 2.8-Å resoln. crystal structure of the ligand binding domain of human PXR in complex with colupulone was elucidated, and colupulone was obsd. to bind in a single orientation stabilized by both van der Waals and hydrogen bonding contacts.  The crystal structure also indicates that related α- and β-bitter acids have the capacity to serve as PXR agonists as well.  Taken together, these results reveal the structural basis for drug-drug interactions mediated by colupulone and related constituents of hops exts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkNovjK7bNo7Vg90H21EOLACvtfcHk0li9vUwHX9DnFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGls7zF&md5=5a2bbd34a55cfd4cbdc719126b42d3d8</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.050732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.050732%26sid%3Dliteratum%253Aachs%26aulast%3DTeotico%26aufirst%3DD.%2BG.%26aulast%3DBischof%26aufirst%3DJ.%2BJ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520basis%2520of%2520human%2520pregnane%2520X%2520receptor%2520activation%2520by%2520the%2520hops%2520constituent%2520colupulone%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26issue%3D6%26spage%3D1512%26epage%3D1520%26doi%3D10.1124%2Fmol.108.050732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosise, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taremi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span> <span> </span><span class="NLM_article-title">Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1093/protein/gzn017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fprotein%2Fgzn017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18456871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=425-433&issue=7&author=W.+Wangauthor=W.+W.+Prosiseauthor=J.+Chenauthor=S.+S.+Taremiauthor=H.+V.+Leauthor=V.+Madisonauthor=X.+Cuiauthor=A.+Thomasauthor=K.+C.+Chengauthor=C.+A.+Lesburg&title=Construction+and+characterization+of+a+fully+active+PXR%2FSRC-1+tethered+protein+with+increased+stability&doi=10.1093%2Fprotein%2Fgzn017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability</span></div><div class="casAuthors">Wang, Wenyan; Prosise, Winifred W.; Chen, Jun; Taremi, S. Shane; Le, Hung V.; Madison, Vincent; Cui, Xiaoming; Thomas, Ann; Cheng, K.-C.; Lesburg, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">425-433</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The nuclear xenobiotic receptor PXR is a ligand-inducible transcription factor regulating drug-metabolizing enzymes and transporters and a master switch mediating potentially adverse drug-drug interactions.  In addn. to binding a coactivator protein such as SRC-1, the C-terminal ligand-binding domain (LBD) is solely responsible for ligand recognition and thus the ligand-dependent downstream effects.  In an effort to facilitate structural studies of PXR to understand and abolish the interactions between PXR and its ligands, several recombinant PXR/SRC-1 constructs were designed and evaluated for expression, stability and activity.  Expression strategies employing either dual expression or translationally coupled bicistronic expression were found to be unsuitable for producing stable PXR in a stoichiometric complex with a peptide derived from SRC-1 (SRC-1p).  A single polypeptide chain encompassing PXR and SRC-1p tethered with a peptidyl linker was designed to promote intramol. complex formation.  This tethered protein was overexpressed as a sol. protein and required no addnl. SRC-1p for further stabilization.  X-ray crystal structures in the presence and absence of the known PXR agonist SR-12813 were detd. to high resoln.  In addn., a CD-based binding assay was developed to allow rapid evaluation of PXR ligand affinity, making this tethered protein a convenient and effective reagent for the rational attenuation of drug-induced PXR-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaIAHYXZGyYLVg90H21EOLACvtfcHk0lisurkMVG07dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sks7s%253D&md5=87a30decb4445d6b713b55eedc2b7038</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzn017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzn017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DProsise%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaremi%26aufirst%3DS.%2BS.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26atitle%3DConstruction%2520and%2520characterization%2520of%2520a%2520fully%2520active%2520PXR%252FSRC-1%2520tethered%2520protein%2520with%2520increased%2520stability%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2008%26volume%3D21%26issue%3D7%26spage%3D425%26epage%3D433%26doi%3D10.1093%2Fprotein%2Fgzn017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1002/pro.706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fpro.706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21805522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2isrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1713-1719&issue=10&author=Y.+Chengauthor=M.+R.+Redinbo&title=Activation+of+the+human+nuclear+xenobiotic+receptor+PXR+by+the+reverse+transcriptase-targeted+anti-HIV+drug+PNU-142721&doi=10.1002%2Fpro.706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721</span></div><div class="casAuthors">Cheng, Yuan; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1713-1719</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a member of the nuclear receptor superfamily of ligand-regulated transcription factors.  PXR responds to a structurally diverse variety of endogenous and xenobiotic compds., and coordinates the expression of genes central to the metab. and excretion of potentially harmful chems., including human therapeutics.  The reverse transcriptase inhibitor PNU-142721 has been designed to treat human immunodeficiency virus (HIV) infection.  Although this compd. has anti-HIV activity, it was established using cell-based assays that PNU-142721 is an efficacious PXR agonist.  We present here the 2.8 Å resoln. crystal structure of the human PXR ligand-binding domain in complex with PNU-142721.  PXR employs one hydrogen bond and fourteen van der Waals contacts to interact with the ligand, but allows two loops adjacent to the ligand-binding pocket to remain disordered in the structure.  These observations highlight the role structural flexibility plays in PXR's promiscuous responses to xenobiotics.  The crystal structure also explains why PNU-173575, a thiomethyl metabolite of PNU-142721, exhibits enhanced PXR activation relative to the unmodified compd. and why PNU-142721 can also activate rat PXR.  Taken together, the results presented here elucidate the structural basis for PXR activation by PNU-142721 and related chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5Vb_GQVVVLVg90H21EOLACvtfcHk0lisurkMVG07dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2isrjJ&md5=c28e70e9ec58b599b9f4279ecfc88f74</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fpro.706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.706%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DActivation%2520of%2520the%2520human%2520nuclear%2520xenobiotic%2520receptor%2520PXR%2520by%2520the%2520reverse%2520transcriptase-targeted%2520anti-HIV%2520drug%2520PNU-142721%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26issue%3D10%26spage%3D1713%26epage%3D1719%26doi%3D10.1002%2Fpro.706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J. B.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grafstrom, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7550</span>– <span class="NLM_lpage">7564</span>, <span class="refDoi"> DOI: 10.1021/jm5003167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7550-7564&issue=18&author=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=J.+V.+Dunciaauthor=H.+Wuauthor=M.+Dharauthor=C.+Cavallaroauthor=A.+J.+Tebbenauthor=P.+H.+Carterauthor=J.+C.+Barrishauthor=M.+Yardeauthor=S.+W.+Bricenoauthor=M.+E.+Cvijicauthor=R.+R.+Grafstromauthor=R.+Liuauthor=S.+R.+Patelauthor=A.+J.+Watsonauthor=G.+Yangauthor=A.+V.+Roseauthor=R.+D.+Vickeryauthor=J.+Caceres-Cortesauthor=C.+Caporuscioauthor=D.+M.+Camacauthor=J.+A.+Khanauthor=Y.+Anauthor=W.+R.+Fosterauthor=P.+Daviesauthor=J.+Hynes&title=Discovery+of+the+CCR1+antagonist%2C+BMS-817399%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm5003167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Santella, Joseph B.; Gardner, Daniel S.; Duncia, John V.; Wu, Hong; Dhar, Murali; Cavallaro, Cullen; Tebben, Andrew J.; Carter, Percy H.; Barrish, Joel C.; Yarde, Melissa; Briceno, Stephanie W.; Cvijic, Mary Ellen; Grafstrom, R. Robert; Liu, Richard; Patel, Sima R.; Watson, Andrew J.; Yang, Guchen; Rose, Anne V.; Vickery, Rodney D.; Caceres-Cortes, Janet; Caporuscio, Christian; Camac, Daniel M.; Khan, Javed A.; An, Yongmi; Foster, William R.; Davies, Paul; Hynes, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7550-7564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered.  Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 I, which entered clin. trials for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB85zyhe5Qr7Vg90H21EOLACvtfcHk0lisurkMVG07dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fO&md5=33610179f9bcef718507168a5b82ab6f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm5003167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003167%26sid%3Dliteratum%253Aachs%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDhar%26aufirst%3DM.%26aulast%3DCavallaro%26aufirst%3DC.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DS.%2BW.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DGrafstrom%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRose%26aufirst%3DA.%2BV.%26aulast%3DVickery%26aufirst%3DR.%2BD.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DCaporuscio%26aufirst%3DC.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DFoster%26aufirst%3DW.%2BR.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520the%2520CCR1%2520antagonist%252C%2520BMS-817399%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D18%26spage%3D7550%26epage%3D7564%26doi%3D10.1021%2Fjm5003167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenny, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhire, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Developing adnectins that target SRC co-activator binding to PXR: A structural approach toward understanding promiscuity of PXR</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>427</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.jmb.2014.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25579995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2015&pages=924-942&issue=4&author=J.+A.+Khanauthor=D.+M.+Camacauthor=S.+Lowauthor=A.+J.+Tebbenauthor=D.+L.+Wenselauthor=M.+C.+Wrightauthor=J.+Suauthor=V.+Jennyauthor=R.+D.+Guptaauthor=M.+Ruzanovauthor=K.+A.+Russoauthor=A.+Bellauthor=Y.+Anauthor=J.+W.+Brysonauthor=M.+Gaoauthor=P.+Gambhireauthor=E.+T.+Baldwinauthor=D.+Gardnerauthor=C.+L.+Cavallaroauthor=J.+V.+Dunciaauthor=J.+Hynes&title=Developing+adnectins+that+target+SRC+co-activator+binding+to+PXR%3A+A+structural+approach+toward+understanding+promiscuity+of+PXR&doi=10.1016%2Fj.jmb.2014.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Adnectins That Target SRC Co-Activator Binding to PXR: A Structural Approach toward Understanding Promiscuity of PXR</span></div><div class="casAuthors">Khan, Javed A.; Camac, Daniel M.; Low, Simon; Tebben, Andrew J.; Wensel, David L.; Wright, Martin C.; Su, Julie; Jenny, Victoria; Das Gupta, Ruchira; Ruzanov, Max; Russo, Katie A.; Bell, Aneka; An, Yongmi; Bryson, James W.; Gao, Mian; Gambhire, Pallavi; Baldwin, Eric T.; Gardner, Daniel; Cavallaro, Cullen L.; Duncia, John; Hynes, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">427</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">924-942</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a promiscuous nuclear receptor that functions as a sensor to a wide variety of xenobiotics and regulates expression of several drug metabolizing enzymes and transporters.  We have generated "Adnectins", derived from 10th fibronectin type III domain (10Fn3), that target the PXR ligand binding domain (LBD) interactions with the steroid receptor co-activator-1 (SRC-1) peptide, displacing SRC-1 binding.  Adnectins are structurally homologous to the Ig superfamily.  Three different co-crystal structures of PXR LBD with Adnectin-1 and CCR1 (CC chemokine receptor-1) antagonist Compd.-1 were detd.  This structural information was used to modulate PXR affinity for a related CCR1 antagonist compd. that entered into clin. trials for rheumatoid arthritis.  The structures of PXR with Adnectin-1 reveal specificity of Adnectin-1 in not only targeting the interface of the SRC-1 interactions but also engaging the same set of residues that are involved in binding of SRC-1 to PXR.  Substituting SRC-1 with Adnectin-1 does not alter the binding conformation of Compd.-1 in the ligand binding pocket.  The structure also reveals the possibility of using Adnectins as crystn. chaperones to generate structures of PXR with compds. of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHClQpf22lALVg90H21EOLACvtfcHk0licE8jgl4CVyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVCmsg%253D%253D&md5=84634f9ee24a93b583f1bf1c99e0b2e3</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DWensel%26aufirst%3DD.%2BL.%26aulast%3DWright%26aufirst%3DM.%2BC.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DJenny%26aufirst%3DV.%26aulast%3DGupta%26aufirst%3DR.%2BD.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DK.%2BA.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DBryson%26aufirst%3DJ.%2BW.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGambhire%26aufirst%3DP.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DDeveloping%2520adnectins%2520that%2520target%2520SRC%2520co-activator%2520binding%2520to%2520PXR%253A%2520A%2520structural%2520approach%2520toward%2520understanding%2520promiscuity%2520of%2520PXR%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D427%26issue%3D4%26spage%3D924%26epage%3D942%26doi%3D10.1016%2Fj.jmb.2014.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delfosse, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendele, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavailles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daujat-Chavanieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8089</span>, <span class="refDoi"> DOI: 10.1038/ncomms9089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fncomms9089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26333997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC287ptVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8089&author=V.+Delfosseauthor=B.+Dendeleauthor=T.+Huetauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=S.+Gerbal-Chaloinauthor=B.+Beucherauthor=D.+Roecklinauthor=C.+Mullerauthor=R.+Rahmaniauthor=V.+Cavaillesauthor=M.+Daujat-Chavanieuauthor=V.+Vivatauthor=J.+M.+Pascussiauthor=P.+Balaguerauthor=W.+Bourguet&title=Synergistic+activation+of+human+pregnane+X+receptor+by+binary+cocktails+of+pharmaceutical+and+environmental+compounds&doi=10.1038%2Fncomms9089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds</span></div><div class="casAuthors">Delfosse Vanessa; Huet Tiphaine; Bourguet William; Delfosse Vanessa; Huet Tiphaine; Bourguet William; Delfosse Vanessa; Dendele Beatrice; Huet Tiphaine; Grimaldi Marina; Boulahtouf Abdelhay; Gerbal-Chaloin Sabine; Beucher Bertrand; Cavailles Vincent; Daujat-Chavanieu Martine; Pascussi Jean-Marc; Balaguer Patrick; Bourguet William; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Dendele Beatrice; Grimaldi Marina; Boulahtouf Abdelhay; Cavailles Vincent; Balaguer Patrick; Gerbal-Chaloin Sabine; Daujat-Chavanieu Martine; Beucher Bertrand; Pascussi Jean-Marc; Beucher Bertrand; Pascussi Jean-Marc; Roecklin Dominique; Muller Christina; Vivat Valerie; Rahmani Roger; Daujat-Chavanieu Martine</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Humans are chronically exposed to multiple exogenous substances, including environmental pollutants, drugs and dietary components.  Many of these compounds are suspected to impact human health, and their combination in complex mixtures could exacerbate their harmful effects.  Here we demonstrate that a pharmaceutical oestrogen and a persistent organochlorine pesticide, both exhibiting low efficacy when studied separately, cooperatively bind to the pregnane X receptor, leading to synergistic activation.  Biophysical analysis shows that each ligand enhances the binding affinity of the other, so the binary mixture induces a substantial biological response at doses at which each chemical individually is inactive.  High-resolution crystal structures reveal the structural basis for the observed cooperativity.  Our results suggest that the formation of 'supramolecular ligands' within the ligand-binding pocket of nuclear receptors contributes to the synergistic toxic effect of chemical mixtures, which may have broad implications for the fields of endocrine disruption, toxicology and chemical risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPLYllG1trW2mbXvSEQle5fW6udTcc2eZEOIylIxKP7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287ptVWhsw%253D%253D&md5=2416828dd3854d2dea6727fbf0b1f8ed</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Fncomms9089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9089%26sid%3Dliteratum%253Aachs%26aulast%3DDelfosse%26aufirst%3DV.%26aulast%3DDendele%26aufirst%3DB.%26aulast%3DHuet%26aufirst%3DT.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DBeucher%26aufirst%3DB.%26aulast%3DRoecklin%26aufirst%3DD.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DRahmani%26aufirst%3DR.%26aulast%3DCavailles%26aufirst%3DV.%26aulast%3DDaujat-Chavanieu%26aufirst%3DM.%26aulast%3DVivat%26aufirst%3DV.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DBourguet%26aufirst%3DW.%26atitle%3DSynergistic%2520activation%2520of%2520human%2520pregnane%2520X%2520receptor%2520by%2520binary%2520cocktails%2520of%2520pharmaceutical%2520and%2520environmental%2520compounds%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8089%26doi%3D10.1038%2Fncomms9089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castriotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamhi, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of benzimidazole sulfonamides as orally bioavailable sphingosine 1-phosphate receptor 1 antagonists with in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7057</span>– <span class="NLM_lpage">7075</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7057-7075&issue=17&author=E.+J.+Hennessyauthor=V.+Ozaauthor=A.+Adamauthor=K.+Bythauthor=L.+Castriottaauthor=G.+Grewalauthor=G.+A.+Hamiltonauthor=V.+M.+Kamhiauthor=P.+Lewisauthor=D.+Liauthor=P.+Lyneauthor=L.+Osterauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=L.+Shaauthor=Q.+Suauthor=S.+Wenauthor=Y.+Xueauthor=B.+Yang&title=Identification+and+optimization+of+benzimidazole+sulfonamides+as+orally+bioavailable+sphingosine+1-phosphate+receptor+1+antagonists+with+in+vivo+activity&doi=10.1021%2Facs.jmedchem.5b01078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity</span></div><div class="casAuthors">Hennessy, Edward J.; Oza, Vibha; Adam, Ammar; Byth, Kate; Castriotta, Lillian; Grewal, Gurmit; Hamilton, Geraldine A.; Kamhi, Victor M.; Lewis, Paula; Li, Danyang; Lyne, Paul; Oster, Linda; Rooney, Michael T.; Saeh, Jamal C.; Sha, Li; Su, Qibin; Wen, Shengua; Xue, Yafeng; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7057-7075</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compds. described previously.  Lead compd. 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor phys. properties and metabolic stability.  Evolution of this compd. through structure-activity relationship development and property optimization led to in vivo probes such as 4.  However, this compd. was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chem. efforts were directed at addressing this liability.  By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compds. for further testing in human hepatocytes, we identified lipophilicity as a key mol. property influencing the likelihood of P 450 induction.  Ultimately, we have identified compds. such as 46 and 47, which demonstrate the desired S1P1 antagonist activity while having greatly reduced risk of CYP3A induction in humans.  These compds. have excellent oral bioavailability in preclin. species and exhibit pharmacodynamic effects of S1P1 antagonism in several in vivo models following oral dosing.  Relatively modest antitumor activity was obsd. in multiple xenograft models, however, suggesting that selective S1P1 antagonists would have limited utility as anticancer therapeutics as single agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNi1iJjQfobVg90H21EOLACvtfcHk0ljZo90rzkCGIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7%252FE&md5=28b0841316d6e02b852341ebe9944ef8</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01078%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DCastriotta%26aufirst%3DL.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLewis%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DOster%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520benzimidazole%2520sulfonamides%2520as%2520orally%2520bioavailable%2520sphingosine%25201-phosphate%2520receptor%25201%2520antagonists%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D7057%26epage%3D7075%26doi%3D10.1021%2Facs.jmedchem.5b01078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemagiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudzianowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORgamma/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2017.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29233651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCqtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=85-93&issue=2&author=H.+Gongauthor=D.+S.+Weinsteinauthor=Z.+Luauthor=J.+J.+Duanauthor=S.+Stachuraauthor=L.+Haqueauthor=A.+Karmakarauthor=H.+Hemagiriauthor=D.+K.+Rautauthor=A.+K.+Guptaauthor=J.+Khanauthor=D.+Camacauthor=J.+S.+Sackauthor=A.+Pudzianowskiauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=V.+Borowskiauthor=J.+H.+Xieauthor=H.+Sunauthor=C.+D%E2%80%99Arienzoauthor=M.+Dabrosauthor=M.+A.+Galellaauthor=F.+Wangauthor=C.+A.+Weigeltauthor=Q.+Zhaoauthor=W.+Fosterauthor=J.+E.+Somervilleauthor=L.+M.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Identification+of+bicyclic+hexafluoroisopropyl+alcohol+sulfonamides+as+retinoic+acid+receptor-related+orphan+receptor+gamma+%28RORgamma%2FRORc%29+inverse+agonists.+Employing+structure-based+drug+design+to+improve+pregnane+X+receptor+%28PXR%29+selectivity&doi=10.1016%2Fj.bmcl.2017.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity</span></div><div class="casAuthors">Gong, Hua; Weinstein, David S.; Lu, Zhonghui; Duan, James J.-W.; Stachura, Sylwia; Haque, Lauren; Karmakar, Ananta; Hemagiri, Hemalatha; Raut, Dhanya Kumar; Gupta, Arun Kumar; Khan, Javed; Camac, Dan; Sack, John S.; Pudzianowski, Andrew; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Borowski, Virna; Xie, Jenny H.; Sun, Huadong; D'Arienzo, Celia; Dabros, Marta; Galella, Michael A.; Wang, Faye; Weigelt, Carolyn A.; Zhao, Qihong; Foster, William; Somerville, John E.; Salter-Cid, Luisa M.; Barrish, Joel C.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists.  However, a majority of these compds. showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα).  Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR.  Pharmacodynamic (PD) data for compd. 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclin. pharmacokinetic (PK) studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosFyMm8wpiSbVg90H21EOLACvtfcHk0ljZo90rzkCGIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCqtr%252FJ&md5=be0dfef2d7494dca1979711a03ac7878</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DHemagiri%26aufirst%3DH.%26aulast%3DRaut%26aufirst%3DD.%2BK.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DCamac%26aufirst%3DD.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DPudzianowski%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFoster%26aufirst%3DW.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DIdentification%2520of%2520bicyclic%2520hexafluoroisopropyl%2520alcohol%2520sulfonamides%2520as%2520retinoic%2520acid%2520receptor-related%2520orphan%2520receptor%2520gamma%2520%2528RORgamma%252FRORc%2529%2520inverse%2520agonists.%2520Employing%2520structure-based%2520drug%2520design%2520to%2520improve%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D85%26epage%3D93%26doi%3D10.1016%2Fj.bmcl.2017.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chellaraj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzweiler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosley, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3194</span>– <span class="NLM_lpage">3196</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30146095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wiu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3194-3196&issue=19&author=R.+J.+Vazauthor=Y.+Liauthor=V.+Chellarajauthor=S.+Reilingauthor=T.+Kuntzweilerauthor=D.+Yangauthor=H.+Shenauthor=J.+D.+Batchelorauthor=Y.+Zhangauthor=X.+Chenauthor=L.+R.+McLeanauthor=R.+Kosley&title=Amelioration+of+PXR-mediated+CYP3A4+induction+by+mGluR2+modulators&doi=10.1016%2Fj.bmcl.2018.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators</span></div><div class="casAuthors">Vaz, Roy J.; Li, Yi; Chellaraj, Vinolia; Reiling, Stephan; Kuntzweiler, Theresa; Yang, Donglai; Shen, Hong; Batchelor, Joseph D.; Zhang, Ying; Chen, Xin; McLean, Larry R.; Kosley, Raymond Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3194-3196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This work describes the rational amelioration of Cytochrome P 450 4/5 (CYP3A4/5) induction through the Pregnane-X Receptor (PXR) pathway in a series of compds. that modulate the metabotropic glutamate Receptor 2 (mGluR2) via an allosteric mechanism.  The compds. were initially shown to induce CYP3A4/5 via the gold-std. induction assay measured in primary human hepatocytes.  This was followed up by testing the compds. in a PXR assay which correlated well with the assay in primary cells.  Further, one of the compds. was crystd. with PXR (pdb code 6DUP).  Anal. of this co-crystal structure, together with previously published PXR co-crystal structures, lead to modification ideas.  The compds. synthesized based on these ideas were shown not to be CYP3A4/5 inducers.  The mGluR2 activity of the resulting compds. was maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZvB8bb2rNg7Vg90H21EOLACvtfcHk0ljZo90rzkCGIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wiu7vF&md5=82d75ed0dce08ab5b62827e9a522e463</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChellaraj%26aufirst%3DV.%26aulast%3DReiling%26aufirst%3DS.%26aulast%3DKuntzweiler%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DBatchelor%26aufirst%3DJ.%2BD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcLean%26aufirst%3DL.%2BR.%26aulast%3DKosley%26aufirst%3DR.%26atitle%3DAmelioration%2520of%2520PXR-mediated%2520CYP3A4%2520induction%2520by%2520mGluR2%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D19%26spage%3D3194%26epage%3D3196%26doi%3D10.1016%2Fj.bmcl.2018.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Focken, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofstrand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodchild, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldbrook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkenbrecher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sojo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Empfield, J. R.</span></span> <span> </span><span class="NLM_article-title">Identification of CNS-penetrant aryl sulfonamides as isoform-selective NaV1.6 inhibitors with efficacy in mouse models of epilepsy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9618</span>– <span class="NLM_lpage">9641</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyjsrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9618-9641&issue=21&author=T.+Fockenauthor=K.+Burfordauthor=M.+E.+Grimwoodauthor=A.+Zenovaauthor=J.+C.+Andrezauthor=W.+Gongauthor=M.+Wilsonauthor=M.+Taronauthor=S.+Deckerauthor=V.+Lofstrandauthor=S.+Chowdhuryauthor=N.+Shuartauthor=S.+Linauthor=S.+J.+Goodchildauthor=C.+Youngauthor=M.+Sorianoauthor=P.+K.+Tariauthor=M.+Waldbrookauthor=K.+Nelkenbrecherauthor=R.+Kwanauthor=A.+Lindgrenauthor=G.+de+Boerauthor=S.+Leeauthor=L.+Sojoauthor=R.+J.+DeVitaauthor=C.+J.+Cohenauthor=S.+S.+Wesolowskiauthor=J.+P.+Johnsonauthor=C.+M.+Dehnhardtauthor=J.+R.+Empfield&title=Identification+of+CNS-penetrant+aryl+sulfonamides+as+isoform-selective+NaV1.6+inhibitors+with+efficacy+in+mouse+models+of+epilepsy&doi=10.1021%2Facs.jmedchem.9b01032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy</span></div><div class="casAuthors">Focken, Thilo; Burford, Kristen; Grimwood, Michael E.; Zenova, Alla; Andrez, Jean-Christophe; Gong, Wei; Wilson, Michael; Taron, Matt; Decker, Shannon; Lofstrand, Verner; Chowdhury, Sultan; Shuart, Noah; Lin, Sophia; Goodchild, Samuel J.; Young, Clint; Soriano, Maegan; Tari, Parisa K.; Waldbrook, Matthew; Nelkenbrecher, Karen; Kwan, Rainbow; Lindgren, Andrea; de Boer, Gina; Lee, Stephanie; Sojo, Luis; DeVita, Robert J.; Cohen, Charles J.; Wesolowski, Steven S.; Johnson, J. P.; Dehnhardt, Christoph M.; Empfield, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9618-9641</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonselective antagonists of voltage-gated sodium (NaV) channels have been long used for the treatment of epilepsies.  The efficacy of these drugs is thought to be due to the block of sodium channels on excitatory neurons, primarily NaV1.6 and NaV1.2.  However, these currently marketed drugs require high drug exposure and suffer from narrow therapeutic indexes.  Selective inhibition of NaV1.6, while sparing NaV1.1, is anticipated to provide a more effective and better tolerated treatment for epilepsies.  In addn., block of NaV1.2 may complement the anticonvulsant activity of NaV1.6 inhibition.  We discovered a novel series of aryl sulfonamides as CNS-penetrant, isoform-selective NaV1.6 inhibitors, which also displayed potent block of NaV1.2.  Optimization focused on increasing selectivity over NaV1.1, improving metabolic stability, reducing active efflux, and addressing a pregnane X-receptor liability.  We obtained compds. 30-32, which produced potent anticonvulsant activity in mouse seizure models, including a d.c. maximal electroshock seizure assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIs_b1ouzZDbVg90H21EOLACvtfcHk0lg_n30nYEKFdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyjsrnM&md5=aecc63b693edbbd19fa88b0696e0f123</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01032%26sid%3Dliteratum%253Aachs%26aulast%3DFocken%26aufirst%3DT.%26aulast%3DBurford%26aufirst%3DK.%26aulast%3DGrimwood%26aufirst%3DM.%2BE.%26aulast%3DZenova%26aufirst%3DA.%26aulast%3DAndrez%26aufirst%3DJ.%2BC.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DWilson%26aufirst%3DM.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DS.%26aulast%3DLofstrand%26aufirst%3DV.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DShuart%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DGoodchild%26aufirst%3DS.%2BJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DM.%26aulast%3DTari%26aufirst%3DP.%2BK.%26aulast%3DWaldbrook%26aufirst%3DM.%26aulast%3DNelkenbrecher%26aufirst%3DK.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DLindgren%26aufirst%3DA.%26aulast%3Dde%2BBoer%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DSojo%26aufirst%3DL.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BP.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DEmpfield%26aufirst%3DJ.%2BR.%26atitle%3DIdentification%2520of%2520CNS-penetrant%2520aryl%2520sulfonamides%2520as%2520isoform-selective%2520NaV1.6%2520inhibitors%2520with%2520efficacy%2520in%2520mouse%2520models%2520of%2520epilepsy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D21%26spage%3D9618%26epage%3D9641%26doi%3D10.1021%2Facs.jmedchem.9b01032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Laak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klint, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neagoe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux-Biehlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahllof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puetter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nubbemeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmeyer, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of the potent and selective P2 × 4 inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11194</span>– <span class="NLM_lpage">11217</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01304</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01304" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11194-11217&issue=24&author=S.+Wernerauthor=S.+Meschauthor=R.+C.+Hilligauthor=A.+Ter+Laakauthor=J.+Klintauthor=I.+Neagoeauthor=A.+Laux-Biehlmannauthor=H.+Dahllofauthor=N.+Brauerauthor=V.+Puetterauthor=R.+Nubbemeyerauthor=S.+Schulzauthor=M.+Bairleinauthor=T.+M.+Zollnerauthor=A.+Steinmeyer&title=Discovery+and+characterization+of+the+potent+and+selective+P2+%C3%97+4+inhibitor+N-%5B4-%283-Chlorophenoxy%29-3-sulfamoylphenyl%5D-2-phenylacetamide+%28BAY-1797%29+and+structure-guided+amelioration+of+its+CYP3A4+induction+profile&doi=10.1021%2Facs.jmedchem.9b01304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile</span></div><div class="casAuthors">Werner, Stefan; Mesch, Stefanie; Hillig, Roman C.; ter Laak, Antonius; Klint, Julie; Neagoe, Ioana; Laux-Biehlmann, Alexis; Dahlloef, Henrik; Braeuer, Nico; Puetter, Vera; Nubbemeyer, Reinhard; Schulz, Simone; Bairlein, Michaela; Zollner, Thomas M.; Steinmeyer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11194-11217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The P2X4 receptor is a ligand-gated ion channel that is expressed on a variety of cell types, esp. those involved in inflammatory and immune processes.  High-throughput screening led to a new class of P2X4 inhibitors with substantial CYP 3A4 induction in human hepatocytes.  A structure-guided optimization with respect to decreased pregnane X receptor (PXR) binding was started.  It was found that the introduction of larger and more polar substituents on the ether linker led to less PXR binding while maintaining the P2X4 inhibitory potency.  This translated into significantly reduced CYP 3A4 induction for compds. 71 and 73.  Unfortunately, the in vivo pharmacokinetic (PK) profiles of these compds. were insufficient for the desired profile in humans.  However, BAY-1797 (10) was identified and characterized as a potent and selective P2X4 antagonist.  This compd. is suitable for in vivo studies in rodents, and the anti-inflammatory and anti-nociceptive effects of BAY-1797 were demonstrated in a mouse complete Freund's adjuvant (CFA) inflammatory pain model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob3M_JZ6IYi7Vg90H21EOLACvtfcHk0lg_n30nYEKFdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nt7bL&md5=412d7541969d82bdb8afcc9fc1030e25</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01304%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DMesch%26aufirst%3DS.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DTer%2BLaak%26aufirst%3DA.%26aulast%3DKlint%26aufirst%3DJ.%26aulast%3DNeagoe%26aufirst%3DI.%26aulast%3DLaux-Biehlmann%26aufirst%3DA.%26aulast%3DDahllof%26aufirst%3DH.%26aulast%3DBrauer%26aufirst%3DN.%26aulast%3DPuetter%26aufirst%3DV.%26aulast%3DNubbemeyer%26aufirst%3DR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DBairlein%26aufirst%3DM.%26aulast%3DZollner%26aufirst%3DT.%2BM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520the%2520potent%2520and%2520selective%2520P2%2520%25C3%2597%25204%2520inhibitor%2520N-%255B4-%25283-Chlorophenoxy%2529-3-sulfamoylphenyl%255D-2-phenylacetamide%2520%2528BAY-1797%2529%2520and%2520structure-guided%2520amelioration%2520of%2520its%2520CYP3A4%2520induction%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11194%26epage%3D11217%26doi%3D10.1021%2Facs.jmedchem.9b01304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanteru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of phenyl (3-phenylpyrrolidin-3-yl)sulfones as selective, orally active RORgamm inverse agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVyltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367-373&issue=3&author=J.+J.+Duanauthor=Z.+Luauthor=B.+Jiangauthor=S.+Stachuraauthor=C.+A.+Weigeltauthor=J.+S.+Sackauthor=J.+Khanauthor=M.+Ruzanovauthor=M.+A.+Galellaauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=D.+J.+Shusterauthor=V.+Borowskiauthor=J.+H.+Xieauthor=L.+Zhangauthor=S.+Vanteruauthor=A.+K.+Guptaauthor=A.+Mathurauthor=Q.+Zhaoauthor=W.+Fosterauthor=L.+M.+Salter-Cidauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Structure-based+discovery+of+phenyl+%283-phenylpyrrolidin-3-yl%29sulfones+as+selective%2C+orally+active+RORgamm+inverse+agonists&doi=10.1021%2Facsmedchemlett.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists</span></div><div class="casAuthors">Duan, James J.-W.; Lu, Zhonghui; Jiang, Bin; Stachura, Sylwia; Weigelt, Carolyn A.; Sack, John S.; Khan, Javed; Ruzanov, Max; Galella, Michael A.; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Shuster, David J.; Borowski, Virna; Xie, Jenny H.; Zhang, Lisa; Vanteru, Sridhar; Gupta, Arun Kumar; Mathur, Arvind; Zhao, Qihong; Foster, William; Salter-Cid, Luisa M.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new Ph (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1.  Through a combination of structure-based design and structure-activity relationship studies, a polar set of amides at N1-position of the pyrrolidine ring and perfluoroisopropyl group at para-position of the 3-Ph group were identified as crit. structural elements to achieve high selectivity against PXR, LXRα, and LXRβ.  Further optimization led to the discovery of (1R,4r)-4-((R)-3-((4-fluorophenyl)sulfonyl)-3-(4-(perfluoropropan-2-yl)phenyl)pyrrolidine-1-carbonyl)cyclohexane-1-carboxylic acid (26), which displayed excellent selectivity, desirable liability and pharmacokinetic properties in vitro, and a good pharmacokinetic profile in mouse.  Oral administration of 26 demonstrated dose-dependent inhibition of IL-17 prodn. in a mouse IL-2/IL-23-induced pharmacodynamic model and biol.-like efficacy in an IL-23-induced mouse acanthosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZBJUkp-y6zbVg90H21EOLACvtfcHk0lgSjfqF0rOUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVyltLw%253D&md5=16114ce5cec852904e038f8d33be67a1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DVanteru%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFoster%26aufirst%3DW.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DStructure-based%2520discovery%2520of%2520phenyl%2520%25283-phenylpyrrolidin-3-yl%2529sulfones%2520as%2520selective%252C%2520orally%2520active%2520RORgamm%2520inverse%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D3%26spage%3D367%26epage%3D373%26doi%3D10.1021%2Facsmedchemlett.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torquato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellezza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, F.</span></span> <span> </span><span class="NLM_article-title">Garcinoic acid is a natural and selective agonist of pregnane X receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3701</span>– <span class="NLM_lpage">3712</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3701-3712&issue=7&author=D.+Bartoliniauthor=F.+De+Francoauthor=P.+Torquatoauthor=R.+Marinelliauthor=B.+Cerraauthor=R.+Ronchettiauthor=A.+Schonauthor=F.+Fallarinoauthor=A.+De+Lucaauthor=G.+Bellezzaauthor=I.+Ferriauthor=A.+Sidoniauthor=W.+G.+Waltonauthor=S.+J.+Pellockauthor=M.+R.+Redinboauthor=S.+Maniauthor=R.+Pellicciariauthor=A.+Gioielloauthor=F.+Galli&title=Garcinoic+acid+is+a+natural+and+selective+agonist+of+pregnane+X+receptor&doi=10.1021%2Facs.jmedchem.0c00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor</span></div><div class="casAuthors">Bartolini, Desiree; De Franco, Francesca; Torquato, Pierangelo; Marinelli, Rita; Cerra, Bruno; Ronchetti, Riccardo; Schon, Arne; Fallarino, Francesca; De Luca, Antonella; Bellezza, Guido; Ferri, Ivana; Sidoni, Angelo; Walton, William G.; Pellock, Samuel J.; Redinbo, Matthew R.; Mani, Sridhar; Pellicciari, Roberto; Gioiello, Antimo; Galli, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3701-3712</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) is a master xenobiotic-sensing transcription factor and a validated target for immune and inflammatory diseases.  The identification of chem. probes to investigate the therapeutic relevance of the receptor is still highly desired.  In fact, currently available PXR ligands are not highly selective and can exhibit toxicity and/or potential off-target effects.  In this study, we have identified garcinoic acid as a selective and efficient PXR agonist.  The properties of this natural mol. as a specific PXR agonist were demonstrated by the screening on a panel of nuclear receptors, the assessment of the phys. and thermodn. binding affinity, and the detn. of the PXR-garcinoic acid complex crystal structure.  Cytotoxicity, transcriptional, and functional properties were investigated in human liver cells, and compd. activity and target engagement were confirmed in vivo in mouse liver and gut tissue.  In conclusion, garcinoic acid is a selective natural agonist of PXR and a promising lead compd. toward the development of new PXR-regulating modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpzvQ2Jz97SbVg90H21EOLACvtfcHk0lgSjfqF0rOUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWkuro%253D&md5=1ece939693aca922c4cf745fe1fb9664</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00012%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DD.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DTorquato%26aufirst%3DP.%26aulast%3DMarinelli%26aufirst%3DR.%26aulast%3DCerra%26aufirst%3DB.%26aulast%3DRonchetti%26aufirst%3DR.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DBellezza%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DI.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DWalton%26aufirst%3DW.%2BG.%26aulast%3DPellock%26aufirst%3DS.%2BJ.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DGioiello%26aufirst%3DA.%26aulast%3DGalli%26aufirst%3DF.%26atitle%3DGarcinoic%2520acid%2520is%2520a%2520natural%2520and%2520selective%2520agonist%2520of%2520pregnane%2520X%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D7%26spage%3D3701%26epage%3D3712%26doi%3D10.1021%2Facs.jmedchem.0c00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klakouski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discotto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peese, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhulu Naidu, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">127531</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32890685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127531&issue=22&author=P.+Sivaprakasamauthor=Z.+Wangauthor=N.+A.+Meanwellauthor=J.+A.+Khanauthor=D.+R.+Langleyauthor=S.+R.+Johnsonauthor=G.+Liauthor=A.+Pendriauthor=T.+P.+Connollyauthor=M.+Gaoauthor=D.+M.+Camacauthor=C.+Klakouskiauthor=T.+Zvyagaauthor=C.+Cianciauthor=B.+McAuliffeauthor=B.+Dingauthor=L.+Discottoauthor=M.+R.+Krystalauthor=S.+Jenkinsauthor=K.+M.+Peeseauthor=B.+Narasimhulu+Naidu&title=Structure-based+amelioration+of+PXR+transactivation+in+a+novel+series+of+macrocyclic+allosteric+inhibitors+of+HIV-1+integrase&doi=10.1016%2Fj.bmcl.2020.127531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Wang, Zhongyu; Meanwell, Nicholas A.; Khan, Javed A.; Langley, David R.; Johnson, Stephen R.; Li, Guo; Pendri, Annapurna; Connolly, Timothy P.; Gao, Mian; Camac, Daniel M.; Klakouski, Cheryl; Zvyaga, Tatyana; Cianci, Christopher; McAuliffe, Brian; Ding, Bo; Discotto, Linda; Krystal, Mark R.; Jenkins, Susan; Peese, Kevin M.; Narasimhulu Naidu, B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">127531</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivs. as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture.  However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition pathways.  In an attempt to modify PXR activity without affecting anti-HIV-1 activity, rational structure-based design and modeling approaches were used.  An X-ray cocrystal structure of (S,S)-1 in the PXR ligand binding domain (LBD) allowed an examn. of the potential of rational structural modifications designed to abrogate PXR.  The introduction of bulky basic amines at the C-8 position provided macrocyclic IZP derivs. that displayed potent HIV-1 inhibitory activity in cell culture with no detectable PXR transactivation at the highest concn. tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iQTZwxuzbLVg90H21EOLACvtfcHk0ljL5PRC_h9J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsbzF&md5=6c5aa7db7e553e2fea5cf9c4da1c25b2</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127531%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DKlakouski%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DB.%26aulast%3DDiscotto%26aufirst%3DL.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DPeese%26aufirst%3DK.%2BM.%26aulast%3DNarasimhulu%2BNaidu%26aufirst%3DB.%26atitle%3DStructure-based%2520amelioration%2520of%2520PXR%2520transactivation%2520in%2520a%2520novel%2520series%2520of%2520macrocyclic%2520allosteric%2520inhibitors%2520of%2520HIV-1%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127531%26doi%3D10.1016%2Fj.bmcl.2020.127531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roehrig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnoth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puetter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitmeier, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological characterization of a neutral, non-prodrug thrombin inhibitor with good oral pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12574</span>– <span class="NLM_lpage">12594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKlsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12574-12594&issue=21&author=A.+Hillischauthor=K.+M.+Gerickeauthor=S.+Allerheiligenauthor=S.+Roehrigauthor=M.+Schaeferauthor=A.+Tersteegenauthor=S.+Schulzauthor=P.+Lienauauthor=M.+Gnothauthor=V.+Puetterauthor=R.+C.+Hilligauthor=S.+Heitmeier&title=Design%2C+synthesis%2C+and+pharmacological+characterization+of+a+neutral%2C+non-prodrug+thrombin+inhibitor+with+good+oral+pharmacokinetics&doi=10.1021%2Facs.jmedchem.0c01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics</span></div><div class="casAuthors">Hillisch, Alexander; Gericke, Kersten M.; Allerheiligen, Swen; Roehrig, Susanne; Schaefer, Martina; Tersteegen, Adrian; Schulz, Simone; Lienau, Philip; Gnoth, Mark; Puetter, Vera; Hillig, Roman C.; Heitmeier, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12574-12594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite extensive research on small mol. thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug.  We have undertaken major efforts to identify neutral, non-prodrug inhibitors.  Using a holistic anal. of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability.  In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochem. properties to balance absorption and metabolic stability.  Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P 450 3A4 induction problem.  The selected compd. series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivs.  The resulting optimized compd., BAY1217224, has reached first clin. trials, which have confirmed the desired pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH5c8QWf1cdrVg90H21EOLACvtfcHk0ljL5PRC_h9J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKlsbfL&md5=d1230b8fb189a2b3d5164d49637f77b3</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01035%26sid%3Dliteratum%253Aachs%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DGericke%26aufirst%3DK.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DRoehrig%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DTersteegen%26aufirst%3DA.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DGnoth%26aufirst%3DM.%26aulast%3DPuetter%26aufirst%3DV.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DHeitmeier%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%2520of%2520a%2520neutral%252C%2520non-prodrug%2520thrombin%2520inhibitor%2520with%2520good%2520oral%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D21%26spage%3D12574%26epage%3D12594%26doi%3D10.1021%2Facs.jmedchem.0c01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toporova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">Assessing the selectivity of FXR, LXRs, CAR, and RORgamma pharmaceutical ligands with reporter cell lines</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1122</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.01122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3389%2Ffphar.2020.01122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32792956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlSitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1122&author=L.+Toporovaauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=P.+Balaguer&title=Assessing+the+selectivity+of+FXR%2C+LXRs%2C+CAR%2C+and+RORgamma+pharmaceutical+ligands+with+reporter+cell+lines&doi=10.3389%2Ffphar.2020.01122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the selectivity of FXR, LXRs, CAR, and RORγ pharmaceutical ligands with reporter cell lines</span></div><div class="casAuthors">Toporova, Lucia; Grimaldi, Marina; Boulahtouf, Abdelhay; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1122</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">To characterize human nuclear receptor (NR) specificity of synthetic pharmaceutical chems. we established stable cell lines expressing the ligand binding domains (LBDs) of human FXR, LXRa, LXRb, CAR, and RORγ fused to the yeast GAL4 DNA binding domain (DBD).  As we have already done for human PXR, a two-step transfection procedure was used.  HeLa cells stably expressing a Gal4 responsive gene (HG5LN cell line) were transfected by Gal4-NRs expressing plasmids.  At first, using these cell lines as well as the HG5LN PXR cells, we demonstrated that the basal activities varied from weak (FXR and LXRs), intermediate (PXR), to strong (CAR and RORγ), reflecting the recruitment of HeLa co-regulators in absence of ligand.  Secondly, we finely characterized the activities of com. available FXR, LXRa, LXRb, CAR, RORγ, and PXR agonists/antagonists GW4064, feraxamine, DY268, T0901317, GW3965, WAY252623, SR9238, SR9243, GSK2033, CITCO, CINPA1, PK11195, S07662, SR1078, SR0987, SR1001, SR2211, XY018, clotrimazole, dabrafenib, SR12813, and SPA70, resp.  Among these compds. we revealed both, receptor specific agonists/antagonists, as well as less selective ligands, activating or inhibiting several nuclear receptors.  FXR ligands manifested high receptor selectivity.  Vice versa, LXR ligands behaved in non-selective manner, all activating at least PXR.  CAR was selectively influenced by their ligands, while it also responded to several LXR ligands.  Finally, although PXR was quite selectively activated or antagonized by its own ligands, it responded to several NRs ligands as well.  Thus, using these reporter cell lines enabled us to precisely characterize the selectivity of pharmaceutical ligands for different nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPsrgA4IC48rVg90H21EOLACvtfcHk0ljL5PRC_h9J0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlSitbvF&md5=5990f8dc695e3c448125bb66f680ba77</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.01122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.01122%26sid%3Dliteratum%253Aachs%26aulast%3DToporova%26aufirst%3DL.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DAssessing%2520the%2520selectivity%2520of%2520FXR%252C%2520LXRs%252C%2520CAR%252C%2520and%2520RORgamma%2520pharmaceutical%2520ligands%2520with%2520reporter%2520cell%2520lines%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D1122%26doi%3D10.3389%2Ffphar.2020.01122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span> <span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&issue=2&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0lh5jHk_5rPmqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D2%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngan, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudnitskaya, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">The structural basis of pregnane X receptor binding promiscuity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">11572</span>– <span class="NLM_lpage">11581</span>, <span class="refDoi"> DOI: 10.1021/bi901578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKrsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=11572-11581&issue=48&author=C.+H.+Nganauthor=D.+Beglovauthor=A.+N.+Rudnitskayaauthor=D.+Kozakovauthor=D.+J.+Waxmanauthor=S.+Vajda&title=The+structural+basis+of+pregnane+X+receptor+binding+promiscuity&doi=10.1021%2Fbi901578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The Structural Basis of Pregnane X Receptor Binding Promiscuity</span></div><div class="casAuthors">Ngan, Chi-Ho; Beglov, Dmitri; Rudnitskaya, Aleksandra N.; Kozakov, Dima; Waxman, David J.; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">11572-11581</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The steroid and xenobiotic-responsive human pregnane X receptor (PXR) binds a broad range of structurally diverse compds.  The structures of the apo and ligand-bound forms of PXR are very similar, in contrast to most promiscuous proteins that generally adapt their shape to different ligands.  The authors investigated the structural origins of PXR's recognition promiscuity using computational solvent mapping, a technique developed for the identification and characterization of hot spots, i.e., regions of the protein surface that are major contributors to the binding free energy.  Results reveal that the smooth and nearly spherical binding site of PXR has a well-defined hot spot structure, with four hot spots located on four different sides of the pocket and a fifth close to its center.  Three of these hot spots are already present in the ligand-free protein.  The most important hot spot is defined by three structurally and sequentially conserved residues, W299, F288, and Y306.  This largely hydrophobic site is not very specific and interacts with all known PXR ligands.  Depending on their sizes and shapes, individual PXR ligands extend into two, three, or four more hot spot regions.  The large no. of potential arrangements within the binding site explains why PXR is able to accommodate a large variety of compds.  All five hot spots include at least one important residue, which is conserved in all mammalian PXRs, suggesting that the hot spot locations have remained largely invariant during mammalian evolution.  The same side chains also show a high level of structural conservation across hPXR structures.  However, each of the hPXR hot spots also includes residues with moveable side chains, further increasing the size variation in ligands that PXR can bind.  Results also suggest a unique signal transduction mechanism between the PXR homodimerization interface and its coactivator binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9monJ4ISxxrVg90H21EOLACvtfcHk0lh5jHk_5rPmqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKrsb3E&md5=6d5d3c85fd1cffedc4e6610cb3c4914a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Fbi901578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901578n%26sid%3Dliteratum%253Aachs%26aulast%3DNgan%26aufirst%3DC.%2BH.%26aulast%3DBeglov%26aufirst%3DD.%26aulast%3DRudnitskaya%26aufirst%3DA.%2BN.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DThe%2520structural%2520basis%2520of%2520pregnane%2520X%2520receptor%2520binding%2520promiscuity%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26issue%3D48%26spage%3D11572%26epage%3D11581%26doi%3D10.1021%2Fbi901578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani Tagliabue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonati, L.</span></span> <span> </span><span class="NLM_article-title">Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16207</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-34373-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1038%2Fs41598-018-34373-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=30385820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BB3cvlslOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=16207&author=S.+Mottaauthor=L.+Calleaauthor=S.+Giani+Tagliabueauthor=L.+Bonati&title=Exploring+the+PXR+ligand+binding+mechanism+with+advanced+Molecular+Dynamics+methods&doi=10.1038%2Fs41598-018-34373-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods</span></div><div class="casAuthors">Motta Stefano; Callea Lara; Giani Tagliabue Sara; Bonati Laura</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16207</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Pregnane X Receptor (PXR) is a ligand-activated transcription factor belonging to the nuclear receptor family.  PXR can bind diverse drugs and environmental toxicants with different binding modes, making it an intriguing target for drug discovery.  Here we investigated the binding mechanism of the SR12813 ligand to elucidate the significant steps, from the ligand entrance pathway into the binding cavity, to the ligand-induced conformational changes, and to the exploration of its alternative binding geometries.  We used the advanced Molecular Dynamics-based methods implemented in the BiKi suite and developed specific methodological approaches to overcome the complexity induced by the buried and flexible binding cavity.  The adopted methods provided a full dynamic description of the binding event and allowed rationalization of the observed multiple binding modes.  These results suggest that the same approach could be exploited for the study of other binding processes with similar characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDjtJBTMU9EAHqQV89nF-2fW6udTcc2eavnoY5_qy00Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvlslOntg%253D%253D&md5=6a528d82c22cc7296caf74d2cde4e68c</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-34373-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-34373-z%26sid%3Dliteratum%253Aachs%26aulast%3DMotta%26aufirst%3DS.%26aulast%3DCallea%26aufirst%3DL.%26aulast%3DGiani%2BTagliabue%26aufirst%3DS.%26aulast%3DBonati%26aufirst%3DL.%26atitle%3DExploring%2520the%2520PXR%2520ligand%2520binding%2520mechanism%2520with%2520advanced%2520Molecular%2520Dynamics%2520methods%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D16207%26doi%3D10.1038%2Fs41598-018-34373-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulators of PXR and CAR</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1859</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2016.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bbagrm.2016.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12nt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1859&publication_year=2016&pages=1141-1154&issue=9&author=S.+C.+Chaiauthor=M.+T.+Cherianauthor=Y.+M.+Wangauthor=T.+Chen&title=Small-molecule+modulators+of+PXR+and+CAR&doi=10.1016%2Fj.bbagrm.2016.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulators of PXR and CAR</span></div><div class="casAuthors">Chai, Sergio C.; Cherian, Milu T.; Wang, Yue-Ming; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1859</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1141-1154</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two nuclear receptors, the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR), participate in the xenobiotic detoxification system by regulating the expression of drug-metabolizing enzymes and transporters in order to degrade and excrete foreign chems. or endogenous metabolites.  This review aims to expand the perceived relevance of PXR and CAR beyond their established role as master xenosensors to disease-oriented areas, emphasizing their modulation by small mols.  Structural studies of these receptors have provided much-needed insight into the nature of their binding promiscuity and the important elements that lead to ligand binding.  Reports of species- and isoform-selective activation highlight the need for further scrutiny when extrapolating from animal data to humans, as animal models are at the forefront of early drug discovery.  This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr.  Wen Xie.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDuudq7xVhrVg90H21EOLACvtfcHk0lh5jHk_5rPmqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12nt7c%253D&md5=9caac4ee368cff75ae6201f383bb0332</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2016.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2016.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DS.%2BC.%26aulast%3DCherian%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DSmall-molecule%2520modulators%2520of%2520PXR%2520and%2520CAR%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2016%26volume%3D1859%26issue%3D9%26spage%3D1141%26epage%3D1154%26doi%3D10.1016%2Fj.bbagrm.2016.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span> <span> </span><span class="NLM_article-title">PXR antagonists and implication in drug metabolism</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.3109/03602532.2012.746363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3109%2F03602532.2012.746363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23330542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=60-72&issue=1&author=S.+Maniauthor=W.+Douauthor=M.+R.+Redinbo&title=PXR+antagonists+and+implication+in+drug+metabolism&doi=10.3109%2F03602532.2012.746363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">PXR antagonists and implication in drug metabolism</span></div><div class="casAuthors">Mani, Sridhar; Dou, Wei; Redinbo, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-72</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Adopted orphan nuclear receptor (NR), pregnane X receptor (PXR), plays a central role in the regulation of xeno- and endobiotic metab.  Since the discovery of the functional role of PXR in 1998, there is evolving evidence for the role of PXR agonists in abrogating metabolic pathophysiol. (e.g., cholestasis, hypercholesterolemia, and inflammation).  However, more recently, it is clear that PXR is also an important mediator of adverse xeno- (e.g., enhances acetaminophen toxicity) and endobiotic (e.g., hepatic steatosis) metabolic phenotypes.  Moreover, in cancer therapeutics, PXR activation can induce drug resistance, and there is growing evidence for tissue-specific enhancement of the malignant phenotype.  Thus, in these instances, there may be a role for PXR antagonists.  However, as opposed to the discovery efforts for PXR agonists, there are only a few antagonists described.  The mode of action of these antagonists (e.g., sulforaphane) remains less clear.  Our lab. efforts have focused on this question.  Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.  In this review, we describe our published and unpublished findings on recent structure-function studies involving the azole chem. scaffold.  Further work in the future is needed to fully define potent, more-selective PXR antagonists that may be useful in clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxOh0MSugxrVg90H21EOLACvtfcHk0ljyUCm8n4Tvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaksL4%253D&md5=52e26d69dddea8827caa8d71b3e8c659</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.3109%2F03602532.2012.746363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2012.746363%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DS.%26aulast%3DDou%26aufirst%3DW.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26atitle%3DPXR%2520antagonists%2520and%2520implication%2520in%2520drug%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2013%26volume%3D45%26issue%3D1%26spage%3D60%26epage%3D72%26doi%3D10.3109%2F03602532.2012.746363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Elucidating the ‘Jekyll and Hyde’ nature of PXR: the case for discovering antagonists or allosteric antagonists</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9901-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-009-9901-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19415465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlyls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1807-1815&issue=8&author=A.+Biswasauthor=S.+Maniauthor=M.+R.+Redinboauthor=M.+D.+Krasowskiauthor=H.+Liauthor=S.+Ekins&title=Elucidating+the+%E2%80%98Jekyll+and+Hyde%E2%80%99+nature+of+PXR%3A+the+case+for+discovering+antagonists+or+allosteric+antagonists&doi=10.1007%2Fs11095-009-9901-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the 'Jekyll and Hyde' Nature of PXR: The Case for Discovering Antagonists or Allosteric Antagonists</span></div><div class="casAuthors">Biswas, Arunima; Mani, Sridhar; Redinbo, Matthew R.; Krasowski, Matthew D.; Li, Hao; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1807-1815</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The pregnane X receptor belongs to the nuclear hormone receptor superfamily and is involved in the transcriptional control of numerous genes.  It was originally thought that it was a xenobiotic sensor controlling detoxification pathways.  Recent studies have shown an increasingly important role in inflammation and cancer, supporting its function in abrogating tissue damage.  PXR orthologs and PXR-like pathways have been identified in several non-mammalian species which corroborate a conserved role for PXR in cellular detoxification.  In summary, PXR has a multiplicity of roles in vivo and is being revealed as behaving like a "Jekyll and Hyde" nuclear hormone receptor.  The importance of this review is to elucidate the need for discovery of antagonists of PXR to further probe its biol. and therapeutic applications.  Although several PXR agonists are already reported, virtually nothing is known about PXR antagonists.  Here, we propose the development of PXR antagonists through chem., genetic and mol. modeling approaches.  Based on this review it will be clear that antagonists of PXR and PXR-like pathways will have widespread utility in PXR biol. and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJN0vcXp3bVrVg90H21EOLACvtfcHk0ljyUCm8n4Tvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlyls7o%253D&md5=b1e19595ac79f661f55faeff53a8515a</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9901-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9901-7%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DA.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DElucidating%2520the%2520%25E2%2580%2598Jekyll%2520and%2520Hyde%25E2%2580%2599%2520nature%2520of%2520PXR%253A%2520the%2520case%2520for%2520discovering%2520antagonists%2520or%2520allosteric%2520antagonists%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26issue%3D8%26spage%3D1807%26epage%3D1815%26doi%3D10.1007%2Fs11095-009-9901-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchman, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span> <span> </span><span class="NLM_article-title">Mutation of a single amino acid of pregnane X receptor switches an antagonist to agonist by altering AF-2 helix positioning</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1007/s00018-020-03505-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00018-020-03505-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32232515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFKhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2021&pages=317-335&author=A.+D.+Huberauthor=W.+C.+Wrightauthor=W.+Linauthor=K.+Majumderauthor=J.+A.+Lowauthor=J.+Wuauthor=C.+D.+Buchmanauthor=D.+J.+Pintelauthor=T.+Chen&title=Mutation+of+a+single+amino+acid+of+pregnane+X+receptor+switches+an+antagonist+to+agonist+by+altering+AF-2+helix+positioning&doi=10.1007%2Fs00018-020-03505-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of a single amino acid of pregnane X receptor switches an antagonist to agonist by altering AF-2 helix positioning</span></div><div class="casAuthors">Huber, Andrew D.; Wright, William C.; Lin, Wenwei; Majumder, Kinjal; Low, Jonathan A.; Wu, Jing; Buchman, Cameron D.; Pintel, David J.; Chen, Taosheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">317-335</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) is activated by chems. to transcriptionally regulate drug disposition and possibly decrease drug efficacy and increase resistance, suggesting therapeutic value for PXR antagonists.  We previously reported the antagonist SPA70 and its analog SJB7, which unexpectedly is an agonist.  Here, we describe another unexpected observation: mutating a single residue (W299A) within the PXR ligand-binding domain converts SPA70 to an agonist.  After characterizing wild-type and W299A PXR activity profiles, we used mol. dynamics simulations to reveal that in wild-type PXR, agonists stabilize the activation function 2 (AF-2) helix in an "inward" position, but SPA70 displaces the AF-2.  In W299A, however, SPA70 stabilizes the AF-2 "inward", like agonists.  We validated our model by predicting the antagonist SJC2 to be a W299A agonist, which was confirmed exptl.  Our work correlates previously unobserved ligand-induced conformational changes to PXR cellular activity and, for the first time, reveals how PXR antagonists work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6taSvgJPjrVg90H21EOLACvtfcHk0ljyUCm8n4Tvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFKhsL8%253D&md5=a56ffd0d65fdac5dcfbd50cbf6da6ad2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs00018-020-03505-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-020-03505-y%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%2BD.%26aulast%3DWright%26aufirst%3DW.%2BC.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DMajumder%26aufirst%3DK.%26aulast%3DLow%26aufirst%3DJ.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBuchman%26aufirst%3DC.%2BD.%26aulast%3DPintel%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DT.%26atitle%3DMutation%2520of%2520a%2520single%2520amino%2520acid%2520of%2520pregnane%2520X%2520receptor%2520switches%2520an%2520antagonist%2520to%2520agonist%2520by%2520altering%2520AF-2%2520helix%2520positioning%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2021%26volume%3D78%26spage%3D317%26epage%3D335%26doi%3D10.1007%2Fs00018-020-03505-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fauber, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Leon Boenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rene, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6604</span>– <span class="NLM_lpage">6609</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2013.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24239186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslygtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6604-6609&issue=24&author=B.+P.+Fauberauthor=G.+de+Leon+Boenigauthor=B.+Burtonauthor=C.+Eidenschenkauthor=C.+Everettauthor=A.+Gobbiauthor=S.+G.+Hymowitzauthor=A.+R.+Johnsonauthor=M.+Liimattaauthor=P.+Lockeyauthor=M.+Normanauthor=W.+Ouyangauthor=O.+Reneauthor=H.+Wong&title=Structure-based+design+of+substituted+hexafluoroisopropanol-arylsulfonamides+as+modulators+of+RORc&doi=10.1016%2Fj.bmcl.2013.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc</span></div><div class="casAuthors">Fauber, Benjamin P.; de Leon Boenig, Gladys; Burton, Brenda; Eidenschenk, Celine; Everett, Christine; Gobbi, Alberto; Hymowitz, Sarah G.; Johnson, Adam R.; Liimatta, Marya; Lockey, Peter; Norman, Maxine; Ouyang, Wenjun; Rene, Olivier; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6604-6609</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of T0901317 analogs were explored as RORc inverse agonists using the principles of property- and structure-based drug design.  An X-ray co-crystal structure of T0901317 and RORc was obtained and provided mol. insight into why T0901317 functioned as an inverse agonist of RORc; whereas, the same ligand functioned as an agonist of FXR, LXR, and PXR.  The structural data was also used to design inhibitors with improved RORc biochem. and cellular activities.  The improved inhibitors possessed enhanced selectivity profiles (rationalized using the X-ray crystallog. data) against other nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxTcPky8JCMbVg90H21EOLACvtfcHk0ljOXEHiw8P_6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslygtrzL&md5=fb0331ebb12017c746f1a4f791e21637</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3Dde%2BLeon%2BBoenig%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLockey%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DRene%26aufirst%3DO.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DStructure-based%2520design%2520of%2520substituted%2520hexafluoroisopropanol-arylsulfonamides%2520as%2520modulators%2520of%2520RORc%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D24%26spage%3D6604%26epage%3D6609%26doi%3D10.1016%2Fj.bmcl.2013.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T.G.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert
Grafstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span> <span> </span><span class="NLM_article-title">The discovery of BMS-457, a potent and selective CCR1 antagonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3833</span>– <span class="NLM_lpage">3840</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2013.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23707259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Cks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3833-3840&issue=13&author=D.+S.+Gardnerauthor=J.+B.+Santellaauthor=J.+V.+Dunciaauthor=P.+H.+Carterauthor=T.G.M.+Dharauthor=H.+Wuauthor=W.+Guoauthor=C.+Cavallaroauthor=K.+Van+Kirkauthor=M.+Yardeauthor=S.+W.+Bricenoauthor=R.+Robert%0AGrafstromauthor=R.+Liuauthor=S.+R.+Patelauthor=A.+J.+Tebbenauthor=D.+Camacauthor=J.+Khanauthor=A.+Watsonauthor=G.+Yangauthor=A.+Roseauthor=W.+R.+Fosterauthor=M.+E.+Cvijicauthor=P.+Daviesauthor=J.+Hynes&title=The+discovery+of+BMS-457%2C+a+potent+and+selective+CCR1+antagonist&doi=10.1016%2Fj.bmcl.2013.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of BMS-457, a potent and selective CCR1 antagonist</span></div><div class="casAuthors">Gardner, Daniel S.; Santella, Joseph B.; Duncia, John V.; Carter, Percy H.; Dhar, T. G. Murali; Wu, Hong; Guo, Weiwei; Cavallaro, Cullen; Van Kirk, Katy; Yarde, Melissa; Briceno, Stephanie W.; Robert Grafstrom, R.; Liu, Richard; Patel, Sima R.; Tebben, Andrew J.; Camac, Dan; Khan, Javed; Watson, Andrew; Yang, Guchen; Rose, Anne; Foster, William R.; Cvijic, Mary Ellen; Davies, Paul; Hynes, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3833-3840</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor.  Issues of PXR activity, ion-channel potency, and poor metabolic stability were addressed by the addn. of a hydroxyl group to an otherwise lipophilic area in the mol. resulting in the discovery of preclin. candidate BMS-457 for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwglrqThzB7Vg90H21EOLACvtfcHk0ljOXEHiw8P_6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Cks7g%253D&md5=0edb8fb8e1d1a8fd2579a360dee50f47</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.G.M.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DCavallaro%26aufirst%3DC.%26aulast%3DVan%2BKirk%26aufirst%3DK.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DS.%2BW.%26aulast%3DRobert%2BGrafstrom%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCamac%26aufirst%3DD.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DW.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DHynes%26aufirst%3DJ.%26atitle%3DThe%2520discovery%2520of%2520BMS-457%252C%2520a%2520potent%2520and%2520selective%2520CCR1%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3833%26epage%3D3840%26doi%3D10.1016%2Fj.bmcl.2013.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. F.</span></span> <span> </span><span class="NLM_article-title">CXIX.—The formation and stability of spiro-compounds. Part I. spiro-Compounds from cyclohexane</span>. <i>J. Chem. Soc., Trans.</i> <span class="NLM_year" style="font-weight: bold;">1915</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1106</span>, <span class="refDoi"> DOI: 10.1039/CT9150701080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FCT9150701080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADyaC2MXhvVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=1915&pages=1080-1106&author=R.+M.+Beesleyauthor=C.+K.+Ingoldauthor=J.+F.+Thorpe&title=CXIX.%E2%80%94The+formation+and+stability+of+spiro-compounds.+Part+I.+spiro-Compounds+from+cyclohexane&doi=10.1039%2FCT9150701080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Formation and stability of spiro-compounds. I. Spiro-compounds from cyclohexano</span></div><div class="casAuthors">Beesley, Richard M.; Ingold, Christopher K.; Thorpe, Jocelyn F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Transactions</span>
        (<span class="NLM_cas:date">1915</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1080-1106</span>CODEN:
                <span class="NLM_cas:coden">JCHTA3</span>;
        ISSN:<span class="NLM_cas:issn">0368-1645</span>.
    </div><div class="casAbstract">A series of investigations has been undertaken with the object of ascertaining "the effect produced by the alteration of the tetrahedral angle consequent on ring formation, on the formation and stability of a 2nd ring joined to the existing ring by a quaternary C atom common to both."  The hypothesis was advanced that the angle formed by the 2 side chains attached to any 1 C atom of the cyclohexane ring will be altered in proportion to any change in angle between those valencies which participate in ring formation; i. e., the groups attached to 2 side chains emanating from the same C atom of a cyclohexane deriv., type (I), will be closer together than in a corresponding compd. having the open chain structure, type (II).  Expts. show that this hypothesis is probably correct.  For example a trans-spiro-acid, derived from a compd. of type (I) is more stable than trans-caronic acid, derived from a compd. of type (II).  The above hypothesis and another untenable one are presented and discussed in some detail and diagrammatically represented by showing the effect of "strain" on the angles between the valencies (represented by the apices of an inscribed tetrahedron) of a (spherical) C atom.  The bromination of CH2(CH2)4C(CH2CO2H)2 by means of PBr5 and Br led to the formation of a mixt. containing an acid product, probably C5H10>C(CHBrCO2H)(CH2CO2Et) (A), and a neutral product (B).  The latter was shown to be a mixt. of cis-diethyl α,α'-dibromocyclohexane-1,1-diacetate (C) (not obtained in the pure state) and the trans-lactone (D), C5H10>C.CH(CO2Et).O.CO.CHBr, prisms from petroleum or alc., m. 96°, b20 225-30°. (D) was sepd. from the mixt. (B) by the addition of an equal vol. of petroleum (b. 60-70°) and was also synthesized by boiling (C) with C5H5N [whereby only the trans-form of (C) was converted into (D)] or by distg. (C), whereby both the cis- and trans-forms were converted.  The isomeric cis-lactone (D'), microneedles, m. 69-70°, was formed in 25% yield upon distg. (C) from which (D) had been previously removed by means of C5H5N.  α-Hydroxycyclohexane-1,1-diacetic acid lactone (E), C5H10>C.CH(CO2H).O.CO.CH2, b13 240-1°, crystg. after long standing and seeding, microneedles, m. 91-2° (silver salt, amorphous), was formed from (A) by the action of boiling Na2CO3.  The free acid (F) corresponding to (E) could not be isolated and was found to be stable only in the form of its salts.  The amorphous silver salt and cryst. sodium salt of (F) were prepd.  The dianilide of (F), C5H10>C(CH2CONHPh)CH(OH)CONHPh, needles, m. 97°.  The aniline salt of (E), silky needles, m. 104°.  When (A) was added to boiling concd. KOH and the reaction mixt. cooled and acidified, trans-cyclohexane-spiro-cyclopropane-1,2-dicarboxylic acid (G), C5H10>C.CH(CO2H).CHCO2H, flattened needles, m. 237°, was formed.  Its silver salt sepd. in the form of a cryst. powder: its dianilide, needles, m. 292°.  The filtrate from (G) after extn. with Et2O and fractionation under reduced pressure yielded the cis-isomer (H) of (G), needles, m. 198°, more readily formed by distg. (G) which is first converted into the anhydride (J), C5H10>C.CH.CO.O.CO.CH, needles, m. 102°, which on treatment with alkali and subsequent acidification yields (H).  (J) was also readily prepd. by the interaction of (H) and AcCl, whereas (G) is not acted upon by this reagent.  The anilic acid, C5H10>C.CH(CO2H).CHCONHPh, derived from (J), small needles,m. 207° (decompn.); the corresponding anil, m. 119°.  When heated in a sealed tube with 50% concd. HCl at 180° for 5 hrs., (H) is partially reconverted into (G).  On attempting to replace the Br in (D) by an OH group, by means of moist Ag2O, ethyl α-hydroxycyclohexane-1,1-diacetate lactone, C5H10> C.CH2CO.O.CHCO2Et, b21 210°, was obtained and yielded (E) on hydrolysis.  The following hydrolysis products were formed when (D) was treated with boiling 15% aq. NaOH:C5H10>C:CHCO2H (K), m. 92° (identical with Wallach's acid as shown by the formation of the dibromide, m. 135-6°; ref. not given), and the trans-lactonic acid of α,α'-dihydroxycyclohexane-1,1-diacetic acid (L), C5H10>C.CH(OH).CO.O.CHCO2H.H2O, prisms, 100°, anhydrous, m. 145°.  (D') when subjected to a similar hydrolysis gave rise to a mixt. of (K), the cis-isomer (M) of (L), prisms, m. 168°, and cyclohexane-spiro-cyclopropanol-2,3-dicarboxylic acid (N), C5H10>C.C(OH)(CO2H).CHCO2H, pearly plates, m. 217°.  Boiling alc. KOH, reacting with (D), yielded (K), (L) and (N).  The action of 64% aq. KOH on (D) gave rise to a mixt. of (L), (N) and Δ1-cyclohexeneacetic acid, (O), CH2(CH2)3CH:C.CH2CO2H, m. 38° (identical with Wallach's compd.; also quant. formed by boiling (K) with 64% KOH, thus indicating that it was a byproduct in the above reaction).  The Et ester of (O), b25 118-2° (cf. Auwers and Ellinger, C. A. 6, 1147).  A similar reaction between 64% KOH and (D') gave rise to (O), (M) and (N).  (K) and (N) were sepd. by treatment with dry Et2O in which (N) is insol.  (L) was ordinarily sepd. from hydrolysis mixts. by esterifying and fractionating the ethyl ester, b25 206-10°.  The following derivs. of (L) are described: disodium salt, cryst.; disilver salt, powder; aniline salt, microcrystals, m. 133-4°; dianilide, C5H10>C[CH(OH)CONHPh]2, short needles, m. 169°.  (L) does not react with AcCl, is not reduced by AgOH, and when heated with H2O in a sealed tube or when distd., passes into (M).  The isolation of (M) was effected by esterifying hydrolysis mixts. and collecting the fraction of highest b. p., which was subsequently hydrolyzed with HCl.  (M) was readily acetylated.  The following derivs. of (M) were prepd.: disilver salt; dianilide, needles, m. 169° (not identical with the dianilide derived from (L)); acetate, C5H10>CH(OAc).CO.O.CHCO2H, m. 156° (silver salt of the acetate, cryst. powder).  The spiro-acid (N), which like (L) could not be acetylated, which is not converted into the lactone on heating and is otherwise stable, gave rise to the following compds.: silver salt, cryst. powder; anilide, needles, m. 202°.  Concd. H2SO4 acting upon (L) at 95-100°, gave rise to small amts. of cyclohexane-spiro-cyclopentanone, oil (forming a semicarbazone, needles, m. 175°), and an unidentified compd., m. 105°.  When heated with an equal amt. of H2O in a sealed tube at 240° for 0.5 hr., (L) yielded the lactonic acid of α-hydroxy-α'-cyclohexan-1-olsuccinic acid, C5H10>C.O.CO.CH(OH).CHCO2H, cubical prisms, m. 131°, whose disodium salt, disilver salt and aniline salt, m. 123°, were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLfaoba7kGULVg90H21EOLACvtfcHk0lhzYMzqplQKDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaC2MXhvVGiuw%253D%253D&md5=de4306fddc79f71809a8556525abc983</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2FCT9150701080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FCT9150701080%26sid%3Dliteratum%253Aachs%26aulast%3DBeesley%26aufirst%3DR.%2BM.%26aulast%3DIngold%26aufirst%3DC.%2BK.%26aulast%3DThorpe%26aufirst%3DJ.%2BF.%26atitle%3DCXIX.%25E2%2580%2594The%2520formation%2520and%2520stability%2520of%2520spiro-compounds.%2520Part%2520I.%2520spiro-Compounds%2520from%2520cyclohexane%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Trans.%26date%3D1915%26volume%3D107%26spage%3D1080%26epage%3D1106%26doi%3D10.1039%2FCT9150701080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Cortez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truillet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbecker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletterick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, P. M.</span></span> <span> </span><span class="NLM_article-title">Development of 5N-bicalutamide, a high-affinity reversible covalent antiandrogen</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2934</span>– <span class="NLM_lpage">2939</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sksr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2934-2939&issue=12&author=F.+de+Jesus+Cortezauthor=P.+Nguyenauthor=C.+Truilletauthor=B.+Tianauthor=K.+M.+Kuchenbeckerauthor=M.+J.+Evansauthor=P.+Webbauthor=M.+P.+Jacobsonauthor=R.+J.+Fletterickauthor=P.+M.+England&title=Development+of+5N-bicalutamide%2C+a+high-affinity+reversible+covalent+antiandrogen&doi=10.1021%2Facschembio.7b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen</span></div><div class="casAuthors">de Jesus Cortez, Felipe; Nguyen, Phuong; Truillet, Charles; Tian, Boxue; Kuchenbecker, Kristopher M.; Evans, Michael J.; Webb, Paul; Jacobson, Matthew P.; Fletterick, Robert J.; England, Pamela M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2934-2939</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to clin. antiandrogens has plagued the evolution of effective therapeutics for advanced prostate cancer.  As with the first-line therapeutic bicalutamide (Casodex), resistance to newer antiandrogens (enzalutamide, ARN-509) develops quickly in patients, despite the fact that these drugs have ∼10-fold better affinity for androgen receptor than bicalutamide.  Improving affinity alone is often not sufficient to prevent resistance and alternative strategies are needed to improve antiandrogen efficacy.  Covalent and reversible covalent drugs are being used to thwart drug resistance in other contexts, and activated aryl nitriles are among the moieties being exploited for this purpose.  The authors capitalized on the presence of an aryl nitrile in bicalutamide, and the existence of a native cysteine residue (Cys784) in the androgen receptor ligand binding pocket, to develop 5N-bicalutamide I, a cysteine-reactive antiandrogen.  I exhibits a 150-fold improvement in Ki and 20-fold improvement in IC50 over the parent compd.  The authors attribute the marked improvement in affinity and activity to the formation of a covalent adduct with Cys784, a residue that is not among the more than 160 androgen receptor point mutations assocd. with prostate cancer.  Increasing the residence time of bound antiandrogen via formation of a covalent adduct may forestall the drug resistance seen with current clin. antiandrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNOswnQtRSebVg90H21EOLACvtfcHk0lhzYMzqplQKDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sksr%252FP&md5=3871dfbf0cd53790a8e63f84a1157416</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00702%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJesus%2BCortez%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DP.%26aulast%3DTruillet%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DKuchenbecker%26aufirst%3DK.%2BM.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFletterick%26aufirst%3DR.%2BJ.%26aulast%3DEngland%26aufirst%3DP.%2BM.%26atitle%3DDevelopment%2520of%25205N-bicalutamide%252C%2520a%2520high-affinity%2520reversible%2520covalent%2520antiandrogen%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D12%26spage%3D2934%26epage%3D2939%26doi%3D10.1021%2Facschembio.7b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berteotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/ml400489b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400489b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=501-505&issue=5&author=A.+Berteottiauthor=F.+Vacondioauthor=A.+Lodolaauthor=M.+Bassiauthor=C.+Silvaauthor=M.+Morauthor=A.+Cavalli&title=Predicting+the+reactivity+of+nitrile-carrying+compounds+with+cysteine%3A+a+combined+computational+and+experimental+study&doi=10.1021%2Fml400489b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study</span></div><div class="casAuthors">Berteotti, Anna; Vacondio, Federica; Lodola, Alessio; Bassi, Michele; Silva, Claudia; Mor, Marco; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-505</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we report on a mechanistic investigation based on DFT calcns. and kinetic measures aimed at detg. the energetics related to the cysteine nucleophilic attack on nitrile-carrying compds.  Activation energies were found to correlate well with exptl. kinetic measures of reactivity with cysteine in phosphate buffer.  The agreement between computations and expts. points to this DFT-based approach as a tool for predicting both nitrile reactivity toward cysteines and the toxicity of nitriles as electrophile agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow33svQfComrVg90H21EOLACvtfcHk0lhzYMzqplQKDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqs7k%253D&md5=8ccf41d312457a209f372d99e7f88910</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Fml400489b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400489b%26sid%3Dliteratum%253Aachs%26aulast%3DBerteotti%26aufirst%3DA.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DBassi%26aufirst%3DM.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DPredicting%2520the%2520reactivity%2520of%2520nitrile-carrying%2520compounds%2520with%2520cysteine%253A%2520a%2520combined%2520computational%2520and%2520experimental%2520study%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D5%26spage%3D501%26epage%3D505%26doi%3D10.1021%2Fml400489b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oballa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthelette, C.</span></span> <span> </span><span class="NLM_article-title">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2006.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17157022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=998-1002&issue=4&author=R.+M.+Oballaauthor=J.+F.+Truchonauthor=C.+I.+Baylyauthor=N.+Chauretauthor=S.+Dayauthor=S.+Craneauthor=C.+Berthelette&title=A+generally+applicable+method+for+assessing+the+electrophilicity+and+reactivity+of+diverse+nitrile-containing+compounds&doi=10.1016%2Fj.bmcl.2006.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span></div><div class="casAuthors">Oballa, Renata M.; Truchon, Jean-Francois; Bayly, Christopher I.; Chauret, Nathalie; Day, Stephen; Crane, Sheldon; Berthelette, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">998-1002</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrile-based inhibitors of cathepsin K have been known for some time and mechanism-of-action studies have demonstrated that cysteinyl proteases interact with nitriles in a reversible fashion.  Three main classes of nitrile-contg. inhibitors have been published in the cathepsin K field: (i) cyanamides, (ii) arom. nitriles, and (iii) aminoacetonitriles.  A computational approach was used to calc. the theor. reactivities of diverse nitriles and this was found to correlate with their extent of reactivity with free cysteine.  Moreover, there is a tentative link between high reactivity with cysteine and the potential to lead to irreversible covalent binding to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFCCd4sSYvbVg90H21EOLACvtfcHk0lhGTvnYoUO7hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D&md5=b8fff00bdd6a746753f8f244d25b0cc8</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DBerthelette%26aufirst%3DC.%26atitle%3DA%2520generally%2520applicable%2520method%2520for%2520assessing%2520the%2520electrophilicity%2520and%2520reactivity%2520of%2520diverse%2520nitrile-containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D4%26spage%3D998%26epage%3D1002%26doi%3D10.1016%2Fj.bmcl.2006.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Irizarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starr, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uccello, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A.</span></span> <span> </span><span class="NLM_article-title">Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-l-lysine as an amine nucleophile</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1039/C6MD00017G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1039%2FC6MD00017G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=864-872&issue=5&author=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=R.+S.+Obachauthor=M.+E.+Flanaganauthor=J.+M.+Chenauthor=C.+Garcia-Irizarryauthor=J.+T.+Starrauthor=B.+Schuffauthor=D.+P.+Uccelloauthor=J.+A.+Young&title=Intrinsic+reactivity+profile+of+electrophilic+moieties+to+guide+covalent+drug+design%3A+N-%CE%B1-acetyl-l-lysine+as+an+amine+nucleophile&doi=10.1039%2FC6MD00017G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-L-lysine as an amine nucleophile</span></div><div class="casAuthors">Dahal, Upendra P.; Gilbert, Adam M.; Obach, R. Scott; Flanagan, Mark E.; Chen, Jinshan M.; Garcia-Irizarry, Carmen; Starr, Jeremy T.; Schuff, Brandon; Uccello, Daniel P.; Young, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">864-872</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent drugs contain a reactive electrophilic moiety or covalent reactive group (CRG), which forms an irreversible bond between the drug and a biol. target.  Consequently, the intrinsic reactivity of the CRG is an important consideration in the design of irreversible inhibitors.  Although reactivity assessments of CRGs with sulfur nucleophiles, such as glutathione and cysteine have been reported, reactivity of these moieties with amine-contg. nucleophiles is not well described.  In this study, intrinsic reactivities were detd. for a series of electrophiles (acrylamides, nitriles, cyanamides, sulfones, and sulfonamides) using N-α-acetyl-L-lysine as a model amine-based nucleophile and compared with results using glutathione (GSH).  Since the ε-amine of N-α-acetyl-L-lysine is protonated at neutral pH, reactions were carried out at pH 10.2.  In addn. to reporting rate data for reactions of CRGs with N-α-acetyl-L-lysine, elements of selectivity relative to thiol-contg. nucleophiles are also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofuy3ICddAE7Vg90H21EOLACvtfcHk0lhGTvnYoUO7hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFyjtrk%253D&md5=08e681ea8dfb353f89d8cdedba685694</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1039%2FC6MD00017G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00017G%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Irizarry%26aufirst%3DC.%26aulast%3DStarr%26aufirst%3DJ.%2BT.%26aulast%3DSchuff%26aufirst%3DB.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%26atitle%3DIntrinsic%2520reactivity%2520profile%2520of%2520electrophilic%2520moieties%2520to%2520guide%2520covalent%2520drug%2520design%253A%2520N-%25CE%25B1-acetyl-l-lysine%2520as%2520an%2520amine%2520nucleophile%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D864%26epage%3D872%26doi%3D10.1039%2FC6MD00017G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zeeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popplestone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span> <span> </span><span class="NLM_article-title">4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4507</span>– <span class="NLM_lpage">4510</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.06.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20580231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4507-4510&issue=15&author=J.+Caiauthor=X.+Fraderaauthor=M.+van+Zeelandauthor=M.+Dempsterauthor=K.+S.+Cameronauthor=D.+J.+Bennettauthor=J.+Robinsonauthor=L.+Popplestoneauthor=M.+Baughauthor=P.+Westwoodauthor=J.+Bruinauthor=W.+Hamiltonauthor=E.+Kinghornauthor=C.+Longauthor=J.+C.+Uitdehaag&title=4-%283-Trifluoromethylphenyl%29-pyrimidine-2-carbonitrile+as+cathepsin+S+inhibitors%3A+N3%2C+not+N1+is+critically+important&doi=10.1016%2Fj.bmcl.2010.06.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important</span></div><div class="casAuthors">Cai, Jiaqiang; Fradera, Xavier; van Zeeland, Mario; Dempster, Maureen; Cameron, Kenneth S.; Bennett, D. Jonathan; Robinson, John; Popplestone, Lucy; Baugh, Mark; Westwood, Paul; Bruin, John; Hamilton, William; Kinghorn, Emma; Long, Clive; Uitdehaag, Joost C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4507-4510</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using computer aided modeling studies, a new extended P2/S2 interaction was identified.  This extended region can accommodate a variety of functional groups, such as aryls and basic amines.  It was discovered that the N3 nitrogen of the pyrimidine-2-carbonitrile is crit. for its cathepsin cysteine protease inhibition.  N1 nitrogen also contributes to the inhibitory activity, but to a very limited degree.  An in situ double activation' mechanism was proposed to explain these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8NO3F-fwoJrVg90H21EOLACvtfcHk0lhGTvnYoUO7hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSktL8%253D&md5=c4f3a722e29616dca5e47b0c8cbcadef</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.043%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3Dvan%2BZeeland%26aufirst%3DM.%26aulast%3DDempster%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DK.%2BS.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DPopplestone%26aufirst%3DL.%26aulast%3DBaugh%26aufirst%3DM.%26aulast%3DWestwood%26aufirst%3DP.%26aulast%3DBruin%26aufirst%3DJ.%26aulast%3DHamilton%26aufirst%3DW.%26aulast%3DKinghorn%26aufirst%3DE.%26aulast%3DLong%26aufirst%3DC.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26atitle%3D4-%25283-Trifluoromethylphenyl%2529-pyrimidine-2-carbonitrile%2520as%2520cathepsin%2520S%2520inhibitors%253A%2520N3%252C%2520not%2520N1%2520is%2520critically%2520important%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D15%26spage%3D4507%26epage%3D4510%26doi%3D10.1016%2Fj.bmcl.2010.06.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+inhibitors%3A+Applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0lhZmFXBSWcaGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520inhibitors%253A%2520Applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism of decyanation of GDC-0425 by cytochrome P450</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.116.074336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28188299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=430-440&issue=5&author=R.+H.+Takahashiauthor=J.+S.+Halladayauthor=M.+Siuauthor=Y.+Chenauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=S.+Ma&title=Novel+mechanism+of+decyanation+of+GDC-0425+by+cytochrome+P450&doi=10.1124%2Fdmd.116.074336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism of decyanation of GDC-0425 by cytochrome P450</span></div><div class="casAuthors">Takahashi, Ryan H.; Halladay, Jason S.; Siu, Michael; Chen, Yuan; Hop, Cornelis E. C. A.; Khojasteh, S. Cyrus; Ma, Shuguang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GDC-0425 [5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile] is an orally bioavailable small-mol. inhibitor of checkpoint kinase 1 that was investigated as a novel cotherapy to potentiate chemotherapeutic drugs, such as gemcitabine.  In a radiolabeled absorption, distribution, metab., and excretion study in Sprague-Dawley rats, trace-level but long-lived 14C-labeled thiocyanate was obsd. in circulation.  This thiocyanate originated from metabolic decyanation of GDC-0425 and rapid conversion of cyanide to thiocyanate.  Excretion studies indicated decyanation was a minor metabolic pathway, but placing 14C at nitrile magnified its observation.  Cytochrome P450s catalyzed the oxidative decyanation reaction in vitro when tested with liver microsomes, and in the presence of 18O2, one atom of 18O was incorporated into the decyanated product.  To translate this finding to a clin. risk assessment, the total circulating levels of thiocyanate (endogenous plus drug-derived) were measured following repeated administration of GDC-0425 to rats and cynomolgus monkeys.  No overt increases were obsd. with thiocyanate concns. of 121-154 μM in rats and 71-110 μM in monkeys receiving vehicle and all tested doses of GDC-0425.  These findings were consistent with results from the radiolabel rat study where decyanation accounted for conversion of <1% of the administered GDC-0425 and contributed less than 1 μM thiocyanate to systemic levels.  Further, in vitro studies showed only trace oxidative decyanation for humans.  These data indicated that, although cyanide was metabolically released from GDC-0425 and formed low levels of thiocyanate, this pathway was a minor route of metab., and GDC-0425-related increases in systemic thiocyanate were unlikely to pose safety concerns for subjects of clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRG6UnL6fnKrVg90H21EOLACvtfcHk0lhZmFXBSWcaGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLjJ&md5=d971d1844f8a12b17ebed60c50a45e56</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074336%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%2BH.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DMa%26aufirst%3DS.%26atitle%3DNovel%2520mechanism%2520of%2520decyanation%2520of%2520GDC-0425%2520by%2520cytochrome%2520P450%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D430%26epage%3D440%26doi%3D10.1124%2Fdmd.116.074336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvakumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunath, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanteru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrichelvan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Rationally designed, conformationally constrained inverse agonists of RORgammat-identification of a potent, selective series with biologic-like in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9931</span>– <span class="NLM_lpage">9946</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9931-9946&issue=21&author=D.+Marcouxauthor=J.+J.+Duanauthor=Q.+Shiauthor=R.+J.+Cherneyauthor=A.+S.+Srivastavaauthor=L.+Corneliusauthor=D.+G.+Battauthor=Q.+Liuauthor=M.+Beaudoin-Bertrandauthor=C.+A.+Weigeltauthor=P.+Khandelwalauthor=S.+Vishwakrishnanauthor=K.+Selvakumarauthor=A.+Karmakarauthor=A.+K.+Guptaauthor=M.+Bashaauthor=S.+Ramlingamauthor=N.+Manjunathauthor=S.+Vanteruauthor=S.+Karmakarauthor=N.+Maddalaauthor=M.+Vetrichelvanauthor=A.+Guptaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=S.+Yipauthor=P.+Liauthor=D.+R.+Wuauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+S.+Sackauthor=J.+Wangauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=S.+Liauthor=D.+J.+Shusterauthor=V.+Borowskiauthor=J.+H.+Xieauthor=K.+W.+McIntyreauthor=M.+T.+Obermeierauthor=A.+Furaauthor=K.+Stefanskiauthor=G.+Corneliusauthor=J.+Hynesauthor=J.+A.+Tinoauthor=J.+E.+Macorauthor=L.+Salter-Cidauthor=R.+Dentonauthor=Q.+Zhaoauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Rationally+designed%2C+conformationally+constrained+inverse+agonists+of+RORgammat-identification+of+a+potent%2C+selective+series+with+biologic-like+in+vivo+efficacy&doi=10.1021%2Facs.jmedchem.9b01369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy</span></div><div class="casAuthors">Marcoux, David; Duan, James J.-W.; Shi, Qing; Cherney, Robert J.; Srivastava, Anurag S.; Cornelius, Lyndon; Batt, Douglas G.; Liu, Qingjie; Beaudoin-Bertrand, Myra; Weigelt, Carolyn A.; Khandelwal, Purnima; Vishwakrishnan, Sureshbabu; Selvakumar, Kumaravel; Karmakar, Ananta; Gupta, Arun Kumar; Basha, Mushkin; Ramlingam, Sridharan; Manjunath, Naveen; Vanteru, Sridhar; Karmakar, Sukhen; Maddala, Nageswara; Vetrichelvan, Muthalagu; Gupta, Anuradha; Rampulla, Richard A.; Mathur, Arvind; Yip, Shiuhang; Li, Peng; Wu, Dauh-Rurng; Khan, Javed; Ruzanov, Max; Sack, John S.; Wang, Jinhong; Yarde, Melissa; Cvijic, Mary Ellen; Li, Sha; Shuster, David J.; Borowski, Virna; Xie, Jenny H.; McIntyre, Kim W.; Obermeier, Mary T.; Fura, Aberra; Stefanski, Kevin; Cornelius, Georgia; Hynes, John; Tino, Joseph A.; Macor, John E.; Salter-Cid, Luisa; Denton, Rex; Zhao, Qihong; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9931-9946</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RORγt is an important nuclear receptor that regulates the prodn. of several pro-inflammatory cytokines such as IL-17 and IL-22.  As a result, RORγt has been identified as a potential target for the treatment of various immunol. disorders such as psoriasis, psoriatic arthritis and inflammatory bowel diseases.  Structure and computer assisted drug design led to the identification of a novel series of tricyclic RORγt inverse agonists with significantly improved in vitro activity in the reporter (Gal4) and human whole blood assays compared to the previous chemotype.  Through careful SAR, several potent and selective RORγt inverse agonists have been identified.  Pharmacokinetic studies allowed the identification of the lead mol. I with a low peak-to-trough ratio.  This mol. showed excellent activity in an IL-2/IL-23-induced mouse pharmacodynamic study and demonstrated biol.-like efficacy in an IL-23-induced preclin. model of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopLftyCaracbVg90H21EOLACvtfcHk0lhZmFXBSWcaGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7jI&md5=f96792289cff2eed2d072476a160630c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01369%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DKhandelwal%26aufirst%3DP.%26aulast%3DVishwakrishnan%26aufirst%3DS.%26aulast%3DSelvakumar%26aufirst%3DK.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DBasha%26aufirst%3DM.%26aulast%3DRamlingam%26aufirst%3DS.%26aulast%3DManjunath%26aufirst%3DN.%26aulast%3DVanteru%26aufirst%3DS.%26aulast%3DKarmakar%26aufirst%3DS.%26aulast%3DMaddala%26aufirst%3DN.%26aulast%3DVetrichelvan%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DRationally%2520designed%252C%2520conformationally%2520constrained%2520inverse%2520agonists%2520of%2520RORgammat-identification%2520of%2520a%2520potent%252C%2520selective%2520series%2520with%2520biologic-like%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D21%26spage%3D9931%26epage%3D9946%26doi%3D10.1021%2Facs.jmedchem.9b01369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-986251: A clinically viable, potent, and selective RORgammat inverse agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1221-1227&issue=6&author=R.+J.+Cherneyauthor=L.+A.+M.+Corneliusauthor=A.+Srivastavaauthor=C.+A.+Weigeltauthor=D.+Marcouxauthor=J.+J.+Duanauthor=Q.+Shiauthor=D.+G.+Battauthor=Q.+Liuauthor=S.+Yipauthor=D.+R.+Wuauthor=M.+Ruzanovauthor=J.+Sackauthor=J.+Khanauthor=J.+Wangauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=A.+Mathurauthor=S.+Liauthor=D.+Shusterauthor=P.+Khandelwalauthor=V.+Borowskiauthor=J.+Xieauthor=M.+Obermeierauthor=A.+Furaauthor=K.+Stefanskiauthor=G.+Corneliusauthor=J.+A.+Tinoauthor=J.+E.+Macorauthor=L.+Salter-Cidauthor=R.+Dentonauthor=Q.+Zhaoauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Discovery+of+BMS-986251%3A+A+clinically+viable%2C+potent%2C+and+selective+RORgammat+inverse+agonist&doi=10.1021%2Facsmedchemlett.0c00063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist</span></div><div class="casAuthors">Cherney, Robert J.; Cornelius, Lyndon A. M.; Srivastava, Anurag; Weigelt, Carolyn A.; Marcoux, David; Duan, James J.-W.; Shi, Qing; Batt, Douglas G.; Liu, Qingjie; Yip, Shiuhang; Wu, Dauh-Rurng; Ruzanov, Max; Sack, John; Khan, Javed; Wang, Jinhong; Yarde, Melissa; Cvijic, Mary Ellen; Mathur, Arvind; Li, Sha; Shuster, David; Khandelwal, Purnima; Borowski, Virna; Xie, Jenny; Obermeier, Mary; Fura, Aberra; Stefanski, Kevin; Cornelius, Georgia; Tino, Joseph A.; Macor, John E.; Salter-Cid, Luisa; Denton, Rex; Zhao, Qihong; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1221-1227</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel tricyclic analogs were designed, synthesized, and evaluated as RORγt inverse agonists.  Several of these compds. were potent in an IL-17 human whole blood assay and exhibited excellent oral bioavailability in mouse pharmacokinetic studies.  This led to the identification of compd. 5 (I), which displayed dose-dependent inhibition of IL-17F prodn. in a mouse IL-2/IL-23 stimulated pharmacodynamic model.  In addn., compd. 5 was studied in mouse acanthosis and imiquimod-induced models of skin inflammation, where it demonstrated robust efficacy comparable to a pos. control.  As a result of this excellent overall profile, compd. 5 (BMS-986251) was selected as a clin. viable developmental candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVYYYYm5tXnLVg90H21EOLACvtfcHk0lgVi2L-zZBPKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFOjtbY%253D&md5=564e4b778fb70ac5d05acc6f1d205306</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00063%26sid%3Dliteratum%253Aachs%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DKhandelwal%26aufirst%3DP.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DDiscovery%2520of%2520BMS-986251%253A%2520A%2520clinically%2520viable%252C%2520potent%252C%2520and%2520selective%2520RORgammat%2520inverse%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1221%26epage%3D1227%26doi%3D10.1021%2Facsmedchemlett.0c00063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Ligand- and structure-based pregnane X receptor models</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-050-2_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2F978-1-62703-050-2_15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=23007437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2012&pages=359-375&author=S.+Kortagereauthor=M.+D.+Krasowskiauthor=S.+Ekins&title=Ligand-+and+structure-based+pregnane+X+receptor+models&doi=10.1007%2F978-1-62703-050-2_15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand- and structure-based pregnane X receptor models</span></div><div class="casAuthors">Kortagere, Sandhya; Krasowski, Matthew D.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Computational Toxicology, Volume I</span>),
    <span class="NLM_cas:pages">359-375</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a ligand dependent transcription factor that can be activated by structurally diverse agonists including steroid hormones, bile acids, herbal drugs, and prescription medications.  PXR regulates the transcription of several genes involved in xenobiotic detoxification and apoptosis.  Activation of PXR has the potential to initiate adverse effects by altering drug pharmacokinetics or perturbing physiol. processes.  Hence, more reliable prediction of PXR activators would be valuable for pharmaceutical drug discovery to avoid potential toxic effects.  Ligand- and protein structure-based computational models for PXR activation have been developed in several studies.  There has been limited success with structure-based modeling approaches to predict human PXR activators, which can be attributed to the large and promiscuous site of this protein.  Slightly better success has been achieved with ligand-based modeling methods including quant. structure-activity relationship (QSAR) anal., pharmacophore modeling and machine learning that use appropriate descriptors to account for the diversity of the ligand classes that bind to PXR.  These combined computational approaches using mol. shape information may assist scientists to more confidently identify PXR activators.  This chapter reviews the various ligand and structure based methods undertaken to date and their results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqJD7yRO3KbVg90H21EOLACvtfcHk0lgVi2L-zZBPKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2htrw%253D&md5=34f0180db44e223a19e735535be1dcc8</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-050-2_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-050-2_15%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLigand-%2520and%2520structure-based%2520pregnane%2520X%2520receptor%2520models%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D929%26spage%3D359%26epage%3D375%26doi%3D10.1007%2F978-1-62703-050-2_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batayneh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambucetti, L.</span></span> <span> </span><span class="NLM_article-title">PXR and the regulation of apoA1 and HDL-cholesterol in rodents</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2004.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.phrs.2004.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15225665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1agt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=237-246&issue=3&author=K.+Bachmannauthor=H.+Patelauthor=Z.+Bataynehauthor=J.+Slamaauthor=D.+Whiteauthor=J.+Poseyauthor=S.+Ekinsauthor=D.+Goldauthor=L.+Sambucetti&title=PXR+and+the+regulation+of+apoA1+and+HDL-cholesterol+in+rodents&doi=10.1016%2Fj.phrs.2004.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">PXR and the regulation of apoA1 and HDL-cholesterol in rodents</span></div><div class="casAuthors">Bachmann, Kenneth; Patel, Hiral; Batayneh, Zaid; Slama, James; White, Donald; Posey, Julie; Ekins, Sean; Gold, David; Sambucetti, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-246</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Orphan nuclear receptors (ONRs) have been implicated in the regulation of lipids.  Several clin. studies conducted either prospectively or epidemiol. have pointed to a link between the regulation of hepatic CYP enzymes and HDL-cholesterol (HDL-C) and/or apolipoprotein A1 (apoA1).  The treatment of rats with a series of imidazole inducers of CYP3A yielded correlations between in vitro CYP3A activity measured as erythromycin demethylase activity and plasma HDL-C and hepatic apoA1 mRNA.  Similarly, a correlation was established between in vivo CYP3A activity, measured as ethosuximide clearance, and plasma HDL-C and hepatic apoA1 mRNA.  The treatment of wild-type (WT) mice with PXR agonists elicited increases in serum HDL-C and serum apoA1 levels.  On the other hand, the treatment of PXR-knockout mice (PXR-KOs) with the same PXR agonists failed to elicit increases in either serum HDL-C or serum apoA1 levels.  Superposition of the structures of three imidazoles known to be active CYP3A inducers in rats with the human PXR pharmacophore demonstrated a partial fit and predicted EC50 values typical of weak-moderate hPXR inducers in humans.  These imidazoles have been shown to increase apoA1 and HDL-C in rats and mice.  Taken together, these data suggest that PXR plays an important role in the regulation of apoA1 and HDL-C in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3BApfwdjzeLVg90H21EOLACvtfcHk0liY-xtNGlPd7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1agt7g%253D&md5=96ed41c10c1a27aa5248ebcdd2ce0014</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2004.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2004.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DBatayneh%26aufirst%3DZ.%26aulast%3DSlama%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DD.%26aulast%3DPosey%26aufirst%3DJ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DGold%26aufirst%3DD.%26aulast%3DSambucetti%26aufirst%3DL.%26atitle%3DPXR%2520and%2520the%2520regulation%2520of%2520apoA1%2520and%2520HDL-cholesterol%2520in%2520rodents%26jtitle%3DPharmacol.%2520Res.%26date%3D2004%26volume%3D50%26issue%3D3%26spage%3D237%26epage%3D246%26doi%3D10.1016%2Fj.phrs.2004.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirny, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E. G.</span></span> <span> </span><span class="NLM_article-title">A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1788</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1023/A:1021429105173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1023%2FA%3A1021429105173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12523656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVSjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1788-1800&issue=12&author=S.+Ekinsauthor=L.+Mirnyauthor=E.+G.+Schuetz&title=A+ligand-based+approach+to+understanding+selectivity+of+nuclear+hormone+receptors+PXR%2C+CAR%2C+FXR%2C+LXRalpha%2C+and+LXRbeta&doi=10.1023%2FA%3A1021429105173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">A Ligand-Based Approach to Understanding Selectivity of Nuclear Hormone Receptors PXR, CAR, FXR, LXRα, and LXRβ</span></div><div class="casAuthors">Ekins, Sean; Mirny, Leonid; Schuetz, Erin G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1788-1800</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">A review.  In recent years discussion of nuclear hormone receptors, transporters, and drug-metabolizing enzymes has begun to take place as our knowledge of the overlapping ligand specificity of each of these proteins has deepened.  This ligand specificity is potentially valuable information for influencing future drug design, as it is important to avoid certain enzymes or transporters in order to circumvent potential drug-drug interactions.  Similarly, it is crit. that the induction of these same proteins via nuclear hormone receptors is avoided, as this can result in further toxicities.  Using a ligand-based approach in this review we describe new and previously published computational models for PXR, CAR, FXR, LXRα, and LXRβ that may help in understanding the complexity of interactions between transporters and enzymes.  The value of these types of models is that they may enable us to design mols. to selectively modulate pathways for therapeutic effect and in addn. predict the potential for drug interactions more reliably.  Simultaneously, we might learn which came first: the transporter, the enzyme, or the nuclear hormone receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo352_uBuNwELVg90H21EOLACvtfcHk0liY-xtNGlPd7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVSjsL0%253D&md5=73ec4700ce545b7fa1b0caed95c9e08c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1023%2FA%3A1021429105173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1021429105173%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DMirny%26aufirst%3DL.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26atitle%3DA%2520ligand-based%2520approach%2520to%2520understanding%2520selectivity%2520of%2520nuclear%2520hormone%2520receptors%2520PXR%252C%2520CAR%252C%2520FXR%252C%2520LXRalpha%252C%2520and%2520LXRbeta%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26issue%3D12%26spage%3D1788%26epage%3D1800%26doi%3D10.1023%2FA%3A1021429105173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, K.</span></span> <span> </span><span class="NLM_article-title">A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.108.020701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18505790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1689-1697&issue=8&author=K.+Yasudaauthor=A.+Ranadeauthor=R.+Venkataramananauthor=S.+Stromauthor=J.+Chupkaauthor=S.+Ekinsauthor=E.+Schuetzauthor=K.+Bachmann&title=A+comprehensive+in+vitro+and+in+silico+analysis+of+antibiotics+that+activate+pregnane+X+receptor+and+induce+CYP3A4+in+liver+and+intestine&doi=10.1124%2Fdmd.108.020701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine</span></div><div class="casAuthors">Yasuda, Kazuto; Ranade, Aarati; Venkataramanan, Raman; Strom, Stephen; Chupka, Jonathan; Ekins, Sean; Schuetz, Erin; Bachmann, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1689-1697</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have investigated several in silico and in vitro methods to improve our ability to predict potential drug interactions of antibiotics.  Our focus was to identify those antibiotics that activate pregnane X receptor (PXR) and induce CYP3A4 in human hepatocytes and intestinal cells.  Human PXR activation was screened using reporter assays in HepG2 cells, kinetic measurements of PXR activation were made in DPX-2 cells, and induction of CYP3A4 expression and activity was verified by quant. polymerase chain reaction, immunoblotting, and testosterone 6β-hydroxylation in primary human hepatocytes and LS180 cells.  We found that in HepG2 cells CYP3A4 transcription was activated strongly (>10-fold) by rifampin and troleandomycin; moderately (≥7-fold) by dicloxacillin, tetracycline, clindamycin, griseofulvin, and (≥4-fold) erythromycin; and weakly (>2.4-fold) by nafcillin, cefaclor, sulfisoxazole, and (>2-fold) cefadroxil and penicillin V.  Similar although not identical results were obtained in DPX-2 cells.  CYP3A4 mRNA and protein expression were induced by these antibiotics to differing extents in both liver and intestinal cells.  CYP3A4 activity was significantly increased by rifampin (9.7-fold), nafcillin and dicloxacillin (5.9-fold), and weakly induced (2-fold) by tetracycline, sufisoxazole, troleandomycin, and clindamycin.  Multiple pharmacophore models and docking indicated a good fit for dicloxacillin and nafcillin in PXR.  These results suggest that in vitro and in silico methods can help to prioritize and identify antibiotics that are most likely to reduce exposures of medications (such as oral contraceptive agents) which interact with enzymes and transporters regulated by PXR.  In summary, nafcillin, dicloxacillin, cephradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin exhibit a clear propensity to induce CYP3A4 and warrant further clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5qr3K9SkNbVg90H21EOLACvtfcHk0liY-xtNGlPd7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlams70%253D&md5=cd828b4967af1761264391538a8afbc5</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020701%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DRanade%26aufirst%3DA.%26aulast%3DVenkataramanan%26aufirst%3DR.%26aulast%3DStrom%26aufirst%3DS.%26aulast%3DChupka%26aufirst%3DJ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DE.%26aulast%3DBachmann%26aufirst%3DK.%26atitle%3DA%2520comprehensive%2520in%2520vitro%2520and%2520in%2520silico%2520analysis%2520of%2520antibiotics%2520that%2520activate%2520pregnane%2520X%2520receptor%2520and%2520induce%2520CYP3A4%2520in%2520liver%2520and%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D8%26spage%3D1689%26epage%3D1697%26doi%3D10.1124%2Fdmd.108.020701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">The identification of ligand features essential for PXR activation by pharmacophore modeling</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1021/ci049722q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049722q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsVSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=431-439&issue=2&author=D.+Schusterauthor=T.+Langer&title=The+identification+of+ligand+features+essential+for+PXR+activation+by+pharmacophore+modeling&doi=10.1021%2Fci049722q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling</span></div><div class="casAuthors">Schuster, Daniela; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-439</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug metabolizing enzymes and transporters are often involved in clin. relevant drug-drug interactions.  These functional proteins can be induced by a wide range of xenobiotics.  The induction is mediated by a group of receptors known as orphan nuclear receptors.  The pregnane X receptor (PXR) is a member of this receptor family and regulates the expression of multiple Cytochrome P 450 enzyme families (e.g. CYP3A and 2B), phase II enzymes (e.g. UDP glucuronosyl transferases), and transporters (e.g. Multidrug resistance protein 1).  The software package Catalyst was employed to derive pharmacophore models for PXR activation.  A structure based pharmacophore hypothesis and several ligand based ones were compared in order to identify ligand receptor interactions essential for receptor activation.  The results suggest that hydrogen bonding to Gln285 is indispensable for PXR activation.  Most ligands were found to form a second hydrogen bond to His407.  Hydrophobic interactions are not essential for receptor activation but contribute to ligand affinity.  Highly active compds. share up to five hydrophobic features that allow the ligand to occupy large areas of the predominantly hydrophobic binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyN4cEgMvr7Vg90H21EOLACvtfcHk0libu0FEGRQeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsVSksQ%253D%253D&md5=e3f3105881379b3f1768b094d718a3b8</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fci049722q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049722q%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DThe%2520identification%2520of%2520ligand%2520features%2520essential%2520for%2520PXR%2520activation%2520by%2520pharmacophore%2520modeling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26issue%3D2%26spage%3D431%26epage%3D439%26doi%3D10.1021%2Fci049722q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahoum, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussioux, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascussi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavanieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1124/mol.106.033415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.106.033415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17573484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=572-581&issue=3&author=G.+Lemaireauthor=C.+Benodauthor=V.+Nahoumauthor=A.+Pillonauthor=A.+M.+Boussiouxauthor=J.+F.+Guichouauthor=G.+Subraauthor=J.+M.+Pascussiauthor=W.+Bourguetauthor=A.+Chavanieuauthor=P.+Balaguer&title=Discovery+of+a+highly+active+ligand+of+human+pregnane+x+receptor%3A+a+case+study+from+pharmacophore+modeling+and+virtual+screening+to+%E2%80%9Cin+vivo%E2%80%9D+biological+activity&doi=10.1124%2Fmol.106.033415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity</span></div><div class="casAuthors">Lemaire, Geraldine; Benod, Cindy; Nahoum, Virginie; Pillon, Arnaud; Boussioux, Anne-Marie; Guichou, Jean-Francois; Subra, Guy; Pascussi, Jean-Marc; Bourguet, William; Chavanieu, Alain; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-581</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) is a nuclear receptor that regulates the expression of phase I and II drug-metabolizing enzymes as well as that of drug transporters.  In addn., this receptor plays a crit. role in cholesterol homeostasis and in protecting tissues from potentially toxic endobiotics.  HPXR is activated by a broad spectrum of low-affinity compds. including xenobiotics and endobiotics such as bile acids and their precursors.  Crystallog. studies revealed a ligand binding domain (LBD) with a large and conformable binding pocket that is likely to contribute to the ability of hPXR to respond to compds. of varying size and shape.  Here, we describe an in silico method that allowed the identification of nine novel hPXR agonists.  We further characterize the compd. 1-(2-chlorophenyl)-N-[1-(1-phenylethyl)- 1H-benzimidazol-5-yl]methanesulfonamide (C2BA-4), a methanesulfonamide that activates PXR specifically and more potently than does the ref. compd. 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butyl-phenol (SR12813) in our stable cell line expressing a Gal4-PXR and a GAL4 driven luciferase reporter gene.  Furthermore treatment of primary human hepatocytes with C2BA-4 results in a marked induction of the mRNA expression of hPXR target genes, such as cytochromes P 450 3A4 and 2B6.  Finally, C2BA-4 is also able to induce hPXR-mediated in vivo luciferase expression in HGPXR stable bioluminescent cells implanted in mice.  The study suggests new directions for the rational design of selective hPXR agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGory5EF3Mx4UbVg90H21EOLACvtfcHk0libu0FEGRQeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgurfM&md5=43de9126ad28627951b2a5b04d0bb410</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.033415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.033415%26sid%3Dliteratum%253Aachs%26aulast%3DLemaire%26aufirst%3DG.%26aulast%3DBenod%26aufirst%3DC.%26aulast%3DNahoum%26aufirst%3DV.%26aulast%3DPillon%26aufirst%3DA.%26aulast%3DBoussioux%26aufirst%3DA.%2BM.%26aulast%3DGuichou%26aufirst%3DJ.%2BF.%26aulast%3DSubra%26aufirst%3DG.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DBourguet%26aufirst%3DW.%26aulast%3DChavanieu%26aufirst%3DA.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520active%2520ligand%2520of%2520human%2520pregnane%2520x%2520receptor%253A%2520a%2520case%2520study%2520from%2520pharmacophore%2520modeling%2520and%2520virtual%2520screening%2520to%2520%25E2%2580%259Cin%2520vivo%25E2%2580%259D%2520biological%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D572%26epage%3D581%26doi%3D10.1124%2Fmol.106.033415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahaye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagury, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M.</span></span> <span> </span><span class="NLM_article-title">Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13321-016-0154-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1186%2Fs13321-016-0154-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=43&author=N.+Lagardeauthor=S.+Delahayeauthor=J.+F.+Zaguryauthor=M.+Montes&title=Discriminating+agonist+and+antagonist+ligands+of+the+nuclear+receptors+using+3D-pharmacophores&doi=10.1186%2Fs13321-016-0154-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores</span></div><div class="casAuthors">Lagarde, Nathalie; Delahaye, Solenne; Zagury, Jean-Francois; Montes, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/18</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) constitute an important class of therapeutic targets.  We evaluated the performance of 3D structure-based and ligand-based pharmacophore models in predicting the pharmacol. profile of NRs ligands using the NRLiSt BDB database.  We could generate selective pharmacophores for agonist and antagonist ligands and we found that the best performances were obtained by combining the structure-based and the ligand-based approaches.  The combination of pharmacophores that were generated allowed to cover most of the chem. space of the NRLiSt BDB datasets.  By screening the whole NRLiSt BDB on our 3D pharmacophores, we demonstrated their selectivity towards their dedicated NRs ligands.  The 3D pharmacophores herein presented can thus be used as a predictor of the pharmacol. activity of NRs ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS5Wkx5Jr5vLVg90H21EOLACvtfcHk0libu0FEGRQeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvF2kt78%253D&md5=7fa0ac5226a55070052478782b46ef8d</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0154-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0154-2%26sid%3Dliteratum%253Aachs%26aulast%3DLagarde%26aufirst%3DN.%26aulast%3DDelahaye%26aufirst%3DS.%26aulast%3DZagury%26aufirst%3DJ.%2BF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DDiscriminating%2520agonist%2520and%2520antagonist%2520ligands%2520of%2520the%2520nuclear%2520receptors%2520using%25203D-pharmacophores%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D43%26doi%3D10.1186%2Fs13321-016-0154-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Nasr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jérémie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laville, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labib, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagury, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M.</span></span> <span> </span><span class="NLM_article-title">NRLiSt BDB, the manually curated nuclear receptors ligands and structures benchmarking database</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3117</span>– <span class="NLM_lpage">3125</span>, <span class="refDoi"> DOI: 10.1021/jm500132p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500132p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlens7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3117-3125&issue=7&author=N.+Lagardeauthor=N.+Ben+Nasrauthor=A.+J%C3%A9r%C3%A9mieauthor=H.+Guillemainauthor=V.+Lavilleauthor=T.+Labibauthor=J.+F.+Zaguryauthor=M.+Montes&title=NRLiSt+BDB%2C+the+manually+curated+nuclear+receptors+ligands+and+structures+benchmarking+database&doi=10.1021%2Fjm500132p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">NRLiSt BDB, the Manually Curated Nuclear Receptors Ligands and Structures Benchmarking Database</span></div><div class="casAuthors">Lagarde, Nathalie; Ben Nasr, Nesrine; Jeremie, Aurore; Guillemain, Helene; Laville, Vincent; Labib, Taoufik; Zagury, Jean-Francois; Montes, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3117-3125</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nuclear receptors (NRs) constitute an important class of drug targets.  We created the most exhaustive NR-focused benchmarking database to date, the NRLiSt BDB (NRs ligands and structures benchmarking database).  The 9905 compds. and 339 structures of the NRLiSt BDB are ready for structure-based and ligand-based virtual screening.  In the present study, we detail the protocol used to generate the NRLiSt BDB and its features.  We also give some examples of the errors that we found in ChEMBL that convinced us to manually review all original papers.  Since extensive and manually curated exptl. data about NR ligands and structures are provided in the NRLiSt BDB, it should become a powerful tool to assess the performance of virtual screening methods on NRs, to assist the understanding of NR's function and modulation, and to support the discovery of new drugs targeting NRs.  NRLiSt BDB is freely available online at http://nrlist.drugdesign.fr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxrFfpq27WbVg90H21EOLACvtfcHk0lhW6W52fbokEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlens7g%253D&md5=d495ead29255e6944983527ba3d05416</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm500132p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500132p%26sid%3Dliteratum%253Aachs%26aulast%3DLagarde%26aufirst%3DN.%26aulast%3DBen%2BNasr%26aufirst%3DN.%26aulast%3DJ%25C3%25A9r%25C3%25A9mie%26aufirst%3DA.%26aulast%3DGuillemain%26aufirst%3DH.%26aulast%3DLaville%26aufirst%3DV.%26aulast%3DLabib%26aufirst%3DT.%26aulast%3DZagury%26aufirst%3DJ.%2BF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DNRLiSt%2520BDB%252C%2520the%2520manually%2520curated%2520nuclear%2520receptors%2520ligands%2520and%2520structures%2520benchmarking%2520database%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D7%26spage%3D3117%26epage%3D3125%26doi%3D10.1021%2Fjm500132p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torimoto-Katori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span> <span> </span><span class="NLM_article-title">In silico prediction of hPXR activators using structure-based pharmacophore modeling</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.xphs.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=28315689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=1752-1759&issue=7&author=N.+Torimoto-Katoriauthor=R.+Huangauthor=H.+Katoauthor=R.+Ohashiauthor=M.+Xia&title=In+silico+prediction+of+hPXR+activators+using+structure-based+pharmacophore+modeling&doi=10.1016%2Fj.xphs.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Prediction of hPXR Activators Using Structure-Based Pharmacophore Modeling</span></div><div class="casAuthors">Torimoto-Katori, Nao; Huang, Ruili; Kato, Harutoshi; Ohashi, Rikiya; Xia, Menghang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1752-1759</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The activation of pregnane X receptor (PXR), a member of the nuclear receptor superfamily, can mediate potential drug-drug interactions by regulating the expression of several drug-mediated enzymes and transporters, resulting in reduced therapeutic efficacy or increased toxicity by producing reactive metabolites.  Therefore, in the early stage of drug development, it is important to predict these risks using an in silico approach.  The authors constructed a human PXR (hPXR) pharmacophore model based on known structural information of compds. that activate PXR.  The authors evaluated the prediction accuracy of the model using data sets generated on 68 original synthetic compds. from the Mitsubishi Tanabe Pharma Corporation and over 2500 drugs from the National Institutes of Health Chem. Genomics Center Pharmaceutical Collection for their ability to activate hPXR.  The prediction accuracies of the PXR pharmacophore model were 0.78 and 0.86 for the Mitsubishi Tanabe Pharma Corporation and National Institutes of Health Chem. Genomics Center Pharmaceutical Collection, resp.  The compds. resulting in the smallest root-mean square deviation hit by pharmacophore search were the well-known PXR inducers such as Bosentan.  These results suggest that using the in silico approach developed in this study is useful to identify potential hPXR activators and modify the drug design during the early stage of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9DxsCLSwFtbVg90H21EOLACvtfcHk0lhW6W52fbokEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVaqtb8%253D&md5=36e6f7390ec7030ae1b6f337fa8d8710</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DTorimoto-Katori%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26atitle%3DIn%2520silico%2520prediction%2520of%2520hPXR%2520activators%2520using%2520structure-based%2520pharmacophore%2520modeling%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26issue%3D7%26spage%3D1752%26epage%3D1759%26doi%3D10.1016%2Fj.xphs.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. N.</span></span> <span> </span><span class="NLM_article-title">In silico tools to aid risk assessment of endocrine disrupting chemicals</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>205</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2004.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tox.2004.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=15458789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2004&pages=43-53&issue=1%E2%80%932&author=M.+N.+Jacobs&title=In+silico+tools+to+aid+risk+assessment+of+endocrine+disrupting+chemicals&doi=10.1016%2Fj.tox.2004.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">In silico tools to aid risk assessment of endocrine disrupting chemicals</span></div><div class="casAuthors">Jacobs, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In silico or computational tools could be used more effectively in endocrine disruptor risk assessment for prescreening potential endocrine disruptors, improving exptl. in vitro screening assay design and facilitating more thorough data analyses.  The in silico tools reviewed here are three-fold and include the use of: (1) nuclear receptor (NR) crystal structures and homol. models to examine potential modes of ligand binding by different representative compds.; (2) multivariate principal component analyses (PCA) techniques to select best predicted cell lines for endocrine disrupting chems. (EDC) risk assessment purposes; (3) NR quant. structure-activity relationships (QSARs) that can be constructed from varied biol. data sources, using multivariate partial least squares (PLS) techniques and specific descriptors.  The cytosolic and NR examples discussed here include the Ah receptor, (AhR), the human estrogen receptor α (hERα) and the human pregnane X receptor (PXR).  The varied biol. data sets can be compared to give a more integrated dimension to receptor cross talk mechanisms, with further support from mol. modeling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogY_tV_NpBwbVg90H21EOLACvtfcHk0lhW6W52fbokEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2msbc%253D&md5=3bc6f6019beee6c288153d7e6c48c7db</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2004.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2004.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%2BN.%26atitle%3DIn%2520silico%2520tools%2520to%2520aid%2520risk%2520assessment%2520of%2520endocrine%2520disrupting%2520chemicals%26jtitle%3DToxicology%26date%3D2004%26volume%3D205%26issue%3D1%25E2%2580%25932%26spage%3D43%26epage%3D53%26doi%3D10.1016%2Fj.tox.2004.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirillov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhmatulin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorokina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugrim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span> <span> </span><span class="NLM_article-title">A combined approach to drug metabolism and toxicity assessment</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.008458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.105.008458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=16381662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=495-503&issue=3&author=S.+Ekinsauthor=S.+Andreyevauthor=A.+Ryabovauthor=E.+Kirillovauthor=E.+A.+Rakhmatulinauthor=S.+Sorokinaauthor=A.+Bugrimauthor=T.+Nikolskaya&title=A+combined+approach+to+drug+metabolism+and+toxicity+assessment&doi=10.1124%2Fdmd.105.008458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">A combined approach to drug metabolism and toxicity assessment</span></div><div class="casAuthors">Ekins, Sean; Andreyev, Sergey; Ryabov, Andy; Kirillov, Eugene; Rakhmatulin, Eugene A.; Sorokina, Svetlana; Bugrim, Andrej; Nikolskaya, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-503</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The challenge of predicting the metab. or toxicity of a drug in humans has been approached using in vivo animal models, in vitro systems, high throughput genomics and proteomics methods, and, more recently, computational approaches.  Understanding the complexity of biol. systems requires a broader perspective rather than focusing on just one method in isolation for prediction.  Multiple methods may therefore be necessary and combined for a more accurate prediction.  In the field of drug metab. and toxicol., we have seen the growth, in recent years, of computational quant. structure-activity relationships (QSARs), as well as empirical data from microarrays.  In the current study we have further developed a novel computational approach, Meta-Drug, that (1) predicts metabolites for mols. based on their chem. structure, (2) predicts the activity of the original compd. and its metabolites with various absorption, distribution, metab., excretion, and toxicity models, (3) incorporates the predictions with human cells signaling and metabolic pathways and networks, and (4) integrates networks and metabolites, with relevant toxicogenomic or other high throughput data.  We have demonstrated the utility of such an approach using recently published data from in vitro metab. and microarray studies for aprepitant, 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)phenyl-4-((3-oxo-1,2,4- triazol-5-yl)methyl)morpholine (L-742694), trovafloxacin, 4-hydroxytamoxifen, and artemisinin and other artemisinin analogs to show the predicted interactions with cytochromes P 450, pregnane X receptor, and P-glycoprotein, and the metabolites and the networks of genes that are affected.  As a comparison, we used a second computational approach, MetaCore, to generate statistically significant gene networks with the available expression data.  These case studies demonstrate the combination of QSARs and systems biol. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Kh8B58qO9LVg90H21EOLACvtfcHk0lhW6W52fbokEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7c%253D&md5=0c6a510ad01cd2fba49132f84e313949</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008458%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DAndreyev%26aufirst%3DS.%26aulast%3DRyabov%26aufirst%3DA.%26aulast%3DKirillov%26aufirst%3DE.%26aulast%3DRakhmatulin%26aufirst%3DE.%2BA.%26aulast%3DSorokina%26aufirst%3DS.%26aulast%3DBugrim%26aufirst%3DA.%26aulast%3DNikolskaya%26aufirst%3DT.%26atitle%3DA%2520combined%2520approach%2520to%2520drug%2520metabolism%2520and%2520toxicity%2520assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D3%26spage%3D495%26epage%3D503%26doi%3D10.1124%2Fdmd.105.008458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Machine learning methods and docking for predicting human pregnane X receptor activation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1021/tx800102e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800102e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntVygsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1457-1467&issue=7&author=A.+Khandelwalauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+W.+Sinzauthor=P.+W.+Swaanauthor=S.+Ekins&title=Machine+learning+methods+and+docking+for+predicting+human+pregnane+X+receptor+activation&doi=10.1021%2Ftx800102e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Machine Learning Methods and Docking for Predicting Human Pregnane X Receptor Activation</span></div><div class="casAuthors">Khandelwal, Akash; Krasowski, Matthew D.; Reschly, Erica J.; Sinz, Michael W.; Swaan, Peter W.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1457-1467</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) regulates the expression of genes involved in xenobiotic metab. and transport.  In vitro methods to screen for PXR agonists are used widely.  In the current study, computational models for human PXR activators and PXR nonactivators were developed using recursive partitioning (RP), random forest (RF), and support vector machine (SVM) algorithms with VolSurf descriptors.  Following 10-fold randomization, the models correctly predicted 82.6-98.9% of activators and 62.0-88.6% of nonactivators.  The models were validated using sep. test sets.  The overall (n = 15) test set prediction accuracy for PXR activators with RP, RF, and SVM PXR models is 80-93.3%, representing an improvement over models previously reported.  All models were tested with a second test set (n = 145), and the prediction accuracy ranged from 63 to 67% overall.  These test set mols. were found to cover the same area in a principal component anal. plot as the training set, suggesting that the predictions were within the applicability domain.  The FlexX docking method combined with logistic regression performed poorly in classifying this PXR test set as compared with RP, RF, and SVM but may be useful for qual. interpretion of interactions within the LBD.  From this anal., VolSurf descriptors and machine learning methods had good classification accuracy and made reliable predictions within the model applicability domain.  These methods could be used for high throughput virtual screening to assess for PXR activation, prior to in vitro testing to predict potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo94faSaQs9LVg90H21EOLACvtfcHk0lifsFjWdmNRuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntVygsbk%253D&md5=3e84ea13c5eae46e90f16b4980212d9a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Ftx800102e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800102e%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DMachine%2520learning%2520methods%2520and%2520docking%2520for%2520predicting%2520human%2520pregnane%2520X%2520receptor%2520activation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26issue%3D7%26spage%3D1457%26epage%3D1467%26doi%3D10.1021%2Ftx800102e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anger, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giegerich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussregen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span> <span> </span><span class="NLM_article-title">Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5352</span>– <span class="NLM_lpage">5365</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmc.2012.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22560839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms12rsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5352-5365&issue=18&author=H.+Matterauthor=L.+T.+Angerauthor=C.+Giegerichauthor=S.+Gussregenauthor=G.+Hesslerauthor=K.+H.+Baringhaus&title=Development+of+in+silico+filters+to+predict+activation+of+the+pregnane+X+receptor+%28PXR%29+by+structurally+diverse+drug-like+molecules&doi=10.1016%2Fj.bmc.2012.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules</span></div><div class="casAuthors">Matter, Hans; Anger, Lennart T.; Giegerich, Clemens; Guessregen, Stefan; Hessler, Gerhard; Baringhaus, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5352-5365</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR), a member of the nuclear hormone superfamily, regulates the expression of several enzymes and transporters involved in metabolically relevant processes.  The significant induction of CYP450 enzymes by PXR, in particular CYP3A4, might significantly alter the metab. of prescribed drugs.  In order to early identify mols. in drug discovery with a potential to activate PXR as antitarget, we developed fast and reliable in silico filters by ligand-based QSAR techniques.  Two classification models were established on a diverse dataset of 434 drug-like mols.  A second augmented set allowed focusing on interesting regions in chem. space.  These classifiers are based on decision trees combined with a genetic algorithm based variable selection to arrive at predictive models.  The classifier for the first dataset on 29 descriptors showed good performance on a test set with a correct classification of both 100% for PXR activators and non-activators plus 87% for activators and 83% for non-activators in an external dataset.  The second classifier then correctly predicts 97% activators and 91% non-activators in a test set and 94% for activators and 64% non-activators in an external set of 50 mols., which still qualifies for application as a filter focusing on PXR activators.  Finally a quant. model for PXR activation for a subset of these mols. was derived using a regression-tree approach combined with GA variable selection.  This final model shows a predictive r2 of 0.774 for the test set and 0.452 for an external set of 33 mols.  Thus, the combination of these filters consistently provide guidelines for lowering PXR activation in novel candidate mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFIMqHB3fyKbVg90H21EOLACvtfcHk0lifsFjWdmNRuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms12rsr4%253D&md5=9f2ce599c60a3290670ce53eedab0ed7</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DMatter%26aufirst%3DH.%26aulast%3DAnger%26aufirst%3DL.%2BT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DGussregen%26aufirst%3DS.%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26atitle%3DDevelopment%2520of%2520in%2520silico%2520filters%2520to%2520predict%2520activation%2520of%2520the%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520by%2520structurally%2520diverse%2520drug-like%2520molecules%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D18%26spage%3D5352%26epage%3D5365%26doi%3D10.1016%2Fj.bmc.2012.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekmarev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid scoring and classification approaches to predict human pregnane X receptor activators</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1007/s11095-008-9809-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs11095-008-9809-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19115096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCmtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1001-1011&issue=4&author=S.+Kortagereauthor=D.+Chekmarevauthor=W.+J.+Welshauthor=S.+Ekins&title=Hybrid+scoring+and+classification+approaches+to+predict+human+pregnane+X+receptor+activators&doi=10.1007%2Fs11095-008-9809-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Scoring and Classification Approaches to Predict Human Pregnane X Receptor Activators</span></div><div class="casAuthors">Kortagere, Sandhya; Chekmarev, Dmitriy; Welsh, William J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The human pregnane X receptor (PXR) is a transcriptional regulator of many genes involved in xenobiotic metab. and excretion.  Reliable prediction of high affinity binders with this receptor would be valuable for pharmaceutical drug discovery to predict potential toxicol. responses.  Computational models were developed and validated for a dataset consisting of human PXR activators and non-activators.  The authors used support vector machine (SVM) algorithms with mol. descriptors derived from two sources, Shape Signatures and the Mol. Operating Environment (MOE) application software.  The authors also employed the mol. docking program GOLD in which the GoldScore method was supplemented with other scoring functions to improve docking results.  The overall test set prediction accuracy for PXR activators with SVM was 72% to 81%.  This indicates that mol. shape descriptors are useful in classification of compds. binding to this receptor.  The best docking prediction accuracy (61%) was obtained using 1D Shape Signature descriptors as a weighting factor to the GoldScore.  By pooling the available human PXR data sets the authors revealed those mol. features that are assocd. with human PXR activators.  These combined computational approaches using mol. shape information may assist scientists to more confidently identify PXR activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3B-l1nbBOe7Vg90H21EOLACvtfcHk0lifsFjWdmNRuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCmtrfO&md5=e2e15b9655cdb73f0ff1ab1da41f8df7</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs11095-008-9809-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-008-9809-7%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DChekmarev%26aufirst%3DD.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DHybrid%2520scoring%2520and%2520classification%2520approaches%2520to%2520predict%2520human%2520pregnane%2520X%2520receptor%2520activators%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26issue%3D4%26spage%3D1001%26epage%3D1011%26doi%3D10.1007%2Fs11095-008-9809-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">In silico prediction of pregnane X receptor activators by machine learning approaches</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1124/mol.106.027623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fmol.106.027623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17003167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2007&pages=158-168&issue=1&author=C.+Y.+Ungauthor=H.+Liauthor=C.+W.+Yapauthor=Y.+Z.+Chen&title=In+silico+prediction+of+pregnane+X+receptor+activators+by+machine+learning+approaches&doi=10.1124%2Fmol.106.027623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">In silico prediction of pregnane X receptor activators by machine learning approaches</span></div><div class="casAuthors">Ung, C. Y.; Li, H.; Yap, C. W.; Chen, Y. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pregnane X receptor (PXR) regulates drug metab. and is involved in drug-drug interactions.  Prediction of PXR activators is important for evaluating drug metab. and toxicity.  Computational pharmacophore and quant. structure-activity relationship models have been developed for predicting PXR activators.  Because of the structural diversity of PXR activators, more efforts are needed for exploring methods applicable to a broader spectrum of compds.  The authors explored three machine learning methods (MLMs) for predicting PXR activators, which were trained and tested by using significantly higher no. of compds., 128 PXR activators (98 human) and 77 PXR nonactivators, than those of previous studies.  The recursive feature-selection method was used to select mol. descriptors relevant to PXR activator prediction, which are consistent with conclusions from other computational and structural studies.  In a 10-fold cross-validation test, our MLM systems correctly predicted 81.2 to 84.0% of PXR activators, 80.8 to 85.0% of hPXR activators, 61.2 to 70.3% of PXR nonactivators, and 67.7 to 73.6% of hPXR nonactivators.  Our systems also correctly predicted 73.3 to 86.7% of 15 newly published hPXR activators.  MLMs seem to be useful for predicting PXR activators and for providing clues to physicochem. features of PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtf9BO0pCK5LVg90H21EOLACvtfcHk0likjXY4bNrLzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Grug%253D%253D&md5=258c12724e390d9c616e280f77ed181a</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.027623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.027623%26sid%3Dliteratum%253Aachs%26aulast%3DUng%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DIn%2520silico%2520prediction%2520of%2520pregnane%2520X%2520receptor%2520activators%2520by%2520machine%2520learning%2520approaches%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D71%26issue%3D1%26spage%3D158%26epage%3D168%26doi%3D10.1124%2Fmol.106.027623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches</span>. <i>Chemom. Intell. Lab. Syst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.chemolab.2012.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.chemolab.2012.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=271-279&author=H.+Raoauthor=Y.+Wangauthor=X.+Zengauthor=X.+Wangauthor=Y.+Liuauthor=J.+Yinauthor=H.+Heauthor=F.+Zhuauthor=Z.+Li&title=In+silico+identification+of+human+pregnane+X+receptor+activators+from+molecular+descriptors+by+machine+learning+approaches&doi=10.1016%2Fj.chemolab.2012.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches</span></div><div class="casAuthors">Rao, Hanbing; Wang, Yanying; Zeng, Xianyin; Wang, Xianxiang; Liu, Yong; Yin, Jiajian; He, Hua; Zhu, Feng; Li, Zerong</div><div class="citationInfo"><span class="NLM_cas:title">Chemometrics and Intelligent Laboratory Systems</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">CILSEN</span>;
        ISSN:<span class="NLM_cas:issn">0169-7439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the current study, computational models for hPXR activators and hPXR non-activators were developed using support vector machine (SVM), k-nearest neighbor (k-NN), and artificial neural networks (ANN) algorithms. 73 mol. descriptors used for hPXR activator and hPXR non-activator prediction were selected from a pool of 548 descriptors by using a multi-step hybrid feature selection method combining Fischer's score and Monte Carlo simulated annealing method.  The y-scrambling method was used to test if there is a chance correlation in the developed SVM model.  In the meantime, five-fold cross validation of these machine learning methods results in the prediction accuracies of 87.2-92.5% for hPXR activators and 73.8-87.8% for hPXR non-activators, and the prediction accuracies for external test set are 93.8-95.8% for hPXR activators and 86.7-92.8% for hPXR non-activators.  Our study suggested that the tested machine learning methods are potentially useful for hPXR activators identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr1gGOaS3QirVg90H21EOLACvtfcHk0likjXY4bNrLzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnt73O&md5=b4d68deab6b184d7c356bf145b451282</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.chemolab.2012.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemolab.2012.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DIn%2520silico%2520identification%2520of%2520human%2520pregnane%2520X%2520receptor%2520activators%2520from%2520molecular%2520descriptors%2520by%2520machine%2520learning%2520approaches%26jtitle%3DChemom.%2520Intell.%2520Lab.%2520Syst.%26date%3D2012%26volume%3D118%26spage%3D271%26epage%3D279%26doi%3D10.1016%2Fj.chemolab.2012.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redinbo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span> <span> </span><span class="NLM_article-title">Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e1000594</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1000594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1371%2Fjournal.pcbi.1000594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20011107" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&issue=12&author=S.+Ekinsauthor=S.+Kortagereauthor=M.+Iyerauthor=E.+J.+Reschlyauthor=M.+A.+Lillauthor=M.+R.+Redinboauthor=M.+D.+Krasowski&title=Challenges+predicting+ligand-receptor+interactions+of+promiscuous+proteins%3A+the+nuclear+receptor+PXR&doi=10.1371%2Fjournal.pcbi.1000594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1000594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1000594%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DM.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DLill%26aufirst%3DM.%2BA.%26aulast%3DRedinbo%26aufirst%3DM.%2BR.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26atitle%3DChallenges%2520predicting%2520ligand-receptor%2520interactions%2520of%2520promiscuous%2520proteins%253A%2520the%2520nuclear%2520receptor%2520PXR%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D12%26doi%3D10.1371%2Fjournal.pcbi.1000594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span> <span> </span><span class="NLM_article-title">Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.110.035808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21068194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=337-344&issue=2&author=Y.+Panauthor=L.+Liauthor=G.+Kimauthor=S.+Ekinsauthor=H.+Wangauthor=P.+W.+Swaan&title=Identification+and+validation+of+novel+human+pregnane+X+receptor+activators+among+prescribed+drugs+via+ligand-based+virtual+screening&doi=10.1124%2Fdmd.110.035808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening</span></div><div class="casAuthors">Pan, Yongmei; Li, Linhao; Kim, Gregory; Ekins, Sean; Wang, Hongbing; Swaan, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human pregnane X receptor (hPXR) plays a key role in regulating metab. and clearance of endogenous and exogenous substances.  Identification of novel hPXR activators among com. drugs may aid in avoiding drug-drug interactions during coadministration.  We applied ligand-based computational approaches for virtual screening of a commonly prescribed drug database (SCUT).  Bayesian classification models were generated with a training set comprising 177 compds. using Fingerprints and 117 structural descriptors.  A cell-based luciferase reporter assay was used for evaluation of chem.-mediated hPXR activation in HepG2 cells.  All compds. were tested at 10 μM concn. with rifampicin and DMSO as pos. and neg. controls, resp.  The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compds.  Screening the SCUT database with this model retrieved 105 hits and 17 compds. from the top 25 hits were chosen for in vitro testing.  The reporter assay confirmed that nine drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, megestrol, secobarbital, and aminoglutethimide, were previously unidentified hPXR activators.  Thus, the present study demonstrates that novel hPXR activators can be efficiently identified among U.S. Food and Drug Administration-approved and commonly prescribed drugs, which should lead to detection and prevention of potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsnBrsWk1drVg90H21EOLACvtfcHk0liriQTJwtTx4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKmtrg%253D&md5=90ff1f16993d3697e6b35ac70457e0eb</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035808%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26atitle%3DIdentification%2520and%2520validation%2520of%2520novel%2520human%2520pregnane%2520X%2520receptor%2520activators%2520among%2520prescribed%2520drugs%2520via%2520ligand-based%2520virtual%2520screening%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D2%26spage%3D337%26epage%3D344%26doi%3D10.1124%2Fdmd.110.035808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-McLeod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1021/tx900417f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900417f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFWgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=664-676&issue=3&author=M.+Zientekauthor=C.+Stonerauthor=R.+Ayscueauthor=J.+Klug-McLeodauthor=Y.+Jiangauthor=M.+Westauthor=C.+Collinsauthor=S.+Ekins&title=Integrated+in+silico-in+vitro+strategy+for+addressing+cytochrome+P450+3A4+time-dependent+inhibition&doi=10.1021%2Ftx900417f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated in Silico-in Vitro Strategy for Addressing Cytochrome P450 3A4 Time-Dependent Inhibition</span></div><div class="casAuthors">Zientek, Michael; Stoner, Chad; Ayscue, Robyn; Klug-McLeod, Jacquelyn; Jiang, Ying; West, Michael; Collins, Claire; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">664-676</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Throughout the past decade, the expectations from the regulatory agencies for safety, drug-drug interactions (DDIs), pharmacokinetic, and disposition characterization of new chem. entities (NCEs) by pharmaceutical companies seeking registration have increased.  DDIs are frequently assessed using in silico, in vitro, and in vivo methodologies.  However, a key gap in this screening paradigm is a full structural understanding of time-dependent inhibition (TDI) on the cytochrome P 450 systems, particularly P 450 3A4.  To address this, a no. of high-throughput in vitro assays have been developed.  This work describes an automated assay for TDI using two concns. at two time points (2 + 2 assay).  Data generated with this assay for over 2000 compds. from multiple therapeutic programs were used to generate in silico Bayesian classification models of P 450 3A4-mediated TDI.  These in silico models were validated using several external test sets and multiple random group testing (receiver operator curve value >0.847).  We identified a no. of substructures that were likely to elicit TDI, the majority contg. indazole rings.  These in vitro and in silico approaches have been implemented as a part of the Pfizer screening paradigm.  The Bayesian models are available on the intranet to guide synthetic strategy, predict whether a NCE is likely to cause a TDI via P 450 3A4, filter for in vitro testing, and identify substructures important for TDI as well as those that do not cause TDI.  This represents an integrated in silico-in vitro strategy for addressing P 450 3A4 TDI and improving the efficiency of screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJqcGKVUJZLVg90H21EOLACvtfcHk0liriQTJwtTx4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFWgtLc%253D&md5=97bb12a82e0f445e629b5241c6ead119</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Ftx900417f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900417f%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DStoner%26aufirst%3DC.%26aulast%3DAyscue%26aufirst%3DR.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DIntegrated%2520in%2520silico-in%2520vitro%2520strategy%2520for%2520addressing%2520cytochrome%2520P450%25203A4%2520time-dependent%2520inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26issue%3D3%26spage%3D664%26epage%3D676%26doi%3D10.1021%2Ftx900417f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AbdulHameed, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Predicting rat and human pregnane X receptor activators using bayesian classification models</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1729-1740&issue=10&author=M.+D.+AbdulHameedauthor=D.+L.+Ippolitoauthor=A.+Wallqvist&title=Predicting+rat+and+human+pregnane+X+receptor+activators+using+bayesian+classification+models&doi=10.1021%2Facs.chemrestox.6b00227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Rat and Human Pregnane X Receptor Activators Using Bayesian Classification Models</span></div><div class="casAuthors">AbdulHameed, Mohamed Diwan M.; Ippolito, Danielle L.; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1729-1740</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a ligand-activated transcription factor that acts as a master regulator of metabolizing enzymes and transporters.  To avoid adverse drug-drug interactions and diseases such as steatosis and cancers assocd. with PXR activation, identifying drugs and chems. that activate PXR is of crucial importance.  The authors developed ligand-based predictive computational models for both rat and human PXR activation, which allowed the authors to identify potentially harmful chems. and evaluate species-specific effects of a given compd.  The authors utilized a large publicly available dataset of nearly 2000 compds. screened in cell-based reporter gene assays to develop Bayesian quant. structure-activity relationship models using physicochem. properties and structural descriptors.  The authors' anal. showed that PXR activators tend to be hydrophobic and significantly different from non-activators in terms of their physicochem. properties such as mol. wt., logP, no. of rings, and soly.  The authors' Bayesian models, evaluated by using five-fold cross validation, displayed a sensitivity of 75% (76%), specificity of 76% (75%), and accuracy of 89% for human (rat) PXR activation.  The authors identified structural features shared by rat and human PXR activators as well as those unique to each species.  The authors compared rat in vitro PXR activation data to in vivo data by using DrugMatrix, a large toxicogenomics database with gene expression data obtained from rats after exposure to diverse chems.  Although in vivo gene expression data pointed to cross-talk between nuclear receptor activators that is captured only by in vivo assays, overall the authors found broad agreement between in vitro and in vivo PXR activation.  Thus, the models developed here serve primarily as efficient initial high-throughput in silico screens of in vitro activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAUUcToXfeALVg90H21EOLACvtfcHk0liriQTJwtTx4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOitrzK&md5=c215fd0adad8ebc93bf10c714fc25c11</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00227%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulHameed%26aufirst%3DM.%2BD.%26aulast%3DIppolito%26aufirst%3DD.%2BL.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DPredicting%2520rat%2520and%2520human%2520pregnane%2520X%2520receptor%2520activators%2520using%2520bayesian%2520classification%2520models%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D10%26spage%3D1729%26epage%3D1740%26doi%3D10.1021%2Facs.chemrestox.6b00227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism, excretion, and toxicity evaluation in drug discovery. 14. Prediction of human pregnane X receptor activators by using naive bayesian classification technique</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1021/tx500389q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500389q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=116-125&issue=1&author=H.+Shiauthor=S.+Tianauthor=Y.+Liauthor=D.+Liauthor=H.+Yuauthor=X.+Zhenauthor=T.+Hou&title=Absorption%2C+distribution%2C+metabolism%2C+excretion%2C+and+toxicity+evaluation+in+drug+discovery.+14.+Prediction+of+human+pregnane+X+receptor+activators+by+using+naive+bayesian+classification+technique&doi=10.1021%2Ftx500389q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique</span></div><div class="casAuthors">Shi, Huali; Tian, Sheng; Li, Youyong; Li, Dan; Yu, Huidong; Zhen, Xuechu; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-125</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The activation of pregnane X receptor (PXR), a member of the nuclear receptor (NR) superfamily, can mediate potential drug-drug interactions, and therefore, prediction of PXR activation is of great importance for evaluating drug metab. and toxicity.  In this study, based on 532 structurally diverse compds., we present a comprehensive anal. with the aim to build accurate classification models for distinguishing PXR activators from nonactivators by using a naive Bayesian classification technique.  First, the distributions of eight important mol. physicochem. properties of PXR activators vs. nonactivators were compared, illustrating that the hydrophobicity-related mol. descriptors (AlogP and log D) show slightly better capability to discriminate PXR activators from nonactivators than the others.  Then, based on mol. physicochem. properties, VolSurf descriptors, and mol. fingerprints, naive Bayesian classifiers were developed to sep. PXR activators from nonactivators.  The results demonstrate that the introduction of mol. fingerprints is quite essential to enhance the prediction accuracy of the classifiers.  The best Bayesian classifier based on the 21 physicochem. properties, VolSurf descriptors, and LCFC_10 fingerprints descriptors yields a prediction accuracy of 92.7% for the training set based on leave-one-out (LOO) cross-validation and of 85.2% for the test set.  Moreover, by exploring the important structural fragments derived from the best Bayesian classifier, we obsd. that flexibility is an important structural pattern for PXR activation.  In addn., chem. compds. contg. more halogen atoms, unsatd. alkanes chains relevant to π-π stacking, and fewer nitrogen atoms tend to be PXR activators.  We believe that the naive Bayesian classifier can be used as a reliable virtual screening tool to predict PXR activation in the drug design and discovery pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobB6jA90OqW7Vg90H21EOLACvtfcHk0lh-Cbq3PMG5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfF&md5=37931968857ae6808944195d9b57cf17</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Ftx500389q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500389q%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZhen%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%252C%2520and%2520toxicity%2520evaluation%2520in%2520drug%2520discovery.%252014.%2520Prediction%2520of%2520human%2520pregnane%2520X%2520receptor%2520activators%2520by%2520using%2520naive%2520bayesian%2520classification%2520technique%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26issue%3D1%26spage%3D116%26epage%3D125%26doi%3D10.1021%2Ftx500389q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dybdahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolov, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedebye, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsdottir, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J. R.</span></span> <span> </span><span class="NLM_article-title">QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>262</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2012.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.taap.2012.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=22627063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=2012&pages=301-309&issue=3&author=M.+Dybdahlauthor=N.+G.+Nikolovauthor=E.+B.+Wedebyeauthor=S.+O.+Jonsdottirauthor=J.+R.+Niemela&title=QSAR+model+for+human+pregnane+X+receptor+%28PXR%29+binding%3A+screening+of+environmental+chemicals+and+correlations+with+genotoxicity%2C+endocrine+disruption+and+teratogenicity&doi=10.1016%2Fj.taap.2012.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR model for human pregnane X receptor (PXR) binding: Screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity</span></div><div class="casAuthors">Dybdahl, Marianne; Nikolov, Nikolai G.; Wedebye, Eva Bay; Jonsdottir, Svava Osk; Niemela, Jay R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) has a key role in regulating the metab. and transport of structurally diverse endogenous and exogenous compds.  Activation of PXR has the potential to initiate adverse effects, causing drug-drug interactions, and perturbing normal physiol. functions.  Therefore, identification of PXR ligands would be valuable information for pharmaceutical and toxicol. research.  In the present study, we developed a quant. structure-activity relationship (QSAR) model for the identification of PXR ligands using data based on a human PXR binding assay.  A total of 631 mols., representing a variety of chem. structures, constituted the training set of the model.  Cross-validation of the model showed a sensitivity of 82%, a specificity of 85%, and a concordance of 84%.  The developed model provided knowledge about mol. descriptors that may influence the binding of mols. to PXR.  The model was used to screen a large inventory of environmental chems., of which 47% was found to be within domain of the model.  Approx. 35% of the chems. within domain were predicted to be PXR ligands.  The predicted PXR ligands were found to be overrepresented among chems. predicted to cause adverse effects, such as genotoxicity, teratogenicity, estrogen receptor activation and androgen receptor antagonism compared to chems. not causing these effects.  The developed model may be useful as a tool for predicting potential PXR ligands and for providing mechanistic information of toxic effects of chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGTM7-zx2iobVg90H21EOLACvtfcHk0lh-Cbq3PMG5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nsrk%253D&md5=50d00b71e17120507c517950f7f84f54</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2012.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2012.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DDybdahl%26aufirst%3DM.%26aulast%3DNikolov%26aufirst%3DN.%2BG.%26aulast%3DWedebye%26aufirst%3DE.%2BB.%26aulast%3DJonsdottir%26aufirst%3DS.%2BO.%26aulast%3DNiemela%26aufirst%3DJ.%2BR.%26atitle%3DQSAR%2520model%2520for%2520human%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520binding%253A%2520screening%2520of%2520environmental%2520chemicals%2520and%2520correlations%2520with%2520genotoxicity%252C%2520endocrine%2520disruption%2520and%2520teratogenicity%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2012%26volume%3D262%26issue%3D3%26spage%3D301%26epage%3D309%26doi%3D10.1016%2Fj.taap.2012.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagome, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaotsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional quantitative structure-activity relationship analysis for human pregnane X receptor for the prediction of CYP3A4 induction in human hepatocytes: structure-based comparative molecular field analysis</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1002/jps.24235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjps.24235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=25381754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyhsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=223-232&issue=1&author=K.+Handaauthor=I.+Nakagomeauthor=N.+Yamaotsuauthor=H.+Goudaauthor=S.+Hirono&title=Three-dimensional+quantitative+structure-activity+relationship+analysis+for+human+pregnane+X+receptor+for+the+prediction+of+CYP3A4+induction+in+human+hepatocytes%3A+structure-based+comparative+molecular+field+analysis&doi=10.1002%2Fjps.24235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Dimensional Quantitative Structure-Activity Relationship Analysis for Human Pregnane X Receptor for the Prediction of CYP3A4 induction in Human Hepatocytes: Structure-Based Comparative Molecular Field Analysis</span></div><div class="casAuthors">Handa, Koichi; Nakagome, Izumi; Yamaotsu, Noriyuki; Gouda, Hiroaki; Hirono, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The pregnane X receptor [PXR (NR1I2)] induces the expression of xenobiotic metabolic genes and transporter genes.  In this study, we aimed to establish a computational method for quantifying the enzyme-inducing potencies of different compds. via their ability to activate PXR, for the application in drug discovery and development.  To achieve this purpose, we developed a three-dimensional quant. structure-activity relationship (3D-QSAR) model using comparative mol. field anal. (CoMFA) for predicting enzyme-inducing potencies, based on computer-ligand docking to multiple PXR protein structures sampled from the trajectory of a mol. dynamics simulation.  Mol. mechanics-generalized born/surface area scores representing the ligand-protein-binding free energies were calcd. for each ligand.  As a result, the predicted enzyme-inducing potencies for compds. generated by the CoMFA model were in good agreement with the exptl. values.  Finally, we concluded that this 3D-QSAR model has the potential to predict the enzyme-inducing potencies of novel compds. with high precision and therefore has valuable applications in the early stages of the drug discovery process. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp876yp57PFFrVg90H21EOLACvtfcHk0lh-Cbq3PMG5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyhsbvI&md5=396cb725f1ec541a9a7b1e495c1187e7</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2Fjps.24235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24235%26sid%3Dliteratum%253Aachs%26aulast%3DHanda%26aufirst%3DK.%26aulast%3DNakagome%26aufirst%3DI.%26aulast%3DYamaotsu%26aufirst%3DN.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26atitle%3DThree-dimensional%2520quantitative%2520structure-activity%2520relationship%2520analysis%2520for%2520human%2520pregnane%2520X%2520receptor%2520for%2520the%2520prediction%2520of%2520CYP3A4%2520induction%2520in%2520human%2520hepatocytes%253A%2520structure-based%2520comparative%2520molecular%2520field%2520analysis%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26issue%3D1%26spage%3D223%26epage%3D232%26doi%3D10.1002%2Fjps.24235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myatt, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blower, P. E.,  Jr.</span></span> <span> </span><span class="NLM_article-title">LeadScope: software for exploring large sets of screening data</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/ci0000631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0000631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlalt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=1302-1314&issue=6&author=G.+Robertsauthor=G.+J.+Myattauthor=W.+P.+Johnsonauthor=K.+P.+Crossauthor=P.+E.+Blower&title=LeadScope%3A+software+for+exploring+large+sets+of+screening+data&doi=10.1021%2Fci0000631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">LeadScope: Software for Exploring Large Sets of Screening Data</span></div><div class="casAuthors">Roberts, Gulsevin; Myatt, Glenn J.; Johnson, Wayne P.; Cross, Kevin P.; Blower, Paul E. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1302-1314</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern approaches to drug discovery have dramatically increased the speed and quantity of compds. that are made and tested for potential potency.  The task of collecting, organizing, and assimilating this information is a major bottleneck in the discovery of new drugs.  We have developed LeadScope a novel, interactive computer program for visualizing, browsing, and interpreting chem. and biol. screening data that can assist pharmaceutical scientists in finding promising drug candidates.  The software organizes the chem. data by structural features familiar to medicinal chemists.  Graphs are used to summarize the data, and structural classes are highlighted that are statistically correlated with biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZfT6LgmN8LVg90H21EOLACvtfcHk0ljBWfuBjzQdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlalt7g%253D&md5=7d95b14d7b5ff89706ee724425aeff2b</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1021%2Fci0000631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0000631%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DG.%26aulast%3DMyatt%26aufirst%3DG.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BP.%26aulast%3DCross%26aufirst%3DK.%2BP.%26aulast%3DBlower%26aufirst%3DP.%2BE.%26atitle%3DLeadScope%253A%2520software%2520for%2520exploring%2520large%2520sets%2520of%2520screening%2520data%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2000%26volume%3D40%26issue%3D6%26spage%3D1302%26epage%3D1314%26doi%3D10.1021%2Fci0000631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span> <span> </span><span class="NLM_article-title">Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2010.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.tox.2010.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21115097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2011&pages=77-87&issue=3&author=H.+Kojimaauthor=F.+Sataauthor=S.+Takeuchiauthor=T.+Sueyoshiauthor=T.+Nagai&title=Comparative+study+of+human+and+mouse+pregnane+X+receptor+agonistic+activity+in+200+pesticides+using+in+vitro+reporter+gene+assays&doi=10.1016%2Fj.tox.2010.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays</span></div><div class="casAuthors">Kojima, Hiroyuki; Sata, Fumihiro; Takeuchi, Shinji; Sueyoshi, Tatsuya; Nagai, Tadanori</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">77-87</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The nuclear receptor, pregnane X receptor (PXR), is a ligand-dependent transcription factor that regulates genes involved in xenobiotic metab.  Recent studies have shown that PXR activation may affect energy metab. as well as the endocrine and immune systems.  In this study, the authors characterized and compared the agonistic activities of a variety of pesticides against human PXR (hPXR) and mouse PXR (mPXR).  The hPXR and mPXR agonistic activity of 200 pesticides (29 organochlorines, 11 di-Ph ethers, 56 organophosphorus pesticides, 12 pyrethroids, 22 carbamates, 12 acid amides, 7 triazines, 7 ureas, and 44 others) was tested by reporter gene assays using COS-7 simian kidney cells.  Of the 200 pesticides tested, 106 and 93 activated hPXR and mPXR, resp., and a total of 111 had hPXR and(or) mPXR agonistic activity with greater or lesser interspecies differences.  Although all of the pyrethroids and most of the organochlorines and acid amides acted as PXR agonists, a wide range of pesticides with diverse structures also showed hPXR and(or) mPXR agonistic activity.  Among the 200 pesticides, pyributicarb, pretilachlor, piperophos, and butamifos for hPXR, and phosalone, prochloraz, pendimethalin, and butamifos for mPXR, acted as particularly potent activators at low concns. in the order of 10-8-10-7M.  In addn., several organophosphorus oxon- and pyributicarb oxon-metabolites decreased PXR activation potency compared to their parent compds.  These results suggest that a large no. of structurally diverse pesticides and their metabolites possess PXR-mediated transcriptional activity, and their ability to do so varies in a species-dependent manner in humans and mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmLQNlWlAQY7Vg90H21EOLACvtfcHk0ljBWfuBjzQdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaktLg%253D&md5=4823bd6aef9afcac088b8ad360ccfee3</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2010.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2010.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DSata%26aufirst%3DF.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DSueyoshi%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DT.%26atitle%3DComparative%2520study%2520of%2520human%2520and%2520mouse%2520pregnane%2520X%2520receptor%2520agonistic%2520activity%2520in%2520200%2520pesticides%2520using%2520in%2520vitro%2520reporter%2520gene%2520assays%26jtitle%3DToxicology%26date%3D2011%26volume%3D280%26issue%3D3%26spage%3D77%26epage%3D87%26doi%3D10.1016%2Fj.tox.2010.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of random forest and Pipeline Pilot Naive Bayes in prospective QSAR predictions</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/ci200615h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200615h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC38XislajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=792-803&issue=3&author=B.+Chenauthor=R.+P.+Sheridanauthor=V.+Hornakauthor=J.+H.+Voigt&title=Comparison+of+random+forest+and+Pipeline+Pilot+Naive+Bayes+in+prospective+QSAR+predictions&doi=10.1021%2Fci200615h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Random Forest and Pipeline Pilot Naive Bayes in Prospective QSAR Predictions</span></div><div class="casAuthors">Chen, Bin; Sheridan, Robert P.; Hornak, Viktor; Voigt, Johannes H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">792-803</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Random forest is currently considered one of the best QSAR methods available in terms of accuracy of prediction.  However, it is computationally intensive.  Naive Bayes is a simple, robust classification method.  The Laplacian-modified Naive Bayes implementation is the preferred QSAR method in the widely used com. chemoinformatics platform Pipeline Pilot.  We made a comparison of the ability of Pipeline Pilot Naive Bayes (PLPNB) and random forest to make accurate predictions on 18 large, diverse inhouse QSAR data sets.  These include on-target and ADME-related activities.  These data sets were set up as classification problems with either binary or multicategory activities.  We used a time-split method of dividing training and test sets, as we feel this is a realistic way of simulating prospective prediction.  PLPNB is computationally efficient.  However, random forest predictions are at least as good and in many cases significantly better than those of PLPNB on our data sets.  PLPNB performs better with ECFP4 and ECFP6 descriptors, which are native to Pipeline Pilot, and more poorly with other descriptors we tried.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopM-mDzNRvcLVg90H21EOLACvtfcHk0ljBWfuBjzQdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislajtbY%253D&md5=63488794c7eebebed1f34c2e6989e104</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fci200615h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200615h%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DR.%2BP.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26atitle%3DComparison%2520of%2520random%2520forest%2520and%2520Pipeline%2520Pilot%2520Naive%2520Bayes%2520in%2520prospective%2520QSAR%2520predictions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D3%26spage%3D792%26epage%3D803%26doi%3D10.1021%2Fci200615h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoufir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">eMolTox: Prediction of molecular toxicity with confidence</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/bty135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1093%2Fbioinformatics%2Fbty135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29522123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFCmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=2508-2509&issue=14&author=C.+Jiauthor=F.+Svenssonauthor=A.+Zoufirauthor=A.+Bender&title=eMolTox%3A+Prediction+of+molecular+toxicity+with+confidence&doi=10.1093%2Fbioinformatics%2Fbty135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">eMolTox: prediction of molecular toxicity with confidence</span></div><div class="casAuthors">Ji, Changge; Svensson, Fredrik; Zoufir, Azedine; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2508-2509</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4811</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Summary: In this work, we present eMolTox, a web server for the prediction of potential toxicity assocd. with a given mol.  A total of 174 toxicol.-related in vitro/vivo exptl. datasets were used for model construction and Mondrian conformal prediction was used to est. the confidence of the resulting predictions.  Toxic substructure anal. is also implemented in eMolTox. eMolTox predicts and displays a wealth of information of potential mol. toxicities for safety anal. in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_aaES1i5cZrVg90H21EOLACvtfcHk0ljBWfuBjzQdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFCmtL4%253D&md5=1f0f8c08e396e45109bfbc6fa1ced3fb</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbty135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbty135%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DF.%26aulast%3DZoufir%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DeMolTox%253A%2520Prediction%2520of%2520molecular%2520toxicity%2520with%2520confidence%26jtitle%3DBioinformatics%26date%3D2018%26volume%3D34%26issue%3D14%26spage%3D2508%26epage%3D2509%26doi%3D10.1093%2Fbioinformatics%2Fbty135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleifer, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsiedel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span> <span> </span><span class="NLM_article-title">KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/s13321-020-00422-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1186%2Fs13321-020-00422-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=24&author=A.+Morgerauthor=M.+Matheaauthor=J.+H.+Achenbachauthor=A.+Wolfauthor=R.+Buesenauthor=K.-J.+Schleiferauthor=R.+Landsiedelauthor=A.+Volkamer&title=KnowTox%3A+pipeline+and+case+study+for+confident+prediction+of+potential+toxic+effects+of+compounds+in+early+phases+of+development&doi=10.1186%2Fs13321-020-00422-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development</span></div><div class="casAuthors">Morger, Andrea; Mathea, Miriam; Achenbach, Janosch H.; Wolf, Antje; Buesen, Roland; Schleifer, Klaus-Juergen; Landsiedel, Robert; Volkamer, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">SpringerOpen</span>)
        </div><div class="casAbstract">Abstr.: Risk assessment of newly synthesized chems. is a prerequisite for regulatory approval.  In this context, in silico methods have great potential to reduce time, cost, and ultimately animal testing as they make use of the ever-growing amt. of available toxicity data.  Here, KnowTox is presented, a novel pipeline that combines three different in silico toxicol. approaches to allow for confident prediction of potentially toxic effects of query compds., i.e. machine learning models for 88 endpoints, alerts for 919 toxic substructures, and computational support for read-across.  Therefore, first, the conformal prediction technique was deployed, comprising an addnl. calibration step and per definition creating internally valid predictors at a given significance level.  Second, to further improve validity and information efficiency, two adaptations are suggested, exemplified at the androgen receptor antagonism endpoint.  This increase in validity comes at the cost of efficiency, which could again be improved by 20% for the initial ToxCast model by balancing the dataset during model training.  Finally, the value of the developed pipeline for risk assessment is discussed using two inhouse triazole mols.  Compared to a single toxicity prediction method, complementing the outputs of different approaches can have a higher impact on guiding toxicity testing and de-selecting most likely harmful development-candidate compds. early in the development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFOlJUVmwH3rVg90H21EOLACvtfcHk0lgE8WWHvyyk7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVOlu74%253D&md5=49acdc1fad1e28857f3d7511121c0c1e</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1186%2Fs13321-020-00422-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-020-00422-x%26sid%3Dliteratum%253Aachs%26aulast%3DMorger%26aufirst%3DA.%26aulast%3DMathea%26aufirst%3DM.%26aulast%3DAchenbach%26aufirst%3DJ.%2BH.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DBuesen%26aufirst%3DR.%26aulast%3DSchleifer%26aufirst%3DK.-J.%26aulast%3DLandsiedel%26aufirst%3DR.%26aulast%3DVolkamer%26aufirst%3DA.%26atitle%3DKnowTox%253A%2520pipeline%2520and%2520case%2520study%2520for%2520confident%2520prediction%2520of%2520potential%2520toxic%2520effects%2520of%2520compounds%2520in%2520early%2520phases%2520of%2520development%26jtitle%3DJ.%2520Cheminf.%26date%3D2020%26volume%3D12%26spage%3D24%26doi%3D10.1186%2Fs13321-020-00422-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grulke, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volarath, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainadarajah, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wambaugh, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kancherla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patlewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crofton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. S.</span></span> <span> </span><span class="NLM_article-title">ToxCast chemical landscape: Paving the road to 21st century toxicology</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00135</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00135" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2it77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1225-1251&issue=8&author=A.+M.+Richardauthor=R.+S.+Judsonauthor=K.+A.+Houckauthor=C.+M.+Grulkeauthor=P.+Volarathauthor=I.+Thillainadarajahauthor=C.+Yangauthor=J.+Rathmanauthor=M.+T.+Martinauthor=J.+F.+Wambaughauthor=T.+B.+Knudsenauthor=J.+Kancherlaauthor=K.+Mansouriauthor=G.+Patlewiczauthor=A.+J.+Williamsauthor=S.+B.+Littleauthor=K.+M.+Croftonauthor=R.+S.+Thomas&title=ToxCast+chemical+landscape%3A+Paving+the+road+to+21st+century+toxicology&doi=10.1021%2Facs.chemrestox.6b00135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology</span></div><div class="casAuthors">Richard, Ann M.; Judson, Richard S.; Houck, Keith A.; Grulke, Christopher M.; Volarath, Patra; Thillainadarajah, Inthirany; Yang, Chihae; Rathman, James; Martin, Matthew T.; Wambaugh, John F.; Knudsen, Thomas B.; Kancherla, Jayaram; Mansouri, Kamel; Patlewicz, Grace; Williams, Antony J.; Little, Stephen B.; Crofton, Kevin M.; Thomas, Russell S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1225-1251</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The U.S. Environmental Protection Agency's (EPA) ToxCast program is testing a large library of Agency-relevant chems. using in vitro high-throughput screening (HTS) approaches to support the development of improved toxicity prediction models.  Launched in 2007, Phase I of the program screened 310 chems., mostly pesticides, across hundreds of ToxCast assay end points.  In Phase II, the ToxCast library was expanded to 1878 chems., culminating in the public release of screening data at the end of 2013.  Subsequent expansion in Phase III has resulted in more than 3800 chems. actively undergoing ToxCast screening, 96% of which are also being screened in the multi-Agency Tox21 project.  The chem. library unpinning these efforts plays a central role in defining the scope and potential application of ToxCast HTS results.  The history of the phased construction of EPA's ToxCast library is reviewed, followed by a survey of the library contents from several different vantage points.  CAS Registry Nos. are used to assess ToxCast library coverage of important toxicity, regulatory, and exposure inventories.  Structure-based representations of ToxCast chems. are then used to compute physicochem. properties, substructural features, and structural alerts for toxicity and biotransformation.  Cheminformatics approaches using these varied representations are applied to defining the boundaries of HTS testability, evaluating chem. diversity, and comparing the ToxCast library to potential target application inventories, such as used in EPA's Endocrine Disruption Screening Program (EDSP).  Through several examples, the ToxCast chem. library is demonstrated to provide comprehensive coverage of the knowledge domains and target inventories of potential interest to EPA.  Furthermore, the varied representations and approaches presented here define local chem. domains potentially worthy of further investigation (e.g., not currently covered in the testing library or defined by toxicity "alerts") to strategically support data mining and predictive toxicol. modeling moving forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7PtwfIqvibVg90H21EOLACvtfcHk0lgE8WWHvyyk7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2it77J&md5=d3a11c36e02ef799785702d93344bf42</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00135%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DA.%2BM.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DHouck%26aufirst%3DK.%2BA.%26aulast%3DGrulke%26aufirst%3DC.%2BM.%26aulast%3DVolarath%26aufirst%3DP.%26aulast%3DThillainadarajah%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRathman%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DWambaugh%26aufirst%3DJ.%2BF.%26aulast%3DKnudsen%26aufirst%3DT.%2BB.%26aulast%3DKancherla%26aufirst%3DJ.%26aulast%3DMansouri%26aufirst%3DK.%26aulast%3DPatlewicz%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DLittle%26aufirst%3DS.%2BB.%26aulast%3DCrofton%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DR.%2BS.%26atitle%3DToxCast%2520chemical%2520landscape%253A%2520Paving%2520the%2520road%2520to%252021st%2520century%2520toxicology%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D8%26spage%3D1225%26epage%3D1251%26doi%3D10.1021%2Facs.chemrestox.6b00135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Creusot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gassiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaterre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiavarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahtouf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toporova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daujat-Chavanieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evrard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span> <span> </span><span class="NLM_article-title">The anti-cancer drug dabrafenib is a potent activator of the human pregnane X receptor</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1641</span>, <span class="refDoi"> DOI: 10.3390/cells9071641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.3390%2Fcells9071641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1ymtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1641&issue=7&author=N.+Creusotauthor=M.+Gassiotauthor=E.+Alaterreauthor=B.+Chiavarinaauthor=M.+Grimaldiauthor=A.+Boulahtoufauthor=L.+Toporovaauthor=S.+Gerbal-Chaloinauthor=M.+Daujat-Chavanieuauthor=A.+Matheuxauthor=R.+Rahmaniauthor=C.+Gongoraauthor=A.+Evrardauthor=P.+Pourquierauthor=P.+Balaguer&title=The+anti-cancer+drug+dabrafenib+is+a+potent+activator+of+the+human+pregnane+X+receptor&doi=10.3390%2Fcells9071641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-cancer drug dabrafenib is a potent activator of the human pregnane X receptor</span></div><div class="casAuthors">Creusot, Nicolas; Gassiot, Matthieu; Alaterre, Elina; Chiavarina, Barbara; Grimaldi, Marina; Boulahtouf, Abdelhay; Toporova, Lucia; Gerbal-Chaloin, Sabine; Daujat-Chavanieu, Martine; Matheux, Alice; Rahmani, Roger; Gongora, Celine; Evrard, Alexandre; Pourquier, Philippe; Balaguer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1641</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The human pregnane X receptor (hPXR) is activated by a large set of endogenous and exogenous compds. and plays a crit. role in the control of detoxifying enzymes and transporters regulating liver and gastrointestinal drug metab. and clearance. hPXR is also involved in both the development of multidrug resistance and enhanced cancer cells aggressiveness.  Moreover, its unintentional activation by pharmaceutical drugs can mediate drug-drug interactions and cause severe adverse events.  In that context, the potential of the anticancer BRAF inhibitor dabrafenib suspected to activate hPXR and the human constitutive androstane receptor (hCAR) has not been thoroughly investigated yet.  Using different reporter cellular assays, we demonstrate that dabrafenib can activate hPXR as efficiently as its ref. agonist SR12813, whereas it does not activate mouse or zebrafish PXR nor hCAR.We also showed that dabrafenib binds to recombinant hPXR, induces the expression of hPXR responsive genes in colon LS174T-hPXR cancer cells and human hepatocytes and finally increases the proliferation in LS174T-hPXR cells.  Our study reveals that by using a panel of different cellular techniques it is possible to improve the assessment of hPXR agonist activity for new developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjivaoeQRdPLVg90H21EOLACvtfcHk0lgE8WWHvyyk7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1ymtb3J&md5=46d8bab509ceff1fa9d157864984bd72</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.3390%2Fcells9071641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9071641%26sid%3Dliteratum%253Aachs%26aulast%3DCreusot%26aufirst%3DN.%26aulast%3DGassiot%26aufirst%3DM.%26aulast%3DAlaterre%26aufirst%3DE.%26aulast%3DChiavarina%26aufirst%3DB.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DBoulahtouf%26aufirst%3DA.%26aulast%3DToporova%26aufirst%3DL.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DDaujat-Chavanieu%26aufirst%3DM.%26aulast%3DMatheux%26aufirst%3DA.%26aulast%3DRahmani%26aufirst%3DR.%26aulast%3DGongora%26aufirst%3DC.%26aulast%3DEvrard%26aufirst%3DA.%26aulast%3DPourquier%26aufirst%3DP.%26aulast%3DBalaguer%26aufirst%3DP.%26atitle%3DThe%2520anti-cancer%2520drug%2520dabrafenib%2520is%2520a%2520potent%2520activator%2520of%2520the%2520human%2520pregnane%2520X%2520receptor%26jtitle%3DCells%26date%3D2020%26volume%3D9%26issue%3D7%26spage%3D1641%26doi%3D10.3390%2Fcells9071641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database</span>. <i>Environ. Health Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1289/ehp.1001930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1289%2Fehp.1001930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20558333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyjtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=1412-1417&issue=10&author=S.+Kortagereauthor=M.+D.+Krasowskiauthor=E.+J.+Reschlyauthor=M.+Venkateshauthor=S.+Maniauthor=S.+Ekins&title=Evaluation+of+computational+docking+to+identify+pregnane+X+receptor+agonists+in+the+ToxCast+database&doi=10.1289%2Fehp.1001930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database</span></div><div class="casAuthors">Kortagere, Sandhya; Krasowski, Matthew D.; Reschly, Erica J.; Venkatesh, Madhukumar; Mani, Sridhar; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Health Perspectives</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1412-1417</span>CODEN:
                <span class="NLM_cas:coden">EVHPAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-6765</span>.
    
            (<span class="NLM_cas:orgname">U. S. Department of Health and Human Services, Public Health Services</span>)
        </div><div class="casAbstract">The pregnane X receptor (PXR) is a key transcriptional regulator of many genes [e.g., cytochrome P450s (CYP2C9, CYP3A4, CYP2B6), MDR1] involved in xenobiotic metab. and excretion.  As part of an evaluation of different approaches to predict compd. affinity for nuclear hormone receptors, we used the mol. docking program GOLD and a hybrid scoring scheme based on similarity weighted GoldScores to predict potential PXR agonists in the ToxCast database of pesticides and other industrial chems.  We present some of the limitations of different in vitro systems, as well as docking and ligand-based computational models.  Each ToxCast compd. was docked into the five published crystallog. structures of human PXR (hPXR), and 15 compds. were selected based on their consensus docking scores for testing.  In addn., we used a Bayesian model to classify the ToxCast compds. into PXR agonists and nonagonists.  HPXR activation was detd. by luciferase-based reporter assays in the HepG2 and DPX-2 human liver cell lines.  We tested 11 compds., of which 6 were strong agonists and 2 had weak agonist activity.  Docking results of addnl. compds. were compared with data reported in the literature.  The prediction sensitivity of PXR agonists in our sample ToxCast data set (n = 28) using docking and the GoldScore was higher than with the hybrid score at 66.7%.  The prediction sensitivity for PXR agonists using GoldScore for the entire ToxCast data set (n = 308) compared with data from the NIH (National Institutes of Health) Chem. Genomics Center data was 73.8%.  Docking and the GoldScore may be useful for prioritizing large data sets prior to in vitro testing with good sensitivity across the sample and entire ToxCast data set for hPXR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1lXdlLX7jzLVg90H21EOLACvtfcHk0ljAc6KqQRXSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyjtrbO&md5=d9906fc4eb0f1eade813b79d66cc3163</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1289%2Fehp.1001930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.1001930%26sid%3Dliteratum%253Aachs%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DReschly%26aufirst%3DE.%2BJ.%26aulast%3DVenkatesh%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520computational%2520docking%2520to%2520identify%2520pregnane%2520X%2520receptor%2520agonists%2520in%2520the%2520ToxCast%2520database%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D2010%26volume%3D118%26issue%3D10%26spage%3D1412%26epage%3D1417%26doi%3D10.1289%2Fehp.1001930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span> <span> </span><span class="NLM_article-title">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1080/00498250601050412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1080%2F00498250601050412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=17484516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=124-138&issue=2&author=Y.+D.+Gaoauthor=S.+H.+Olsonauthor=J.+M.+Balkovecauthor=Y.+Zhuauthor=I.+Royoauthor=J.+Yabutauthor=R.+Eversauthor=E.+Y.+Tanauthor=W.+Tangauthor=D.+P.+Hartleyauthor=R.+T.+Mosley&title=Attenuating+pregnane+X+receptor+%28PXR%29+activation%3A+a+molecular+modelling+approach&doi=10.1080%2F00498250601050412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span></div><div class="casAuthors">Gao, Y.-D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that the pregnane X receptor (PXR) is a key regulator of cytochromes P 450 3A (e.g. CYP3A4 in human) gene expression.  As a result, activation of PXR may lead to CYP3A4 protein over-expression.  Because induction of CYP3A4 could result in clin. important drug-drug interactions, there has been a great interest in reducing the possibility of PXR activation by drug candidates in drug-discovery programs.  In order to provide structural insight for attenuating drug candidate-mediated PXR activation, we used a docking approach to study the structure-activity relationship for PXR activators.  Based on our docking models, it is proposed that introducing polar groups to the end of an activator should reduce its human PXR (hPXR) activity via destabilizing interactions in the hydrophobic areas of the PXR ligand-binding pocket.  A no. of analogs that incorporate these structural features then were designed and synthesized, and they exhibited significantly lower hPXR activation in a transactivation assay and decreased CYP3A4 induction in a human hepatocytes-based assay.  In addn., an example in which attenuating hPXR activation was achieved by sterically destabilizing the helixes 11 and 12 of the receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBZSC0secQoLVg90H21EOLACvtfcHk0ljAc6KqQRXSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D&md5=400688510dd165a4a9632b6ba10bf267</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1080%2F00498250601050412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250601050412%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRoyo%26aufirst%3DI.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DE.%2BY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26atitle%3DAttenuating%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520activation%253A%2520a%2520molecular%2520modelling%2520approach%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26issue%3D2%26spage%3D124%26epage%3D138%26doi%3D10.1080%2F00498250601050412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span> <span> </span><span class="NLM_article-title">Insights from a three-dimensional model into ligand binding to constitutive active receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.9.951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1124%2Fdmd.30.9.951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=12167558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=951-956&issue=9&author=L.+Xiaoauthor=X.+Cuiauthor=V.+Madisonauthor=R.+E.+Whiteauthor=K.+C.+Cheng&title=Insights+from+a+three-dimensional+model+into+ligand+binding+to+constitutive+active+receptor&doi=10.1124%2Fdmd.30.9.951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Insights from a three-dimensional model into ligand binding to constitutive active receptor</span></div><div class="casAuthors">Xiao, Li; Cui, Xiaoming; Madison, Vincent; White, Ronald E.; Cheng, K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">951-956</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two orphan nuclear receptors, constitutive active (or androstane) receptor (CAR) and pregnane X receptor (PXR), are among the most important mediators of ligand-activated transcriptional induction of liver microsomal cytochrome P 450 drug-metabolizing enzymes.  CAR and PXR belong to the same NR1I receptor subfamily and show high sequence homol. to each other.  The vitamin D receptor (VDR) also belongs to the NR1I subfamily and has the second highest homol. to CAR in the ligand binding domain.  A 3D model of the ligand binding domain of human CAR (hCAR) was constructed based on the available x-ray structures of human PXR (hPXR) and VDR (hVDR).  The model shows that the size of the ligand binding cavities of hCAR and hPXR are similar, but larger than that of hVDR.  HPXR's capability of binding to extremely large ligands, such as rifampicin, implies that its binding cavity may be able to expand further through the flexibility of a surface loop.  In contrast, hCAR does not have this loop so that its cavity cannot expand, suggesting that hCAR would not bind to the largest hPXR ligands.  Docking calcns. of selected ligands to hCAR, based on the structural model, are consistent with previously reported receptor binding data.  The results from this study indicate that structural modeling will be a useful tool for understanding ligand binding to hCAR and for design of drugs free of hCAR-mediated enzyme induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMVoVyEEGrnLVg90H21EOLACvtfcHk0ljAc6KqQRXSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVShur4%253D&md5=e1bf7beb49daf4e496f216d9f6899baf</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.9.951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.9.951%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26atitle%3DInsights%2520from%2520a%2520three-dimensional%2520model%2520into%2520ligand%2520binding%2520to%2520constitutive%2520active%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26issue%3D9%26spage%3D951%26epage%3D956%26doi%3D10.1124%2Fdmd.30.9.951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Molecular insights into the promiscuous interaction of human pregnane X receptor (hPXR) with diverse environmental chemicals and drug compounds</span>. <i>Chemosphere</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.chemosphere.2013.09.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.chemosphere.2013.09.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24182399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ksrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=138-145&author=S.+Chenauthor=N.+Heauthor=W.+Chenauthor=F.+Sunauthor=L.+Liauthor=R.+Dengauthor=Y.+Hu&title=Molecular+insights+into+the+promiscuous+interaction+of+human+pregnane+X+receptor+%28hPXR%29+with+diverse+environmental+chemicals+and+drug+compounds&doi=10.1016%2Fj.chemosphere.2013.09.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular insights into the promiscuous interaction of human pregnane X receptor (hPXR) with diverse environmental chemicals and drug compounds</span></div><div class="casAuthors">Chen, Sheng; He, Nianhai; Chen, Wensheng; Sun, Fengjun; Li, Luquan; Deng, Rui; Hu, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Chemosphere</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-145</span>CODEN:
                <span class="NLM_cas:coden">CMSHAF</span>;
        ISSN:<span class="NLM_cas:issn">0045-6535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The nuclear receptor member human pregnane X receptor (hPXR) regulates enzymes and transporters involved in xenobiotic detoxification as well as maintains homeostatic balance of bile acids, thyroid and steroid hormones.  HPXR can be recognized and activated by a structurally diverse array of environmental chems. and drug compds. to initiate adverse biol. effects, such as perturbing normal physiol. functions and causing dangerous drug-drug interactions and exhibiting a high promiscuity in its ligand spectrum.  Understanding of the mol. mechanism and biol. implication underlying the promiscuous interaction of hPXR with its diverse ligands is fundamentally important for toxicol. and pharmaceutical researches.  In the current study, mol. docking and hybrid quantum mechanics/mol. mechanics (QM/MM) were employed to investigate the binding mode, structural basis and energetic property of hPXR interactions with various activators and non-activators.  It was found that, as compared to non-activators, the activators adopt few dominant modes to tightly interact with hPXR, which are specified by few polar spots located on the hydrophobic surface of hPXR active pocket.  Based on the findings, a novel method called multiple binding mode-based quant. structure-activity relationship (MBMB-QSAR) that characterizes the nonbonded interaction profile of hPXR with its ligand in multiple binding modes was proposed to model and predict the activating potency of small-mol. compds. on hPXR.  Several partial least square (PLS) predictors derived from the MBMB-QSAR modeling were demonstrated to be effective for quant. characterization of the biol. behavior of exptl. confirmed activators, and for qual. differentiating the activators from a large no. of non-activators.  From the predictor models it is suggested that the hydrophobic force and electrostatic interaction play an important role in hPXR-ligand binding, while steric factor contributes moderately to the binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mRzy_7rpRLVg90H21EOLACvtfcHk0lhySGWwdcyDsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ksrvO&md5=998e892317253d03527593cbf0bb627c</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.chemosphere.2013.09.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemosphere.2013.09.084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DMolecular%2520insights%2520into%2520the%2520promiscuous%2520interaction%2520of%2520human%2520pregnane%2520X%2520receptor%2520%2528hPXR%2529%2520with%2520diverse%2520environmental%2520chemicals%2520and%2520drug%2520compounds%26jtitle%3DChemosphere%26date%3D2014%26volume%3D96%26spage%3D138%26epage%3D145%26doi%3D10.1016%2Fj.chemosphere.2013.09.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaquiquzzaman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular interactions of dioxins and DLCs with the xenosensors (PXR and CAR): An in silico risk assessment approach</span>. <i>J. Mol. Recognit.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e2651</span> <span class="refDoi"> DOI: 10.1002/jmr.2651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1002%2Fjmr.2651" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&issue=12&author=G.+Vermaauthor=M.+F.+Khanauthor=M.+Shaquiquzzamanauthor=W.+Akhtarauthor=M.+Akhterauthor=S.+M.+Hasanauthor=M.+M.+Alam&title=Molecular+interactions+of+dioxins+and+DLCs+with+the+xenosensors+%28PXR+and+CAR%29%3A+An+in+silico+risk+assessment+approach&doi=10.1002%2Fjmr.2651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1002%2Fjmr.2651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.2651%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DM.%2BF.%26aulast%3DShaquiquzzaman%26aufirst%3DM.%26aulast%3DAkhtar%26aufirst%3DW.%26aulast%3DAkhter%26aufirst%3DM.%26aulast%3DHasan%26aufirst%3DS.%2BM.%26aulast%3DAlam%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520interactions%2520of%2520dioxins%2520and%2520DLCs%2520with%2520the%2520xenosensors%2520%2528PXR%2520and%2520CAR%2529%253A%2520An%2520in%2520silico%2520risk%2520assessment%2520approach%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2017%26volume%3D30%26issue%3D12%26doi%3D10.1002%2Fjmr.2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Screening ingredients from herbs against pregnane X receptor in the study of inductive herb-drug interactions: Combining pharmacophore and docking-based rank aggregation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">657159</span>, <span class="refDoi"> DOI: 10.1155/2015/657159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1155%2F2015%2F657159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=26339628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A280%3ADC%252BC287psVOrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=657159&author=Z.+Cuiauthor=H.+Kangauthor=K.+Tangauthor=Q.+Liuauthor=Z.+Caoauthor=R.+Zhu&title=Screening+ingredients+from+herbs+against+pregnane+X+receptor+in+the+study+of+inductive+herb-drug+interactions%3A+Combining+pharmacophore+and+docking-based+rank+aggregation&doi=10.1155%2F2015%2F657159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Screening Ingredients from Herbs against Pregnane X Receptor in the Study of Inductive Herb-Drug Interactions: Combining Pharmacophore and Docking-Based Rank Aggregation</span></div><div class="casAuthors">Cui Zhijie; Kang Hong; Tang Kailin; Liu Qi; Cao Zhiwei; Zhu Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">657159</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The issue of herb-drug interactions has been widely reported.  Herbal ingredients can activate nuclear receptors and further induce the gene expression alteration of drug-metabolizing enzyme and/or transporter.  Therefore, the herb-drug interaction will happen when the herbs and drugs are coadministered.  This kind of interaction is called inductive herb-drug interactions.  Pregnane X Receptor (PXR) and drug-metabolizing target genes are involved in most of inductive herb-drug interactions.  To predict this kind of herb-drug interaction, the protocol could be simplified to only screen agonists of PXR from herbs because the relations of drugs with their metabolizing enzymes are well studied.  Here, a combinational in silico strategy of pharmacophore modelling and docking-based rank aggregation (DRA) was employed to identify PXR's agonists.  Firstly, 305 ingredients were screened out from 820 ingredients as candidate agonists of PXR with our pharmacophore model.  Secondly, DRA was used to rerank the result of pharmacophore filtering.  To validate our prediction, a curated herb-drug interaction database was built, which recorded 380 herb-drug interactions.  Finally, among the top 10 herb ingredients from the ranking list, 6 ingredients were reported to involve in herb-drug interactions.  The accuracy of our method is higher than other traditional methods.  The strategy could be extended to studies on other inductive herb-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFWR8GWePJMynGiHuhFGv8fW6udTcc2ebra6TZrbxp0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287psVOrtA%253D%253D&md5=98b18daf73aebe11f776a2c7eec7321a</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1155%2F2015%2F657159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F657159%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DScreening%2520ingredients%2520from%2520herbs%2520against%2520pregnane%2520X%2520receptor%2520in%2520the%2520study%2520of%2520inductive%2520herb-drug%2520interactions%253A%2520Combining%2520pharmacophore%2520and%2520docking-based%2520rank%2520aggregation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D657159%26doi%3D10.1155%2F2015%2F657159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avolio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paonessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, F.</span></span> <span> </span><span class="NLM_article-title">Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4547</span>– <span class="NLM_lpage">4557</span>, <span class="refDoi"> DOI: 10.1021/jm050056+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050056%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4547-4557&issue=14&author=S.+Harperauthor=S.+Avolioauthor=B.+Paciniauthor=M.+Di+Filippoauthor=S.+Altamuraauthor=L.+Tomeiauthor=G.+Paonessaauthor=S.+Di+Marcoauthor=A.+Carfiauthor=C.+Giulianoauthor=J.+Padronauthor=F.+Bonelliauthor=G.+Migliaccioauthor=R.+De+Francescoauthor=R.+Lauferauthor=M.+Rowleyauthor=F.+Narjes&title=Potent+inhibitors+of+subgenomic+hepatitis+C+virus+RNA+replication+through+optimization+of+indole-N-acetamide+allosteric+inhibitors+of+the+viral+NS5B+polymerase&doi=10.1021%2Fjm050056%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase</span></div><div class="casAuthors">Harper, Steven; Avolio, Salvatore; Pacini, Barbara; Di Filippo, Marcello; Altamura, Sergio; Tomei, Licia; Paonessa, Giacomo; Di Marco, Stefania; Carfi, Andrea; Giuliano, Claudio; Padron, Julio; Bonelli, Fabio; Migliaccio, Giovanni; De Francesco, Raffaele; Laufer, Ralph; Rowley, Michael; Narjes, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4547-4557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand.  Compds. that block replication of subgenomic HCV RNA in liver cells are of interest because of their demonstrated antiviral effect in the clinic.  In followup to a recent report that indole-N-acetamides were potent allosteric inhibitors of the HCV NS5B polymerase enzyme, the optimization as cell-based inhibitors are described.  The crystal structure of I bound to NS5B was a guide in the design of a two-dimensional compd. array that highlighted that formally zwitterionic inhibitors have strong intracellular potency and that pregnane X receptor (PXR) activation (an undesired off-target activity) was linked to a structural feature of the inhibitor.  Optimized analogs devoid of PXR activation (EC50 = 127 nM) retain strong cell-based efficacy under high serum conditions and showed acceptable pharmacokinetics parameters in rat and dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPuXP6GW8l7bVg90H21EOLACvtfcHk0ljgyxWEcuXG-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVSltb8%253D&md5=eda6f08c07dd89cc20360c555a860bdf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjm050056%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050056%252B%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DAvolio%26aufirst%3DS.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DPaonessa%26aufirst%3DG.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DCarfi%26aufirst%3DA.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPadron%26aufirst%3DJ.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DPotent%2520inhibitors%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520through%2520optimization%2520of%2520indole-N-acetamide%2520allosteric%2520inhibitors%2520of%2520the%2520viral%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D14%26spage%3D4547%26epage%3D4557%26doi%3D10.1021%2Fjm050056%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes-Seeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiselle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacci-Daniel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3979</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2014.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=24986660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jt7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3979-3985&issue=16&author=D.+Barnes-Seemanauthor=C.+Boiselleauthor=C.+Capacci-Danielauthor=R.+Chopraauthor=K.+Hoffmasterauthor=C.+T.+Jonesauthor=M.+Katoauthor=K.+Linauthor=S.+Maauthor=G.+Panauthor=L.+Shuauthor=J.+Wangauthor=L.+Whitemanauthor=M.+Xuauthor=R.+Zhengauthor=J.+Fu&title=Design+and+synthesis+of+lactam-thiophene+carboxylic+acids+as+potent+hepatitis+C+virus+polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors</span></div><div class="casAuthors">Barnes-Seeman, David; Boiselle, Carri; Capacci-Daniel, Christina; Chopra, Rajiv; Hoffmaster, Keith; Jones, Christopher T.; Kato, Mitsunori; Lin, Kai; Ma, Sue; Pan, Guoyu; Shu, Lei; Wang, Jianling; Whiteman, Leah; Xu, Mei; Zheng, Rui; Fu, Jiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3979-3985</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors.  Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor I.  This lead compd. has a favorable pharmacokinetic profile in rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYh3RQ4DmSFrVg90H21EOLACvtfcHk0ljgyxWEcuXG-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jt7zM&md5=441c6d42d6947272b185499ab33ad64b</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DBoiselle%26aufirst%3DC.%26aulast%3DCapacci-Daniel%26aufirst%3DC.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DHoffmaster%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DC.%2BT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DShu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWhiteman%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520lactam-thiophene%2520carboxylic%2520acids%2520as%2520potent%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3979%26epage%3D3985%26doi%3D10.1016%2Fj.bmcl.2014.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilimoria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selliah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawgo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waal, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allosteric HCV NS5B inhibitors. 2. Lactam-containing thiophene carboxylates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=251-255&issue=2&author=P.+Liauthor=W.+Dorschauthor=D.+J.+Laufferauthor=D.+Bilimoriaauthor=N.+Chauretauthor=J.+J.+Courtauthor=S.+K.+Dasauthor=F.+Denisauthor=N.+Maniauthor=S.+Nanthakumarauthor=O.+Nicolasauthor=B.+G.+Raoauthor=S.+Ronkinauthor=S.+Selliahauthor=R.+S.+Shawgoauthor=R.+Stearnsauthor=Q.+Tangauthor=N.+D.+Waalauthor=J.+Green&title=Discovery+of+novel+allosteric+HCV+NS5B+inhibitors.+2.+Lactam-containing+thiophene+carboxylates&doi=10.1021%2Facsmedchemlett.6b00479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates</span></div><div class="casAuthors">Li, Pan; Dorsch, Warren; Lauffer, David J.; Bilimoria, Darius; Chauret, Nathalie; Court, John J.; Das, Sanjoy Kumar; Denis, Francois; Mani, Nagraj; Nanthakumar, Suganthini; Nicolas, Olivier; Rao, B. Govinda; Ronkin, Steven; Selliah, Subajini; Shawgo, Rebecca S.; Stearns, Ralph; Tang, Qing; Waal, Nathan D.; Green, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-255</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lomibuvir is a nonnucleoside, allosteric inhibitor of the hepatitis C virus NS5B polymerase with demonstrated clin. efficacy.  Further development efforts within this class of inhibitor focused on improving the antiviral activity and physicochem. and pharmacokinetic properties.  Recently, the authors reported the development of this series, leading to a compd. with comparable potency and an improved physicochem. profile relative.  Further exploration of the amino amide-derived side chain led to a series of lactam derivs., inspired by the x-ray crystal structure of related thiophene carboxylate inhibitors.  This series, exemplified by 12f, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[[(3S)-hexahydro-1-methyl-2-oxo-1H-azepin-3-yl][(trans-4-methylcyclohexyl)carbonyl]amino]-2-thiophenecarboxylic acid [1355038-54-8], provided 3-5-fold improvement in potency against HCV replication, as measured by replicon assays.  The synthesis, structure-activity relationships, in vitro ADME characterization, and in vivo evaluation of this novel series are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojwI0P91VScLVg90H21EOLACvtfcHk0ljKh7p1DXwIRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSqsrg%253D&md5=6e9026adde8c5f5ca7e432da136c6992</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00479%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DDorsch%26aufirst%3DW.%26aulast%3DLauffer%26aufirst%3DD.%2BJ.%26aulast%3DBilimoria%26aufirst%3DD.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DDenis%26aufirst%3DF.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DNicolas%26aufirst%3DO.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DRonkin%26aufirst%3DS.%26aulast%3DSelliah%26aufirst%3DS.%26aulast%3DShawgo%26aufirst%3DR.%2BS.%26aulast%3DStearns%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DWaal%26aufirst%3DN.%2BD.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520allosteric%2520HCV%2520NS5B%2520inhibitors.%25202.%2520Lactam-containing%2520thiophene%2520carboxylates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D2%26spage%3D251%26epage%3D255%26doi%3D10.1021%2Facsmedchemlett.6b00479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanowski-Vosatka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieringer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3405</span>– <span class="NLM_lpage">3411</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2008.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18440811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3405-3411&issue=11&author=Y.+Zhuauthor=S.+H.+Olsonauthor=A.+Hermanowski-Vosatkaauthor=S.+Mundtauthor=K.+Shahauthor=M.+Springerauthor=R.+Thieringerauthor=S.+Wrightauthor=J.+Xiaoauthor=H.+Zokianauthor=J.+M.+Balkovec&title=4-Methyl-5-phenyl+triazoles+as+selective+inhibitors+of+11beta-hydroxysteroid+dehydrogenase+type+I&doi=10.1016%2Fj.bmcl.2008.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I</span></div><div class="casAuthors">Zhu, Yuping; Olson, Steven H.; Hermanowski-Vosatka, Anne; Mundt, Steven; Shah, Kashmira; Springer, Marty; Thieringer, Rolf; Wright, Samuel; Xiao, Jianying; Zokian, Hratch; Balkovec, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3405-3411</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">4-Methyl-5-phenyl-(1,2,4)-triazoles were identified as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).  They were active in vitro and in an in vivo mouse pharmacodynamic (PD) model.  The synthesis and structure activity relationships are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohs8pGTNpvTbVg90H21EOLACvtfcHk0ljKh7p1DXwIRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yhsbY%253D&md5=321b69d6467e3fc67d1359f5edfd78cb</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DHermanowski-Vosatka%26aufirst%3DA.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSpringer%26aufirst%3DM.%26aulast%3DThieringer%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZokian%26aufirst%3DH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26atitle%3D4-Methyl-5-phenyl%2520triazoles%2520as%2520selective%2520inhibitors%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%2520I%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D11%26spage%3D3405%26epage%3D3411%26doi%3D10.1016%2Fj.bmcl.2008.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maletic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J.</span></span> <span> </span><span class="NLM_article-title">Substituted phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase Type 1</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2141</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2011.01.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=21334894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFCkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2141-2145&issue=7&author=W.+Sunauthor=M.+Maleticauthor=S.+S.+Mundtauthor=K.+Shahauthor=H.+Zokianauthor=K.+Lyonsauthor=S.+T.+Waddellauthor=J.+Balkovec&title=Substituted+phenyl+triazoles+as+selective+inhibitors+of+11beta-hydroxysteroid+dehydrogenase+Type+1&doi=10.1016%2Fj.bmcl.2011.01.125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1</span></div><div class="casAuthors">Sun, Wanying; Maletic, Milana; Mundt, Steven S.; Shah, Kashmira; Zokian, Hratch; Lyons, Kathy; Waddell, Sherman T.; Balkovec, James</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2141-2145</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3-(Phenylcyclobutyl)-1,2,4-triazoles were identified as inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD1).  They were shown to be active in the mouse in vivo pharmacodynamic model (PD) for HSD1 but exhibited a potent off-target activation of the Pregnane X Receptor (PXR).  SAR studies and synthesis of analogs that led to the discovery of a selective HSD1 inhibitor are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfIHxLo32eC7Vg90H21EOLACvtfcHk0ljKh7p1DXwIRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFCkurs%253D&md5=8711f6f6bc517ecd508b33ca8e303205</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.125%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DMaletic%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%2BS.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DZokian%26aufirst%3DH.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DWaddell%26aufirst%3DS.%2BT.%26aulast%3DBalkovec%26aufirst%3DJ.%26atitle%3DSubstituted%2520phenyl%2520triazoles%2520as%2520selective%2520inhibitors%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520Type%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D2141%26epage%3D2145%26doi%3D10.1016%2Fj.bmcl.2011.01.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercot, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guram, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komorowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veniant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7953</span>– <span class="NLM_lpage">7967</span>, <span class="refDoi"> DOI: 10.1021/jm801073z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801073z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7953-7967&issue=24&author=C.+Fotschauthor=M.+D.+Bartbergerauthor=E.+A.+Bercotauthor=M.+Chenauthor=R.+Cupplesauthor=M.+Emeryauthor=J.+Fretlandauthor=A.+Guramauthor=C.+Haleauthor=N.+Hanauthor=D.+Hickmanauthor=R.+W.+Hungateauthor=M.+Hayashiauthor=R.+Komorowskiauthor=Q.+Liuauthor=G.+Matsumotoauthor=D.+J.+St.+Jeanauthor=S.+Ursuauthor=M.+Veniantauthor=G.+Xuauthor=Q.+Yeauthor=C.+Yuanauthor=J.+Zhangauthor=X.+Zhangauthor=H.+Tuauthor=M.+Wang&title=Further+studies+with+the+2-amino-1%2C3-thiazol-4%285H%29-one+class+of+11beta-hydroxysteroid+dehydrogenase+type+1+inhibitors%3A+reducing+pregnane+X+receptor+activity+and+exploring+activity+in+a+monkey+pharmacodynamic+model&doi=10.1021%2Fjm801073z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model</span></div><div class="casAuthors">Fotsch, Christopher; Bartberger, Michael D.; Bercot, Eric A.; Chen, Michelle; Cupples, Rod; Emery, Maury; Fretland, Jenne; Guram, Anil; Hale, Clarence; Han, Nianhe; Hickman, Dean; Hungate, Randall W.; Hayashi, Michael; Komorowski, Renee; Liu, Qingyian; Matsumoto, Guy; St. Jean, David J.; Ursu, Stefania; Veniant, Murielle; Xu, Guifen; Ye, Qiuping; Yuan, Chester; Zhang, Jiandong; Zhang, Xiping; Tu, Hua; Wang, Minghan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7953-7967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. contg. the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).  One of our lead compds. from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR).  To try and mitigate the PXR activity, we prepd. analogs of our lead series that contained polar groups on the right-hand side of the thiazolone.  Several analogs contg. amides or alcs. appended to the C-5 position of the thiazolone showed a significant redn. in PXR activity.  Through these structure-activity efforts, a compd. contg. a tert-alc. group off the C-5 position, analog (S)-33a, was found to have an 11β-HSD1 Ki = 35 nM and negligible PXR activity.  Compd. (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11β-HSD1 activity after being orally administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRKNSaUFCaPrVg90H21EOLACvtfcHk0lg-HIO7BCwmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2jsb%252FK&md5=282c537175cf7d06a3dd99ddd73924aa</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fjm801073z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801073z%26sid%3Dliteratum%253Aachs%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBercot%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGuram%26aufirst%3DA.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DN.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHungate%26aufirst%3DR.%2BW.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DKomorowski%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMatsumoto%26aufirst%3DG.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DUrsu%26aufirst%3DS.%26aulast%3DVeniant%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DFurther%2520studies%2520with%2520the%25202-amino-1%252C3-thiazol-4%25285H%2529-one%2520class%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520inhibitors%253A%2520reducing%2520pregnane%2520X%2520receptor%2520activity%2520and%2520exploring%2520activity%2520in%2520a%2520monkey%2520pharmacodynamic%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7953%26epage%3D7967%26doi%3D10.1021%2Fjm801073z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villemure, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1801</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2009.01.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19217779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1797-1801&issue=6&author=Y.+Rewauthor=D.+L.+McMinnauthor=Z.+Wangauthor=X.+Heauthor=R.+W.+Hungateauthor=J.+C.+Jaenauthor=A.+Sudomauthor=D.+Sunauthor=H.+Tuauthor=S.+Ursuauthor=E.+Villemureauthor=N.+P.+Walkerauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+and+optimization+of+piperidyl+benzamide+derivatives+as+a+novel+class+of+11beta-HSD1+inhibitors&doi=10.1016%2Fj.bmcl.2009.01.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors</span></div><div class="casAuthors">Rew, Yosup; McMinn, Dustin L.; Wang, Zhulun; He, Xiao; Hungate, Randall W.; Jaen, Juan C.; Sudom, Athena; Sun, Daqing; Tu, Hua; Ursu, Stefania; Villemure, Elisia; Walker, Nigel P. C.; Yan, Xuelei; Ye, Qiuping; Powers, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1797-1801</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Discovery and optimization of a piperidyl benzamide series of 11β-HSD1 inhibitors is described.  This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor soly., limited in vivo exposure, and in vitro cytotoxicity issues obsd. with the cyclohexyl benzamide structures.  These efforts led to the discovery of piperidyl benzamide 15 which features improved properties over the cyclohexyl benzamide derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaYVcvPuFyJLVg90H21EOLACvtfcHk0lg-HIO7BCwmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltbw%253D&md5=3ffc3c0dadf23d90cc91a247a0e97bb4</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.058%26sid%3Dliteratum%253Aachs%26aulast%3DRew%26aufirst%3DY.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHungate%26aufirst%3DR.%2BW.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTu%26aufirst%3DH.%26aulast%3DUrsu%26aufirst%3DS.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DWalker%26aufirst%3DN.%2BP.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520piperidyl%2520benzamide%2520derivatives%2520as%2520a%2520novel%2520class%2520of%252011beta-HSD1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D6%26spage%3D1797%26epage%3D1801%26doi%3D10.1016%2Fj.bmcl.2009.01.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayeem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrity, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponticiello, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 1,2,4-triazolopyridines as inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1021/ml500144h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500144h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=803-808&issue=7&author=J.+Liauthor=L.+J.+Kennedyauthor=H.+Wangauthor=J.+J.+Liauthor=S.+J.+Walkerauthor=Z.+Hongauthor=S.+P.+O%E2%80%99Connorauthor=A.+Nayeemauthor=D.+M.+Camacauthor=P.+E.+Morinauthor=S.+Sheriffauthor=M.+Wangauthor=T.+Harperauthor=R.+Gollaauthor=R.+Seethalaauthor=T.+Harrityauthor=R.+P.+Ponticielloauthor=N.+N.+Morganauthor=J.+R.+Taylorauthor=R.+Zeboauthor=D.+A.+Gordonauthor=J.+A.+Robl&title=Optimization+of+1%2C2%2C4-triazolopyridines+as+inhibitors+of+human+11beta-hydroxysteroid+dehydrogenase+type+1+%2811beta-HSD-1%29&doi=10.1021%2Fml500144h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)</span></div><div class="casAuthors">Li, Jun; Kennedy, Lawrence J.; Wang, Haixia; Li, James J.; Walker, Steven J.; Hong, Zhenqiu; O'Connor, Stephen P.; Nayeem, Akbar; Camac, Daniel M.; Morin, Paul E.; Sheriff, Steven; Wang, Mengmeng; Harper, Timothy; Golla, Rajasree; Seethala, Ramakrishna; Harrity, Thomas; Ponticiello, Randolph P.; Morgan, Nathan N.; Taylor, Joseph R.; Zebo, Rachel; Gordon, David A.; Robl, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small alkyl groups and spirocyclic-arom. rings directly attached to the left side and right side of the 1,2,4-triazolopyridines (TZP), resp., were found to be potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase-type 1 (11β-HSD-1) enzyme. 3-(1-(4-Chlorophenyl)cyclopropyl)-8-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridine (9f) was identified as a potent inhibitor of the 11β-HSD-1 enzyme with reduced Pregnane-X receptor (PXR) transactivation activity.  The binding orientation of this TZP series was revealed by X-ray crystallog. structure studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8M6fo9BKqH7Vg90H21EOLACvtfcHk0lgm2Zlcn1yfKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOgu7o%253D&md5=0a64d071b7a7c0e0c6d54d91d740f427</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fml500144h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500144h%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DL.%2BJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%2BJ.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BP.%26aulast%3DNayeem%26aufirst%3DA.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DT.%26aulast%3DGolla%26aufirst%3DR.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DHarrity%26aufirst%3DT.%26aulast%3DPonticiello%26aufirst%3DR.%2BP.%26aulast%3DMorgan%26aufirst%3DN.%2BN.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DZebo%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26atitle%3DOptimization%2520of%25201%252C2%252C4-triazolopyridines%2520as%2520inhibitors%2520of%2520human%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520%252811beta-HSD-1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D7%26spage%3D803%26epage%3D808%26doi%3D10.1021%2Fml500144h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sa, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-((R)-4-(2-fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A highly potent, selective, and orally bioavailable inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10189</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01122</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01122" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10176-10189&issue=22&author=J.+H.+Ryuauthor=J.+A.+Leeauthor=S.+Kimauthor=Y.+A.+Shinauthor=J.+Yangauthor=H.+Y.+Hanauthor=H.+J.+Sonauthor=Y.+H.+Kimauthor=J.+H.+Saauthor=J.+S.+Kimauthor=J.+Leeauthor=J.+Leeauthor=H.+G.+Park&title=Discovery+of+2-%28%28R%29-4-%282-fluoro-4-%28methylsulfonyl%29phenyl%29-2-methylpiperazin-1-yl%29-N-%28%281R%2C2s%2C3S%2C5S%2C7S%29-5-hydroxyadamantan-2-yl%29pyrimidine-4-carboxamide+%28SKI2852%29%3A+A+highly+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+11beta-hydroxysteroid+dehydrogenase+type+1+%2811beta-HSD1%29&doi=10.1021%2Facs.jmedchem.6b01122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</span></div><div class="casAuthors">Ryu, Je Ho; Lee, Jung A.; Kim, Shinae; Shin, Young Ah; Yang, Jewon; Han, Hye Young; Son, Hyun Joo; Kim, Yong Hyuk; Sa, Joon Ho; Kim, Jae-Sun; Lee, Jungeun; Lee, Jeeyeon; Park, Hyeung-geun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10176-10189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of picolinamide- and pyrimidine-4-carboxamide-based inhibitors of 11β-hydroxysteroid dehydrogenase type 1 was synthesized and evaluated to optimize the lead compd.  The combination of the replacement of a pyridine ring of the lead compd with a pyrimidine ring and the introduction of an addnl. fluorine substituent at the 2-position of the Ph ring resulted in the discovery of a potent, selective, and orally bioavailable inhibitor, SKI2852, which demonstrated no CYP and PXR liabilities, excellent PK profiles across species, and highly potent and sustainable PD activity.  Repeated oral administration of SKI2852 significantly reduced blood glucose and HbA1c levels and improved the lipid profiles in ob/ob mice.  Moreover, the HbA1c-lowering effect of metformin was synergistically enhanced in combination with SKI2852.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqgyIMAhNv7rVg90H21EOLACvtfcHk0lgm2Zlcn1yfKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgtrzI&md5=9ecc2500a3f4ab996d0416395765a7bf</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01122%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%2BY.%26aulast%3DSon%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSa%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DH.%2BG.%26atitle%3DDiscovery%2520of%25202-%2528%2528R%2529-4-%25282-fluoro-4-%2528methylsulfonyl%2529phenyl%2529-2-methylpiperazin-1-yl%2529-N-%2528%25281R%252C2s%252C3S%252C5S%252C7S%2529-5-hydroxyadamantan-2-yl%2529pyrimidine-4-carboxamide%2520%2528SKI2852%2529%253A%2520A%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%252011beta-hydroxysteroid%2520dehydrogenase%2520type%25201%2520%252811beta-HSD1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10176%26epage%3D10189%26doi%3D10.1021%2Facs.jmedchem.6b01122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPardo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span> <span> </span><span class="NLM_article-title">A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2007.11.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=18240388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=682-687&issue=2&author=D.+M.+Fengauthor=R.+M.+DiPardoauthor=J.+M.+Waiauthor=R.+K.+Changauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bockauthor=S.+D.+Kuduk&title=A+new+class+of+bradykinin+B1+receptor+antagonists+with+high+oral+bioavailability+and+minimal+PXR+activity&doi=10.1016%2Fj.bmcl.2007.11.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity</span></div><div class="casAuthors">Feng, Dong-Mei; DiPardo, Robert M.; Wai, Jenny M.; Chang, Ronald K.; Di Marco, Christina N.; Murphy, Kathy L.; Ransom, Richard W.; Reiss, Duane R.; Tang, Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas J.; Bock, Mark G.; Kuduk, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and synthesis of a novel class of human bradykinin B1 antagonists featuring difluoroethyl ether and isoxazole carboxamide moieties are disclosed.  Compd. I displayed excellent pharmacokinetic properties, efficient ex vivo receptor occupancy, and low potential for P 450 induction via PXR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGlnJu6rHabVg90H21EOLACvtfcHk0lhtbIbjApjYew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWltQ%253D%253D&md5=0935638967e236a493bb58690625a313</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.057%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26atitle%3DA%2520new%2520class%2520of%2520bradykinin%2520B1%2520receptor%2520antagonists%2520with%2520high%2520oral%2520bioavailability%2520and%2520minimal%2520PXR%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D2%26spage%3D682%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2007.11.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reger, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondiskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmick
Graufelds, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uebele, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renger, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,4-disubstituted quinazolin-2-ones as T-type calcium channel antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1021/ml100004r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100004r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=75-79&issue=2&author=J.+C.+Barrowauthor=K.+E.+Rittleauthor=T.+S.+Regerauthor=Z.+Q.+Yangauthor=P.+Bondiskeyauthor=G.+B.+McGaugheyauthor=M.+G.+Bockauthor=G.+D.+Hartmanauthor=C.+Tangauthor=J.+Ballardauthor=Y.+Kuoauthor=T.+Prueksaritanontauthor=C.+E.+Nussauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=R.+L.+Krausauthor=Y.+Liauthor=M.+J.+Marinoauthor=V.+Kuzmick%0AGraufeldsauthor=V.+N.+Uebeleauthor=J.+J.+Renger&title=Discovery+of+4%2C4-disubstituted+quinazolin-2-ones+as+T-type+calcium+channel+antagonists&doi=10.1021%2Fml100004r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists</span></div><div class="casAuthors">Barrow, James C.; Rittle, Kenneth E.; Reger, Thomas S.; Yang, Zhi-Qiang; Bondiskey, Phung; McGaughey, Georgia B.; Bock, Mark G.; Hartman, George D.; Tang, Cuyue; Ballard, Jeanine; Kuo, Yuhsin; Prueksaritanont, Thomayant; Nuss, Cindy E.; Doran, Scott M.; Fox, Steven V.; Garson, Susan L.; Kraus, Richard L.; Li, Yuxing; Marino, Michael J.; Graufelds, Valerie Kuzmick; Uebele, Victor N.; Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-79</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of quinazolinone T-type calcium channel antagonists have been prepd. and evaluated using in vitro and in vivo assays.  Optimization of the screening hit 3 (I) by modifications of the 3- and 4-positions of the quinazolinone ring afforded potent and selective antagonists that displayed in vivo central nervous system efficacy in epilepsy and tremor models, as well as significant effects on rat active wake as measured by electrocorticogram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4CrnH3JZ9dbVg90H21EOLACvtfcHk0lhtbIbjApjYew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlt74%253D&md5=5a5a073bcadfd16f2c80c56b4a077b82</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Fml100004r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100004r%26sid%3Dliteratum%253Aachs%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DReger%26aufirst%3DT.%2BS.%26aulast%3DYang%26aufirst%3DZ.%2BQ.%26aulast%3DBondiskey%26aufirst%3DP.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DNuss%26aufirst%3DC.%2BE.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DKraus%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DKuzmick%2BGraufelds%26aufirst%3DV.%26aulast%3DUebele%26aufirst%3DV.%2BN.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%25204%252C4-disubstituted%2520quinazolin-2-ones%2520as%2520T-type%2520calcium%2520channel%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26issue%3D2%26spage%3D75%26epage%3D79%26doi%3D10.1021%2Fml100004r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reger, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondiskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uebele, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renger, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5147</span>– <span class="NLM_lpage">5152</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20673719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5147-5152&issue=17&author=K.+A.+Schlegelauthor=Z.+Q.+Yangauthor=T.+S.+Regerauthor=Y.+Shuauthor=R.+Cubeauthor=K.+E.+Rittleauthor=P.+Bondiskeyauthor=M.+G.+Bockauthor=G.+D.+Hartmanauthor=C.+Tangauthor=J.+Ballardauthor=Y.+Kuoauthor=T.+Prueksaritanontauthor=C.+E.+Nussauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=R.+L.+Krausauthor=Y.+Liauthor=V.+N.+Uebeleauthor=J.+J.+Rengerauthor=J.+C.+Barrow&title=Discovery+and+expanded+SAR+of+4%2C4-disubstituted+quinazolin-2-ones+as+potent+T-type+calcium+channel+antagonists&doi=10.1016%2Fj.bmcl.2010.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists</span></div><div class="casAuthors">Schlegel, Kelly-Ann S.; Yang, Zhi-Qiang; Reger, Thomas S.; Shu, Youheng; Cube, Rowena; Rittle, Kenneth E.; Bondiskey, Phung; Bock, Mark G.; Hartman, George D.; Tang, Cuyue; Ballard, Jeanine; Kuo, Yuhsin; Prueksaritanont, Thomayant; Nuss, Cindy E.; Doran, Scott M.; Fox, Steven V.; Garson, Susan L.; Kraus, Richard L.; Li, Yuxing; Uebele, Victor N.; Renger, John J.; Barrow, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5147-5152</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported.  Based on lead compds. I and II, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified III as a potent T-type Ca2+ channel antagonist with minimized PXR activation.  In vivo, III suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptfwYqPK3qq7Vg90H21EOLACvtfcHk0ljeLTnxeSvYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr7P&md5=d557eccc05fcb93de8d2d59c9bcea1a8</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DSchlegel%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DZ.%2BQ.%26aulast%3DReger%26aufirst%3DT.%2BS.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DCube%26aufirst%3DR.%26aulast%3DRittle%26aufirst%3DK.%2BE.%26aulast%3DBondiskey%26aufirst%3DP.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DNuss%26aufirst%3DC.%2BE.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DKraus%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DUebele%26aufirst%3DV.%2BN.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520expanded%2520SAR%2520of%25204%252C4-disubstituted%2520quinazolin-2-ones%2520as%2520potent%2520T-type%2520calcium%2520channel%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D17%26spage%3D5147%26epage%3D5152%26doi%3D10.1016%2Fj.bmcl.2010.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frennesson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span> <span> </span><span class="NLM_article-title">SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.01.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20153189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitleht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1744-1748&issue=5&author=K.+Zimmermannauthor=M.+D.+Wittmanauthor=M.+G.+Saulnierauthor=U.+Velaparthiauthor=X.+Sangauthor=D.+B.+Frennessonauthor=C.+Struzynskiauthor=S.+P.+Seitzauthor=L.+Heauthor=J.+M.+Carboniauthor=A.+Liauthor=A.+F.+Greerauthor=M.+Gottardisauthor=R.+M.+Attarauthor=Z.+Yangauthor=P.+Balimaneauthor=L.+N.+Discenzaauthor=F.+Y.+Leeauthor=M.+Sinzauthor=S.+Kimauthor=D.+Vyas&title=SAR+of+PXR+transactivation+in+benzimidazole-based+IGF-1R+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors</span></div><div class="casAuthors">Zimmermann, Kurt; Wittman, Mark D.; Saulnier, Mark G.; Velaparthi, Upender; Sang, Xiaopeng; Frennesson, David B.; Struzynski, Charles; Seitz, Steven P.; He, Liqi; Carboni, Joan M.; Li, Aixin; Greer, Ann F.; Gottardis, Marco; Attar, Ricardo M.; Yang, Zheng; Balimane, Praveen; Discenza, Lorell N.; Lee, Francis Y.; Sinz, Michael; Kim, Sean; Vyas, Dolatrai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1744-1748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SAR of PXR transactivation by 3-(benzimidazol-2-yl)-pyridine-2-one based ATP competitive inhibitors of Insulin-like Growth Factor 1 Receptor kinase (IGF-1R) is discussed.  Compds. without PXR transactivation, with in vivo antitumor activity, reduced protein binding and improved oral exposure are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWYqNCYfwPbVg90H21EOLACvtfcHk0ljeLTnxeSvYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitleht7s%253D&md5=ea60b27acff314cef6744d8b496c45cd</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.087%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DFrennesson%26aufirst%3DD.%2BB.%26aulast%3DStruzynski%26aufirst%3DC.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%2BF.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DSAR%2520of%2520PXR%2520transactivation%2520in%2520benzimidazole-based%2520IGF-1R%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D5%26spage%3D1744%26epage%3D1748%26doi%3D10.1016%2Fj.bmcl.2010.01.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5897</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/jm800832q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&issue=19&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperidin-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity&doi=10.1021%2Fjm800832q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity</span></div><div class="casAuthors">Velaparthi, Upender; Wittman, Mark; Liu, Peiying; Carboni, Joan M.; Lee, Francis Y.; Attar, Ricardo; Balimane, Praveen; Clarke, Wendy; Sinz, Michael W.; Hurlburt, Warren; Patel, Karishma; Discenza, Lorell; Kim, Sean; Gottardis, Marco; Greer, Ann; Li, Aixin; Saulnier, Mark; Yang, Zheng; Zimmermann, Kurt; Trainor, George; Vyas, Dolatrai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5897-5900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity.  This lead compd. was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PXR transactivation, poor aq. soly., and high plasma protein binding.  Herein we disclose the evolution of this chemotype to address these issues.  This effort led to 10 (BMS-695735, I), which exhibits improved ADME properties, a low risk for drug-drug interactions, and in vivo efficacy in multiple xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMOvd77Lq3rVg90H21EOLACvtfcHk0ljeLTnxeSvYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3I&md5=524b5a89b9e550d7871d462843224194</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperidin-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D19%26spage%3D5897%26epage%3D5900%26doi%3D10.1021%2Fjm800832q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercovici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfmacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torhan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2519</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2009.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=19339177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslyiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2519-2523&issue=9&author=G.+D.+Hoauthor=J.+Anthesauthor=A.+Bercoviciauthor=J.+P.+Caldwellauthor=K.+C.+Chengauthor=X.+Cuiauthor=A.+Fawziauthor=X.+Fernandezauthor=W.+J.+Greenleeauthor=J.+Heyauthor=W.+Korfmacherauthor=S.+X.+Luauthor=R.+L.+McLeodauthor=F.+Ngauthor=A.+S.+Torhanauthor=Z.+Tanauthor=D.+Tulshianauthor=G.+B.+Vartyauthor=X.+Xuauthor=H.+Zhang&title=The+discovery+of+tropane+derivatives+as+nociceptin+receptor+ligands+for+the+management+of+cough+and+anxiety&doi=10.1016%2Fj.bmcl.2009.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety</span></div><div class="casAuthors">Ho, Ginny D.; Anthes, John; Bercovici, Ana; Caldwell, John P.; Cheng, Kuo-Chi; Cui, Xiaoming; Fawzi, Ahmad; Fernandez, Xiomara; Greenlee, William J.; Hey, John; Korfmacher, Walter; Lu, Sherry X.; McLeod, Robbie L.; Ng, Fay; Torhan, April Smith; Tan, Zheng; Tulshian, Deen; Varty, Geoffrey B.; Xu, Xiaoying; Zhang, Hongtao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2519-2523</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter, we present the synthesis and highlight the structure-activity relationship of tropane (8-methyl-8-azabicyclo[3.2.1]octane) derivs. culminating in the identification of I (Ar = phenyl) and I (Ar = 4-fluorophenyl) as potent and orally active antitussive and anxiolytic agents.  The in vitro and in vivo activities, pharmacokinetic profile, and the hPXR activity, which predicts the potential 3A4 induction in human, are disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqeKhX1PcTALVg90H21EOLACvtfcHk0lhUXj6UKpMbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslyiur4%253D&md5=46923d57e072bb7e55c64107986df87f</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DG.%2BD.%26aulast%3DAnthes%26aufirst%3DJ.%26aulast%3DBercovici%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DFawzi%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DX.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHey%26aufirst%3DJ.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DMcLeod%26aufirst%3DR.%2BL.%26aulast%3DNg%26aufirst%3DF.%26aulast%3DTorhan%26aufirst%3DA.%2BS.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520tropane%2520derivatives%2520as%2520nociceptin%2520receptor%2520ligands%2520for%2520the%2520management%2520of%2520cough%2520and%2520anxiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D9%26spage%3D2519%26epage%3D2523%26doi%3D10.1016%2Fj.bmcl.2009.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aaron, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toteva, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4607</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2010.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=20594845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4607-4610&issue=15&author=J.+A.+Kaizermanauthor=W.+Aaronauthor=S.+Anauthor=R.+Austinauthor=M.+Brownauthor=A.+Chongauthor=T.+Huangauthor=R.+Hungateauthor=B.+Jiangauthor=M.+G.+Johnsonauthor=G.+Leeauthor=B.+S.+Lucasauthor=J.+Orfauthor=M.+Rongauthor=M.+M.+Totevaauthor=D.+Wickramasingheauthor=G.+Xuauthor=Q.+Yeauthor=W.+Zhongauthor=D.+L.+McMinn&title=Addressing+PXR+liabilities+of+phthalazine-based+hedgehog%2Fsmoothened+antagonists+using+novel+pyridopyridazines&doi=10.1016%2Fj.bmcl.2010.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines</span></div><div class="casAuthors">Kaizerman, Jacob A.; Aaron, Wade; An, Songzhu; Austin, Richard; Brown, Matt; Chong, Angela; Huang, Tom; Hungate, Randall; Jiang, Ben; Johnson, Michael G.; Lee, Gary; Lucas, Brian S.; Orf, Jessica; Rong, Minqing; Toteva, Maria M.; Wickramasinghe, Dineli; Xu, Guifen; Ye, Qiuping; Zhong, Wendy; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4607-4610</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyridopyridazine antagonists of the hedgehog signaling pathway are described.  Designed to optimize our previously described phthalazine smoothened antagonists, a representative compd. eliminates a PXR liability while retaining potency and in vitro metabolic stability.  Moreover, the compd. has improved efficacy in a hedgehog/smoothened signaling mouse pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXaldfRtLH7Vg90H21EOLACvtfcHk0lhUXj6UKpMbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSkur0%253D&md5=6927105e59b3859aea28cccefe464c3a</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DKaizerman%26aufirst%3DJ.%2BA.%26aulast%3DAaron%26aufirst%3DW.%26aulast%3DAn%26aufirst%3DS.%26aulast%3DAustin%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DChong%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLucas%26aufirst%3DB.%2BS.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DM.%26aulast%3DToteva%26aufirst%3DM.%2BM.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DAddressing%2520PXR%2520liabilities%2520of%2520phthalazine-based%2520hedgehog%252Fsmoothened%2520antagonists%2520using%2520novel%2520pyridopyridazines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D15%26spage%3D4607%26epage%3D4610%26doi%3D10.1016%2Fj.bmcl.2010.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMauro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feric Bojic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornecook, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngblood, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Sulfonamides as selective Na<sub>V</sub>1.7 inhibitors: Optimizing potency and pharmacokinetics while mitigating metabolic liabilities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5969</span>– <span class="NLM_lpage">5989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01851</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01851" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5969-5989&issue=14&author=M.+M.+Weissauthor=T.+A.+Dineenauthor=I.+E.+Marxauthor=S.+Altmannauthor=A.+Boezioauthor=H.+Bregmanauthor=M.+Chu-Moyerauthor=E.+F.+DiMauroauthor=E.+Feric+Bojicauthor=R.+S.+Fotiauthor=H.+Gaoauthor=R.+Graceffaauthor=H.+Gunaydinauthor=A.+Guzman-Perezauthor=H.+Huangauthor=L.+Huangauthor=M.+Jaroshauthor=T.+Kornecookauthor=C.+R.+Kreimanauthor=J.+Liguttiauthor=D.+S.+Laauthor=M.+J.+Linauthor=D.+Liuauthor=B.+D.+Moyerauthor=H.+N.+Nguyenauthor=E.+A.+Petersonauthor=P.+E.+Roseauthor=K.+Tabornauthor=B.+D.+Youngbloodauthor=V.+Yuauthor=R.+T.+Fremeau&title=Sulfonamides+as+selective+NaV1.7+inhibitors%3A+Optimizing+potency+and+pharmacokinetics+while+mitigating+metabolic+liabilities&doi=10.1021%2Facs.jmedchem.6b01851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities</span></div><div class="casAuthors">Weiss, Matthew M.; Dineen, Thomas A.; Marx, Isaac E.; Altmann, Steven; Boezio, Alessandro; Bregman, Howard; Chu-Moyer, Margaret; DiMauro, Erin F.; Feric Bojic, Elma; Foti, Robert S.; Gao, Hua; Graceffa, Russell; Gunaydin, Hakan; Guzman-Perez, Angel; Huang, Hongbing; Huang, Liyue; Jarosh, Michael; Kornecook, Thomas; Kreiman, Charles R.; Ligutti, Joseph; La, Daniel S.; Lin, Min-Hwa Jasmine; Liu, Dong; Moyer, Bryan D.; Nguyen, Hanh N.; Peterson, Emily A.; Rose, Paul E.; Taborn, Kristin; Youngblood, Beth D.; Yu, Violeta; Fremeau, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5969-5989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several reports have recently emerged regarding the identification of heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms.  The optimization of a series of internal NaV1.7 leads that address a no. of metabolic liabilities including bioactivation, PXR activation, as well as CYP3A4 induction and inhibition led to the identification of potent and selective inhibitors that demonstrated favorable pharmacokinetic profiles and were devoid of the aforementioned liabilities.  The key to achieving this within a series prone to transporter-mediated clearance was the identification of a small range of optimal cLogD values and the discovery of subtle PXR SAR that was not lipophilicity dependent.  This enabled the identification of compd. 20, which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal of histamine-induced scratching bouts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovsPC2UZpxsbVg90H21EOLACvtfcHk0li5Xo-Q2_knQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtbw%253D&md5=6333a6b936e48f9d18cf9df10ea12853</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01851%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DAltmann%26aufirst%3DS.%26aulast%3DBoezio%26aufirst%3DA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DChu-Moyer%26aufirst%3DM.%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DFeric%2BBojic%26aufirst%3DE.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DJarosh%26aufirst%3DM.%26aulast%3DKornecook%26aufirst%3DT.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DTaborn%26aufirst%3DK.%26aulast%3DYoungblood%26aufirst%3DB.%2BD.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26atitle%3DSulfonamides%2520as%2520selective%2520NaV1.7%2520inhibitors%253A%2520Optimizing%2520potency%2520and%2520pharmacokinetics%2520while%2520mitigating%2520metabolic%2520liabilities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5969%26epage%3D5989%26doi%3D10.1021%2Facs.jmedchem.6b01851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Able, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMauro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feric
Bojic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornecook, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milgram, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescourio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparling, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeoman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span> <span> </span><span class="NLM_article-title">Sulfonamides as selective Na<sub>V</sub>1.7 inhibitors: Optimizing potency, pharmacokinetics, and metabolic properties to obtain atropisomeric quinolinone (AM-0466) that affords robust in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5990</span>– <span class="NLM_lpage">6017</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5990-6017&issue=14&author=R.+F.+Graceffaauthor=A.+A.+Boezioauthor=J.+Ableauthor=S.+Altmannauthor=L.+M.+Berryauthor=C.+Boezioauthor=J.+R.+Butlerauthor=M.+Chu-Moyerauthor=M.+Cookeauthor=E.+F.+DiMauroauthor=T.+A.+Dineenauthor=E.+Feric%0ABojicauthor=R.+S.+Fotiauthor=R.+T.+Fremeauauthor=A.+Guzman-Perezauthor=H.+Gaoauthor=H.+Gunaydinauthor=H.+Huangauthor=L.+Huangauthor=C.+Ilchauthor=M.+Jaroshauthor=T.+Kornecookauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=J.+Liguttiauthor=B.+C.+Milgramauthor=M.+J.+Linauthor=I.+E.+Marxauthor=H.+N.+Nguyenauthor=E.+A.+Petersonauthor=G.+Rescourioauthor=J.+Robertsauthor=L.+Schenkelauthor=R.+Shimanovichauthor=B.+A.+Sparlingauthor=J.+Stellwagenauthor=K.+Tabornauthor=K.+R.+Vaidaauthor=J.+Wangauthor=J.+Yeomanauthor=V.+Yuauthor=D.+Zhuauthor=B.+D.+Moyerauthor=M.+M.+Weiss&title=Sulfonamides+as+selective+NaV1.7+inhibitors%3A+Optimizing+potency%2C+pharmacokinetics%2C+and+metabolic+properties+to+obtain+atropisomeric+quinolinone+%28AM-0466%29+that+affords+robust+in+vivo+activity&doi=10.1021%2Facs.jmedchem.6b01850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity</span></div><div class="casAuthors">Graceffa, Russell F.; Boezio, Alessandro A.; Able, Jessica; Altmann, Steven; Berry, Loren M.; Boezio, Christiane; Butler, John R.; Chu-Moyer, Margaret; Cooke, Melanie; DiMauro, Erin F.; Dineen, Thomas A.; Feric Bojic, Elma; Foti, Robert S.; Fremeau, Robert T.; Guzman-Perez, Angel; Gao, Hua; Gunaydin, Hakan; Huang, Hongbing; Huang, Liyue; Ilch, Christopher; Jarosh, Michael; Kornecook, Thomas; Kreiman, Charles R.; La, Daniel S.; Ligutti, Joseph; Milgram, Benjamin C.; Lin, Min-Hwa Jasmine; Marx, Isaac E.; Nguyen, Hanh N.; Peterson, Emily A.; Rescourio, Gwen; Roberts, John; Schenkel, Laurie; Shimanovich, Roman; Sparling, Brian A.; Stellwagen, John; Taborn, Kristin; Vaida, Karina R.; Wang, Jean; Yeoman, John; Yu, Violeta; Zhu, Dawn; Moyer, Bryan D.; Weiss, Matthew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5990-6017</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of its strong genetic validation, NaV1.7 has attracted significant interest as a target for the treatment of pain.  We have previously reported on a no. of structurally distinct bicyclic heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms.  Herein, we report the discovery and optimization of a series of atropisomeric quinolinone sulfonamide inhibitors [Bicyclic sulfonamide compds. as sodium channel inhibitors and their prepn. WO 2014201206, 2014] of NaV1.7, which demonstrate nanomolar inhibition of NaV1.7 and exhibit high levels of selectivity over other sodium channel isoforms.  After optimization of metabolic and pharmacokinetic properties, including PXR activation, CYP2C9 inhibition, and CYP3A4 TDI, several compds. were advanced into in vivo target engagement and efficacy models.  When tested in mice, compd. 39 (AM-0466) demonstrated robust pharmacodynamic activity in a NaV1.7-dependent model of histamine-induced pruritus (itch) and addnl. in a capsaicin-induced nociception model of pain without any confounding effect in open-field activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ofeMhgMFqbVg90H21EOLACvtfcHk0li5Xo-Q2_knQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKltr4%253D&md5=5b48afe24a97290ea5e44a71deaa0303</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01850%26sid%3Dliteratum%253Aachs%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAble%26aufirst%3DJ.%26aulast%3DAltmann%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DButler%26aufirst%3DJ.%2BR.%26aulast%3DChu-Moyer%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DM.%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DFeric%2BBojic%26aufirst%3DE.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DIlch%26aufirst%3DC.%26aulast%3DJarosh%26aufirst%3DM.%26aulast%3DKornecook%26aufirst%3DT.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DMilgram%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BJ.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DRescourio%26aufirst%3DG.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DSchenkel%26aufirst%3DL.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSparling%26aufirst%3DB.%2BA.%26aulast%3DStellwagen%26aufirst%3DJ.%26aulast%3DTaborn%26aufirst%3DK.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYeoman%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26atitle%3DSulfonamides%2520as%2520selective%2520NaV1.7%2520inhibitors%253A%2520Optimizing%2520potency%252C%2520pharmacokinetics%252C%2520and%2520metabolic%2520properties%2520to%2520obtain%2520atropisomeric%2520quinolinone%2520%2528AM-0466%2529%2520that%2520affords%2520robust%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5990%26epage%3D6017%26doi%3D10.1021%2Facs.jmedchem.6b01850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&issue=4&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cuiauthor=P.+Chenauthor=K.+Straleyauthor=E.+Tobinauthor=F.+Wangauthor=M.+D.+Davidauthor=V.+Penard-Lacroniqueauthor=C.+Quivoronauthor=V.+Saadaauthor=S.+de+Bottonauthor=S.+Grossauthor=L.+Dangauthor=H.+Yangauthor=L.+Utleyauthor=Y.+Chenauthor=H.+Kimauthor=S.+Jinauthor=Z.+Guauthor=G.+Yaoauthor=Z.+Luoauthor=X.+Lvauthor=C.+Fangauthor=L.+Yanauthor=A.+Olaharskiauthor=L.+Silvermanauthor=S.+Billerauthor=S.+M.+Suauthor=K.+Yen&title=Discovery+of+AG-120+%28Ivosidenib%29%3A+A+first-in-class+mutant+IDH1+inhibitor+for+the+treatment+of+IDH1+mutant+cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0lgBXWsM4sh35Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DTobin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DUtley%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DOlaharski%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520AG-120%2520%2528Ivosidenib%2529%253A%2520A%2520first-in-class%2520mutant%2520IDH1%2520inhibitor%2520for%2520the%2520treatment%2520of%2520IDH1%2520mutant%2520cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1007/s00280-020-04064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1007%2Fs00280-020-04064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32296873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=959-968&issue=5&author=B.+Fanauthor=D.+Daiauthor=C.+D.+DiNardoauthor=E.+Steinauthor=S.+de+Bottonauthor=E.+C.+Attarauthor=H.+Liuauthor=G.+Liuauthor=I.+Lemieuxauthor=S.+V.+Agrestaauthor=H.+Yang&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+ivosidenib+in+patients+with+advanced+hematologic+malignancies+with+an+IDH1+mutation&doi=10.1007%2Fs00280-020-04064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation</span></div><div class="casAuthors">Fan, Bin; Dai, David; DiNardo, Courtney D.; Stein, Eytan; de Botton, Stephane; Attar, Eyal C.; Liu, Hua; Liu, Guowen; Lemieux, Ian; Agresta, Samuel V.; Yang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: Isocitrate dehydrogenase (IDH) mutations lead to formation of the oncometabolite 2-hydroxyglutarate (2-HG), which is elevated in several solid and liq. tumors.  Ivosidenib (AG-120) is a targeted, potent, oral inhibitor of the mutant IDH1 protein.  We describe detailed pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematol. malignancies with an IDH1 mutation treated in a phase I study (ClinicalTrials.gov NCT02074839).  Methods: Patients received single and multiple oral doses of ivosidenib from 100 mg twice daily to 1200 mg once daily (QD) in 28-day continuous cycles.  Concns. of ivosidenib and 2-HG in plasma, and 2-HG in bone marrow, were assessed at routine intervals.  Plasma 4β-hydroxycholesterol/cholesterol ratios were assessed as a marker of CYP3A activity.  Results: Ivosidenib was rapidly absorbed and slowly eliminated (half-life 72-138 h) after single and multiple dosing.  Ivosidenib exhibited dose- and time-dependent pharmacokinetics, with exposure increasing sub-proportionally to dose, and clearance increasing with increasing dose.  Plasma 2-HG concns. were maximally and persistently inhibited in the majority of patients receiving 500-mg QD ivosidenib, to concns. close to those obsd. in healthy subjects.  Ivosidenib pharmacokinetics were not affected by mild or moderate renal impairment, mild hepatic impairment, age, wt., sex, race, or co-administration of weak CYP3A4 inhibitors or inducers.  Moderate-to-strong CYP3A4 inhibitors decreased ivosidenib clearance.  Ivosidenib also induced CYP3A enzyme activity, with increases in 4β-hydroxycholesterol/cholesterol ratios of 119-168% at 500-mg QD ivosidenib.  Conclusions: Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematol. malignancies with an IDH1 mutation.  Clin. trial registration: ClinicalTrials.gov NCT02074839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS-BnXjEPoPrVg90H21EOLACvtfcHk0lgBXWsM4sh35Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOrtb4%253D&md5=87a108f5c5bbb9086c3d58f3b1a295e7</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1007%2Fs00280-020-04064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-020-04064-6%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DStein%26aufirst%3DE.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLemieux%26aufirst%3DI.%26aulast%3DAgresta%26aufirst%3DS.%2BV.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520ivosidenib%2520in%2520patients%2520with%2520advanced%2520hematologic%2520malignancies%2520with%2520an%2520IDH1%2520mutation%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26issue%3D5%26spage%3D959%26epage%3D968%26doi%3D10.1007%2Fs00280-020-04064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginnetti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segerdell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anquandah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calamari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillgrove, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Identification of second-generation P2 × 3 antagonists for treatment of pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1396</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.02.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29548573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1392-1396&issue=8&author=A.+T.+Ginnettiauthor=D.+V.+Paoneauthor=S.+R.+Staufferauthor=C.+M.+Potteigerauthor=A.+W.+Shawauthor=J.+Dengauthor=J.+J.+Mulhearnauthor=D.+N.+Nguyenauthor=C.+Segerdellauthor=J.+Anquandahauthor=A.+Calamariauthor=G.+Chengauthor=M.+D.+Leitlauthor=A.+Liangauthor=E.+Mooreauthor=J.+Panigelauthor=M.+Urbanauthor=J.+Wangauthor=K.+Fillgroveauthor=C.+Tangauthor=S.+Cookauthor=S.+Kaneauthor=C.+A.+Salvatoreauthor=S.+L.+Grahamauthor=C.+S.+Burgey&title=Identification+of+second-generation+P2+%C3%97+3+antagonists+for+treatment+of+pain&doi=10.1016%2Fj.bmcl.2018.02.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of second-generation P2X3 antagonists for treatment of pain</span></div><div class="casAuthors">Ginnetti, Anthony T.; Paone, Daniel V.; Stauffer, Shaun R.; Potteiger, Craig M.; Shaw, Anthony W.; Deng, James; Mulhearn, James J.; Nguyen, Diem N.; Segerdell, Carolyn; Anquandah, Juliana; Calamari, Amy; Cheng, Gong; Leitl, Michael D.; Liang, Annie; Moore, Eric; Panigel, Jacqueline; Urban, Mark; Wang, Jixin; Fillgrove, Kerry; Tang, Cuyue; Cook, Sean; Kane, Stefanie; Salvatore, Christopher A.; Graham, Samuel L.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1392-1396</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A second-generation small mol. P2X3 receptor antagonist has been developed.  The lead optimization strategy to address shortcomings of the first-generation preclin. lead compd. is described herein.  These studies were directed towards the identification and amelioration of preclin. hepatobiliary findings, reducing potential for drug-drug interactions, and decreasing the projected human dose of the first-generation lead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGgzmlO0F8bVg90H21EOLACvtfcHk0liiPUTC0XIQIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslWqsLY%253D&md5=96b6cb25c0cee2ddb671cd624ea6c138</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.039%26sid%3Dliteratum%253Aachs%26aulast%3DGinnetti%26aufirst%3DA.%2BT.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BW.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DMulhearn%26aufirst%3DJ.%2BJ.%26aulast%3DNguyen%26aufirst%3DD.%2BN.%26aulast%3DSegerdell%26aufirst%3DC.%26aulast%3DAnquandah%26aufirst%3DJ.%26aulast%3DCalamari%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DLiang%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DPanigel%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFillgrove%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DS.%26aulast%3DKane%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DIdentification%2520of%2520second-generation%2520P2%2520%25C3%2597%25203%2520antagonists%2520for%2520treatment%2520of%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D8%26spage%3D1392%26epage%3D1396%26doi%3D10.1016%2Fj.bmcl.2018.02.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youngblood, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavva, N. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of TRPM8 antagonist (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoy l)nicotinic acid (AMG 333), a clinical candidate for the treatment of migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8186</span>– <span class="NLM_lpage">8201</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8186-8201&issue=18&author=D.+B.+Horneauthor=K.+Biswasauthor=J.+Brownauthor=M.+D.+Bartbergerauthor=J.+Clarineauthor=C.+D.+Davisauthor=V.+K.+Goreauthor=S.+Harriedauthor=M.+Hornerauthor=M.+R.+Kallerauthor=S.+G.+Lehtoauthor=Q.+Liuauthor=V.+V.+Maauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=C.+C.+Yuanauthor=B.+D.+Youngbloodauthor=M.+Zhangauthor=W.+Zhongauthor=J.+R.+Allenauthor=J.+J.+Chenauthor=N.+R.+Gavva&title=Discovery+of+TRPM8+antagonist+%28S%29-6-%28%28%283-fluoro-4-%28trifluoromethoxy%29phenyl%29%283-fluoropyridin-2-yl%29methyl%29carbamoy+l%29nicotinic+acid+%28AMG+333%29%2C+a+clinical+candidate+for+the+treatment+of+migraine&doi=10.1021%2Facs.jmedchem.8b00518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine</span></div><div class="casAuthors">Horne, Daniel B.; Biswas, Kaustav; Brown, James; Bartberger, Michael D.; Clarine, Jeffrey; Davis, Carl D.; Gore, Vijay K.; Harried, Scott; Horner, Michelle; Kaller, Matthew R.; Lehto, Sonya G.; Liu, Qingyian; Ma, Vu V.; Monenschein, Holger; Nguyen, Thomas T.; Yuan, Chester C.; Youngblood, Beth D.; Zhang, Maosheng; Zhong, Wenge; Allen, Jennifer R.; Chen, Jian Jeffrey; Gavva, Narender R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8186-8201</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Transient-receptor-potential melastatin 8 (TRPM8), the predominant mammalian cold-temp. thermosensor, is a nonselective cation channel expressed in a subpopulation of sensory neurons in the peripheral nervous system, including nerve circuitry implicated in migraine pathogenesis: the trigeminal and pterygopalatine ganglia.  Genome-wide assocn. studies have identified an assocn. between TRPM8 and reduced risk of migraine.  This disclosure focuses on medicinal-chem. efforts to improve the druglike properties of initial leads, particularly removal of CYP3A4-induction liability and improvement of pharmacokinetic properties.  A novel series of biarylmethanamide TRPM8 antagonists was developed, and a subset of leads were evaluated in preclin. toxicol. studies to identify a clin. candidate with an acceptable preclin. safety profile leading to clin. candidate AMG 333, a potent and highly selective antagonist of TRPM8 that was evaluated in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL2alekBC2xbVg90H21EOLACvtfcHk0liiPUTC0XIQIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyqtbvI&md5=6b251d0823e6f5a3a7f393d2aeeb5b38</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00518%26sid%3Dliteratum%253Aachs%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DBiswas%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DC.%2BD.%26aulast%3DGore%26aufirst%3DV.%2BK.%26aulast%3DHarried%26aufirst%3DS.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DLehto%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DV.%2BV.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DYoungblood%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DGavva%26aufirst%3DN.%2BR.%26atitle%3DDiscovery%2520of%2520TRPM8%2520antagonist%2520%2528S%2529-6-%2528%2528%25283-fluoro-4-%2528trifluoromethoxy%2529phenyl%2529%25283-fluoropyridin-2-yl%2529methyl%2529carbamoy%2520l%2529nicotinic%2520acid%2520%2528AMG%2520333%2529%252C%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D18%26spage%3D8186%26epage%3D8201%26doi%3D10.1021%2Facs.jmedchem.8b00518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greszler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vortherms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kym, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid (ABBV/GLPG-2222), a potent cystic fibrosis transmembrane conductance regulator (CFTR) corrector for the treatment of cystic fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1449</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01339</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01339" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2gsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1436-1449&issue=4&author=X.+Wangauthor=B.+Liuauthor=X.+Searleauthor=C.+Yeungauthor=A.+Bogdanauthor=S.+Greszlerauthor=A.+Singhauthor=Y.+Fanauthor=A.+M.+Swensenauthor=T.+Vorthermsauthor=C.+Balutauthor=Y.+Jiaauthor=K.+Desinoauthor=W.+Gaoauthor=H.+Yongauthor=C.+Tseauthor=P.+Kym&title=Discovery+of+4-%5B%282R%2C4R%29-4-%28%7B%5B1-%282%2C2-Difluoro-1%2C3-benzodioxol-5-yl%29cyclopropyl%5Dcarbonyl%7Damino%29-7-%28difluoromethoxy%29-3%2C4-dihydro-2H-chromen-2-yl%5Dbenzoic+acid+%28ABBV%2FGLPG-2222%29%2C+a+potent+cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29+corrector+for+the+treatment+of+cystic+fibrosis&doi=10.1021%2Facs.jmedchem.7b01339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis</span></div><div class="casAuthors">Wang, Xueqing; Liu, Bo; Searle, Xenia; Yeung, Clinton; Bogdan, Andrew; Greszler, Stephen; Singh, Ashvani; Fan, Yihong; Swensen, Andrew M.; Vortherms, Timothy; Balut, Corina; Jia, Ying; Desino, Kelly; Gao, Wenqing; Yong, Hong; Tse, Chris; Kym, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1436-1449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed.  To effectively treat the most prevalent patient population (F508del mutation), two biomol. modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel.  Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors.  Herein, the authors disclose the discovery of a highly potent series of CFTR correctors and the structure-activity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222, which is currently in clin. trials in patients harboring the F508del CFTR mutation on at least one allele.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4J11loTFmPLVg90H21EOLACvtfcHk0lic_L4X-CzdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2gsbzI&md5=34bea6adb0b8696288fedce258a661fd</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01339%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSearle%26aufirst%3DX.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DBogdan%26aufirst%3DA.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DDesino%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DKym%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25204-%255B%25282R%252C4R%2529-4-%2528%257B%255B1-%25282%252C2-Difluoro-1%252C3-benzodioxol-5-yl%2529cyclopropyl%255Dcarbonyl%257Damino%2529-7-%2528difluoromethoxy%2529-3%252C4-dihydro-2H-chromen-2-yl%255Dbenzoic%2520acid%2520%2528ABBV%252FGLPG-2222%2529%252C%2520a%2520potent%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%2520corrector%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1436%26epage%3D1449%26doi%3D10.1021%2Facs.jmedchem.7b01339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. K.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 3A4 induction: Lumacaftor versus Ivacaftor potentially resulting in significantly reduced plasma concentration of Ivacaftor</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.2174/1872312812666180328105259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.2174%2F1872312812666180328105259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29595119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=71-74&issue=1&author=E.+K.+Schneider&title=Cytochrome+P450+3A4+induction%3A+Lumacaftor+versus+Ivacaftor+potentially+resulting+in+significantly+reduced+plasma+concentration+of+Ivacaftor&doi=10.2174%2F1872312812666180328105259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor</span></div><div class="casAuthors">Schneider, Elena K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-74</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Since the release of ivacaftor-lumacaftor, several red-flags have been raised that highlight the clin. efficacy of this combination strategy that may be limited due to antagonistic drug-drug interactions.  The effect of ivacaftor, its major metabolites M1 and M6, lumacaftor and the novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator tezacaftor at 10 g/mL on the enzymic activity of the major xenobiotic metabolizing enzymes CYP1A2 and CYP3A4 as well as the minor enzymes CYP2B6 and CYP2C9 was assayed.  Lumacaftor (3.74 x 105 ± 3.11 × 104 RLU), and ivacaftor-M6 (3.43 × 105 ± 7.61 × 103 RLU) markedly induced the activity of CYP3A4.  Ivacaftor (2.22 x 105 ± 3.94 × 104 RLU) showed a lower relative ratio of luminescence units compared to chloramphenicol (3.17 × 105 ± 1.55 x 104 RLU).  Interestingly, ivacaftor-M1 (6.74 × 104 ± 3.09 × 104 RLU) and the novel CFTR modulator tezacaftor (2.40 × 104 ± 8.14 × 104 RLU) did not show CYP3A4 induction.  In the CYP1A2 and CYP2C9 assay, all metabolites showed a decrease in the ratio of luminescence units compared to the controls.  Ivacaftor, its major metabolites, lumacaftor and tezacaftor all showed a slight increase in the ratio of luminescence units compared to the control rifampin with CYP2B6.  All in all, present findings would suggest that lumacaftor and ivacaftor-M6 are strong inducers of CYP3A4, potentially reducing ivacaftor concns.; ivacaftor itself induces CYP3A4 to some extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Pg98lMvTxLVg90H21EOLACvtfcHk0lic_L4X-CzdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtLbL&md5=a6b6b0840adcc707fc3a47ff371a39e4</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.2174%2F1872312812666180328105259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1872312812666180328105259%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DE.%2BK.%26atitle%3DCytochrome%2520P450%25203A4%2520induction%253A%2520Lumacaftor%2520versus%2520Ivacaftor%2520potentially%2520resulting%2520in%2520significantly%2520reduced%2520plasma%2520concentration%2520of%2520Ivacaftor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2018%26volume%3D12%26issue%3D1%26spage%3D71%26epage%3D74%26doi%3D10.2174%2F1872312812666180328105259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scanio, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altenbach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gfesser, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greszler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vortherms, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrimpf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kym, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of ABBV/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVGks7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1543-1548&issue=11&author=M.+J.+C.+Scanioauthor=X.+B.+Searleauthor=B.+Liuauthor=J.+R.+Koenigauthor=R.+Altenbachauthor=G.+A.+Gfesserauthor=A.+Bogdanauthor=S.+Greszlerauthor=G.+Zhaoauthor=A.+Singhauthor=Y.+Fanauthor=A.+M.+Swensenauthor=T.+Vorthermsauthor=A.+Manelliauthor=C.+Balutauthor=Y.+Jiaauthor=W.+Gaoauthor=H.+Yongauthor=M.+Schrimpfauthor=C.+Tseauthor=P.+Kymauthor=X.+Wang&title=Discovery+of+ABBV%2FGLPG-3221%2C+a+potent+corrector+of+CFTR+for+the+treatment+of+cystic+fibrosis&doi=10.1021%2Facsmedchemlett.9b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABBV/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis</span></div><div class="casAuthors">Scanio, Marc J. C.; Searle, Xenia B.; Liu, Bo; Koenig, John R.; Altenbach, Robert; Gfesser, Gregory A.; Bogdan, Andrew; Greszler, Stephen; Zhao, Gang; Singh, Ashvani; Fan, Yihong; Swensen, Andrew M.; Vortherms, Timothy; Manelli, Arlene; Balut, Corina; Jia, Ying; Gao, Wenqing; Yong, Hong; Schrimpf, Michael; Tse, Chris; Kym, Philip; Wang, Xueqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a genetic disorder that affects multiple tissues and organs.  CF is caused by mutations in the CFTR gene, resulting in insufficient or impaired cystic fibrosis transmembrane conductance regulator (CFTR) protein.  The deletion of phenylalanine at position 508 of the protein (F508del-CFTR) is the most common mutation obsd. in CF patients.  The most effective treatments of these patients employ two CFTR modulator classes, correctors and potentiators.  CFTR correctors increase protein levels at the cell surface; CFTR potentiators enable the functional opening of CFTR channels at the cell surface.  Triple-combination therapies utilize two distinct corrector mols. (C1 and C2) to further improve the overall efficacy.  We identified the need to develop a C2 corrector series that had the potential to be used in conjunction with our existing C1 corrector series and provide robust clin. efficacy for CF patients.  The identification of a pyrrolidine series of CFTR C2 correctors and the structure-activity relationship of this series is described.  This work resulted in the discovery and selection of (2S,3R,4S,5S)-3-(tert-butyl)-4-((2-methoxy-5-(trifluoromethyl)pyridin-3-yl)methoxy)-1-((S)-tetrahydro-2H-pyran-2-carbonyl)-5-(o-tolyl)pyrrolidine-2-carboxylic acid (ABBV/GLPG-3221), which was advanced to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB4FeR_QyZBrVg90H21EOLACvtfcHk0lic_L4X-CzdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVGks7rK&md5=9894641a51117b34921b7a886a4ab1d0</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00377%26sid%3Dliteratum%253Aachs%26aulast%3DScanio%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DSearle%26aufirst%3DX.%2BB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DKoenig%26aufirst%3DJ.%2BR.%26aulast%3DAltenbach%26aufirst%3DR.%26aulast%3DGfesser%26aufirst%3DG.%2BA.%26aulast%3DBogdan%26aufirst%3DA.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DSchrimpf%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DKym%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520ABBV%252FGLPG-3221%252C%2520a%2520potent%2520corrector%2520of%2520CFTR%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1543%26epage%3D1548%26doi%3D10.1021%2Facsmedchemlett.9b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelen, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurlino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Identification and biological evaluation of thiazole-based inverse agonists of RORgammat</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2018.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=29631962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1446-1455&issue=9&author=C.+Gegeauthor=M.+D.+Cummingsauthor=M.+Albersauthor=O.+Kinzelauthor=G.+Kleymannauthor=T.+Schluterauthor=C.+Steeneckauthor=M.+I.+Nelenauthor=C.+Milliganauthor=J.+Spurlinoauthor=X.+Xueauthor=K.+Leonardauthor=J.+P.+Edwardsauthor=A.+Fourieauthor=S.+D.+Goldbergauthor=T.+Hoffmann&title=Identification+and+biological+evaluation+of+thiazole-based+inverse+agonists+of+RORgammat&doi=10.1016%2Fj.bmcl.2018.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological evaluation of thiazole-based inverse agonists of RORγt</span></div><div class="casAuthors">Gege, Christian; Cummings, Maxwell D.; Albers, Michael; Kinzel, Olaf; Kleymann, Gerald; Schlueter, Thomas; Steeneck, Christoph; Nelen, Marina I.; Milligan, Cindy; Spurlino, John; Xue, Xiaohua; Leonard, Kristi; Edwards, James P.; Fourie, Anne; Goldberg, Steven D.; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1446-1455</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear receptor retinoic acid receptor-related orphan receptor gamma t (RORγt) is a transcription factor that drives Th17 cell differentiation and IL-17 prodn. in both innate and adaptive immune cells.  The IL-23/IL-17 pathway is implicated in major autoimmune and inflammatory diseases.  RORγt lies at the core of this pathway and represents an attractive opportunity for intervention with a small mol.  Despite diverse chem. series having been reported, combining high potency and nuclear receptor selectivity with good physicochem. properties remains a challenging endeavor in the field of RORγt drug discovery.  The authors describe the discovery and evaluation of a new class of potent and selective RORγt inverse agonists based on a thiazole core.  Acid analog 1j (Et 5-[4-[N-(tert-butyl)sulfamoyl]naphthalen-1-yl]-4-(cyclohexylmethyl)thiazole-2-carboxylate) demonstrated oral bioavailability in rats and was potent in a human whole blood assay, suggesting potential utility in treating autoimmune and inflammatory diseases such as psoriasis.  X-ray crystallog. data helped to elucidate the mol. mechanism for RORγt inhibition with this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8APFwgPE97Vg90H21EOLACvtfcHk0liZEa7eCd7K4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejtLg%253D&md5=5eb11be2492120db73c94733d56ae126</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DNelen%26aufirst%3DM.%2BI.%26aulast%3DMilligan%26aufirst%3DC.%26aulast%3DSpurlino%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DIdentification%2520and%2520biological%2520evaluation%2520of%2520thiazole-based%2520inverse%2520agonists%2520of%2520RORgammat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D9%26spage%3D1446%26epage%3D1455%26doi%3D10.1016%2Fj.bmcl.2018.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of new oxadiazole substituted thiazole RORgammat inverse agonists through a bioisosteric amide replacement approach</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127174</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32334912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127174&issue=12&author=C.+Steeneckauthor=C.+Gegeauthor=O.+Kinzelauthor=M.+Albersauthor=G.+Kleymannauthor=T.+Schluterauthor=A.+Schulzauthor=X.+Xueauthor=M.+D.+Cummingsauthor=A.+M.+Fourieauthor=K.+A.+Leonardauthor=B.+Scottauthor=J.+P.+Edwardsauthor=T.+Hoffmannauthor=S.+D.+Goldberg&title=Discovery+and+optimization+of+new+oxadiazole+substituted+thiazole+RORgammat+inverse+agonists+through+a+bioisosteric+amide+replacement+approach&doi=10.1016%2Fj.bmcl.2020.127174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach</span></div><div class="casAuthors">Steeneck, Christoph; Gege, Christian; Kinzel, Olaf; Albers, Michael; Kleymann, Gerald; Schlueter, Thomas; Schulz, Andreas; Xue, Xiaohua; Cummings, Maxwell D.; Fourie, Anne M.; Leonard, Kristi A.; Scott, Brian; Edwards, James P.; Hoffmann, Thomas; Goldberg, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127174</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from previously identified thiazole-2-carboxamides exemplified by compd. I, two new series of RORγt inverse agonists with significantly improved aq. soly., ADME parameters and oral PK properties were discovered.  These scaffolds were identified from a bioisosteric amide replacement approach.  Amongst the variety of heterocycles explored, a 1,3,4-oxadiazole led to compds. with the best overall profile for SAR development and in vivo exploration.  In an ex vivo mouse PD model, concn. dependent efficacy was demonstrated and compds. II and III were profiled in a 5-day rat tolerability study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb8R3FUJDRdrVg90H21EOLACvtfcHk0liZEa7eCd7K4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb4%253D&md5=e853db68a306e4424a143003e54db5b4</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127174%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DGege%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DLeonard%26aufirst%3DK.%2BA.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520new%2520oxadiazole%2520substituted%2520thiazole%2520RORgammat%2520inverse%2520agonists%2520through%2520a%2520bioisosteric%2520amide%2520replacement%2520approach%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127174%26doi%3D10.1016%2Fj.bmcl.2020.127174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gege, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurlino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. D.</span></span> <span> </span><span class="NLM_article-title">Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORgammat</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">127205</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32336498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127205&issue=12&author=C.+Gegeauthor=M.+Albersauthor=O.+Kinzelauthor=G.+Kleymannauthor=T.+Schluterauthor=C.+Steeneckauthor=T.+Hoffmannauthor=X.+Xueauthor=M.+D.+Cummingsauthor=J.+Spurlinoauthor=C.+Milliganauthor=A.+M.+Fourieauthor=J.+P.+Edwardsauthor=K.+Leonardauthor=K.+Coeauthor=B.+Scottauthor=D.+Pippelauthor=S.+D.+Goldberg&title=Optimization+and+biological+evaluation+of+thiazole-bis-amide+inverse+agonists+of+RORgammat&doi=10.1016%2Fj.bmcl.2020.127205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt</span></div><div class="casAuthors">Gege, Christian; Albers, Michael; Kinzel, Olaf; Kleymann, Gerald; Schlueter, Thomas; Steeneck, Christoph; Hoffmann, Thomas; Xue, Xiaohua; Cummings, Maxwell D.; Spurlino, John; Milligan, Cynthia; Fourie, Anne M.; Edwards, James P.; Leonard, Kristi; Coe, Kevin; Scott, Brian; Pippel, Dan; Goldberg, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">127205</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear receptor retinoic acid receptor-related orphan receptor gamma t (RORγt) is a transcription factor that drives Th17 cell differentiation and IL-17 prodn. in both innate and adaptive immune cells.  The IL-23/IL-17 pathway is implicated in major autoimmune and inflammatory diseases.  RORγt lies at the core of this pathway and represents an attractive opportunity for intervention with small mol. therapeutics.  Despite diverse chem. series having been reported, combining high potency and nuclear receptor selectivity with good physicochem. properties remains a challenging endeavor in the field of RORγt drug discovery.  We recently described the discovery and evaluation of a new class of potent and selective RORγt inverse agonists based on a thiazole scaffold.  Herein we describe the successful optimization of this class by incorporation of an addnl. amide moiety at the 4-position of the thiazole core.  In several optimization cycles, we have reduced human PXR activation, improved soly., and increased potency while maintaining nuclear receptor selectivity.  X-ray crystallog. anal. of compd. 1g bound in the sterol binding site of the ligand binding domain of RORγt was largely consistent with an earlier structure, guiding further insight into the mol. mechanism for RORγt inhibition with this series.  Compd. 1g is orally bioavailable, potent in a human whole blood assay and proved to be efficacious in an ex-vivo IL-17A assay, and was selected for preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlRppte3yxrVg90H21EOLACvtfcHk0lisR6geOo8B-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSnur4%253D&md5=f2bc572a7452257eaa29260df1a6837b</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127205%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DSchluter%26aufirst%3DT.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DSpurlino%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DC.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DCoe%26aufirst%3DK.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DPippel%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DS.%2BD.%26atitle%3DOptimization%2520and%2520biological%2520evaluation%2520of%2520thiazole-bis-amide%2520inverse%2520agonists%2520of%2520RORgammat%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D127205%26doi%3D10.1016%2Fj.bmcl.2020.127205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemagiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2- yl)phenyl)pyrrolidines as novel RORgammat inverse agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">127392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1016%2Fj.bmcl.2020.127392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=32738966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127392&issue=17&author=B.+Jiangauthor=J.+J.+Duanauthor=S.+Stachuraauthor=A.+Karmakarauthor=H.+Hemagiriauthor=D.+K.+Rautauthor=A.+K.+Guptaauthor=C.+A.+Weigeltauthor=J.+Khanauthor=J.+S.+Sackauthor=D.+R.+Wuauthor=M.+Yardeauthor=D.+R.+Shenauthor=M.+A.+Galellaauthor=A.+Mathurauthor=Q.+Zhaoauthor=L.+M.+Salter-Cidauthor=P.+H.+Carterauthor=T.+G.+M.+Dhar&title=Discovery+of+%283S%2C4S%29-3-methyl-3-%284-fluorophenyl%29-4-%284-%281%2C1%2C1%2C3%2C3%2C3-hexafluoro-2-hydroxyprop-2-+yl%29phenyl%29pyrrolidines+as+novel+RORgammat+inverse+agonists&doi=10.1016%2Fj.bmcl.2020.127392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists</span></div><div class="casAuthors">Jiang, Bin; Duan, James J.-W.; Stachura, Sylwia; Karmakar, Ananta; Hemagiri, Hemalatha; Raut, Dhanya Kumar; Gupta, Arun Kumar; Weigelt, Carolyn A.; Khan, Javed; Sack, John S.; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Galella, Michael A.; Mathur, Arvind; Zhao, Qihong; Salter-Cid, Luisa M.; Carter, Percy H.; Dhar, T. G. Murali</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">127392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of cis-3,4-diphenylpyrrolidines were designed as RORγt inverse agonists based on the binding conformation of previously reported bicyclic sulfonamide I.  Preliminary synthesis and structure-activity relationship (SAR) study established (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidine as the most effective scaffold.  Subsequent SAR optimization led to identification of a piperidinyl carboxamide II, which was potent against RORγt (EC50 of 61 nM in an inverse agonist assay), selective relative to RORα, RORβ, LXRα and LXRβ, and stable in human and mouse liver microsomes.  Furthermore, compd. II exhibited considerably lower PXR Ymax (46%) and emerged as a promising lead.  The binding mode of the diphenylpyrrolidine series was established with an X-ray co-crystal structure of III/RORγt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonLsaq8L7Su7Vg90H21EOLACvtfcHk0lisR6geOo8B-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrt77P&md5=a3a584c64a9b19d1d09685366dcd3616</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127392%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DDuan%26aufirst%3DJ.%2BJ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DKarmakar%26aufirst%3DA.%26aulast%3DHemagiri%26aufirst%3DH.%26aulast%3DRaut%26aufirst%3DD.%2BK.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26atitle%3DDiscovery%2520of%2520%25283S%252C4S%2529-3-methyl-3-%25284-fluorophenyl%2529-4-%25284-%25281%252C1%252C1%252C3%252C3%252C3-hexafluoro-2-hydroxyprop-2-%2520yl%2529phenyl%2529pyrrolidines%2520as%2520novel%2520RORgammat%2520inverse%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127392%26doi%3D10.1016%2Fj.bmcl.2020.127392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiffe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eerdenbrugh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span> <span> </span><span class="NLM_article-title">New potent DOT1L inhibitors for in vivo evaluation in mouse</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00452</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00452" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1OhurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1655-1660&issue=12&author=F.+Staufferauthor=A.+Weissauthor=C.+Scheuflerauthor=H.+Mobitzauthor=C.+Ragotauthor=K.+S.+Beyerauthor=K.+Calkinsauthor=D.+Guthyauthor=M.+Kiffeauthor=B.+Van+Eerdenbrughauthor=R.+Tiedtauthor=C.+Gaul&title=New+potent+DOT1L+inhibitors+for+in+vivo+evaluation+in+mouse&doi=10.1021%2Facsmedchemlett.9b00452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse</span></div><div class="casAuthors">Stauffer, Frederic; Weiss, Andreas; Scheufler, Clemens; Mobitz, Henrik; Ragot, Christian; Beyer, Kim S.; Calkins, Keith; Guthy, Daniel; Kiffe, Michael; Van Eerdenbrugh, Bernard; Tiedt, Ralph; Gaul, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1660</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes.  A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclin. mouse tumor xenograft model.  Compds. displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKjK-qoNQ0bVg90H21EOLACvtfcHk0lisR6geOo8B-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1OhurnM&md5=2d51f814db9aded229a51fda1e9d2213</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00452%26sid%3Dliteratum%253Aachs%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DRagot%26aufirst%3DC.%26aulast%3DBeyer%26aufirst%3DK.%2BS.%26aulast%3DCalkins%26aufirst%3DK.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DKiffe%26aufirst%3DM.%26aulast%3DVan%2BEerdenbrugh%26aufirst%3DB.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DGaul%26aufirst%3DC.%26atitle%3DNew%2520potent%2520DOT1L%2520inhibitors%2520for%2520in%2520vivo%2520evaluation%2520in%2520mouse%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1655%26epage%3D1660%26doi%3D10.1021%2Facsmedchemlett.9b00452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">A new approach of mitigating CYP3A4 induction led to the discovery of potent hepatitis B virus (HBV) capsid inhibitor with optimal ADMET profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10352</span>– <span class="NLM_lpage">10361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10352-10361&issue=22&author=X.+Linauthor=H.+Shiauthor=W.+Zhangauthor=Z.+Qiuauthor=Z.+Zhouauthor=F.+Deyauthor=S.+Zhongauthor=H.+Qiuauthor=J.+Xieauthor=X.+Zhouauthor=G.+Yangauthor=G.+Tangauthor=H.+C.+Shenauthor=W.+Zhu&title=A+new+approach+of+mitigating+CYP3A4+induction+led+to+the+discovery+of+potent+hepatitis+B+virus+%28HBV%29+capsid+inhibitor+with+optimal+ADMET+profiles&doi=10.1021%2Facs.jmedchem.9b01421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles</span></div><div class="casAuthors">Lin, Xianfeng; Shi, Houguang; Zhang, Weixing; Qiu, Zongxing; Zhou, Zheng; Dey, Fabian; Zhong, Sheng; Qiu, Hongxia; Xie, Jianxun; Zhou, Xue; Yang, Guang; Tang, Guozhi; Shen, Hong C.; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10352-10361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein is a new approach to mitigate CYP3A4 induction.  In this unconventional approach, a fine-tuning of the dihedral angle between the C4 Ph and the dihydropyrimidine core of the heteroaryldihydropyrimidine (HAP) class of capsid inhibitors successfully altered the structure-activity-relationships (SARs) of the unwanted CYP3A4 induction and the desired HBV capsid inhibition to more favorable values.  This eventually led to the discovery of a new capsid inhibitor with significantly reduced CYP3A4 induction, excellent anti-HBV activity, favorable preclin. PK/PD profiles, and no early safety flags.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNfHXvhTVCabVg90H21EOLACvtfcHk0lgshFo8KZym5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7rK&md5=21f92e9b739581463229d5bf46d47c3d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01421%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDey%26aufirst%3DF.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DA%2520new%2520approach%2520of%2520mitigating%2520CYP3A4%2520induction%2520led%2520to%2520the%2520discovery%2520of%2520potent%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitor%2520with%2520optimal%2520ADMET%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10352%26epage%3D10361%26doi%3D10.1021%2Facs.jmedchem.9b01421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruderek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of second generation EZH2 inhibitors with long residence time</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1205-1212&issue=6&author=A.+Khannaauthor=A.+Coteauthor=S.+Aroraauthor=L.+Moineauthor=V.+S.+Gehlingauthor=J.+Brennemanauthor=N.+Cantoneauthor=J.+I.+Stuckeyauthor=S.+Apteauthor=A.+Ramakrishnanauthor=K.+Bruderekauthor=W.+D.+Bradleyauthor=J.+E.+Audiaauthor=R.+T.+Cummingsauthor=R.+J.+Simsauthor=P.+Trojerauthor=J.+R.+Levell&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+second+generation+EZH2+inhibitors+with+long+residence+time&doi=10.1021%2Facsmedchemlett.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time</span></div><div class="casAuthors">Khanna, Avinash; Cote, Alexandre; Arora, Shilpi; Moine, Ludivine; Gehling, Victor S.; Brenneman, Jehrod; Cantone, Nico; Stuckey, Jacob I.; Apte, Shruti; Ramakrishnan, Ashwin; Bruderek, Kamil; Bradley, William D.; Audia, James E.; Cummings, Richard T.; Sims, Robert J.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1212</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM).  EZH2 is commonly mutated in hematol. malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis.  First generation EZH2 inhibitors are beginning to show clin. benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition.  During our medicinal chem. campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time.  Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochem. properties, which have the potential to expand the clin. use of EZH2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx-ixCY_R5KrVg90H21EOLACvtfcHk0lgshFo8KZym5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsro%253D&md5=e54bac34b75f41d6b82666016df08c1f</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DBrenneman%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DStuckey%26aufirst%3DJ.%2BI.%26aulast%3DApte%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DBruderek%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%2520second%2520generation%2520EZH2%2520inhibitors%2520with%2520long%2520residence%2520time%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1205%26epage%3D1212%26doi%3D10.1021%2Facsmedchemlett.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndifor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugovic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shireman, B. T.</span></span> <span> </span><span class="NLM_article-title">Substituted azabicyclo[2.2.1]heptanes as selective orexin-1 antagonists: Discovery of JNJ-54717793</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2002</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1Wmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2002-2009&issue=10&author=C.+Previlleauthor=P.+Bonaventureauthor=T.+Koudriakovaauthor=B.+Lordauthor=D.+Nepomucenoauthor=M.+Rizzolioauthor=N.+Maniauthor=K.+J.+Coeauthor=A.+Ndiforauthor=C.+Dugovicauthor=C.+A.+Dvorakauthor=H.+Coateauthor=D.+J.+Pippelauthor=A.+Fitzgeraldauthor=B.+Allisonauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=B.+T.+Shireman&title=Substituted+azabicyclo%5B2.2.1%5Dheptanes+as+selective+orexin-1+antagonists%3A+Discovery+of+JNJ-54717793&doi=10.1021%2Facsmedchemlett.0c00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793</span></div><div class="casAuthors">Preville, Cathy; Bonaventure, Pascal; Koudriakova, Tatiana; Lord, Brian; Nepomuceno, Diane; Rizzolio, Michele; Mani, Neelakandha; Coe, Kevin J.; Ndifor, Anthony; Dugovic, Christine; Dvorak, Curt A.; Coate, Heather; Pippel, Daniel J.; Fitzgerald, Anne; Allison, Brett; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Shireman, Brock T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2002-2009</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The orexin system consists of two neuropeptides (orexin-A and orexin-B) that exert their mode of action on two receptors (orexin-1 and orexin-2).  While the role of the orexin-2 receptor is established as an important modulator of sleep wake states, the role of the orexin-1 receptor is believed to play a role in addiction, panic, or anxiety.  In this manuscript, we describe the optimization of a nonselective substituted azabicyclo[2.2.1]heptane dual orexin receptor antagonist (DORA) into orally bioavailable, brain penetrating, selective orexin-1 receptor (OX1R) antagonists.  This resulted in the discovery of our first candidate for clin. development, JNJ-54717793.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp66G0rIU1vJbVg90H21EOLACvtfcHk0lhUhzj5KM2NGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1Wmtbs%253D&md5=0dccbf0362cfd6ba9dbaee0a40031064</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00085%26sid%3Dliteratum%253Aachs%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DNdifor%26aufirst%3DA.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCoate%26aufirst%3DH.%26aulast%3DPippel%26aufirst%3DD.%2BJ.%26aulast%3DFitzgerald%26aufirst%3DA.%26aulast%3DAllison%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26atitle%3DSubstituted%2520azabicyclo%255B2.2.1%255Dheptanes%2520as%2520selective%2520orexin-1%2520antagonists%253A%2520Discovery%2520of%2520JNJ-54717793%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D2002%26epage%3D2009%26doi%3D10.1021%2Facsmedchemlett.0c00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delfosse, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardia-Parège, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiavarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Mével, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruszczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeneix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianférani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fini, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, W.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into the synergistic activation of the RXR-PXR heterodimer by endocrine disruptor mixtures</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e2020551118</span> <span class="refDoi"> DOI: 10.1073/pnas.2020551118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=10.1073%2Fpnas.2020551118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;key=33361153" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2021&issue=1&author=V.+Delfosseauthor=T.+Huetauthor=D.+Harrusauthor=M.+Granellauthor=M.+Bourguetauthor=C.+Gardia-Par%C3%A8geauthor=B.+Chiavarinaauthor=M.+Grimaldiauthor=S.+Le+M%C3%A9velauthor=P.+Blancauthor=D.+Huangauthor=J.+Gruszczykauthor=B.+Demeneixauthor=S.+Cianf%C3%A9raniauthor=J.+B.+Finiauthor=P.+Balaguerauthor=W.+Bourguet&title=Mechanistic+insights+into+the+synergistic+activation+of+the+RXR-PXR+heterodimer+by+endocrine+disruptor+mixtures&doi=10.1073%2Fpnas.2020551118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2020551118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2020551118%26sid%3Dliteratum%253Aachs%26aulast%3DDelfosse%26aufirst%3DV.%26aulast%3DHuet%26aufirst%3DT.%26aulast%3DHarrus%26aufirst%3DD.%26aulast%3DGranell%26aufirst%3DM.%26aulast%3DBourguet%26aufirst%3DM.%26aulast%3DGardia-Par%25C3%25A8ge%26aufirst%3DC.%26aulast%3DChiavarina%26aufirst%3DB.%26aulast%3DGrimaldi%26aufirst%3DM.%26aulast%3DLe%2BM%25C3%25A9vel%26aufirst%3DS.%26aulast%3DBlanc%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DGruszczyk%26aufirst%3DJ.%26aulast%3DDemeneix%26aufirst%3DB.%26aulast%3DCianf%25C3%25A9rani%26aufirst%3DS.%26aulast%3DFini%26aufirst%3DJ.%2BB.%26aulast%3DBalaguer%26aufirst%3DP.%26aulast%3DBourguet%26aufirst%3DW.%26atitle%3DMechanistic%2520insights%2520into%2520the%2520synergistic%2520activation%2520of%2520the%2520RXR-PXR%2520heterodimer%2520by%2520endocrine%2520disruptor%2520mixtures%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2021%26volume%3D118%26issue%3D1%26doi%3D10.1073%2Fpnas.2020551118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4J5X','PDB','4J5X'); return false;">PDB: 4J5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XHD','PDB','4XHD'); return false;">PDB: 4XHD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4SOT','PDB','4SOT'); return false;">PDB: 4SOT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NX1','PDB','6NX1'); return false;">PDB: 6NX1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1G','PDB','4X1G'); return false;">PDB: 4X1G</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SKX','PDB','1SKX'); return false;">PDB: 1SKX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R8D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R8D','PDB','3R8D'); return false;">PDB: 3R8D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NRL','PDB','1NRL'); return false;">PDB: 1NRL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HVL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HVL','PDB','3HVL'); return false;">PDB: 3HVL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILH','PDB','1ILH'); return false;">PDB: 1ILH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1NLR','PDB','1NLR'); return false;">PDB: 1NLR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O9I','PDB','2O9I'); return false;">PDB: 2O9I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQC','PDB','1PQC'); return false;">PDB: 1PQC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NY9','PDB','4NY9'); return false;">PDB: 4NY9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S0T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S0T','PDB','4S0T'); return false;">PDB: 4S0T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86','PDB','5A86'); return false;">PDB: 5A86</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUP','PDB','6DUP'); return false;">PDB: 6DUP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BNS','PDB','6BNS'); return false;">PDB: 6BNS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BN6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BN6','PDB','6BN6'); return false;">PDB: 6BN6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S41','PDB','6S41'); return false;">PDB: 6S41</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HTY','PDB','6HTY'); return false;">PDB: 6HTY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S41" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4S41','PDB','4S41'); return false;">PDB: 4S41</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HTY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HTY','PDB','4HTY'); return false;">PDB: 4HTY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XP9','PDB','6XP9'); return false;">PDB: 6XP9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UM8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UM8','PDB','6UM8'); return false;">PDB: 6UM8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFI','PDB','6TFI'); return false;">PDB: 6TFI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M13" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M13','PDB','1M13'); return false;">PDB: 1M13</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ILG','PDB','1ILG'); return false;">PDB: 1ILG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WRE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WRE','PDB','5WRE'); return false;">PDB: 5WRE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXJ','PDB','7AXJ'); return false;">PDB: 7AXJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXA','PDB','7AXA'); return false;">PDB: 7AXA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXD','PDB','7AXD'); return false;">PDB: 7AXD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXF','PDB','7AXF'); return false;">PDB: 7AXF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXC','PDB','7AXC'); return false;">PDB: 7AXC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXE','PDB','7AXE'); return false;">PDB: 7AXE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AXH','PDB','7AXH'); return false;">PDB: 7AXH</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02245&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-10%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02245%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02245" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                16MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a94d1898e3d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
